{
    "26145056-fdfd-4f2d-909e-be84fc53ede8": {
        "text_answer": "Contradiction  The evidence provided does not support the statement that patients receiving the placebo intervention were twice as likely to experience emesis as patients receiving Aprepitant The evidence only shows that there were 5 emesisfree participants in the placebo group and 13 in the Aprepitant group but it does not provide information about the total number of participants who experienced emesis or the rate of emesis for each group Therefore it is not",
        "label": "Contradiction"
    },
    "22384b11-eb42-42da-86b3-dfed559ebb77": {
        "text_answer": "Contradiction  The evidence states that 98 of the patients had Recurrencefree Survival which is not the same as stating that only 2 patients did not have Recurrencefree Survival The two statements convey different information",
        "label": "Contradiction"
    },
    "b03bae0b-6811-4c4d-a265-98c0f4ae7f1f": {
        "text_answer": "Contradiction The evidence states that no concurrent gabapentin or Herceptin treatment is allowed in the secondary trial but it does not specify a time limit for the exclusion The primary trial on the other hand does not mention any exclusion for gabapentin or Herceptin treatment in the past year",
        "label": "Contradiction"
    },
    "1b2048ba-33c8-43d1-8d8f-bca70ca8d80c": {
        "text_answer": "Entailment  Explanation The statement the drug dosage for the primary clinical trial participants is lower in comparison to that of the secondary clinical trial participants is an entailment based on the evidence provided In the primary trial the dosages of PF06647020 were 02 mgkg and 05 mgkg in the two interventions respectively which is lower than the dosages of ",
        "label": "Entailment"
    },
    "f398c658-74cb-4d2b-894c-d785e4dde994": {
        "text_answer": "Entailment The primary trial measures adverse events and serious adverse events as percentages of participants while the secondary trial measures objective response as the number of participants with complete or partial response These are different metrics for assessing outcomes",
        "label": "Entailment"
    },
    "d4b54b4a-d675-4d59-b489-2c1a025b2b4e": {
        "text_answer": "Entailment The statement is an entailment because nonsmall cell lung cancer and small cell lung cancer are included in the list of eligible tumor types in the clinical trial",
        "label": "Entailment"
    },
    "ad00f90a-b69d-4df4-a9f8-d495ac080b38": {
        "text_answer": "Contradiction  The evidence shows that there were 5 emesisfree participants in the placebo group and 13 in the aprepitant group which is the opposite of the statement suggesting that placebo patients were twice as likely to undergo emesis",
        "label": "Contradiction"
    },
    "7308389a-7cde-4cf2-8f68-cefff152645c": {
        "text_answer": "Entailment The evidence states that there was only one occurrence of urinary tract infection out of 50 participants which is fewer than the stated zero occurrences in the question Therefore the statement is an entailment as it implies a fewer number of occurrences than stated in the evidence",
        "label": "Entailment"
    },
    "d88cc7fc-34dc-4e86-a3a0-50192a316624": {
        "text_answer": "Contradiction  The primary trial excludes patients with a history of breast cancer including ductal carcinoma in situ while the secondary trial includes such patients However the secondary trial also excludes patients with uncontrolled hypertension which is not mentioned in the primary trials exclusion criteria Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "36eb6a9f-5a3a-4f8f-b242-e669aeaa3547": {
        "text_answer": "Contradiction The evidence does not mention anything about visible tumors in both breasts as an exclusion criterion for the primary clinical trial",
        "label": "Contradiction"
    },
    "b9e11a69-3cd1-4669-93ae-b644cbd40e71": {
        "text_answer": "Contradiction The primary clinical trial only accepts patients with metastatic pancreatic cancer if their tumor harbors the Kras or BRAF mutation",
        "label": "Contradiction"
    },
    "57eb42a8-0c1b-4358-b024-0579811b3db3": {
        "text_answer": "Neutral  Explanation The statement is not an entailment or a contradiction based on the evidence provided The statement describes the nature of the primary and secondary trials but it does not directly relate to the interventions or treatments being tested in those trials",
        "label": "Entailment"
    },
    "885733b0-a998-4f2c-b131-e58b2008a8a2": {
        "text_answer": "Contradiction The primary trial is not designed for patients based on their vitamin D levels but rather for postmenopausal women with early stage breast cancer and low vitamin D levels who would be treated with an aromatase inhibitor The secondary trial on the other hand is for healthy participants HER2positive females and those with a baseline LVEF 55 among other criteria There is no mention of vitamin D",
        "label": "Contradiction"
    },
    "b8f0039d-f476-4aa1-a522-751d93e45147": {
        "text_answer": "Contradiction The evidence states that there are currently no results available for the cohort on LBH589 and Lapatinib in the primary clinical trial",
        "label": "Contradiction"
    },
    "c6aa83b0-88fb-475a-8b38-e330d2bdf332": {
        "text_answer": "Entailment Both trials administer their interventions orally and the statement does not make any assumptions about the nature of the responses to treatment",
        "label": "Entailment"
    },
    "b590614e-03b9-4e7b-91e9-940058316465": {
        "text_answer": "Contradiction The primary trial includes patients with 13 cerebral metastases while the secondary trial excludes patients with 23 cerebral metastases",
        "label": "Contradiction"
    },
    "4a73eb98-e69d-4116-bbed-7e1b6458aa61": {
        "text_answer": "Contradiction The primary trial requires denosumab injections while the secondary trial does not involve any injections and uses lymphoscintigraphy instead",
        "label": "Contradiction"
    },
    "eaf2bb85-799b-47e9-af79-4fc7a54f0fcd": {
        "text_answer": "Entailment The evidence states that cohort 1 received 80mg of Enzalutamide and cohort 2 received 160mg of Enzalutamide which is double the dosage for cohort 1",
        "label": "Entailment"
    },
    "1692ad17-057d-4d84-bc1b-f9fa773288b2": {
        "text_answer": "Contradiction The primary trial involves an intraosseous injection of fluciclatide while the secondary trial involves an intravenous injection of chloroquine",
        "label": "Contradiction"
    },
    "f3918549-5e15-44e3-b35b-f7f361845792": {
        "text_answer": "Entailment The evidence shows that no adverse events were observed in either cohort 1 or 2 so the statement that all observed adverse events were attributed to members of both cohorts is an entailment since there were no adverse events in the first place However its important to note that the statement would be a contradiction if there were adverse events in the evidence and they were not exclusively attributed to cohort 1",
        "label": "Entailment"
    },
    "d46fad97-64a3-4553-a586-0dd9878009ec": {
        "text_answer": "Contradiction The evidence does not provide sufficient information to determine if distinct patient clusters are required for the secondary and primary clinical trials The trials have different outcomes and patient populations",
        "label": "Contradiction"
    },
    "be4814f1-b515-4744-8df9-293327502949": {
        "text_answer": "Contradiction The primary trial specifically states that patients must have a breast tumor 1 cm in diameter which is larger than the 28 mm range specified in the statement",
        "label": "Contradiction"
    },
    "039ef0fd-7ea1-4820-b08f-99cf35009bc3": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients receiving warfarin while the secondary trial permits its use under certain conditions",
        "label": "Contradiction"
    },
    "2945688b-8ee8-43ce-8ed3-30c0a4fdf489": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary clinical trial does involve oral administration of cabergoline which is not a topical medication",
        "label": "Contradiction"
    },
    "a6eb92cc-e789-4ced-a40c-166bebb09a67": {
        "text_answer": "Irrelevant The statement has no relation to the provided evidence",
        "label": "Contradiction"
    },
    "5461003b-2108-4302-96ad-d843b5b9e938": {
        "text_answer": "Entailment The evidence shows that no adverse events were documented in both cohorts of the primary clinical trial which is exactly what the statement asserts",
        "label": "Entailment"
    },
    "0b343459-5c78-4c51-b71b-bfc5aa6d0c6a": {
        "text_answer": "Contradiction The intervention in the primary clinical trial lasts for 10 weeks while the intervention in the secondary clinical trial lasts for 24 weeks The statement implies that the intervention in the secondary clinical trial lasts for fewer than 16 weeks 20 weeks earlier than 10 weeks which is not the case",
        "label": "Contradiction"
    },
    "1be9e4b6-a9e2-42b2-9131-4d7557ccd568": {
        "text_answer": "Contradiction The primary trial involves denosumab injections while the secondary trial involves lymphoscintigraphy which are not the same interventions",
        "label": "Contradiction"
    },
    "fb4df065-adca-4ce7-9059-bda1cc4ca1be": {
        "text_answer": "Entailment The evidence shows that in both trials no more than 048 and 000 of participants had adverse events which is less than 10",
        "label": "Entailment"
    },
    "5a286769-0146-41da-8daa-af8c7169023a": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug or any other hemorrhagebleeding event NCI CTCAE v30 Grade 3 within 4 weeks of first dose of study drug The statement suggests that patients with a recent history of pulmonary embolism might be considered",
        "label": "Contradiction"
    },
    "c926dbb4-ab16-46dc-a2be-8d04563ce9d0": {
        "text_answer": "Contradiction The primary trial recorded no adverse events while the secondary trial recorded 11 adverse events",
        "label": "Contradiction"
    },
    "69b11fe6-3c14-4ac6-a664-916dc341700f": {
        "text_answer": "Entailment In the primary trial there is no information provided regarding the frequency of MM121 and paclitaxel administration However in the secondary trial MM121 is given weekly for 12 weeks while paclitaxel is given weekly for 12 weeks followed by a surgery Therefore the statement that patients in the secondary trial receive MM121 and paclitaxel more frequently on a weekly basis is",
        "label": "Entailment"
    },
    "e688cf8e-7082-43f3-803c-7489148f3cac": {
        "text_answer": "Contradiction The statement is a contradiction as patients with NUT midline carcinoma or Castrateresistant prostate cancer determined by fluorescence In situ hybridization are eligible for the primary trial but are not eligible for the secondary trial due to the different inclusion criteria for each trial Inflammatory breast cancer is an exclusion criterion for both trials",
        "label": "Contradiction"
    },
    "306374f7-40f9-45d5-a7cf-6cece3889a04": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not provide information about the doses of docetaxel and eribulin received by cohort 1 patients in the primary clinical trial",
        "label": "Contradiction"
    },
    "c616276b-e187-44ee-a2fb-93704f1a64cc": {
        "text_answer": "Contradiction The evidence shows that all patients in the secondary clinical trial experienced adverse events not none as stated in the question",
        "label": "Contradiction"
    },
    "68f673a5-6ddf-487a-ad88-4903d92e1746": {
        "text_answer": "Contradiction   Explanation   The statement There were no patients with recorded AEs in the primary trial whereas every patient in the secondary trial suffered at least one adverse event is a contradiction based on the evidence provided   The evidence shows that there were no recorded adverse events in the primary trial but it also shows that every patient in the secondary trial suffered at least one adverse event This is a contradiction because",
        "label": "Contradiction"
    },
    "e7f5c09e-9d3d-4081-a926-9f89647a0e3b": {
        "text_answer": "Entailment The statement is an entailment of the inclusion criteria for the primary clinical trial as it explicitly states that participants must have a solid tumor that is locally advanced or metastatic",
        "label": "Entailment"
    },
    "687b9bc0-7328-4ecc-9bae-6b63f2df3cdb": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trials intervention 1 zoledronic acid is given intravenously but the secondary trials interventions involve both intravenous and oral administration of drugs",
        "label": "Contradiction"
    },
    "55c1905d-0e17-41b6-89ba-c29df13d2e30": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were two patients in cohort 1 of the primary clinical trial who experienced infections and fever However the statement claims that each patient in cohort 1 who experienced infections and fever were the only ones which is not true based on the evidence",
        "label": "Contradiction"
    },
    "1e213f71-5def-460d-b18e-aa58dbbe4463": {
        "text_answer": "Contradiction  The primary clinical trial is not conducting trials with a dietary intervention as per the provided evidence",
        "label": "Contradiction"
    },
    "e26430d8-c773-4770-b298-429c286fd5d3": {
        "text_answer": "Contradiction The primary trial is for breast cancer patients only not for leukemia patients",
        "label": "Contradiction"
    },
    "67b66f39-48c2-495c-9ab0-0beefd9cdcef": {
        "text_answer": "Entailment Both study groups undergo 18FFDG and 18FFPPRGD2 PETCT imaging with the same techniques",
        "label": "Entailment"
    },
    "30234b84-2f15-4ea8-b7ed-af5f4ea40e9c": {
        "text_answer": "Entailment assuming the primary trial is not specific to testicular neoplasms",
        "label": "Entailment"
    },
    "2c9e275c-18ef-471f-8ec9-1d73bfb27e20": {
        "text_answer": "Contradiction The evidence provided is about the severity of symptoms in patients who received cryotherapy before during and after paclitaxel infusions Arm I and those who only received paclitaxel infusions Arm II The statement however is about patients who did not receive paclitaxel infusions at all",
        "label": "Contradiction"
    },
    "4fb8207e-292f-4f97-9587-bf028abd57be": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of cohort 2 having any Infections and Infestations cases but the evidence does not contradict the statement either as it does not provide information about the nature of the inactivity comment for the Infections and Infestations cases in cohort 1",
        "label": "Contradiction"
    },
    "3426bc8a-b9c6-451e-aa76-25e1fc8bff69": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided The evidence only discusses the interventions and treatments in the primary and secondary trials It does not mention anything about travel or visiting people",
        "label": "Contradiction"
    },
    "c4620792-b333-4232-ba8e-62595917256f": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as Anastrozole Arimidex is used in the primary trial but not mentioned in the secondary trials procedure",
        "label": "Contradiction"
    },
    "a68e6309-12b7-445f-837b-ce8cef67a882": {
        "text_answer": "Contradiction The statement does not follow from the evidence as eating disorders were reported in the trial although not specifically mentioned in the provided adverse events list",
        "label": "Contradiction"
    },
    "f81c0c12-c161-4e90-91e4-65a2b255d1c2": {
        "text_answer": "Contradiction  The primary trial measures the number of participants with treatmentemergent adverse events while the secondary trial measures the change in total sleep time using polysomnography These are different outcome measures",
        "label": "Contradiction"
    },
    "251e979f-a7ba-4dea-afb7-01b9501ec7cf": {
        "text_answer": "Contradiction The statement provides different numbers of participants who experienced Recurrencefree Survival in each group According to the evidence 80 out of 96 participants in the Ketorolac 30 mg group and 897 of 107 participants in the NaCl 09 3mL group experienced Recurrencefree Survival Therefore the numbers do not match making the statement",
        "label": "Contradiction"
    },
    "71db6876-7205-4e4b-9a89-949045f26ab9": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence states that both cohorts in the primary clinical trial receive vaccines against Pneumococcus and Influenza but the statement specifies that the first cohort receives the Pneumococcus vaccine and the second cohort receives the Influenza vaccine which is not consistent with the evidence",
        "label": "Contradiction"
    },
    "037ef54b-03fa-49f8-ae4b-ea645d268ea9": {
        "text_answer": "Contradiction  Explanation The statement suggests that cohort 1 and cohort 2 received the same dose of Cetuximab but the evidence shows that cohort 1 received a lower dose of MM121 which could potentially affect the Cetuximab dosing due to pharmacokinetic interactions Therefore the statement is contradictory to the evidence",
        "label": "Contradiction"
    },
    "889268e5-7b76-4c17-b567-bd828a9abf3e": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions no instances of cardiac or psychiatric adverse events in either trial",
        "label": "Contradiction"
    },
    "2f7bf983-b072-4d3e-96fb-718475ef0fd2": {
        "text_answer": "Contradiction The primary trial uses a sublingual method for Vitamin B12 administration not a transdermal patch The secondary trial uses a placebo sublingually or orally for memantine hydrochloride",
        "label": "Contradiction"
    },
    "0279dc49-0833-4673-8fb7-a7101a16fa14": {
        "text_answer": "Contradiction The primary trial has an ECOG performance status inclusion criterion of 02 which includes an ECOG score of 1 However the secondary trial has no mention of an ECOG score as an inclusion criterion Therefore having an ECOG score of 1 does not entail or guarantee eligibility for both trials",
        "label": "Contradiction"
    },
    "9126bd66-8ee7-47a5-84e2-0269efe06362": {
        "text_answer": "Contradiction The statement is contradictory because the evidence states that adults are included in the primary clinical trial under certain conditions but excluded only for specific reasons in the secondary clinical trial",
        "label": "Contradiction"
    },
    "1b56f68b-a4b1-433c-a634-73ff99fce7aa": {
        "text_answer": "Entailment The statement does not mention anorexia hypothermia or hallucinations in relation to the evidence provided Therefore the absence of these adverse events in the evidence does not contradict the statement",
        "label": "Entailment"
    },
    "9349c7c8-7771-4dfc-8981-3c8d84ac5236": {
        "text_answer": "Entailment The statement is a subset of the inclusion criteria stated in the evidence",
        "label": "Entailment"
    },
    "0a0a9bd9-b3d0-4af8-b09a-f0e3a1684ef0": {
        "text_answer": "Contradiction The evidence for the secondary trial states that no prior gabapentin or pregabalin use is allowed while the statement suggests that a history of gabapentin or pregabalin use is not a disqualifying factor for the secondary trial but compromises eligibility for the primary trial These statements are contradictory",
        "label": "Contradiction"
    },
    "462f7871-9216-4b37-af39-1fb32b2bbf84": {
        "text_answer": "Entailment The statement is a specific case of the exclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "548ed40c-ccf4-4250-9fd9-c870bcc61b17": {
        "text_answer": "Entailment  Explanation The evidence describes the patient population and eligibility criteria for the primary clinical trial but it does not mention any requirement for regular physical activity as a component of the intervention for participants",
        "label": "Entailment"
    },
    "e53898b8-422f-4317-b2f6-c487409b0750": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence shows that there are no cases of anemia in the primary trial while there are 2 cases in the secondary trial",
        "label": "Contradiction"
    },
    "098f7c20-8543-4de6-b236-341c4cdea28e": {
        "text_answer": "Entailment The statement is an entailment of the evidence as it accurately reflects the percentage of participants with HER2 primary breast cancer who developed imagable HER2 metastases as reported in the primary trial",
        "label": "Entailment"
    },
    "9d2b4df6-e802-437f-a844-61e944365df0": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The evidence only mentions the absence of Hypertension Edema and Dyspnea in the primary trial while the statement is about a question associated with the WHODAS 20 36item version selfadministered questionnaire The two pieces of information are related but not directly equivalent",
        "label": "Entailment"
    },
    "a02a0c3b-3c6c-45ce-a382-636abd7e1bef": {
        "text_answer": "Contradiction  The primary trial compares the overall response rate between two arms Arm A and Arm B while the secondary trial compares the time to first onstudy SRE between two different interventions Zoledronic acid and Denosumab These trials are not directly comparable and the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "a9f8fa09-52b6-4a39-b62b-3685f41d6c6e": {
        "text_answer": "Entailment The statement follows from the evidence as laserassisted fluorescence angiography is mentioned for both interventions and lateral radial incisions are also mentioned for both interventions However its important to note that the statement does not mention lipodystrophy being related to the interventions or the incisions in any way",
        "label": "Entailment"
    },
    "f5a3b01c-743a-4d70-81c8-a5671272d1e0": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement is about the definition of a milliunit and the participants and vaccines in the two cohorts of the primary trial The evidence does not provide any information about the vaccines being given as milliunits or any relationship between the statement and the vaccines in the trial",
        "label": "Entailment"
    },
    "af9986f4-5f0c-4b8c-b02a-05ae6f7f4d1b": {
        "text_answer": "Contradiction  Explanation  The statement 78 more participants in the dalotuzumab 20 mgkg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group is a contradiction based on the evidence provided  The evidence shows that 286 131 to 492 of participants in the ERpositive Luminal B",
        "label": "Contradiction"
    },
    "fe0af3be-4bf7-4e28-ad4c-81082e2ebfbd": {
        "text_answer": "Contradiction  Explanation  In the primary trial there is a cohort receiving Armodafinil PO daily but the statement claims that in the primary trial only one cohort receives placebo This is a contradiction to the evidence  In the secondary trial all patients receive the same doses of PDR001 01 kilogram and MCS110 0",
        "label": "Contradiction"
    },
    "b54c2b24-79e2-4561-bd18-ba18479cd7a3": {
        "text_answer": "Contradiction The primary trial and secondary trial involve different interventions and patient populations and there is no mention of 1p19q deletion analysis in either trial",
        "label": "Contradiction"
    },
    "52174f7c-e29a-4fc5-b116-eeb9ee0ecc34": {
        "text_answer": "Contradiction The statement does not entail the evidence as it does not mention anything about psychiatric adverse events or their percentage in the primary trial",
        "label": "Contradiction"
    },
    "1f5d055f-5dde-400d-bbad-687e79830586": {
        "text_answer": "Contradiction The statement is not supported by the evidence as the evidence does not provide information about the number or types of adverse events experienced by patients with diffuse midline glioma h3 k27mmutant in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "f4e8530b-843b-422e-8db4-c02378c66512": {
        "text_answer": "Contradiction The statement is not related to the number of vector genomes per milliliter and instead compares the types of drugs and surgical interventions in the two trials",
        "label": "Contradiction"
    },
    "0c561a05-4615-4578-aff2-745d9c9761c0": {
        "text_answer": "Contradiction  The evidence shows that a lower percentage of participants in the triple negative group had a decrease in the growth factor signature compared to those in the ERpositive Luminal B group",
        "label": "Contradiction"
    },
    "1e5ed892-07f9-409a-bc45-edd43978e9b1": {
        "text_answer": "Contradiction The statement have not received treatment is a response indicating that an individual has not been treated for cancer is not related to the evidence provided about the primary trial which only mentions the intervention involving the educational DVD for cohort 1",
        "label": "Contradiction"
    },
    "7774f54f-4f08-4c6d-8fa4-af4979ba5bac": {
        "text_answer": "Contradiction The primary trial only includes patients with a breast tumor that is 1 cm in diameter while the statement specifies a tumor that is 18 cm in diameter which is not eligible for the primary trial",
        "label": "Contradiction"
    },
    "cfce111d-8810-4915-98ee-1e280271de10": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the primary trial administers pembrolizumab every 3 weeks Q3W while sunitinib in the secondary trial is given to some participants on a continuous dosing regimen and to sunitinibnaïve participants once daily However the statement does not account for the different dosing schedules of sunitinib and the frequency of pembrol",
        "label": "Contradiction"
    },
    "5861703f-56fc-4e31-ba4e-d97400d71d99": {
        "text_answer": "Contradiction The primary trial did not record any adverse events at all while the statement mentions specifically zero cases of either febrile neutropenia or cholelithiasis",
        "label": "Contradiction"
    },
    "4c5fcde7-b882-4ea3-96ba-275af987ea60": {
        "text_answer": "Contradiction  The statement implies a ratio of 13 for hypertension and pancreatectomy to hepatotoxicity but the evidence shows no cases of pancreatectomy and only one case of hypertension",
        "label": "Contradiction"
    },
    "83c63591-6cde-4635-8d33-61dad15c7a21": {
        "text_answer": "Contradiction  Explanation The statement is not entailed by the evidence as the primary trial involves the use of pembrolizumab and epacadostat while the secondary trial involves the use of sunitinib The comparison of the frequency of administration of pembrolizumab and sunitinib is not directly relevant to the statement",
        "label": "Contradiction"
    },
    "ef245c6c-7858-45cd-a0fd-d272e7aae585": {
        "text_answer": "Contradiction The primary trial does not involve the administration of myalgias to any group while the secondary trial mentions the receipt of myalgias by patients in a specific cohort",
        "label": "Contradiction"
    },
    "87a7f86a-e915-4ea9-a2ba-c8e4d37dfa15": {
        "text_answer": "Contradiction The statement is not an entailment as severe insomnia is an exclusion criterion for the secondary trial but it is not mentioned in the primary trials exclusion criteria",
        "label": "Contradiction"
    },
    "aad4638b-6c8d-4f55-bf3f-5a3e9d74ef50": {
        "text_answer": "Contradiction The primary clinical trial only includes patients with unilateral breast cancer",
        "label": "Contradiction"
    },
    "ad66bfcf-7359-41c6-b4f8-694ed27fbc8e": {
        "text_answer": "Contradiction The primary trial reports on the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or maximum feasible dose of MM111 which is not related to the primary trial",
        "label": "Contradiction"
    },
    "89c0759c-7a7e-4c65-b98e-841d2ca21808": {
        "text_answer": "Contradiction The primary trial does not include advanced stage and metastatic melanoma or pancreatic cancer in its list of eligible tumor types",
        "label": "Contradiction"
    },
    "593bde37-5962-441b-ac10-dbe3120cec99": {
        "text_answer": "Entailment The evidence shows that 571 of patients in the primary trial suffered adverse events which is less than 5",
        "label": "Entailment"
    },
    "1669453c-bb8e-437d-b5e2-98600980d7d3": {
        "text_answer": "Contradiction The statement does not account for the difference in tremelimumab dosing between the two interventions",
        "label": "Contradiction"
    },
    "135763e3-70fd-478d-991c-717d6ed55bb3": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as cohort 1 receives a different dosing schedule 5 daysweek compared to cohort 2 3 daysweek despite the same maximum tolerated dose of CUDC101 being administered in each arm",
        "label": "Contradiction"
    },
    "72c54a84-aa51-4250-ba38-3646a07391b9": {
        "text_answer": "Contradiction The evidence does not mention tumour lysis syndrome in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "ab957edd-8a87-49e2-a7cf-0a55fb30c54f": {
        "text_answer": "Entailment for MM111 intervention the method of administration dosage or schedule is not specified in the evidence provided",
        "label": "Entailment"
    },
    "884486ed-0e11-41be-9792-d2765bd977a2": {
        "text_answer": "Entailment for both Results 1 and 2  Explanation The statement every individual in the first cohort of the primary clinical trial experienced some form of adverse event is an entailment based on the evidence provided This is because the evidence clearly states that all participants in both Results 1 and 2 experienced adverse events which can be either serious or nonserious according to the definition provided Therefore the statement that every",
        "label": "Entailment"
    },
    "a77a5845-0747-4291-b6de-4903e453ae6a": {
        "text_answer": "Contradiction The primary trial recorded 0 adverse events while the secondary trial recorded 12 adverse events but the statement requires a greater number in the secondary trial",
        "label": "Contradiction"
    },
    "19738717-25bb-443f-8c7f-050bbc0c7a06": {
        "text_answer": "Contradiction The primary trial measures tumor response using RECIST criteria but it does not mention anything about Ki67 expression The secondary trial does not measure Ki67 expression in tumors",
        "label": "Contradiction"
    },
    "dfea11ab-1a3f-4a76-9fae-96d486f76e10": {
        "text_answer": "Entailment The statement is a more specific version of the exclusion criteria listed in the evidence",
        "label": "Entailment"
    },
    "bffa5810-1ace-45e0-bf6d-6a3d35d6d4d7": {
        "text_answer": "Entailment The evidence provided does not mention the use of xrays CT scans or MRIs as part of the interventions in either the primary or secondary trials",
        "label": "Entailment"
    },
    "264b1943-377e-4466-ad48-b4ba143f6bdb": {
        "text_answer": "Contradiction as the statement does not relate to the adverse events in the trials",
        "label": "Contradiction"
    },
    "a6dad239-adab-48d2-b63a-0325c718ddf9": {
        "text_answer": "Contradiction The statement is incorrect as asthma was not mentioned in the evidence provided for either the primary or secondary clinical trials The most common adverse events mentioned in the primary trial were syncope and dyspnea each occurring in 1667 of patients In the secondary trial no adverse events were reported",
        "label": "Contradiction"
    },
    "2f813222-a2b6-488e-96e6-f1a3d8713550": {
        "text_answer": "Contradiction  Explanation The evidence states that there were 24 participants with treatmentemergent adverse events and 11 participants with serious adverse events in the Sunitinib  Docetaxel  Trastuzumab arm of the primary trial The statement however claims that a total of 35 patients suffered a treatmentemergent adverse event This is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "2b58a234-e92e-475b-a0c9-a947776bf332": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial allows the use of antineoplastic chemotherapy with the exception of antiHER2 agents and estrogensprogestogens but only if the patient has been on a constant dose for at least 28 days and is not expected to stop the medication during the study period",
        "label": "Contradiction"
    },
    "c179c437-ffe9-4120-9390-58d88fb596f3": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the interventions for breast cancer and ovarianperitoneal cancer have different dosing regimens",
        "label": "Contradiction"
    },
    "ce185781-5c8f-4849-b96c-734228f2a323": {
        "text_answer": "Irrelevant The statement does not relate to the inclusion or exclusion criteria provided in the evidence for either trial",
        "label": "Entailment"
    },
    "2717fbc9-ffe5-419f-8c2d-ac9505f7cd01": {
        "text_answer": "Contradiction  Explanation  The primary trial requires the provision of written informed consent as an inclusion criterion while the secondary trial does not mention this requirement in its inclusion or exclusion criteria Therefore the statement that the two trials do not share any inclusion or exclusion criteria including the requirement to provide written informed consent is a contradiction of the evidence",
        "label": "Contradiction"
    },
    "1f77bf31-ae19-4adc-9af1-4c982718bbf6": {
        "text_answer": "Contradiction  Explanation  In the primary trial the treatment cycles are defined as 21 days and the administration of PF05212384 and docetaxel is specified for each cycle Therefore the statement no cycle is applied to the intervention is a contradiction to the evidence  In contrast the secondary trial does not mention the length of the treatment cycles explicitly but it does mention that",
        "label": "Contradiction"
    },
    "1672004b-d668-4441-95b4-eaab6fd70818": {
        "text_answer": "  Contradiction   The primary trial requires a minimum ANC of 1800 cellsmm3 and a minimum platelet count of 60000 cellsmm3 while the statement describes an ANC of 1807 x 106µl and a platelet count of 79 x 104µl which do not meet the",
        "label": "Contradiction"
    },
    "91afbc39-fae6-483e-8b8d-dc4ce8d0ea5c": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the longest PFS in the primary trial was 35 months for CDX011 and 32 months for Capecitabine which are both shorter than 7 months",
        "label": "Contradiction"
    },
    "dbe6803f-8c85-45d2-a9b8-1bbd0e772733": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence as both interventions involve the injection of the same amount 04 to 10 mCi of radioactive Tc99M sulfur colloid",
        "label": "Contradiction"
    },
    "12279abc-fae3-49d8-ac68-95ed47f4de12": {
        "text_answer": "Contradiction The evidence shows that no serious adverse reactions were reported in the primary trial at all while the secondary trial reported some serious adverse reactions but no specific numbers were given Therefore it cannot be determined that the primary trial reported more frequent serious adverse reactions based on the given evidence",
        "label": "Contradiction"
    },
    "df141af2-f34d-4e16-aee3-72c015ccc995": {
        "text_answer": "Entailment The evidence shows that all 5 participants in the placebo group experienced no emesis which is a stronger statement than the statement that none of them experienced emesis",
        "label": "Entailment"
    },
    "0dfa4e06-e226-4d46-be1f-90249c1f34d4": {
        "text_answer": "Contradiction The primary trial did not report any cases of chest pain while the secondary trial did not report any cases of chest pain either Therefore it is a contradiction to state that a higher number of patients in the secondary clinical trial were documented to have chest pain compared to those in the primary clinical trial",
        "label": "Contradiction"
    },
    "44ccb908-9444-4137-a227-c47b65207de7": {
        "text_answer": "Contradiction  Explanation The evidence provided shows that in the primary trial 132 313 patients experienced an infection and in the secondary trial 2112 179 patients experienced an infection The total number of patients in both trials is 32  112  144 Therefore the total number of patients who experienced an infection is 313",
        "label": "Contradiction"
    },
    "3e7895ff-0e1a-40d9-830d-bab9c5b59706": {
        "text_answer": "Contradiction  Explanation  The primary trial involves participants receiving a combination of various drugs doxorubicin hydrochloride cyclophosphamide paclitaxel filgrastim capecitabine methotrexate vinorelbine tartrate trastuzumab tamoxifen citrate and letrozole and undergoing surgery  The secondary trial",
        "label": "Contradiction"
    },
    "172e14bc-4f23-4d47-9e94-1d65291ef090": {
        "text_answer": "Contradiction  Explanation  The primary trial includes women with carcinoma of the breast undergoing lumpectomy partial mastectomy procedure while the secondary trial includes patients undergoing immediate tissue expander reconstruction following mastectomy or skinsparing mastectomy utilizing bioprosthetic mesh Although the primary trial does not explicitly mention the type of breast reconstruction it does not exclude patients based on their intention to undergo impl",
        "label": "Contradiction"
    },
    "21f268fa-899c-43ab-a7c2-78c0f940f014": {
        "text_answer": "Entailment The statement correctly identifies that the difference between the two interventions is the dose of durvalumab in the biweekly IV infusions",
        "label": "Entailment"
    },
    "448d6b4e-e05a-4971-9aea-cabeb8ce2c00": {
        "text_answer": "Contradiction The primary clinical trial is for patients with unilateral breast cancer and upper extremity lymphedema not for individuals with bilateral noncancerous breast lesions",
        "label": "Contradiction"
    },
    "bae24418-25bc-4334-be92-d7f341ac3f14": {
        "text_answer": "Entailment The primary trial includes patients with ER positive PR positive or HER2neu negative stage 4 breast adenocarcinoma and the secondary trial also includes these patients The statement that rivoglitazone is an antidiabetic agent does not contradict the eligibility criteria for either trial",
        "label": "Entailment"
    },
    "d6cc1a08-fbff-4ef1-b44f-6bc1b1ed0ef2": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as there are no instances of palpitations pericardial effusions or abdominal pains documented in the secondary clinical trial while there are instances of these conditions in the primary trial",
        "label": "Contradiction"
    },
    "4763223f-0ecd-4d19-a9ee-d466648ce4ea": {
        "text_answer": "Contradiction The statement does not account for the difference in paclitaxel dosages between the two cohorts",
        "label": "Contradiction"
    },
    "2771bac1-0b7c-4049-9971-6c3129efb634": {
        "text_answer": "Contradiction  The evidence provided does not mention anything about patients receiving fentanyl sublingual spray during radiation therapy",
        "label": "Contradiction"
    },
    "d9682530-105c-4e04-a26b-5d5985aac260": {
        "text_answer": "Contradiction  Explanation  The statement stage 4 cancer patients are excluded from the secondary clinical trial but may participate in the primary clinical trial is a contradiction based on the provided evidence According to the evidence stage IV breast cancer patients are explicitly excluded from both the primary and secondary clinical trials Therefore the statement is incorrect as it suggests that stage IV patients can participate in the secondary trial which is not the case",
        "label": "Contradiction"
    },
    "28e1ae2b-668d-48c5-a17b-169460475af0": {
        "text_answer": "Entailment The evidence mentions that the participants received a vaccine using a biopath nanoparticle delivery system The statement in question also mentions the administration of the biopath nanoparticle delivery system so it is an entailment",
        "label": "Entailment"
    },
    "f00c0288-b56a-45b4-9908-1c679e5043e8": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 patients receive 1 mgkg of MCS110 every 3 weeks which is less than 30 mg every 4 weeks In Intervention 2 patients receive 3 mgkg of MCS110 every 3 weeks which is more than 30 mg every 4 weeks but it does not meet the requirement of over ",
        "label": "Contradiction"
    },
    "13311b5b-36d8-455d-bf27-8a5adf1c913e": {
        "text_answer": "Contradiction The statement is a contradiction because the secondary trial does have uniform inclusionexclusion specifications for all participants but the primary trial does not as it has different sets of eligibility norms for its different study cohorts",
        "label": "Contradiction"
    },
    "6938fd4c-78be-4e24-b385-835d2be9f3c1": {
        "text_answer": "Contradiction  The evidence states that there were 16 participants with pCR in Arm 1 and 14 participants with pCR in Arm 2 making a total of 30 participants However the statement suggests that there were more than 42 patients with pCR which is not supported by the evidence",
        "label": "Contradiction"
    },
    "56bdbd86-0233-4eb9-bc63-0199e196966b": {
        "text_answer": "Contradiction  The evidence states that 9 out of 21 participants had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products This is a contradiction to the statement that less than 087 of the participants had a reduction in circulating tumor cells",
        "label": "Contradiction"
    },
    "adb18104-31a9-4eef-817b-0ab742bd4093": {
        "text_answer": "Contradiction The statement goes beyond the evidence which only provides information on the change in lean body mass at 4 months and does not provide any information on the change over a 10year period",
        "label": "Contradiction"
    },
    "20ee9640-9334-41a2-b8aa-62cc27aeab70": {
        "text_answer": "Contradiction The primary trial does not involve ALT801",
        "label": "Contradiction"
    },
    "ff78e7a6-b997-49b3-be7f-2604a1e00308": {
        "text_answer": "Contradiction Arimidex is not mentioned in the evidence for the secondary trial",
        "label": "Contradiction"
    },
    "076f0bbd-6b10-44e1-a7c6-9853d9457509": {
        "text_answer": "Contradiction The statement specify another form of birth control that was used is not mentioned in the evidence regarding the primary trial of SunitinibCapecitabine",
        "label": "Contradiction"
    },
    "b79be25a-c0ac-442e-adaf-821e42a3349b": {
        "text_answer": "Contradiction The statement is not related to the given evidence as it discusses a completely different type of neoplasm benign ciliary body neoplasm and the eligibility criteria for morbidly obese patients in the context of breast cancer trials",
        "label": "Contradiction"
    },
    "be30d480-b4d8-4768-8244-3a3d267418d2": {
        "text_answer": "Contradiction The secondary trial does not mention any agespecific inclusion criteria",
        "label": "Contradiction"
    },
    "4d1b524f-e8d8-4444-bc99-6631e049fde8": {
        "text_answer": "Neutral The evidence does not provide enough information to determine if the statement is an entailment or a contradiction  Explanation The statement hispanic patients without any state residence restrictions can take part in the primary clinical trial is neutral with respect to the provided evidence The evidence only specifies inclusion and exclusion criteria related to the type of cancer disease status prior therapy laboratory values and other health conditions It does not mention any restrictions based",
        "label": "Entailment"
    },
    "3ab9a40f-bbd8-43ed-a468-7fdbe3d9ce19": {
        "text_answer": "Entailment The primary trial results do not report any discernible pattern for expression of the set of 40 evaluated genes in either the Normal Vitamin D Levels or the Lownormal Vitamin D Levels groups",
        "label": "Entailment"
    },
    "ddee09ab-2af9-4c93-a64e-58371896a08e": {
        "text_answer": "Entailment  Explanation The statement cohort 1 of the primary clinical trial receives twice the dose of alt801 compared to cohort 2 is an entailment based on the evidence provided The evidence states that cohort 1 received a dose of 0015 mgkgdose while cohort 2 received a dose of 0040 mgkgd",
        "label": "Entailment"
    },
    "93118a13-cb16-4c4d-8f7a-ad0cb815e179": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided as the statement is about a DNA sequencing strategy and does not mention any adverse events or cohorts from the evidence",
        "label": "Contradiction"
    },
    "4eb2221b-a478-4b64-bed8-230e4eab958d": {
        "text_answer": "Contradiction The evidence shows that the total adverse events in the primary trial were less than 20 571",
        "label": "Contradiction"
    },
    "49e76af6-53c7-458d-a091-0aa8edf2f2aa": {
        "text_answer": "Contradiction  The statement is not entailed by the evidence as the evidence does not provide information about the difference in percentage of participants demonstrating a decrease in the growth factor signature between the two groups The evidence only reports the percentage of participants in each group that demonstrated a decrease in the growth factor signature",
        "label": "Contradiction"
    },
    "c4a67b84-c8c7-4922-a5fb-5fb9a1a3160a": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the provided evidence  Explanation The statement does not directly relate to the interventions administered in the primary and secondary trials The statement is about the type of follicular lymphoma and the fact that both trials administer their interventions orally The trials interventions are not mentioned to be related to follicular lymphoma or its grade",
        "label": "Entailment"
    },
    "4e832d71-c3c2-4209-9a57-8bd40ed3b08a": {
        "text_answer": "Contradiction The primary trial does not involve alisertib while the secondary trial does",
        "label": "Contradiction"
    },
    "4a06c463-8c8b-454e-9664-bac7871cbb95": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial measures the percentage of participants with any treatmentemergent adverse events TEAEs and serious TEAEs in different populations The secondary clinical trial measures the number of participants with objective response to talazoparib treatment  Although the outcome measures are different they are not completely different as they both relate to the clinical trial participants and their responses to treatment The primary trial measures",
        "label": "Contradiction"
    },
    "adf1424b-3b15-478f-acab-72d4217db886": {
        "text_answer": "Contradiction The statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "31ad3c14-faaa-42e1-93aa-d9f9b8687cae": {
        "text_answer": "Contradiction The primary trial does not evaluate the percentage of participants with adverse events of primary interest related to osteitis fibrosa cystica as it focuses on toxicity assessment using NCI Common Terminology Criteria for Adverse Events CTCAE v30 The secondary trial evaluates the percentage of participants with adverse events of primary interest related to trastuzumab emtansine hepatic events allergic reactions",
        "label": "Contradiction"
    },
    "396273f3-1e8f-4aa7-a50e-4c36c243748b": {
        "text_answer": "Contradiction  Explanation The statement over 320 of patients in the primary trial and the secondary trial suffered from infections during the study period is a contradiction to the evidence because the evidence shows that there were a total of 2 infections in the primary trial out of 32 patients 625 and 3 infections in the secondary trial out of 15 patients 2000 Therefore",
        "label": "Contradiction"
    },
    "50171a05-0f3d-434e-a43d-9310a845fa3f": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not provide any information about the occurrence of childhood brain anaplastic astrocytoma or pericardial effusions or corneal deposits in the trials",
        "label": "Contradiction"
    },
    "c8a83ca7-bc34-4afe-9323-7439ed841bca": {
        "text_answer": "Entailment The statement more than 42 patients across both batches of the primary clinical trial demonstrated a pathologic complete response in breast and axillary lymph nodes is an entailment of the evidence provided as the evidence states that 16 participants in Arm 1 and 14 participants in Arm 2 achieved a pCR totaling 30 participants across both arms which is more than 42 when considering that the statement allows",
        "label": "Entailment"
    },
    "0a266c52-2a4e-4aed-a04c-85c148f2cd41": {
        "text_answer": "Contradiction The evidence shows that a lower percentage of participants in the Bevacizumab  Capecitabine cohort experienced disease progression or death compared to the Bevacizumab cohort 758 vs 883 Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "c67afffa-bf41-4562-bf5e-1ba035fe653c": {
        "text_answer": "Contradiction  Explanation The statement biliary colic and clostridium difficile colitis are less prevalent in the secondary trial compared to the primary trial is a contradiction based on the evidence provided The evidence shows that biliary colic was present in 166 152 of patients in the secondary trial while it was present in 4122 328 in the",
        "label": "Contradiction"
    },
    "7b860f15-132f-423e-ac6d-1c73f7a2d0d5": {
        "text_answer": "Contradiction  The primary trial uses pregabalin 150mg twice daily for a total of 300mg daily not 200mg biweekly Additionally the secondary trial uses Depocyt liposomal cytarabine and HDMTX which are not mentioned in the statement",
        "label": "Contradiction"
    },
    "fba4a92c-e18b-4029-b3bd-4b967db7faa1": {
        "text_answer": "Contradiction The evidence mentions niraparib not talazoparib",
        "label": "Contradiction"
    },
    "3cbea791-dc12-4c0e-b672-031b43c49bf2": {
        "text_answer": "Contradiction The statement has no relation to the provided evidence",
        "label": "Contradiction"
    },
    "50b6f969-8637-47a1-ab63-9067b009bd2c": {
        "text_answer": "Contradiction The evidence does not mention anything about fentanyl spray being administered during radiation therapy in the primary trial",
        "label": "Contradiction"
    },
    "aca44925-657c-47d1-9325-f3933deee650": {
        "text_answer": "Entailment The evidence states that cohort 1 had 0 adverse events which implies that neither cohort 1 nor cohort 2 reported any adverse events The statement is an entailment of the evidence",
        "label": "Entailment"
    },
    "f074cadc-99e3-4603-8095-aa09822d174d": {
        "text_answer": "Contradiction The primary trial measures the number of participants with treatmentemergent adverse events not the average time a patient spends sleeping",
        "label": "Contradiction"
    },
    "6146e7c3-2c76-4881-88bd-1c547c9f732a": {
        "text_answer": "Contradiction The evidence states that participants received niraparib 200 mg daily not talazoparib 1000 mg",
        "label": "Contradiction"
    },
    "cc411bc6-900e-4ef3-96ef-09f6e5565a18": {
        "text_answer": "Contradiction The primary trial explicitly excludes children but the secondary trial does not have an explicit inclusion or exclusion criterion for children",
        "label": "Contradiction"
    },
    "9b50ab6a-abe0-4082-8ebc-0cc297945062": {
        "text_answer": "Contradiction The evidence clearly states that laserassisted fluorescence angiography Spy Elite LifeCell is used in the primary clinical trial for perfusion monitoring in both intervention groups",
        "label": "Contradiction"
    },
    "964f8275-1095-4d48-953d-8d77152cecb8": {
        "text_answer": "Contradiction The evidence states that participants in both interventions receive less than 10 mCi of 18FFPPRGD2 but it does not guarantee that all groups receive equal doses",
        "label": "Contradiction"
    },
    "2ceabe21-98c6-44e3-9cb2-03d3e73124a7": {
        "text_answer": "Contradiction The primary trial excludes smokers while the secondary trial does not mention smoking as a criterion However the secondary trial does mention alcohol consumption as a criterion",
        "label": "Contradiction"
    },
    "47485ca0-43cb-4525-9417-a8222961e1cd": {
        "text_answer": "Entailment given that the evidence does not report any cases of swelling hypothermia or confusion in either trial",
        "label": "Entailment"
    },
    "1ee86f9f-6119-4cce-a036-324aea1fb251": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the administration of denosumab which is a medication while the secondary trial involves the administration of radioactive Tc99M sulfur colloid which is a different type of substance used for lymphoscintigraphy The statement incorrectly combines two different interventions denosumab and radioactive Tc99M sulfur colloid and incorrect",
        "label": "Contradiction"
    },
    "1d8450d1-ac32-4f98-ac75-1d6e212b0879": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial had no recorded adverse events and the secondary trial had none in the provided data The statement implies that the secondary trial had more adverse events than the primary trial but the evidence does not support this claim",
        "label": "Contradiction"
    },
    "9c180516-eca4-490b-b661-b47c625e3ab9": {
        "text_answer": "Entailment  Explanation The statement within the adverse events of both the primary and secondary clinical trials only one fatality was documented is an entailment based on the evidence provided The evidence shows that in the primary trial there was one fatality not otherwise specified documented in Adverse Events 1 and 0 fatalities in Adverse Events 2 In the secondary trial there was one fatality not otherwise specified",
        "label": "Entailment"
    },
    "2df3c784-8e32-4d92-9770-63087b7c7f62": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement does not directly relate to the information provided in the evidence The evidence describes the interventions and treatment schedules for two different cohorts in a primary trial but it does not provide any information about the ability of participants to get up from kneeling",
        "label": "Entailment"
    },
    "100d5efd-de88-4127-b6c1-cb870fff9e82": {
        "text_answer": "Contradiction The statement is not related to the evidence provided as the evidence only reports adverse event frequencies and does not mention anything about the extent of hyperperfusion",
        "label": "Contradiction"
    },
    "038bc748-0ea5-4d83-b799-b986177f9dbf": {
        "text_answer": "Contradiction  Explanation  In the primary trial only one intervention Intervention 2 includes Armodafinil and the dosage varies In contrast the secondary trial does not involve Armodafinil at all  Regarding the second part of the statement in the secondary trial there are two interventions and each intervention has different dosages for MCS110 Therefore it is not accurate to",
        "label": "Contradiction"
    },
    "63a60028-ee0a-4f47-a8f2-b5edf081579a": {
        "text_answer": "Contradiction The primary trial excludes patients with significant cardiovascular impairment including congestive heart failure clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the last 6 months andor a current ECG tracing that is abnormal in the opinion of the treating Investigator or unstable angina QTc prolongation 480 msec Bazetts",
        "label": "Contradiction"
    },
    "b11dea7c-ef4b-4042-9267-40934719c44e": {
        "text_answer": "Contradiction The primary trial reported no anaemia cases while the statement claims that anaemia was the most prevalent negative reaction in the secondary trial with over 5 of participants",
        "label": "Contradiction"
    },
    "a56ade78-3385-4789-b86a-3aef67188d2c": {
        "text_answer": "Neutral The statement is not directly related to the evidence",
        "label": "Entailment"
    },
    "ad271913-e4a5-4a4a-9b0a-d3ae24415a54": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence states that the trabectedin intervention was administered intravenously not orally",
        "label": "Contradiction"
    },
    "bb01dea7-5b49-41b7-997b-70cc1e980226": {
        "text_answer": "Contradiction  Explanation The statement does not follow from the evidence as the evidence does not provide information about the cognitive function of patients with atypical carcinoid tumors in the primary trial The statement is about a different type of tumor and does not relate to the cognitive function data presented in the evidence",
        "label": "Contradiction"
    },
    "776b3152-7fa5-480d-8235-cd6e472bf0a6": {
        "text_answer": "Contradiction  Explanation The statement adverse events were not reported in the primary clinical trial is not consistent with the evidence from the primary trial which states that there were no reported adverse events However the statement any recorded adverse event had an impact on less than 30 of patients excluding skin infections is consistent with the evidence from the secondary trial Therefore the statement is a contradiction as it contains two parts",
        "label": "Contradiction"
    },
    "5099ee2b-f5ea-47be-ba1e-ce2e4462a0c5": {
        "text_answer": "Contradiction The statement is incorrect as patients with NUT midline carcinoma determined by fluorescence In situ hybridization are eligible for the primary trial but patients with inflammatory breast cancer are excluded from both the primary and secondary trials",
        "label": "Contradiction"
    },
    "37257ef8-1772-4b94-9bb9-0433a83b83fe": {
        "text_answer": "Contradiction The statement is contradictory because patients with malignant ductal carcinina in situ and uncontrolled hypertension are excluded from both the primary and secondary trials according to the provided evidence",
        "label": "Contradiction"
    },
    "e50a24aa-fbee-4cf7-b91b-661c5173c787": {
        "text_answer": "Contradiction The statement has no relation to the given evidence The evidence only discusses inclusion and exclusion criteria for the primary and secondary trials and there is no mention of smoking status for the tsukamurellaceae taxonomic family",
        "label": "Contradiction"
    },
    "25cbaa44-4715-417b-9bd0-12fef06053b8": {
        "text_answer": "Contradiction The evidence states that there were 2 patients with adverse events in the primary trial which is more than 10 if less than 10 patients are assumed to have suffered adverse events",
        "label": "Contradiction"
    },
    "146a72f6-cba2-4056-94a2-21d2e05ac04e": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence only reports one case of increased pleural effusion in cohort 2 which is 25 of the total number of patients in that cohort but it does not necessarily mean that 25 of all cohort 2 patients suffered from increased pleural effusion",
        "label": "Contradiction"
    },
    "2cf5335c-74b8-4122-bf27-caf0cdf94b8a": {
        "text_answer": "Contradiction  The evidence provided does not include data on the number of treatment emergent adverse events and serious treatment emergent adverse events for each group Therefore it is not possible to determine if the statement is an entailment or a contradiction based on the evidence alone",
        "label": "Contradiction"
    },
    "6432c266-a7b8-4cda-b5b8-7fd13cb023fb": {
        "text_answer": "Contradiction  The primary trial and the secondary trial are about different studies and the statement compares the results of the two trials which are not directly related to each other The primary trial is about the diagnostic accuracy of two algorithms in breast cancer diagnosis while the secondary trial is about the effect of reflexology on fatigue levels in breast cancer patients undergoing radiation therapy",
        "label": "Contradiction"
    },
    "8d1ad83d-8298-46fe-971d-3fadc862bd5e": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher ORR compared to the Paclitaxel Plus Bevacizumab group",
        "label": "Contradiction"
    },
    "a378ea56-7b9b-4ee9-b304-ff9597744fb7": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "1060fd94-b24c-43cb-884e-b10f70e0ea23": {
        "text_answer": "Contradiction The statement mentions picalm gene rearrangement but the evidence does not mention this specific molecular abnormality as a criterion for exclusion from the primary trial The statement contradicts the evidence by implying that the presence of unmeasurable metastasis or nonspread of cancer to other parts of the body is related to picalm gene rearrangement which is not the case according to the provided evidence",
        "label": "Contradiction"
    },
    "1c13e304-89af-4ef5-95c6-cabc803d81b8": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the two intervention groups in the primary trial have different patient populations cancer patients vs healthy volunteers",
        "label": "Contradiction"
    },
    "65f90fcc-a7ce-4d52-b010-b8e482c02f9c": {
        "text_answer": "Entailment assuming no serious adverse events were reported in Results 1  Explanation The statement lifethreatening adverse events were absent in the first cohort of the primary clinical trial is an entailment based on the evidence provided assuming that no serious adverse events were reported in Results 1 The evidence states that there were no participants with grade 5 adverse events lifethreatening consequences in the",
        "label": "Entailment"
    },
    "ef2af81d-e19c-49c9-8ff0-309b87eb6f38": {
        "text_answer": "Contradiction The evidence states that there is one adverse event recorded but the statement implies that there is only one type of adverse event recorded",
        "label": "Contradiction"
    },
    "47d5620b-1b48-4a55-920f-35879c6e85eb": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence clearly states that all patients in the primary clinical trial received doses of doxorubicin cyclophosphamide and docetaxel",
        "label": "Contradiction"
    },
    "b0b78244-40a7-46d4-888d-1ccfe70d3645": {
        "text_answer": "Entailment The evidence states that the frequency of administration of docetaxel doxorubicin and cyclophosphamide is different between the two cohorts in the primary clinical trial",
        "label": "Entailment"
    },
    "840c7b65-e801-4dec-b9dd-b97680e5e3ba": {
        "text_answer": "Contradiction The primary clinical trial is not applying immunooncology techniques but rather using hormone therapy Estring and Testosterone Cream The secondary clinical trial is using chemotherapy FEC paclitaxel and epirubicin hydrochloride",
        "label": "Contradiction"
    },
    "577c7755-64ae-4b78-bbe3-627cef6e3ece": {
        "text_answer": "Contradiction  Explanation The statement More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery is a contradiction to the evidence provided The evidence shows that a total of 84 participants were analyzed in the trial with 16 participants in Arm 1 and 381 or",
        "label": "Contradiction"
    },
    "ffa844c8-752d-48df-aa7a-e0ba58305b12": {
        "text_answer": "Contradiction  Explanation  The statement ret gene translocation is a cytogenetic abnormality that refers to any translocation involving the ret gene Any cancer patient diagnosed with either Epilepsy thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial is a contradiction based on the provided evidence  The primary trial has an exclusion criterion for epilepsy",
        "label": "Contradiction"
    },
    "012a3705-05f7-4a26-adf2-1ae4244bd576": {
        "text_answer": "Contradiction  The primary trial uses oral pregabalin while the secondary trial uses intrathecal Liposomal Cytarabine Depocyt and HighDose Methotrexate HDMTX There is no mention of oral pregabalin being used in the secondary trial in the given statement",
        "label": "Contradiction"
    },
    "18d3b58f-42ca-4178-adb6-4a5f0c9fafde": {
        "text_answer": "Contradiction assuming the worst pain imaginable is a score of 10 on the numeric rating scale  Explanation The evidence does not provide information on the number or percentage of patients in either group who experienced the worst pain imaginable a score of 10 for 10 weeks Therefore it is impossible to determine if the statement is an entailment or contradiction based on the given evidence alone However the evidence does show",
        "label": "Contradiction"
    },
    "fd88904b-8a23-46ad-b337-3c7eef4e7bef": {
        "text_answer": "Contradiction The statement is a contradiction because patients with a history of pulmonary embolisms are excluded from the secondary trial but patients with breast implants are excluded from the primary trial",
        "label": "Contradiction"
    },
    "7a831a11-8edd-42ef-81e7-fd8bca5ca0cc": {
        "text_answer": "Entailment The statement that equal amounts of radiation therapy are provided to patients of cohort 1 and 2 is entailed by the evidence as both groups receive radiation therapy with the same dose range and schedule The statement about the SPECT scan is also entailed by the evidence as it is mentioned for both groups",
        "label": "Entailment"
    },
    "7e791f30-68d4-4a11-86e4-c2e88d737913": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of nausea in the primary trial Additionally the number of cases for Infection and Asymmetry is lower in the primary trial than stated in the statement",
        "label": "Contradiction"
    },
    "ff07ae9a-9106-443b-b584-a7522ec3f71d": {
        "text_answer": "Contradiction The primary trial does involve Suramin and Paclitaxel but the secondary trial does not mention any specific drugs being administered",
        "label": "Contradiction"
    },
    "1e47ae4a-c57b-47fa-9b85-1b15ebdbf1fc": {
        "text_answer": "Contradiction The statement is not an entailment as small cell adenocarcinoma is not a type of breast cancer and the age eligibility criteria for the two trials are different",
        "label": "Contradiction"
    },
    "871378d6-a6e5-461c-af83-d82fe8f44f4e": {
        "text_answer": "Contradiction The statement does not entail the evidence as it is not related to the inclusion or exclusion criteria for the primary trial The statement is about a genus of bacteria while the evidence pertains to the inclusion and exclusion criteria for a breast cancer clinical trial",
        "label": "Contradiction"
    },
    "3c06901b-29be-43be-8da7-c23d80cc4d89": {
        "text_answer": "Contradiction  The evidence shows that a lower percentage of participants in the bevacizumab  capecitabine cohort experienced disease progression or death compared to the bevacizumab monotherapy cohort",
        "label": "Contradiction"
    },
    "e115652e-6728-47a8-bc2e-1866a7c257ec": {
        "text_answer": "Entailment assuming that the primary trial mentioned in the evidence is the same as the one in the statement and that the trial did not involve any invasive operations or administration of neratinib for any of the cohorts",
        "label": "Entailment"
    },
    "2aa1c4f5-a46c-4004-9a8a-52e2ac476181": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as it is not mentioned in the evidence that lordosis was an adverse event in the primary trial",
        "label": "Contradiction"
    },
    "f0f8a0a6-1148-4592-a9b4-27c005038900": {
        "text_answer": "Entailment   Explanation The statement participants in the primary trial receive 4 different drugs throughout the study duration is an entailment of the evidence as the evidence clearly states that the neoadjuvant therapy consists of epirubicin cyclophosphamide docetaxel and trastuzumab",
        "label": "Entailment"
    },
    "b9f262d7-23e5-42d1-9020-0e516ce3505c": {
        "text_answer": "Contradiction The primary clinical trial employs hormonal approaches Estring Testosterone Cream as a form of intervention while the secondary clinical trial does not employ hormonal approaches as a form of intervention but rather tests the effectiveness of acupuncture",
        "label": "Contradiction"
    },
    "0b5e78d7-d717-41d0-98e5-564eda711bec": {
        "text_answer": "Contradiction The primary trial includes severe insomnia patients in the exclusion criteria but the secondary trial includes severe insomnia patients in the inclusion criteria with the Sleep Disruption Evaluation form or Insomnia Severity Index score of 3 or 8 respectively",
        "label": "Contradiction"
    },
    "d201eee8-33d1-4ae4-9540-b37fa07536e0": {
        "text_answer": "Entailment The statement people having extreme obesity can be accepted in the primary clinical trial is an entailment of the inclusion criteria which state that participants must have a BMI of 25 kgm2 or greater and weight 400 lbs",
        "label": "Entailment"
    },
    "d9d5a341-26ba-4f5d-a730-14561dea5c17": {
        "text_answer": "Irrelevant The statement does not relate to the adverse events listed in the evidence",
        "label": "Entailment"
    },
    "b9a1b80e-4c45-4a78-962b-13dfe98ab56c": {
        "text_answer": "Contradiction The primary trial reported 0 cases of acute myocardial infarction not 2 as stated in the question",
        "label": "Contradiction"
    },
    "c8bd9404-6d9c-4048-9d19-639aefd4ab08": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of potassium levels in the inclusion or exclusion criteria for the secondary trial",
        "label": "Contradiction"
    },
    "973b8d05-863f-4978-a197-bd08355b7834": {
        "text_answer": "Contradiction The primary and secondary trials involve different treatments and do not involve radiation therapy",
        "label": "Contradiction"
    },
    "0bc7c5c7-6e64-4eee-ba84-e2168d64a8ef": {
        "text_answer": "Contradiction The statement is incorrect as patients with NUT midline carcinoma as determined by fluorescence in situ hybridization are eligible for the primary trial but patients with inflammatory breast cancer are excluded from the secondary trial",
        "label": "Contradiction"
    },
    "4318ce37-10b6-4318-868e-f533a1fd000e": {
        "text_answer": "Entailment The statement is an entailment of the evidence as it accurately reflects the percentage of participants in the trial who developed imagable HER2 metastases",
        "label": "Entailment"
    },
    "d0bcf0db-e64d-4aff-a63b-ba3571ebfad4": {
        "text_answer": "Contradiction The primary trial does not mention anything about CBT Cognitive Behavioral Therapy treatments being prohibited The secondary trial does not mention anything about the type of cancer being cardiac diffuse large Bcell lymphoma",
        "label": "Contradiction"
    },
    "e0c92d00-132b-4e76-ba59-2fa14e67bf53": {
        "text_answer": "Entailment The evidence does not provide a specific number for adverse events but it does state that treatment repeats in the absence of unacceptable toxicity indicating that adverse events were indeed a common occurrence",
        "label": "Entailment"
    },
    "c39031be-e4dd-4943-a3fe-97164ac7a5e9": {
        "text_answer": "Contradiction The secondary trial involves a combination of ibrutinib and MEDI4736 not protonbeam therapy and capecitabine",
        "label": "Contradiction"
    },
    "1bf99d45-84a7-41cb-8263-d1ccb489bc66": {
        "text_answer": "Contradiction   Explanation The statement is a contradiction because according to the evidence there was an occurrence of Eyelid oedema in the secondary trial but there were no reported adverse events in the primary trial However the statement claims that no adverse events were recorded in the primary trial at all",
        "label": "Contradiction"
    },
    "a7efab48-443a-4728-a4b5-0c837052aab7": {
        "text_answer": "Contradiction Perjeta pertuzumab is mentioned in the primary trial but not in the secondary trials treatment protocol However the statement in the question specifically mentions Perjeta while utilized in the primary trial is not a part of the secondary trials treatment protocol which is an entailment if the primary trial did not use Perjeta in the intervention that is being compared between the trials The evidence provided shows that Perj",
        "label": "Contradiction"
    },
    "e16eb398-b70e-42d2-90d5-d17172fda47f": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the interventions in the primary trial use different chemotherapy regimens and carboplatin and paraplatin are not the same drug",
        "label": "Contradiction"
    },
    "ce896357-cc87-4eb3-b588-61c1f99fc5f4": {
        "text_answer": "Contradiction  The evidence shows that patients in Arm I Cryotherapy had a lower median aAUCpa score 14 compared to patients in Arm II Control 44 indicating that patients in Arm I reported fewer symptoms on average Therefore the statement that patients in Arm I reported higher symptom severity is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "3d081c7c-10e8-490f-8943-260f27175c56": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the evidence states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial",
        "label": "Contradiction"
    },
    "54aa7f2d-b774-4530-ad47-3848ca093433": {
        "text_answer": "Contradiction  Explanation The primary trial and the secondary trial have different outcome measurements and different patient populations The primary trial measures the duration of neutropenia in days while the secondary trial measures the incidence of neutropenia as a number of participants Therefore it is not possible to directly compare the results of the two trials and make a statement about higher rates of neutropenia in one cohort compared to the other based on the",
        "label": "Contradiction"
    },
    "024c2c6d-e462-439c-baa2-a8639cd68d30": {
        "text_answer": "Contradiction   Explanation   The statement There were no patients with recorded AEs in the primary trial whereas every patient in the secondary trial suffered at least one adverse event is a contradiction based on the evidence provided   In the primary trial there were no recorded adverse events out of a total of 42 patients In contrast in the secondary trial every one of the six patients experienced at least one ad",
        "label": "Contradiction"
    },
    "d8e5f1e2-76e1-405a-9920-c21c7f105eb2": {
        "text_answer": "Contradiction  Explanation In the primary trial patients receive 2 mgkg of trastuzumab weekly throughout the treatment In contrast in the second trial patients in the second cohort receive Herceptin 4 mgkg IV infusion on Day 1 of Cycle 5 followed by Herceptin 2 mgkg by IV infusion weekly starting from Day 8 which is a different dosage reg",
        "label": "Contradiction"
    },
    "1ecd0f33-cffb-4c0e-917f-6ae5f8570183": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there were no cases of infection asymmetry or nausea reported in the secondary trial according to the provided data",
        "label": "Contradiction"
    },
    "c71fced3-2da3-4471-a72f-0dec2e7bbb02": {
        "text_answer": "Contradiction The statement is about alpha lipoic acid but the evidence provided is about necitumumab",
        "label": "Contradiction"
    },
    "decd387b-7da2-4f7b-8f32-4e009d9f6ee5": {
        "text_answer": "Contradiction The statement suggests that more than 3333 of patients in both cohorts experienced pCR but the actual percentages are 381 in Arm 1 and 333 in Arm 2 Therefore the statement is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "41b2eac1-36a4-4cd8-a163-c7ab7b3636ee": {
        "text_answer": "Contradiction  Explanation  The statement suggests that the primary trial candidates receive less weekly administration of MM121 and paclitaxel but more Herceptin trastuzumab and Docetaxel not mentioned in the evidence compared to the first cohort of the secondary trial However the evidence provided does not mention the dosage or administration frequency of Herceptin or Docetaxel in either trial",
        "label": "Contradiction"
    },
    "72d1b9c7-56d4-487c-8170-752c86b764ec": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial involves two interventions one of which is massage therapy and the other is notouch therapy Both interventions do not involve any drugbased treatments However the secondary clinical trial involves two interventions one of which is a drugbased treatment PF06647020 with two different dosages  Therefore the statement is a contradiction as the",
        "label": "Contradiction"
    },
    "ae1b63ed-25c5-484a-8221-3bee0af17594": {
        "text_answer": "Contradiction  Explanation The statement mentions two patients from the primary trial suffered an Incidence of Doselimiting Toxicity both from cohort 2 However the evidence provided only mentions the results of two arms of the primary trial neither of which have any information about the number of patients in cohort 2 who suffered from doselimiting toxicity Therefore the statement is a contradiction as it goes",
        "label": "Contradiction"
    },
    "365dc837-fcfb-49f6-8dc3-bb74a0f60507": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction to the evidence because  1 The primary trial involves the use of 12 different medications doxorubicin hydrochloride cyclophosphamide paclitaxel filgrastim capecitabine methotrexate vinorelbine tartrate trastuzumab tamoxifen citrate",
        "label": "Contradiction"
    },
    "517f5131-6807-4537-ae4c-308be1f98d17": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports the number of adverse events in each trial but it does not provide any information about the number of adverse events being more or less in one trial compared to the other The second part of the statement is not related to the evidence at all",
        "label": "Contradiction"
    },
    "ce29883b-654b-4124-ac60-40ff13cb9f3e": {
        "text_answer": "Contradiction The primary trial explicitly lists cefuroxime and nitrofurantoin as exclusion criteria while the secondary trial mentions no such exclusion for these drugs",
        "label": "Contradiction"
    },
    "4b9aeee6-6ad8-477a-a09a-15fd52c8fec8": {
        "text_answer": "Contradiction  Explanation  The statement suggests that candidates for the secondary trial receive 3 weekly subcutaneous injections while the primary trial participants only receive a single injection However the evidence provided for the primary trial indicates that all patients receive a single subcutaneous injection at the beginning of the study not 3 weekly injections Therefore the statement is a contradiction to the evidence presented",
        "label": "Contradiction"
    },
    "48206c2e-1f24-4248-8c06-bfac596dcaa5": {
        "text_answer": "Contradiction The primary trial includes a tissue expander intervention which is a surgical procedure but it does not mention arthroscopic surgery specifically However the statement excludes all surgical procedures including arthroscopic surgery from both trials",
        "label": "Contradiction"
    },
    "fdc63af9-e802-4ef7-8f6d-bec415bf2537": {
        "text_answer": "Contradiction The evidence does not provide information about the difference in recurrencefree survival percentage between the two groups",
        "label": "Contradiction"
    },
    "437fedde-1e69-4514-ac5f-d8d532497280": {
        "text_answer": "Contradiction The statement is not an entailment as Stomatitis is not mentioned in the evidence The evidence only states that Surgery was recorded as an adverse event with a frequency of 345",
        "label": "Contradiction"
    },
    "957f4300-757b-40ee-926c-3c7deae05ade": {
        "text_answer": "Entailment The statement is a specific case of the exclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "da5c1eb1-b093-45cf-b607-e40504be981b": {
        "text_answer": "Contradiction  Explanation  In the primary trial Armodafinil is given to one of the intervention groups but it is not mentioned that all intervention groups receive Armodafinil In contrast in the secondary trial PDR001 is given to all patients with a consistent dose of MCS110 but it is not mentioned that all patients receive the same dose of PDR001  Therefore",
        "label": "Contradiction"
    },
    "56f41ab4-6a20-4593-af47-b5cab9dabdd2": {
        "text_answer": "Contradiction  In the primary trial participants in both intervention groups receive injections at the beginning of the study but the number of injections and the medication are different In contrast in the secondary trial participants receive weekly injections for a total of 12 weeks which is not the same as daily injections for 6 days",
        "label": "Contradiction"
    },
    "35c16ab6-47c9-48ed-b92d-967b89df4869": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided The evidence does not mention anything about adverse events related to colon nonhodgkin lymphoma or syncope in the patient cohorts",
        "label": "Contradiction"
    },
    "4d702550-2f94-46be-92f2-ea6659c69ddb": {
        "text_answer": "Contradiction The evidence states that some patients receive a dose of 1 mgkg of MCS110 every 3 weeks which is less than 20 mg",
        "label": "Contradiction"
    },
    "490ea7b9-ad4e-4741-8dce-65a050f9a776": {
        "text_answer": "Contradiction  Explanation  The statement all participants in the primary clinical trial showed partial or no response by the 24th week is a contradiction to the evidence presented as the evidence shows that 4 participants had a partial response at both Week 12 and Week 24",
        "label": "Contradiction"
    },
    "20de5f49-227b-4d5f-9a4e-868354842985": {
        "text_answer": "Contradiction A quadrantectomy is a type of breast surgery that involves removing a entire quadrant onefourth of the breast tissue However neither the primary nor the secondary trial specifically mention quadrantectomy as an exclusion criterion Therefore a woman who has undergone a quadrantectomy can be eligible for both trials depending on whether she meets the other inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "55220fb9-bef7-4c72-bf60-982c0ec903e6": {
        "text_answer": "Entailment with the caveat that the woman meets the other inclusion criteria for each trial",
        "label": "Entailment"
    },
    "9bd55a1f-e5dc-4620-ba52-73b4bf792459": {
        "text_answer": "Contradiction The primary trial explicitly excludes individuals with a history of clotting disorders including pulmonary embolisms from participating Additionally individuals with breast implants are excluded from the primary trial Therefore the statement that individuals with a history of pulmonary embolisms and current breast implants are allowed to participate in the primary clinical trial is a contradiction to the trials inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "a9d72bc6-9396-4a8a-986a-e64587f02e9e": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as radiation therapy is indeed administered to patients in both cohorts of the primary clinical trial",
        "label": "Contradiction"
    },
    "74aebfd6-c201-4c6f-a7af-7e4e0de6b661": {
        "text_answer": "Contradiction  Explanation The statement The most common adverse event in the secondary trial was Anaemia there were no recorded AEs in the primary trial is a contradiction based on the evidence provided The evidence shows that there were no recorded adverse events at all in the primary trial while in the secondary trial Anaemia was not the most common adverse event but it was present with a frequency of 234",
        "label": "Contradiction"
    },
    "75cd8c4d-e0e6-4db0-8157-a76ac5bcf555": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement is asking if KRAS mutation analysis was performed but the evidence provided does not mention anything about KRAS mutations or their analysis Therefore the statement is neutral with respect to the evidence",
        "label": "Entailment"
    },
    "b52201dd-cbd7-4b92-8aae-3d8da980f4a1": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the dosage of denosumab in intervention 1 of the primary trial is 120 mg Q4W which is higher than the dosage of tamoxifen in intervention 1 of the secondary trial which is 10 mg once daily for 21 days per month approximately 35 mg per month",
        "label": "Contradiction"
    },
    "5a17f44e-b8ba-4598-96e3-992b0022b5ca": {
        "text_answer": "Contradiction The primary clinical trial involves the use of epirubicin cyclophosphamide docetaxel and trastuzumab which are pharmaceutical interventions",
        "label": "Contradiction"
    },
    "3559fa92-e0d7-4e4f-9b1f-7f087fbff0d1": {
        "text_answer": "Contradiction The evidence provided for the primary trial does not mention the use of xrays and CT scans as part of the procedural interventions The secondary trial mentions FFDM exam and DBT scan in the secondary trial but it is not mentioned in the primary trial",
        "label": "Contradiction"
    },
    "0433b29d-6509-420d-ba83-4ddcf8907e2b": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only mentions the number of adverse events in cohort 1 of the primary trial and the statement is about a mathematical concept unrelated to the trial data",
        "label": "Contradiction"
    },
    "ec5c7b6f-dfae-4681-9b8f-4f0b3635d232": {
        "text_answer": "Contradiction  Explanation The statement all patients in the primary trial receive at least 20mg of MCS110 every 3 weeks and over 130 mg of PDR001 every other week is a contradiction to the evidence provided The evidence states that in Intervention 1 patients receive 1 mgkg of MCS110 every 3 weeks which is less than 20",
        "label": "Contradiction"
    },
    "06ec7728-efe1-408c-afa8-a6b679a9cd57": {
        "text_answer": "Contradiction for MM111 intervention only  Explanation The statement details regarding the mode of administration dosage or cycle are absent in the intervention sector of the primary clinical trial is a contradiction for the MM111 intervention because the intervention description for MM111 does not provide any information about the mode of administration dosage or cycle However the statement is an entailment for",
        "label": "Contradiction"
    },
    "cffc1c21-5e4d-485a-a167-32841ff01f4c": {
        "text_answer": "Contradiction The statement explicitly mentions that there are no interventions involving Xrays transendocardial injections CT scans or MRIs in the primary or secondary trials However the evidence for the secondary trial includes interventions involving transendocardial injections",
        "label": "Contradiction"
    },
    "9dd13c76-10e0-4dd0-ad16-42d135f6c2c5": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there were no adverse events reported in Cohort 1 of the primary clinical trial",
        "label": "Contradiction"
    },
    "f6bfaa2d-0171-4bbe-a65c-0e3b217ac61f": {
        "text_answer": "Contradiction The primary trial intervention is not related to the intervention in the secondary trial",
        "label": "Contradiction"
    },
    "bf140d08-90da-4fb4-90da-b86a87b5bb07": {
        "text_answer": "Contradiction The primary trial does not mention any agespecific inclusionexclusion criteria while the secondary trial does not segregate its criteria into two age groups",
        "label": "Contradiction"
    },
    "8ee8670b-6200-4309-8fd6-545572945b7c": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports the number of participants who experienced treatmentemergent adverse events or serious adverse events in the Sunitinib  Docetaxel  Trastuzumab arm of the primary trial The statement about a fissure is unrelated to the trial results",
        "label": "Contradiction"
    },
    "64f9b5b3-cd20-4b90-94b5-14e08a9999f0": {
        "text_answer": "Contradiction The primary trial did not report any cases of chest pain while the secondary trial did not report chest pain as a common adverse event",
        "label": "Contradiction"
    },
    "f99f83b0-66dd-4c77-b422-113e0cb758bf": {
        "text_answer": "Contradiction  The evidence provided indicates that 417 of the participants in the Prevention Care Management PCM group had not received a cervical cancer screening before the intervention Therefore it is not the case that every one of the 61 cervical cancer patients in the initial cohort complied with their screenings before the intervention commenced",
        "label": "Contradiction"
    },
    "02addfef-d1b3-4e62-865c-aa0bd1ddfab4": {
        "text_answer": "Contradiction The primary and secondary trials have different inclusion criteria The statement mentions nothing related to the inclusion criteria of the trials",
        "label": "Contradiction"
    },
    "8cd22d45-e829-47df-8ae1-cb50a163fc27": {
        "text_answer": "Contradiction The primary trial involves the use of oral pregabalin while the secondary trial involves the use of intravenous highdose methotrexate and intrathecal liposomal cytarabine Depocyt",
        "label": "Contradiction"
    },
    "27950c75-7035-435a-a7df-6f7abd504d30": {
        "text_answer": "Contradiction The statement mentions cohort 1 of the primary trial is administered PR negative ER negative and HER which is not related to the given information in the evidence about cohort 1 being TripleNegative The evidence states that cohort 1 is Phase 2 TripleNegative but it does not mention PR ER or HER status The statement also mentions cohort ",
        "label": "Contradiction"
    },
    "eec36c42-c1fb-45c8-9db9-82f10f4f7af7": {
        "text_answer": "Contradiction The primary trial measures changes in pain intensity not BMD of the lumbar spine",
        "label": "Contradiction"
    },
    "902a36e5-a751-44c6-9844-465aaa0f1d75": {
        "text_answer": "Contradiction The evidence shows that no adverse events were reported in over 30 of participants in either trial",
        "label": "Contradiction"
    },
    "8f319cf4-ec84-4f34-a4d8-2af54adbaab9": {
        "text_answer": "Contradiction The statement does not relate to the evidence provided The evidence only reports the number of participants with adverse events in two different dosing groups of a primary trial for a vaccine and does not mention anything about SARS coronavirus 2 variant lineages or their relationship to the trial participants",
        "label": "Contradiction"
    },
    "0f42fd08-8cba-4861-a89c-bf898270ea29": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only mentions the interventions and the drugs used in each arm but it does not mention Paraplatin or its dose in the primary trial",
        "label": "Contradiction"
    },
    "5a378399-ff09-418f-8797-9e122617d8d6": {
        "text_answer": "Contradiction The statement contradicts the exclusion criteria in the evidence which states that there should be no history of significant psychiatric disorders",
        "label": "Contradiction"
    },
    "894b1c21-f4ab-4145-ac19-9f973184b5bd": {
        "text_answer": "Entailment Both trials use the same outcome measurement of tumor diameter or size although the primary trial reports the mean tumor diameter and the secondary trial reports the number of participants with solid tumor response based on RECIST 11 criteria",
        "label": "Entailment"
    },
    "097ca9f3-901b-4072-b2d5-2e36f5bfccf0": {
        "text_answer": "Contradiction The evidence states that the primary trial includes patients with various types of cancer but it does not specify that talazoparib is not part of the intervention",
        "label": "Contradiction"
    },
    "f27c4b19-1479-48ea-92a0-28da5256b7b8": {
        "text_answer": "Contradiction The primary trial does not mention any exclusion for cerebral metastases within the brainstem",
        "label": "Contradiction"
    },
    "6582c5f8-507a-459d-82e4-b0b8e80be34d": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not state that the 1000 mcgday dose is only used for breast cancer patients",
        "label": "Contradiction"
    },
    "17660aaf-9218-4119-b00c-f3b863718e97": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence shows that Cohort 1 received a lower dose of MM121 compared to Cohort 2 but the statement does not mention any difference in the doses of MM121 between the two cohorts Instead it only mentions the same dose of Cetuximab for both cohorts which is not supported",
        "label": "Contradiction"
    },
    "232cfca0-08b4-45e3-ac2a-01ce31ecb857": {
        "text_answer": "Contradiction The statement is not related to the information provided about the primary trial which focuses on the intervention and control groups receiving different approaches for endoflife care planning and radiotherapy respectively The statement mentions a gray commissure which is not mentioned or relevant to the trial",
        "label": "Contradiction"
    },
    "fa23fd31-c7c2-4887-a982-174f355a2035": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only mentions adverse events in the primary trial and none of them are related to pedal spasms",
        "label": "Contradiction"
    },
    "81521795-13b4-46d4-a03e-51ab823e9756": {
        "text_answer": "Entailment  Explanation The statement Both interventions in the primary trial include trastuzumab is an entailment because the evidence shows that one intervention Arm 1 includes Herceptin which is a form of trastuzumab and the other intervention Arm 2 includes Herceptin as well Therefore the statement that both interventions include trastuzumab is a logical consequence of the evidence provided",
        "label": "Entailment"
    },
    "0164b2f8-a87d-4bb8-8487-6eb1f65b9804": {
        "text_answer": "Contradiction The statement does not provide information about the number of patients with cervical cancer who had progression gvhd in the primary trial The statement only mentions the number of patients who were up to date for their cervical cancer screenings before the intervention",
        "label": "Contradiction"
    },
    "e0c8ebce-a242-4619-9e96-7a80e6d157dd": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the number of adverse events in the primary trial is 0 while the number in the secondary trial is 11",
        "label": "Contradiction"
    },
    "de91b720-a7f8-4c27-8182-f642de29ddee": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients who require use of coumarinderivative anticoagulants such as warfarin while the secondary trial permits lowdose warfarin less than or equal to 1 mgday for prophylactic or therapeutic use",
        "label": "Contradiction"
    },
    "91e178f6-c6ec-426d-8799-629c2f512038": {
        "text_answer": "Contradiction The evidence does not provide information about the difference in recurrencefree survival between the two groups only the percentage of participants achieving recurrencefree survival in each group",
        "label": "Contradiction"
    },
    "0aab1829-69a6-4db5-ae99-78b1f9c9cbc0": {
        "text_answer": "Irrelevant The statement does not relate to the given evidence The evidence only discusses the use of laserassisted fluorescence angiography and different incision types in the primary trial while the statement is about the Ann Arbor staging system for Tcell nonHodgkin lymphoma",
        "label": "Entailment"
    },
    "f83654b1-c44c-40eb-a7b1-91db95cb71f6": {
        "text_answer": "Contradiction  Explanation The statement does not follow from the evidence as the evidence does not provide any information about the frequency of recurrent malignancies Graftversushost disease Infection Altered mental status and Diffuse alveolar hemorrhage in the secondary trial in comparison to the primary trial The statement only mentions that atevirdine mesylate is a form of atevirdine used to treat a",
        "label": "Contradiction"
    },
    "a0294da5-368d-4341-9084-1d42b995be34": {
        "text_answer": "Entailment The evidence shows that no adverse events were documented for cohort 1 patients in the primary clinical trial which is exactly what the statement asserts",
        "label": "Entailment"
    },
    "079d70f0-b586-466d-aeb0-38f67273c1c6": {
        "text_answer": "Contradiction The primary trial measures patientreported symptoms on the MYMOP questionnaire which is not related to treatmentemergent adverse events The secondary trial measures the change in isothiocyanate in urine samples which is also not related to treatmentemergent adverse events",
        "label": "Contradiction"
    },
    "8ef9ed3d-ab31-4ef7-be9a-113b31e3ed2a": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation  The statement does not directly relate to the pCR rates or the comparison between the two trials The statement mentions qualityoflife assessment which is not mentioned in the evidence provided Therefore it cannot be determined as an entailment or contradiction based on the given evidence",
        "label": "Entailment"
    },
    "13d66853-9b8a-4d79-b0d9-884c8d744acd": {
        "text_answer": "Contradiction The statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "4cc838c3-caee-492c-8092-c74844d68cd1": {
        "text_answer": "Entailment Both trials require a certain performance status for eligibility but they use different scoring systems This does not contradict the statement as it only specifies that performance status is used in both trials",
        "label": "Entailment"
    },
    "51d7f113-1dba-48f0-9e5c-1f16bfcd5394": {
        "text_answer": "Contradiction The evidence states that there were three cases of hepatotoxicity while the statement claims there were zero cases",
        "label": "Contradiction"
    },
    "87c5ee7a-a65a-4633-9efc-b51e2956db27": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement does not make any claim about the number of participants in each arm of the trial and the evidence only provides the number of participants analyzed in each arm Therefore the statement is not an entailment or a contradiction based on the evidence",
        "label": "Entailment"
    },
    "21ae5802-04f7-4f06-86d6-9ee8ee9cdd84": {
        "text_answer": "Contradiction The primary trial does not have a requirement for Her2neu breast cancer",
        "label": "Contradiction"
    },
    "eef90c1d-1b9c-459e-a895-47b9012a8d1a": {
        "text_answer": "Contradiction The evidence does not mention anything about eating disorders in the primary clinical trial candidates",
        "label": "Contradiction"
    },
    "bcfd2c0f-411a-462a-acd8-7dcd6818c1c6": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the use of FMX and MM398 with specific dosing schedules and administration techniques while the secondary trial involves the use of lapatinib and paclitaxel with a different dosing schedule and administration technique Additionally the primary trial uses FMXMRI scans and preMM398 treatment biopsies while the secondary trial uses CT scans exclusively",
        "label": "Contradiction"
    },
    "2dc8c214-bbe5-49b7-a48e-0945fddcd9da": {
        "text_answer": "Entailment Both trials include the use of docetaxel in their interventions",
        "label": "Entailment"
    },
    "e41035c2-246d-43a1-b2d4-5ff9af1f789e": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events in cohort 1 while the statement suggests that there were 4 more patients with adverse events in cohort 1 than in cohort 2",
        "label": "Contradiction"
    },
    "f9ac9b4b-4033-416b-b66c-0ecf23a9a06c": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of mucositis oral epileptic seizures or thromboembolic events in the secondary trial",
        "label": "Contradiction"
    },
    "24e7fb4c-e279-4b61-8c7f-6dc6a09e8d55": {
        "text_answer": "Contradiction  Patients with malignant ductal carcinoma in situ are excluded from the primary trial but the statement does not specify whether they have controlled or uncontrolled hypertension Therefore it is possible for patients with malignant ductal carcinoma in situ and controlled hypertension to be eligible for the primary trial making the statement a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "a031053e-a514-4484-9624-bcddef1628d3": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there is no mention of counseling as a component of Intervention 1 or Intervention 2 in the provided evidence",
        "label": "Contradiction"
    },
    "4493c1ed-668a-44d4-9b3e-767f597d4fa8": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of Asthenia or Pyrexia in the provided adverse events data",
        "label": "Contradiction"
    },
    "42f1e6c1-7775-4513-b810-a5559fcf60be": {
        "text_answer": "Contradiction The evidence states that patients with a history of interstitial lung disease or pneumonitis are excluded from the primary trial The statement describes a patient with a diagnosis of ILDDPLD within the last 3 years which falls under the category of interstitial lung disease Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "260b2917-54c5-43db-8beb-50f4e1bad69c": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because Cohort 2 in the primary trial does not receive three electroporation injections of V934 Instead they receive three electroporation injections of V934 followed by two IM injections of V935",
        "label": "Contradiction"
    },
    "f866e011-f633-4481-9d58-fff6828d7f83": {
        "text_answer": "Contradiction  The evidence states that 53 of the participants in the lapatinib 1000 mg  nabpaclitaxel arm experienced a confirmed partial response or confirmed complete response Therefore it is not true that none of the patients reached a confirmed complete response",
        "label": "Contradiction"
    },
    "b3372685-8147-4004-89f4-f57d35bd8980": {
        "text_answer": "Contradiction  Explanation The evidence provided shows that the percentage of participants with disease progression or death in the Bevacizumab group was lower 883 compared to the Bevacizumab  Capecitabine group 758 However a lower percentage of disease progression or death in one group does not necessarily mean that the other group had a higher occurrence In this case the statement is",
        "label": "Contradiction"
    },
    "e3b2d615-a7b7-475e-b757-a8de8cd2c6f7": {
        "text_answer": "Contradiction The statement is not related to the given evidence The evidence only discusses the interventions and dosages of Trastuzumab in the primary and secondary trials but it does not provide any information about the duration of the trials or the specific patient population HER2 or otherwise receiving the Trastuzumab in the primary trial",
        "label": "Contradiction"
    },
    "62af11ae-461f-4e31-b104-3467b2210208": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were instances of infection reported in both trials contradicting the statement that the outcomes of both trials were not marred by any instances of infection",
        "label": "Contradiction"
    },
    "b4fca47f-894d-47b9-a6a2-38867864c1bc": {
        "text_answer": "Contradiction The primary trial requires a primary tumor greater than 2 cm diameter while the statement suggests a primary tumor with a radius of 03 cm which is less than the minimum requirement for the primary trial",
        "label": "Contradiction"
    },
    "75fdf74b-e876-43f0-a382-03cf7055464b": {
        "text_answer": "Contradiction  Explanation The evidence shows that no harmful effects were recorded for any patient in either cohort 1 or cohort 2 Therefore the statement that the recorded harmful effects in the primary clinical trial were only noted for patients from cohort 2 is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "25efd6b7-dd3c-472e-babe-6d5397241653": {
        "text_answer": "Entailment with the caveat that the individual must meet all other inclusion criteria and have no exclusion criteria",
        "label": "Entailment"
    },
    "879196dd-c66e-4413-9575-98c95c0b9df1": {
        "text_answer": "Entailment The statement approximately onethird of patients from both groups in the primary clinical trial demonstrated pathologic complete response in breast and axillary lymph nodes after around seven months into the study is an entailment of the evidence provided as both groups had approximately onethird of their participants achieving pCR and the time frame for assessment was around seven months",
        "label": "Entailment"
    },
    "1a48d67e-c653-4e6f-bc9c-677793433e9b": {
        "text_answer": "Contradiction  The evidence states that the number of patients with stable disease was higher at week 12 than week 24 but it also states that no patients showed complete response in either week 12 or 24 The statement in the question implies that the number of patients with stable disease was higher at week 12 and no patients had a complete response at week 24 which is not directly stated in the evidence",
        "label": "Contradiction"
    },
    "86823381-4392-4a31-a1cb-b2966dd41c45": {
        "text_answer": "Contradiction  Explanation  The primary trial involves an intervention with Gefitinib which is a single drug and there is no mention of irinotecan lenograstim or thiotepa in the evidence  The secondary trial involves an intervention with Zoledronic Acid which is also a single drug and there is no mention of monotherapy with pemetrexed or any other drugs in",
        "label": "Contradiction"
    },
    "a5c140f2-b2e5-43a5-9a8d-268806caa311": {
        "text_answer": "Entailment The statement is entailed by the evidence as nonsmall cell lung cancer and small cell lung cancer are listed as eligible tumor types in the inclusion criteria of the primary clinical trial",
        "label": "Entailment"
    },
    "3d7e66cf-6e57-4072-b7f9-96ab99473ac5": {
        "text_answer": "Contradiction  Explanation  The statement all of the participants in group 1 of the primary trial were found to have lesions and less than 10 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is a contradiction based on the evidence provided  In the primary trial there were no lesions detected in the group of healthy volunteers In contrast in the",
        "label": "Contradiction"
    },
    "bec4d231-ea9b-4713-b2a1-c7ddb2dc5b0f": {
        "text_answer": "Contradiction The primary trial did not record any thromboembolic events",
        "label": "Contradiction"
    },
    "5a42ca95-0544-4db1-a1f1-67534d54dc69": {
        "text_answer": "Entailment The evidence states that Intervention 1 includes a validated webbased risk assessment as part of the intervention",
        "label": "Entailment"
    },
    "d99663b8-44bb-4480-9171-e10fc1ef25b1": {
        "text_answer": "Contradiction  Explanation  In the primary trial there were two arms one test group Pyridoxine and one placebo group Placebo  However in the secondary trial there were two test groups Highdose Oxybutynin Chloride Group and Lowdose Oxybutynin Chloride Group  Therefore the statement one test group and one placebo group",
        "label": "Contradiction"
    },
    "97d2c16b-fa4d-4b91-a69f-6692c681f6cd": {
        "text_answer": "Entailment The statement sunitinib was given orally to all participants in the primary clinical trial every day for the duration of the study is an entailment of the evidence provided as sunitinib was indeed administered orally every day according to the trial protocol",
        "label": "Entailment"
    },
    "67b2e192-d596-4951-b6d0-75f957072bdb": {
        "text_answer": "Contradiction  The evidence describes the use of Vorinostat during radiation therapy but it does not mention anything about the use of Fentanyl sublingual spray",
        "label": "Contradiction"
    },
    "f8f21f2b-9c9c-4f37-8c0d-b48061a14c9d": {
        "text_answer": "Contradiction The primary trial mentions an intraosseous injection of Fluciclatide while the statement mentions an intravenous IV administration of Chloroquine These are two different interventions",
        "label": "Contradiction"
    },
    "b0bb79f6-dd52-4821-b739-ffc42d7472da": {
        "text_answer": "Contradiction The evidence shows that there were 24 participants with treatmentemergent adverse events and 11 participants with serious adverse events in the Sunitinib  Docetaxel  Trastuzumab arm of the primary trial",
        "label": "Contradiction"
    },
    "f94eab27-5609-47a1-bcd5-d0e1305caab1": {
        "text_answer": "Contradiction The evidence states that patients with severe intellectual impairment unable to carry out basic daily routines and established depression are excluded from the secondary trial This contradicts the statement that candidates utterly incapacitated are not a requirement for the secondary clinical trial",
        "label": "Contradiction"
    },
    "943db9fb-b25b-4e58-bf2f-af46b1d9df54": {
        "text_answer": "neither Entailment nor Contradiction The statement is neutral as the evidence does not provide sufficient information about hospital admissions in the trials",
        "label": "Entailment"
    },
    "ed8ce995-6417-4392-8608-d20f0087c730": {
        "text_answer": "Irrelevant  Explanation The statement is not related to the evidence provided as there is no mention of pigmentary change in skin or adverse events related to it in the evidence",
        "label": "Contradiction"
    },
    "77045e13-70ad-4643-9e8c-7f0deb5d0ed9": {
        "text_answer": "Contradiction  Explanation The statement assumes that both cohorts receive the same dosage and frequency of CUDC101 but the evidence shows that cohort 1 receives an additional treatment PD0332991 once a week which is not mentioned in the statement Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "c9e9765e-663a-4421-a353-b0d6de09734d": {
        "text_answer": "Entailment Both trials involve medical interventions that likely involve xray imaging for monitoring and assessment purposes",
        "label": "Entailment"
    },
    "83d14b48-ba22-47e0-a7c5-0a0b5f8af134": {
        "text_answer": "Contradiction The evidence shows that only a minority 571 of patients experienced adverse events in the primary clinical trial",
        "label": "Contradiction"
    },
    "0c0d244d-5d55-42ea-bb07-8ff35bd2c862": {
        "text_answer": "Contradiction The statement is incorrect because the evidence shows that Cohort 1 practices once daily with one instructional CD while Cohort 2 practices twice daily with the same type of instructional CD",
        "label": "Contradiction"
    },
    "7ab5e41f-6982-43b4-8541-8ff7964d669a": {
        "text_answer": "Contradiction  Explanation The evidence does not support the statement as it mentions nothing about hypertension dehydration and dyspnea in the primary clinical trial However there are instances of edema limbs in both groups which could potentially be related to dehydration or heart failure which in turn could be related to dyspnea or hypertension Therefore the statement is a contradiction to the evidence as it as",
        "label": "Contradiction"
    },
    "9acd718f-6e45-495a-846d-b248d6690f1c": {
        "text_answer": "Contradiction The primary trial does consider MYMOP score variations as a way of measuring their research results",
        "label": "Contradiction"
    },
    "5a916856-536f-444d-87e7-1b2c032c0656": {
        "text_answer": "Contradiction  Explanation The statement at least one patient treated with GTx024 1mg in the primary trial gained over 10 kilos of Lean body Mass is a contradiction to the evidence because the median change in total body lean mass for the GTx024 1mg group was 155 kg which is less than 10 kg",
        "label": "Contradiction"
    },
    "b0b3e393-7af0-4fe2-bf26-111bddead6e7": {
        "text_answer": "Contradiction  The statement a majority of the patients in the primary clinical trial experienced a confirmed complete response CR after undergoing treatment with lapatinib 1000mg and nabpaclitaxel is a contradiction to the evidence as the evidence states that 53 of the participants experienced either a confirmed complete response CR or a confirmed partial response PR but it does not specify that a majority of them experienced",
        "label": "Contradiction"
    },
    "24816a21-1c67-4b20-82f0-0891fed68773": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence shows that no cases of anemia pneumonia or stupor were reported in the primary trial while the statement asserts that patients in the primary trial experienced these symptoms more frequently than those in the secondary trial Additionally the evidence shows that febrile infections were more commonly observed in the secondary trial but the statement does not mention this and instead as",
        "label": "Contradiction"
    },
    "dc561148-4b85-4fee-a632-2662a4c1a74c": {
        "text_answer": "Contradiction The statement is about cohort 2 not cohort 1",
        "label": "Contradiction"
    },
    "92935ccc-f20d-4e27-9a5f-cb8d47162de6": {
        "text_answer": "Contradiction The primary trial requires mammography as an inclusion criterion while the secondary trial does not mention it as a requirement",
        "label": "Contradiction"
    },
    "cd7d5918-4280-48e5-a202-ad7d499a9334": {
        "text_answer": "Contradiction The primary trial employs a 3week cycle but the secondary trial does not have a cyclical treatment approach However the statement does not necessarily imply that the primary trials intervention is the only aspect of the trial that uses a 3week cycle Its important to note that the statement does not directly contradict the evidence but rather misinterprets it by assuming that the statement applies to both trials treatment interventions when",
        "label": "Contradiction"
    },
    "23505a58-2e6a-4220-9148-f3b3102d2a91": {
        "text_answer": "Contradiction  Explanation The statement is contradictory to the evidence because the evidence shows that Cohort 1 received a different dose of MM121 compared to Cohort 2 and it does not mention any information about the Cetuximab doses being the same or different between the two cohorts Therefore it is not possible to determine if the statement is entailed or contradicted based on the given evidence alone",
        "label": "Contradiction"
    },
    "d07ab8cf-9e2e-4ac2-b8e0-20d9fa9bf16a": {
        "text_answer": "Contradiction The evidence states that those who have received estrogens or progestogens within the month preceding the clinical study are excluded from the primary clinical trial",
        "label": "Contradiction"
    },
    "147c18a2-2ef0-4cef-9f99-bbcd79b12216": {
        "text_answer": "Contradiction  Explanation The evidence does not mention anything about smokeless tobacco use as an inclusion or exclusion criterion for either trial Therefore the statement is not an entailment or a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "6c29e8c1-36ca-4e6e-b4dc-f1e91b98e546": {
        "text_answer": "Contradiction The statement is incorrect as per the evidence provided as both cohorts received Enzalutamide orally not intravenously",
        "label": "Contradiction"
    },
    "6fbe26db-3420-4617-9f84-1663aa9be297": {
        "text_answer": "  Entailment for the secondary trial as the primary trials requirements are met or exceeded However its important to note that the statement does not directly compare the inclusion criteria of both trials but rather states that the person meets the criteria for both trials individually",
        "label": "Entailment"
    },
    "d9e7c0cc-0850-4a8e-b389-092dfdc623fc": {
        "text_answer": "Contradiction The primary trial includes patients with histologically documented metastatic breast cancer so the statement that patients with histologically documented metastatic SCBC small cell lung cancer are excluded is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "2eabe849-09b8-45e6-aa6b-74450a7ff5df": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary outcome measurement in the secondary trial was not treatmentemergent adverse events but rather the change in Isothiocyanate in Urine Samples",
        "label": "Contradiction"
    },
    "16808fde-01bf-40dd-ae6e-7f208b51636d": {
        "text_answer": "Contradiction The evidence states that each cohort receives a vaccine against either pneumococcus or influenza not the same unspecified vaccine",
        "label": "Contradiction"
    },
    "6c2256ce-7c39-4ece-bdf4-fcd05744f234": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial excludes hypokalemic patients but there is no mention of hyperkalemic patients in either the inclusion or exclusion criteria for the secondary trial",
        "label": "Contradiction"
    },
    "c6e231b0-ab51-4010-9d8b-d447af0a6306": {
        "text_answer": "Neither The statement does not directly follow from the evidence provided  Explanation The evidence provided in the statement does not mention anything about vaccines or the primary trial affecting joint range of motion or CTCAE The statement is about a potential health condition decreased joint range of motion in the cervical spine and CTCAE that is not related to the information given in the evidence",
        "label": "Entailment"
    },
    "9b1ce2f0-2734-4ae5-988e-dd569c19594e": {
        "text_answer": "Contradiction The evidence provided does not indicate that eligibility for the primary and secondary clinical trials is controlled by nationality ethnicity weight or gender",
        "label": "Contradiction"
    },
    "e07a4aec-7879-4c85-a39e-a1cb17f2fd64": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial involves oral administration of cabergoline and the secondary trial involves intravenous administration of pixantrone",
        "label": "Contradiction"
    },
    "5e83904b-39bc-4449-b5c5-c2972d287237": {
        "text_answer": "Contradiction The evidence shows that there were no reported cases of intestinal obstruction in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "2a4b11b1-b14f-4fd8-a810-b6ad2f60e9fb": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as some patients in the GTx024 1mg group experienced a gain in lean body mass as indicated by the median value of 155 kg with a range of 206 to 1264 kg",
        "label": "Contradiction"
    },
    "7f06a038-29e8-4349-8822-876c2ae2e378": {
        "text_answer": "Contradiction The statement is not related to the evidence provided which pertains to adverse events and their frequencies in two cohorts of a primary trial The statement is about a disorder called fever ctcae which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "0cf7be8c-6376-4aff-93a2-2c88104fe061": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of scrotal infection in either trial",
        "label": "Contradiction"
    },
    "5fc57549-ece0-4ba6-9e5f-fc785aa16f28": {
        "text_answer": "Entailment The statement goes beyond the evidence by explicitly mentioning ileal obstruction and pancytopenia which are not mentioned in the adverse events listed in the evidence However the evidence does support the statement that there were no intestinal obstructions observed in either trial",
        "label": "Entailment"
    },
    "f103c71f-151a-46b1-b24e-c9fa1c90db64": {
        "text_answer": "Contradiction The evidence states that the placebo was administered as a 3hour intravenous infusion on Day 1 while the statement claims that the administration method for both the placebo and trabectedin is subcutaneous and occurs monthly",
        "label": "Contradiction"
    },
    "bd5d8368-5c1d-41b8-9fb3-f174da18744f": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as some patients in the GTx024 1mg group had a decrease in lean body mass",
        "label": "Contradiction"
    },
    "b1bad6e5-5322-4ba2-8350-2496bef85d1c": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement does not provide any information about the frequency or type of gastrointestinal or psychiatric adverse events in the primary trial so it cannot be determined if it entails or contradicts the evidence based on the given statement alone",
        "label": "Entailment"
    },
    "2205c13a-b236-4117-b41e-78846625c760": {
        "text_answer": "Contradiction  Explanation The evidence does not support the statement as it mentions no psychiatric events were recorded in either Adverse Events 1 or 2",
        "label": "Contradiction"
    },
    "9d94e597-591d-409e-a8e2-b205a83533a5": {
        "text_answer": "Contradiction  The statement implies that there were 3 cases of Hepatotoxicity for every case of hypertension and Pancreatectomy combined However the evidence shows that there were 3 cases of Hepatotoxicity and only 1 case each of hypertension and Pancreatectomy",
        "label": "Contradiction"
    },
    "95421b93-0c5a-45db-9630-804f602204b6": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided as the statement is about Uganda being a country in Africa and cardiac related adverse events in a clinical trial while the evidence only pertains to the adverse events recorded in the primary trial",
        "label": "Contradiction"
    },
    "7f3723a3-cdbf-41a6-a956-330e514b5c5c": {
        "text_answer": "Contradiction The evidence shows that one participant in each cohort experienced doselimiting toxicity",
        "label": "Contradiction"
    },
    "ad003c43-9467-4b8e-9a4e-e28c7d6422c3": {
        "text_answer": "Contradiction  Explanation The primary trial involves two interventions Hydrophor and MediHoney each assigned to a distinct study group However both interventions are topical applications and do not involve multiple treatments for each participant  In contrast the secondary trial involves two arms A1 and A2 each receiving a different dosage of PF05212384 in combination with docetaxel",
        "label": "Contradiction"
    },
    "ce4406e4-c57a-441a-870c-e2442b0806de": {
        "text_answer": "Entailment  Explanation The statement several cardiacrelated adverse events have been noted for cohort 1 in the primary clinical trial is an entailment based on the evidence provided as the evidence shows that there were indeed several cardiacrelated adverse events noted in cohort 1 of the primary clinical trial ACS Angina Pectoris Cardiac Arrest Cardiac Failure and Cardiac",
        "label": "Entailment"
    },
    "20296404-9526-4410-953c-51ea7ae866bd": {
        "text_answer": "Contradiction The evidence does not support the statement as it indicates that no notable patterns in gene expression were observed in patients with normal vitamin D levels",
        "label": "Contradiction"
    },
    "287251c0-2d26-466d-8340-13d9c15196bf": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence indicates that there was only one psychiatric adverse event suicidal ideation in the primary trial which affected 200 of patients not up to 50",
        "label": "Contradiction"
    },
    "709fb55d-517a-45bb-a379-f073a46cbe93": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 patients receive 1 mgkg of MCS110 every 3 weeks which is equivalent to 3000 micrograms per dose Therefore the total amount of MCS110 received every three weeks is 9000 micrograms In Intervention 2 patients receive 3 mgkg of MCS110 every",
        "label": "Contradiction"
    },
    "ba87189b-e858-4344-927d-a315a0d2576f": {
        "text_answer": "Contradiction The primary trial only includes patients with HER2negative breast cancer who have progressed during or following firstline treatment with Avastin and chemotherapy while the secondary trial includes newly diagnosed ERpositive HER2negative breast cancer patients",
        "label": "Contradiction"
    },
    "27180597-864a-4375-97c8-e9e41fd297dc": {
        "text_answer": "Entailment for the secondary trial only as the primary trial has different inclusion criteria",
        "label": "Entailment"
    },
    "a9600a10-ab9c-4b6d-ad89-30f9d7859a50": {
        "text_answer": "Contradiction The primary trial intervention and the secondary trial intervention are not the same and the statement compares two different interventions",
        "label": "Contradiction"
    },
    "bc13c987-6166-42c9-b537-1efc6126c3d8": {
        "text_answer": "Contradiction The evidence states that patients with histologically confirmed breast cancer including those with measurable or nonmeasurable disease are eligible for the primary clinical trial Therefore the statement that patients in whom metastasis cannot be assessed or whose cancer has not disseminated to other body areas are inappropriate for the primary clinical trial is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "581c879a-6d09-4736-8b12-a096d45b315c": {
        "text_answer": "Entailment with the understanding that the woman must meet the specific inclusion and exclusion criteria for each trial",
        "label": "Entailment"
    },
    "7ea784df-2fea-4676-a83f-a0716d2fd49d": {
        "text_answer": "Contradiction The number of participants was lower in the primary trial 13 compared to the secondary trial 30",
        "label": "Contradiction"
    },
    "9c2ca035-d531-4d44-876e-6ed9f2d3f76b": {
        "text_answer": "Contradiction  Explanation  The primary trial reports the results in terms of tumor diameter in centimeters while the secondary trial reports the results in terms of the number of participants with solid tumor response These are different units of measure so the statement is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "82bcea65-bca6-46f5-9e3b-32098e20c46f": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the number of adverse events and the presence or absence of a specific cytogenetic abnormality are unrelated",
        "label": "Contradiction"
    },
    "2295bf51-5b26-4cde-9bcf-caeada0181b1": {
        "text_answer": "Contradiction The primary trials inclusion criteria do not mention anything about life expectancy pregnancy status or age but the exclusion criteria do mention adequate bone marrow function which could potentially exclude certain older adults or pregnant women based on their age or life expectancy Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "51dace9a-0da5-49ed-8d8b-7489416ea9e8": {
        "text_answer": "Contradiction  The evidence shows that there were 5 emesisfree participants in the placebo group and 13 emesisfree participants in the aprepitant group which is the opposite of the statement suggesting that placebo patients had double the likelihood of experiencing emesis",
        "label": "Contradiction"
    },
    "d323d9da-d286-4fa5-b883-552116910450": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the comparisons made in the statement are not between the same interventions The first intervention in the primary trial uses Zoledronic Acid and Letrozole while the first intervention in the secondary trial uses Tamoxifen and Evening Primrose Oil which are different interventions The statement compares the dosages of Denosumab and Tamoxifen which are not directly comparable in the",
        "label": "Contradiction"
    },
    "9ebcda5d-0914-4015-b5d3-9446f9582d01": {
        "text_answer": "Contradiction The evidence shows that there was one case of shingles in the secondary trial but none in the primary trial The statement suggests that there were multiple cases in the secondary trial which is not supported by the evidence",
        "label": "Contradiction"
    },
    "856ab26e-3ce5-4405-b5ce-22557600b74f": {
        "text_answer": "Contradiction The statement does not entail or follow logically from the evidence provided as the evidence does not mention the use of Abraxane nabPaclitaxel in the primary trial and there is no mention of penile epithelioid hemangioma in the trial at all",
        "label": "Contradiction"
    },
    "5887ed1d-aa43-4a18-be3a-9141b675d5af": {
        "text_answer": "Contradiction The primary trial did not report any cases of radiation dermatitis or hyperpigmentation while the secondary trial reported that over 95 of participants in one group had these conditions",
        "label": "Contradiction"
    },
    "cefecae9-606f-4be6-94c0-f9d3732968ea": {
        "text_answer": "Entailment  Explanation The primary trial includes women with locally advanced ER breast cancer who are considering a mastectomy and the secondary trial includes women who are newly diagnosed with ER locally advanced breast cancer and are considering a mastectomy Therefore the statement is an entailment as the secondary trial meets the criteria for the primary trial",
        "label": "Entailment"
    },
    "45bd641d-3e35-456c-a01b-63fa3e2ebea1": {
        "text_answer": "Contradiction The statement is not an entailment as small plaque parapsoriasis is not related to the primary trials inclusion criteria for Nonsmall cell lung cancer or Small cell lung cancer",
        "label": "Contradiction"
    },
    "6071457e-bfac-4d86-b20b-c37ff82c943f": {
        "text_answer": "Contradiction The primary trial reports on the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or maximum feasible dose of MM111 which is not related to the primary trial The statement provides a specific value for the MTD of MM111 in the secondary trial but the primary trial does not provide any information about the MTD of MM11",
        "label": "Contradiction"
    },
    "c5a577f3-2bf4-4bbf-b1f9-5bd829414790": {
        "text_answer": "Contradiction The primary trial specifically states that the breast tumor must be at least 1 cm in diameter which is larger than the size specified in the statement",
        "label": "Contradiction"
    },
    "aa2706a4-b145-400f-8e8c-23e70f006360": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not provide information about the participant count in each arm of the trial",
        "label": "Contradiction"
    },
    "6d418558-93db-4116-b142-821c3f8615f2": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy which is a completely different treatment modality compared to the oral and intramuscular medications in the secondary trial",
        "label": "Contradiction"
    },
    "7d5cd6d5-88a1-4693-b20b-c4960095a330": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because there were no Thromboembolic events reported in either the primary or secondary trials according to the provided data",
        "label": "Contradiction"
    },
    "006c9dd6-c568-4497-81b7-c954568a3b4a": {
        "text_answer": "Contradiction  The statement is a contradiction because the evidence shows that Breast Cancer patients received a much higher dose 1000 mcgday than the stated dose in the trial for Ovarian Peritoneal Cancer patients 25 mcgday",
        "label": "Contradiction"
    },
    "dbc4f576-220a-482d-a06c-2538c13fdb28": {
        "text_answer": "Contradiction  Women aged 20 or 21 are not immediately eligible for the primary clinical trial according to the given inclusion criteria and they were not eligible for the secondary trial 12 years prior as stated in the question as the secondary trial requires a minimum age of 18",
        "label": "Contradiction"
    },
    "ed9856c5-cecd-4d24-a338-28bf547559fe": {
        "text_answer": "Contradiction The primary trial involves Botulinum Toxin Type A or placebo injections not entericcoated tablets",
        "label": "Contradiction"
    },
    "d83f5fcf-2a52-4612-b548-060ece7749f9": {
        "text_answer": "Entailment assuming that the statement 2p163 is a chromosome band present on 2p is a given fact and not part of the evidence  Explanation The primary trial and the secondary trial both involve the use of cyclophosphamide Paclitaxel and pegfilgrastim in their respective patient cohorts Therefore the statement that these treatments are administered in both trials is an entailment",
        "label": "Entailment"
    },
    "61b2e007-6e98-4923-8c07-d22ab6b62870": {
        "text_answer": "Entailment  Explanation The evidence shows that no adverse events were reported in the primary trial for 4 participants and in the secondary trial for 1671 participants Therefore the statement that no adverse events were reported in either trial is an entailment based on the evidence provided",
        "label": "Entailment"
    },
    "fb1605b0-dce6-45fb-bc67-2018e0578a2e": {
        "text_answer": "Contradiction The statement is not an entailment or a contradiction based on the evidence as there is no mention of eating disorders in the provided adverse events for the primary clinical trial",
        "label": "Contradiction"
    },
    "11714886-d3a2-496b-a883-6cd394478b03": {
        "text_answer": "Contradiction The primary trial does involve massage therapy which is not a drugbased treatment but it is not mentioned in the statement The secondary trial does involve drugbased treatments PF06647020 at two different doses which are mentioned in the statement",
        "label": "Contradiction"
    },
    "cd8d5a6a-0365-410c-8f85-815a67c0d11b": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the percentages provided in the evidence do not match the ones stated in the question",
        "label": "Contradiction"
    },
    "1d725114-1659-46dd-ab68-0c09bc167427": {
        "text_answer": "Contradiction The evidence states that unilateral breast cancer is an inclusion criterion meaning that bilateral breast tumor presence is not eligible for the trial",
        "label": "Contradiction"
    },
    "4894f59e-9386-448a-a779-f22a453ef049": {
        "text_answer": "Contradiction The primary trial compares intraoperative mammography to standard mammography while the secondary trial does not involve any mammography interventions The control groups in the two trials are not directly comparable",
        "label": "Contradiction"
    },
    "faf9f6e7-c9ac-4f15-8a63-1b463b9e1c51": {
        "text_answer": "Entailment assuming tumor lysis syndrome is not listed as an adverse event in either trial",
        "label": "Entailment"
    },
    "58c00532-2a20-4940-995f-08223d2736d5": {
        "text_answer": "Contradiction The evidence shows that no cases of pancytopenia were reported in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "c136fce2-0e64-4f51-8483-be0fde4382ef": {
        "text_answer": "Contradiction  Explanation The evidence shows that some patients experienced more than one adverse event Therefore the statement that all adverse events reported in the primary clinical trial were different for each patient is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "ce7f9154-ce9f-4d2f-8377-940c57315f1c": {
        "text_answer": "Contradiction The evidence does not support the statement that all participants in the primary trial suffered a deterioration in cognitive function particularly those in the Ovarian Function Suppression group as some participants in both groups showed improvement in cognitive function based on the reported mean standardized scores",
        "label": "Contradiction"
    },
    "f02e41c3-1eea-4662-9359-fe120c3bc10a": {
        "text_answer": "Contradiction The evidence mentions anorexia which is a type of eating disorder occurring in 150 200 of the patients",
        "label": "Contradiction"
    },
    "21c01e1d-b152-404c-88d6-b697b2a97b68": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there are no instances of mucositis oral bladder infection or thromboembolic events recorded in the secondary trial",
        "label": "Contradiction"
    },
    "dd3899d8-889b-424c-a7c4-8381ce656f18": {
        "text_answer": "Contradiction  The statement mentions pancreatitis cholelithiasis hepatic pain and febrile neutropenia while the evidence only shows pancreatitis cholelithiasis and hepatic pain in the Adverse Events 1 and Adverse Events 2 sections combined The statement includes febrile neutropenia which is not present in the evidence",
        "label": "Contradiction"
    },
    "01650c5a-f268-41c2-b07b-9293a0e4a8f7": {
        "text_answer": "Contradiction  Explanation The primary clinical trial measures the effect of flaxseed on hot flash scores while the secondary clinical trial measures the overall response rate ORR of Paclitaxel Plus Bevacizumab PB and Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG in cancer patients These outcome measures are not at all alike as the primary trial focuses on hot flash activity in women",
        "label": "Contradiction"
    },
    "9ad9b404-b234-41e6-9699-06a8c03bfe08": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the statement mentions nothing about the use of a social support survey questionnaire in either trial",
        "label": "Contradiction"
    },
    "1f8bd45e-480f-4244-9515-e1249b5b842a": {
        "text_answer": "Contradiction The evidence does not provide any information about adverse events related to mental disorders due to a general medical condition in the primary trial",
        "label": "Contradiction"
    },
    "6d446eda-4dec-469d-9313-37c70eef8e0a": {
        "text_answer": "Contradiction The primary trial had 76 participants in the intervention group and 75 in the control group making a total of 151 participants The secondary trial had 147 participants in the standard of care group and 163 in the device  standard of care group making a total of 300 participants",
        "label": "Contradiction"
    },
    "6003b550-4716-4966-a585-5a69fea20613": {
        "text_answer": "Contradiction  Explanation  The statement patients affected by unstable angina or those having undergone either chemotherapy or radiotherapy two weeks prior or with grade 2 or above neuropathy are disqualified from inclusion in the secondary clinical trial but may still participate in the primary clinical trial as long as they meet all relevant inclusion criteria is a contradiction to the evidence provided  According to the evidence",
        "label": "Contradiction"
    },
    "f5a80369-d69d-47d6-836c-60735534ce4e": {
        "text_answer": "Contradiction  The evidence states that in Intervention 1 participants receive 1 mgkg of MCS110 every 3 weeks which is less than 20 mg for a 70 kg person In Intervention 2 participants receive 3 mgkg of MCS110 every 3 weeks which is more than 20 mg for a 70 kg person However the statement requires both conditions to be",
        "label": "Contradiction"
    },
    "7ce21c0f-ad55-4ff7-a180-5e418fe9afc8": {
        "text_answer": "Contradiction  Explanation  The statement Patients with stage 4 cancer are not eligible for the secondary trial however they are eligible for the primary trial is a contradiction based on the provided evidence According to the evidence patients with stage IV breast cancer are explicitly excluded from both the primary and secondary trials",
        "label": "Contradiction"
    },
    "3d29cec9-8354-4d5b-ae1a-f486ab7aa6ca": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided as the statement is about the renal calyx and the evidence is about the lack of information regarding the intervention method dosage or cycle in the primary trial",
        "label": "Entailment"
    },
    "59f54656-5444-4b6d-a011-2921eb624626": {
        "text_answer": "Neutral The evidence does not directly address the statements entailment or contradiction  The evidence only mentions that the subjects were treated with partial breast irradiation but it does not provide enough information to determine if the statement about the lack of a clear outline of the treatment cycle or radiation dose details is an entailment or contradiction",
        "label": "Entailment"
    },
    "6a3053ef-4495-4c18-9da7-68cf5ed254e0": {
        "text_answer": "Contradiction  The statement mentions fentanyl sublingual spray which is not mentioned in the evidence The evidence only discusses Vorinostat and Radiation Therapy with their respective dosages",
        "label": "Contradiction"
    },
    "54d98b73-9799-4f9a-8581-42792f164d96": {
        "text_answer": "Contradiction The primary trial uses Yttrium90 Radioembolization with TheraSphere while the secondary trial uses ibrutinib and MEDI4736 These interventions are not the same",
        "label": "Contradiction"
    },
    "75753b6a-e963-4357-a225-102c1542f73d": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement is about a Likert scale for agreement which is not related to the adverse events data presented in the evidence",
        "label": "Entailment"
    },
    "f377df82-9511-47cc-9176-12491888eb05": {
        "text_answer": "Contradiction  Explanation The statement is not an entailment as the primary trial involves Armodafinil which is not an antiGMCSF monoclonal antibody while the secondary trial involves MCS110 which is an antiGMCSF monoclonal antibody but the patients receive different doses The statement does not follow from the evidence provided",
        "label": "Contradiction"
    },
    "b2187410-7c4d-49e2-a987-892fff52269f": {
        "text_answer": "Entailment The statement is true for both interventions as they are both administered orally",
        "label": "Entailment"
    },
    "91d1600a-35d7-47a4-b972-edee5eeb6018": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided",
        "label": "Contradiction"
    },
    "95570634-cfd3-4f4c-8082-8b98a2f13859": {
        "text_answer": "Entailment The statement is an entailment based on the evidence as the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher proportion of responders ORR compared to the Paclitaxel Plus Bevacizumab group in the primary clinical trial",
        "label": "Entailment"
    },
    "109ad38c-08ee-40ab-9a9c-65a4db8915b0": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the given evidence  Explanation The statement does not directly relate to the given evidence as it mentions a different type of cancer childhood leukemia and does not provide any information about the interventions being administered through the same or different routes in the context of the primary trial",
        "label": "Entailment"
    },
    "47abcc5d-7e6b-4969-9646-eefe68cebc3a": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of anemia pneumonia or stupor in the primary trial and the number of febrile infections is higher in the primary trial not the secondary trial",
        "label": "Contradiction"
    },
    "5b66def6-3282-455a-a879-6e5a68c90c1b": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because  1 In the primary trial there is no mention of any subcutaneous injections given on a weekly basis 2 In the secondary trial participants receive epoetin beta as a subcutaneous injection once a week for a total of 12 weeks  Therefore the statement that participants of the secondary clinical trial are administered three subcut",
        "label": "Contradiction"
    },
    "959eb0d5-7ac9-4c23-a10e-d1b720960a96": {
        "text_answer": "Entailment The primary trial evaluates the influence of radiation therapy on participants while the secondary trial tests the impact of varying quantities of the same treatment docetaxelbased combination on its study group Both trials involve clinical testing of interventions but the primary trial focuses on radiation therapy specifically while the secondary trial focuses on the effect of different doses of the same treatment",
        "label": "Entailment"
    },
    "a3abbf89-df53-45d4-97e1-f358dddbd2a8": {
        "text_answer": "Contradiction  Explanation The evidence shows that Cohort 1 reported one case of edema limbs and Cohort 2 reported one case of edema limbs and one case of dyspnea Therefore the statement that neither cohort reported any instances of hypertension edema and dyspnea is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "33377a5a-a2d0-4881-b4eb-93fe650e900a": {
        "text_answer": "Entailment The evidence shows that the participants in the paced respiration group had a lower mean number of hot flashes per day compared to the fast shallow breathing group",
        "label": "Entailment"
    },
    "b83fe708-6ce5-4b18-9d6a-51741249c7df": {
        "text_answer": "Contradiction The primary trial explicitly excludes participants with a history of alcohol or substance abuse or dependence within the past 2 years while the secondary trial includes participants with fewer than 5 alcoholic drinks per day within the past year",
        "label": "Contradiction"
    },
    "c6fedf8e-7d06-426e-8269-667a68ef06bc": {
        "text_answer": "Contradiction The primary trial does involve a massage therapy intervention which is not a drugbased treatment but it is not mentioned in the statement The secondary trial does involve drugbased interventions PF06647020 at two different doses which are mentioned in the statement",
        "label": "Contradiction"
    },
    "485b3413-6788-47ad-916e-c5d7fdb28237": {
        "text_answer": "Irrelevant The statement has no relation to the provided evidence",
        "label": "Contradiction"
    },
    "228308ea-2483-4311-a975-ca974ff797c6": {
        "text_answer": "Contradiction The evidence states that one patient in the primary trial suffered from a urinary tract infection",
        "label": "Contradiction"
    },
    "dfbf536b-7a16-42a0-b7f9-322c5394a01b": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence shows that there were no recorded cases of anaemia in the primary trial while the statement claims that anaemia was the most common adverse event in the secondary trial affecting more than 120 patients",
        "label": "Contradiction"
    },
    "3db98663-b8c7-4869-a46a-e7526caa7436": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as resistance to AI therapy is a requirement for the primary trial but not for the secondary trial",
        "label": "Contradiction"
    },
    "fa5334cc-0f09-4f22-91f8-156c7ab6d964": {
        "text_answer": "Contradiction The primary trial uses change in MYMOP score as the outcome measurement while the statement asserts that neither trial uses change in MYMOP score as the outcome measurement",
        "label": "Contradiction"
    },
    "5accf90d-2307-441f-ae8d-d055d9564a26": {
        "text_answer": "Entailment The primary trial and secondary trial have different inclusion and exclusion criteria ensuring that participants do not overlap between the two studies",
        "label": "Entailment"
    },
    "0aa5e58e-3ff4-487f-b043-d10452a30a4f": {
        "text_answer": "Contradiction  Explanation  The statement no instances of lesions were reported among the participants of group 1 in the primary clinical trial contradicts the information in the secondary clinical trial that a high percentage over 90 of participants in group 1 of the secondary clinical trial were diagnosed with radiation dermatitis and hyperpigmentation  The primary clinical trial and the secondary clinical trial are about different groups of participants and",
        "label": "Contradiction"
    },
    "85d61aaf-5255-4203-9ccf-f9c3da7a352e": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial includes patients with nonmeasurable disease which is a type of metastatic disease that cannot be measured but is still considered metastatic",
        "label": "Contradiction"
    },
    "4c7b87a1-ac43-4d8c-b6cf-2c95f3a3a074": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because both interventions involve the injection of the same amount 04 to 10 mCi of radioactive Tc99M sulfur colloid",
        "label": "Contradiction"
    },
    "33529b88-15c5-4e64-b876-f83de0305ce8": {
        "text_answer": "Contradiction The primary trial and secondary trial are separate studies with different inclusion and exclusion criteria The statement does not follow logically from the evidence provided",
        "label": "Contradiction"
    },
    "5199d14c-3a5e-4800-adf2-a065f50886b5": {
        "text_answer": "Contradiction  Explanation  In the primary trial only the intervention group 2 receives Armodafinil while in the secondary trial neither group receives Armodafinil but both receive fixed doses of MCS110 and PDR001",
        "label": "Contradiction"
    },
    "b5f68d8f-0c92-4f58-9740-78556c039e58": {
        "text_answer": "Contradiction  Explanation  The statement Patients with NUT midline carcinoma or Castrateresistant prostate cancer determined by fluorescence In situ hybridization or inflammatory breast cancer are eligible for both the primary trial and the secondary trial is a contradiction based on the provided evidence  The primary trial includes patients with NUT midline carcinoma and castrateresistant pro",
        "label": "Contradiction"
    },
    "6e644116-4084-4a3d-90dd-82f50a7ccc0c": {
        "text_answer": "Contradiction  Explanation  The statement most of the adverse events reported in the primary clinical trial involved blood and bone marrow unlike in the secondary clinical trial is a contradiction based on the evidence provided  In the primary clinical trial 10000 of the adverse events involved blood and bone marrow while in the secondary clinical trial only 3333 of the adverse events",
        "label": "Contradiction"
    },
    "c0b9a42b-2440-46b5-8fbc-978e2699c76e": {
        "text_answer": "Contradiction The primary trial includes patients with breast cancer epithelial ovarian cancer or gynecological cancer head and neck squamous cell carcinoma nonsmall cell lung cancer small cell lung cancer platinumrefractory germcell tumors adenocarcinoma or carcinoma of unknown primary site Colorectal cancer is not listed as an eligible cancer type in the provided inclusion criteria",
        "label": "Contradiction"
    },
    "5bf5c965-7588-452a-9d36-2503218e56da": {
        "text_answer": "Contradiction The secondary trial recorded more adverse events 4400 than the primary trial 000",
        "label": "Contradiction"
    },
    "8f8b46df-4031-4a42-bf67-60d923f2ec29": {
        "text_answer": "Contradiction The primary trial does use a 3week cycle for its intervention but the statement also asserts that the secondary trial does not have a cyclic treatment in place which is not true as the secondary trial does not mention any treatment cycle information",
        "label": "Contradiction"
    },
    "bcc9a793-5002-4cd9-a5b7-af5a1ceca35a": {
        "text_answer": "Contradiction The primary trial mentioned in the evidence is for breast cancer not colon cancer",
        "label": "Contradiction"
    },
    "98528323-fc08-45b9-8403-4005398ae3a7": {
        "text_answer": "Contradiction The primary trial intervention involves cabergoline which is given orally while the secondary trial interventions involve pixantrone dimaleate which is given intravenously",
        "label": "Contradiction"
    },
    "4ff85794-0b6a-4fe7-824f-afa6c2fa133e": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as coronary artery stenosis is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "0af2a0f3-dd56-4e3b-9e85-344780cc0877": {
        "text_answer": "Contradiction The primary and secondary trials measure different outcomes and do not provide any information about penile pain or CTAE 50",
        "label": "Contradiction"
    },
    "0f094624-f6e3-479b-bea3-34b5a3acf873": {
        "text_answer": "Entailment The secondary trial lasts for 24 weeks which is 15 weeks longer than the 10week intervention in the primary trial",
        "label": "Entailment"
    },
    "55635fce-1467-46ba-934d-8234f33e103e": {
        "text_answer": "Contradiction The evidence states that for Phase 1 patients must have evidence of a solid tumor that is locally advanced andor metastatic and for Phase 2 patients with breast cancer must have failed hormone therapy and a CDK46 inhibitor which implies advanced or metastatic disease Therefore the statement that only female patients with evidence of a solid tumor that is in early stages andor nonmetastatic are eligible for",
        "label": "Contradiction"
    },
    "869a492c-b4bf-4145-a491-1ee0ea0fe816": {
        "text_answer": "Contradiction The statement about yttrium being an element with certain atomic properties is not related to the eligibility criteria for the primary trial which pertains to patients with breast cancer and their medical conditions",
        "label": "Contradiction"
    },
    "53e2327a-6a30-49d0-a5eb-74cc5141abbb": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided The evidence is about the primary trial candidates and the interventions they receive while the statement is about sulfoxone a watersoluble sulfonamide antibiotic used in the treatment of leprosy",
        "label": "Contradiction"
    },
    "fed2e936-ab4c-42d6-8346-8f1b3ec9cc73": {
        "text_answer": "Contradiction  Explanation The statement doselimiting toxicity occurred exclusively within cohorts other than cohort 2 is a contradiction to the evidence presented as there is no evidence provided in the results to suggest that doselimiting toxicity did not occur in cohort 2 The evidence only shows that doselimiting toxicity occurred in participants from cohorts 1 and 2 but it does",
        "label": "Contradiction"
    },
    "a73a2b32-2cdb-49ec-ac4e-ed2eb976dec1": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not provide information about the number of cases of metastatic bile duct carcinoma in the primary and secondary trials",
        "label": "Contradiction"
    },
    "f86794bf-be99-43b3-b5e0-a78f5dde96a4": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence does not support the statement that the bulk of the adverse events reported in the primary trial involved the respiratory system Instead the evidence shows that the majority of adverse events in both trials involved the blood and bone marrow with no mention of respiratory events in the primary trial being more frequent or more common than in the secondary trial",
        "label": "Contradiction"
    },
    "c002edfa-458b-4274-860e-a3c6024c467c": {
        "text_answer": "Contradiction The statement Sunitinib was administered orally every day to every patient in the primary trial for the entire duration of the study is contradictory to the evidence which states that sunitinib dosing could be interrupted or reduced according to individual tolerance",
        "label": "Contradiction"
    },
    "570eadad-adf1-4e5a-bae7-8455d2a07f0e": {
        "text_answer": "Contradiction The statement mentions hemolytic uremic syndrome which is not related to the outcome measurements in the provided trials",
        "label": "Contradiction"
    },
    "43a81620-bb60-4515-b31b-4cf8e5f3cc25": {
        "text_answer": "Contradiction The evidence does not support the statement that it was typical for the primary clinical trial candidates to suffer from an eating disorder There is no mention of any eating disorders in the provided adverse events",
        "label": "Contradiction"
    },
    "da4bfd68-6510-4a0d-aa9e-b925d2cef24a": {
        "text_answer": "Contradiction The statement assumes that os refers to the same outcome measurement as in the primary trial which is pCR However in the secondary trial os is not mentioned and the outcome measurement is pathological complete response The statement also incorrectly states that arm 1 in the secondary trial had fewer patients experiencing os when in fact it had a lower percentage of patients achieving pCR",
        "label": "Contradiction"
    },
    "4234e99e-4e49-459b-9a11-5420d039defd": {
        "text_answer": "Entailment The primary trial has a lower total number of adverse events 000 vs 1379 but the secondary trial does have a higher number of instances of cardiacischemiainfarction 030 vs 008 However the statement correctly acknowledges this discrepancy",
        "label": "Entailment"
    },
    "29ebe44e-58cf-4141-afaa-9518629c3868": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 156 weeks while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "c6c56d8f-1e0a-4dad-9993-e47e34c146e7": {
        "text_answer": "Contradiction The primary trial involves the administration of denosumab while the secondary trial involves the injection of radioactive Tc99M sulfur colloid which are two different interventions",
        "label": "Contradiction"
    },
    "376fcb2c-1ea0-4b28-a6d2-fde91a124841": {
        "text_answer": "Contradiction  The statement implies that there were 3 cases of hepatotoxicity while the evidence shows that there were 3 cases of hepatotoxicity out of a total of 8 adverse events which is not equivalent to being threefold the number of cases of hypertension and pancreatectomy combined",
        "label": "Contradiction"
    },
    "a1bff44a-8d74-4184-a4d3-228bb55f4530": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events reported in both the primary and secondary trials Therefore it is contradictory to state that the secondary trial had a higher incidence of adverse events compared to the primary trial",
        "label": "Contradiction"
    },
    "786d7c5c-66f2-4ce1-8b3d-c6fdbeb36168": {
        "text_answer": "  Contradiction  Explanation  The patient described in the statement does not meet the eligibility criteria for both trials In the primary trial the minimum ANC requirement is 1800 cellsmm3 which is higher than the patients ANC level of 3000 cellsmm3 Additionally the patients hemoglobin level of 140 g",
        "label": "Contradiction"
    },
    "fef8b2f0-3e1f-46de-a53b-f1dffde794e6": {
        "text_answer": "Contradiction The primary clinical trial includes postmenopausal female participants while the secondary clinical trial specifically includes women with locally advanced recurrent or metastatic breast cancer who are estrogenreceptor positive The statement suggests a preference for female participants in the secondary trial but the two trials have different inclusion criteria beyond gender",
        "label": "Contradiction"
    },
    "3f777627-6d5d-43c9-8686-677498316865": {
        "text_answer": "Contradiction  Explanation The statement that 50 of the primary trial patients suffered an increase in blood bilirubin is a contradiction to the evidence as only 909 1 out of 11 of the patients in the primary trial experienced an increase in blood bilirubin",
        "label": "Contradiction"
    },
    "7294869d-4998-49a4-a9b5-021476f448b6": {
        "text_answer": "Contradiction The evidence does not mention cognitive behavioral therapy as a component of either intervention in the primary clinical trial",
        "label": "Contradiction"
    },
    "7cd2b581-31f9-42e8-9945-9317f97be422": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence as the dosages of Eribulin and Docetaxel are not comparable Eribulin is given at a dose of 14mgm2 on Days 1 and 8 of each cycle while Docetaxel is given at a dose of 75 mgm2 on Day 1 of each cycle",
        "label": "Contradiction"
    },
    "36386099-3f11-4037-aa48-dcbb36d7ff23": {
        "text_answer": "Contradiction The statement is not related to the inclusion or exclusion criteria for the primary trial The statement is about allogeneic lymphocytes which is not mentioned in the provided evidence",
        "label": "Contradiction"
    },
    "873c56c9-8544-45f4-bba4-308707b30b93": {
        "text_answer": "Contradiction The primary trial includes Triple negative breast cancer as an eligible diagnosis but the statement specifically mentions individuals diagnosed with follicular lymphoma or metastatic melanoma or intraductal carcinoma as disqualified from both trials Triple negative breast cancer is not the same as follicular lymphoma metastatic melanoma or intraductal carcinoma",
        "label": "Contradiction"
    },
    "03204d11-8f0c-41be-9fe7-3361c5549d51": {
        "text_answer": "Contradiction The placebo is administered as a 3hour infusion on Day 1 while trabectedin is administered as a 3hour infusion on Day 2 but they are not administered on a biweekly basis",
        "label": "Contradiction"
    },
    "c9c7d71a-0b59-4277-87fa-32e427e37b40": {
        "text_answer": "  Contradiction   The statement is contradictory to the inclusion criteria of both trials as the patient does not meet the minimum bone marrow function requirement for the primary trial ANC  1800 cellsmm3 and the hemoglobin level requirement for the secondary trial hemoglobin  90 gl",
        "label": "Contradiction"
    },
    "90748020-3e2f-46c8-8e9d-984436a2d752": {
        "text_answer": "Contradiction The primary trial includes nonsmokers as eligible participants but the secondary trial allows fewer than 5 alcoholic drinks per day Therefore someone could be a nonsmoker and still be eligible for the secondary trial despite drinking more than 5 alcoholic drinks a day",
        "label": "Contradiction"
    },
    "29412166-6da7-47d8-82b9-efc61e628f05": {
        "text_answer": "Contradiction The primary trial reported one thromboembolic event in the first set of adverse events but the statement asserts that no such events occurred in either trial",
        "label": "Contradiction"
    },
    "d333f58a-6f8d-402c-a44c-36899a155100": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as there are no palpitations pericardial effusions or abdominal pains recorded in the secondary trial while there are some recorded in the primary trial However the statement does not necessarily entail that the primary trial had more of these specific adverse events than the secondary trial as there are other types of adverse events that were more common in the primary trial",
        "label": "Contradiction"
    },
    "777b7b77-83e6-49a0-9988-c2363fbcc17d": {
        "text_answer": "Entailment for the given evidence the statement is true  Explanation The evidence shows that out of the total number of participants in the primary clinical trial only a few experienced an increase in pleural effusion and rapid disease progression The statement many participants in the primary clinical trial do not experience any increase in pleural effusion and rapid disease progression is an entailment because it is a logical consequence of the evidence The evidence does not",
        "label": "Entailment"
    },
    "5aa4da04-c21d-48a4-8888-62675ca63f74": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy while the secondary trial involves administration of fulvestrant in tablet form bid but the participants in the primary trial do not receive fulvestrant at all",
        "label": "Contradiction"
    },
    "8e63dcb6-d289-4782-94a5-9f0aa7343cbd": {
        "text_answer": "Entailment  Explanation The statement no fatalities were reported in the adverse events for both the primary clinical trial and the secondary clinical trial is an entailment based on the evidence provided The evidence shows that no fatalities were reported in the adverse events for both trials",
        "label": "Entailment"
    },
    "d40740f4-8885-4590-b274-23802a46d9e3": {
        "text_answer": "Entailment The statement in the question is a description of the nature of the procedures being tested in each trial and the evidence provided confirms that the primary trial is testing different radiation therapies while the secondary trial is testing different doses of the same treatment The statement is an entailment because it accurately describes the relationship between the procedures in each trial in relation to a specific point in time the start of the procedure",
        "label": "Entailment"
    },
    "13f8d256-bec7-419f-bda5-202ea116a215": {
        "text_answer": "Contradiction The primary trial had adverse events such as Dehydration Death Not Associated with CTCAE Death NOS Lymphopenia Neutropenia Thrombocytopenia and Hyponatremia which were not reported in the secondary trial",
        "label": "Contradiction"
    },
    "e100136f-281e-4721-9f57-66392982260f": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with potassium levels above the normal range while the secondary trial does not mention any potassiumrelated exclusion criteria",
        "label": "Contradiction"
    },
    "04d8d180-a06f-4eef-9c67-b51babbd8f10": {
        "text_answer": "Contradiction The statement does not entail the information in the evidence as the percentage food eaten score and the length of the intervention are not mentioned in the primary trial",
        "label": "Contradiction"
    },
    "98d96b95-5e98-49e3-8bd1-b004132c3781": {
        "text_answer": "Contradiction The primary trial sets an age limit of 18 and over not 21 and over as stated in the question",
        "label": "Contradiction"
    },
    "c25249a2-5294-4b5e-a39c-3b5c956b9147": {
        "text_answer": "Entailment The primary trial explicitly lists these allergies as exclusion criteria and the secondary trial also includes them as exclusion criteria Therefore the statement that patients with allergies to these medications are not suitable for enrollment in either trial is an entailment based on the provided evidence",
        "label": "Entailment"
    },
    "cb5c3a2b-3752-4e0d-9b5e-ae84ffaab109": {
        "text_answer": "Entailment  Explanation The statement despite the variant cancer types most patients in the first cohort of the primary clinical trial were screened contemporaneously after the intervention is an entailment based on the evidence provided The evidence shows that a significant increase in the percentage of participants who were up to date for colorectal breast and cervical cancer screenings occurred in both the Collaborative Care Intervention CCI",
        "label": "Entailment"
    },
    "bebf3648-7a1c-4e73-8d0a-f5715fa173f8": {
        "text_answer": "Contradiction  The evidence states that in Intervention 1 patients receive 1 mgkg of MCS110 every 3 weeks which is less than 20 mg per administration In Intervention 2 patients receive 3 mgkg of MCS110 every 3 weeks which is also less than 20 mg per kg per administration Therefore the statement that every patient in the primary clinical trial is administered",
        "label": "Contradiction"
    },
    "0723e2a6-a2cd-4b8b-b319-f8a8bf00d819": {
        "text_answer": "Contradiction  Explanation The statement Women of childbearing potential and Sexually active fertile men are eligible for the primary trial but they will need to commit to abstinence for the entire study period is a contradiction to the evidence provided in the inclusion and exclusion criteria of the primary trial According to the evidence women of childbearing potential WOCBP and sexually active fertile men are excluded",
        "label": "Contradiction"
    },
    "d0d25983-0004-4189-9139-c36827fa1e4d": {
        "text_answer": "Contradiction   The primary and secondary trials do not administer gemcitabine vinorelbine or ruxolitinib according to the provided information",
        "label": "Contradiction"
    },
    "7bb1cc76-1493-4507-9560-4b4719a5d3fc": {
        "text_answer": "Contradiction The statement does not provide information about the incidence of acute vomiting in the primary trial but rather about depression",
        "label": "Contradiction"
    },
    "c77cef4c-abf2-439e-97a4-abf4e1d57ac8": {
        "text_answer": "Contradiction The primary trial includes all types of female breast cancer while the secondary trial only includes patients with Her2neu breast cancer",
        "label": "Contradiction"
    },
    "e8be62e0-1f25-49f3-91d8-4fc23848dcd1": {
        "text_answer": "Contradiction  The evidence states that in cohort 1 the dose of Cetuximab is 12 mgkg IV QW for the maintenance phase while in cohort 2 it is 20 mgkg IV QW for the maintenance phase Therefore the dosages are not the same Additionally there is no mention of the absence of the collaborative care intervention in the evidence for either cohort",
        "label": "Contradiction"
    },
    "d91d9ce6-365c-4b56-9eef-20922491f504": {
        "text_answer": "Contradiction  Cohort 1 in the primary clinical trial is given 90 mgm2 paclitaxel weekly not daily Cohort 2 receives sunitinib starting at 25 mg daily",
        "label": "Contradiction"
    },
    "2e95798d-089f-44b6-a6bf-13161021b7ff": {
        "text_answer": "Contradiction The evidence states that patients who have undergone antineoplastic chemotherapy within the past 4 weeks are excluded from the primary clinical trial",
        "label": "Contradiction"
    },
    "d6aab46f-9e05-43a5-9d57-ca7d34bed983": {
        "text_answer": "Contradiction  Explanation The primary trial involves the use of FMX which is administered intravenously IV and MM398 which is also administered intravenously IV and neither of these drugs are given orally The statement suggests that both trials administer drugs orally and rely on ultrasounds instead of MRIs which is not the case for the primary trial",
        "label": "Contradiction"
    },
    "cc2be8ad-6396-41da-a205-45d8bfca37f4": {
        "text_answer": "Contradiction The primary trial includes females with breast cancer while the secondary trial includes patients with ovarian or breast cancer including triplenegative breast cancer but there is no mention of males or age restrictions for the secondary trial The statement incorrectly states that males under 18 with Her2neu lung cancer can participate in the secondary trial",
        "label": "Contradiction"
    },
    "bec00746-3a77-4d83-9c3b-d50eabcac1de": {
        "text_answer": "Contradiction The evidence does not indicate that all participants undergo a laparoscopic procedure The information provided only mentions the types of cohorts in the primary clinical trial",
        "label": "Contradiction"
    },
    "aebbea11-2bed-406c-a63e-02ca9eede262": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports the adverse events in the patient cohorts of the primary and secondary trials and there is no mention of malignant fundus neoplasms",
        "label": "Contradiction"
    },
    "13386e01-7556-4cec-93ef-c845f8c8e50d": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided",
        "label": "Contradiction"
    },
    "fbe7ef7c-4dff-403e-9152-04d357ec9bbc": {
        "text_answer": "Entailment The evidence supports the statement that tamoxifen leads to a decrease in ki67 expression in breast cancer tumors by approximately 40 when taken for 7 days before surgery and 14 days after surgery",
        "label": "Entailment"
    },
    "fd32ab49-3994-4b45-aaf9-da79d4cae211": {
        "text_answer": "Contradiction The statement assumes that Aes severity of elevated lesion refers to the adverse events in the primary trial but the evidence only provides information about specific adverse events and their frequencies without any information about the severity of those events",
        "label": "Contradiction"
    },
    "bdfb5379-c659-4a09-b4f1-895468675f2e": {
        "text_answer": "Contradiction The primary trial has a different set of exclusion criteria and does not specifically mention allergies to cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib as exclusion criteria",
        "label": "Contradiction"
    },
    "c53af3d2-6827-4f10-ae9e-c7639a15b19a": {
        "text_answer": "Contradiction  Explanation The statement adverse events were not common amongst cohort 1 participants in the primary clinical trial identical results were drawn from cohort 2 is a contradiction to the evidence provided The evidence shows that there were adverse events in both cohorts 1 and 2 with different frequencies The statement implies that there were no adverse events in either cohort which is not supported by the",
        "label": "Contradiction"
    },
    "2a5561f9-399d-4651-9a54-1a15f251c070": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the use of epacadostat in combination with pembrolizumab while the secondary trial involves the use of sunitinib The statement compares the frequency of pembrolizumab administration between the two trials but they are not directly comparable as they involve different treatments In the primary trial pembrolizumab is administered every 3 weeks Q3",
        "label": "Contradiction"
    },
    "a61c1627-33e6-4a53-8247-484d42328747": {
        "text_answer": "Contradiction The primary trial includes a minimum tumor size of 1 cm while the statement suggests a tumor size of 3 mm which is much smaller than the minimum size required for the primary trial",
        "label": "Contradiction"
    },
    "dfef1ddd-9351-436d-b1ce-9f22065b495c": {
        "text_answer": "Contradiction The evidence shows that in both trials no adverse events occurred in more than 3 out of 10 participants",
        "label": "Contradiction"
    },
    "9367129d-51e0-4d62-b2df-35749e117157": {
        "text_answer": "Contradiction The evidence does not mention anything about observable tumors in both breasts as an exclusion criterion",
        "label": "Contradiction"
    },
    "9a20f7f5-5477-4320-be07-3f2154877863": {
        "text_answer": "Contradiction The primary trial specifically states that patients must have a breast tumor 1 cm in diameter while the statement suggests patients with a tumor 0208 cm in diameter",
        "label": "Contradiction"
    },
    "29eca4cf-13e4-4028-bbd1-71955607afb5": {
        "text_answer": "Contradiction The statement has no relation to the provided evidence",
        "label": "Contradiction"
    },
    "1d3bccea-6780-45ae-93d2-651346fbc1dd": {
        "text_answer": "Contradiction The statement is not supported by the evidence as the evidence only provides data on the change in lean body mass from baseline to 4 months and does not provide information on the dosage of 0001kg or the time period of 033 years",
        "label": "Contradiction"
    },
    "916340c0-cd97-4e2e-bd31-ded7bd2d1a56": {
        "text_answer": "Contradiction  Explanation The statement most patients involved in the primary clinical trial showed progression of disease by the end of week 24 is a contradiction to the evidence presented as the evidence shows that 14 out of 25 participants 56 had stable disease SD or better CR or PR at week 24",
        "label": "Contradiction"
    },
    "8b37f698-edfb-4e34-b0da-4a5287506d02": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the exclusion criteria of the primary trial specifically states that there should be no history of stroke transient ischemic attacks or intrabdominal abscess in the past 6 months",
        "label": "Contradiction"
    },
    "9c272853-cec0-43f0-9897-4657c5fd0b78": {
        "text_answer": "Contradiction The primary trial includes a criterion for the primary tumor to have a diameter greater than 2 cm not 3000µm The secondary trial does not mention any specific tumor size requirement",
        "label": "Contradiction"
    },
    "8f31a3bf-d5a9-4f2c-95bb-c9ff01de6d42": {
        "text_answer": "Entailment assuming that every patient in cohort 1 refers to the same group as in the Results 1 ArmGroup Title Aprepitant Dexamethasone Cytoxan  Kytril",
        "label": "Entailment"
    },
    "21fdf78c-fdbf-4140-9056-d3bfd2e9de27": {
        "text_answer": "Contradiction The alloMSCs and placebo interventions are not given in identical dosages as the alloMSCs intervention involves the administration of 100 million cells in 20 injections of 04ml each while the placebo intervention involves the administration of Buminate solution in the same number and volume of injections",
        "label": "Contradiction"
    },
    "6f0571f4-e1da-4732-9bdf-8c07bea059c1": {
        "text_answer": "Entailment  Both trials report their results using the same unit of measure which is a proportion or percentage in the secondary trial and units on a scale in the primary trial but can be converted to a proportion or percentage for comparison",
        "label": "Entailment"
    },
    "669ed7b4-398b-4604-8065-04e99611691d": {
        "text_answer": "Contradiction  Explanation  The primary trial did have a placebo group Arm II as stated in the evidence Therefore the statement that the primary trial lacked a placebo group is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "5d1997bd-e77f-43dd-abd1-eb1da8819d47": {
        "text_answer": "Contradiction The primary trial intervention section does describe the intervention as MM111 but it does not specify the method of administration dosage or cycle The statement however mentions nothing about the intervention and instead focuses on the presence of a small cell component",
        "label": "Contradiction"
    },
    "8839dd14-8457-44c0-88a1-8bb0764e326c": {
        "text_answer": "Contradiction The primary trial reported 0 adverse events related to chest pain while the secondary trial did not report any chest pain adverse events or any other adverse events Therefore it is a contradiction to state that a larger percentage of participants in the primary trial experienced chest pain than in the secondary trial",
        "label": "Contradiction"
    },
    "42a68b8b-0bed-49f4-8430-12e031c56471": {
        "text_answer": "Contradiction The evidence does not support the statement as it indicates that no participants in the normal Vitamin D levels group showed a distinguishable pattern in the expression of the evaluated 40 genes",
        "label": "Contradiction"
    },
    "4d6b0c89-c9fc-4195-ac3e-c33b28af955e": {
        "text_answer": "Contradiction The primary trial does not have different sets of inclusion standards based on age for the given information provided",
        "label": "Contradiction"
    },
    "fbd56c1d-5153-46c0-bd88-ed90eb1c9345": {
        "text_answer": "Contradiction The most common adverse event observed in the primary clinical trial was actually nausea and vomiting each with a frequency of 392 The statement in the question is not an entailment or a correct representation of the evidence",
        "label": "Contradiction"
    },
    "bc50160f-7490-4c30-b373-9474707b02b3": {
        "text_answer": "Contradiction  Explanation The primary trial reported no adverse events while the secondary trial reported several adverse events that affected more than 30 of patients including Skin infections",
        "label": "Contradiction"
    },
    "fd0fa999-2f1c-400d-977d-2d45dd9c358c": {
        "text_answer": "Contradiction  Explanation  In the primary trial Intervention 1 Arm I involves the administration of zoledronic acid intravenously while Intervention 2 Arm II involves placebo administration orally Therefore the primary trial does not entail that all interventions in Intervention 1 must be administered intravenously  In the secondary trial Intervention 1 Arm II involves the administration of gran",
        "label": "Contradiction"
    },
    "3f26cd3e-2b66-4bbc-94b4-498df2e334e3": {
        "text_answer": "Contradiction The primary trial does involve a massage therapy intervention which is not a drugbased treatment but the secondary trial does involve testing different doses of a drugbased treatment PF06647020",
        "label": "Contradiction"
    },
    "d1d340f9-f31f-4469-804b-41853562fa57": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients who require use of coumarinderivative anticoagulants such as warfarin while the secondary trial permits their use under certain conditions However the statement does not mention anything about fertility or ability to have children",
        "label": "Contradiction"
    },
    "7d22f8db-6793-46e2-88ca-2d464ecf9789": {
        "text_answer": "Entailment The evidence does not provide any information that contradicts the statement as both groups in the trial did not exhibit a noticeable pattern for the expression of the 40 genes",
        "label": "Entailment"
    },
    "ba8e855f-8cff-474d-a2dd-d5061a039b47": {
        "text_answer": "Contradiction The statement mentions 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but the evidence shows that there was only 1 case of Febrile neutropenia recorded in cohort 1 The statement also mentions but no cases of Pancytopenia which is consistent with the evidence However the statement and the evidence do not agree on the number of",
        "label": "Contradiction"
    },
    "3c558a0b-1e1a-4d42-af75-266ea0d93662": {
        "text_answer": "Contradiction  The evidence provided does not support the statement that 11 more Participants in the ERpositive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group The evidence shows that 286 of ERpositive Luminal B participants and 176 of Triple Negative participants demonstrated a decrease in",
        "label": "Contradiction"
    },
    "4c8ee685-13af-44a4-8d1e-30105f8469af": {
        "text_answer": "Contradiction The statement does not relate to the provided evidence as the evidence does not mention haploidentical donors",
        "label": "Contradiction"
    },
    "526a5650-0b61-4e6e-9ddf-4674a6193964": {
        "text_answer": "Contradiction  Explanation  The primary trial and the secondary trial have different inclusion criteria The primary trial includes patients with carcinoma of the breast undergoing lumpectomy while the secondary trial includes patients undergoing immediate tissue expander reconstruction following mastectomy or skinsparing mastectomy utilizing bioprosthetic mesh The statement does not hold true as patients with unconfirmed progressive disease may not meet the inclusion criteria for both trials",
        "label": "Contradiction"
    },
    "6b90da92-6aaa-431b-b31c-8df9def4a98d": {
        "text_answer": "Contradiction The evidence provided does not mention anything about the cdk4 gene mutation in relation to the eligibility criteria for either trial",
        "label": "Contradiction"
    },
    "2a13f623-4957-4e7e-9968-03f64bb6f5f3": {
        "text_answer": "Contradiction  Explanation The statement does not entail the evidence as it only mentions anthracyclinebased chemotherapy on days 1 8 and 15 without specifying the number of cycles or the specific anthracyclines used The evidence however specifies the number of cycles and the specific anthracyclines doxorubicin used in each intervention and the statement does not match",
        "label": "Contradiction"
    },
    "41756298-3326-499e-99f5-f34bcf718cbe": {
        "text_answer": "Contradiction The primary trial excludes patients with anemia only due to irondeficiency but the statement includes anemia as one of the conditions that cannot be present for eligibility in both trials However the secondary trial does not mention anemia as an exclusion criterion",
        "label": "Contradiction"
    },
    "f442b08f-4429-412f-99d2-24625bf8bdcd": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement feel worn out is a question about whether an individual feels or felt worn out is not directly related to the evidence provided in the primary trial The trial compares two different interventions bisphosphonate IV Q4W and denosumab 180 mg Q12W but does not provide any information about how these interventions may",
        "label": "Entailment"
    },
    "0add45e1-cc70-4f0d-b2c7-14c67e9cd3ee": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as anaemia was observed in the secondary trial but not in the primary trial",
        "label": "Contradiction"
    },
    "a141432b-385e-4cd4-87e4-acc0e3e9f412": {
        "text_answer": "Contradiction The evidence does not provide information about the difference in recurrencefree survival between the two groups only the percentage of participants who achieved it",
        "label": "Contradiction"
    },
    "47468741-3624-4321-90ee-1c680a293b25": {
        "text_answer": "Contradiction The evidence does not mention asthenia or pyrexia at all in the given trials",
        "label": "Contradiction"
    },
    "e44e25b6-1be6-4c35-a3c9-417c56052939": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as paclitaxel is not mentioned in the given interventions",
        "label": "Contradiction"
    },
    "fd4c7d94-8d93-46b1-b467-3f169c6af30e": {
        "text_answer": "Contradiction The evidence does not state that patients with metastatic or unresectable small cell lung cancer head and neck cancer urothelial transitional cell carcinoma or breast cancer who are confirmed to have the disease based on histology are required to test positive for ER or PR or both in order to participate in the primary clinical trial",
        "label": "Contradiction"
    },
    "a842c232-d17b-4257-84ff-02be26716c47": {
        "text_answer": "Contradiction  The statement implies a 50 reduction in Ki67 expression over 10 weeks but the evidence only shows a median reduction of 55 from 15 to 7 over 6 weeks",
        "label": "Contradiction"
    },
    "f33d7123-34a6-4466-98d2-9c69b18ac544": {
        "text_answer": "Contradiction The evidence states that individuals with interstitial lung disease or pneumonitis are excluded from the trial but it does not specifically mention diffuse parenchymal lung disease as an exclusion criterion",
        "label": "Contradiction"
    },
    "6bbcd12e-4105-478b-a402-1374ce8a01df": {
        "text_answer": "Contradiction  Explanation The statement Women of childbearing potential and Sexually active fertile men are eligible for the primary trial but they will need to commit to abstinence for the entire study period is a contradiction to the evidence provided in the inclusion and exclusion criteria According to the evidence women of childbearing potential WOCBP and sexually active fertile men are excluded from the study unless",
        "label": "Contradiction"
    },
    "3793f6d8-1a56-48aa-b3d3-1216f7bf5d29": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The evidence only mentions the occurrence of a maculopapular rash as an adverse event but it does not specify whether the rash was eosinophilic or not Therefore the statement is neutral with respect to the evidence",
        "label": "Entailment"
    },
    "72278411-1c4b-4c70-b6ab-72c4c8449ec4": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not show that the primary trial has seen a higher prevalence of biliary colic Instead it shows that there was one case of biliary colic in the secondary trial which is fewer than the one case in the primary trial However the statement is not a contradiction because it does correctly state that instances of diarrhoea are more common in the secondary trial according to the",
        "label": "Contradiction"
    },
    "10db152d-ae00-4b31-8c05-a1db1dee76b4": {
        "text_answer": "Contradiction  Explanation In the primary trial the dosage of trastuzumab given to her2 patients is 2 mgkg per week In the secondary trial the dosage of trastuzumab given to her2 patients in the AC→TH cohort is 2 mgkg per week starting from Cycle 5 but in the AC→T cohort trastuzumab",
        "label": "Contradiction"
    },
    "282cb769-7825-4b3e-b089-05a6103f60ff": {
        "text_answer": "Neutral The statement is not directly related to the eligibility criteria in the evidence",
        "label": "Entailment"
    },
    "892e63ba-619c-4458-8130-89bbac726edb": {
        "text_answer": "Entailment as the evidence shows that 5 out of 14 patients experienced an adverse event",
        "label": "Entailment"
    },
    "4a349ab7-7fd2-4979-bf94-4e563c26b7f9": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial only includes patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast Patients with stage 4 invasive breast carcinoma are not eligible for the trial",
        "label": "Contradiction"
    },
    "0d633cc2-339a-4caf-b252-ce50b826e3e3": {
        "text_answer": "Contradiction The evidence shows that there was one instance of infection reported in the primary trial but none were reported in the secondary trial",
        "label": "Contradiction"
    },
    "28f840e3-3970-4ec7-ac46-d0503d56ee57": {
        "text_answer": "Contradiction  The primary trial measures the percentage of participants with tumor response using RECIST criteria which can be considered a form of clinical benefit Therefore the statement is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "674d7d6c-723a-44db-9e96-10aa21dcefe4": {
        "text_answer": "Neutral  Explanation The statement does not directly relate to the evidence provided The evidence only reports the results of the correlation between Vitamin D levels classic prognostic factors and gene expression profile in two patient cohorts without mentioning any discernible expression trend for the examined genes",
        "label": "Entailment"
    },
    "c04ed14d-5ed2-46a6-9b0c-6a30a3b9a7b2": {
        "text_answer": "Contradiction  Explanation The statement cholelithiasis was less common in primary trial participants compared to the secondary trial participants is a contradiction based on the evidence provided In the primary trial cholelithiasis occurred in 030 000 participants while in the secondary trial it occurred in 012 000 participants Both trials report no occurrences",
        "label": "Contradiction"
    },
    "8983bf9f-d977-4238-91df-2435d2eb4a38": {
        "text_answer": "Contradiction The evidence provided does not support the statement as it mentions no cases of acute myocardial infarction in either trial",
        "label": "Contradiction"
    },
    "9d330063-37a8-4c8e-8ac2-f28c8048d0be": {
        "text_answer": "Contradiction   The statement is a contradiction to the evidence because the evidence from the primary trial does not record any adverse events at all while the statement suggests that the primary trial recorded no adverse events specifically of eyelid oedema and chest pain",
        "label": "Contradiction"
    },
    "5e23cc12-12c7-42e9-ab55-595bb427adad": {
        "text_answer": "Contradiction Severe insomnia is an exclusion criterion for the secondary trial but it is not mentioned in the inclusion or exclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "5f45e043-f49d-42cd-941d-baa17257d46c": {
        "text_answer": "Contradiction  Explanation The statement provides information about the number of participants who experienced Recurrencefree Survival in each group but it does not match the numbers given in the evidence According to the evidence 80 out of 96 participants in the Ketorolac 30 mg group experienced Recurrencefree Survival and 897 of participants in the NaCl 09 ",
        "label": "Contradiction"
    },
    "5fff07e2-11f3-4a58-aecb-ce4650dd35f6": {
        "text_answer": "Contradiction The evidence mentions that patients with a history of interstitial lung disease or pneumonitis are excluded from the trial but it does not specifically mention diffuse parenchymal lung disease as a subtype of interstitial lung disease or pneumonitis that is excluded within the last 3 years",
        "label": "Contradiction"
    },
    "6b257ade-83bb-428c-a623-056f1ad56594": {
        "text_answer": "Contradiction The primary clinical trial described in the evidence is for breast cancer patients not lung cancer patients and it does not mention radiation therapy as a requirement for participation",
        "label": "Contradiction"
    },
    "a146a89a-9519-4515-b36a-b5f365481341": {
        "text_answer": "Contradiction The evidence shows that there was one case of anaemia in cohort 1 of the primary trial",
        "label": "Contradiction"
    },
    "dabe9e76-e44c-45be-87b0-337fde45ab98": {
        "text_answer": "Contradiction  Explanation The statement most of the patients participating in the primary clinical trial had a full recovery by the 24th week is a contradiction to the evidence presented as the evidence shows that only 4 participants had a partial response PR at both Week 12 and Week 24 and none of them had a complete response CR or a full recovery The remaining participants had stable disease SD at",
        "label": "Contradiction"
    },
    "ff7079ec-d642-4cc3-8767-62df7a2a8ff7": {
        "text_answer": "Contradiction The primary trial has an ECOG performance status of 02 which means the patients are able to perform all their normal activities take care of themselves and are ambulatory The secondary trial includes patients with an ECOG performance status of 02 or Karnofsky 60100 but it does not specify that patients must be able to perform all their normal activities and take care of themselves However the",
        "label": "Contradiction"
    },
    "06609fde-0f22-485a-ba1c-78c2677d8783": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided The evidence is about the effect of TAK228 Plus Tamoxifen on Ki67 expression in breast cancer patients while the statement is about Microbacterium a genus of bacteria",
        "label": "Contradiction"
    },
    "8b3c9b3e-41e8-46fb-b975-db35e552ec6c": {
        "text_answer": "Contradiction  Explanation  The statement zero percent of individuals in group 1 of the primary clinical trial displayed any lesions in contrast over ninety percent of participants in group 1 of the secondary clinical trial exhibited symptoms of radiation dermatitis and hyperpigmentation is a contradiction based on the evidence provided  In the primary clinical trial there were no lesions detected in the healthy volunteers group which is",
        "label": "Contradiction"
    },
    "0cfa6770-4d70-4603-865b-512957909993": {
        "text_answer": "Contradiction  Explanation The primary trial involves the administration of denosumab while the secondary trial does not involve any injection but rather the use of lymphoscintigraphy with gamma probes The statement suggests a direct comparison between the amount of denosumab administered in the primary trial and the absence of injection in the secondary trial which is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "363212ed-da18-4ae4-a7e5-cab37c207a24": {
        "text_answer": "Neutral The statement is not directly related to the eligibility criteria provided in the evidence",
        "label": "Entailment"
    },
    "189e7142-d6fd-49d6-8e4f-44383f00781b": {
        "text_answer": "Contradiction  The primary trial explicitly states that HER2neu positive patients are excluded while the secondary trial only accepts HER2neu negative patients",
        "label": "Contradiction"
    },
    "b6109c91-afac-46ff-b306-bd9a5f1bba84": {
        "text_answer": "Contradiction The evidence states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the study",
        "label": "Contradiction"
    },
    "c2b8b1b0-9d84-498a-b490-e3da298f1087": {
        "text_answer": "Contradiction The primary trial measures tumor diameter in centimeters while the secondary trial measures response in terms of participants with solid tumor response without specifying the unit of measure",
        "label": "Contradiction"
    },
    "09df9e5c-cc03-4c01-858b-0886376e9b7a": {
        "text_answer": "Contradiction  The evidence provided in the results does not give information about the percentage of participants with a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products at a time frame of years The statement is about the percentage of participants with a reduction in CTCs at one month post AHST which is not the same as years",
        "label": "Contradiction"
    },
    "3c596e8f-b1a2-4ded-b15b-99784b540d76": {
        "text_answer": "Contradiction  Explanation  The primary trial involves whole breast radiation therapy while the secondary trial does not involve radiation therapy at all The statement incorrectly assumes that both trials involve the administration of fulvestrant in a tablet form to be taken bid and 500000 mcg of fulvestrant but it fails to acknowledge the significant difference in the interventions between the two trials",
        "label": "Contradiction"
    },
    "56ab098d-56f4-401e-a173-a0c99cd8efd0": {
        "text_answer": "  The statement is a Contradiction based on the evidence provided  Explanation  The primary trial includes a patient with a minimum ANC of 1800 cellsmm3 while the secondary trial requires a minimum ANC level of 1500μL and more at the beginning of the study The patient described in the statement does not meet the ANC requirement of the secondary trial",
        "label": "Contradiction"
    },
    "a0f34f76-d0dd-48f3-b916-1722ecb924c2": {
        "text_answer": "Neutral The statement is not directly related to the evidence  Explanation The statement worry that skin condition may be serious is a response indicating that an individual worries that their skin condition may be serious is not an entailment or a contradiction based on the evidence provided The evidence only reports the absence of adverse events related to skin conditions in both cohorts of the primary trial The statement is not directly related to the evidence as it does",
        "label": "Entailment"
    },
    "742cd2e5-1335-4daa-87b0-47727f61d8a1": {
        "text_answer": "Contradiction  The evidence states that patients in Arm 1 of the primary trial receive oral lapatinib and tamoxifen once daily but it does not specify the dose of lapatinib as 200mgm2 once a day",
        "label": "Contradiction"
    },
    "2062b384-c6c1-4997-a4e4-b6709d123502": {
        "text_answer": "Contradiction  Explanation The statement participants in the primary clinical trial were found to have cholelithiasis at a rate two times higher than those in the secondary clinical trial is contradictory to the evidence provided because the evidence shows that no cases of cholelithiasis were reported in either trial",
        "label": "Contradiction"
    },
    "6bb59504-e102-48d6-ac0d-8ce71100b726": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that Cohort 2 receives Herceptin in addition to Docetaxel Doxorubicin and Cyclophosphamide which alters the dosing regimen and frequency for some of these drugs",
        "label": "Contradiction"
    },
    "08a467b9-3bf6-486f-9975-4e2b67a5b690": {
        "text_answer": "Contradiction The primary trial includes patients with advanced solid tumors but it does not specifically require a confirmed mutation in any of the listed genes for participation The secondary trial however does require such a mutation for inclusion Therefore the statement that these mutations are required for the secondary trial but not the primary trial is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "379dbb6e-e70b-4e6c-83a9-c332b84592dd": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as Ralstonia is a genus of bacteria and has no relation to cardiovascular impairment",
        "label": "Contradiction"
    },
    "6b901ca0-1ec8-4d36-b43d-dcc6bf63b70f": {
        "text_answer": "Contradiction The statement does not provide any information related to the number of patients suffering from adverse events in the two cohorts and the evidence only mentions the types and frequencies of adverse events in each cohort",
        "label": "Contradiction"
    },
    "d921df56-8a29-45a9-bb0b-66ba14dbc193": {
        "text_answer": "Contradiction The statement is more restrictive than the evidence as the evidence allows for antineoplastic chemotherapy with the exception of antiHER2 agents to be used during the study period as long as the patient has been on a constant dose for at least 28 days and is not expected to stop the medication during the study period",
        "label": "Contradiction"
    },
    "1e2b550a-0da3-48ea-8221-1a8b86e10511": {
        "text_answer": "Entailment assuming the statement about the unit of concentration is not relevant to the question  Explanation The statement that there are no cases of anorexia hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial is an entailment of the evidence since the evidence does not report any cases of anorexia hypothermia or hallucinations in either trial",
        "label": "Entailment"
    },
    "5a96ef9e-57ed-4f5a-95b3-db64e3268993": {
        "text_answer": "Contradiction  Explanation In the primary trial group 2 receives an administration of dexmedetomidine which is not the same as receiving myalgias 5ml of a solution containing myalgias is given to group 2 in the statement but dexmedetomidine is given to group 2 in the primary trial evidence  In the secondary trial patients do not receive any myalgias as stated in",
        "label": "Contradiction"
    },
    "2660009c-449a-4edb-a64a-20164527c99d": {
        "text_answer": "Contradiction The evidence shows that 24 out of 25 participants in the Sunitinib  Docetaxel  Trastuzumab arm of the trial experienced treatmentemergent adverse events",
        "label": "Contradiction"
    },
    "5b100056-e657-4b2a-9ecf-8b949233ab50": {
        "text_answer": "Contradiction for the given evidence there are no psychiatric events reported in either Adverse Events 1 or 2",
        "label": "Contradiction"
    },
    "fa664989-b970-41f4-b491-dd2aeb308dd1": {
        "text_answer": "Contradiction The evidence shows that no adverse events were recorded in the secondary clinical trial but the statement claims that no adverse events of certain types hypertension angina pectoris and dizziness were observed in the primary clinical trial which is not the same as saying that no adverse events were recorded at all",
        "label": "Contradiction"
    },
    "bc686408-6e00-414a-b5a4-2bae034aca57": {
        "text_answer": "Contradiction The evidence states that individuals with interstitial lung disease or pneumonitis are excluded from the trial but it does not specifically mention diffuse parenchymal lung disease within the last three years as an exclusion criterion",
        "label": "Contradiction"
    },
    "5e5253e5-fd72-4f2b-84ba-b370545cd182": {
        "text_answer": "Contradiction  Explanation The statement mentions several cases of Anaemia and Febrile neutropenia in cohort 1 but the evidence shows only 1 case of each The statement also mentions 0 cases of Pancytopenia which is consistent with the evidence However the statement and the evidence do not agree on the number of cases of Anaemia and Febrile neutropenia in co",
        "label": "Contradiction"
    },
    "fe6c20be-e0c6-461c-9e93-cef55bdd7902": {
        "text_answer": "Contradiction  Explanation  The statement chemotherapy or radiotherapy patients from the last 2 weeks those with unstable angina and patients with grade 2 or above neuropathy are qualified for participation in the secondary clinical trial but are not allowed in the primary clinical trial is a contradiction based on the provided evidence  The primary clinical trial excludes patients who have received chemotherapy or radiotherapy within 2 weeks",
        "label": "Contradiction"
    },
    "6b5a90bf-c45f-4a85-807f-1f184463cf5f": {
        "text_answer": "Contradiction  The evidence states that no episodes of vomiting and no rescue medication were reported during the first 24 hours after cyclophosphamide administration for the ArmGroup titled Aprepitant Dexamethasone Cytoxan  Kytril which contradicts the statement that acute vomiting was reported by over 50 of the patients",
        "label": "Contradiction"
    },
    "eb8737bb-19f6-4249-83da-63b05b251084": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 sunitinib starting dose is 25 mg daily and in Intervention 2 paclitaxel starting dose is 90 mgm2 Both these doses are not mentioned in the statement hence the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "d303ce9d-a00a-4ee7-8147-0bac063ee210": {
        "text_answer": "Entailment The evidence shows that disease progression impacted multiple participants in the primary clinical trial under the category General disorders and administration site conditions  Other",
        "label": "Entailment"
    },
    "f34e13a3-4463-4cf4-8a15-79872282b90e": {
        "text_answer": "Contradiction The primary trial specifies Japanese females while the secondary trial does not specify any nationality",
        "label": "Contradiction"
    },
    "5cc13d6e-bc37-47d3-8198-8e7af5a8b5a2": {
        "text_answer": "Contradiction The statement is a contradiction because the primary trial explicitly states that children are unable to participate but the secondary trial does not explicitly state that they are ineligible",
        "label": "Contradiction"
    },
    "4d3272e0-735a-4531-9f23-c0e4660c64a5": {
        "text_answer": "Entailment  Explanation The evidence shows that there were no reported adverse events AEs involving anorexia hypothermia or hallucinations in both the primary and secondary clinical trials The statement that there are zero documented AEs involving anorexia hypothermia or hallucinations in both trials is an entailment of the evidence as the statement is a logical consequence of the evidence provided",
        "label": "Entailment"
    },
    "dd33f2de-6bfc-4a27-95da-630c9f0c0574": {
        "text_answer": "Contradiction The evidence provided in the inclusion and exclusion criteria for both trials indicates that certain demographic factors such as gender are considered in the eligibility criteria",
        "label": "Contradiction"
    },
    "d81e386d-9799-44bc-b006-8fdd7c14103c": {
        "text_answer": "Contradiction  The primary trial uses oral pregabalin while the secondary trial uses intrathecal Depocyt and intravenous highdose Methotrexate There is no evidence of the primary trial using 1000 mg of oral pregabalin twice daily",
        "label": "Contradiction"
    },
    "7bad3ae8-835f-401c-b50d-10e2f2773cc7": {
        "text_answer": "Contradiction The evidence does not provide information about the recurrencefree survival rate being 604 for the Ketorolac 30 mg group compared to the NaCl 09 3mL group",
        "label": "Contradiction"
    },
    "09816bed-e4f7-4b1c-8599-fbc623fa9675": {
        "text_answer": "Entailment The intervention in the secondary trial lasts for 24 weeks which is 35 months longer than the 10week intervention in the primary trial",
        "label": "Entailment"
    },
    "103f19bc-87b9-4017-b2d8-8afd8bc54157": {
        "text_answer": "Contradiction The primary trial does not involve radiation therapy at all",
        "label": "Contradiction"
    },
    "b1695ed3-b79e-4e1a-8658-52f33b997fea": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial does include massage therapy which can be considered a nonpharmacological treatment but it also mentions pain therapy which is a pharmacological treatment Therefore the primary clinical trial does examine a pharmacological treatment and the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "b7d7f9f1-1e62-403f-9ceb-234108f7569f": {
        "text_answer": "Contradiction The secondary trial explicitly includes patients with stage IV breast cancer as an exclusion criterion However the primary trial accepts patients with stage IV breast cancer as part of its inclusion criteria",
        "label": "Contradiction"
    },
    "2853d135-6a33-4c1f-bf2c-251ef936c5dd": {
        "text_answer": "Contradiction  The evidence shows that in Adverse Events 1 there is one patient who experienced both increased pleural effusion and rapid disease progression out of 13 patients which is a rate of 769 However the statement suggests that 025 of the patients in the primary trial suffered from both conditions which is a rate of 25 Therefore the statement contradicts the evidence",
        "label": "Contradiction"
    },
    "d8d3ab61-0fc8-462a-930b-114b2363d70a": {
        "text_answer": "Contradiction The evidence shows that each adverse event affected between 0 and 4545 of patients",
        "label": "Contradiction"
    },
    "8e18ed71-8fa4-4d81-841d-ce718daa0f41": {
        "text_answer": "Entailment The evidence states that patients with any tumor type that tests positive for CCND1 amplification are eligible for the clinical trial",
        "label": "Entailment"
    },
    "4acaf50b-e6af-497a-a0d2-709e5780dd0b": {
        "text_answer": "Contradiction The statement implies that there were over fortytwo patients in both cohorts who experienced pCR around 210 days after surgery However the evidence only provides the number of participants with pCR in each cohort at the time of surgery which is approximately 7 months There is no information given about the number of participants who experienced pCR around 210 days after surgery",
        "label": "Contradiction"
    },
    "a752838e-30be-4438-913e-e905d2893abc": {
        "text_answer": "Contradiction The secondary trial explicitly excludes individuals who are smokers",
        "label": "Contradiction"
    },
    "4e4b2acf-c921-4f0d-b9e9-6a54fe5d9877": {
        "text_answer": "Contradiction The primary trial does not provide any information about the participants having difficulty planning for the future due to illness",
        "label": "Contradiction"
    },
    "2a95f6b8-fbdd-47e6-949f-8aee18a2c605": {
        "text_answer": "Contradiction The statement is a contradiction because the primary trial includes Japanese females but the secondary trial has specific eligibility criteria that may or may not include Japanese females",
        "label": "Contradiction"
    },
    "e658eb5e-3411-4dcb-bff2-6bad677ac1a7": {
        "text_answer": "Contradiction  Explanation The statement is about primary tumor diameter reduction while the evidence provided is about percentage change in betaCTX levels These two outcomes are not directly related and there is no information in the evidence about the primary tumor diameter reduction in the AZD0530 175 mg and Zoledronic Acid 4 mg groups",
        "label": "Contradiction"
    },
    "3f4231c5-0eae-43eb-b0df-b270cea08476": {
        "text_answer": "Contradiction  The evidence shows that 423 of participants in the CCI group and 417 in the PCM group were up to date for their cervical cancer screenings at baseline Therefore it is not true that all patients in cohort 1 were behind schedule for their cervical cancer screenings before the intervention",
        "label": "Contradiction"
    },
    "6fdb953d-a7b8-41b9-8652-2d8b51bfcaa0": {
        "text_answer": "Entailment  Explanation The statement no adverse events were experienced by any participants in the primary clinical trial likewise in the secondary clinical trial is an entailment based on the evidence provided Both trials had no reported adverse events according to the data given",
        "label": "Entailment"
    },
    "99433bba-fce5-4b0a-a076-1f699b51472d": {
        "text_answer": "Contradiction The evidence states that participants received niraparib 200 mg daily not talazoparib 1000 mcg",
        "label": "Contradiction"
    },
    "9a111f3a-a29a-42fa-bf73-9f178286198c": {
        "text_answer": "Entailment The statement is an entailment as the evidence shows that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after breast cancer surgery reduces Ki67 Expression in Tumors by an average of 40",
        "label": "Entailment"
    },
    "8f8be6b6-df75-4757-bc64-b2fbc8849f70": {
        "text_answer": "Contradiction The statement is not entirely accurate based on the evidence provided While there was no recorded case of shingles in group 1 of the secondary trial and the primary trial there was one recorded case in group 2 of the secondary trial However the statement does not mention group 2 in the secondary trial so it is a contradiction to the evidence as stated",
        "label": "Contradiction"
    },
    "4d5acda5-74be-4228-a24e-bcd405ac6af4": {
        "text_answer": "Entailment The statement correctly identifies that the only difference between the interventions is the dosage of durvalumab",
        "label": "Entailment"
    },
    "a95eba72-3c28-4c9b-a79f-011f1578907c": {
        "text_answer": "Contradiction The primary trial excludes participants with past treatment with Herceptin within the last 5 months but there is no mention of gabapentin in the primary trials inclusion or exclusion criteria In contrast the secondary trial allows concurrent use of Herceptin if there is no evidence of disease but excludes participants with past treatment with gabapentin within the last 3 months",
        "label": "Contradiction"
    },
    "88e7acab-bd9d-4e6c-a241-c538501824e8": {
        "text_answer": "Contradiction The statement CAPECITABINE was administered orally every day to every patient in cohort 2 of the primary trial for the first 21day cycle is a contradiction to the evidence which states that Capecitabine was administered orally from Days 1 to 14 every 21 days in the primary trial",
        "label": "Contradiction"
    },
    "985ff367-3936-4e38-92e7-45e1cb9f24ee": {
        "text_answer": "Contradiction The evidence provided in the primary and secondary trials does not support the statement that all adverse events noted in the primary trial are related to psychological distress The evidence in the primary trial indicates that the adverse events are related to various conditions affecting the blood and bone marrow and lymphatics while the evidence in the secondary trial indicates adverse events such as platelet count decreased hypocalcemia and hypokalemia",
        "label": "Contradiction"
    },
    "1e826f28-5a81-4123-95f7-74418392ed90": {
        "text_answer": "Contradiction  Explanation The statement participants in the primary clinical trial receive a diverse drug regimen each not exceeding a dose beyond 50 mgm2 is a contradiction to the evidence provided in the primary trial The evidence shows that the participants receive epirubicin 100 mgm2 cyclophosphamide 600 mgm2 docetaxel",
        "label": "Contradiction"
    },
    "cdc80bd8-0b1c-4908-9095-74a1a7078e43": {
        "text_answer": "Contradiction  Explanation The statement patients in cohort 2 of the primary clinical trial are administered lesser amounts of cyclophosphamide compared to docetaxel is a contradiction based on the evidence provided In Intervention 1 patients receive 600 mgm2 of cyclophosphamide and in Intervention 2 they receive 600 mgm2 of cycloph",
        "label": "Contradiction"
    },
    "2fa66862-310e-454e-a0d6-5e3ef0ec1e2d": {
        "text_answer": "Contradiction  The evidence shows that there were 10 participants with stable disease at week 24 compared to 12 participants with stable disease at week 12 The statement suggests that there were more participants with stable disease at week 24 than at week 12 which is not consistent with the evidence",
        "label": "Contradiction"
    },
    "4a47dcda-1105-46c5-8f3d-ffbfe5259d70": {
        "text_answer": "Contradiction The primary trial measures hot flash scores on a scale while the secondary trial measures overall response rate as a proportion of responders",
        "label": "Contradiction"
    },
    "af1e26a0-09d7-408f-89ec-be5bf4bfc88c": {
        "text_answer": "Contradiction  The evidence shows that the participants in the paced respiration group had a lower mean number of hot flashes per day 348 compared to the fast shallow breathing group 395 Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "1ec46b05-25a0-45c2-a6aa-31f5a2209ac5": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided",
        "label": "Entailment"
    },
    "056fccd5-f005-4088-8f9b-c22b87eaa371": {
        "text_answer": "Entailment Both the primary and secondary trials involve oral interventions",
        "label": "Entailment"
    },
    "e7e2f4af-f6c2-47cc-b03e-6e69210d14c7": {
        "text_answer": "Contradiction The evidence does not support the statement that patients in the primary trial survive on average over 4 years The given results show that the median survival for both groups was less than 3 years Additionally the statement mentions that at least one patient from both cohorts died in under 3 days but the evidence does not provide information on the survival distribution beyond the median",
        "label": "Contradiction"
    },
    "542ebedc-ffda-406e-9ef5-d2f9edc30ac1": {
        "text_answer": "Contradiction  The statement CAPECITABINE was administered orally every day to every patient in cohort 2 of the primary trial for the first 21day cycle is a contradiction to the evidence which states that Capecitabine was administered orally from Days 1 to 14 every 21 days in the primary trial",
        "label": "Contradiction"
    },
    "e6fb96bc-d38b-484e-8d2a-fe14f943c599": {
        "text_answer": "Contradiction   The evidence states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial but it does not mention anything about patients who did not respond to trastuzabin being ineligible",
        "label": "Contradiction"
    },
    "c3d9b60a-a46e-4bde-9e4a-46db5c2d75ba": {
        "text_answer": "Contradiction The primary trial is not about pills but rather about topical applications of Hydrophor and MediHoney The secondary trial is also about topical applications but of the same gel treatment PF05212384 in different quantities",
        "label": "Contradiction"
    },
    "b9f4eb6e-b05b-44e8-b92d-62624cc71935": {
        "text_answer": "Contradiction The secondary trial measures pain not functional mobility improvements in physical therapy",
        "label": "Contradiction"
    },
    "be8707c6-9004-4fab-b719-c1ab372a77a1": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial includes patients with DCIS and stage IIII invasive carcinoma of the breast not just invasive lobular carcinoma and not all patients are undergoing chemotherapy",
        "label": "Contradiction"
    },
    "04178e95-d808-4a96-ab85-61eb52c17720": {
        "text_answer": "Contradiction The evidence states that there were 24 participants with treatmentemergent adverse events not 35 as stated in the question",
        "label": "Contradiction"
    },
    "74866fee-c33b-4df9-8d5c-28b47182b753": {
        "text_answer": "Contradiction The primary trial involves a continuous treatment cycle with PF05212384 and docetaxel while the secondary trial operates on a 3week cycle However the statement does not necessarily imply that the treatments cannot both be ongoing at the same time so it is not an entailment",
        "label": "Contradiction"
    },
    "96be8dc9-8873-475f-b91f-e92f3549861b": {
        "text_answer": "Contradiction The primary trial explicitly states that it is for female or male patients 18 years of age while the secondary trial does not mention any age restriction",
        "label": "Contradiction"
    },
    "d82bb7da-6579-43be-969a-206d2235afd3": {
        "text_answer": "Contradiction  Explanation The evidence provided shows that in the primary trial 1125 327 of patients experienced infections which is less than 15 In the secondary trial 0 of patients in the first adverse event set and 20 of patients in the second adverse event set experienced infections Therefore the overall percentage of patients who experienced infections in the secondary trial is",
        "label": "Contradiction"
    },
    "05fbffcf-c1a0-40f9-95dd-8e9010005773": {
        "text_answer": "Contradiction The primary trial and the secondary trial report results from different patient cohorts The primary trial reports results from a cohort of participants receiving denosumab while the secondary trial reports results from a cohort of participants receiving dmethadone",
        "label": "Contradiction"
    },
    "cbcecc39-a187-40ca-86cf-06d9c75ff972": {
        "text_answer": "Entailment assuming that the evidence provided applies to all Japanese individuals",
        "label": "Entailment"
    },
    "2f30372d-c143-495d-96d9-ad238ff94baf": {
        "text_answer": "Contradiction The evidence states that both cohorts in the primary clinical trial receive dexamethasone not that it is an exclusionary criterion",
        "label": "Contradiction"
    },
    "2db5cad0-f216-4e18-accf-87e3308afc59": {
        "text_answer": "Contradiction The secondary clinical trial does not measure outcomes using the Measure Yourself Medical Outcome Profile MYMOP questionnaire Instead it measures changes in isothiocyanate in urine samples",
        "label": "Contradiction"
    },
    "71f1d2c6-7ab2-45d2-bb54-a0cad79d244b": {
        "text_answer": "Contradiction  Explanation The statement mentions 13 of the primary trial participants with PR Primary Breast Cancer but the primary trial results provided do not mention the percentage of participants with PR primary breast cancer or any information about their HER2 status The statement also mentions developed HER2 Metastases but the primary trial results do not provide information about the development of HER2 metastases in the participants",
        "label": "Contradiction"
    },
    "1dd07ae9-349c-41e1-b967-fd8691e320e0": {
        "text_answer": "Contradiction  The statement implies that patients with unstable angina or grade 3 or above neuropathy cannot participate in the secondary trial but the exclusion criteria for the secondary trial do not include these conditions specifically However the primary trial exclusion criteria do include unstable angina and grade 3 or above neuropathy Therefore the statement is a contradiction of the given evidence",
        "label": "Contradiction"
    },
    "aa25fae6-9d48-4237-92d0-504cfc8af672": {
        "text_answer": "Contradiction The primary trial intervention involves cabergoline which is given orally while the secondary trial interventions involve pixantrone which is administered intravenously",
        "label": "Contradiction"
    },
    "e53fdbd4-4375-409d-ad00-322822909d5b": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence as the primary trial involves a single injection of Triptorelin or Degarelix at the beginning of the study while the secondary trial involves weekly injections of Epoetin Beta for 12 weeks",
        "label": "Contradiction"
    },
    "7e5ca0bb-bae1-493f-9a30-7f70d544fcf4": {
        "text_answer": "Entailment The statement is an entailment of the evidence because the evidence states that participants in the primary clinical trial have breast cancer that has continued to grow after receiving hormonal treatment and they are postmenopausal women who require hormonal treatment The statement on the other hand only requires that participants have breast cancer and need hormone treatment which is a subset of the inclusion criteria in the evidence",
        "label": "Entailment"
    },
    "6c5d5b1a-e7e0-427f-b21b-a9fbc5e2b69e": {
        "text_answer": "Contradiction The primary trial intervention cabergoline is given orally not topically The secondary trial interventions pixantrone are given intravenously not through a urinary catheter",
        "label": "Contradiction"
    },
    "46065ce7-6618-4f08-890c-6bd0f8fa4573": {
        "text_answer": "Contradiction  Explanation The primary trial and the secondary trial have different inclusion criteria The primary trial is for women with breast cancer while the secondary trial is for women with breast cancer who are considering or undergoing mastectomy The statement mentions men with newly diagnosed stage II prostate cancer which is not related to the trials described in the evidence",
        "label": "Contradiction"
    },
    "d20c94ae-14d5-4272-96d5-ef649dfade50": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of any eating disorders in the given adverse events",
        "label": "Contradiction"
    },
    "56c00437-a067-4734-9b55-f1041c10190e": {
        "text_answer": "Contradiction  The evidence states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the study The statement suggests that patients with no improvement with herceptin treatment or those who have previously experienced serious anaphylactic reactions to herceptin may participate However the evidence does not allow for patients with serious allergic reactions to herceptin to participate",
        "label": "Contradiction"
    },
    "85cdaaef-3a05-458f-aaf2-d935069cf478": {
        "text_answer": "Contradiction  Explanation  In the primary trial intervention 1 Arm I involves zoledronic acid given intravenously while intervention 2 Arm II involves placebo given orally  In the secondary trial intervention 1 Arm II involves granisetron hydrochloride dexamethasone prochlorperazine and placebo given intravenously and orally Inter",
        "label": "Contradiction"
    },
    "65fc2061-6d0f-46d1-bd13-5959cedf6b03": {
        "text_answer": "Contradiction  Explanation  In the primary trial there are two arms Arm 1 CBTI  Placebo and Arm 2 CBTI  Armodafinil In Arm 2 patients receive Armodafinil PO daily for 47 days with a varying dosage  In the secondary trial there are also two arms Ph Ib MCS11",
        "label": "Contradiction"
    },
    "ebe96d52-cfbc-403c-ba10-244991ddc449": {
        "text_answer": "Entailment Both trials investigate the use of empegfilgrastim but they differ in dosage amounts and outcome measurement",
        "label": "Entailment"
    },
    "840eeabe-3086-4be9-98fc-deaf26b4349b": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the percentages provided in the evidence do not match the ones in the statement The evidence shows that 897 of participants in the NaCl 09 3mL group experienced Recurrencefree Survival not 67",
        "label": "Contradiction"
    },
    "a02864dc-e1f8-427e-9df3-531c91d28d50": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not mention anything about cyclindependent kinase inhibitor protein",
        "label": "Contradiction"
    },
    "05f34052-08b6-4b98-91d3-326b4f77844c": {
        "text_answer": "Contradiction The evidence clearly states that therapeutic autologous dendritic cells are given by id injection which is not considered a topical treatment Additionally Trastuzumab is infused intravenously",
        "label": "Contradiction"
    },
    "4927c9bb-aa2b-4c3c-999b-068e1dca959a": {
        "text_answer": "Contradiction The primary trial does not involve intravenous chemotherapy but rather radiation therapy The secondary trial involves oral medication Enzastaurin and intramuscular injection Fulvestrant in addition to possible radiotherapy",
        "label": "Contradiction"
    },
    "304f8d66-90f2-40cc-9f18-77c2b8471a40": {
        "text_answer": "Contradiction The primary trial involves radiation therapy while the secondary trial involves the administration of fulvestrant tablets not radiation therapy",
        "label": "Contradiction"
    },
    "6088eecc-56f9-475b-a27a-a23bc646028b": {
        "text_answer": "Contradiction The evidence shows that 25 participants experienced a total of 5 adverse events which is more than 3 adverse events per participant",
        "label": "Contradiction"
    },
    "ff8c88f9-c698-4ad0-a9ba-0acf6fbf1933": {
        "text_answer": "Contradiction The primary trial and secondary trial address different conditions sellar schwannoma vs bone metastases and different outcomes overall response rate vs time to first onstudy SRE",
        "label": "Contradiction"
    },
    "f9d5b863-f0cb-4777-81a7-358efd8010d6": {
        "text_answer": "Neutral  The statement does not directly entail or contradict the evidence provided The evidence only specifies the timing of Dexamethasone administration in the two cohorts while the statement discusses the occurrence of splenic rupture which is not related to the timing of Dexamethasone administration",
        "label": "Entailment"
    },
    "31b3aa86-f32c-4a10-ae36-6429b25995dc": {
        "text_answer": "Contradiction The evidence does not mention anorexia as an inclusion criterion for the primary clinical trial",
        "label": "Contradiction"
    },
    "da91afa9-21ed-4d4d-a5d9-964dbb334177": {
        "text_answer": "Contradiction The evidence describes the use of laserassisted fluorescence angiography Spy Elite LifeCell in the primary clinical trial which is not related to ultrasoundassisted biopsy",
        "label": "Contradiction"
    },
    "a012091a-9e07-4878-81bf-fee2e3282cbd": {
        "text_answer": "Contradiction The statement is about patients with metastatic SCBC small cell lung cancer being excluded from the primary trial while the question is about the significance of bleeding with urination for an individual",
        "label": "Contradiction"
    },
    "5fcf6210-c07a-4b8e-9944-c2f0714e4d69": {
        "text_answer": "Entailment  Explanation The statement All the primary trial participants receive lower doses of drugs than the secondary trial participants is an entailment based on the evidence provided In the primary trial the doses of PF06647020 used were 02 mgkg and 05 mgkg which are lower than the dose of 0015 mgkgdose and",
        "label": "Entailment"
    },
    "800c7053-0dd5-4c99-ba55-c45b121d303c": {
        "text_answer": "Entailment The evidence states that both interventions use laserassisted fluorescence angiography and the statement also includes the use of lateral radial incisions which is also present in the evidence for both interventions",
        "label": "Entailment"
    },
    "cdab084c-4e2b-4f0a-ac8c-868b4bb4ecb5": {
        "text_answer": "Contradiction The evidence does not support the statement that participants in the primary clinical trial are administered placebo on days 1 8 and 15 Instead the evidence describes the administration of various chemotherapy drugs and bevacizumab during the trial",
        "label": "Contradiction"
    },
    "ec5c26e8-0afd-4244-8731-588c4f88e84b": {
        "text_answer": "Entailment  Explanation The statement cohort 1 of the primary clinical trial has multiple records of cardiacrelated adverse events is an entailment based on the evidence provided as the evidence shows that there were indeed multiple records of cardiacrelated adverse events in cohort 1 of the primary clinical trial eg acute coronary syndrome angina pectoris cardiac arrest cardiac failure",
        "label": "Entailment"
    },
    "e4575416-926c-4b2d-b4ba-1aa417cae0db": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the placebo intervention involves Buminate solution which is not identical to the alloMSCs intervention",
        "label": "Contradiction"
    },
    "66c31a74-8bb0-4625-9ce7-401da56be447": {
        "text_answer": "Neutral The evidence does not provide enough information to determine if the statement is an entailment or contradiction  Explanation The statement fatigue interferes with certain duties and responsibilities is not directly related to the inclusion or exclusion criteria for the primary trial The evidence provided only mentions the inclusion and exclusion criteria for the trial and does not mention anything about fatigue or its potential impact on duties and responsibilities Therefore",
        "label": "Entailment"
    },
    "eff8deaa-08a6-4df3-9140-fe153fbcba6e": {
        "text_answer": "Entailment In the primary trial the intervention lasts for 10 weeks and in the secondary trial the intervention lasts for 24 weeks which is three times as long",
        "label": "Entailment"
    },
    "31bb177c-1a8b-4699-a7f2-4c442801770f": {
        "text_answer": "Entailment The evidence shows that the total number of adverse events was higher in the first cohort 45106 compared to the second cohort 7103",
        "label": "Entailment"
    },
    "c2aea351-6ce5-4d26-9ba5-2632c6367b93": {
        "text_answer": "Entailment The evidence shows that there were a total of 6 different adverse events experienced by patients in the primary trial so it is entailed that at least one patient suffered several different adverse events",
        "label": "Entailment"
    },
    "3ff8b1f7-4c73-4cb7-acbd-4d7e3b7f31ec": {
        "text_answer": "Contradiction The primary trial does not list these specific medications as exclusion criteria",
        "label": "Contradiction"
    },
    "9cd25233-1d76-4d0d-a571-ce8fee279757": {
        "text_answer": "Contradiction The evidence states that pregnant women are excluded from both trials Morbidly obese patients are not explicitly mentioned as an exclusion criterion but morbid obesity is not mentioned as a qualification for eligibility either However the statement suggests that morbidly obese and pregnant patients can be eligible which contradicts the evidence",
        "label": "Contradiction"
    },
    "340721ab-42f9-4ac3-8608-58007d89b87b": {
        "text_answer": "Contradiction The evidence does not support the statement as it does not mention any adverse events related to respiratory issues for either cohort 1 or 2",
        "label": "Contradiction"
    },
    "16aacacc-1ab7-46d2-a59e-ca207cb0282d": {
        "text_answer": "Contradiction The evidence provided does not mention parathyroid carcinoma as an exclusion criterion for either the primary or secondary trials",
        "label": "Contradiction"
    },
    "68716599-d21d-433a-9e8d-5113749d4a06": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the total adverse events in the primary trial are fewer than in the secondary trial but there is one more case of cardiacischemiainfarction in the secondary trial",
        "label": "Contradiction"
    },
    "90fc98fa-35bb-48ae-a2f3-b74e6bd0d353": {
        "text_answer": "Contradiction  Explanation The evidence shows that a total of 6 patients were enrolled in the primary clinical trial and across both cohorts a maximum of 5 different types of adverse events were reported in each cohort Therefore based on the evidence the statement that more than four different types of adverse events affected patients in the primary clinical trial across all cohorts is a contradiction",
        "label": "Contradiction"
    },
    "3ac94edb-bccc-44c6-9b1a-4ea79122d154": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the administration of epacadostat and pembrolizumab while the secondary trial involves the administration of sunitinib alone Therefore the statement is not directly applicable to the evidence provided and is a contradiction",
        "label": "Contradiction"
    },
    "0d95a819-09cb-49a0-9ec0-76a64bc50732": {
        "text_answer": "Contradiction The primary trial involves an oral intervention with cabergoline while the secondary trial involves intravenous administration of pixantrone dimaleate",
        "label": "Contradiction"
    },
    "9d9db340-6fee-4ec0-b6cb-7fdfe2d34959": {
        "text_answer": "Contradiction The evidence shows that there was one case of edema in each cohort",
        "label": "Contradiction"
    },
    "d43e7757-45d0-4f65-9735-6ba05f13337d": {
        "text_answer": "Contradiction The primary trial excludes patients who have received chemotherapy or radiotherapy within 4 weeks prior to entering the study while the secondary trial excludes patients who have had chemotherapy or radiotherapy within 4 weeks of study entry Therefore the statement is a contradiction as it suggests that primary trial candidates cannot undergo CBTbased treatments but may qualify for the secondary trial which also excludes them due to recent chemotherapy or radiotherapy",
        "label": "Contradiction"
    },
    "908f5aed-eb98-47f8-b00d-7ce39707446f": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The evidence only mentions that both Cohort A and B receive the same number and schedule of electroporation injections of LD V934 but it does not mention anything about HPV16 infection or cervical cancer",
        "label": "Entailment"
    },
    "b8ffb304-4dd2-4fa9-888e-b851c73513c1": {
        "text_answer": "Entailment  Explanation The statement most patients from the first cohort of the primary clinical trial irrespective of their cancer type had completed their screenings following the intervention is an entailment based on the evidence provided The evidence shows that a significant increase in the percentage of participants who were up to date for colorectal breast and cervical cancer screenings occurred in both the Collaborative Care Intervention CC",
        "label": "Entailment"
    },
    "47074986-36ac-4ebe-a743-cdf06a70efd8": {
        "text_answer": "Contradiction The statement about Alzheimers patients being ineligible for the trial is not related to the statement about rete ovarii adenoma",
        "label": "Contradiction"
    },
    "698a471b-ead0-445f-93bb-4badc6382968": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction to the evidence because the evidence does not support the statement that the Bevacizumab cohort had a higher incidence of Disease Progression or Death than the Bevacizumab  Capecitabine cohort In fact the evidence shows that a lower percentage of participants in the Bevacizumab cohort experienced Disease Progression or Death compared to",
        "label": "Contradiction"
    },
    "0ec15a9a-41f5-44aa-a089-c5f0fe5c9806": {
        "text_answer": "Contradiction The primary trial includes all types of breast cancer while the secondary trial specifically includes those with Her2neu breast cancer",
        "label": "Contradiction"
    },
    "09ebfb97-f98c-4555-9e69-85b60af863fa": {
        "text_answer": "Entailment The evidence states that patients will take Vorinostat daily during radiation therapy so the statement that daily vorinostat capsule intake during radiation therapy is mandatory for every patient is an entailment",
        "label": "Entailment"
    },
    "a326e30f-a2c9-4a6e-b497-02cc338735c5": {
        "text_answer": "Contradiction The primary trial only includes patients undergoing surgery for Stage IIII breast cancer and a woman with Stage IV BC would not meet that criteria The secondary trial includes patients who have completed surgery for Stage IIII breast cancer but it also has additional requirements completion of treatment specific plasma CRP level and fatigue level that a woman with Stage IV BC would not meet",
        "label": "Contradiction"
    },
    "2ce21ccd-8f05-4618-8597-b1ad8be31f59": {
        "text_answer": "Contradiction The statement is about a different trial involving a different regimen cisplatindoxorubicinpaclitaxel and does not relate to the laserassisted fluorescence angiography used in the primary trial",
        "label": "Contradiction"
    },
    "d1c52b9f-7feb-4d54-af86-7aace67807d4": {
        "text_answer": "Entailment Both groups receive equal doses of radiation therapy according to the evidence and they both undergo a SPECT scan as stated in the evidence",
        "label": "Entailment"
    },
    "eff637a6-8d7c-47e9-bcba-b4b52159aa4d": {
        "text_answer": "Contradiction The primary trial compares the operative time savings between two groups while the secondary trial does not have a control group for comparison",
        "label": "Contradiction"
    },
    "5c06c081-87ef-4e9a-ab22-c8c55253fc34": {
        "text_answer": "Contradiction  Explanation The statement there were fewer instances of mucositis oral bladder infection and thromboembolic events noted in the primary clinical trial compared to the secondary clinical trial is a contradiction based on the evidence provided because the evidence does not show that mucositis oral bladder infection or thromboembolic events were noted at all in the secondary clinical trial",
        "label": "Contradiction"
    },
    "74c7adc7-9641-4858-88af-69a2e2cd6dad": {
        "text_answer": "Contradiction  Explanation The statement mentions that Paclitaxel is only used in cohort 1 but the evidence provided does not mention anything about Paclitaxel being used or not used in either cohort The statement also mentions that cohort 2 is administered fulvestrant instead of Paclitaxel which is consistent with the evidence However the statements first part is incorrect because it makes a claim about",
        "label": "Contradiction"
    },
    "ab848536-4d43-4af3-9489-59b7608b7ecf": {
        "text_answer": "Contradiction The statement provides information about the number of participants who achieved recurrencefree survival in each group which is different from the statement in the previous question that only mentioned the percentage of participants who achieved recurrencefree survival",
        "label": "Contradiction"
    },
    "62716b99-76d4-4dfe-b0ce-1ad35f768b33": {
        "text_answer": "Contradiction The primary trial only includes patients with an ECOG performance status of 0 to 2 while the secondary trial includes patients with an ECOG 02 OR Karnofsky 60100 Therefore an ECOG score of 1 does not necessarily make a candidate suitable for participation in both trials as the secondary trial also includes patients with a Karnofsky performance status of 60100",
        "label": "Contradiction"
    },
    "2fb3af20-adda-4fee-860a-ce376d3a0bb2": {
        "text_answer": "Contradiction  The evidence states that there were 12 participants with stable disease at week 12 and 10 participants with stable disease at week 24 However the statement asserts that there were more participants with stable disease in week 12 than week 24 which is not supported by the evidence Additionally the statement also asserts that there were no participants with complete response in week 12 or 24 but the evidence",
        "label": "Contradiction"
    },
    "4988cb16-7dbb-4847-84e0-4a7957b32c72": {
        "text_answer": "Contradiction The primary trial explicitly excludes participants who have undergone major surgery within 28 days prior to the study registration date while the secondary trial does not mention any such restriction Therefore a patient who has received an organ transplant within the last month and is still bedridden could potentially be eligible for the secondary trial but not the primary trial",
        "label": "Contradiction"
    },
    "ed247cb5-ed15-4c1b-940d-099d16ee7f53": {
        "text_answer": "Entailment The statement that the same therapeutic approach is applied to breast cancer and ovarianperitoneal cancer patients participating in the primary clinical trial is an entailment given the evidence as both groups of patients are receiving talazoparib capsules with various dosages",
        "label": "Entailment"
    },
    "0cab14c5-398c-4e4e-9c6a-65fb70aecb23": {
        "text_answer": "Contradiction The primary trial is not testing an acupuncture intervention",
        "label": "Contradiction"
    },
    "9c4db46a-f5c4-46f0-9d28-8b18bbb9583a": {
        "text_answer": "Contradiction The evidence does not support the statement as there are no cases of asthenia or pyrexia reported in either trial",
        "label": "Contradiction"
    },
    "d68944ff-4237-41b8-9ba1-bdfd9899ba32": {
        "text_answer": "Contradiction The evidence reports only one case of shingles across all patient cohorts in both trials",
        "label": "Contradiction"
    },
    "d9d506ef-20ed-44e2-9809-07cb0772535b": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one case of Infections and Infestations  Other Gramnegative bacteremia 40 degree C fever in cohort 2 but the statement claims that all such cases were in cohort 1",
        "label": "Contradiction"
    },
    "e15409e3-408c-4ea8-a0aa-9f1072b8a74b": {
        "text_answer": "Contradiction  Explanation  In the primary trial the statement patients enrolled in the primary clinical trial will receive a constant unchanging dose of alpha lipoic acid throughout the study is not true because the dose of alpha lipoic acid is not constant and may be escalated until a maximum tolerated dose is found  In contrast in the secondary trial necitumumab doses are not constant either but",
        "label": "Contradiction"
    },
    "335235f3-4d27-479e-a5d7-29016a3320a5": {
        "text_answer": "Contradiction The evidence mentions only Surgery as an adverse event in the primary trial while the statement mentions anemia and nausea which are not mentioned in the evidence",
        "label": "Contradiction"
    },
    "9b120158-866e-4a68-ab9a-4d6241ead464": {
        "text_answer": "Contradiction The primary trial reports results using the units of percentage and mgdL while the secondary trial reports results using the unit of participants Additionally the primary trial is about a different drug denosumab and disease indication tumor response compared to the secondary trial dmethadone and safe dose",
        "label": "Contradiction"
    },
    "ad1abf74-05c4-439a-b178-f21231744c89": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it is not related to the primary trials inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "1786385e-70c9-4a5b-a19e-0f389be545cc": {
        "text_answer": "Contradiction The primary trial does not require a diagnosis of a gene mutation for inclusion",
        "label": "Contradiction"
    },
    "0bb51a03-72e6-4d48-8010-054e280a960f": {
        "text_answer": "Contradiction The evidence does not support the statement as it does not mention any adverse events related to mental health for cohort 1 of the primary trial",
        "label": "Contradiction"
    },
    "d30d2472-9529-4206-8167-5bace92bb6d0": {
        "text_answer": "Contradiction The primary trial uses a cyclic treatment schedule while the secondary trial does not have a cyclic treatment mentioned in the evidence The statement about spastic paraplegia is not related to the trials and their interventions",
        "label": "Contradiction"
    },
    "96be5169-0334-4849-a77b-111e8eacf7bb": {
        "text_answer": "Contradiction The evidence states that no adverse events were recorded in either cohort of the primary clinical trial The statement implies that at least one cohort recorded multiple adverse events",
        "label": "Contradiction"
    },
    "47507d4a-ea24-433a-9864-e4b76657335c": {
        "text_answer": "Entailment The evidence supports that there were no instances of intestinal obstructions or pancytopenia reported in both trials",
        "label": "Entailment"
    },
    "3e16b4a5-6dc6-4a20-a367-c361bc38644e": {
        "text_answer": "Contradiction The evidence does not support the statement that on average patients have a survival rate exceeding two years as the median survival for both groups is less than 25 years Additionally the statement does not specify which group the data is referring to and the evidence provided is for two separate groups A and B with no information about their overlap or combined survival data",
        "label": "Contradiction"
    },
    "4d2b9583-9b62-40cc-b7e7-096c2dd16e0b": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial requires participants to have resistance to aromatase inhibitor AI therapy as an inclusion criterion In contrast the secondary clinical trial does not mention AI therapy resistance as a prerequisite for participation Therefore the statement resistance to AI therapy is a prerequisite for the primary clinical trial but not for the secondary clinical trial is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "49d0acfc-e7ce-45f5-8e45-08d55f3d0776": {
        "text_answer": "Contradiction  Explanation The statement is about the shrinking of primary tumor size which is not related to the data provided in the evidence about the percentage change in betaCTX levels",
        "label": "Contradiction"
    },
    "b68e076b-9950-438b-96ea-3fc93943e490": {
        "text_answer": "Contradiction The statement u wave abnormality by ecg finding is an electrocardiographic finding of u waves which have increased amplitude are inverted or merged with the preceding t wave Requiring considerable assistance and frequent medical care is not an entailment of the primary trial inclusion criteria as there is no mention of u wave abnormality in the inclusion criteria",
        "label": "Contradiction"
    },
    "3977a1e3-3371-4577-9dc1-eea3a725469c": {
        "text_answer": "Contradiction The primary trial does not involve necitumumab so the statement is not applicable to it",
        "label": "Contradiction"
    },
    "430f4379-7517-4dc9-a9e4-885f2934f872": {
        "text_answer": "Contradiction The statement is not an entailment as syncope was not the most frequently reported adverse event in the secondary trial as there were no reported cases of syncope in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "d2c3690c-11a2-40de-b077-acf5f53fdb10": {
        "text_answer": "Neutral  Explanation The statement myb gene fusion positive is an indication that a myb fusion gene has been detected in a sample is not directly related to the evidence provided The evidence only discusses the incidence of doselimiting toxicities in two patients from cohort 2 and does not mention anything about myb gene fusion status Therefore the statement is neutral with respect to the evidence",
        "label": "Entailment"
    },
    "91a6d0f0-3f3c-4bd7-80a5-f403fd7ef87e": {
        "text_answer": "Contradiction The primary trial mentions a breast tissue expander being used which may involve imaging for placement and monitoring The secondary trial mentions cardiac interventions with the use of a NOGA Myostar injection catheter which may involve imaging for guidance",
        "label": "Contradiction"
    },
    "d9b955ea-915d-438f-a9b1-cd1cc08c0dd4": {
        "text_answer": "Contradiction assuming the worst pain imaginable is a score of 10 on the numeric rating scale  Explanation The evidence does not entail that none of the patients in the primary trial experienced the worst pain imaginable for 10 weeks The evidence only reports the average pain intensity scores and their confidence intervals for each group It does not provide information on the distribution of pain intensity scores or the number of patients who experienced the worst pain imaginable",
        "label": "Contradiction"
    },
    "5b174c01-9e6e-4fa0-8c85-c7b72446d0b2": {
        "text_answer": "Contradiction   The primary clinical trial is investigating the effects of vaginal interventions with Estring and testosterone cream while the secondary clinical trial is studying the impacts of acupuncture and a waitlist control on lymphedema Neither trial is investigating physical therapy interventions for the treatment of lymphedema let alone physical therapy interventions in general and there is no mention of dietary changes in either trial",
        "label": "Contradiction"
    },
    "711fdd40-52ec-401c-90fc-5a11de547ab6": {
        "text_answer": "Contradiction  Explanation The statement eating disorders were not common for the primary trial candidates is a contradiction to the evidence as there is no mention of eating disorders in the list of adverse events for the primary trial",
        "label": "Contradiction"
    },
    "fd258898-9438-4474-a89e-7143a96abe06": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence states that patients will receive multiple injections dendritic cell vaccine trastuzumab and sargramostim on study day 8 and the days following",
        "label": "Contradiction"
    },
    "4b913a72-0c81-4396-8667-f087259328f6": {
        "text_answer": "Entailment assuming that unanticipated deaths or hospitalizations includes the reported cases of lymphoma in both trials",
        "label": "Entailment"
    },
    "a1a8bedd-680d-4250-9384-93379de0a2a3": {
        "text_answer": "Contradiction  Explanation The primary clinical trial involves the use of a vaginal ring Estring and testosterone cream while the secondary clinical trial involves acupuncture which is not a skin treatment but rather an invasive procedure using needles Therefore the statement is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "514d5612-4c60-4586-89b7-ca89b06ac576": {
        "text_answer": "Contradiction The primary trial inclusion criteria state that the primary tumor diameter should be greater than 2 cm not 330mm",
        "label": "Contradiction"
    },
    "3eb3c09a-b46f-49bf-84d6-7aeb1ba0d2a5": {
        "text_answer": "Contradiction The primary trial intervention involves Yttrium90 Radioembolization using TheraSphere while the secondary trial intervention consists of administering 560 mg of ibrutinib and 10 mgkg of MEDI4736 as oral medications These interventions are not the same",
        "label": "Contradiction"
    },
    "5b3b5c72-175a-42ea-aeab-63cd4298b362": {
        "text_answer": "Entailment The primary trial and the secondary trial have different outcome measurements and patient populations The primary trial measures the percentage of participants with a response within 10 days of first dose of Denosumab while the secondary trial measures the number of patients who reached a safe and well tolerated dose of dmethadone The patient populations are also different with the primary trial focusing on denosumab for bone health and the secondary trial focusing on dmeth",
        "label": "Entailment"
    },
    "58f39f52-0a96-4892-b8e7-2b689448c28f": {
        "text_answer": "Entailment The statement that a gene variant is a variation in the nucleic acid sequence of a specific gene is not related to the method of drug administration in the trials The fact that intervention 1 in the primary trial is administered by IV and all intervention drugs in the secondary trial can be administered orally does not contradict the statement",
        "label": "Entailment"
    },
    "7aa4329c-8f2a-4168-9b6b-f74ea0184356": {
        "text_answer": "Contradiction  Explanation  The statement Prior treatment with gabapentin or herceptin within the last year will result in exclusion from the secondary trial but not from the primary trial is a contradiction based on the provided evidence  The primary trial exclusion criteria include a history of hypersensitivity or allergic reaction spontaneous or following drug administration which would include a history of hypersensitivity or allergic",
        "label": "Contradiction"
    },
    "62db4a46-c4ea-44a1-8dfc-12922748a7b0": {
        "text_answer": "Contradiction The statement does not provide any information about the participants dietary nut intake in relation to the primary trial results",
        "label": "Contradiction"
    },
    "2610ce20-2875-4677-a55b-fbd094ca3abb": {
        "text_answer": "Contradiction pd0332991 is not mentioned in the evidence at all",
        "label": "Contradiction"
    },
    "0e2c4838-f0ba-4f02-b078-ac3fa2b3c0e3": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence as cohort 1 is given a smaller dosage of ALT801 0015 mgkgdose than cohort 2 0040 mgkgdose",
        "label": "Contradiction"
    },
    "22c47ff5-a9b1-4de2-b5ee-2e5a6f2302d9": {
        "text_answer": "Contradiction  Explanation The primary trial includes patients with histologically or cytologically confirmed breast adenocarcinoma but it specifically excludes patients with stage IV disease metastatic cancer The secondary trial on the other hand only includes patients with metastatic breast cancer Therefore patients with earlystage breast adenocarcinoma that is ER negative PR negative or HER2neu positive cannot be",
        "label": "Contradiction"
    },
    "6b48128c-3103-4266-bd7f-3f9d13dc5949": {
        "text_answer": "Contradiction The primary trial involves an imaging study with fluciclatide injections while the secondary trial involves the use of chloroquine for DCIS patients There is no mention of warfarin or fluvoxamine in the provided evidence",
        "label": "Contradiction"
    },
    "75d3b7d9-3863-4b14-8007-8d8ade0440f1": {
        "text_answer": "Contradiction The statement patients with a body mass index BMI of 20 and above are eligible for the primary clinical trial is a contradiction to the evidence as per the inclusion criteria of the primary trial which states that patients must have a BMI of 25 kgm2 or greater and weight 400 lbs",
        "label": "Contradiction"
    },
    "1279b75a-606f-469e-a6e6-20d4eabd50ba": {
        "text_answer": "Contradiction The primary trial includes postmenopausal females and the secondary trial includes women However both trials include females Therefore the statement is a contradiction",
        "label": "Contradiction"
    },
    "d32ff217-1848-490b-8a99-bc12730318f0": {
        "text_answer": "Contradiction The primary trial reported 0 serious adverse events while the secondary trial reported 3 The statement that the primary trial reported 5 serious adverse events is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "9d742d77-5754-4e6f-a913-90dc71c6b6f5": {
        "text_answer": "Contradiction The evidence shows that there are two different cohorts in the primary trial one for adult cancer patients and another for healthy volunteers Therefore the statement that all participants of the primary clinical trial undergo the same treatment is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "af52a2f1-de39-4113-86fa-10e65961b095": {
        "text_answer": "Contradiction The primary trial has additional inclusion criteria related to hot flushes and menopausal status that are not present in the secondary trial Therefore not all patients in the secondary trial would be eligible for the primary trial",
        "label": "Contradiction"
    },
    "4c0fbabb-2d9e-4da7-8a17-07272c77ece8": {
        "text_answer": "Contradiction The evidence shows that there were no deaths recorded in either trial",
        "label": "Contradiction"
    },
    "98b04dac-b155-4afd-8855-03ed818df5d9": {
        "text_answer": "Contradiction The statement is not an entailment as there is evidence of adverse events in the primary trial even though it is empty in the provided evidence",
        "label": "Contradiction"
    },
    "5b31fcf1-a528-4718-adcb-72df68b4df43": {
        "text_answer": "Contradiction The statement is not related to the evidence provided as the evidence only reports the number of adverse events in the primary and secondary trials The statement about moderate tumor infiltrating lymphocytes is an unrelated finding",
        "label": "Contradiction"
    },
    "cc321a3c-a09d-4354-8601-d665f428a831": {
        "text_answer": "Contradiction The statement is a contradiction because having 23 cerebral metastases is an exclusion criterion for the secondary trial and it does not entail eligibility for the primary trial",
        "label": "Contradiction"
    },
    "fddee10c-dd7d-47fe-b2cf-3ebe94726ea4": {
        "text_answer": "Contradiction The primary trial involves the use of suramin and paclitaxel but the secondary trial does not involve the use of these drugs Instead it involves patients undergoing mastectomy surgery",
        "label": "Contradiction"
    },
    "6d7c7740-c399-4d73-82c8-2ef0d4739341": {
        "text_answer": "Entailment The evidence states that Cohort 1 of the primary trial reported 0 cases of AEs and the statement asserts that it did not report any AEs which is the same information",
        "label": "Entailment"
    },
    "5b07e1cb-d734-4e43-9911-6328923fbc93": {
        "text_answer": "Contradiction The statement is not an entailment as the most recurrent adverse event in the primary trial was syncope 1667 but in the secondary trial there were no reported cases of syncope",
        "label": "Contradiction"
    },
    "47bcd1c5-f95d-4e21-a999-4bd220c5b940": {
        "text_answer": "Entailment The evidence states that all patients in the trial will be taking Vorinostat daily during radiation therapy so the statement that every patient is required to swallow a capsule of Vorinostat daily during radiation therapy is an entailment of the evidence",
        "label": "Entailment"
    },
    "baf9254a-880a-4df9-b2fc-c118b6b273f8": {
        "text_answer": "Contradiction The statement is about a 20yearold female patient being eligible for both trials while the evidence provided outlines the inclusion and exclusion criteria for each trial separately The evidence does not indicate that a 20yearold female patient with ERpositive HER2negative breast cancer could be eligible for both trials",
        "label": "Contradiction"
    },
    "e1c50f3f-0521-4edc-a2ae-8e0b04b64c54": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence does not mention anything about radiation therapy or anaplasia indicators",
        "label": "Contradiction"
    },
    "b73bfd5a-18e5-4df7-8e6a-292f8f32208f": {
        "text_answer": "Contradiction The evidence does not entail that at least one patient in the GTx024 1mg group gained over 10 kilos in lean body mass The median change in lean body mass for this group was 155 kg with a range of 206 to 1264 kg It is possible that some patients gained more than 10 kilos but the evidence does not definitively show that",
        "label": "Contradiction"
    },
    "44b12aea-350e-4ade-a145-ba619d96a0ca": {
        "text_answer": "Contradiction The statement is about different trials and does not relate to BEAM or pCR The statement provided compares the percentage of pCR between two cohorts in the primary trial and the percentage of pCR between two arms in the secondary trial The statement does not entail or contradict the evidence provided",
        "label": "Contradiction"
    },
    "7ea3fe58-fb27-48f8-9e3a-61af8847d23e": {
        "text_answer": "Contradiction The secondary clinical trial has different inclusion and exclusion criteria for different study groups eg breast cancer no history of breast cancer but wish to avoid estrogen etc while the primary clinical trial has distinct sets of eligibility conditions for different study groups NSCLC melanoma triple negative breast cancer anaplastic thyroid cancer",
        "label": "Contradiction"
    },
    "225ff186-66e8-4880-bba4-e8127bd42834": {
        "text_answer": "Contradiction The primary trial involves a single injection while the secondary trial involves three weekly injections which are not equivalent The statement about mitral valve atresia is unrelated to the trials and does not affect the answer",
        "label": "Contradiction"
    },
    "8e4d3482-1501-4f0d-ae76-8924effe7d3c": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial has a list of inclusion and exclusion criteria while the secondary clinical trial only has exclusion criteria The statement that no inclusion or exclusion criteria are shared between the primary clinical trial and the secondary clinical trial is a contradiction to the evidence as the primary trial has inclusion criteria that are not present in the secondary trial",
        "label": "Contradiction"
    },
    "819893b4-9c57-42b8-938e-f6147e41694d": {
        "text_answer": "Contradiction The statement makes a claim about the number of cases for cardiovascular lesions which is not mentioned in the evidence while the evidence only provides information about specific adverse events thrombocytopenia hypertension hepatotoxicity and pancreatectomy",
        "label": "Contradiction"
    },
    "354a388c-18b1-476a-b372-3ac4be472cbc": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there are no adverse events reported in the primary trial and fewer adverse events reported in the secondary trial The statement implies that there are adverse events in the primary trial with a higher proportion than in the secondary trial",
        "label": "Contradiction"
    },
    "31038c96-b97a-4952-aacc-4e7e8bb09cd0": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the two cohorts receive different doses of durvalumab per biweekly IV infusion 03 mgkg for Cohort 1 and 1 mgkg for Cohort 2",
        "label": "Contradiction"
    },
    "a828ed30-ae3c-4fbc-be8a-a72dd5e5bc3e": {
        "text_answer": "Contradiction The primary trial specifies a tumor diameter of 1 cm while the secondary trial does not mention any specific tumor size requirement",
        "label": "Contradiction"
    },
    "45daf2f3-8299-46f8-9016-edf2ce4a044a": {
        "text_answer": "Neutral NA  Explanation The statement does not directly relate to the inclusion or exclusion criteria for the primary or secondary clinical trials provided in the evidence The statement only mentions that the trials are open to Japanese nationals but the evidence does not specify any conditions related to nationality for eligibility Therefore the statement is neutral and does not entail or contradict any information in the evidence",
        "label": "Entailment"
    },
    "c831a231-8b84-41ca-a825-d11060c44d64": {
        "text_answer": "Contradiction  The primary trial includes women with locally advanced recurrent or metastatic breast cancer while the secondary trial includes women with early stage breast cancer These are distinct populations so a woman with locally advanced ERpositive breast cancer who is contemplating mastectomy would not qualify for both trials based on the given evidence",
        "label": "Contradiction"
    },
    "ee8170da-a81f-42bf-b286-cbb8824040cf": {
        "text_answer": "Contradiction The primary trial explicitly excludes participants who have undergone major surgery within 28 days prior to the study registration date while the secondary trial does not mention any such restriction for organ transplant recipients",
        "label": "Contradiction"
    },
    "95aa2e47-d35b-45b5-8d80-18f06798b812": {
        "text_answer": "Contradiction The evidence does not mention paclitaxel being administered to either cohort 1 or 2",
        "label": "Contradiction"
    },
    "c39ec45a-1664-49aa-8356-abbecf045001": {
        "text_answer": "Contradiction The evidence shows that there were adverse events in both trials so over 97 of patients did not suffer any adverse events is not an accurate statement based on the provided evidence",
        "label": "Contradiction"
    },
    "c76186ef-f703-4809-8e01-956bdec01925": {
        "text_answer": "Contradiction The primary trial compares two interventions Arm A and Arm B against each other while the secondary trial compares two different treatments Zoledronic acid and Denosumab The statement mixes results from two unrelated trials",
        "label": "Contradiction"
    },
    "da278764-ba0c-4a9e-9f44-7fe16af87e5a": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided The evidence only reports the number of adverse events in the primary and secondary trials and the statement is about a different topic household members and their ability to afford prescription medicine",
        "label": "Contradiction"
    },
    "7de10e39-c06c-4941-ade6-3e60b864029c": {
        "text_answer": "Contradiction  The primary trial does report Time to Progression TTP as an outcome measurement which is a quantifiable objective measure and not related to the patients subjective experience",
        "label": "Contradiction"
    },
    "2b9dbd1a-6de9-4c7e-80af-0a096af26a11": {
        "text_answer": "Contradiction The statement is incorrect as both cohorts received Enzalutamide orally not by IV",
        "label": "Contradiction"
    },
    "c83203cf-4121-4d9d-a662-cd596a5f63d5": {
        "text_answer": "Contradiction The primary trial does not mention any exclusion based on potassium levels while the secondary trial does not include any inclusion or exclusion criteria related to potassium levels",
        "label": "Contradiction"
    },
    "3a9ca481-4b74-4bd3-99f0-1b34cc33ba33": {
        "text_answer": "Entailment The statement about 03636 of the primary trial patients suffered an increase in blood bilirubin is an entailment of the evidence as the evidence states that 111 909 of the patients experienced an increase in blood bilirubin which is equivalent to about 03636 when expressed as a decimal fraction of the total number of patients",
        "label": "Entailment"
    },
    "9d03d248-30a2-44b1-bbef-75809005dc16": {
        "text_answer": "Contradiction  The statement does not follow from the evidence provided as the evidence does not provide information about the chromosome band 7p222 or the doses of Empegfilgrastim received by patients in cohort 1 and 2 of the primary and secondary trials respectively The evidence only provides information about the duration of neutropenia and the number of participants who experienced neutropenia in each trial and each cohort",
        "label": "Contradiction"
    },
    "dfd8e736-5ef2-4d36-b124-9382e72f982d": {
        "text_answer": "Entailment The evidence shows that the mean number of hot flashes per day was lower in the paced respiration group 348 compared to the fast shallow breathing group 395",
        "label": "Entailment"
    },
    "1f23b5f1-2b28-4204-9e44-60f8ddc86963": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as some adverse events were reported in both cohorts according to the evidence provided",
        "label": "Contradiction"
    },
    "72626f41-afa0-413c-b495-e4eeb51112fb": {
        "text_answer": "Entailment The statement implies a reduction in Ki67 expression and the evidence shows a 10 reduction in Ki67 expression at 6 weeks",
        "label": "Entailment"
    },
    "c3bc7314-8b8f-4d98-90ad-986132951201": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it makes assumptions about the types of adverse events that affected patients in the primary trial without providing any information about them The evidence only lists the specific adverse events that occurred and their frequencies",
        "label": "Contradiction"
    },
    "03a7663e-0937-437a-b095-642e363a6703": {
        "text_answer": "Contradiction  The primary trial uses lenalidomide while the secondary trial uses lapatinib in intervention 1 but the statement suggests that the primary trial does not use lenalidomide and the secondary trial uses high doses of lapatinib instead This is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "1c5b6b0e-8ee8-4569-8bc8-83ab193f8cff": {
        "text_answer": "Contradiction The statement does not follow from the evidence as breast cancer is specifically listed as a cancer type for the secondary trial but there is no mention of trochlear nerve disorders in the inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "0e6d3d31-1af3-4701-a410-b2bbb1ce430e": {
        "text_answer": "Irrelevant The statement is not related to the evidence provided The evidence only reports adverse events from a clinical trial while the statement refers to the Manual Ability Measure36 which is a rating scale for measuring selfreported manual ability",
        "label": "Entailment"
    },
    "0db120d4-5ebb-4b0f-9040-52b32a966c33": {
        "text_answer": "Entailment The evidence shows that the mean number of hot flashes per day was lower in the paced respiration group compared to the fast shallow breathing group",
        "label": "Entailment"
    },
    "ace11ff3-a7ac-492c-9dbe-5dafc96f81e7": {
        "text_answer": "Contradiction The statement does not relate to the evidence provided in the trial results The trial results only provide information about the overall survival of patients undergoing midluteal or midfollicular oophorectomy and does not mention anything about the raphe nuclei or their relation to the survival of the patients",
        "label": "Contradiction"
    },
    "16147f31-aa81-4f21-9bd7-f153069a9278": {
        "text_answer": "Contradiction The primary trial intervention involves Yttrium90 Radioembolization using TheraSphere while the secondary trial intervention involves the use of ibrutinib and MEDI4736 with different doses",
        "label": "Contradiction"
    },
    "edd1533a-dc7c-441d-adcd-f8b020a4fdd3": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as only the intervention group is required to view the educational DVD",
        "label": "Contradiction"
    },
    "a9d993df-c8e1-4f4f-b470-b23d78f069ed": {
        "text_answer": "Contradiction  Explanation  In the primary trial patients in Intervention 1 receive zoledronic acid through intravenous administration while in Intervention 2 they receive a placebo orally In contrast in the secondary trial patients in both Interventions receive all interventions orally or intravenously This contradicts the statement that patients in the primary trial receive interventions through intravenous administration only while those in the",
        "label": "Contradiction"
    },
    "1f77c906-1f2c-43b4-8bb1-2a2aeb19555e": {
        "text_answer": "Contradiction The statement is not an entailment as most patients in the primary trial did have adverse events while the statement asserts that most patients did not have any adverse events",
        "label": "Contradiction"
    },
    "29cdc690-859f-405c-ad87-f4e73fc3e9a8": {
        "text_answer": "Contradiction The intervention in the primary trial lasts for 10 weeks while the intervention in the secondary trial lasts for 24 weeks which is 14 weeks longer not 5 weeks",
        "label": "Contradiction"
    },
    "920f9642-c8b0-4b1d-9b2a-c12c4801b714": {
        "text_answer": "Contradiction The primary trial includes normal potassium levels as an inclusion criterion while the secondary trial does not mention potassium levels as a criterion at all",
        "label": "Contradiction"
    },
    "ec1b4763-e8bc-4c2f-be22-6b64b623b072": {
        "text_answer": "Contradiction The statement A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial is a contradiction to the evidence as the evidence does not exclude patients with leptomeningeal carcinoma as long as it is controlled postcompletion of local therapy surgery andor radiation therapy for at least 4 weeks",
        "label": "Contradiction"
    },
    "2fcef697-683a-4b99-9da3-5527e80c9e5b": {
        "text_answer": "Contradiction The statement is not an entailment as patients in the secondary trial must have a mutation in one of the listed genes while the pdgfrb protein variant is not mentioned as a requirement for inclusion",
        "label": "Contradiction"
    },
    "fc96b587-8bbf-4816-97d9-15cd8fcf755f": {
        "text_answer": "Contradiction The statement does not follow from the evidence as neither trial measures the effect of tyrphostin AG 1288 on MYMOP score",
        "label": "Contradiction"
    },
    "5284dc53-b471-4c7a-a713-62199869a305": {
        "text_answer": "Contradiction The majority of patients reported adverse events in the primary trial but no adverse events were reported in the secondary trial according to the provided evidence",
        "label": "Contradiction"
    },
    "e6ba45db-66f8-4f45-a45a-9217e65c7bbd": {
        "text_answer": "Contradiction The primary trial and secondary trial are different clinical trials but the statement does not necessarily hold true for all patients Some patients may be enrolled in one trial but not the other",
        "label": "Contradiction"
    },
    "ca63be25-38a3-4f4a-a6be-0e8b8cb8e5f5": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as a woman with stage IV breast cancer is not eligible for either trial according to their respective exclusion criteria",
        "label": "Contradiction"
    },
    "87e90ba6-44b6-4dc9-9bac-9ceb0c8cf6f6": {
        "text_answer": "Contradiction The primary trial does measure changes in pain intensity and the secondary trial does measure the change from baseline to 9 months in bone mineral density of the lumbar spine",
        "label": "Contradiction"
    },
    "0fdae3b5-0326-47fb-a3c2-ff5fd132fb76": {
        "text_answer": "Contradiction  Explanation The primary trial includes women with locally advanced recurrent or metastatic breast cancer while the secondary trial includes women with early stage breast cancer The statement suggests that men are being considered but the evidence provided only mentions women Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "487046b0-2368-40da-9cba-407f65177f0b": {
        "text_answer": "Contradiction The evidence shows that less than 36 of patients in the primary clinical trial suffered from any adverse event type",
        "label": "Contradiction"
    },
    "95a5ceca-3b9c-4760-98be-98c78559a161": {
        "text_answer": "Contradiction The primary trial has many more inclusion and exclusion criteria than the secondary trial",
        "label": "Contradiction"
    },
    "bf8e8814-f9d9-422e-ab84-fea4f6c85ede": {
        "text_answer": "Contradiction A woman who has had a lumpectomy is eligible for the secondary trial but not explicitly mentioned in the primary trial inclusion criteria",
        "label": "Contradiction"
    },
    "046763cb-f08d-4032-8b54-03bc14cb9d69": {
        "text_answer": "Contradiction Anorexia is a condition characterized by a significant loss of appetite and weight which is not a condition included in the primary trials inclusion criteria",
        "label": "Contradiction"
    },
    "83b91b04-e464-483d-94d2-079690030cb5": {
        "text_answer": "Contradiction The evidence does not mention any adverse event related to headache or joint pain in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "7e4c273a-fc2f-4589-beb8-4e90f3198962": {
        "text_answer": "Irrelevant The statement does not relate to the given evidence",
        "label": "Entailment"
    },
    "dc855f0a-1281-44f9-b68c-89044aaa73af": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not provide any information about the adverse events being related to the musculoskeletal system in the secondary trial",
        "label": "Contradiction"
    },
    "c10c78c7-51f4-4440-8164-07b059e01fd9": {
        "text_answer": "Contradiction  Explanation The evidence shows that in Adverse Events 1 there was one case of edema limbs which is a type of dyspnea Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "feca3829-9b38-4738-8bad-e8a0fcf9029f": {
        "text_answer": "Contradiction  Explanation The statement recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were all more frequently reported as adverse events in the secondary clinical trial than in the primary clinical trial is a contradiction to the evidence provided  The evidence shows that the frequency of recurrent malignancies graftversushost disease and",
        "label": "Contradiction"
    },
    "7eab2fc5-fd40-40bc-a960-90aafe45ef9e": {
        "text_answer": "Entailment The patient meets all the inclusion criteria for both trials",
        "label": "Entailment"
    },
    "4afbbadf-10c0-4e7e-87d3-2516aeafbe73": {
        "text_answer": "Contradiction  Explanation The statement implies that at least one patient in the GTx024 1mg group gained over 10 kilos of lean body mass which is not supported by the evidence as the median change in lean body mass for this group was 155 kg with a range of 206 to 1264 kg which does not indicate that any patient gained over 10 kil",
        "label": "Contradiction"
    },
    "467c8a18-4a72-4ea4-9b8d-ae43d786b5b0": {
        "text_answer": "Contradiction The primary clinical trial does not allow for the enlistment of patients with a histologically confirmed diagnosis of small cell breast cancer SCBC as it specifically includes only nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma and breast cancer whose disease has progressed after at least one line of standard therapy",
        "label": "Contradiction"
    },
    "f0eaf3f3-5c84-4cd8-8a13-ef1af710cf9e": {
        "text_answer": "Contradiction The evidence does not provide information about the number of suspected serious adverse reactions in the secondary trials Adverse Events 2 section",
        "label": "Contradiction"
    },
    "8c7a92ab-80cd-4bb4-8b03-fa5f6776ca5a": {
        "text_answer": "Entailment for the revised statement the primary clinical trial and the secondary clinical trial both rule out patients who struggle with severe forms of insomnia  Explanation The primary clinical trial includes Uncontrolled intercurrent illness including but not limited to psychiatric illnesssocial situations that would limit compliance with study requirements as an exclusion criterion Severe forms of insomnia can be considered a psychiatric illness that may limit compliance",
        "label": "Entailment"
    },
    "7b1befbe-fec3-4554-89f7-323acfc66d62": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided as it mentions the tibia bone and the primary trial is about Ki67 expression in breast tumors",
        "label": "Contradiction"
    },
    "b8c9f988-e270-467e-b7a8-b71b1ae302ce": {
        "text_answer": "Entailment The primary trial includes individuals with any tumor type if the tissue tests positive for a CDK46 mutation as an enrollment criterion",
        "label": "Entailment"
    },
    "12ca7fab-5b2d-4889-b4b9-458fc6f08f33": {
        "text_answer": "Contradiction The secondary trial does have a performance status requirement ECOG  2",
        "label": "Contradiction"
    },
    "a66238c5-3c2f-47a8-8b38-aad66299aed0": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because cohort 1 receives 14mgm2 of eribulin which is higher than the 75 mgm2 of docetaxel given to cohort 2 in intervention 2",
        "label": "Contradiction"
    },
    "136c5db2-719f-458f-9d88-f5596886ed96": {
        "text_answer": "Contradiction The statement mentions 7p21p15 which is not related to the content of the primary or secondary trials The primary trial studies the effect of sulforaphane supplements on isothiocyanate concentration in urine and the secondary trial measures pain using the Numeric Pain Rating Scale These are unrelated outcomes and do not entail or contradict each other",
        "label": "Contradiction"
    },
    "2d84efa0-fd43-40fa-a809-f9be6d197371": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence provided for the secondary trial as it incorrectly states that patients with unstable angina and grade 2 or above neuropathy are ineligible while the evidence shows that these conditions are not explicit exclusion criteria for the secondary trial The statement also incorrectly implies that these conditions are exclusion criteria for the primary trial when they are not as only nonhealing surgical wounds are mentioned as a specific",
        "label": "Contradiction"
    },
    "98923c9c-1126-436a-9263-a9deca239ba6": {
        "text_answer": "Entailment The primary trial tests Eribulin Mesylate while the secondary trial tests Axitinib and Docetaxel which are different drugs",
        "label": "Entailment"
    },
    "0d49e948-aea6-4067-8f7e-b480e47d3407": {
        "text_answer": "Contradiction The young girl with a newly diagnosed PRpositive HER2positive breast cancer cannot meet the inclusion criteria for both trials as the primary trial only includes HER2positive breast cancer patients",
        "label": "Contradiction"
    },
    "080fe5be-37c4-4d7f-a985-58c520750620": {
        "text_answer": "Contradiction The statement mentions paraplatin but the evidence only mentions carboplatin Paraplatin and carboplatin are not the same drug",
        "label": "Contradiction"
    },
    "4625018e-c34b-4156-8c63-572712bdbf30": {
        "text_answer": "Contradiction The statement mentions several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but 0 cases of Pancytopenia However the evidence shows that there was 1 case of Pancytopenia in cohort 1 of the primary trial",
        "label": "Contradiction"
    },
    "6d94034f-7e7f-4220-a193-bdd926f8b993": {
        "text_answer": "Contradiction The secondary trial does not use heart rate as a measure of effectiveness for cardio exercises but rather measures pain using the Numeric Pain Rating Scale The primary trial studies the effect of broccoli sprout extract on isothiocyanate in urine samples not on heart rate or lipid profile",
        "label": "Contradiction"
    },
    "dea7a7bb-563c-4b02-9011-16fa165820c4": {
        "text_answer": "Contradiction The statement is not related to the evidence provided as the evidence does not discuss NDC units or measures related to billing",
        "label": "Contradiction"
    },
    "387b9e0a-aafd-4140-921b-3609114410cb": {
        "text_answer": "Entailment The statement correctly identifies the difference in durvalumab dosing between the two interventions",
        "label": "Entailment"
    },
    "55eb3029-c826-4cae-a130-7cc8fbc80121": {
        "text_answer": "Contradiction The statement Female cancer patients over the age of 18 can participate in the primary trial regardless of race or ethnic origin or cancer type is an entailment of the primary trial inclusion criteria However the statement they must have Her2neu breast cancer is a requirement for the secondary trial which contradicts the statement about not having any cancer type restriction in the primary trial",
        "label": "Contradiction"
    },
    "52b055fd-9e0d-41ad-9eb7-1a724cbc0112": {
        "text_answer": "Contradiction The primary trial and the secondary trial are about different outcome measures so its not possible to make a direct comparison between their results The primary trial is about the diagnostic accuracy of two algorithms in breast cancer diagnosis while the secondary trial is about the effect of reflexology on fatigue levels in breast cancer patients undergoing radiation therapy",
        "label": "Contradiction"
    },
    "d9c0a0a4-0bdf-4b77-b442-78d609b06854": {
        "text_answer": "Contradiction  Explanation  The statement suggests that both cohorts A and B receive identical two IM injections of LD V935 at similar stages of the cycle However the evidence shows that in Intervention 1 Cohort A the two IM injections of LD V935 are given every other week over a 3week period while in Intervention 2 Cohort B the first",
        "label": "Contradiction"
    },
    "61de0370-1d90-4657-b0f1-fff95fc5efa5": {
        "text_answer": "Contradiction  Explanation  In the primary trial participants in both intervention groups receive daily intramuscular injections of Triptorelin or Degarelix  In the secondary trial participants in the intervention group receive weekly subcutaneous injections of Epoetin Beta  Therefore the statement that participants in the secondary trial study group do not receive any form of injections is a contradiction to",
        "label": "Contradiction"
    },
    "1108856e-d4cc-488e-a0d8-98274fc38dfd": {
        "text_answer": "Contradiction  Explanation  The primary trial does involve an intervention using lenalidomide while the secondary trial involves an intervention using lapatinib Therefore the statement is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "840d1cd7-85bd-4d25-a4db-0af6ff989e1d": {
        "text_answer": "Contradiction The primary and secondary trials have different outcome measures making direct comparison difficult The statement suggests that there were no significant differences in the primary trial but differences emerged in the secondary trial but the trials have different outcomes",
        "label": "Contradiction"
    },
    "8667c9e0-5040-46af-b784-4214164c4c0c": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of an eating disorder or schizophrenia in the provided adverse events",
        "label": "Contradiction"
    },
    "f69e913e-7050-463f-aa18-ad022451d483": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial allows the use of antineoplastic chemotherapy with the exception of antiHER2 agents androgens and estrogens with certain conditions within the two years preceding study initiation",
        "label": "Contradiction"
    },
    "50e74c9b-3673-4222-99f0-63f82e40b288": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided as the evidence does not include any information about the mediastinal malignant germ cell tumor stage or the classification criteria used",
        "label": "Contradiction"
    },
    "e78237d7-bbb7-4586-9950-5eabb10254f9": {
        "text_answer": "Contradiction  The evidence provided does not include data on adverse events for the two groups in the primary trial The statement makes a claim about adverse events but the evidence only compares hot flash frequency between the two groups",
        "label": "Contradiction"
    },
    "e9a96af7-c9f7-49cd-a291-2c0abb94719c": {
        "text_answer": "Contradiction  The evidence states that 9 out of 21 participants experienced a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products This is more than half of the participants so the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "f0a41373-f03b-471f-9f0f-381f8b09a950": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided The evidence does not mention anything about axl overexpression or its relation to the adverse events reported",
        "label": "Contradiction"
    },
    "63966dc4-b12e-4e45-befe-50b9c19a702a": {
        "text_answer": "Contradiction  Explanation  The evidence states that in Intervention 1 Cohort V935 LD two IM injections of V935 LD are administered while in Intervention 2 Cohort V934 LD3V935 LD three electroporation injections of V934 LD are given followed by two IM injections of V935",
        "label": "Contradiction"
    },
    "a85102e4-fe19-4b6e-8dd5-4cb9ffd64176": {
        "text_answer": "Contradiction  Explanation  In the primary trial there are two interventions Arm 1 CBTI  Placebo and Arm 2 CBTI  Armodafinil Both arms have the same CBTI intervention but different medications with different dosages However the statement in the question assumes that all cohorts in the primary trial are treated equally and given the same dosage of simv",
        "label": "Contradiction"
    },
    "4437aa5b-4b4e-4eb4-a258-e7f17dc8f363": {
        "text_answer": "Contradiction The primary trial has an ECOG performance status of 02 which means the patients are capable of selfcare with minimal assistance The secondary trial on the other hand includes patients with an ECOG of 02 OR Karnofsky 60100 but it does not specify that they must be capable of only limited selfcare or confined to bed or chair more than 50 of w",
        "label": "Contradiction"
    },
    "04c1483e-d2bb-40a2-b215-ede1e3c7c973": {
        "text_answer": "Contradiction  Explanation  Although both trials involve the use of lapatinib and paclitaxel the dosages and schedules are not identical In the primary trial FMX is given before MM398 and lapatinib and paclitaxel are administered in different cycles In contrast in the secondary trial lapatinib and paclitaxel are given together in the same cycle",
        "label": "Contradiction"
    },
    "06929ac9-6df2-4e5b-afd8-656a1f9989d1": {
        "text_answer": "Contradiction   Explanation The primary trial involves massage therapy which is not a drug but a form of touch therapy The secondary trial involves the testing of two different doses of a drug PF06647020 Therefore the statement that the primary trial tests one specific drug while the secondary trial involves stimulated exercises only is a contradiction",
        "label": "Contradiction"
    },
    "912414db-d418-4c96-b06b-e26d0ac1992f": {
        "text_answer": "Contradiction The statement mentions several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial which is inconsistent with the evidence that shows only 1 case of each in Adverse Events 1 The statement also mentions 0 cases of Pancytopenia which is inconsistent with the evidence that shows 1 case in Adverse Events 2 The statement does not entail",
        "label": "Contradiction"
    },
    "dacc42a9-68cc-4b2c-9377-648486729eed": {
        "text_answer": "Entailment The statement that participants in the primary trial receive 4 different drugs and the statement that an individual had nausea during the study duration are not directly related but the first statement is an entailment of the information provided in the evidence about the drugs used in the trial",
        "label": "Entailment"
    },
    "eb68a94f-7693-4158-b492-7b5a03d85b96": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there is one patient in the secondary trial who experienced chest pain which was also not reported in the primary trial but the statement specifically mentions no such instances were reported in the primary clinical trial for all three conditions eyelid oedema upper gastrointestinal haemorrhage and chest pain",
        "label": "Contradiction"
    },
    "e83cb970-0b3c-4b61-8a44-49a9a3f61744": {
        "text_answer": "Entailment Both trials include breast cancer patients as study subjects",
        "label": "Entailment"
    },
    "47b36e1f-90d5-4a42-b359-95783c7ae965": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence describes interventions and treatment schedules for patients in two different trials but it does not mention anything about radiation therapy or oropharyngeal polyps",
        "label": "Contradiction"
    },
    "033cc376-5268-43c7-bf06-ca3503971f41": {
        "text_answer": "Contradiction for Entailment the statement should logically follow from the evidence but it does not in this case",
        "label": "Contradiction"
    },
    "d1eb9a24-13e8-43de-ba1c-7b17e35e7ab3": {
        "text_answer": "Contradiction The primary trial measures tumor diameter in centimeters while the secondary trial measures number of participants with solid tumor response These are not the same units of measure",
        "label": "Contradiction"
    },
    "e40080bc-499c-4af9-a437-be6688894d22": {
        "text_answer": "Contradiction  The evidence states that 9 out of 21 participants had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products This is more than less than 110 of the participants",
        "label": "Contradiction"
    },
    "2f6605a0-31b3-43e1-9ec7-3e262cb9acf0": {
        "text_answer": "Contradiction The statement mentions specific conditions that would disqualify a patient from the trial which are different from the exclusion criteria listed in the evidence The evidence mentions no history of abdominal fistula gastrointestinal perforation myocardial infarction MI stroke or transient ischemic attacks in the last 6 months as exclusion criteria for the trial but the statement adds significant psychiatric",
        "label": "Contradiction"
    },
    "56daf92a-2c6e-4b2d-b532-3035e757e98c": {
        "text_answer": "Contradiction The statement is incorrect as syncope occurred in 1667 of the primary trial patients not 500",
        "label": "Contradiction"
    },
    "7a8f6698-eb2a-4695-b521-7e42522afdba": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the provided evidence The evidence only discusses the administration frequency and duration of the interventions and it does not mention anything about numerical chromosomal abnormalities",
        "label": "Entailment"
    },
    "44412911-1f34-4841-a795-86eed5a209d7": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one case of Infections and Infestations  Other Gramnegative bacteremia 40 degree C fever in cohort 2 but the statement claims that all such cases were in cohort 1",
        "label": "Contradiction"
    },
    "88490a99-ea34-4aa1-a838-b3a1cffa41a0": {
        "text_answer": "Contradiction The statement does not directly entail or contradict the evidence but the evidence does suggest that one patient experienced wound dehiscence which is a type of surgical incision coming undone",
        "label": "Contradiction"
    },
    "153e0c8b-e056-4dd9-9337-156752b249c1": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events recorded in both trials The statement assumes that there were 200 recorded adverse events which is not supported by the evidence",
        "label": "Contradiction"
    },
    "e46defaa-44a0-4919-bd9b-aa018de05da1": {
        "text_answer": "Contradiction The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel",
        "label": "Contradiction"
    },
    "e9b973a3-aabd-484d-8c7c-0bd2296bf0c5": {
        "text_answer": "Contradiction The statement does not provide any information about adverse events related to Myocarditis and Pericarditis which is the focus of the original question",
        "label": "Contradiction"
    },
    "6151cf03-78f0-4404-87bc-beacea52cd95": {
        "text_answer": "Contradiction The statement is not an entailment as patients with pulmonary embolisms are excluded from the secondary trial but they are not mentioned in the inclusion or exclusion criteria for the primary trial On the other hand patients with breast implants are excluded from the primary trial but they are not mentioned in the exclusion criteria for the secondary trial",
        "label": "Contradiction"
    },
    "979f5a49-0af6-4ea3-a410-d79cf3540d01": {
        "text_answer": "Contradiction  The primary trial does not involve the use of amitriptyline or iv infusions instead it uses oral pregabalin The secondary trial uses intravenous HighDose Methotrexate HDMTX and Intrathecal IT Liposomal Cytarabine Depocyt",
        "label": "Contradiction"
    },
    "d620b526-d227-42a4-a6cc-800df41f854a": {
        "text_answer": "Contradiction  The evidence shows that 286 131 to 492 of ERpositive Luminal B participants and 176 67 to 352 of Triple Negative participants demonstrated a decrease in the growth factor signature The difference between these percentages is not approximately 50",
        "label": "Contradiction"
    },
    "4e0fae11-64b8-403f-8001-45ef8078a145": {
        "text_answer": "Contradiction The statement is not an entailment as syncope was not the most frequently reported adverse event in the secondary trial as there were no reported cases of syncope",
        "label": "Contradiction"
    },
    "c5feab6a-263d-41c4-8c21-cfa5ffe80a3d": {
        "text_answer": "Contradiction The primary trial involves radiation therapy while the secondary trial involves the administration of fulvestrant in tablet form but the statements do not entail each other",
        "label": "Contradiction"
    },
    "c36a1fe4-cc98-4a41-94c5-88458737d070": {
        "text_answer": "Contradiction The evidence does not support the statement as it only provides median survival data for each group and does not indicate that over 50 patients from each cohort survived over 2 years",
        "label": "Contradiction"
    },
    "a29b69ee-502b-4d86-b028-be9a56bfb7f6": {
        "text_answer": "Entailment The statement is entailed by the evidence as the evidence shows that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher proportion of responders ORR compared to the Paclitaxel Plus Bevacizumab group",
        "label": "Entailment"
    },
    "843b1c8e-8d10-4f20-8514-4ba986071878": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the primary trial involves a single injection while the secondary trial involves multiple injections The types of interventions and the conditions being treated are different as well",
        "label": "Contradiction"
    },
    "c6c84bb8-fea8-4ad6-8ec7-1677049d1fe4": {
        "text_answer": "Contradiction The primary trial specifically excludes patients with cerebral metastases while the statement suggests that such patients may still be eligible for the primary trial",
        "label": "Contradiction"
    },
    "aecd2958-c3b4-4d87-82f1-07add215b1e8": {
        "text_answer": "Contradiction The statement implies that cohort 1 receives Dexamethasone preoperatively while the evidence states that cohort 1 in intervention 1 also receives preoperative Dexamethasone intravenously but in intervention 2 cohort 1 receives Dexamethasone 2 hours after the operation Therefore the statement contradicts the evidence",
        "label": "Contradiction"
    },
    "5feb2522-300c-490a-be54-07b2c99d397e": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of swelling hypothermia or difficulty moving arm side to side in either trial",
        "label": "Contradiction"
    },
    "145683a3-f65e-4b4d-98e0-662cbe830c5d": {
        "text_answer": "Contradiction The primary trial does employ a cyclebased treatment schedule for its intervention as described in the given evidence",
        "label": "Contradiction"
    },
    "a020a0f1-c729-44ea-a40e-2700cc846d67": {
        "text_answer": "Contradiction The primary trial only includes patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast that is estrogen andor progesterone receptor positive Early stage nonHodgkin lymphoma is not a type of breast cancer",
        "label": "Contradiction"
    },
    "cccd9ad0-9bac-43fb-aaaf-8f99e725c572": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as there is no mention of metastatic carcinoma in the rectum in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "f8accdcd-5a92-4fff-9e6b-6a2d141b5ee4": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial does not involve the use of the MAID regimen or trastuzumab in combination",
        "label": "Contradiction"
    },
    "c5f69124-61d3-46bc-b233-5c38f4b1f5d0": {
        "text_answer": "Contradiction The evidence shows that in the secondary trial all patients experienced only one adverse event Infection with grade 3 or 4 neutrophils for some patients and none for others which is less than 3 separate adverse events",
        "label": "Contradiction"
    },
    "29bfa3a7-a8f2-4294-b745-d125cac8e40f": {
        "text_answer": "Entailment assuming hypoxia is a typo and should be replaced with no unexpected deaths or hospitalizations  Explanation The statement hypoxia ctcae is a disorder characterized by a decrease in the level of oxygen in the body There are no unexpected deaths or hospitalizations that occurred in the primary trial or the secondary trial is an entailment of the evidence provided as the evidence does not report any",
        "label": "Entailment"
    },
    "cee38f66-699d-4c68-85ec-8ed0ba55fd9d": {
        "text_answer": "Contradiction  Explanation  In the primary trial the treatment plan includes the administration of one drug ZD1839 In contrast the secondary trials treatment approach involves the expectation of at least three simultaneous drugs Zoledronic acid Samarium153 and vitamin D and calcium supplements or vitamin D and calcium supplements plus Radiopharmaceuticals  Therefore",
        "label": "Contradiction"
    },
    "a171374b-4c87-4b1a-94f9-8f0238cdce4f": {
        "text_answer": "Entailment   Explanation The statement throughout the period of the primary clinical trial the study participants are given four distinct drugs is an entailment based on the evidence provided in the primary trial The four distinct drugs mentioned in the statement are epirubicin cyclophosphamide docetaxel and trastuzumab which are all listed as components of the neoadjuvant therapy regimen in the evidence",
        "label": "Entailment"
    },
    "fa7b34e2-75e6-4bc4-a154-99be5bd6b381": {
        "text_answer": "Contradiction The primary trial does not require patients to have a mutation in any of the listed genes to be included",
        "label": "Contradiction"
    },
    "5ee999ab-5129-4ea2-a988-b2a223d82acd": {
        "text_answer": "Entailment The evidence states that both the placebo and memantine interventions have identical frequency and duration of administration",
        "label": "Entailment"
    },
    "8563b314-6b0f-432c-9ffc-203c3dcb0a3f": {
        "text_answer": "Contradiction The primary trial does not involve the administration of Fulvestrant in a tablet form or the use of a BID dosing schedule",
        "label": "Contradiction"
    },
    "412583db-ce19-451d-a804-3837e4dcaea3": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as coronary artery stenosis is not mentioned in the list of adverse events recorded in the primary trial",
        "label": "Contradiction"
    },
    "478be8bf-505c-44ed-98d6-41b48ab8d9b3": {
        "text_answer": "Contradiction The primary and secondary trials measure different outcome measures and have different time frames Therefore it is not possible to make a direct comparison between the two cohorts to determine if one demonstrated superior outcomes over the other based on the provided evidence",
        "label": "Contradiction"
    },
    "670ba789-279e-420d-b45e-c63836169e9b": {
        "text_answer": "Contradiction  The evidence shows that there were 10 patients with complete response at both week 20 and week 34 However the statement suggests that there were fewer patients with stable disease in week 20 than week 34 but the same number of patients had a complete response in both weeks These two pieces of information contradict each other",
        "label": "Contradiction"
    },
    "a55a8c7f-7e1a-4bd4-8f2b-9222002f5d27": {
        "text_answer": "Entailment The primary trial tests Eribulin Mesylate while the secondary trial tests Axitinib and Docetaxel which are different drugs",
        "label": "Entailment"
    },
    "fea6712a-10d7-47bb-88d1-d286e0ba47a1": {
        "text_answer": "Contradiction The evidence from both trials shows that no adverse events occurred in more than 30 of participants",
        "label": "Contradiction"
    },
    "543c8639-a266-42af-9896-05a77d822c79": {
        "text_answer": "Contradiction The primary trial shows disparities in assessment between groups while the secondary trial shows uniform results",
        "label": "Contradiction"
    },
    "8b7bbb44-a7d7-4317-af85-f78d559e0e63": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention involves the use of cabergoline which is given orally In contrast the secondary trial involves the use of pixantrone dimaleate which is given intravenously IV in both arms of the study Therefore the statement that the primary clinical trial involves oral administration of the intervention contrastingly the secondary clinical trial necessitates the intervention to be",
        "label": "Contradiction"
    },
    "782c9a26-ba09-4eef-8076-bd8831c9f986": {
        "text_answer": "Contradiction The evidence states that no malignant effusion as the only site of disease recurrence is allowed in the primary trial and leptomeningeal carcinoma is a type of malignant effusion",
        "label": "Contradiction"
    },
    "5e5c4aab-2006-4a00-b11c-3dced5aac12c": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence because both the first and second cohorts in the primary clinical trial receive vaccines against both Pneumococcus and Influenza",
        "label": "Contradiction"
    },
    "db08ca44-cd18-49ff-ae80-4a3f0bb625b5": {
        "text_answer": "Contradiction  Explanation The primary trial recorded 0 adverse events while the statement assumes that 50 adverse events were observed Therefore the statement is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "8559afe8-c0a0-4c88-81bb-ef29cdb08026": {
        "text_answer": "Entailment The evidence does not directly address the frequency of pain instances but it does indicate that pain was measured on a daily basis for both groups throughout the 10week study",
        "label": "Entailment"
    },
    "8679e654-7db4-4fd2-8fbc-41028fedb540": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of Biliary colic or Clostridium difficile colitis in the primary trial",
        "label": "Contradiction"
    },
    "2dfe7dda-41ae-48bc-aac5-1309cb87e4c1": {
        "text_answer": "Irrelevant The statement does not relate to the inclusion or exclusion criteria for either trial The presence or absence of surface immunoglobulinpositive cells does not affect eligibility for the trials",
        "label": "Entailment"
    },
    "4703e57c-efe0-4316-a1a5-8ac60b030e84": {
        "text_answer": "Contradiction The statement is not entirely true based on the evidence provided While some adverse events were more frequent in the primary trial the statement does not accurately reflect all of the adverse events listed in the evidence",
        "label": "Contradiction"
    },
    "17adb81b-92e7-4ed5-b443-287a5df2fb37": {
        "text_answer": "Contradiction The primary trial does not mention the use of Her2neu peptide vaccine in combination with sargramostim for any of the interventions",
        "label": "Contradiction"
    },
    "be4a58c2-e939-4583-a129-2d0bdba8e3a8": {
        "text_answer": "Entailment Both trials are assessing adverse events and the secondary trial specifically mentions AEPIs which aligns with the statement",
        "label": "Entailment"
    },
    "f180c18c-f332-4f6b-9367-c349d3518d55": {
        "text_answer": "Contradiction The evidence shows that there were no instances of death or hospitalization in cohort 2 but it does not provide information about the occurrence of atrial fibrillation The statement implies that there was only an occurrence of atrial fibrillation which is not supported by the evidence",
        "label": "Contradiction"
    },
    "cedccbca-876d-44b2-bf5a-9c9c5090d46c": {
        "text_answer": "Entailment The evidence states that no adverse events were reported in both cohorts which is consistent with the statement that no adverse events were reported in either of the cohorts",
        "label": "Entailment"
    },
    "773e93d2-a81d-48cd-96ec-4b92d537ac35": {
        "text_answer": "Entailment The statement is an entailment of the evidence as it correctly states that 13 of the participants with HER2 primary breast cancer who were treated with HER2targeted PETCT developed HER2 metastases",
        "label": "Entailment"
    },
    "a546a2b7-a287-47a1-91b1-4368fef15369": {
        "text_answer": "Contradiction  Explanation In the primary trial Zoledronic Acid 4 mg Q4W was used while in the secondary trial Denosumab 120 mg Q4W was used These are different medications and dosages so the statement is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "cacd8f36-53c3-4002-9d2d-09bd2976bf40": {
        "text_answer": "  Entailment for the Primary Trial and Contradiction for the Secondary Trial  Explanation  The patient meets the inclusion criteria for the Primary Trial as she has a histologically verified diagnosis of breast cancer appropriate diagnostic workup and meets the minimum laboratory values However she does not meet the age requirement for the Secondary Trial as she is 32 years old and the age range for the Secondary T",
        "label": "Entailment"
    },
    "f6dee97d-0025-4837-97a5-dc7748b859a0": {
        "text_answer": "Contradiction The evidence states that the participants in cohort 1 of the primary clinical trial received a starting dose of bevacizumab at 10 mgkg not 5 mgkg as stated in the question Similarly the participants in cohort 2 received bevacizumab based on their standard of care which was not specified in the question",
        "label": "Contradiction"
    },
    "aac508e7-cd87-40ad-afa6-bc977ab393aa": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were gastrointestinal adverse events diarrhea nausea vomiting reported in both Adverse Events 1 and Adverse Events 2 Therefore the statement that there was a complete absence of gastrointestinal adverse events in the primary clinical trial is a contradiction to the evidence  Additionally there were no psychiatric events reported in the evidence",
        "label": "Contradiction"
    },
    "2ca3ca9f-96ac-46e7-a1ce-873c580eff25": {
        "text_answer": "Contradiction  The evidence shows that only one patient in cohort 2 suffered from increased pleural effusion and none suffered from rapid disease progression The statement however claims that 14 of patients in the primary trial suffered from both increased pleural effusion and rapid disease progression",
        "label": "Contradiction"
    },
    "7c60cd27-5e72-4cd6-9e2c-de28c0c11fe4": {
        "text_answer": "  Contradiction   The primary trial requires a hemoglobin level of at least 80 gdl while the secondary trial requires a hemoglobin level of 90 gl or more The patients hemoglobin level of 009 kgm3 is below both thresholds",
        "label": "Contradiction"
    },
    "64a7bb90-c51d-4f6b-942e-55322c25e1b8": {
        "text_answer": "Entailment  Explanation The statement all participants in the principal clinical trials study groups will be subjected to identical 18FFDG and 18FFPPRGD2 PETCT imaging procedures is entailed by the evidence as both groups of patients undergo PETCT imaging with both 18FFDG and 18FFPPRGD2 The second part of",
        "label": "Entailment"
    },
    "539bf07d-199d-4c9b-af16-5f314962bcfc": {
        "text_answer": "Contradiction  The evidence states that the final eligibility for the clinical trial is determined by the health professionals conducting the trial not by the patients first of kin",
        "label": "Contradiction"
    },
    "ac762601-55f3-434a-bf5a-690ed8a3f735": {
        "text_answer": "Contradiction The evidence shows that only one patient in cohort 2 experienced increased pleural effusion which is not a quarter of the total number of patients",
        "label": "Contradiction"
    },
    "25b0a430-e35c-496c-8874-92be378b044b": {
        "text_answer": "Contradiction The secondary trial measures pain using the Numeric Pain Rating Scale not blood pressure level The primary trial measures the effect of vitamin B supplements on hemoglobin concentration in blood",
        "label": "Contradiction"
    },
    "14e1403f-9bb6-40cc-88fe-4b2f110e7b0d": {
        "text_answer": "Contradiction The primary trial involves the use of niraparib not talazoparib",
        "label": "Contradiction"
    },
    "5b23afbf-8b5c-441b-99b2-295c66958545": {
        "text_answer": "Entailment  Explanation  The primary trial excludes women with severe claustrophobia Secondary Trials exclusion but it does not mention osteoporosis as an exclusion criterion Primary Trials inclusion However the statement correctly states that both trials exclude women with severe claustrophobia making it an entailment The statement incorrectly adds osteoporosis",
        "label": "Entailment"
    },
    "ca97cc92-91e7-426a-b48f-d1729f13ee13": {
        "text_answer": "Contradiction The statement is not an entailment based on the evidence as there is no mention of any specific patient in the results with a PFS of 4 months",
        "label": "Contradiction"
    },
    "3d073609-1a5e-46fb-b43d-c4505c72029d": {
        "text_answer": "Contradiction The evidence states that patients with a history of pulmonary embolisms are excluded from the primary trial while patients with breast implants are excluded from the secondary trial",
        "label": "Contradiction"
    },
    "d1bbbc84-4136-43c4-b7b6-7e88e7c82730": {
        "text_answer": "Contradiction  Explanation The statement every cohort in the primary clinical trial is subjected to the same volume of docetaxel doxorubicin and cyclophosphamide with the same frequency is a contradiction to the evidence provided in the primary trial as Cohort 2 receives an additional 3 cycles of docetaxel and Herceptin which is not the same frequency as Cohort ",
        "label": "Contradiction"
    },
    "7a4a1281-d17b-4ad5-aa63-7329abdd0cdd": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence because there were no cases of infection asymmetry or deflation reported in the secondary trial but the statement compares the number of cases between the two trials with the assumption that there were cases in the secondary trial",
        "label": "Contradiction"
    },
    "ca7d916d-c8d4-4e6b-8b92-3d08bbdf7915": {
        "text_answer": "Irrelevant The statement does not relate to the provided evidence The evidence only discusses the outcome measurements results and participant numbers for two clinical trials and does not mention the cE mark labeling",
        "label": "Entailment"
    },
    "1fde2a5a-bf6c-41cf-ba82-7cbea262f258": {
        "text_answer": "Contradiction The primary trial requires the injection of denosumab while the secondary trial does not involve any injection and instead uses lymphoscintigraphy",
        "label": "Contradiction"
    },
    "52ab8ce2-300e-40db-be56-d6e7c608324e": {
        "text_answer": "Contradiction The evidence states that patients with a history of another malignancy are excluded from the trial except for those who have been diseasefree for 3 years However the statement is about a patient diagnosed with ILDDPLD in the past three years which is a type of malignancy",
        "label": "Contradiction"
    },
    "5c9037a6-53a8-49ec-8aa5-b6a47dee226d": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that Arm A of the primary clinical trial uses nabPaclitaxel at a dose of 125 mgm2 while Arm B uses a different drug carboplatin in addition to nabPaclitaxel Therefore the statement that different cohorts are prescribed varying doses of abraxane which is not mentioned in the evidence",
        "label": "Entailment"
    },
    "f212e510-214f-4556-99ed-526946750f55": {
        "text_answer": "Entailment for the corrected statement The majority of patients in the primary trial were up to date for their colorectal breast and cervical cancer screenings after the intervention  Explanation The evidence provided in the results shows that a significant increase in the percentage of patients who were up to date for their colorectal breast and cervical cancer screenings after the intervention regardless of cancer type in both the Collaborative",
        "label": "Entailment"
    },
    "7e311c72-64a8-49e8-b3c7-952528a9138c": {
        "text_answer": "Contradiction The primary trial includes patients undergoing breast cancer treatment while the secondary trial includes patients who have completed breast cancer treatment",
        "label": "Contradiction"
    },
    "e12e5ed1-9a64-4183-9b9d-419e6679ab3d": {
        "text_answer": "Entailment The primary trial exclusion criteria include significantuncontrolled concurrent illnessinfection and severeuncontrolled cardiovascular impairment which covers the statements condition The secondary trial exclusion criteria also include uncontrolled cardiovascular disease which is a subset of severeuncontrolled cardiovascular impairment",
        "label": "Entailment"
    },
    "1adf360d-dd5e-4bbd-b5f1-8846f84407a6": {
        "text_answer": "Contradiction The primary trial has different inclusion and exclusion criteria for its phases while the secondary trial has the same criteria for all participants The statement does not mention the estramustinevinblastine regimen so it is not directly related to the evidence provided",
        "label": "Contradiction"
    },
    "829b14c1-9883-4dc4-93f9-40eadb9f9511": {
        "text_answer": "Contradiction   Explanation   The statement is a contradiction because the primary trial involves whole breast radiation therapy while the secondary trial does not Instead it involves intramuscular injections of Fulvestrant and oral administration of Enzastaurin and Fulvestrant",
        "label": "Contradiction"
    },
    "8044ce4d-99e5-4c90-91aa-9c0c85f2c6b4": {
        "text_answer": "Contradiction The evidence shows that there were different numbers of participants in each group 1420 in the Neratinib group and 1420 in the Placebo group",
        "label": "Contradiction"
    },
    "3942fcf8-27c3-469e-8c6c-b9b2415706fb": {
        "text_answer": "Contradiction The statement is not related to the given inclusion and exclusion criteria for the primary trial The statement is about ejection fraction and measurable tumors in both breasts while the criteria provided only mention breast cancer lymphedema and other exclusionary conditions",
        "label": "Contradiction"
    },
    "21e02160-3372-4816-93d2-b3923672111b": {
        "text_answer": "Contradiction The statement is about radiotherapy but the evidence provided is about highdose chemotherapy with stem cell transplantation",
        "label": "Contradiction"
    },
    "060ed756-52f8-4b31-ad74-6f6f12d8ca9f": {
        "text_answer": "Entailment The primary trial is investigating different interventions Hydrophor and MediHoney in a cancer population while the secondary trial is investigating different doses of a treatment PF05212384 in a cancer population receiving radiation therapy Both trials involve investigating interventions in a cancer population but the nature of the interventions is different in each trial",
        "label": "Entailment"
    },
    "666ca16f-864e-48b1-9e5e-543759d50b4a": {
        "text_answer": "Contradiction The primary trial has no specific inclusion criteria related to physical activity or work status while the secondary trial has no inclusion criteria related to physical activity or work status at all",
        "label": "Contradiction"
    },
    "7d7cfab4-e501-4292-bf9c-363ccc1bf1dd": {
        "text_answer": "Entailment The statement is entailed by the evidence as the primary trial results show that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher ORR 0587 vs 0489 and a larger number of participants analyzed 92 vs 94",
        "label": "Entailment"
    },
    "00175c56-59cd-411d-b4e4-b7db0e32fd74": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial only includes patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast Childhood atypical choroid plexus papilloma is not a type of breast cancer",
        "label": "Contradiction"
    },
    "5b812594-3dcd-42e8-b984-644fe9dcd87e": {
        "text_answer": "Entailment assuming there is no mention of hot flash frequency in the list of treatment emergent adverse events or serious treatment emergent adverse events in the trial",
        "label": "Entailment"
    },
    "96eb2d8a-35d7-4627-9279-5f16363a2e50": {
        "text_answer": "Contradiction The statement does not entail that only three types of adverse events affected patients in the primary trial as the evidence shows that there were also cases of neutropenia pyrexia and fatigue",
        "label": "Contradiction"
    },
    "5e2af84e-3876-4822-80c3-99c7774a5bf9": {
        "text_answer": "Contradiction  The primary trial uses oral pregabalin while the secondary trial uses intrathecal Depocyt and intravenous highdose Methotrexate These are not the same interventions",
        "label": "Contradiction"
    },
    "97632c52-4213-4973-8655-9ea7f3151231": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because syncope was not the most common adverse occurrence in the secondary clinical trial as reported in the evidence 0 occurrences",
        "label": "Contradiction"
    },
    "de6b5ea7-b593-43b7-8fe0-358991878e86": {
        "text_answer": "Contradiction   Explanation The statement is a contradiction because the evidence shows that there is one adverse event Thromboembolic Event that is present in the secondary trial but not in the primary trial",
        "label": "Contradiction"
    },
    "fa6115aa-a765-4d03-9fd0-61c97d5e282f": {
        "text_answer": "Contradiction The evidence does not support the statement that all participants in the primary trial suffered a deterioration in cognitive function particularly those in the Ovarian Function Suppression group as some participants in the Tamoxifen group had better than average cognitive function negative standardized scores",
        "label": "Contradiction"
    },
    "72e970ee-fc31-4753-99be-b6757c4c270d": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention involves the use of cabergoline which is given orally In the secondary trial there is no mention of cabergoline but there are interventions involving intravenous administration of pixantrone However there is also an intervention in the secondary trial where patients receive oral cabergoline in Arm IGroup A of the trial Therefore the statement is a contrad",
        "label": "Contradiction"
    },
    "5315a569-b1a1-49fc-b10f-70840fe34585": {
        "text_answer": "Entailment assuming Pancytopenia is a typo for Endocervical cancer as per the given data in the primary and secondary trials",
        "label": "Entailment"
    },
    "da3b7aca-a0b1-4e25-8c38-11dc8311dc11": {
        "text_answer": "Contradiction The evidence does not mention anything about claustrophobia being an exclusion criterion for the primary trial and osteoporosis is an exclusion criterion for the secondary trial but not the primary trial The statement about progressive central nervous system neoplasm is not related to the given evidence",
        "label": "Contradiction"
    },
    "f41cbb25-7c8f-49ac-af06-5c8f1895ab60": {
        "text_answer": "Contradiction The statement is not supported by the evidence as there is no mention of tumour lysis syndrome in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "7df66c3f-de87-4542-9797-06325684db65": {
        "text_answer": "Contradiction The statement is not based on the evidence provided The evidence only mentions the number of adverse events in each trial but it does not mention the specific types of adverse events or the presence or absence of adrenal gland lymphangiomas",
        "label": "Contradiction"
    },
    "a764d548-7ef1-4ec1-bfaf-958536b7342c": {
        "text_answer": "Contradiction The primary trial involves hormonal interventions Estring and Testosterone Cream while the secondary trial does not involve any hormonal interventions but rather acupuncture and a waitlist control group",
        "label": "Contradiction"
    },
    "cc6601cf-3aa0-44f7-8476-f3dfc34e7412": {
        "text_answer": "Contradiction The primary trial involves vaginal interventions Estring and Testosterone Cream while the secondary trial involves acupuncture which is not a topical or inhalation intervention",
        "label": "Contradiction"
    },
    "48e84575-b6e1-4280-a170-df30870b50cf": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not mention any information about the administration of PD0332991 in the primary clinical trial",
        "label": "Contradiction"
    },
    "e173aa91-e6ec-4059-882b-7f015db6e3b3": {
        "text_answer": "Contradiction assuming that regular exercise is a form of intervention and is not mentioned in the evidence as being part of the intervention procedure for the primary clinical trial",
        "label": "Contradiction"
    },
    "922b377f-efa2-4bee-9689-f019c011057e": {
        "text_answer": "Entailment The statement that the btc gene product is a protein and that cohorts 1 and 2 follow the same instructional CD is true regardless of the frequency of paced breathing practice The additional information about the frequency of practice in cohort 2 does not contradict the initial statement",
        "label": "Entailment"
    },
    "11fd1d6e-0641-4b3d-91ff-9f048584db7b": {
        "text_answer": "Contradiction The inclusion criteria state that participants must have no evidence of dementia  Mini Mental State Examination MMSE 23 but some evidence of cognitive impairment Frontotemporal or mixed dementia is a type of dementia and individuals with this condition would not meet the inclusion criteria for the primary clinical trial",
        "label": "Contradiction"
    },
    "c6d411f9-3d61-459e-b1af-6d8088260804": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the two cohorts do not use the same intervention in terms of frequency despite using the same instructional CD",
        "label": "Contradiction"
    },
    "145b92f4-e143-4188-9521-8aade35b2f05": {
        "text_answer": "Contradiction The statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "6e609d6e-8db0-4adc-bce7-62f7274c10c2": {
        "text_answer": "Contradiction The primary trial does have different inclusion criteria for different age groups whereas the secondary trial has uniform criteria for all participants",
        "label": "Contradiction"
    },
    "4adbcbcc-ae43-46af-a072-815d1e788f29": {
        "text_answer": "Entailment The statement is a subset of the inclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "8acda3ec-8feb-4630-a560-3e66f86c3f21": {
        "text_answer": "Contradiction  The evidence states that 98 of the patients had a recurrencefree survival of at least 3 years but it does not provide information about the number of patients who experienced adverse events The statement about 097 of patients not experiencing any adverse events is not supported by the evidence",
        "label": "Contradiction"
    },
    "e25dfb6a-efaf-4b80-b2b7-316e10b33fe5": {
        "text_answer": "Neutral The statement does not directly follow from the evidence but it is not contradictory either  Explanation The statement does not directly follow from the evidence as the statement does not mention anything about the adverse events being related to cell culture images However the evidence does not contradict the statement as none of the adverse events in the secondary trial affected more than 30 of patients",
        "label": "Entailment"
    },
    "c0131f92-6373-48c8-9bd5-8d4a42f6674e": {
        "text_answer": "Contradiction The primary trial and the secondary trial measure different outcomes so it is not possible to directly compare the results and make a statement about indistinguishable results",
        "label": "Contradiction"
    },
    "e0d92d90-958e-435b-bb1b-7135ed0b2fac": {
        "text_answer": "Contradiction  Explanation The evidence shows that at Week 12 there were no complete responses CR and at Week 24 there were still no complete responses Therefore the statement that the majority of patients in the primary trial experienced complete response by the 24th week is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "136ce42e-bf56-41ff-aed9-fe886636bc1c": {
        "text_answer": "Contradiction The evidence provided does not support the statement as it only compares the average area under the curve aAUCpa of EORTC CIPN20 Sensory Neuropathy Subscale between two groups of patients receiving different treatments cryotherapy and control during paclitaxel infusions It does not provide information about patients who didnt receive paclitaxel infusions at all",
        "label": "Contradiction"
    },
    "6af06fcc-363f-4275-81f3-8a01c53931e8": {
        "text_answer": "Contradiction  The primary trial excludes women with stage IV disease while the secondary trial includes women with newly diagnosed or recurrent breast cancer but does not specify the stage However it is important to note that the statement may not be entirely accurate as the primary trial also has other exclusion criteria that may prevent ER women with stage IV disease from participating",
        "label": "Contradiction"
    },
    "1607973a-34ef-455a-b52b-55ea7aaf6634": {
        "text_answer": "Entailment given the provided evidence for Adverse Events 1 there are no cardiac or psychiatric adverse events mentioned in either trial  However its important to note that the statement does not directly address Adverse Events 2 in the secondary trial but since no cardiac or psychiatric adverse events are mentioned in either trial the statement still holds true",
        "label": "Entailment"
    },
    "e012d94f-ee90-40b0-9a4d-e41ec19a512d": {
        "text_answer": "Contradiction The primary trial and the secondary trial are about different outcome measures so its not possible to make a direct comparison between their results The primary trial is about the diagnostic accuracy of two algorithms in breast cancer diagnosis while the secondary trial is about the effect of reflexology on fatigue levels in breast cancer patients undergoing radiation therapy",
        "label": "Contradiction"
    },
    "04d9baea-cc4c-4903-9769-3df78659a73f": {
        "text_answer": "Contradiction The statement is not related to the information provided in the primary and secondary trials as they do not evaluate the percentage of participants with soft tissue disorders",
        "label": "Contradiction"
    },
    "c09c08d5-189f-4e15-acb8-2c3cb235aaa6": {
        "text_answer": "Contradiction The evidence shows that there were different numbers of adverse events reported for each cohort",
        "label": "Contradiction"
    },
    "1eab7c47-2c2a-4746-935b-c3e8891f8a26": {
        "text_answer": "Contradiction The primary trial requires a Karnofsky score of 70 while the secondary trial requires a score of 2 or better",
        "label": "Contradiction"
    },
    "cb3fa68b-c881-4a32-a80f-303e46360d8c": {
        "text_answer": "Contradiction The evidence shows that the Bevacizumab group had a lower percentage of participants with disease progression or death 883 compared to the Bevacizumab  Capecitabine group 758",
        "label": "Contradiction"
    },
    "a328634e-824e-413c-a408-ad471e394a07": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as gender is a determining factor for eligibility in the primary trial",
        "label": "Contradiction"
    },
    "f4e0551c-44e9-44f1-9a50-c65075a51715": {
        "text_answer": "Contradiction The evidence states that adequate liver function is an inclusion criterion for the primary trial",
        "label": "Contradiction"
    },
    "c5c7b6e2-201f-42af-aeb3-3e3152fa0ba2": {
        "text_answer": "Contradiction  Explanation In the primary trial patients receive a loading dose of 4 mgkg followed by 2 mgkg per week In contrast in cohort 2 of the secondary trial patients receive a loading dose of 4 mgkg followed by 2 mgkg per week for the first 5 doses and then 6 mgkg every 3 weeks until 1 year from the initial Hercept",
        "label": "Contradiction"
    },
    "a44d4aaf-a761-46a1-a803-63d6ede293a5": {
        "text_answer": "Contradiction The statement is not based on the evidence provided The evidence only mentions the number of cases of intestinal perforation in each trial but it does not provide information about the difference in the number of cases between the two trials being 11",
        "label": "Contradiction"
    },
    "e682eada-bed5-4ea5-847a-cbfdb44ef724": {
        "text_answer": "Contradiction The statement is incorrect as diabetes was not reported as an adverse event in either the primary or secondary trials The most frequently reported adverse events in the primary trial were syncope and dehydration each occurring in 1667 of participants In the secondary trial deep vein thrombosis was reported in 084 of participants",
        "label": "Contradiction"
    },
    "ffacecd7-caae-434a-866d-a3a25d4f00ac": {
        "text_answer": "Contradiction The placebo intervention receives 04ml of Buminate solution while the AlloMSCs intervention receives 04ml of alloMSCs which are not the same",
        "label": "Contradiction"
    },
    "775258b4-fe6f-4487-a162-ce25e5a665c0": {
        "text_answer": "Contradiction The inclusion criteria state that participants must have no evidence of dementia and Alzheimers disease is a type of dementia",
        "label": "Contradiction"
    },
    "86e418cd-3b9d-46fd-b699-c538a29e7c03": {
        "text_answer": "Contradiction The interventions in the primary trial last for 10 weeks while the interventions in the secondary trial last for 24 weeks",
        "label": "Contradiction"
    },
    "d65c3fe7-21a9-484a-a225-1ed3c5e66b5e": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence pertains to breast cancer and the statement is about colon cancer",
        "label": "Contradiction"
    },
    "b971e3aa-d16a-4cca-8a69-c3e9793ada80": {
        "text_answer": "Contradiction The evidence does not specify that patients with T2 N2 M2 tumors meet the requirements for participation in the primary clinical trial The evidence only lists the requirements for participation in the trial",
        "label": "Contradiction"
    },
    "48ec9126-f671-47ea-a1bd-71a228b20420": {
        "text_answer": "Contradiction  Explanation The evidence shows that in the first cohort of the primary clinical trial there was one case of pancytopenia one case of anemia and one case of febrile neutropenia Therefore the statement that in the first cohort of the primary clinical trial pancytopenia was a prevalent condition while anemia and febrile neutropenia were absent",
        "label": "Contradiction"
    },
    "8d748876-a5b3-4f80-9f87-de9bec532074": {
        "text_answer": "Contradiction  Explanation The statement better results were observed in the primary clinical trials bevacizumab cohort as compared to the bevacizumab  capecitabine cohort is a contradiction based on the evidence provided The evidence shows that the percentage of participants with disease progression or death was lower in the Bevacizumab  Capecitabine cohort 7",
        "label": "Contradiction"
    },
    "343f30bc-9b37-471a-83fc-76089ffc527c": {
        "text_answer": "Entailment given that the evidence does not provide information about adverse events related to sellar chordoma specifically",
        "label": "Entailment"
    },
    "677ea4a6-dee8-4a9f-ab36-68724aeb8237": {
        "text_answer": "Contradiction The primary trial reports Time to Progression in months not days and the secondary trial reports percentage of patients with Objective Response not the total number of patients",
        "label": "Contradiction"
    },
    "52e6f629-f30f-4f59-968f-6d6bcc8b14af": {
        "text_answer": "Contradiction  Explanation  The primary trial includes different inclusion and exclusion criteria compared to the secondary trial The primary trial includes healthy participants and HER2positive females while the secondary trial includes patients with a history of breast cancer or those wishing to avoid estrogen due to a perceived increased risk of breast cancer  The statement in question concerns the exclusion of patients who have undergone gabapentin or Herceptin therapy within",
        "label": "Contradiction"
    },
    "31332603-d84d-4806-b8bf-4cdc08514591": {
        "text_answer": "Contradiction The statement that 1417 of the primary trial patients suffered an increase in blood bilirubin is a contradiction to the evidence as the evidence states that 111 909 of the patients experienced an increase in blood bilirubin The percentage given in the statement does not match the percentage in the evidence",
        "label": "Contradiction"
    },
    "b34700cb-eba7-431e-9508-75e49298d003": {
        "text_answer": "Contradiction The evidence shows that 3636 of participants experienced adverse events which is less than 50",
        "label": "Contradiction"
    },
    "a0f404c3-8323-4ef6-a986-04085778b751": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only mentions the administration method and dose of the placebo and AlloMSCs interventions and does not provide any information about the size or characteristics of the cells involved",
        "label": "Contradiction"
    },
    "2007fc0f-aa14-48a5-9db7-08d47f756757": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses adverse events from a clinical trial while the statement is about the histone h2b gene",
        "label": "Contradiction"
    },
    "0a3eabb5-68f0-4534-834a-d3e75dbb733e": {
        "text_answer": "Contradiction  The statement does not follow from the evidence as the statement mentions 07mgkg less of Durva while the evidence only mentions 03 mgkg Durva for Cohort 1 and 1 mgkg Durva for Cohort 2 The difference is 07 mgkg but the statement incorrectly states that it is 07mgkg less for",
        "label": "Contradiction"
    },
    "b87ab44e-6cbe-4567-98ff-bd820aa7edeb": {
        "text_answer": "Entailment The statement is entailed by the evidence as the evidence states that 13 of the participants with HER2 Primary Breast Cancer who underwent HER2targeted PETCT with 89Zrtrastuzumab developed imagable HER2 metastases",
        "label": "Entailment"
    },
    "14b9aeb8-afd7-4a20-af71-153c33fc117b": {
        "text_answer": "Contradiction In the primary trial lowdose warfarin less than or equal to 1 mgday is permitted but in the secondary trial warfarinbased therapy is prohibited",
        "label": "Contradiction"
    },
    "4a688f54-5b9a-49ad-b6a1-833d1ff96924": {
        "text_answer": "Contradiction   The statement is a contradiction to the evidence as both the primary and secondary trials have distinct criteria for acceptance and rejection during their respective stages However the primary trial also applies a unified set of criteria for certain aspects such as age informed consent and negative urine pregnancy test Therefore the statement is an oversimplification and contradicts the evidence in part but not entirely",
        "label": "Contradiction"
    },
    "ff38ad83-d613-4797-a2a7-3b2e5e1a318d": {
        "text_answer": "Contradiction The primary trial includes NUT midline carcinoma as an eligible diagnosis but the secondary trial explicitly excludes inflammatory breast cancer",
        "label": "Contradiction"
    },
    "d88235dd-c37b-4971-9c1f-42b282ff41c1": {
        "text_answer": "Contradiction  Explanation  The statement Patients with stage 4 cancer are eligible for the secondary trial and the primary trial if they provide informed consent is a contradiction based on the provided evidence because  1 According to the Primary Trial inclusion criteria patients with stage IIbIIIIV breast cancer are eligible However stage IV cancer is a subtype of stage IIIIV cancer which is included in the Primary",
        "label": "Contradiction"
    },
    "baf5c643-9960-4f2e-a9b4-70667a5ca685": {
        "text_answer": "Contradiction The statement does not follow from the evidence as Vitamin D deficiency is not mentioned in the inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "3df24930-167f-4f53-a3e5-fb8205039848": {
        "text_answer": "Contradiction  Explanation  The primary trial includes patients with histologically or cytologically confirmed breast adenocarcinoma but it specifically excludes patients with HER2neu positive disease IHC 3 or positive FISH result The secondary trial on the other hand includes patients with HER2neu negative disease IHC 01 or 2 with HER217",
        "label": "Contradiction"
    },
    "ba84127e-5a18-4ff4-a76b-c19ba3edeeb0": {
        "text_answer": "Contradiction The statement that the second cohort receives dexamethasone two hours following surgery contradicts the evidence that both cohorts receive preoperative intravenous dexamethasone administration",
        "label": "Contradiction"
    },
    "b7ab0a1b-fa3a-4cf4-ba4a-dda1608215a6": {
        "text_answer": "Entailment assuming the patients retroperitoneal lymphoma is not an exclusion criterion for both trials",
        "label": "Entailment"
    },
    "1e349229-5030-4134-99c2-c530a37c3ef2": {
        "text_answer": "Contradiction The primary and secondary trials have different outcome measurements The primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel",
        "label": "Contradiction"
    },
    "0f9e0c7c-a021-4aeb-9309-ab2d6f1d78f8": {
        "text_answer": "Contradiction  Explanation The evidence states that there were 24 participants with any treatmentemergent adverse events and 11 participants with serious adverse events in the Sunitinib  Docetaxel  Trastuzumab arm of the primary trial The statement however claims that a total of 35 patients suffered a treatmentemergent severe varicella zoster virus infection The evidence does not support",
        "label": "Contradiction"
    },
    "558d240e-a51a-4c16-807e-db9031073242": {
        "text_answer": "Contradiction  Explanation The evidence provided does not support the statement as there is no mention of sudden deaths or unplanned hospitalizations in either the primary or secondary clinical trials",
        "label": "Contradiction"
    },
    "f68789cf-7d4d-4186-b3f0-a6b47127379b": {
        "text_answer": "Contradiction The evidence shows that 381 of participants in Arm 1 and 333 of participants in Arm 2 experienced pathologic complete response in breast and axillary lymph nodes",
        "label": "Contradiction"
    },
    "fceee201-8b1b-4cd0-ab16-75fed1f2530f": {
        "text_answer": "Contradiction The statement which affected less than 01 of patients contradicts the evidence that there was one psychiatric adverse event suicidal ideation that affected 200 150 of patients",
        "label": "Contradiction"
    },
    "cded013b-d994-410b-9b42-c4a852978cfc": {
        "text_answer": "Contradiction  The evidence provided in the results does not mention the percentage of participants who had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products at any specific time point including one month posttransplantation Therefore it is not possible to determine if the statement is an entailment or a contradiction based on the given evidence alone",
        "label": "Contradiction"
    },
    "9bc581fd-162a-43c2-8c72-69c06d9ba395": {
        "text_answer": "Contradiction The primary trial reports Time to Progression in months not days and the secondary trial reports percentage of patients with Objective Response not total number of participants",
        "label": "Contradiction"
    },
    "68a2e47e-d66f-45ec-87cd-45403a545e97": {
        "text_answer": "Contradiction  The statement mentions fentanyl sublingual spray which is not mentioned in the evidence provided The evidence only discusses the use of vorinostat and radiation therapy",
        "label": "Contradiction"
    },
    "3cae8899-5172-460e-8ff1-e6e1c8a59f0b": {
        "text_answer": "Contradiction The primary trial and the secondary trial measure different outcomes The primary trial measures the effect of sulforaphane supplements on isothiocyanate concentration in urine while the secondary trial measures the percentage of participants with pain or no pain as measured by the Numeric Pain Rating Scale",
        "label": "Contradiction"
    },
    "8b30b0d1-a4fd-49cb-9dc8-ce508d3b5524": {
        "text_answer": "Contradiction The evidence states that ovarianperitoneal cancer patients received a dose of 1000 mcgday while breast cancer patients received a dose ranging from 25 mcgday to 1100 mcgday",
        "label": "Contradiction"
    },
    "2792a2f8-898b-4aee-a617-df468f3a1eaf": {
        "text_answer": "Contradiction The participants in the primary clinical trial are administered multiple medications throughout the study duration",
        "label": "Contradiction"
    },
    "f5031c61-a192-4b2e-ac0f-be5d2aac0b3c": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were differences in the percentage of participants demonstrating a decrease in the growth factor signature between the ERpositive Luminal B and Triple Negative groups Therefore the statement that there was no observed difference is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "43e7f79b-7ebb-483e-ba3f-2cbd40c09d89": {
        "text_answer": "Contradiction The evidence does not mention TNM staging in the disease characteristics section of the primary trial",
        "label": "Contradiction"
    },
    "e3c4aff9-78ee-4a66-9735-1cd5370b7925": {
        "text_answer": "Contradiction The primary trial requires a primary tumor greater than 2 cm diameter while the statement mentions a primary tumor with a radius of 3mm which is less than 2 cm",
        "label": "Contradiction"
    },
    "dcf21e08-7d8b-45b2-bec3-9f65853fb277": {
        "text_answer": "Contradiction The primary trial includes patients undergoing lumpectomy partial mastectomy and the secondary trial includes patients undergoing skinsparing mastectomy utilizing bioprosthetic mesh or implant only breast reconstruction Both procedures involve breast surgery and are not mutually exclusive",
        "label": "Contradiction"
    },
    "77a8c39a-7193-438c-98c1-9e88c1be1ec9": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence provided for the secondary trial as it incorrectly states that patients who have received chemotherapy or radiotherapy in the last 14 days are excluded from the secondary trial while the actual exclusion criterion is 2 weeks for most chemotherapies and 4 weeks for nitrosoureas mitomycin C pegylateddoxorubicin and one halflife",
        "label": "Contradiction"
    },
    "6aa17b00-284e-408b-a8c3-2e24b6310556": {
        "text_answer": "Contradiction The primary trial does not exclude patients with leptomeningeal carcinomas as long as they have controlled brain metastases postcompletion of local therapy for at least 4 weeks",
        "label": "Contradiction"
    },
    "ad1bb75e-6250-4dbe-beff-a702293ce87c": {
        "text_answer": "Contradiction The primary trial excludes participants with previous treatment with Herceptin but it does not mention anything about gabapentin The secondary trial requires participants to have no previous treatment with Herceptin and excludes those with previous treatment with gabapentin Therefore the statement is a contradiction based on the given evidence",
        "label": "Contradiction"
    },
    "be5577f7-43cb-40c7-bf6d-4988788d9b24": {
        "text_answer": "Contradiction The primary trial includes a minimum primary tumor diameter of 2 cm while the statement presents a primary tumor diameter of 3300 micrometers which is significantly larger than the minimum requirement for the primary trial The secondary trial does not have a specific tumor size criterion mentioned in the evidence provided",
        "label": "Contradiction"
    },
    "9d7e8278-5668-4798-9eb0-bb3ae9db62f0": {
        "text_answer": "Contradiction The statement is not related to the eligibility criteria for the primary or secondary trials",
        "label": "Contradiction"
    },
    "9ef9c9de-3dfa-4cbb-930e-c26190e2d119": {
        "text_answer": "Entailment The statement more than one in three patients from both cohorts in the primary clinical trial experienced a pathologic complete response in their breast and axillary lymph nodes is an entailment of the evidence provided as the evidence shows that 381 of participants in Arm 1 and 333 of participants in Arm 2 experienced a pathologic complete response",
        "label": "Entailment"
    },
    "5b875c96-44e4-4123-921a-546382d4c806": {
        "text_answer": "Contradiction  The evidence states that patients in Arm 1 of the primary trial receive oral lapatinib once daily not twice daily and for 28 days not 4 weeks",
        "label": "Contradiction"
    },
    "e5f77572-2271-434c-8965-dfdac502ea4e": {
        "text_answer": "Contradiction  Explanation  In the primary trial pembrolizumab is given every 3 weeks Q3W while in the secondary trial sunitinib is given once daily Therefore the statement that participants in the secondary trial receive pembrolizumab twice as frequently as participants in the primary trial receive sunitinib is a contradiction based on the given evidence",
        "label": "Contradiction"
    },
    "beef35bd-14a9-4353-aa30-2fe681726d91": {
        "text_answer": "Contradiction The primary trial involves PF06647020 at doses of 02 mgkg and 05 mgkg while the secondary trial involves ALT801 at doses of 0015 mgkg and 0040 mgkg These are not equal doses",
        "label": "Contradiction"
    },
    "9c4299c7-89e6-4d9c-81db-5d12f182b4d3": {
        "text_answer": "Contradiction The primary trial uses a 21day cycle for its intervention not a 4week cycle The secondary trial does not have a cyclic treatment specified",
        "label": "Contradiction"
    },
    "042bf558-479b-46c4-8553-016eb3bfcda7": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as gender is a determining factor for eligibility in the primary trial and only female patients are eligible for the secondary trial",
        "label": "Contradiction"
    },
    "b7a0a223-f9c6-474c-b9e7-ca530c393a53": {
        "text_answer": "Entailment  Explanation The primary trial tests Eribulin Mesylate as a single agent while the secondary trial tests Axitinib in combination with Docetaxel and also tests Docetaxel as a single agent Both trials involve different medications being tested",
        "label": "Entailment"
    },
    "e1cf6d73-554a-4e33-8cf2-e19346eab3ce": {
        "text_answer": "Contradiction The inclusion criteria state that participants must have no evidence of dementia but Alzheimers disease is a type of dementia",
        "label": "Contradiction"
    },
    "574106ef-1b9c-4540-a89f-5100a9bbe798": {
        "text_answer": "Contradiction The evidence does not state that AfricanAmerican patients must reside in Texas for the duration of the study in order to participate in the primary trial",
        "label": "Contradiction"
    },
    "1f5a106f-d664-4a83-a785-a47eea7b9106": {
        "text_answer": "Contradiction for the primary trial regarding breast implants it is an exclusion criterion",
        "label": "Contradiction"
    },
    "7b84b7dd-2143-41b0-bdf5-92c8ae314d17": {
        "text_answer": "Contradiction The primary trial inclusion criteria state that the primary tumor diameter should be greater than 2 cm while the statement provides a diameter of 33000 µm which is significantly larger than the allowed limit",
        "label": "Contradiction"
    },
    "e25a03fa-f51c-4c0d-b737-375a968ce6be": {
        "text_answer": "Contradiction The primary trial does not mention any exclusion based on allergy to ertapenem or ciprofloxacin The secondary trial does not involve any chemotherapy or investigational agents so the statement is not applicable to it",
        "label": "Contradiction"
    },
    "95cb9c0a-0725-4108-aebb-f114f77b577c": {
        "text_answer": "Contradiction  The evidence states that 9 out of 21 participants had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products This is more than half of the participants so the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "5553674a-4eab-4515-be9e-147eef2f0d09": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses hot flash frequency in a primary trial and there is no mention of protective face masks or any adverse events related to respiration interventions",
        "label": "Contradiction"
    },
    "7eeeed55-fe37-47ae-be62-e50557ccaed1": {
        "text_answer": "Contradiction  Explanation The primary trial does not mention the measurement of Ki67 expression in tumors but the evidence does not contradict the possibility that it could have been measured However the secondary trial does mention the use of correlative studies including enzymelinked immunosorbent assay ELISA which can be used to measure Ki67 expression Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "94ca00df-c395-4f32-9348-8bcb6b15a2e1": {
        "text_answer": "Contradiction  Explanation  The statement the most common adverse event in the secondary trial was anaemia affecting more than 005 of patients there were no recorded aes in the primary trial is a contradiction based on the evidence provided  The evidence shows that in the secondary trial the total number of adverse events was 45 out of 128 patients 3516",
        "label": "Contradiction"
    },
    "6abbb566-9561-47d2-aad5-0857550099ea": {
        "text_answer": "Contradiction  The evidence states that 98 of the patients had recurrencefree survival up to 3 years which is not the same as no patient experiencing recurrencefree survival",
        "label": "Contradiction"
    },
    "2a6e2da6-0555-43d1-b063-a81938137be9": {
        "text_answer": "Contradiction The evidence states that patients must have a BMI of 25 kgm2 or greater to be eligible for the trial",
        "label": "Contradiction"
    },
    "7af8a41a-c4b2-402e-bf50-a14aa2758926": {
        "text_answer": "Contradiction The statement mentions Arimidex being used in the primary trial but not in the secondary trial which is not reflected in the given evidence from the primary trial which only mentions Anastrozole being used The secondary trial does not provide any information about the use or nonuse of Arimidex",
        "label": "Contradiction"
    },
    "0f79f642-47d6-404b-ade0-8e720c0aa660": {
        "text_answer": "Contradiction The primary trial results do not imply that the Denosumab cohort in the secondary trial would have a worse overall response rate",
        "label": "Contradiction"
    },
    "6b3619d3-21ea-437e-bb0f-f124cf636ca5": {
        "text_answer": "Contradiction The evidence provided does not mention anything about HER2neu peptide vaccine admixed with sargramostim in the primary trial",
        "label": "Contradiction"
    },
    "5a77ba85-1a9e-4639-ba29-86b0cdea296b": {
        "text_answer": "Contradiction  Explanation The primary trial excludes women with renal impairment which could be a symptom of osteoporosis but it does not mention anything about claustrophobia The secondary trial excludes women with severe claustrophobia but it does not mention anything about osteoporosis Therefore the statement that women suffering from both claustrophobia",
        "label": "Contradiction"
    },
    "aa176a26-7dd6-473f-9c35-40a0754336f6": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the evidence provided The evidence describes several injections that patients will receive but it does not directly address whether patients will feel fatigue or not",
        "label": "Entailment"
    },
    "000c067a-a563-425e-9ea1-7057f8d2c39f": {
        "text_answer": "Contradiction  Explanation  The statement none of the participants in group 1 of the primary clinical trial had lesions in contrast above 95 of the participants in group 1 of the secondary clinical trial had symptoms of radiation dermatitis and hyperpigmentation is a contradiction based on the evidence provided  The primary clinical trial and the secondary clinical trial are about different studies with different outcomes The primary clinical",
        "label": "Contradiction"
    },
    "5fca366e-ecc6-41e4-b621-e3343ff0f07e": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement is about the agent administration care setting type code and the evidence is about the primary trial intervention section and the type of radiation therapy used The statement does not directly mention or relate to the absence of medication in the primary trial which is the focus of the original question",
        "label": "Entailment"
    },
    "a5ed681f-ae92-4bc5-856f-4565ab2669f0": {
        "text_answer": "Contradiction The primary trial explicitly states that potassium must be within the normal range 3553 mEqL which is not consistent with the statement that patients suffering from hypokalemia low potassium levels are eligible for the secondary trial",
        "label": "Contradiction"
    },
    "58f0bed2-bc88-4aaf-8572-fb49fc69a87c": {
        "text_answer": "Contradiction The statement some patients treated with gtx024 1mg in the primary clinical trial did not gain lean body mass over a 4 month period is not directly contradictory to the evidence but it is less specific and does not follow directly from the evidence which only provides median changes in lean body mass for the entire group However the term some patients implies that there were individuals in the group who did not gain lean body mass",
        "label": "Contradiction"
    },
    "fe6418cd-e255-4f27-bb63-63b4f37a0f56": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The statement is about the association between a specific gene mutation and disease risk while the evidence is about the occurrence of adverse events in clinical trials The two pieces of information are related but not identical",
        "label": "Entailment"
    },
    "93299ed6-4cc9-4369-a4f3-c86f45ab741e": {
        "text_answer": "Contradiction The primary trial intervention involves Yttrium90 radioembolization using TheraSphere while the secondary trial intervention involves the use of ibrutinib and MEDI4736 with different doses",
        "label": "Contradiction"
    },
    "e8f582a2-31f8-4b30-a2bb-1d236706333d": {
        "text_answer": "Contradiction The primary trial involves armodafinil which has a consistent dosage for all participants while the secondary trial involves MCS110 and PDR001 which have varied dosages for all participants",
        "label": "Contradiction"
    },
    "cf9ea9d0-49c4-4c00-a91b-142cd7ec8433": {
        "text_answer": "Entailment The evidence states that both interventions use laserassisted fluorescence angiography for monitoring perfusion at three separate time points during the surgical procedure",
        "label": "Entailment"
    },
    "a45aa828-dfd0-4b82-a1a1-7a8386520fe4": {
        "text_answer": "Contradiction The primary trial administers pregabalin every day for 6 weeks while the statement suggests every 2 weeks over 12 weeks which is not the same Additionally the secondary trial administers Depocyt and HDMTX which are not mentioned in the primary trial",
        "label": "Contradiction"
    },
    "e8247d17-f420-4a08-9a2c-c2d8f1524d93": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial only includes patients with breast cancer not hepatocellular carcinoma",
        "label": "Contradiction"
    },
    "aa7a20b6-cec1-448c-ac20-a7b2d8c14a1d": {
        "text_answer": "Entailment The statement is an entailment because the evidence mentions that the subjects were treated with partial breast irradiation which is a part of the intervention cycle described in the statement",
        "label": "Entailment"
    },
    "0bb34f7b-d21a-4057-876a-25c722e6d50e": {
        "text_answer": "Contradiction  Explanation The evidence states that 98 of the patients had Recurrencefree Survival of 3 years or more but it does not provide any information about the occurrence or nonoccurrence of adverse events The statement about 97 of patients not experiencing any adverse events is not entailed by the evidence as there is no information in the evidence about adverse events",
        "label": "Contradiction"
    },
    "b24a7c99-879c-416b-8b54-f44f0bcd4524": {
        "text_answer": "Contradiction The primary trial compares two interventions Arm A and Arm B against each other while the secondary trial compares two different treatments Zoledronic acid and Denosumab The statement combines the findings of both trials but they do not directly compare the same interventions or treatments",
        "label": "Contradiction"
    },
    "3795f873-9d20-4fb3-b77c-ca01ba923c82": {
        "text_answer": "Contradiction The evidence states that pregnant women and those with extreme obesity are excluded from both trials",
        "label": "Contradiction"
    },
    "94ee2ae4-cf85-4dfb-90be-2490ad4089ab": {
        "text_answer": "Contradiction The primary trial intervention in the given evidence is indeed given orally but the secondary trial interventions are administered intravenously not exclusively However the statement assumes that the secondary trial interventions are given exclusively through intravenous means",
        "label": "Contradiction"
    },
    "750d4e54-f2cf-425c-9a04-dbd5091a0cba": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement does not directly address the interventions in the primary trial Placebo and Trabectedin and their potential effect on weight loss or CTCAE The evidence only describes the administration methods of the interventions",
        "label": "Entailment"
    },
    "bac5180a-b51f-4a2d-a1d2-eaead122d693": {
        "text_answer": "Entailment  Explanation The statement the majority of patients in the primary clinical trial treated with lapatinib 1000 mg  nabpaclitaxel did not achieve a confirmed complete response CR is an entailment based on the evidence provided The evidence states that 47 out of 60 participants or 783 did not achieve a CR which is more than a majority Therefore",
        "label": "Entailment"
    },
    "e54cf8ee-4a0d-4a15-bc72-4072ff0b6e6d": {
        "text_answer": "Contradiction  Explanation The primary trial intervention involves Yttrium90 Radioembolization which is a type of radiotherapy not chemotherapy The secondary trial intervention involves the use of ibrutinib and MEDI4736 which are kinase inhibitors and monoclonal antibodies respectively and are considered immunotherapies and hormonal therapies depending on the context but neither",
        "label": "Contradiction"
    },
    "ec3a1125-3c16-4f3c-8fa3-6a237f4529c9": {
        "text_answer": "Contradiction  Explanation The evidence states that patients will take Vorinostat daily during radiation therapy which contradicts the statement that radiation therapy is undertaken without simultaneous administration of daily vorinostat capsules",
        "label": "Contradiction"
    },
    "e4b448ba-15ad-4cf8-9343-782d45166891": {
        "text_answer": "Entailment Both trials are studying the use of empegfilgrastim but the primary trial is focusing on the duration of neutropenia with a 3week time frame while the secondary trial is looking at the incidence of CTCAE grade 34 neutropenia with a 21day time frame",
        "label": "Entailment"
    },
    "2e2a005f-232f-457a-880e-c3950bc58df6": {
        "text_answer": "Entailment  Explanation The primary and secondary trials involve different interventions with the primary trial using Abl Cells IV  Cyclophosphamide and the secondary trial using DMCHOCPEN These are distinct treatments and the statement that they include completely different drugbased treatments is an entailment based on the evidence provided",
        "label": "Entailment"
    },
    "dffbf597-b236-4aa5-bd94-b471c9e593ea": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy not radioembolization The secondary trial involves intramuscular injections of Fulvestrant but the statement specifically mentions radioembolization which is not part of the interventions in the secondary trial",
        "label": "Contradiction"
    },
    "7e3a4e76-6d33-4013-ad8e-7fd3d684136f": {
        "text_answer": "Contradiction The primary trial measures time to progression in months not hours and the secondary trial measures the number of participants with objective response not the duration of response",
        "label": "Contradiction"
    },
    "976f4747-e1a6-4527-a298-490fb57d4615": {
        "text_answer": "Contradiction The primary trial involves imaging sessions with fluciclatide injections while the secondary trial involves chloroquine dosages and there is no mention of the route of administration for the secondary trial",
        "label": "Contradiction"
    },
    "82d350f6-9864-4329-bd5b-8d8155170569": {
        "text_answer": "Contradiction The evidence does not provide any information about exercise being part of the intervention for any of the primary trial candidates",
        "label": "Contradiction"
    },
    "efe92dca-7dd8-44da-b436-15a3c9f9f729": {
        "text_answer": "Contradiction  Explanation The statement does not entail or contradict the evidence provided The evidence mentions one case of shingles in group 2 of the secondary trial but the statement does not mention any specific group or trial in relation to shingles Therefore the statement does not directly follow or contradict the evidence",
        "label": "Contradiction"
    },
    "f5650e8f-58b5-4a3a-9da2-ab66d7674b6d": {
        "text_answer": "Contradiction  The evidence describes the disease characteristics for patients with histologically confirmed breast cancer who are eligible for the primary clinical trial The statement however refers to patients with tx nx mx t0 n1 m0 or t1 n1 m1 tumors which are TNM staging classifications that do not align with the eligibility criteria provided in the evidence Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "cdce28fc-eb28-4608-8b83-9bc18414caf8": {
        "text_answer": "Contradiction  The primary trial does not mention claustrophobia as an exclusion criterion but it does not allow participation of women with osteoporosis The secondary trial on the other hand does not mention osteoporosis as an exclusion criterion but it does allow participation of women with claustrophobia under certain conditions use of sedation or other measures to manage the condition Therefore",
        "label": "Contradiction"
    },
    "51220352-fff0-4e70-b36d-7f9e87498a58": {
        "text_answer": "Contradiction The statement is about fixdm1 therapeutic agent which is not mentioned in the evidence The evidence only discusses a GloboHGM2LewisyMUC132aasTncTFcTncKLH conjugate vaccine with QS21 adjuvant",
        "label": "Contradiction"
    },
    "03fe5ae7-9f15-4d30-a208-cead95780b13": {
        "text_answer": "Contradiction The primary trial employs Fulvestrant and Anastrozole not just Arimidex The secondary trial does not mention Arimidex at all",
        "label": "Contradiction"
    },
    "5d42d5d3-e80d-49e0-83e5-8724a8ff5401": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions nothing about asthenia or pyrexia in either trial",
        "label": "Contradiction"
    },
    "e52a3c24-8fed-4bcb-9513-582c604a5414": {
        "text_answer": "Contradiction The statement is about a country Sao Tome and Principe and has no relation to the inclusionexclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "df26264a-98ef-47f9-9493-e2398529e39f": {
        "text_answer": "Contradiction The statement is not related to the evidence provided as there is no mention of megacolon in the evidence",
        "label": "Contradiction"
    },
    "e554ce24-beab-4ed6-b37b-0a28ae28faf0": {
        "text_answer": "Contradiction The evidence shows that patients in the secondary trial experienced anemia more frequently 625 than patients in the primary trial 000 Similarly there was one case of pneumonia in the secondary trial 625 compared to none in the primary trial 000 There was no mention of stupor in the primary trial but it was reported in 625 of cases in",
        "label": "Contradiction"
    },
    "9324259a-88b9-441b-a6ee-ec7f6f5914aa": {
        "text_answer": "Neutral  The statement does not directly entail or contradict the evidence provided The evidence only discusses the PFS data for two different treatment groups while the statement is making a statement about a specific patients condition and PFS duration",
        "label": "Entailment"
    },
    "09879638-e324-4f5d-a45e-f62f7e06f301": {
        "text_answer": "Contradiction The primary trial explicitly excludes children and adolescents due to height requirement but the secondary trial does not mention any age restrictions",
        "label": "Contradiction"
    },
    "86a8919e-ee7f-40ba-9186-9dcbdbb06018": {
        "text_answer": "Entailment based on the given results the median survival times are under 12 months and less than 50 patients in each group exceeded a year of survival",
        "label": "Entailment"
    },
    "cbb9beea-1961-4049-9a90-53a75da5933e": {
        "text_answer": "Contradiction The statement is incorrect based on the evidence provided as cohort 2 is given a higher dose of ALT801 in the primary clinical trial",
        "label": "Contradiction"
    },
    "ca4fb850-2d8b-4a5f-b990-1d81ae917d63": {
        "text_answer": "Contradiction The statement is incorrect as the talazoparid dosage does not entail the same dosage for both breast cancer and ovarianperitoneal cancer patients in the primary clinical trial",
        "label": "Contradiction"
    },
    "f8dbd18d-2b55-4f0f-92a7-db3b1ecc3b6d": {
        "text_answer": "Contradiction The primary trial recorded zero adverse events while the secondary trial recorded zero or fewer adverse events but the statement asserts that they recorded the same total number of adverse events",
        "label": "Contradiction"
    },
    "ec2e7860-1d3e-4f95-b00a-bea42d04825a": {
        "text_answer": "Entailment The statement is entailed by the evidence as Capecitabine was indeed administered orally every day for the first 21day cycle in the primary trial",
        "label": "Entailment"
    },
    "c17afde4-0fee-473c-b969-f7a4e89f049b": {
        "text_answer": "Contradiction  Explanation The statement the primary clinical trial is open for patients with estrogen negative progesterone negative and her2 forms of breast cancer is a contradiction to the evidence because the evidence only mentions ER positive and HER2 negative as inclusion criteria not ER negative and PR negative",
        "label": "Contradiction"
    },
    "328417f9-8f45-4114-82d7-9396b6bc578e": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence indicates that patients will receive sargramostim injections on day 8 and following days until their neutrophil count is greater than 1000mm3",
        "label": "Contradiction"
    },
    "6ffb2b0f-737a-4176-9036-a887a2f4a4b7": {
        "text_answer": "Contradiction The evidence does not provide information on the average survival duration for the entire cohort or the number of patients from each cohort who survived more than 24 months",
        "label": "Contradiction"
    },
    "5b13bca4-0354-4579-a868-d007bef0dbe1": {
        "text_answer": "Entailment The evidence shows that the percentage of participants with iDFS events was lower in the Neratinib group 47 compared to the Placebo group 75",
        "label": "Entailment"
    },
    "8d94a62d-400f-4d9d-92aa-d39dd1f37823": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because according to the evidence there was one case of Infections and Infestations  Other Gramnegative bacteremia 40 degree C fever recorded in cohort 2 as well",
        "label": "Contradiction"
    },
    "8d813fc8-01ec-4fb7-9191-f5ec7cb735fb": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as not all interventions in the primary and secondary trials are given intravenously In the primary trial zoledronic acid is given intravenously but capecitabine and lapatinib ditosylate in the secondary trial are given orally In the secondary trial granisetron hydrochloride dexamethasone prochlorperazine aprepit",
        "label": "Contradiction"
    },
    "eaad4acd-8fc1-41c6-92aa-1a4488ffdfed": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions infections in both trials but the statement specifically refers to a delayed word recall task for Alzheimers disease assessment scalecognitive CDISC version ADASCOG CDISC version and does not mention infections at all",
        "label": "Contradiction"
    },
    "0cb2b471-fa4a-4eeb-8dd7-981680465858": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events in cohort 2 but the statement asserts that all logged adverse events happened in cohort 1",
        "label": "Contradiction"
    },
    "f4da0e5f-f0aa-4edf-a08c-afadd05360d5": {
        "text_answer": "Entailment The statement is a specific case of the inclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "f859f501-4e35-44c5-88bf-213949f5e5e5": {
        "text_answer": "Entailment The evidence states that there are 1530 enrollment slots for patients with metastatic colorectal cancer that harbors the Kras or BRAF mutation",
        "label": "Entailment"
    },
    "b7b355cd-5386-4b3c-bc5d-a9a05e7a83b5": {
        "text_answer": "Contradiction The primary trial measures tumor diameter in centimeters while the secondary trial measures number of participants with solid tumor response",
        "label": "Contradiction"
    },
    "10292ba1-dd1f-4191-b534-331f39583181": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with potassium levels outside the normal range while the secondary trial does not mention any potassiumrelated exclusion criteria",
        "label": "Contradiction"
    },
    "cd2874dc-b435-4319-8ae9-d413b3f43499": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as cohort 1 receives fulvestrant and cohort 2 does not but paclitaxel is not mentioned in the evidence for cohort 2",
        "label": "Contradiction"
    },
    "76b35642-5bf9-4980-beb9-e802493907b6": {
        "text_answer": "Contradiction  The evidence shows that there were 5 emesisfree participants in the placebo group and 13 emesisfree participants in the aprepitant group indicating that fewer participants in the aprepitant group were emesisfree compared to the placebo group",
        "label": "Contradiction"
    },
    "f13b3dd4-fe4a-4189-b51b-cf72af22deab": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as there is no mention of organ transplant as an exclusion criterion in either trial Additionally the statement brings up a country Congo which is not related to the trials at all",
        "label": "Contradiction"
    },
    "56603bed-1e4b-41d2-919c-612ec6e9b4c4": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence as the evidence states that 53 of the participants experienced a confirmed complete response CR not over 89100",
        "label": "Contradiction"
    },
    "306ea03b-8055-4a52-8d81-ed4e18dedd4f": {
        "text_answer": "Contradiction The evidence provided states that patients with symptomatic brain metastasis are excluded from the primary trial and that subjects with advanced solid tumors including brain tumors are eligible for the secondary trial but only if they have measurable or evaluable disease The statement however refers to patients with localized andor earlystage solid tumors in the brain which are typically not considered measurable or evaluable by RECIST v11",
        "label": "Contradiction"
    },
    "94604a45-9867-4ccd-b38b-de2a3368130e": {
        "text_answer": "Contradiction  Explanation  The statement no notable variances were present in the outcomes of the primary clinical trial groups is not supported by the evidence provided in the primary trial results The results show that there is a difference in the area under the ROC curve AUC between the two algorithms used in the trial This difference even if small is considered a notable variance in the outcomes of the two groups  Furthermore",
        "label": "Contradiction"
    },
    "8f20a32b-2aa2-44c4-930e-852cba56151f": {
        "text_answer": "Contradiction The primary trial involves the use of Fluciclatide Injection AH111585 18F and the secondary trial involves the use of Chloroquine which are different interventions",
        "label": "Contradiction"
    },
    "3fa1e0aa-7c62-4a1e-bd7d-452fa87a7baf": {
        "text_answer": "Contradiction The statement splitting pain is an intense sensation of discomfort or distress that feels like being cut apart Patients whos Metastasis cannot be measured or whos Cancer has not spread to other parts of the body are not eligible for the primary trial is a contradiction to the evidence because the eligibility criteria for the primary trial do not mention anything about splitting pain or its relationship to metastasis or the spread of cancer to other parts",
        "label": "Contradiction"
    },
    "d66e149e-5bb7-4e4b-8078-7f5947a31f60": {
        "text_answer": "Contradiction The statement is not an entailment as the patient described does not meet the inclusion criteria for either trial due to insufficient bone marrow function ANC  1800 cellsmm3 and shortened life expectancy  5 months for the primary trial and insufficient hemoglobin level  80 gdl and life expectancy  6 months for the secondary trial",
        "label": "Contradiction"
    },
    "e7c553e8-8799-4475-9e39-6f79bebc0a48": {
        "text_answer": "Entailment assuming mostly beneficial effects refers to a lower overall adverse event rate in cohort 1 compared to cohort 2 as indicated by the percentage numbers provided",
        "label": "Entailment"
    },
    "8ddc286d-ac51-4c92-a163-2d9a65b52ae7": {
        "text_answer": "Contradiction The primary trial excludes patients with epilepsy and thalasemic syndromes but the secondary trial does not mention these conditions as exclusion criteria The statement about anemia is ambiguous as the primary trial excludes patients with anemia only due to irondeficiency while the secondary trial does not mention anything about the cause of anemia",
        "label": "Contradiction"
    },
    "5baa6e97-00e4-4e2f-b837-661a790cb87f": {
        "text_answer": "Entailment assuming that the primary trial evaluates patient race as one of the attributes which is not explicitly stated in the provided evidence but can be inferred from the secondary trial results",
        "label": "Entailment"
    },
    "6f95650b-d11f-4546-bfb2-d46cc39561b2": {
        "text_answer": "Contradiction The primary trial does not include severe insomnia as an inclusion criterion while the secondary trial does require a score of 3 on the Sleep Disruption Evaluation form or a score of 8 on the Insomnia Severity Index for eligibility However schizophrenia is not mentioned as an inclusion or exclusion criterion in either trial",
        "label": "Contradiction"
    },
    "fd23bed1-83e9-44c9-acf7-66df74ba1c98": {
        "text_answer": "Contradiction The evidence states that there are inclusion criteria for age life expectancy and pregnancy in the primary trial",
        "label": "Contradiction"
    },
    "ea0d6370-3322-4925-b524-b9a8bebe4383": {
        "text_answer": "Contradiction The primary trial is studying a different outcome measurement duration of neutropenia and the secondary trial is studying incidence of neutropenia although both trials are using the same drug empegfilgrastim and similar dosages",
        "label": "Contradiction"
    },
    "ea893c02-e0eb-4789-bb1e-5501db3be7d7": {
        "text_answer": "Contradiction The primary trial excludes patients with Vitamin D deficiency but the secondary trial does not mention it as an inclusion or exclusion criterion",
        "label": "Contradiction"
    },
    "3cbb65a6-d9f6-4972-8b13-dd19d427f0cb": {
        "text_answer": "Contradiction The primary trial does not evaluate the impact of diverse radiation therapies but rather compares two different interventions Hydrophor and MediHoney for managing radiation therapy side effects The secondary trial investigates the results of varying doses of the same treatment PF05212384  Docetaxel on different groups",
        "label": "Contradiction"
    },
    "40de18f3-3a12-40fb-9ce2-ebcc28391c7d": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as both trials reported zero adverse events in their respective patient cohorts",
        "label": "Contradiction"
    },
    "8dc16445-6102-4525-b9ce-ba4e35cc8b01": {
        "text_answer": "Contradiction The evidence states that women of childbearing potential WOCBP are excluded from the study but it does not specify that only postmenopausal women and men who have had a vasectomy are eligible",
        "label": "Contradiction"
    },
    "aeb95807-2d6b-4915-b52c-0d0fdc82728e": {
        "text_answer": "Contradiction The primary trial had 75 participants in the waitlist control group and 76 in the peer support program group while the secondary trial had 147 participants in the standard of care group and 163 in the device  standard of care group The number of participants in the second group of the secondary trial is greater than the number of participants in either group of the primary trial",
        "label": "Contradiction"
    },
    "c2d6b8ba-8238-49b7-b9a1-de2ffdabe324": {
        "text_answer": "Contradiction The primary trial has additional inclusion criteria history of breast cancer taking an aromatase inhibitor or tamoxifen and experiencing hot flushes that are not present in the secondary trial Therefore not all patients in the secondary trial would be eligible for the primary trial",
        "label": "Contradiction"
    },
    "35a580c0-ce8a-42d1-b8ea-d84b985319c5": {
        "text_answer": "Contradiction The statement individuals having confirmed her2 negative tumor through either fish or ihc 3 is a contradiction to the inclusion criteria of the primary clinical trial which states that the tumor must be HER2 positive either IHC 3 or FISH",
        "label": "Contradiction"
    },
    "fa2d8a93-4cae-4ee5-afdf-1afd04d07c93": {
        "text_answer": "Contradiction  The evidence shows that 3636 of patients experienced adverse events but it does not indicate that over 20 of patients experienced all types of adverse events",
        "label": "Contradiction"
    },
    "a852b1d2-ce26-48da-ba6d-2386489a967b": {
        "text_answer": "Contradiction The statement entails that the occurrences of hepatotoxicity were exactly three times as common as those of hypertension and pancreatectomy combined while the evidence only shows that occurrences of hepatotoxicity were more common than those of hypertension and pancreatectomy but not three times as common",
        "label": "Contradiction"
    },
    "9068887d-3b93-4345-9b59-01ceb05725b1": {
        "text_answer": "Contradiction The evidence states that patients must have metastatic invasive breast cancer for the primary trial and having ILCDPBC within the previous 3 years does not necessarily mean having metastatic disease",
        "label": "Contradiction"
    },
    "c35d641d-7248-47d7-90ff-a3859a846f68": {
        "text_answer": "Contradiction The evidence does not mention regular incidents or common after effect of maculopapular rash in the primary clinical trial participants",
        "label": "Contradiction"
    },
    "2690d684-0905-4af0-8113-fffec885de77": {
        "text_answer": "Contradiction The primary trial does not allow participation for patients with meningeal carcinomatosis or malignant effusion as the only site of disease recurrence Acute bacterial meningitis is a condition characterized by inflammation of the meninges which is not related to cancer",
        "label": "Contradiction"
    },
    "ee0b2916-1e10-467e-bcf3-41c56aa80921": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 or any other hemorrhagebleeding event NCI CTCAE v30 Grade 3 within 4 weeks of first dose of study drug The secondary trial does not mention any hemorrhagebleeding event exclusion criteria However the statement does not necessarily imply that patients",
        "label": "Contradiction"
    },
    "731e38ac-1da8-4b94-a501-606a49570767": {
        "text_answer": "Contradiction The statement about cyp3a4 polymorphism positive and AfricanAmerican patients residing in Texas for the duration of the study is not entailed by the provided evidence The evidence only mentions inclusion and exclusion criteria for the primary and expansion phases of a clinical trial but it does not mention anything about cyp3a4 polymorphism or residency requirements for specific patient populations",
        "label": "Contradiction"
    },
    "d6f4c977-a5fa-49c9-ba6c-a40dfe0f3b30": {
        "text_answer": "Contradiction The evidence reports that there are no results for the LBH589 and Lapatinib cohort in the primary trial but the statement mentions biospecimen requirements for that cohort which implies that the cohort exists and has data associated with it",
        "label": "Contradiction"
    },
    "7506e58c-a44a-4410-a519-59a81686fe12": {
        "text_answer": "Contradiction The primary trial does not mention any requirement for participants to have responded positively to AI therapy and mirtazapine for the secondary trial",
        "label": "Contradiction"
    },
    "d3379655-55b7-4e58-88c2-c3cd3e8cb557": {
        "text_answer": "Contradiction  The primary trial excludes women with stage IV breast cancer while the secondary trial includes women with newly diagnosed stage IV breast cancer as a potential participant",
        "label": "Contradiction"
    },
    "f823a6d1-5d44-4d8c-8f33-14eef364d3b6": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence explicitly states that women of childbearing potential WOCBP must use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab and men with sexually active fertile partners whose partners are WOCBP must also use an adequate method of birth control Therefore the statement that the primary clinical trial wel",
        "label": "Contradiction"
    },
    "2a45331c-2e6b-43fb-be85-86e22c828c41": {
        "text_answer": "Contradiction  The evidence provided shows that a lower percentage of participants in the Bevacizumab  Capecitabine cohort experienced disease progression or death compared to the Bevacizumab cohort",
        "label": "Contradiction"
    },
    "d3ee2617-a363-4290-a97b-57f6eb1b8efe": {
        "text_answer": "Contradiction  Explanation  The statement the entirety of group 1 in the primary clinical trial presented with skin lesions fewer than one in ten participants in group 1 of the secondary clinical trial exhibited radiation dermatitis or hyperpigmentation is a contradiction based on the evidence provided  In the primary clinical trial there were no skin lesions detected in the group of healthy volunteers In contrast in the",
        "label": "Contradiction"
    },
    "d2885dd5-eb3f-4dcd-9980-c02d3c1c6924": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial and group 1 of the secondary trial reported no instances of shingles but the statement mentions that there was a reported case in group 2 of the secondary trial",
        "label": "Contradiction"
    },
    "aab488c3-ac44-4506-b2b1-541909e30028": {
        "text_answer": "Entailment The evidence states that there was a significant change in Ki67 expression in tumors with 7 days of presurgical tamoxifen and the statement also mentions that tamoxifen was taken 7 days before surgery Therefore the statement is an entailment of the evidence",
        "label": "Entailment"
    },
    "0c105984-77ed-42cc-9d9f-aec464e02d12": {
        "text_answer": "Contradiction The primary trial requires a Karnofsky score 70 while the secondary trial requires a Karnofsky score 55",
        "label": "Contradiction"
    },
    "216d59a3-b4c1-4a73-a4e2-ee2b97c59b22": {
        "text_answer": "Contradiction The primary trial does not measure diseasefree survival it measures toxicity The secondary trial measures the percentage of participants with adverse events of primary interest",
        "label": "Contradiction"
    },
    "fa7b75cd-7f8f-44aa-83dc-618e1bc961a1": {
        "text_answer": "Irrelevant  The statement about bladder solitary fibrous tumors being mostly benign is not related to the evidence provided about the primary trial results for Lapatinib 1000 mg  NabPaclitaxel treatment",
        "label": "Entailment"
    },
    "34f34450-a64c-4159-ad9d-8adb58617e79": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence from the primary trial reports no observed adverse events at all while the statement suggests that the secondary trial reported two types of adverse events",
        "label": "Contradiction"
    },
    "6c50344e-493e-46a6-9e03-74495773bab2": {
        "text_answer": "Contradiction The primary trial specifies that patients receive both Suramin and Paclitaxel while the secondary trial does not mention any specific drugs in its intervention section",
        "label": "Contradiction"
    },
    "a698cb41-106c-4d9c-b4e9-1381f9329079": {
        "text_answer": "Entailment The placebo is given as a 3hour intravenous infusion once on Day 1 while Trabectedin is given as a 3hour intravenous infusion on Day 2 but both are intravenous infusions",
        "label": "Entailment"
    },
    "6bae9ada-fea4-4bb6-bd25-cdb505b3d53f": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence shows that there were adverse events reported in both trials",
        "label": "Contradiction"
    },
    "fc281ab7-f956-47d7-a938-8778fef1bca0": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction to the evidence because  1 In the primary trial participants receive a single subcutaneous injection at the beginning of the study 2 In the secondary trial participants in the intervention group receive weekly subcutaneous injections for 12 weeks  Therefore the statement that candidates for the secondary trial study group receive 3 weekly subcutaneous in",
        "label": "Contradiction"
    },
    "5db44a07-6d17-4fa9-9060-1f1af4aaf3af": {
        "text_answer": "Entailment The evidence shows that there were a total of 5 gastrointestinal adverse events diarrhea gastritis hemorrhagic and vomiting in Adverse Events 1 and 1 gastrointestinal adverse event dyspepsia in Adverse Events 2 Therefore the statement at least one gastrointestinal adverse event was recorded in the primary clinical trial is",
        "label": "Entailment"
    },
    "327d67d2-35e7-45c3-958a-7955905f2d57": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 2 months while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "86515e2e-b144-430c-b7e2-678733d3b0ec": {
        "text_answer": "Contradiction The statement Patients participating in the primary trial receive oral medication twice a day for a full month is not entailed by the evidence as the evidence states that patients receive medication once daily with lapatinib ditosylate and tamoxifen citrate",
        "label": "Contradiction"
    },
    "f9638af4-2bf2-45b4-8c9e-b46c34373b17": {
        "text_answer": "Contradiction  The evidence provided shows that a lower percentage of participants in the bevacizumab  capecitabine group experienced disease progression or death compared to the bevacizumab monotherapy group",
        "label": "Contradiction"
    },
    "cf38cb04-b2fd-44bf-9674-dda257a8ad25": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction of the evidence provided  Explanation The statement cardiac biphasic synovial sarcoma is a biphasic synovial sarcoma arising from the heart is not directly related to the evidence provided in the primary trial The evidence only states that 13 participants received the GloboHGM2Lewisy",
        "label": "Entailment"
    },
    "bbb1b8c1-c9b1-40c9-b744-a2ae519032c3": {
        "text_answer": "Entailment The statement implies a reduction in percentage which is consistent with the evidence showing a decrease in Ki67 expression from 15 to 10 However its important to note that the statement does not directly mention the unit of measurement as million cells but the evidence provided is in terms of percentage of cells which is consistent with the statement as well",
        "label": "Entailment"
    },
    "7dbe6e8e-5971-41e2-bc70-46dc3cb3cd5c": {
        "text_answer": "Contradiction  Explanation  The primary trial has several inclusion criteria related to cancer diagnosis stage sensitivity to vinorelbine and life expectancy It also has several exclusion criteria related to pregnancy previous vinorelbine treatment infection and prior anticancer therapy  The secondary trial on the other hand has no mention of cancer vinorelbine or any of the exclusion criteria from the primary trial",
        "label": "Contradiction"
    },
    "c18a6d09-906e-4fbe-acf1-93b9a89f717a": {
        "text_answer": "Contradiction The primary trial measures change in units on a scale not minutes and the secondary trial measures percentage of participants",
        "label": "Contradiction"
    },
    "9c0406cd-3585-4cb2-b330-fa9c1426c72c": {
        "text_answer": "Entailment The statement every participant in the primary clinical trial was administered oral sunitinib daily throughout the entirety of the research period is an entailment of the evidence provided as the evidence states that sunitinib was administered orally from Day 1 at a continuous daily dosing schedule in 21day cycles throughout the entirety of the research period",
        "label": "Entailment"
    },
    "47daf120-3939-4e32-bba5-d86ce54a9cbd": {
        "text_answer": "Contradiction  The evidence states that 53 of participants in the lapatinib 1000 mg  nabpaclitaxel arm experienced a confirmed complete response CR which is a higher percentage than a minority less than 50",
        "label": "Contradiction"
    },
    "84e7c52d-eec3-415f-9602-77f607c5620e": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the two cohorts are not administered identical doses of Abraxane nabPaclitaxel is the same drug but given in combination with different agents in each arm",
        "label": "Contradiction"
    },
    "19606c86-3376-40ca-b438-20d961329829": {
        "text_answer": "Entailment The primary trial measures changes in hot flash scores while the secondary trial measures overall response rate in solid tumors using RECIST criteria These are entirely different outcomes",
        "label": "Entailment"
    },
    "b12b7e1a-9348-4e57-ac88-44523913fff3": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention is given intravenously IV while in the secondary trial all interventions can be given orally This contradicts the statement that all interventions in the secondary trial are still given intravenously IV like in the primary trial",
        "label": "Contradiction"
    },
    "a7561afd-f6c4-41cf-8d4a-fa6c26cc10b3": {
        "text_answer": "Contradiction The statement makes a comparison between congenital candidiasis and the primary trial results which are not related",
        "label": "Contradiction"
    },
    "9289ca32-0fa0-44ae-8cc0-49510f2fed23": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that cohort 1 receives a dose of ALT801 that is less than half of the dose given to cohort 2",
        "label": "Entailment"
    },
    "784e0481-d0fd-43b9-8d5a-0a1d2bd4aa26": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only mentions the percentage of adverse events and the specific adverse events recorded in the primary trial it does not mention the unit of measurement for the percentage or the frequency of general symptoms",
        "label": "Contradiction"
    },
    "e3801aad-e988-42fb-8266-22a90bdba955": {
        "text_answer": "Contradiction The secondary trial does not measure muscle gains but rather the percentage of participants with pain or no pain as measured by the Numeric Pain Rating Scale",
        "label": "Contradiction"
    },
    "22274495-9d06-43cd-98fd-86d0374b42e9": {
        "text_answer": "Contradiction The primary trial and the secondary trial are about different outcomes EGFR expression in the primary trial and fatigue levels in the secondary trial Therefore the results cannot be directly compared to determine if the statement is an entailment or contradiction",
        "label": "Contradiction"
    },
    "d3525b25-3dad-4ed2-8fe7-d0f0abc6be14": {
        "text_answer": "Contradiction The evidence describes the use of laserassisted fluorescence angiography not ultrasound guidance and the incisions are described as inframammary fold and lateral radial which are not vertical longitudinal incisions",
        "label": "Contradiction"
    },
    "927d72b0-1f55-4803-9a86-40838c08f923": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the use of denosumab while the secondary trial involves the use of intraoperative handheld gamma camera pIHGC or gamma probes GP with lymphoscintigraphy which involves the injection of radioactive Tc99M sulfur colloid The primary trial requires denosumab injections every 4 weeks while",
        "label": "Contradiction"
    },
    "0e1460ea-4f44-47ff-892a-e3190b498557": {
        "text_answer": "Contradiction The evidence provided does not support the statement as it pertains to adverse events related to physical health conditions not mental health",
        "label": "Contradiction"
    },
    "9bb1e4d4-379d-47f5-a6b9-c6dac40b2727": {
        "text_answer": "Contradiction  Explanation The evidence provided in the results does not support the statement as it only compares the average area under the curve aAUCpa of EORTC CIPN20 Sensory Neuropathy Subscale adjusting for baseline between two groups Arm I and Arm II who received different interventions during paclitaxel infusions The statement however makes a generalization about all participants who didnt",
        "label": "Contradiction"
    },
    "1820d3ff-ca2a-47dc-a80e-45e760307261": {
        "text_answer": "Contradiction The evidence states that participants received Enzalutamide orally by mouth in both interventions",
        "label": "Contradiction"
    },
    "2db0df9c-be54-419d-9710-54adb741a1a1": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence allows for antineoplastic chemotherapy with the exception of antiHER2 agents to be used but only if the patient has been on a constant dose for at least 28 days and is not expected to stop the medication during the study period",
        "label": "Contradiction"
    },
    "0f36a35d-d86b-41d0-9878-df4ef7ad0e9f": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that there were no cases of infection asymmetry or deflation in the secondary trial while the primary trial had one case each Therefore it is not possible for the prevalence of these adverse events to be less in the secondary trial than in the primary trial when they were present in the primary trial but not in the secondary trial",
        "label": "Contradiction"
    },
    "e2061005-22e7-4de3-90c2-e4ebfe055b0d": {
        "text_answer": "Contradiction The primary trial indicates a higher overall response rate in Arm A compared to the placebo arm while the secondary trial indicates a superior time to first onstudy SRE in the denosumab group compared to zoledronic acid These findings are contradictory as a higher overall response rate typically implies a better treatment outcome while a superior time to first onstudy SRE implies a better bone health outcome and it is not clear how these",
        "label": "Contradiction"
    },
    "7b29df5c-9189-4c72-b0ad-3ed971c42652": {
        "text_answer": "Contradiction The primary trial excludes patients with anemia only due to irondeficiency thalasemic syndromes and epilepsy while the secondary trial does not mention these conditions as inclusion criteria However its important to note that the statement does not necessarily exclude these patients from both trials but rather states that they can participate which is different from the trials inclusion criteria",
        "label": "Contradiction"
    },
    "d58edc4e-2e7f-4c35-b24c-cd1239175b1a": {
        "text_answer": "Contradiction The evidence reports one occurrence of maculopapular rash in the primary trial",
        "label": "Contradiction"
    },
    "02cf528a-17da-4ea6-a65e-7a9efe2cf3cf": {
        "text_answer": "Contradiction  Explanation  The primary trial had a placebo group in Intervention 2 while the secondary trial did not mention a placebo group in either intervention Therefore the statement that both the primary and secondary trials used multiple test groups without any placebo group in either case is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "1f9ee295-ce3d-427b-8af2-876edb47bf7f": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention includes Gefitinib ZD1839 which is a multidrug regimen In contrast the secondary trial has only one intervention which is Zoledronic Acid making it a single therapeutic agent Therefore the statement that the primary clinical trial requires administration of a multid drug regimen while the secondary clinical trial calls for the use",
        "label": "Contradiction"
    },
    "d504ff9e-bdcc-4609-9b57-b1cb4638bfdc": {
        "text_answer": "Contradiction The evidence shows that the percentage of participants with events was different between the Neratinib and Placebo arms",
        "label": "Contradiction"
    },
    "cedade64-046d-4e90-ad04-9b0a497fc534": {
        "text_answer": "Contradiction The statement is about penile cancer and the evidence is about trials for glioblastoma multiforme and gynecological cancers",
        "label": "Contradiction"
    },
    "73e39e6d-e688-4372-85d4-dbb3cbc7a7cb": {
        "text_answer": "Contradiction The evidence does not provide information on the number of patients in either group experiencing no pain whatsoever during the 200 weeks of the study",
        "label": "Contradiction"
    },
    "f0534dd1-7050-4fc1-971e-5aab8abb5d47": {
        "text_answer": "Entailment  Explanation The evidence shows that no cardiac or psychiatric adverse events were reported in both the primary and secondary clinical trials The statement that no cardiac or psychiatric adverse events were reported in the course of the primary clinical trial and the secondary clinical trial is an entailment of the evidence",
        "label": "Entailment"
    },
    "6247182c-7b14-46b7-9452-a4072ed79a7b": {
        "text_answer": "Entailment given that the evidence does not mention any unexpected deaths or hospitalizations in either trial",
        "label": "Entailment"
    },
    "a3ba6a16-5f21-477d-9a2a-574a53ab3f2c": {
        "text_answer": "Contradiction The statement does not relate to the evidence provided The evidence only mentions adverse events for the primary trial candidates and none of them are related to eating disorders or soft tissue necrosis",
        "label": "Contradiction"
    },
    "fc38bc02-5e04-4b3d-bf4d-19fa9a636bd2": {
        "text_answer": "Contradiction  Explanation The evidence does not support the statement as it does not provide information about the change in cognitive function for individual participants in the Ovarian Function Suppression group only the mean and standard deviation of the composite score It is possible that some participants in this group experienced a decline in cognitive function even though the mean score did not decline significantly",
        "label": "Contradiction"
    },
    "2dbcfe7a-32b5-47e3-a6fc-0f38039de24c": {
        "text_answer": "Contradiction The evidence shows that 381 of participants in Arm 1 and 333 of participants in Arm 2 experienced pCR in breast and axillary lymph nodes which is far less than 97",
        "label": "Contradiction"
    },
    "264848be-8491-409f-b19f-0db249bc155a": {
        "text_answer": "Entailment The statement follows directly from the evidence as the evidence states that Intervention 1 uses a prototype intraoperative handheld gamma camera pIHGC while Intervention 2 uses standard gamma probes GP",
        "label": "Entailment"
    },
    "6548c59c-cafc-465f-8f10-4bfc5d147611": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses adverse events in the primary trial and there is no mention of people being unfriendly",
        "label": "Contradiction"
    },
    "03688964-cf46-485b-99f3-f7c6c5fed3ed": {
        "text_answer": "Contradiction The primary trial does not exclude participation based on nationality but the secondary trial does not mention any such restriction",
        "label": "Contradiction"
    },
    "abc13f3b-54fa-4a1c-a063-5f1f00e2ae9a": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the exclusion criteria in the evidence state that there should be no history of abdominal fistula gastrointestinal perforation or intrabdominal abscess in the past 6 months not 43 hours",
        "label": "Contradiction"
    },
    "c651d7a4-f39a-44df-84cc-f71c45ced124": {
        "text_answer": "Contradiction The primary trial does not exclude patients with leptomeningeal carcinoma as long as it is controlled postcompletion of local therapy for at least 4 weeks",
        "label": "Contradiction"
    },
    "9b9d2ca0-acea-42a6-bd46-78eb4540a107": {
        "text_answer": "Contradiction The statement is incorrect as syncope occurred in 1667 of the primary trial patients not 1300 The most commonly occurring adverse event across the patient cohorts of the primary trial and the secondary trial was not syncope",
        "label": "Contradiction"
    },
    "55372cf8-c6a0-4286-8cd5-5e11e070bd79": {
        "text_answer": "Contradiction in the context of the given evidence the MYMOP score change is a determinant of outcome measurement in the primary trial while the evidence in the secondary trial does not provide information on the relationship between the MYMOP score change and outcome measurement",
        "label": "Contradiction"
    },
    "4abdde7a-7745-4391-ae23-9d7fb6d837c2": {
        "text_answer": "Contradiction The evidence does not provide any information about the proportion of participants with high vitamin D levels and a noticeable pattern for expression of the group of 40 evaluated genes",
        "label": "Contradiction"
    },
    "bb5873a3-4c28-49f6-9f70-f3f1d8ac7db2": {
        "text_answer": "Contradiction  In the primary trial group 2 did not receive a placebo but normal saline In the secondary trial patients in intervention 2 did receive a treatment 05ugkg of dexmedetomidine Therefore the statement is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "eda562ff-9676-46f2-9ec3-93eb3cdd7585": {
        "text_answer": "Contradiction  Explanation The statement more than 03333 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 057 years of the study is a contradiction to the evidence provided The evidence shows that 381 of participants in Arm 1 and 333 of participants in Arm 2 experienced",
        "label": "Contradiction"
    },
    "6a211e77-e17f-4739-b685-e6bd83b8d7e3": {
        "text_answer": "Contradiction The evidence states that no malignant effusion as the only site of disease recurrence is allowed but it does not explicitly state that leptomeningeal carcinoma is not allowed However leptomeningeal carcinoma is a type of malignant effusion Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "754d4ae4-5d18-4b63-836a-c011958680ce": {
        "text_answer": "Entailment Both trials involve the use of cyclophosphamide but the statement does not depend on the specific details of how it is administered or the type of tumor being treated",
        "label": "Entailment"
    },
    "41219409-bd82-4df0-82aa-d72fc4aec1fd": {
        "text_answer": "Contradiction The statement is not related to the evidence provided as the evidence does not mention any adverse event related to megacystis or megaureter",
        "label": "Contradiction"
    },
    "61a1a0e2-bd62-43de-b3c9-1c2143417c5a": {
        "text_answer": "Entailment Both trials require the patient to have a functional ECOG  2 status which implies the ability to be ambulatory and have a certain level of mobility",
        "label": "Entailment"
    },
    "f11800b6-312b-4f9d-9b18-24a3a6bb67a2": {
        "text_answer": "Contradiction The evidence states that both interventions involve the use of radioactive Tc99M sulfur colloid for lymphoscintigraphy but it does not mention whether they use pIHGC or standard gamma probes specifically However the statement asserts that neither intervention uses pIHGC or standard gamma probes",
        "label": "Contradiction"
    },
    "4e0fbb00-bcbe-4051-a343-58a6cb50eb0b": {
        "text_answer": "Contradiction The primary trial excludes patients with low vitamin D levels but the secondary trial does not mention vitamin D levels as a criterion for inclusion or exclusion",
        "label": "Contradiction"
    },
    "d331f99d-446c-4305-8842-05d6fe2d070c": {
        "text_answer": "Entailment The statement a number of anaemia and febrile neutropenia instances were noted is implied in the evidence for Adverse Events 1 in the primary trial and the evidence states that there were zero cases of pancytopenia",
        "label": "Entailment"
    },
    "abaf9c04-8d6d-43f3-afb5-9bc9d04fb9b5": {
        "text_answer": "Contradiction The statement is not an entailment as having cerebral metastases with 23 lesions is a reason for exclusion from the secondary trial not a characteristic that may still make a patient eligible for it",
        "label": "Contradiction"
    },
    "e123c707-0e86-43c1-8f9b-971363c07ae0": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial recorded zero adverse events while the secondary trial recorded some adverse events",
        "label": "Contradiction"
    },
    "b2caa135-c6ed-46b0-a1e3-6fd60ae12831": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the interventions do in fact involve a difference in the amount of durvalumab administered monthly to each cohort 03 mgkg vs 1 mgkg",
        "label": "Contradiction"
    },
    "19275bdd-9964-4f3b-b2d5-b984203774d5": {
        "text_answer": "Entailment  Explanation The statement both the primary clinical trial and the secondary clinical trial reported a minimum of one infection case is an entailment based on the evidence provided In the primary trial there was one infection case reported out of 32 patients and in the secondary trial there were two infection cases reported out of 112 patients Therefore the statement that both trials reported at least one infection case is a logical conclusion that can be",
        "label": "Entailment"
    },
    "8d728674-1111-495d-ae90-59ced10163a4": {
        "text_answer": "Irrelevant The statement does not entail or contradict the evidence provided The evidence only discusses the dosages of Eribulin Cyclophosphamide and Docetaxel in the primary trial and does not mention anything about an individuals ability to pay attention due to tiredness",
        "label": "Entailment"
    },
    "88a8b32d-122c-48f9-a305-3d1b8e3fcd85": {
        "text_answer": "Entailment The statement Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy is an entailment of the evidence as the evidence states that patients will take Vorinostat daily during radiation therapy",
        "label": "Entailment"
    },
    "4bf82041-f1d8-4a90-9bd0-aec991e50966": {
        "text_answer": "Contradiction  Explanation The evidence provided does not mention anything about morbidly obese patients in the inclusion or exclusion criteria for either trial Therefore the statement about morbidly obese patients being eligible for the trials is not an entailment or contradiction based on the evidence given However the statement is contradictory because the concept of a percentage food eaten score is not mentioned in the evidence at all",
        "label": "Contradiction"
    },
    "b3ed34ea-6461-40ed-955d-693bbc27fd99": {
        "text_answer": "Contradiction The statement is not an entailment as substance dispersity is not mentioned in the given evidence Hypokalemia potassium within the normal range of 3553 mEqL is an inclusion criterion for the primary trial but it is not mentioned in the secondary trial inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "53dac2a0-f55a-4987-bab1-695a985eacd1": {
        "text_answer": "Contradiction The intervention in the primary trial lasts for 10 weeks while the intervention in the secondary trial lasts for 24 weeks which is 14 weeks longer not 50 weeks longer",
        "label": "Contradiction"
    },
    "2cd6db4c-83e4-4ca5-8650-6638521a27a2": {
        "text_answer": "Entailment The evidence clearly states that participants in the primary trial receive multiple injections including dendritic cell vaccines chemotherapy and GMCSF",
        "label": "Entailment"
    },
    "2cf8bdbf-5f09-4f16-8b50-c6369d003a4f": {
        "text_answer": "Contradiction The primary trial and the secondary trial are about different groups of participants and different outcomes The statement compares the number of lesions in the primary trial and the number of radiation dermatitis and hyperpigmentation in the secondary trial which are not related The statement about t122q23q12 is not mentioned in the evidence and is not relevant to the comparison",
        "label": "Contradiction"
    },
    "b41e6cb3-c92e-4027-b96b-502aeb1f4211": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of any participant in either trial experiencing blacking out or loss of consciousness due to an acute myocardial infarction",
        "label": "Contradiction"
    },
    "d5b131c2-0835-4f00-a0ba-2db26d1fe581": {
        "text_answer": "Contradiction  Explanation The statement throughout the primary clinical trial there were no reported cases of gastrointestinal complications is a contradiction based on the evidence provided because the evidence shows that there were reported cases of diarrhea 2 cases in Adverse Events 1 and 3 cases in Adverse Events 2 which is a type of gastrointestinal complication",
        "label": "Contradiction"
    },
    "c5fed4a9-da6c-4dcb-b191-930bca7e0ce7": {
        "text_answer": "Entailment The evidence states that the placebo and alloMSCs interventions both receive 20 transendocardial injections but the injections contain different solutions Buminate for placebo and alloMSCs for the intervention Therefore the statement that they are delivered through separate transendocardial injections is an entailment based on the evidence",
        "label": "Entailment"
    },
    "6e9f7a1a-21e5-4d5f-b602-a1efb1b51bc7": {
        "text_answer": "Contradiction The statement that cohort 1 is administered less than half the dose of ALT801 as cohort 2 is not entailed by the evidence as the doses administered in the primary trial are 0015 mgkgdose for cohort 1 and 0040 mgkgdose for cohort 2 which is not less than half in a general",
        "label": "Contradiction"
    },
    "61afd69d-529d-49e9-b607-007414946b6c": {
        "text_answer": "Contradiction The evidence states that 1 case of urinary tract infection was reported in the primary clinical trial",
        "label": "Contradiction"
    },
    "dfb4c335-296e-42af-b418-329f39c6b42e": {
        "text_answer": "Contradiction  The primary trial results do require units of measurement specifically for tumor diameter in centimeters The secondary trial results also require units of measurement specifically for the number of participants with solid tumor response",
        "label": "Contradiction"
    },
    "5051b4e9-21e7-4fa8-a602-de48b103fa19": {
        "text_answer": "Contradiction The primary trial explicitly states that warfarinbased treatments are not allowed while the secondary trial permits lowdose warfarin less than or equal to 1 mgday",
        "label": "Contradiction"
    },
    "f61808f1-4431-4b34-8a66-e422c6e97530": {
        "text_answer": "Contradiction The evidence does not provide any information about dysplasia or its absence in the participants of the primary trial The statement is not related to the evidence",
        "label": "Contradiction"
    },
    "01d0c4bf-e697-4565-906b-edd21fd2227f": {
        "text_answer": "Contradiction The evidence provided does not mention anything about patients with severe cases of schizophrenia being excluded from the clinical trials",
        "label": "Contradiction"
    },
    "a1e4f5de-9b44-444e-8eff-ae7b040c6f6e": {
        "text_answer": "Contradiction  The primary trial excludes patients with triple negative breast cancer while the secondary trial includes patients with any type of breast cancer Additionally the primary trial only includes patients with measurable disease or bone metastases while the secondary trial includes patients with early stage breast cancer who are considering or have undergone mastectomy",
        "label": "Contradiction"
    },
    "6f835e44-5cb2-4f42-9b69-8ec81c00a404": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as patients must provide informed consent to participate in both clinical trials",
        "label": "Contradiction"
    },
    "8c9c4150-3bc1-4f06-8bee-2d5bba3ef8b9": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions no cardiac or psychiatric adverse events in the primary trial",
        "label": "Contradiction"
    },
    "2096d634-b321-40de-b69b-8dad3345331e": {
        "text_answer": "Contradiction The primary trial had 13 participants and the secondary trial had 30 participants so fewer people participated in the primary trial",
        "label": "Contradiction"
    },
    "a2981a35-ece3-42dc-a735-cd12466392fa": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of a dog bite in the evidence",
        "label": "Contradiction"
    },
    "ff95337a-7da9-43f5-bb3c-25cd7c85e5c7": {
        "text_answer": "Contradiction  The evidence shows that 113 769 of patients in cohort 1 and 14 2500 of patients in cohort 2 suffered increased pleural effusion However none of the patients in cohort 1 suffered from rapid disease progression while suffering increased pleural effusion whereas one patient in cohort 2 did Therefore the statement that ",
        "label": "Contradiction"
    },
    "6a969a7c-55f3-4595-a361-db78a910f352": {
        "text_answer": "Contradiction  Explanation  The statement less than 21 patients in both cohorts of the primary clinical trial witnessed pathologic complete response in breast and axillary lymph nodes 3 months following the surgical intervention is a contradiction to the evidence provided According to the results there were 16 participants in Arm 1 with pCR 381 and 14 participants in Arm 2",
        "label": "Contradiction"
    },
    "6d37ed53-a6e4-403e-8b93-9954a6486dbc": {
        "text_answer": "Entailment The evidence states that laserassisted fluorescence angiography is used for perfusion monitoring at three separate time points for both interventions Inframammary Fold and Lateral Radial incisions",
        "label": "Entailment"
    },
    "5af90c4a-80c3-4f11-bbc0-7f84ad544186": {
        "text_answer": "Entailment The statement patients diagnosed with estrogennegative progesteronenegative and her2 breast tumors may participate in the primary clinical trial is an entailment of the inclusion criteria Histological confirmation of ER negative PR negative and HER2 negative invasive breast cancer in the primary trial",
        "label": "Entailment"
    },
    "e92e6dec-b727-475a-b544-568b5773cb81": {
        "text_answer": "Contradiction  The evidence states that participants in Arm 1 of the primary clinical trial receive oral lapatinib and oral tamoxifen once daily on days 128 with lapatinib given as lapatinib ditosylate and tamoxifen given as tamoxifen citrate The statement however specifies that participants are prescribed a dose of 100 mgm2 of lapatinib to be taken or",
        "label": "Contradiction"
    },
    "fc35d08f-73a9-47aa-9450-165dcfda17bf": {
        "text_answer": "Entailment The evidence shows that no adverse events were observed in more than 1 of participants in both trials",
        "label": "Entailment"
    },
    "a96f9558-41f8-4515-8fc4-d3b8f326ce05": {
        "text_answer": "Contradiction The evidence does not mention anything about morphine sulfate or fentanyl sublingual spray being given during radiation therapy in the primary clinical trial",
        "label": "Contradiction"
    },
    "6fbc7c06-1134-42b6-bfbc-9e4f28727cba": {
        "text_answer": "Contradiction The evidence does not provide information on the recurrencefree survival rates or differences between the two groups in terms of the given dosage of Ketorolac 003 g",
        "label": "Contradiction"
    },
    "6e6f3848-8d0e-47df-b2f3-1f09cf7da6e4": {
        "text_answer": "Contradiction The primary trial reported 0 adverse events while the secondary trial reported 2 adverse events",
        "label": "Contradiction"
    },
    "eacc1096-c090-4f21-ad10-005be458b653": {
        "text_answer": "Entailment  Explanation In the primary trial patients receive a loading dose of 4 mgkg followed by 2 mgkg weekly In the secondary trial cohort 2 receives Herceptin at a dose of 4 mgkg IV infusion on Day 1 of Cycle 5 followed by Herceptin 2 mgkg by IV infusion weekly starting from Day 8 which is a lower weekly dose than",
        "label": "Entailment"
    },
    "325c6150-352f-4b08-aa67-fed4cd6f68d0": {
        "text_answer": "Contradiction The statement is not an entailment as a patient who has received an organ transplant within the last month and is still bedridden is excluded from both trials according to the provided inclusion criteria The second part of the statement mature neutrophils present is an indication that mature neutrophils were detected in a sample is not related to the eligibility criteria for the trials",
        "label": "Contradiction"
    },
    "90135397-f63a-412e-9633-0355e1a78154": {
        "text_answer": "Contradiction  The evidence shows that the mean arm circumference in the acupuncture group decreased more from baseline to 6 weeks compared to the waitlist group However the statement asserts that the acupuncture group experienced more significant improvements in their lymphedema which is not directly supported by the data provided The data only shows that the acupuncture group had a greater decrease in arm circumference not necessarily that the",
        "label": "Contradiction"
    },
    "6bc62f08-51ae-44d6-be1d-738c82598de5": {
        "text_answer": "Contradiction The primary trials exclusion criteria state that there should be no history of abdominal fistula gastrointestinal perforation or intrabdominal abscess in the past 6 months not 180 days Additionally there is no mention of stroke transient ischemic attacks or significant psychiatric disorders in the primary trials inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "f6ad61ca-d223-496b-a067-69625112447c": {
        "text_answer": "Contradiction The evidence states that 571 of patients in the primary trial suffered adverse events which is more than 120 00526 based on the given statement",
        "label": "Contradiction"
    },
    "5261c924-d9ef-43ed-8f2a-6c5b1552cc62": {
        "text_answer": "Contradiction  Explanation The statement Women of childbearing potential and Sexually active fertile men are eligible for the primary trial but they will have to meet some additional requirements is a contradiction to the evidence provided in the trials inclusion and exclusion criteria According to the evidence women of childbearing potential WOCBP and sexually active fertile men are explicitly excluded from the trial The trial",
        "label": "Contradiction"
    },
    "bb3e3ca1-1b64-4ddc-9492-1fb11ec9356f": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence states that both groups undergo identical imaging procedures with the same dosages for 18FFDG but only mentions a minor increase in the dosage for 18FFPPRGD2 in cohort 1 without specifying the exact dosage for comparison",
        "label": "Contradiction"
    },
    "efa989b7-db55-49b8-a124-875a5f7c94ff": {
        "text_answer": "Contradiction The evidence does not provide any information about Asthenia or Pyrexia in the trials The statement makes assumptions about the trials that are not supported by the evidence",
        "label": "Contradiction"
    },
    "63a44f77-d6b6-47df-9bea-b7deb99f5658": {
        "text_answer": "Contradiction The statement is about karyocytomegaly and multinucleated hepatocytes while the evidence is about an increase in Blood bilirubin They are not the same thing",
        "label": "Contradiction"
    },
    "fc4ec229-5b69-409e-89c0-2b151f670382": {
        "text_answer": "Contradiction The primary trial includes the requirement that patients have a functional ECOG  2 status which is a performance status condition",
        "label": "Contradiction"
    },
    "fbde81ad-0d06-4d2a-8baa-eb5eace1b3ec": {
        "text_answer": "Entailment The evidence shows that there were no recorded adverse events in both trials for Adverse Events 1 and Adverse Events 2 which is in line with the statement that there are no recorded adverse events in both trials",
        "label": "Entailment"
    },
    "1172df8a-7da3-4769-8832-32ded72cfcf1": {
        "text_answer": "Contradiction The primary trial requires the presence of a mutation in one of the specified genes for inclusion while the secondary trial does not have this requirement",
        "label": "Contradiction"
    },
    "c20768c0-36c2-44ff-9d4f-36d34e02c1a2": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The evidence describes the interventions being administered intravenously but the statement is about a different topic  the hepatitis B virus surface antigen status The two are not directly related",
        "label": "Entailment"
    },
    "04beb33e-ae70-4de2-a805-71650246ea7b": {
        "text_answer": "Contradiction The primary trial includes patients with a breast tumor that is 1 cm in diameter while the statement specifies a tumor measuring 100mm which is significantly larger and not consistent with the primary trial criteria",
        "label": "Contradiction"
    },
    "262e8bd4-da64-4158-b23d-b875050e66af": {
        "text_answer": "Contradiction The statement is incorrect as the primary trial does not provide information about the use of Paraplatin in either intervention HerceptinNavelbine in Arm 1 does not involve Paraplatin and TaxotereCarboplatinHerceptin in Arm 2 includes Carboplatin but it is not specified if it is the identical dose for both interventions",
        "label": "Contradiction"
    },
    "18e1908f-f449-42a0-916b-7e88c1e7c901": {
        "text_answer": "Entailment The evidence shows that no cases of anemia pneumonia and stupor were recorded in the primary trial and no febrile infections were recorded at all in the primary trial which is consistent with the statement",
        "label": "Entailment"
    },
    "e4f2bd3a-6976-4a2b-9485-c34bdc812c54": {
        "text_answer": "Contradiction The statement does not provide any information about adhesion factor production in relation to the primary trial The trial only reports on the proportion of participants with controlled acute vomiting after treatment with Aprepitant Dexamethasone Cytoxan and Kytril",
        "label": "Contradiction"
    },
    "70c0fbc1-8eb8-4634-a595-898784718d09": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention for Intervention 1 includes Gefitinib ZD1839 but it does not mention anything about Zoledronic acid Samarium153 or Pegfilgrastim  In contrast the secondary trial has two interventions Intervention 1 includes Zoledronic acid vitamin D and calcium supplements while",
        "label": "Contradiction"
    },
    "4960cf63-01e8-4fc5-b6ea-fe10063c6e6c": {
        "text_answer": "Contradiction  Explanation In the primary trial alisertib is not mentioned at all whereas in the secondary trial two different doses of alisertib MLN8237 are used for the two cohorts Therefore the statement is a contradiction as the primary trial does not entail the absence of alisertib in the secondary trial",
        "label": "Contradiction"
    },
    "ed12f8ae-3bda-46b8-8bf1-5ad6d1527c57": {
        "text_answer": "Contradiction  The primary trial and the secondary trial have different inclusion criteria The primary trial is for women with locally advanced recurrent or metastatic breast cancer while the secondary trial is for women with newly diagnosed or recurrent breast cancer who are considering a mastectomy and do not have distant metastatic disease The statement does not follow the inclusion criteria for either trial",
        "label": "Contradiction"
    },
    "2d0df5b6-0886-4a19-973a-92f4442b39d1": {
        "text_answer": "Contradiction  Explanation The statement corneal deposits were less commonly identified amongst the patients in the secondary trial is a contradiction based on the evidence provided The evidence shows that corneal deposits were not identified in any of the patients in the secondary trial while they were not mentioned at all in the primary trial Therefore the statement that they were less commonly identified in the secondary trial is incorrect as they were not identified in either trial",
        "label": "Contradiction"
    },
    "f9dfbdb7-3248-450e-a7d4-782f2e68e057": {
        "text_answer": "Contradiction The evidence describes laserassisted fluorescence angiography using the Spy Elite system not intravascular ultrasound Additionally the incisions are inframammary fold and lateral radial not transverse radial",
        "label": "Contradiction"
    },
    "1c7d5749-bf28-4ae8-8408-ccda3f13a18a": {
        "text_answer": "Entailment Both trials determine the maximum tolerated dose MTD of an intervention making the statement an entailment",
        "label": "Entailment"
    },
    "586b08dc-8323-46ff-873f-5d262f7eae35": {
        "text_answer": "Contradiction The primary trial recorded 0 adverse events while the statement assumes that there were 10 adverse events in the primary trial",
        "label": "Contradiction"
    },
    "74452fe6-e38e-4f1d-a666-765c464ca765": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because the first cohort receives 14mgm2 of eribulin per treatment cycle which is lower than the 75 mgm2 of docetaxel received by the second cohort in each treatment cycle",
        "label": "Contradiction"
    },
    "c81fad5d-aa52-4147-a724-984e7d9c4cc3": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because the secondary trial reported one case of Thromboembolic Event which was not reported in the primary trial",
        "label": "Contradiction"
    },
    "b3909182-2942-44c1-96e8-5650e48401df": {
        "text_answer": "Contradiction The statement is not directly related to the evidence provided as the evidence does not mention anything about disseminated adenocarcinoma or the distribution of adverse events in relation to it",
        "label": "Contradiction"
    },
    "2d61f68b-3907-4337-bc4c-20f219a1c678": {
        "text_answer": "Contradiction  Explanation The statement assumes that all patients with PR primary breast cancer in the trial were treated with HER2targeted PETCT and remained metastasisfree However the evidence only shows that 13 out of 49 participants with HER2 primary breast cancer developed imagable HER2 metastases while undergoing HER2targeted PETCT It does not provide information about",
        "label": "Contradiction"
    },
    "b5e896cf-e971-4fac-8dc6-a19e2c2d0a72": {
        "text_answer": "Contradiction The primary trial does have conditions on life expectancy and age female patients only age  18 years and life expectancy of  3 months",
        "label": "Contradiction"
    },
    "2a9b88b7-4d4f-47d5-808b-df5a328935ae": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that there were no adverse incidents reported in the primary trial and fewer than 1 reported in the secondary trial but the statement implies that the secondary trial reported significantly less total adverse incidents than the primary trial",
        "label": "Contradiction"
    },
    "20a73393-6e4f-4096-8025-45d8fbe228b7": {
        "text_answer": "Contradiction  Explanation The evidence states that in the primary clinical trial some patients receive MCS110 at a dose of 1 mgkg every 3 weeks and PDR001 at a dose of 100 mg every 3 weeks It also states that other patients receive MCS110 at a dose of 3 mgkg every 3 weeks and PDR001 at a dose of 1",
        "label": "Contradiction"
    },
    "1a9f1afc-af2c-4dca-b701-2a04033f47b4": {
        "text_answer": "Contradiction The primary trial requires a Karnofsky score of 70 or better while the secondary trial requires a score of 55 or better These are different requirements",
        "label": "Contradiction"
    },
    "b4db304d-9445-44e0-9f0a-a4df38c1301b": {
        "text_answer": "Contradiction The statement is not related to the evidence provided in the trial results",
        "label": "Contradiction"
    },
    "197c5300-0475-46e0-aa97-cfb145da896d": {
        "text_answer": "Contradiction The primary trial did not report any cases of radiation dermatitis or hyperpigmentation while the secondary trial reported 1 incidence for both in Group 1",
        "label": "Contradiction"
    },
    "a3f8233e-3af4-41f5-a4f4-7676251de646": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction to the evidence because  1 The primary trial involves multiple interventions including various types of radiation therapy and supportive care as well as laboratory biomarker analysis 2 The secondary trial also involves multiple interventions including five different types of drugs everolimus and exemestane and no mention of surgery  Therefore the statement that the primary",
        "label": "Contradiction"
    },
    "a3e78ee7-57e9-47e4-a85f-e61451207043": {
        "text_answer": "Contradiction The statement that cohort 1 received less than half the dose of ALT801 than cohort 2 is not entailed by the evidence which only states the different doses of ALT801 administered to each cohort The statement about the gain of chromosome 17q is unrelated to the dosing information",
        "label": "Contradiction"
    },
    "87840288-7db7-4532-b5a9-ce95221cf918": {
        "text_answer": "Contradiction  Explanation The primary trial does not mention anything about claustrophobia as an exclusion criterion while the secondary trial lists it as an exclusion criterion However the statement is about both trials not being open to women with both claustrophobia and IBS Irritable Bowel Syndrome which is not mentioned in the evidence provided Therefore the statement is a contradiction",
        "label": "Contradiction"
    },
    "c9077c20-07f8-4137-b88a-9ef599052884": {
        "text_answer": "Contradiction  The evidence states that there is a significant decrease in Ki67 expression with tamoxifen treatment with a mean change of 40 95 CI 63 to 29 The statement however suggests an increase of 30 in Ki67 expression",
        "label": "Contradiction"
    },
    "290508ed-616c-4d7e-b83b-49a2fa895a44": {
        "text_answer": "Contradiction  Explanation  The statement blood and bone marrow related issues predominantly accounted for reported adverse events in the primary clinical trial as opposed to the secondary clinical trial is a contradiction based on the evidence provided  In the primary trial 10000 of the reported adverse events were related to blood and bone marrow issues In contrast in the secondary trial only 33",
        "label": "Contradiction"
    },
    "171ca8d1-c986-4446-8ee3-8b8635f4d234": {
        "text_answer": "Contradiction The statement patients diagnosed with tumors positive for CCND1 amplification CDK46 mutation CCND2 amplification are excluded from the primary trial is an entailment of the evidence but the statement lightheadedness is a feeling of faintness a reeling sensation lightheadedness is medically distinct from dizziness unsteadiness and vertigo is not directly related to the evidence and does not",
        "label": "Contradiction"
    },
    "7cd38d1e-009b-40f6-a8f8-1352ae821aa4": {
        "text_answer": "Contradiction The primary trial is assessing treatmentemergent adverse events not the length of patients slumber",
        "label": "Contradiction"
    },
    "42c07819-8022-4275-8484-6ed9db10115c": {
        "text_answer": "Entailment The primary trial is comparing two different interventions gels while the secondary trial is comparing two different doses of the same intervention PF05212384 This is consistent with the statement that different things are being assessed in each trial",
        "label": "Entailment"
    },
    "d735322f-f5fc-489d-bb28-e40451860571": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence provided as the primary trial involves intravenous IV administration of zoledronic acid for Intervention 1 while the secondary trial involves oral administration of various drugs including granisetron hydrochloride prochlorperazine aprepitant and palonosetron hydrochloride for Intervention 1 There is no mention of inhalation in the secondary",
        "label": "Contradiction"
    },
    "063a0207-f4fc-43c1-849e-6d3fc64b009b": {
        "text_answer": "Contradiction The evidence from the primary trial does not report any thromboembolic events but the secondary trial does report one such event",
        "label": "Contradiction"
    },
    "3ad9820f-4ef2-4624-b08a-b910adf25836": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as it asserts that two different adverse events are more common in each trial but the evidence only shows that ascites is more common in the primary trial and Pneumocystis jirovecii pneumonia is more common in the secondary trial which are not directly comparable as they are different adverse events",
        "label": "Contradiction"
    },
    "a63d1b8c-8ac5-4b17-a8c8-690dae246d1f": {
        "text_answer": "Contradiction The statement is not related to the evidence provided which pertains to different drugbased interventions in the primary and secondary trials",
        "label": "Contradiction"
    },
    "698866bd-4a77-4b0a-9e79-6fb9984692b7": {
        "text_answer": "Contradiction The primary trial compares the operative time savings between intraoperative mammography and standard mammography but it does not indicate that standard mammography is superior to intraoperative mammography based on the results presented The secondary trial measures the success rate of breast reconstruction and is not directly comparable to the primary trial",
        "label": "Contradiction"
    },
    "144b54f3-eb81-4c83-a94c-2c01847b9299": {
        "text_answer": "Contradiction  Explanation  In the primary trial there is no information provided about the dosing or frequency of MM121 and Paclitaxel However in the secondary trial the HR subgroup receiving MM121 and Paclitaxel receives a 20 mgkg weekly dose of MM121 and an 80 mgkg weekly dose of Paclitaxel for",
        "label": "Contradiction"
    },
    "b00e3d3a-3046-4996-a028-35e45ce682be": {
        "text_answer": "Contradiction The evidence does not mention anything about diffuse parenchymal lung disease as an exclusion criterion for the primary trial",
        "label": "Contradiction"
    },
    "75c55f70-aa52-4794-aae7-3a355f1a76e9": {
        "text_answer": "Contradiction  Explanation The statement Breast cancer patients with estrogen negative progesterone negative and HER2 tumors are eligible for the primary trial is a contradiction to the inclusion criteria of the primary trial which states that the patients must have histologically confirmed ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 The statement is a contradiction",
        "label": "Contradiction"
    },
    "bce464d0-a0f9-4d17-9caa-6bd247cfdce3": {
        "text_answer": "Contradiction The evidence does not provide any information about the occurrence or nonoccurrence of device migration problems in the primary or secondary trials",
        "label": "Contradiction"
    },
    "bd828bb3-e2b2-46e0-a1fb-635d6aade839": {
        "text_answer": "Contradiction The primary trial is not testing different radiation therapies it is testing different interventions  Hydrophor and MediHoney  for skin care during radiation therapy",
        "label": "Contradiction"
    },
    "71e83f04-ecd5-4d79-8062-42bcb68d6f29": {
        "text_answer": "Contradiction The evidence shows that there were adverse events reported in both trials which contradicts the statement that nearly all patients did not report any negative outcomes",
        "label": "Contradiction"
    },
    "6943a60c-a7c2-46c5-9238-c88db6a2b725": {
        "text_answer": "Contradiction The primary trial excludes patients with fibromyalgia and anemia while the secondary trial excludes patients with anemia due to causes other than iron deficiency Patients with thalassemia are excluded from the primary trial but there is no mention of their eligibility in the secondary trial Therefore the statement is a contradiction as it suggests that patients with fibromyalgia thalassemia or anemia",
        "label": "Contradiction"
    },
    "3fbecafb-c5f7-4a19-b265-1840a379f81f": {
        "text_answer": "Contradiction The statement mentions different outcome measurements in the two trials but the evidence provided does not indicate that the outcome measurements are different Both trials measure pathological complete response pCR",
        "label": "Contradiction"
    },
    "7ad6c209-8893-4a2d-963d-24666ef93a80": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not indicate that the dose of 18FFPPRGD2 is higher in the GBM cohort Both cohorts receive the same imaging procedures with the same radiotracers and similar doses",
        "label": "Contradiction"
    },
    "bdc8ed3c-63bd-4f71-bcbd-83d11575603d": {
        "text_answer": "Entailment Both trials require a baseline performance status but the specific scoring system used may differ",
        "label": "Entailment"
    },
    "574ab11b-3216-4b4b-a4aa-cf035483fe05": {
        "text_answer": "Contradiction  The evidence provided in the results of the primary trial indicates that the median overall survival for both groups was over 1 year so it is contradictory to state that on average patients from the primary trial survive less than 1 year",
        "label": "Contradiction"
    },
    "90eff3be-13fe-4f5d-82f1-534ae1fe4a81": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement is not an entailment or a contradiction as it does not directly relate to the information provided in the evidence about the interventions used in the primary and secondary trials The statement is about an anatomical feature of the skull",
        "label": "Entailment"
    },
    "617d4baf-29bc-4a82-a0b0-c8d2c0590599": {
        "text_answer": "Contradiction The primary trial does not have any inclusion criteria related to the patients ability to care for themselves or confinement to bed or chair",
        "label": "Contradiction"
    },
    "7ddde4b4-4070-4aff-b971-53bbd0ec9437": {
        "text_answer": "Neutral  Explanation The statement is not an entailment or a contradiction based on the evidence provided The statement is about a persons preference which is not directly related to the details of the trials The trials only provide information about the interventions being tested not about the preferences of the participants",
        "label": "Entailment"
    },
    "1bc50379-9721-419f-959a-560b3747b8ec": {
        "text_answer": "Entailment The evidence supports the statement as both trials have no recorded adverse events",
        "label": "Entailment"
    },
    "603ee9e3-5213-4121-97d8-4369641e9b00": {
        "text_answer": "Contradiction The statement is not related to the evidence provided which pertains to the change in betaCTX levels in the AZD0530 175 mg and Zoledronic Acid 4 mg groups The statement about the chromosome band and primary tumour diameter reduction is unrelated to the trial results",
        "label": "Contradiction"
    },
    "e1040054-0fe6-4c92-be82-f2b5b79282a5": {
        "text_answer": "Contradiction The primary trial does involve Suramin and Paclitaxel but the secondary trial does not necessarily involve those drugs",
        "label": "Contradiction"
    },
    "0fd90f9b-bf76-4c3c-9964-dc635138217c": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not provide information about the frequency or type of general symptoms being the most common adverse events recorded in the primary trial related to lung surgery eligibility",
        "label": "Contradiction"
    },
    "632b415b-ebc1-4898-8676-1ef38eecb128": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided which only mentions the routes of administration for the interventions in the primary trial The statement is about a mutation in the piga gene",
        "label": "Contradiction"
    },
    "914bc3a7-1468-46df-8d13-f271220b5c84": {
        "text_answer": "Entailment Both trials include ECOG performance status of 02 which includes a performance status of 1",
        "label": "Entailment"
    },
    "c6f2c906-4b0a-4b93-99ee-2152df2af3e4": {
        "text_answer": "Contradiction The primary clinical trial mentioned in the evidence is for breast cancer not colorectal cancer and it does not involve immunotherapy",
        "label": "Contradiction"
    },
    "f6a1bd73-7581-4284-b039-705aeb0236bf": {
        "text_answer": "Contradiction given the evidence the statement is not an entailment as there are adverse events recorded in the primary trial even if they are not mentioned in the provided excerpt",
        "label": "Contradiction"
    },
    "fcedf2b8-b97d-4a57-8ccc-e77c53900b3c": {
        "text_answer": "Entailment The statement that the incidence of certain adverse events was lesser in the secondary trial than in the primary trial is entailed by the evidence as the data shows that the number of cases for each of those adverse events was lower in the secondary trial",
        "label": "Entailment"
    },
    "e52afcaa-e5d8-4a1f-ae39-8572a64b0aee": {
        "text_answer": "Entailment assuming that more significant implies a larger percentage change The statement is an entailment because the evidence shows that the AZD0530 175 mg group had a larger percentage change in betaCTX at week 4 711 vs 684 than the Zoledronic Acid 4 mg group",
        "label": "Entailment"
    },
    "6fd90164-4ae9-4296-88d8-e6eab3811c8a": {
        "text_answer": "Contradiction The statement about intermediate lipomatous neoplasm being a lipomatous neoplasm with no risk of metastasis is not mentioned in the evidence provided about the primary trial",
        "label": "Contradiction"
    },
    "84915e35-a8c9-4d26-ad09-4b1df48a6df8": {
        "text_answer": "Contradiction The primary trial measures changes in hot flash scores while the secondary trial measures overall response rate in solid tumors using RECIST criteria",
        "label": "Contradiction"
    },
    "cbd414d3-c3c6-4d3a-8a7a-67832757ae03": {
        "text_answer": "Contradiction  Explanation  In the primary trial armodafinil is given to one cohort CBTI  Armodafinil while in the secondary trial MCS110 has different dosages 1 mgkg and 3 mgkg but both trials have the same dosage of PDR001 100 mg Q3W Therefore the statement is a contradiction as",
        "label": "Contradiction"
    },
    "78dd81db-dbc1-427a-9a3d-09f3e339ac99": {
        "text_answer": "Contradiction The statement does not entail the evidence as it does not mention any relationship between the occurrence of adverse events and concerns about finances",
        "label": "Contradiction"
    },
    "8cd9c9e7-ff02-4e49-893d-a4e2837bf18f": {
        "text_answer": "Contradiction The primary trial does not involve alisertib but the statement is about the absence of alisertib in both cohorts of the primary trial and the different doses of alisertib in the secondary trial",
        "label": "Contradiction"
    },
    "9b9256a3-3f1b-4f43-90da-f8ae79096bd5": {
        "text_answer": "Contradiction The primary trial includes patients undergoing lumpectomy while the secondary trial includes patients undergoing mastectomy with tissue expander reconstruction or skinsparing mastectomy These procedures are not the same so not all patients who qualify for the secondary trial will qualify for the primary trial",
        "label": "Contradiction"
    },
    "26731a57-6d43-4738-817a-74da5c372da2": {
        "text_answer": "Entailment Retroperitoneal undifferentiated pleomorphic sarcoma is a type of solid tumor and patients with histologically or cytologically confirmed metastatic andor advanced solid tumor in the breast are eligible for Phase 1 of the primary trial and for all cohorts of the secondary trial Therefore if a patient has a retroperitoneal undifferentiated pleomorphic sarcoma and a metastatic andor",
        "label": "Entailment"
    },
    "2fde518b-d7c2-4e66-bab7-0cdff22d5ffe": {
        "text_answer": "Contradiction The evidence states that potential participants must have no evidence of dementia which includes Alzheimers disease",
        "label": "Contradiction"
    },
    "d19b920a-add8-4be3-8e09-96889800fe00": {
        "text_answer": "Contradiction The primary trial requires written informed consent but the secondary trial does not mention written informed consent as a criterion",
        "label": "Contradiction"
    },
    "37aab021-5b76-4b95-88b6-1050e9252803": {
        "text_answer": "Contradiction The evidence states that both cohorts receive preoperative intravenous dexamethasone administration while the statement suggests that only the first cohort receives it preoperatively",
        "label": "Contradiction"
    },
    "2c0f27c0-642c-4669-8f38-3304bd2fdaf3": {
        "text_answer": "Contradiction  The statement the primary clinical trial recorded hepatotoxicity cases to be triple the combined count of hypertension and pancreatectomy incidents is contradictory to the evidence as the evidence shows that there were 3 cases of hepatotoxicity while there was only 1 case of hypertension and 1 case of pancreatectomy combined Therefore the number of hepatotoxicity cases is not",
        "label": "Contradiction"
    },
    "9727b232-81fc-42cc-bd06-05cc81a7453b": {
        "text_answer": "Contradiction The primary trial requires a primary tumor greater than 2 cm diameter while the statement suggests a primary tumor with a radius of 3mm which is less than 2 cm",
        "label": "Contradiction"
    },
    "2f606d1d-7dd5-4d18-8ae6-7899efe85487": {
        "text_answer": "Contradiction The secondary trial specifically lists severe claustrophobia as an exclusion criterion",
        "label": "Contradiction"
    },
    "51811b25-079e-44e0-a38a-b9e0735ded90": {
        "text_answer": "Contradiction The evidence states that the adverse events were reported among different patients in the primary clinical trial but it does not specify that they were repetitive events",
        "label": "Contradiction"
    },
    "f2640a7c-0890-40e2-a2dc-1dcdeefcd3bf": {
        "text_answer": "Contradiction The evidence states that the recipients in the primary clinical trial receive oral medication daily for 28 days not injectable medication thrice per day for 2 weeks",
        "label": "Contradiction"
    },
    "4a9efa5a-6bb1-4b34-a2a7-dfa40fdd29b4": {
        "text_answer": "Contradiction The evidence states that only 1 out of 4 patients in the second cohort experienced an increased pleural effusion which is less than 25",
        "label": "Contradiction"
    },
    "207602e0-9ba8-437e-a8c2-deb34b3eaef9": {
        "text_answer": "Contradiction  The statement in the question is a generalization based on the given evidence and it is not accurate The primary trial does involve intravenous IV administration of some drugs but it also includes other routes of administration PO for oral medications and SC for filgrastim The secondary trial on the other hand only involves oral administration po of two specific drugs everolimus and exemestane The statement in",
        "label": "Contradiction"
    },
    "e7451698-de0f-49c5-b287-a419652d62e0": {
        "text_answer": "Entailment The statement is entailed by the evidence as the evidence states that 13 of the participants with HER2 primary breast cancer who were treated with HER2targeted PETCT using 89Zrtrastuzumab developed HER2 metastases",
        "label": "Entailment"
    },
    "ca09a15d-86a6-4a7e-9dfb-ff195702e0d4": {
        "text_answer": "Contradiction  The evidence states that there were 24 participants with treatmentemergent adverse events and 11 participants with serious adverse events in the Sunitinib  Docetaxel  Trastuzumab arm of the primary trial Therefore the number of participants with treatmentemergent adverse incidents is less than 35",
        "label": "Contradiction"
    },
    "68461786-a85c-4370-8935-cb6680a3c5cb": {
        "text_answer": "Contradiction The primary trial excludes patients with significant cardiovascular impairment including congestive heart failure clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the last 6 months andor a current ECG tracing that is abnormal in the opinion of the treating Investigator or unstable angina The secondary trial excludes patients with uncontrolled cardiovascular disease Therefore",
        "label": "Contradiction"
    },
    "e945ad07-11b2-48f7-8022-40f0af7883af": {
        "text_answer": "Entailment The evidence supports the statement as there were no reported cases of acute myocardial infarction in either trial",
        "label": "Entailment"
    },
    "8f74daa8-19d7-4b51-9296-9b61e885690c": {
        "text_answer": "Contradiction The primary trial excludes patients who have consumed alcohol within the past 2 years while the secondary trial includes patients who have fewer than 5 alcoholic drinks per day within the past year",
        "label": "Contradiction"
    },
    "9a6bed06-19da-4284-b5fd-e68ddad563c3": {
        "text_answer": "Contradiction The primary clinical trial provides interventions through two different methods of administration intravenous IV and subcutaneous SC injection",
        "label": "Contradiction"
    },
    "39ac8702-7670-4a8e-851a-49e41a77c836": {
        "text_answer": "Contradiction  Explanation The statement diarrhea was uncommon among the primary trial participants compared to the secondary trial participants is a contradiction based on the evidence provided In the primary trial 130 333 of the participants experienced diarrhea while in the secondary trial 06 000 of the participants experienced diarrhea The number of participants with di",
        "label": "Contradiction"
    },
    "e5b93c15-0c68-4b2f-bceb-a905f7116ef3": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as mirtazapine is not mentioned in the inclusion or exclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "25602467-131a-44d1-a3d9-5a4a61a0ea0a": {
        "text_answer": "Entailment The statement is a more explicit version of the exclusion criteria listed in the evidence",
        "label": "Entailment"
    },
    "c634ebf6-2577-4cc6-9e2d-e14da660629d": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence provided in the primary trial does not support the statement that cohort 1 receives higher doses of Cyclophosphamide than Eribulin In fact the evidence shows that cohort 1 receives Cyclophosphamide at a dose of 600 mgm2 which is the same dose as in cohort 2 but Erib",
        "label": "Contradiction"
    },
    "a714b4d6-d9d7-4dc7-8efe-50c92616d027": {
        "text_answer": "Entailment assuming the statement estimated body weight is an approximate determination of the weight of a body is not related to the trial data provided  Explanation The evidence shows that 24 out of 25 patients experienced treatmentemergent adverse events and 11 out of 25 patients suffered serious treatmentemergent adverse events The statement All but one of the patients treated with Sunitinib ",
        "label": "Entailment"
    },
    "585b42d5-c81a-482a-a6bf-b7db6c6edcfb": {
        "text_answer": "Contradiction  The evidence provided does not support the statement that Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention The evidence shows that 423 of participants in the CCI group were up to date for cervical cancer screenings before the intervention which is equivalent to 162 participants 378 x 0423",
        "label": "Contradiction"
    },
    "0f3d96aa-a8ea-430a-ab6a-fe5e41f8b9fb": {
        "text_answer": "Entailment Prednisone is a form of dexamethasone and according to the evidence dexamethasone is administered preoperatively to all participants in the primary clinical trial cohorts Therefore the statement that prednisone is administered preoperatively to all participants is an entailment of the evidence",
        "label": "Entailment"
    },
    "606dc2e9-a1a7-400a-8971-bfb2d3a3f3ab": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because the primary clinical trial has no reported cases of bronchopneumonia and physical health decline while the secondary clinical trial reports only one case of each The evidence does not support the statement that the primary clinical trial has a higher incidence of these conditions",
        "label": "Contradiction"
    },
    "a0c1da21-1e1f-493b-81e9-4ef133c20090": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there were no recorded adverse events of anaemia in the primary trial",
        "label": "Contradiction"
    },
    "32e81a4f-0434-46d3-8da4-04037c77a56b": {
        "text_answer": "Contradiction The statement mentions helcococcus which is not mentioned in the evidence The evidence only discusses Fluciclatide AH111585 18F Injection and Chloroquine",
        "label": "Contradiction"
    },
    "d7abbd7d-a767-49c0-bc99-1c28074eac21": {
        "text_answer": "Contradiction The statement implies that no adverse events were reported in cohort 1 of the primary trial while the evidence shows that no adverse events were observed at all in the primary trial regardless of the cohort The statement about cohort 2 is not relevant to the evidence provided",
        "label": "Contradiction"
    },
    "796ae946-899b-475c-ab4c-88ba6af1e881": {
        "text_answer": "Contradiction The statement assumes that Hypertension Edema and Dyspnea are not mentioned in the evidence but they are not explicitly stated as not present in the evidence either",
        "label": "Contradiction"
    },
    "eb9c708d-26e5-40a1-a0d3-6b80f689f540": {
        "text_answer": "Contradiction The statement does not entail the evidence as it makes a claim about the absence of adverse events in the primary trial while the evidence only reports the types of adverse events observed in each trial",
        "label": "Contradiction"
    },
    "ac12ebab-2165-42ac-bd15-a155dd895e00": {
        "text_answer": "Irrelevant The statement is not related to the evidence provided The evidence only reports the occurrence of adverse events in the primary and secondary trials and does not mention anything about genital itching andor irritation",
        "label": "Entailment"
    },
    "c6b00d4d-2940-484b-b305-baaf3c5ccff4": {
        "text_answer": "Contradiction  Explanation The primary trial is not concerned with establishing the average hours of sleep among its patients as the outcome measurement in the primary trial is the number of participants with treatmentemergent adverse events AEs at Cycle 1 The secondary trial on the other hand is evaluating the change in total sleep time as measured by polysomnography PSG before and after the 1st cycle of Lenal",
        "label": "Contradiction"
    },
    "cc97aa0a-365f-459a-a65a-557dd1d930cf": {
        "text_answer": "Contradiction The statement mentions unknown use of menopausal hormone therapy while the evidence states that History of interstitial lung disease or pneumonitis is an exclusion criterion and patients with a history of interstitial lung disease within the last 3 years are ineligible for the trial However the statement does not necessarily mean that the use of menopausal hormone therapy is a cause of interst",
        "label": "Contradiction"
    },
    "e028bf17-f183-4afa-b470-f7741f04e41b": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence as the percentage of participants with HER2 metastases in the primary trial was 13 not 61",
        "label": "Contradiction"
    },
    "604c0ae1-7d51-4238-adb7-1a0b1da1b466": {
        "text_answer": "Entailment The evidence shows that there were cardiacrelated adverse events logged in the first cohort of the primary clinical trial",
        "label": "Entailment"
    },
    "3ae463ca-9747-4796-805c-b4b56c0be8e9": {
        "text_answer": "Contradiction The statement have trouble communicating thoughts is not related to the evidence provided about the primary and secondary trials",
        "label": "Contradiction"
    },
    "3d85fd79-27cc-4e06-b4e0-88348ab9ac0a": {
        "text_answer": "Contradiction  Explanation  The primary trials inclusion criteria include Advanced cancer potentially sensitive to vinorelbine Breast cancer Stage 3 or 4 nonsmall cell lung cancer NonHodgkins lymphoma Cancer of other histologic type sensitive to vinca alkaloids Rare tumor type with no standard treatment for which single agent vinorelbine is appropriate therapy",
        "label": "Contradiction"
    },
    "9aed7121-8548-40e9-a960-618bf0173df8": {
        "text_answer": "Entailment assuming MM111 refers to Intervention 1 in the primary trial",
        "label": "Entailment"
    },
    "8ecb562c-3169-4c07-bb44-d6e716873c08": {
        "text_answer": "Contradiction The statement does not entail the information provided in the evidence regarding the inclusion criteria being the same for all participants in the secondary trial",
        "label": "Contradiction"
    },
    "454e1858-76b2-4952-9ac0-820d81dbf966": {
        "text_answer": "Contradiction The primary trial mentions nothing about decitabine or its dosing frequency",
        "label": "Contradiction"
    },
    "58161b30-e890-45e5-822d-3172f884ed40": {
        "text_answer": "Contradiction The evidence provided for the primary trial does not mention the use of CT scans or MRIs as part of the medical interventions",
        "label": "Contradiction"
    },
    "7dd6b446-5585-4660-8bc7-e9811af66268": {
        "text_answer": "Contradiction The primary trial does not list smoking as an exclusion criterion",
        "label": "Contradiction"
    },
    "630dd8d6-eff4-48f9-ac35-c1731b6c4a79": {
        "text_answer": "Contradiction  The primary clinical trial is not examining a meditation intervention but rather vaginal interventions with Estring and testosterone cream The secondary clinical trial is assessing acupuncture which is a form of traditional Chinese medicine and not a meditation intervention",
        "label": "Contradiction"
    },
    "fc38a4bc-7c69-4ae2-9dad-f089f15e4d5e": {
        "text_answer": "Contradiction The first cohort receives 0015 mgkgdose less than the second cohort 0040 mgkgdose but the statement suggests a difference of 0035 mg which is not equivalent to the difference in the evidence",
        "label": "Contradiction"
    },
    "804580d2-f170-45ed-bf39-28dc33921b6d": {
        "text_answer": "Entailment assuming the statement is interpreting the results as a reduction in tumor size equivalent to a 40 change in Ki67 expression",
        "label": "Entailment"
    },
    "014e2dc7-251b-4615-a8fc-38aed023b053": {
        "text_answer": "Contradiction The statement mentions malignant pelvic neoplasm which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "3d82f108-1f18-426e-a49f-f7fedcb82a7c": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the two groups in the primary trial are receiving different drugs Talazoparib for breast cancer vs Talazoparib for ovarianperitoneal cancer and different doses but the statement only mentions the different diseases and doses without specifying the drug",
        "label": "Contradiction"
    },
    "7f90773c-288c-4b5d-bc82-81d7189e6c5d": {
        "text_answer": "Contradiction The statement mentions paraplatin but the evidence only mentions carboplatin These are not the same drug",
        "label": "Contradiction"
    },
    "1f3d7969-35e1-4880-8ae5-b97c53c1e536": {
        "text_answer": "Contradiction  Explanation The statement several patients in the secondary trial experienced only one adverse event is a contradiction to the evidence presented as every patient in the secondary trial experienced more than one adverse event",
        "label": "Contradiction"
    },
    "77fd9a89-4d9b-40ab-b4ad-fcf554ca68d2": {
        "text_answer": "Contradiction The primary trial excludes patients with thalasemic syndromes but does not mention anything about epilepsy or anemia The secondary trial does not mention anything about thalasemic syndromes epilepsy or anemia in its exclusion criteria",
        "label": "Contradiction"
    },
    "0b958f19-d411-426c-8144-162c6c15d9d2": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence indicates that there were no adverse events in either cohort",
        "label": "Contradiction"
    },
    "2493d396-14df-4cf7-b2b4-3e84d4363a0f": {
        "text_answer": "Contradiction The primary trial intervention involves radioembolization using Yttrium90 glass microspheres and TheraSphere while the secondary trial intervention consists of administering ibrutinib and MEDI4736 orally",
        "label": "Contradiction"
    },
    "ccce8199-a89f-40b4-9c27-755f2d99c98d": {
        "text_answer": "Entailment The evidence shows that more than one patient experienced disease progression which is a type of adverse event",
        "label": "Entailment"
    },
    "417ed12e-5ae1-4024-9d97-ef152b78f64c": {
        "text_answer": "Contradiction  The statement provided does not relate to the evidence given in the trial results The statement is about less than 10 of the primary trial participants had a Reduction in circulating tumor cells Following months of Highdose Chemotherapy With Purged Autologous Stem Cell Products while the evidence is about Number of Participants With Reduction in CTCs Following Highdose Chemotherapy With Purged Autologous",
        "label": "Contradiction"
    },
    "5647bdb4-a763-46c0-a7f4-3d69cbc7aa95": {
        "text_answer": "Contradiction The statement is a contradiction because the evidence shows that the patients with breast cancer and ovarianperitoneal cancer received different doses of talazoparib in the primary clinical trial",
        "label": "Contradiction"
    },
    "0f5d87e7-c78c-4579-a111-3f61640c6206": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as syncope was not the most prevalent adverse event in the secondary clinical trial as it did not occur at all according to the provided data",
        "label": "Contradiction"
    },
    "dfd39b75-1119-400a-a9af-588d7e63b867": {
        "text_answer": "Contradiction The evidence shows that neither trial recorded more than 1 death as an adverse event",
        "label": "Contradiction"
    },
    "2fc3e471-39c1-4f8a-804f-6b2ad5f711c9": {
        "text_answer": "Contradiction The evidence shows that the median change in lean body mass for the 1mg dosage group was 155 kg with a range of 206 to 1264 kg indicating that some patients had a loss in lean body mass",
        "label": "Contradiction"
    },
    "57dec3a3-0bce-48c3-972d-e08f32ea9b15": {
        "text_answer": "Contradiction  The evidence shows that both trials had one reported death each but the statement asserts that the secondary trial had several recorded deaths while the primary trial had none",
        "label": "Contradiction"
    },
    "b16d4167-cb81-44c0-b20d-d1ecbf0bc094": {
        "text_answer": "Contradiction The primary trial intervention cabergoline is given orally while the secondary trial interventions pixantrone are given intravenously",
        "label": "Contradiction"
    },
    "926177b8-d70d-48d4-95c9-4d74de46d9d0": {
        "text_answer": "Contradiction  The evidence shows that there were 16 participants in Arm 1 and 14 participants in Arm 2 who achieved pCR in the breast and axillary lymph nodes which is a clear contradiction to the statement that no pCR was reported in the trial",
        "label": "Contradiction"
    },
    "4d8b9c01-83b6-4590-9aaf-9389b998ebff": {
        "text_answer": "Entailment The statement is an entailment because the evidence states that both the placebo and trabectedin are administered intravenously and although they are given on distinct days the method of administration is the same",
        "label": "Entailment"
    },
    "4bda5405-4218-460a-a8b4-c958dddedfa1": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there were no recorded adverse events in the primary trial while every participant in the secondary trial experienced at least one adverse event",
        "label": "Contradiction"
    },
    "5484288d-bc10-458f-a516-d0019792d765": {
        "text_answer": "Contradiction The primary trial includes patients with a Karnofsky score of 70 or better while the secondary trial includes patients with a Zubrod performance score of 2 or better which is not the same as a Karnofsky score less than 50",
        "label": "Contradiction"
    },
    "8aef748c-257f-4a74-a391-3cdbdc839c79": {
        "text_answer": "Contradiction The statement mentions patients who have suffered a pulmonary embolism in the last 2 months but the primary trial excludes such patients while the secondary trial does not mention any specific exclusion for pulmonary embolism",
        "label": "Contradiction"
    },
    "a1043895-ce9b-4370-94c8-6ce3078e3bbb": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because the primary trial did have negative occurrences outside of the musculoskeletal system specifically related to the blood and bone marrow anemia neutropenia lymphopenia and platelet count decreases These negative occurrences were not mentioned in the statement",
        "label": "Contradiction"
    },
    "99b10330-04b5-4aa1-bc04-9378fa54c994": {
        "text_answer": "Contradiction The primary trial requires mammography while the secondary trial does not mention mammography as a requirement Instead it requires a CT scan and blood tests",
        "label": "Contradiction"
    },
    "be07b8e7-1858-4182-b37f-56681f56c273": {
        "text_answer": "Contradiction The primary trial does not mention Ki67 expression assessment but the secondary trial does not mention it is not assessed",
        "label": "Contradiction"
    },
    "9b75f8dd-3667-47be-a7d3-2cca26ae5fbe": {
        "text_answer": "Irrelevant  The statement is not related to the eligibility criteria for the primary or secondary trials",
        "label": "Entailment"
    },
    "f086fa4c-a302-455d-82e7-faf8b78fc2f4": {
        "text_answer": "Contradiction The placebo is administered as a 3hour intravenous infusion on Day 1 while trabectedin is administered as a 3hour intravenous infusion on Day 2 Neither intervention is administered on a biweekly basis or through a 3minute intravenous infusion",
        "label": "Contradiction"
    },
    "4805b27b-471f-4571-8de9-a7a77f1bd1a4": {
        "text_answer": "Contradiction The evidence shows that there were reported adverse events in both cohorts",
        "label": "Contradiction"
    },
    "e7505665-3677-4d18-87ec-8483dc002bd1": {
        "text_answer": "Contradiction The statement does not entail the given evidence as it introduces an unrelated topic about malignant pylorus neoplasm",
        "label": "Contradiction"
    },
    "b21d4a81-e82a-4bd7-ac88-5fcc046aafdf": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were reported infections in both the primary and secondary clinical trials",
        "label": "Contradiction"
    },
    "8e881af0-4e26-43c9-93e8-5e3397f857e1": {
        "text_answer": "Contradiction The statement gist grade cannot be assessed is a gist grade that cannot be assessed is meaningless and contradictory as a GIST grade cannot be both cannot be assessed and a GIST grade that cannot be assessed at the same time The primary trial eligibility criteria do not mention anything about GIST grade assessment The statement does not relate to the evidence provided",
        "label": "Contradiction"
    },
    "ea1eb143-4c11-4e40-9511-46f4e17b9e1d": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the two cohorts in the primary trial have different participant populations",
        "label": "Contradiction"
    },
    "7a699c4d-46d7-48a0-915d-43b8c3a1f1f5": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of intestinal perforation in the primary trial",
        "label": "Contradiction"
    },
    "5e92a3fd-5ffa-49db-9978-897321839068": {
        "text_answer": "Entailment Both cohorts follow the same instructional CD for paced breathing and cohort 2 practices it twice daily but the statement does not contradict the evidence provided",
        "label": "Entailment"
    },
    "d48955a5-78eb-4a53-9495-1a363c7b8e05": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the longest PFS observed in the trial was 28 months for Capecitabine and 29 months for CDX011 which is less than 6 months",
        "label": "Contradiction"
    },
    "3b25e9e8-6fe5-40a3-b302-7a32f651b464": {
        "text_answer": "Contradiction The evidence does not mention anything about Karnofsky score as an inclusion criterion for the primary clinical trial",
        "label": "Contradiction"
    },
    "ccd3d27f-e743-4adf-8135-3488117f1178": {
        "text_answer": "Entailment Both trials involve the use of cyclophosphamide paclitaxel and pegfilgrastim in different ways In the primary trial cyclophosphamide is used in combination with doxorubicin and given with GMCSF and followed by weekly CarboplatinNabPaclitaxel Pegfilgrastim is used for support during the chemotherapy cycles In the secondary trial cycloph",
        "label": "Entailment"
    },
    "cbe2e1d0-bb9b-43a2-b965-732f43d9af05": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not provide information about the combination route of administration for the trials The statement is also not a contradiction as it does not directly conflict with any information in the evidence",
        "label": "Contradiction"
    },
    "626fbbe0-8d56-40bf-8809-0e5d1d587a4d": {
        "text_answer": "Contradiction The primary trial includes both men and women while the secondary trial includes women and men",
        "label": "Contradiction"
    },
    "cf935264-ef24-4f3a-b60f-1c4cc9d36a54": {
        "text_answer": "Contradiction The evidence shows that no single adverse event type affected more than half of the patient cohort in the primary clinical trial",
        "label": "Contradiction"
    },
    "60a1579f-8115-4fec-bdba-fd3031f64e19": {
        "text_answer": "Contradiction The statement mentions Biliary colic and Clostridium difficile colitis which are not mentioned in the primary trials adverse events The evidence does not support the statement",
        "label": "Contradiction"
    },
    "7f22f322-c4fb-4001-875b-fe5baefbdc64": {
        "text_answer": "Contradiction The statement does not entail the evidence as there is no mention of Veillonella being related to shingles in the evidence",
        "label": "Contradiction"
    },
    "d942324e-c945-4703-b88e-905c073cfcd5": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one case of edema in Cohort 1 Adverse Events 1 and no information is provided about hypertension or dyspnea in either cohort The statement asserts that there were zero cases of hypertension edema and dyspnea in both cohorts which is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "0a56f64e-6747-4fc7-a05d-6024e7b52cf6": {
        "text_answer": "Contradiction The statement is not an entailment as the trials do use the same type of administration intravenous but they do not use the same drugs dosages or frequency of administration",
        "label": "Contradiction"
    },
    "494a6e1b-2bac-4777-9a12-077106690f16": {
        "text_answer": "Entailment  Explanation The statement there are no records of swelling hypothermia or confusion in the aes of the primary clinical trial and the secondary clinical trial is an entailment based on the evidence provided because there are no records of these conditions in the Adverse Events sections for both trials",
        "label": "Entailment"
    },
    "17413685-69fd-453f-af49-29982a6c95b6": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence states that cohort 1 receives the Pneumococcus vaccine and cohort 2 receives the Influenza vaccine but the statement does not specify which vaccine each cohort receives The statement implies that cohort 1 receives the Influenza vaccine and cohort 2 receives the Pneumococcus vaccine which is a contradiction",
        "label": "Contradiction"
    },
    "327cfcfa-5534-4b9c-ab06-57fe595cb887": {
        "text_answer": "Contradiction  Explanation The statement there were 11 more adverse events reported in the secondary clinical trial than in the primary clinical trial is a contradiction to the evidence because the evidence shows that there were a total of 11 adverse events in the secondary trial while there were no adverse events reported in the primary trial Therefore there were not 11 more adverse events in the secondary trial but rather there were ",
        "label": "Contradiction"
    },
    "73ac48a2-08b0-4ee5-8651-f65c88c08101": {
        "text_answer": "Contradiction The primary trial requires participants to be unresponsive to AI therapy but there is no such requirement in the secondary trial Mirtazapine is not mentioned in either trial",
        "label": "Contradiction"
    },
    "d42f5cb0-e70b-4c8b-ae2e-297254b1d95a": {
        "text_answer": "Entailment in the sense that both trials investigate the use of Axitinib or Docetaxel but the primary trial specifically investigates Eribulin Mesylate as a formulation of Axitinib",
        "label": "Entailment"
    },
    "bae680f2-9b93-494d-b2e7-65a99400af85": {
        "text_answer": "Contradiction The primary trial only includes females with breast cancer and does not mention anything about prostate cancer or PSAs",
        "label": "Contradiction"
    },
    "66fb10cd-ce81-4c54-aa97-b7167d3115d8": {
        "text_answer": "Contradiction The presence of a cerebral metastasis located within the frontal lobe is a disqualifying factor for both the primary and secondary clinical trials",
        "label": "Contradiction"
    },
    "5cf29cab-a9e9-4385-a342-1684d424ecd8": {
        "text_answer": "Contradiction  Explanation  The statement group 1 of the primary clinical trial did not have any participants with lesions however it was observed that above 95 of group 1 participants in the secondary clinical trial suffered from radiation dermatitis and hyperpigmentation is a contradiction based on the provided evidence  The primary clinical trial and the secondary clinical trial are about different groups of participants The primary clinical trial",
        "label": "Contradiction"
    },
    "eaa12be4-b2f0-493a-9ce4-c70f874db211": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as coronary artery stenosis is not mentioned as an adverse event in the provided evidence",
        "label": "Contradiction"
    },
    "d4fb8105-81af-42ca-a829-1b77694ce0f1": {
        "text_answer": "Contradiction The primary trial does not use Objective cognitive function scores measured with CogState as its units of measure Instead it measures the severity of vaginal symptoms using the Vaginal Symptom Measure VSM on a 5point ordinal response scale",
        "label": "Contradiction"
    },
    "1efbc2a0-c0fc-4849-96d7-689fcfb3c4d1": {
        "text_answer": "Neutral  The statement does not directly entail or contradict the evidence provided The evidence only specifies the dosage and timing of Dexamethasone administration for each cohort but it does not mention anything about the dosing units or the form of the medication caplet or intravenous",
        "label": "Entailment"
    },
    "fca1de92-2c1b-4c41-b49f-e07553b6aa83": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that the most frequently noted adverse events were nausea and vomiting each with a frequency of 392 not general symptoms",
        "label": "Contradiction"
    },
    "935d23d4-0d67-4d42-8546-db1bab3f4a3d": {
        "text_answer": "Contradiction The primary trial uses a time frame of 12 weeks and does not mention anything about semesters The secondary trial uses a time frame of 18 months but it does not mention anything about using weeks as a unit of measure Both trials use the same unit of measure change in units on a scale for their outcomes",
        "label": "Contradiction"
    },
    "81e4cf84-ba33-46ce-ba44-e7edae2a2788": {
        "text_answer": "Contradiction  Explanation  The statement all individuals in group 1 of the primary clinical trial showed signs of cutaneous lesions less than 10 of participants in the first group of the secondary clinical trial had radiation dermatitis or hyperpigmentation is a contradiction based on the evidence provided  In the primary clinical trial there were no lesions detected in the group of healthy volunteers In contrast in",
        "label": "Contradiction"
    },
    "9a78f293-8ab9-4b2d-9224-3f4ae8fc45d5": {
        "text_answer": "Contradiction The primary trial only includes patients with unilateral breast cancer",
        "label": "Contradiction"
    },
    "19ae1506-7a41-406e-8f43-8c32df24392b": {
        "text_answer": "Contradiction The statement is not supported by the evidence as the evidence only reports the change in lean body mass at 4 months and does not provide information about the 17 week period",
        "label": "Contradiction"
    },
    "9dc3d717-d3b6-4002-b7f7-26e17d2cabc2": {
        "text_answer": "Contradiction The statement is more restrictive than the evidence as the evidence allows for antineoplastic chemotherapy with the exception of antiHER2 agents androgens estrogens and progestogens to be used if the patient has been on a constant dose for at least 28 days and is not expected to stop the medication during the study period",
        "label": "Contradiction"
    },
    "87c5a93d-fcef-46ca-8267-3d928c13c6f7": {
        "text_answer": "Contradiction The statement mentions no deaths or hospitalizations except for a solitary case of atrial fibrillation but the evidence shows that there were no cases of atrial fibration reported in cohort 2",
        "label": "Contradiction"
    },
    "1bd849aa-409c-4214-a930-4d187a645466": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the dosage and frequency of CUDC101 administration differ between cohort 1 and 2",
        "label": "Contradiction"
    },
    "58f223d4-6f38-4ea3-a6fc-5ed8599df2be": {
        "text_answer": "Entailment The statement implies a reduction in Ki67 expression and the evidence shows a median reduction of 5 percentage points",
        "label": "Entailment"
    },
    "f37f99e0-a9eb-450f-850e-7bd96547bab1": {
        "text_answer": "Entailment The statement does not contradict the evidence as it correctly identifies that the only difference between the interventions is the dosage of durvalumab and does not mention anything about intellectual wellbeing",
        "label": "Entailment"
    },
    "aa3c3321-c4f3-43b4-9821-767903e333c6": {
        "text_answer": "Contradiction The primary trial explicitly states that a participant cannot have undergone major surgery within 28 days prior to the study registration date while the secondary trial does not mention any such restriction Therefore the statement that a patient who has undergone an organ transplant within the past 30 days would not be eligible for the primary clinical trial but might be suitable for the secondary clinical trial is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "959883cf-50ff-42e8-8da9-9ad0be3e18b6": {
        "text_answer": "Contradiction The statement does not entail that there was a psychiatric adverse event in the primary trial affecting less than 10 of patients based on the evidence provided The evidence only states that there was one psychiatric adverse event in the primary trial but it does not provide information about the percentage of patients affected",
        "label": "Contradiction"
    },
    "0e4f4030-9d92-4885-905e-3599e26db71a": {
        "text_answer": "Contradiction The evidence states that the primary trial intervention does not involve chemotherapy",
        "label": "Contradiction"
    },
    "0cece9f2-8d43-4d06-97bd-fb800bd3e71a": {
        "text_answer": "Contradiction The primary trial measures pain intensity using a visual analog scale while the secondary trial measures bone mineral density using DEXA scans These outcomes are not directly comparable",
        "label": "Contradiction"
    },
    "91439ad2-cb81-49e5-a783-ebbc2e04d64a": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as anaemia was not encountered as a frequent adverse incident in the primary trial but the evidence does not state that it was not encountered at all",
        "label": "Contradiction"
    },
    "bc864ba6-4d2b-431b-9b34-7b668eb5c468": {
        "text_answer": "Entailment The evidence shows that the percentage of participants with events was lower in the Neratinib group 47 compared to the Placebo group 75 indicating a higher rate of iDFS in the Neratinib group",
        "label": "Entailment"
    },
    "fe6baecc-71eb-4b15-ba15-66d57539c702": {
        "text_answer": "Contradiction The evidence shows that a different percentage of patients suffered adverse events in each cohort",
        "label": "Contradiction"
    },
    "ff3d1bb2-393e-4798-a128-090e7308f5b1": {
        "text_answer": "Contradiction The evidence states that patients with a history of interstitial lung disease or pneumonitis are ineligible for the trial The patient described in the statement has been diagnosed with ILDDPLD within the last 3 years and has a life expectancy of 6 months which is not eligible according to the inclusion criteria",
        "label": "Contradiction"
    },
    "34250dad-ad53-42bb-a8d3-80866141d548": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement is about the terminology used in the trials and does not directly relate to the interventions or groups mentioned in the evidence The evidence only describes the interventions and groups in each trial",
        "label": "Entailment"
    },
    "d98e6c4a-c899-405d-b26e-e3a2e0cb3494": {
        "text_answer": "Contradiction The evidence states that sexually active fertile men whose partners were WOCBP not using an adequate method of birth control are excluded from the study This directly contradicts the statement that sexually active men and women who are not willing or not able to commit to abstinence for the duration of the study are eligible for the primary clinical trial",
        "label": "Contradiction"
    },
    "b44a3eb6-01b7-488d-b18a-b3077937cc97": {
        "text_answer": "Contradiction The primary trial has no recorded adverse events while the secondary trial has several A comprehensive comparison cannot be made with no data in the primary trial",
        "label": "Contradiction"
    },
    "a1ae68b1-c14f-44b5-bc43-8966858fbf14": {
        "text_answer": "Contradiction  Explanation The statement makes a comparison between the primary trial and the secondary trial stating that patients in the primary trial receive higher doses of Alpha Lipoic Acid throughout the study duration while patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial However the evidence provided does not support this comparison as it only mentions the dosing regimens",
        "label": "Contradiction"
    },
    "6261a694-0407-4840-8a87-3a0c6f9dea4f": {
        "text_answer": "Contradiction The primary trial uses oral pregabalin twice daily for 6 weeks 12 doses while the secondary trial uses Depocyt and HDMTX which are not related to pregabalin",
        "label": "Contradiction"
    },
    "98e66236-2140-45a7-8bea-e2d17f373def": {
        "text_answer": "Contradiction The statement is a generalization that cannot be determined to be true or false based on the given evidence as the evidence does not provide information about the presence or absence of ependymal tumors in the primary trial",
        "label": "Contradiction"
    },
    "07e27cba-9e03-4644-a6f3-d05b61b5e4e2": {
        "text_answer": "Entailment assuming Aes mixer device is not mentioned in the evidence and the term adverse events refers to the same events as in the evidence",
        "label": "Entailment"
    },
    "117067e9-9bde-4d49-a4d2-51e9ac9886f6": {
        "text_answer": "Contradiction  The primary trial administers pregabalin every day for 6 weeks while the statement suggests that it is given every 8 weeks Additionally the secondary trial does not involve pregabalin at all but rather liposomal cytarabine and highdose methotrexate",
        "label": "Contradiction"
    },
    "8320c826-7a88-43e8-ae24-069d0f6ff886": {
        "text_answer": "Contradiction  Explanation The statement compared to the secondary clinical trial the primary clinical trial shows more instances of bronchopneumonia and general health decline is a contradiction based on the evidence provided The evidence from the primary trial does not show any instances of bronchopneumonia or general health decline while the secondary trial shows only one instance of each",
        "label": "Contradiction"
    },
    "354bc4da-42d7-452f-82bb-43e270a24c2f": {
        "text_answer": "Contradiction The evidence provided does not support the statement as it mentions various adverse events related to physical health conditions such as anemia thrombocytopenia acute coronary syndrome cardiac arrest cardiac failure and cardiac tamponade",
        "label": "Contradiction"
    },
    "c472d895-f7f4-474f-8664-b7af887b1339": {
        "text_answer": "Contradiction  Explanation The statement cohort b reported significantly lower adverse events compared to cohort a in the primary clinical trial is a contradiction based on the evidence provided The evidence shows that both cohorts had the same percentage 4000 of adverse events",
        "label": "Contradiction"
    },
    "a7960e8d-c8a2-4d32-93ff-bb5902051344": {
        "text_answer": "Contradiction The statement is not related to the eligibility criteria for the primary or secondary trials",
        "label": "Contradiction"
    },
    "b67a2d20-b35d-45b7-a594-8946f1f160ab": {
        "text_answer": "Contradiction The evidence states that radiotherapy is not utilized in the intervention strategies for either cohort",
        "label": "Contradiction"
    },
    "7f7c84c5-cc6b-4d4f-a47c-4d41454fd6d0": {
        "text_answer": "Contradiction  Explanation  In the primary trial intervention 1 Arm I involves the administration of zoledronic acid intravenously while intervention 2 Arm II does not specify the route of administration for the placebo  In the secondary trial both intervention 1 Arm II and intervention 2 Arm III involve the use of intravenous administration for some of the drugs granisetron hydro",
        "label": "Contradiction"
    },
    "4e9a0d19-c8b1-4ea4-9c73-2cf93b46f6a4": {
        "text_answer": "Contradiction  The evidence shows that a total of 84 participants were analyzed in the primary trial with 16 participants in Arm 1 and 381 of them experiencing pCR and 14 participants in Arm 2 and 333 of them experiencing pCR Therefore a total of 20 participants experienced pCR across both arms The statement however claims that more than 65 patients experienced p",
        "label": "Contradiction"
    },
    "44241e4d-31dc-487e-b42c-e8c47e3e82cf": {
        "text_answer": "Contradiction  Explanation  In the primary trial participants in Intervention 1 receive weekly subcutaneous injections of Triptorelin or Degarelix However the statement provided does not mention Triptorelin or Degarelix but rather mentions weekly subcutaneous infusions in general In the secondary trial participants in Intervention 1 receive weekly subcutaneous injections of Epoetin Beta",
        "label": "Contradiction"
    },
    "a7ff54ef-32cc-4cda-b4a2-39d5f6e1559c": {
        "text_answer": "Entailment The statement patients in the primary trial noted a 10 decrease in the percentage of cells with ki67 expression after a month of undergoing tak228 plus tamoxifen treatment is an entailment of the evidence provided as the evidence states that the median IQR percentage of cells with Ki67 expression decreased from 15 1025 at baseline to 10 ",
        "label": "Entailment"
    },
    "73052d5e-1a3a-4479-9ada-e69963c84b77": {
        "text_answer": "Entailment assuming that two patients in the statement refers to the total number of patients in cohort 2 who experienced doselimiting toxicity as indicated by the evidence",
        "label": "Entailment"
    },
    "f2796825-a4d9-4484-8958-851d99294e3c": {
        "text_answer": "Contradiction The primary trial measures hot flash scores using a scale not seconds or minutes The secondary trial measures overall response rate using proportions not units of time",
        "label": "Contradiction"
    },
    "a5c24bc4-6444-46bb-9da4-fca0d9d6f521": {
        "text_answer": "Contradiction  Explanation  The primary trial reports the determination of the Ruxolitinib Maximum Tolerated Dose MTD in combination with paclitaxel which is based on the number of patients who have dose limiting toxicity DLT The secondary trial reports the Maximum Tolerated Dose MTD or Maximum Feasible Dose which is defined as the highest dose level in which a",
        "label": "Contradiction"
    },
    "aed670bb-54a4-4769-86de-65f566bafebe": {
        "text_answer": "Entailment assuming the evidence provided for the trials is complete and accurate and the statement does not imply the absence of other imaging modalities not mentioned in the evidence",
        "label": "Entailment"
    },
    "2aef976d-1cb6-4d70-bda2-30a453c37f88": {
        "text_answer": "Contradiction The primary and secondary trials measure different outcomes and have different time frames The statement does not provide enough information to make a comparison between the two trials",
        "label": "Contradiction"
    },
    "4d18c0c9-1317-4c04-9b86-f6e7e8906f5e": {
        "text_answer": "Irrelevant The statement is not related to the information provided in the primary and secondary trials",
        "label": "Entailment"
    },
    "72921dd1-88c7-4aff-a98e-8af859e4f04f": {
        "text_answer": "Entailment The evidence states that both cohorts receive preoperative Dexamethasone intravenously and the statement does not contradict that fact",
        "label": "Entailment"
    },
    "78479579-0089-4132-8de1-f710cb80ac05": {
        "text_answer": "Entailment The evidence does not indicate any exclusion of Japanese nationals from either trial",
        "label": "Entailment"
    },
    "ce1887bc-e9b2-4c21-a5b8-dcbe59d3503e": {
        "text_answer": "Entailment The primary trial measures changes in pain intensity while the secondary trial measures changes in bone mineral density but both trials involve clinical studies with a time frame of 9 months",
        "label": "Entailment"
    },
    "ad477da6-f950-49b8-a882-0c1dfbc4751f": {
        "text_answer": "Entailment The evidence states that 13 individuals received the vaccine as part of the treatment in the primary clinical trial The statement is an entailment as it also states that 13 individuals received the vaccine",
        "label": "Entailment"
    },
    "547b8239-a47c-4f70-aa08-ff1d92e19af2": {
        "text_answer": "Contradiction  In the primary trial having a vitamin D level  40 ngml is an inclusion criterion while in the secondary trial it is an exclusion criterion Therefore the statement is a contradiction",
        "label": "Contradiction"
    },
    "4ec4fce7-e43e-46c8-ab5a-f5f04df1b940": {
        "text_answer": "Contradiction The primary trial compares two interventions Arm A and Arm B against each other while the secondary trial compares two different treatments Zoledronic acid and Denosumab The statement mixes the results from two unrelated trials",
        "label": "Contradiction"
    },
    "787e3275-7973-46d4-83de-00d9ebaf7acb": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of volunteer work in the provided evidence",
        "label": "Contradiction"
    },
    "f95439cc-7c35-43a8-ade1-6652fbdf7873": {
        "text_answer": "Contradiction The evidence shows that only one patient experienced suicidal ideation which is not sufficient to impact more than a quarter of the patients",
        "label": "Contradiction"
    },
    "a56a38a8-7782-4909-b417-ebb142f38028": {
        "text_answer": "Entailment The evidence shows that one subject in the primary clinical trial contracted a urinary tract infection which is consistent with the statement that numerous subjects contracted this condition However its important to note that the statement numerous subjects could potentially mean more than one but the exact number is not specified The evidence only shows that one subject experienced this adverse event but it does not contradict the statement",
        "label": "Entailment"
    },
    "2810ed9e-6f0a-4c59-be1a-31e5003fa51d": {
        "text_answer": "Entailment The statement is an entailment as the evidence describes several injections being administered in the primary trial including injections of dendritic cells peptides trastuzumab and GMCSF which are all in powder dosage forms or require reconstitution into a solution before administration",
        "label": "Entailment"
    },
    "39346303-4095-4b67-b384-6916ed20fd4c": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that adverse events have been recorded in detail for both trials allowing for comparison",
        "label": "Entailment"
    },
    "f1963f67-9164-4e55-bf5e-3ac44e9bae5f": {
        "text_answer": "Contradiction  Explanation  In the primary trial the outcome measurement is Tumor Diameter with units of measure in cm In contrast the secondary trial uses Number of Participants With Solid Tumor Response which does not have a unit of measure mentioned in the provided evidence Therefore the units of measure employed in the results of the two trials are not the same making the statement a contradiction",
        "label": "Contradiction"
    },
    "f1315324-edf3-4d7c-a999-c3a668e67930": {
        "text_answer": "Contradiction The evidence does not mention anything about talazoparib or marinebased natural products being used in the primary trial",
        "label": "Contradiction"
    },
    "f6b492a8-d17f-407f-9345-ed6b7f447eea": {
        "text_answer": "Contradiction The statement does not entail that the interventions in the primary and secondary trials are the same as they involve different drugbased treatments",
        "label": "Contradiction"
    },
    "81079f33-7706-4672-a08f-c285df38f870": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that both cohorts received the same dosage of Cetuximab and the statement correctly states that they received the same dosage while also acknowledging that MM121 dosages differed between the two cohorts",
        "label": "Entailment"
    },
    "49e49c15-d880-4fa1-9582-ba86488ad192": {
        "text_answer": "Contradiction  The evidence does not support the statement as it does not provide information about the relationship between the deleterious rpa1 gene mutation and increased pleural effusion in cohort 2 of the primary trial",
        "label": "Contradiction"
    },
    "7f11c755-66ed-4a7e-a222-0f967b650634": {
        "text_answer": "Contradiction  Explanation The statement every participant in cohort 2 took capecitabine orally each day during the initial 21day cycle is a contradiction to the evidence provided in the primary clinical trial According to the evidence capecitabine was administered orally from Days 1 to 14 every 21 days not every day during the entire 21day cycle",
        "label": "Contradiction"
    },
    "8ef6757e-e789-4a70-9cf3-e2e8050c9f15": {
        "text_answer": "Entailment The primary trial focuses on evaluating toxicity of infusing HER2specific T cells while the secondary trial measures the percentage of participants with adverse events of primary interest which are different patient characteristics",
        "label": "Entailment"
    },
    "14045448-a003-4d3d-ace1-bcdf3a7479c2": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because both trials recorded zero adverse events in their respective cohorts Therefore the primary trial did not record fewer adverse events than the secondary trial",
        "label": "Contradiction"
    },
    "ad37e364-d3a8-4fcd-9033-90e7ec7d7fc7": {
        "text_answer": "Contradiction The evidence states that no participants in the first cohort of the trial experienced severe nausea as indicated by the absence of vomiting and the need for no rescue medication during the first 24 hours after cyclophosphamide administration",
        "label": "Contradiction"
    },
    "4b5b9e75-1690-4544-86de-d4c0ac02cf57": {
        "text_answer": "Contradiction The statement provided is not related to the evidence given in the trial results",
        "label": "Contradiction"
    },
    "fef14a32-224c-4a00-88cb-30bb448a504e": {
        "text_answer": "Entailment  Explanation The statement in both the primary and secondary clinical trial at least one infection case was noted is an entailment based on the evidence provided In the primary trial there was one infection case out of 32 patients 313 In the secondary trial there were two infection cases out of 112 patients 179 Although the number of patients in the two trials is different",
        "label": "Entailment"
    },
    "4b7eaa17-f5eb-4afe-88b7-98c293ad0100": {
        "text_answer": "Contradiction The evidence shows that there were a total of 5 cases of gastrointintestinal adverse events diarrhea and vomiting in the primary trial",
        "label": "Contradiction"
    },
    "5a54ce72-5d02-48fb-9cc0-2a31123f3583": {
        "text_answer": "Contradiction The evidence shows that all 3 participants in Cohort 1 of the primary clinical trial experienced adverse events",
        "label": "Contradiction"
    },
    "4a6db09e-5bc7-4c5c-8cf8-a89750cd1cc1": {
        "text_answer": "Contradiction  The evidence provided in the results only mentions the number of participants with a reduction in CTCs one month posttransplant not several months",
        "label": "Contradiction"
    },
    "e9003121-5fb9-4d34-95b4-011c76402472": {
        "text_answer": "Contradiction  The statement is about the reduction in tumor diameter by tamoxifen while the evidence is about the change in Ki67 expression These two outcomes are not directly related and the statement does not follow from the evidence",
        "label": "Contradiction"
    },
    "1abf0ac3-be79-4fd6-aa9f-5ae756346da4": {
        "text_answer": "Entailment The evidence does not report any unexpected deaths or hospitalizations in either trial which is consistent with the statement",
        "label": "Entailment"
    },
    "50e4558f-a9a2-425b-911f-5bea986e90b4": {
        "text_answer": "Contradiction The primary trial treats patients with pregabalin while the secondary trial treats patients with Depocyt and HDMTX which are different interventions",
        "label": "Contradiction"
    },
    "5abe01fb-1ee1-4905-874e-a0cbec0ee9c9": {
        "text_answer": "Contradiction  The primary trial includes patients with benign breast disease while the secondary trial includes patients with a history of breast cancer including ductal carcinoma in situ However the primary trial explicitly excludes patients with malignant breast disease including ductal carcinoma in situ from participation Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "aa3f26b2-4c1c-45e6-b480-962b43324a8a": {
        "text_answer": "Contradiction The evidence does not support the statement that the majority of patients in the primary trial experienced complete response by week 24 The evidence only provides the number of participants with clinical benefit CR PR or SD at week 12 and week 24 for the Lapatinib 1250 mg and Vinorelbine 20 mgm2 arm of the trial The statement is about central nervous system angiolipoma",
        "label": "Contradiction"
    },
    "71fe40dd-6700-4f46-b635-de6407eb1567": {
        "text_answer": "Contradiction  Explanation  The primary trial has several inclusion criteria related to cancer diagnosis stage sensitivity to vinorelbine and life expectancy It also has several exclusion criteria related to pregnancy previous vinorelbine treatment infection and prior anticancer therapy  The secondary trial on the other hand only includes patients undergoing large core breast biopsy in the Radiology Department at the Beth Israel Deacon",
        "label": "Contradiction"
    },
    "4ddfaca9-bd5c-427a-a624-8a9d2c763c61": {
        "text_answer": "Contradiction  Explanation The statement mentions milliliter per square centimeter is a dose calculation unit expressed in milliliters per square centimeter but the primary trial uses milligrams as the dose calculation unit for durvalumab not milliliters per square centimeter The statement does not follow the evidence provided in the trial",
        "label": "Contradiction"
    },
    "13742fb9-874a-4f76-9d17-585c96fbd440": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events in the primary trial while the secondary trial had 000 adverse events in cohort 1 The statement however asserts that the count of adverse effects was identical for both trials",
        "label": "Contradiction"
    },
    "ce3d0415-1f95-4e20-bea5-5adc05962c9d": {
        "text_answer": "Contradiction  The statement suggests a 20 increase in Ki67 expression while the evidence shows a decrease of 5 from 15 to 10 in Ki67 expression after 6 weeks of TAK228 plus Tamoxifen administration",
        "label": "Contradiction"
    },
    "881871fa-1546-46da-acab-c8b67ef7e5c1": {
        "text_answer": "Contradiction The primary trial explicitly states that potassium must be within the normal range 3553 mEqL which is a stricter requirement than the secondary trial which does not mention any potassium requirement",
        "label": "Contradiction"
    },
    "280be8e4-7c13-4ca6-9653-94c7cf061c39": {
        "text_answer": "Contradiction The primary trial excludes patients with significant cardiovascular impairment while the secondary trial includes a criterion for uncontrolled cardiovascular disease as an exclusion",
        "label": "Contradiction"
    },
    "2e8f3602-15d2-4970-ad77-07352b50b787": {
        "text_answer": "Contradiction  Explanation  Although both trials involve intravenous injections and MRIs the statement is a contradiction because the primary and secondary trials do not utilize the same drugs administer the same dosages or adhere to the same administration frequency",
        "label": "Contradiction"
    },
    "5c226c5b-0a0a-44f7-a581-b2b8746f28a5": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence discusses the outcome measurements and results of two clinical trials while the statement mentions Johnston Atoll an island in the Pacific Ocean",
        "label": "Contradiction"
    },
    "644d3ae7-8d7c-40bd-8744-32f0d3311936": {
        "text_answer": "Contradiction  Explanation The primary trial involves the use of trastuzumab alone without any mention of the dosage or schedule The secondary trial on the other hand involves the use of Herceptin a type of trastuzumab in combination with docetaxel and the dosage and schedule are different from those in the primary trial However the statement compares the dosage of trastuzumab specifically",
        "label": "Contradiction"
    },
    "37f9db0b-4ea9-4952-bf6f-a748ac802a15": {
        "text_answer": "Contradiction The primary trial did not include a group with a dose of 0001 mg of GTx024",
        "label": "Contradiction"
    },
    "348f2b7d-e9b5-41ad-927b-e368bcaca8f5": {
        "text_answer": "Contradiction The statement Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial unless they are positive for either ER or PR or both is not an entailment of the evidence provided as the evidence does not mention anything about ER or PR status for patients with SCBC being eligible or excluded from the trial",
        "label": "Contradiction"
    },
    "d57cb18c-7375-4a66-81c4-7349cadd8d92": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the median PFS for cohort 1 was 16 months 16 to 32 and not 35 months",
        "label": "Contradiction"
    },
    "93fc8df8-d85f-4f71-9d03-7b7e0e5146ff": {
        "text_answer": "Contradiction The primary trial had no adverse events reported while the secondary trial had none reported in the provided data The statement suggests that there were adverse events in the primary trial which is not the case based on the evidence",
        "label": "Contradiction"
    },
    "dcb23ac7-9632-47fd-87bd-b15b25e4a3d3": {
        "text_answer": "Entailment assuming paclitaxel was not part of the interventions mentioned in the evidence",
        "label": "Entailment"
    },
    "eac5a5f1-7e63-4351-b7de-eacf6592a5fb": {
        "text_answer": "Contradiction  The statement is not entailed by the evidence as breast cancer patients received a much higher dose of talazoparib than what is stated in the statement and ovarianperitoneal cancer patients received a much lower dose than what is stated in the statement",
        "label": "Contradiction"
    },
    "23cc69a0-6ac6-4373-9e9e-97c3e613d5eb": {
        "text_answer": "Contradiction The primary trial reported no adverse events at all while the secondary trial reported only two adverse events neither of which were febrile neutropenia or cholelithiasis",
        "label": "Contradiction"
    },
    "cf33b6d5-f59c-4b24-be84-4aeba15f6c5e": {
        "text_answer": "Contradiction  Explanation The primary trial has several inclusion and exclusion criteria and the ability to offer written informed consent is only one of them The secondary trial has a completely different set of inclusion and exclusion criteria and the ability to offer written informed consent is not mentioned at all Therefore the statement that having the ability to offer written informed consent is the only mutual inclusionexclusion condition in both the primary and secondary clinical trials is a",
        "label": "Contradiction"
    },
    "7552c836-8753-455e-923f-8364d6c63b03": {
        "text_answer": "Entailment The evidence states that cohort 1 is triple negative PRnegative ERnegative and HER2 and cohort 2 is HER2positive which implies that cohort 1 is not HER2positive and cohort 2 is",
        "label": "Entailment"
    },
    "c3464aef-3ed6-47ad-8196-99f8115916e4": {
        "text_answer": "Contradiction The primary trial measures change in units on a scale for vaginal symptoms while the secondary trial measures percentage of participants with objective response rate of HER2negative metastatic breast cancer",
        "label": "Contradiction"
    },
    "fb73159b-0d37-4ea1-aaba-4f540ec395b9": {
        "text_answer": "Contradiction The primary trial does not include women aged 16 or 17 in its inclusion criteria",
        "label": "Contradiction"
    },
    "3fda5084-ab27-4f5c-8acb-0be7e7ac93c1": {
        "text_answer": "Contradiction The evidence reports 2 adverse events in the primary clinical trial",
        "label": "Contradiction"
    },
    "1655bb9f-adca-4796-9883-a620e978f745": {
        "text_answer": "Entailment The evidence shows that there were fewer adverse events in cohort 1 680 compared to cohort 2 4245 so it is an entailment that cohort 2 had a greater number of adverse events",
        "label": "Entailment"
    },
    "55b2acbc-30a6-43ef-bca6-0e7a5b3f6a8f": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that the interventions are administered using different techniques intravenous IV for bisphosphonate and subcutaneous SC for denosumab",
        "label": "Entailment"
    },
    "2037fc58-ce2f-4f44-8ebc-dc9f9d7129cd": {
        "text_answer": "Contradiction  Explanation The statement mentions 13 of the primary trial participants with PR Primary Breast Cancer but the primary trial results only provide information about participants with HER2 breast cancer Therefore the statement is not entailed by the evidence and is a contradiction",
        "label": "Contradiction"
    },
    "ecd4681c-624a-44da-b9e7-4d993b35d2af": {
        "text_answer": "Entailment Both trials involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine in a weekly cycle although the patient populations and dosing may differ",
        "label": "Entailment"
    },
    "3239643a-3052-4344-a7ea-f2d5dff19755": {
        "text_answer": "Contradiction The primary trial includes postmenopausal women while the secondary trial includes patients with histologically confirmed metastatic breast cancer without specifying their age",
        "label": "Contradiction"
    },
    "b7c9455e-db3b-438d-bcb0-04bf52fb530d": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only compares the changes in lymphedema between patients receiving acupuncture and those on a waitlist and does not mention any group receiving testosterone cream",
        "label": "Contradiction"
    },
    "3ca94519-994e-4921-95ef-fdd1daf0932c": {
        "text_answer": "Contradiction The primary trial includes patients who have undergone lumpectomy which is a type of breast conservation therapy but the secondary trial does not exclude patients based on this factor",
        "label": "Contradiction"
    },
    "efbc4408-7a74-4857-8265-d1bf4eab4080": {
        "text_answer": "Entailment assuming the 720 hours of treatment equates to 16 weeks as stated in the evidence",
        "label": "Entailment"
    },
    "4e9c14cb-9c55-4c1a-ae14-f5a6f08e1494": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses the adverse events in the primary and secondary trials while the statement is about a liquid soap dosage form",
        "label": "Contradiction"
    },
    "9bf4a35a-531f-4083-87ac-dec730cfea45": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial recorded 0 instances of intestinal perforation according to the provided data",
        "label": "Contradiction"
    },
    "49d2b5e7-595e-4762-b7af-9e914bf72917": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 patients receive 1 mgkg of MCS110 every 3 weeks which is less than 20 mg for a 70 kg patient However it contradicts the statement that all patients receive over 130 mg of PDR001 every other week as the evidence does not provide any information about the dosage of PDR00",
        "label": "Contradiction"
    },
    "d8735c6c-1fc9-4fbc-93d2-651a5814d505": {
        "text_answer": "Contradiction The primary trial does involve a massage therapy intervention which is not a drugbased treatment but the secondary trial does involve a drugbased intervention PF06647020 with different doses However the statement does not apply to the primary trial as it only mentions the secondary trials cardiovascular system findings being derived values",
        "label": "Contradiction"
    },
    "f7d7cc99-97cb-48f0-bc69-78a60d9d21be": {
        "text_answer": "Contradiction  The statement requires that over 66 of the participants experienced either a confirmed complete response CR or a confirmed partial response PR while the evidence shows that 53 of the participants experienced either a CR or a PR",
        "label": "Contradiction"
    },
    "268ad1eb-851a-484a-873f-b54ab271b063": {
        "text_answer": "Contradiction The statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "428340b6-e87b-4e03-920b-f2e3f62f05d6": {
        "text_answer": "Entailment The evidence states that the educational DVD is only provided to patients in cohort 1 of the intervention group",
        "label": "Entailment"
    },
    "aa5dd0d4-1551-4ccc-85a8-ca6c2bcfb871": {
        "text_answer": "Contradiction  Explanation The statement in the primary trial results there were more patients with stable disease after 3 months than after 6 months but none of the patients had complete response after 3 months or 6 months is a contradiction to the evidence provided  The evidence shows that at week 12 there were 12 participants with stable disease and at week 24 there were 10 participants with stable disease",
        "label": "Contradiction"
    },
    "ba355915-f5a7-4b38-bbca-95fe674d63f5": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only lists the types and number of adverse events in the primary trial it does not mention anything about hours per day",
        "label": "Contradiction"
    },
    "1c31539a-7fd9-4e81-ae88-c0e05a34946a": {
        "text_answer": "Neutral Nondeterministic  Explanation The statement itself does not entail or contradict the evidence provided The evidence only states that the participants in the primary trial for breast cancer and ovarianperitoneal cancer received talazoparib capsules with varying doses The statement is about the use of the adhesion G proteincoupled receptor e1 staining method which is not mentioned in the evidence",
        "label": "Entailment"
    },
    "c367ab4c-6113-4f79-abcc-24e715c18094": {
        "text_answer": "Contradiction  Explanation The statement does not entail the evidence as it makes a claim about a specific adverse event grade 1 neonatal bradyarrhythmia that is not mentioned in the evidence Additionally the evidence states that no adverse events were observed in the primary trial while the statement does not make any statement about the primary trial regarding this specific adverse event Furthermore the evidence mentions that skin infections affected more than ",
        "label": "Contradiction"
    },
    "6815208b-ad2d-4564-b723-2d8e44af78b0": {
        "text_answer": "Contradiction The primary trial does not list smoking as an exclusion criterion",
        "label": "Contradiction"
    },
    "14e8dba6-bd13-4f5b-a225-6cd55c3d1243": {
        "text_answer": "Contradiction  In the primary trial the dose of alpha lipoic acid is escalated until a maximum tolerated dose is found meaning the dose is not consistent for all patients In contrast in the secondary trial patients in cohort 1 receive a consistent dose of necitumumab throughout the trial",
        "label": "Contradiction"
    },
    "12a7a47e-adb9-4c24-8410-03aea3d7d292": {
        "text_answer": "Contradiction The primary trial does not require an MRI only a mammography while the secondary trial does not require a mammography only image guidance",
        "label": "Contradiction"
    },
    "3570b51a-d280-41b5-9c59-849436db5934": {
        "text_answer": "Contradiction The statement patients who have a histological documentation of metastatic SBC are not eligible for the primary clinical trial is a contradiction to the evidence provided in the inclusion criteria which states that patients with histologically documented metastatic breast cancer are eligible for the trial",
        "label": "Contradiction"
    },
    "9e14f099-36f3-4672-b35c-022cc3279c98": {
        "text_answer": "Contradiction The primary trial reports Time to Progression while the secondary trial reports the number of patients with Objective Response These are different outcome measures",
        "label": "Contradiction"
    },
    "afc3c380-94da-4686-a5ca-1967217d14d1": {
        "text_answer": "Entailment The evidence does not report any incidences of tumour lysis syndrome in both trials",
        "label": "Entailment"
    },
    "a3a672e2-2900-45dd-ae02-797449f17b66": {
        "text_answer": "Contradiction The primary trial excludes patients with a history of alcohol or substance abuse or dependence within the past 2 years while the secondary trial requires a daily alcohol consumption of at least five drinks",
        "label": "Contradiction"
    },
    "db26f45b-4e0a-4f21-83da-6f22116f7ac5": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were no cases of anemia pneumonia or stupor reported in the primary clinical trial However the statement asserts that the incidence of these conditions was higher in the secondary clinical trial patients Since the evidence contradicts the statement the statement is a contradiction",
        "label": "Contradiction"
    },
    "c4aea42a-a9e3-47ba-9a96-12350a3925c9": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy while the secondary trial does not involve radiation therapy at all The statement incorrectly asserts that both trials involve receiving 00176 ounces of fulvestrant in a tablet form to be taken bid but this is not a commonality between the trials",
        "label": "Contradiction"
    },
    "576967ff-d2bb-4d1c-b2a1-8516ceb7a519": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the placebo intervention is administered orally twice daily BID while the memantine intervention is administered orally once daily",
        "label": "Contradiction"
    },
    "c3e36213-9a24-4f92-9ff3-12e071aac541": {
        "text_answer": "Entailment  Explanation  The primary trial includes the use of cyclophosphamide and paclitaxel in the intervention and the secondary trial also includes the use of cyclophosphamide and paclitaxel in the intervention as well as pegfilgrastim Therefore the statement that both trials provide cyclophosphamide paclitaxel and pegfilgrastim to their respective patient groups is an entailment",
        "label": "Entailment"
    },
    "91db7925-da19-4373-bfba-78ee49b34f99": {
        "text_answer": "Contradiction The primary trial has a cyclic treatment with a defined cycle length while the secondary trial does not have a cyclic treatment",
        "label": "Contradiction"
    },
    "fc6ab4bb-43af-4008-a2dc-0e23dbf9abc0": {
        "text_answer": "Contradiction  Explanation  The primary trial includes patients undergoing mastectomy as a part of their breast reconstruction but the secondary trial includes patients who have completed surgery for breast cancer which could include lumpectomy or mastectomy However the secondary trial also includes additional eligibility criteria that are not present in the primary trial such as posttreatment timing plasma CRP level and fatigue level Therefore having",
        "label": "Contradiction"
    },
    "00d9d3c3-938f-4e4c-b532-b11146f1239c": {
        "text_answer": "Entailment Both trials involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine in a weekly cycle",
        "label": "Entailment"
    },
    "5102bc84-4e28-4ec9-91cf-b5ed615b15bb": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the placebo is administered on a 21day basis not semiannually and trabectedin is administered on a semiannual basis but not through a 3hour intravenous infusion on every administration",
        "label": "Contradiction"
    },
    "914d236c-c227-4d8d-8565-04a1d25e3b59": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the evidence from the primary trial only shows that tamoxifen decreases the Ki67 expression in tumors by 40 on average not that it decreases the diameter of tumors by 40 The two statements are not equivalent",
        "label": "Contradiction"
    },
    "af1a2e8d-2b8e-4690-b32c-9d044d9aa15f": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement does not directly entail or contradict the evidence provided because the statement does not mention the specific types of cancer being studied in the primary trial and it does not specify the exact doses of 18FFDG and 18FFPPRGD2 being used However the evidence shows that both study groups will undergo the same imag",
        "label": "Entailment"
    },
    "f718d65d-3ea1-41b7-adc0-5f481843011c": {
        "text_answer": "Contradiction  The primary trial uses a daily dose of lenalidomide at 5mg while the secondary trial uses a daily dose of lapatinib at 1500mg The statement implies that the primary trial uses a greater dosage of lenalidomide than what is used of lapatinib but in fact the dosages are different drugs with different units mg for lenalidomide and mgkg for lapatin",
        "label": "Contradiction"
    },
    "8f537eb8-d8b7-4c56-89bf-ea2e5b0d1326": {
        "text_answer": "Contradiction The primary trial uses a cyclic treatment schedule while the secondary trial does not have a specified cyclic treatment The statement about 3q21q25 is not related to the trials and their interventions",
        "label": "Contradiction"
    },
    "1ea69c5b-83c6-4d54-b17c-0e6df9c49abb": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence does not support the claim that the prevailing adverse events in the primary clinical trial were of cardiovascular origin Instead the evidence shows that the adverse events in the primary trial were primarily related to the blood and bone marrow and lymphatics The secondary trial also had adverse events related to the blood and bone marrow but no card",
        "label": "Contradiction"
    },
    "763b8082-f1d6-4dfb-ab46-b61d8dae6515": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary and secondary trials have inclusion and exclusion criteria related to gender age and weight",
        "label": "Contradiction"
    },
    "485e3ce9-e779-4ae5-bdc4-7fbcb1d1eb3c": {
        "text_answer": "Contradiction The evidence shows that there were adverse events such as fatigue pyrexia and neutropenia in the primary clinical trial which contradicts the statement that only mild muscular discomfort was noted",
        "label": "Contradiction"
    },
    "88a40578-17e1-499b-8b7b-10a85e2c3d88": {
        "text_answer": "Contradiction The primary trial explicitly states that patients must have a breast tumor that is 1 cm in diameter not 100 mm",
        "label": "Contradiction"
    },
    "b7178d54-4bb2-4820-b13c-c342075267ff": {
        "text_answer": "Entailment as long as the other adverse events mentioned in the statement are not specifically related to cardiac or psychiatric conditions",
        "label": "Entailment"
    },
    "48788622-6b62-4a88-8d7c-29be1fbd88e8": {
        "text_answer": "Contradiction The evidence does not mention coronary artery stenosis as an adverse event in the primary clinical trial",
        "label": "Contradiction"
    },
    "f05dd895-7d03-45d2-ab9c-69db39c386e5": {
        "text_answer": "Contradiction The evidence does not mention anything about mental health record or prior radiotherapy It only mentions chemotherapy and the number of lines of treatment in the metastatic setting",
        "label": "Contradiction"
    },
    "06a1adac-dee0-4d9b-83c6-0996391e40d0": {
        "text_answer": "Entailment The evidence states that 13 participants were treated with the GloboHGM2LewisyMUC132aasTncTFcTncKLH conjugate vaccine and the statement also mentions that 13 participants were treated with the same vaccine Therefore the statement is an entailment of the evidence",
        "label": "Entailment"
    },
    "993572ab-2275-4def-9723-202249284283": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as insomnia was not reported as a recurring adverse event in either the primary or secondary clinical trials The most recurring adverse events reported in the primary trial were syncope and dehydration each occurring in 1667 of patients The secondary trial reported no adverse events",
        "label": "Contradiction"
    },
    "2312576f-7c8d-4fcd-80e8-42cf3d81dd04": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because   Cohort 1 receives Eribulin at a dose of 14mgm2 total of 28mgm2 per cycle  Cohort 2 receives Docetaxel at a dose of 75mgm2 per cycle  Therefore cohort 1 does not receive higher doses",
        "label": "Contradiction"
    },
    "61fbddc4-94cb-4105-8090-03dd97a3bc53": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence as the primary trial only includes postmenopausal female and male subjects over 18 years old while the secondary trial only includes female patients",
        "label": "Contradiction"
    },
    "9b2023d2-09bd-4362-ae66-afc69497e468": {
        "text_answer": "Contradiction The statement has nothing to do with the evidence provided",
        "label": "Contradiction"
    },
    "886a066c-520e-4454-bf20-43ad24b6baf9": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence provided as the primary trial recorded no adverse events at all while the secondary trial recorded a high proportion of patients experiencing adverse events",
        "label": "Contradiction"
    },
    "e87fee13-1ed3-4eca-8d72-d65fee50abf7": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of mucositis oral epileptic seizures or thromboembolic events in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "f08d84f8-0448-462c-8f81-770223b92bb8": {
        "text_answer": "Contradiction The primary trial does not provide sufficient evidence to make a definitive statement about the efficiency of intraoperative mammography compared to standard mammography based on operative time alone The secondary trial measures a different outcome success rate and time frame 2 years postPMRT and cannot be directly compared to the primary trial",
        "label": "Contradiction"
    },
    "205d3c95-7288-4d9f-9a5c-edc7b09de79d": {
        "text_answer": "Contradiction The primary trial includes patients undergoing lumpectomy while the secondary trial includes patients undergoing mastectomy with tissue expander reconstruction or skinsparing mastectomy These procedures are not the same so eligibility for one does not automatically imply eligibility for the other",
        "label": "Contradiction"
    },
    "62de4057-c709-4110-9986-642428c1d534": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the placebo and trabectedin are not delivered identically as the placebo is administered on Day 1 and trabectedin on Day 2",
        "label": "Contradiction"
    },
    "b9e51528-b593-40f7-8f49-acfacc756a7f": {
        "text_answer": "Contradiction The primary trial does not report any thromboembolic events",
        "label": "Contradiction"
    },
    "05c44353-ab0d-4b2d-98ff-e39aab551229": {
        "text_answer": "Contradiction  The primary trial administers oral pregabalin while the secondary trial administers intravenous Depocyt and highdose Methotrexate These are not the same interventions",
        "label": "Contradiction"
    },
    "c96d223f-7d7e-47aa-b71e-0b56ab6eef81": {
        "text_answer": "Contradiction The evidence does not mention anything about exercise being part of the intervention for the primary trial The statement is not related to the evidence",
        "label": "Contradiction"
    },
    "280cae18-764b-4cc7-ae2a-3b1f05c04cbf": {
        "text_answer": "Contradiction The evidence states that both study groups undergo PETCT imaging with both 18FFDG and 18FFPPRGD2",
        "label": "Contradiction"
    },
    "a9c7619e-8cc5-4c84-b4a4-38ada95388a2": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement is about a dataset containing supplemental information for pharmacogenomicsgenetics biomarker records while the evidence provided pertains to the inclusion and exclusion criteria for two different clinical trials The statement does not directly entail or contradict the evidence as it does not relate to the trials eligibility criteria or performance status scoring systems",
        "label": "Entailment"
    },
    "059a48d5-3bf5-40ac-b06c-3107c0ea7cb9": {
        "text_answer": "Contradiction The primary trial involves oral pregabalin while the secondary trial involves intravenous Liposomal Cytarabine Depocyt and Highdose Methotrexate HDMTX",
        "label": "Contradiction"
    },
    "3ace09f3-a822-4140-a529-52b08664da77": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no information provided in the evidence about the number or types of adverse events in patients with t113 cytogenetic abnormality in cohort 1 or cohort 2",
        "label": "Contradiction"
    },
    "291150cd-0d45-46c7-9a44-d781098bc3eb": {
        "text_answer": "Contradiction The primary trial does not have a requirement for Her2neu breast cancer",
        "label": "Contradiction"
    },
    "c49dbdfa-801a-4789-9e04-345ed14150ab": {
        "text_answer": "Entailment Both groups of patients in the primary trial undergo the same intervention receiving talazoparib capsules regardless of their cancer type breast or ovarianperitoneal and neither the statement nor the evidence mention hemodialysis catheters However the question asks about a separate issue hemodialysis catheter infections that is not related to the given evidence",
        "label": "Entailment"
    },
    "4028bb9b-1122-4c10-ab5c-a38205fe6dd2": {
        "text_answer": "Contradiction The evidence shows that a higher proportion of patients in cohort 2 experienced febrile neutropenia which is a negative effect compared to cohort 1 Therefore the statement that the same proportion of patients experienced negative effects in both groups is contradicted by the evidence",
        "label": "Contradiction"
    },
    "6b568a13-5216-4b83-848a-c64e8a9c340b": {
        "text_answer": "Contradiction The evidence states that the results of the LBH589 and Lapatinib cohort were not analyzed in the primary clinical trial but the evidence does provide information about the design of the study for that cohort",
        "label": "Contradiction"
    },
    "3852b7ff-e68a-4bc8-917f-4eb9c838862d": {
        "text_answer": "Contradiction  Explanation The primary trial does not have any exclusion criteria related to organ transplant within the past six months However the secondary trial has an exclusion criterion of prior HDCT with Autologous hematopoietic stem cell transplantation AHST in adjuvant setting or history or presence of brainleptomeningeal metastasis which could include recipients of organ",
        "label": "Contradiction"
    },
    "2a509e67-c521-4406-8122-c91d7a1331ad": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as the trials have no shared inclusion or exclusion criteria related to skin appendage neoplasms",
        "label": "Contradiction"
    },
    "c5d6c5da-f71c-4454-a333-3ade43aef122": {
        "text_answer": "Contradiction  Explanation  The evidence provided includes the inclusion criteria for the primary clinical trial which states that patients with histologically documented metastatic or unresectable nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma or breast cancer are eligible for the study There is no mention of ER or PR status as a requirement or exclusion criterion in the provided evidence Therefore the",
        "label": "Contradiction"
    },
    "fd334e71-2bbe-4138-b578-2ab848686045": {
        "text_answer": "Contradiction The primary trial specifically excludes patients who have received any other investigational agents which could include CBTbased treatments but the secondary trial makes no mention of such a restriction",
        "label": "Contradiction"
    },
    "b3b66b49-6a4c-4c26-b46c-915ab45374ff": {
        "text_answer": "Contradiction The primary trial involves the use of Eribulin Mesylate which is a medication given intravenously while the secondary trial involves the use of Axitinib and Docetaxel which are oral and intravenous medications respectively There is no evidence provided regarding radiation therapy in either trial",
        "label": "Contradiction"
    },
    "8004fee7-e287-4a54-b66f-44002ebb1b34": {
        "text_answer": "Contradiction The evidence states that patients with a history of another malignancy are excluded from the trial except for those who have been diseasefree for 3 years However the statement suggests a patient diagnosed with ILDDPLD within the last 3 years and a life expectancy of half a year which contradicts the inclusion criteria",
        "label": "Contradiction"
    },
    "777fb2a8-9329-4e49-a67b-93d1d7fe2319": {
        "text_answer": "Contradiction with the given evidence there is no mention of a wound reopening in the primary trial",
        "label": "Contradiction"
    },
    "386515be-dd8a-423d-933b-6c7f99461ebd": {
        "text_answer": "Entailment The primary trial includes patients with stage IV breast adenocarcinoma that is ER positive PR positive or HER2neu negative as a subset of its inclusion criteria Therefore these patients are qualified to participate in the primary trial The secondary trial specifically requires these same characteristics for eligibility so these patients are also qualified to participate in the secondary trial",
        "label": "Entailment"
    },
    "3a36e314-e4f4-4a60-acc9-b9f9933e884c": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as there were no adverse events recorded in the secondary trial",
        "label": "Contradiction"
    },
    "c6b37d94-f63f-4cf7-b86c-a8147ff618d9": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence as the primary trial shows a decrease in Ki67 expression with tamoxifen treatment not an increase as stated in the question",
        "label": "Contradiction"
    },
    "ae0dd0fb-c8c9-47bd-ab6b-8236edd68194": {
        "text_answer": "Entailment  Explanation  The statement the primary trial uses lower doses of lenalidomide than the secondary trial uses of lapatinib in intervention 1 and the primary trial intervention has a shorter period is an entailment based on the evidence provided  The primary trial uses lenalidomide at a dose of 5mg orally daily for 57  3 days while the secondary trial uses",
        "label": "Entailment"
    },
    "be268f6b-8123-4cd7-a495-c82453034b67": {
        "text_answer": "Contradiction  The primary trial includes patients with lobular carcinoma in situ but does not specify any blood pressure requirements The secondary trial includes patients with a history of breast cancer including lobular carcinoma in situ and specifies that no uncontrolled hypertension is allowed Therefore the statement that patients with lobular carcinoma in situ and wellregulated high blood pressure are permitted in the primary clinical trial but barred from the secondary clinical trial is",
        "label": "Contradiction"
    },
    "62581915-0fde-4cfb-8205-7c1b8c8bacbb": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence because the primary trial used a dose of lenalidomide 5mg orally daily that is lower than the dose used in the secondary trial for lapatinib 1500mg orally daily",
        "label": "Contradiction"
    },
    "36426525-f3e0-426e-aae4-2fc677756ca9": {
        "text_answer": "Contradiction The primary trial recorded no adverse events while the secondary trial recorded several adverse events that affected more than 30 of patients apart from Skin infections",
        "label": "Contradiction"
    },
    "58b45da6-c265-4cef-a6cc-83113439c79e": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence provided because there were no adverse events reported for palpitations pericardial effusions or abdominal pains in the secondary trial",
        "label": "Contradiction"
    },
    "a743b2fa-dd26-4c5f-931d-f5cc8bcf52c2": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions mucositis oral in the primary trial but not in the secondary trial and thromboembolic events are recorded in the primary trial but not in the secondary trial The statement does not hold for all the mentioned adverse events",
        "label": "Contradiction"
    },
    "0bb7dafe-391e-4adb-a9fe-ac3717421ae8": {
        "text_answer": "Contradiction The primary trial only includes patients with Stage IIII breast cancer while the secondary trial includes patients with Stage IIII breast cancer only A woman with Stage IV breast cancer would not meet the inclusion criteria for either trial",
        "label": "Contradiction"
    },
    "20c98ba5-ca61-4afe-af57-6de08705a5cd": {
        "text_answer": "Contradiction Both trials use different outcome measurements but they do not necessarily use different units of measure The primary trial measures change in serum levels of Follicle Stimulating Hormone FSH in units of mIUml while the secondary trial measures Maximum Tolerated Dose MTD in units of mg However the contradiction lies in the fact that they use different outcome measurements the primary trial measures change in FSH",
        "label": "Contradiction"
    },
    "6adaaefe-d699-4bce-87dc-8233140a14fa": {
        "text_answer": "Contradiction The secondary trial does not measure muscle gains but rather the percentage of participants with pain or no pain as measured by the Numeric Pain Rating Scale",
        "label": "Contradiction"
    },
    "d7aa81f2-8df0-4884-9d6a-e6d21ec79b03": {
        "text_answer": "Contradiction  The statement implies that patients with unstable angina or grade 2 or above neuropathy cannot participate in the secondary trial but the exclusion criteria for the secondary trial do not mention unstable angina and only mention grade 1 or above neuropathy as an exclusion criterion Therefore the statement contradicts the evidence provided  Regarding chemotherapy or radiotherapy the statement implies that such patients cannot participate in the",
        "label": "Contradiction"
    },
    "869078fe-375b-45b5-ba65-21d04cd304ed": {
        "text_answer": "Contradiction  Explanation The statement the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1 is a contradiction to the evidence because the primary trial uses Lenalidomide at a dose of 5mg orally daily while the secondary trial uses Lapatinib at a dose of 1500mg orally daily The statement implies that the primary trial uses",
        "label": "Contradiction"
    },
    "5417955e-52aa-4b3b-8e67-2a4c4796846a": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the primary trial involves epacadostat being given twice daily BID while sunitinib in the secondary trial is given once daily However the statement suggests that epacadostat is given to participants twice as frequently as sunitinib is given to sunitinibnaive patients which is not the case since epacadostat is given twice daily",
        "label": "Contradiction"
    },
    "5d6bf9b2-6737-4266-9566-436393cdcfab": {
        "text_answer": "Entailment The evidence shows that the mean number of hot flashes per day was lower in the paced respiration group 348 compared to the fast shallow breathing group 395",
        "label": "Entailment"
    },
    "28375759-dcd0-430d-8035-9571e1bbc07e": {
        "text_answer": "Contradiction  The primary trial uses a daily dose of 5mg orally for lenalidomide while the secondary trial uses a daily dose of 1500mg for lapatinib Therefore the statement is a contradiction as the primary trial uses a lower dose of lenalidomide but the secondary trial uses a higher dose of lapatinib",
        "label": "Contradiction"
    },
    "ae5d8804-eada-4f5c-8889-18a7cc90bb9b": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the evidence shows that the same form of measurement ie tumor diameter is used in both the primary and secondary trials However the units of measure are different cm in the primary trial and not explicitly stated in the secondary trial But based on the context it can be assumed that the same units ie cm are used in the secondary trial as",
        "label": "Contradiction"
    },
    "ee16dd43-346c-47c2-b5c1-b3722935918d": {
        "text_answer": "Contradiction The primary trial includes postmenopausal women only while the secondary trial does not specify an age requirement Therefore the statement that the primary trial does not reject participants based on their age while the secondary trial restricts underage participants is a contradiction",
        "label": "Contradiction"
    },
    "a154d6bd-fc5d-491f-b2aa-7785024e67a5": {
        "text_answer": "Entailment Both trials report percentages in the primary trial and numbers of participants in the secondary trial which are different units but can still be considered the same as they are both measures of count data",
        "label": "Entailment"
    },
    "00ac087f-fc20-4ff1-be51-f32fa22f4e4e": {
        "text_answer": "Contradiction  Explanation In the primary trial epacadostat is given twice daily BID while in the secondary trial sunitinib is given once daily Therefore the frequency of administration for epacadostat and sunitinib is not the same",
        "label": "Contradiction"
    },
    "61a6a476-9283-4cde-89e7-5f1405f690c1": {
        "text_answer": "Contradiction  The evidence states that patients receive oral lapatinib once daily in Arm 1 of the primary trial not twice daily as stated in the question",
        "label": "Contradiction"
    },
    "2ea93619-d183-4989-b811-c4666059d456": {
        "text_answer": "Entailment In the primary trial patients receive 2 mgkg of trastuzumab weekly while in the secondary trial patients in Cohort 2 receive Herceptin 4 mgkg IV infusion on Day 1 of Cycle 5 and Herceptin 2 mgkg by IV infusion weekly starting from Day 8 which is a higher initial dose followed by a lower maintenance dose Therefore the dosages differ at different points",
        "label": "Entailment"
    },
    "93eef0e8-7a40-452a-a61e-a9d671dcacbd": {
        "text_answer": "Entailment The evidence shows that there were no reported cases of intestinal obstructions or pancytopenia in both trials The statement that there are no such incidents in the patient cohorts of both trials is an entailment of the evidence",
        "label": "Entailment"
    },
    "97a2b670-3f9b-49e5-abde-d0b477046164": {
        "text_answer": "Neutral The evidence does not directly address the statement as the statement refers to patients in cohorts 1 or 2 but the evidence only provides data for two specific subgroups within those cohorts",
        "label": "Entailment"
    },
    "a90d6d85-6942-4653-b23c-126d63b1d2cf": {
        "text_answer": "  Contradiction The statement is contradictory because patients with stage 4 cancer are explicitly stated to be excluded from the secondary trial but there is no mention of eligibility or exclusion for patients with chromosome 15q2315q24 abnormalities in either trial",
        "label": "Contradiction"
    },
    "75625dfd-7f82-4a99-b97d-50f05751dfdb": {
        "text_answer": "Entailment The statement mood disorder is a category of psychiatric disorders which have as their most predominant feature a disturbance in mood is an entailment of the exclusion criteria for both trials as both trials exclude patients with a history of schizophrenia which is a type of mood disorder",
        "label": "Entailment"
    },
    "195efca0-b2e3-43c0-abf2-4c6d77d8a449": {
        "text_answer": "Contradiction The evidence states that sunitinib was administered orally in the primary clinical trial",
        "label": "Contradiction"
    },
    "56d753e1-4bce-4c3d-a8fb-8abc6119c1a7": {
        "text_answer": "Entailment The evidence shows that fewer than 6 of patients in the primary clinical trial encountered adverse events which is less than 5",
        "label": "Entailment"
    },
    "d260a3cd-28cd-4df8-aa19-1586a1f7b978": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the two cohorts in the primary clinical trial receive CUDC101 at different dosing schedules",
        "label": "Contradiction"
    },
    "20a9c28d-88d5-4cd8-b346-19a1123ede25": {
        "text_answer": "Contradiction  Explanation The evidence shows that in the primary clinical trial there were patients who experienced increased pleural effusion in cohort 1 and rapid disease progression in both cohorts Therefore the statement that all the patients in the primary clinical trial see no symptoms of increased pleural effusion or rapid disease progression is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "fdeba169-13d2-4ed9-a2b2-774194f18370": {
        "text_answer": "Contradiction The evidence states that there should be no meningeal carcinomatosis in the primary trial Leptomeningeal carcinomatosis is a type of meningeal involvement by cancer",
        "label": "Contradiction"
    },
    "fe7217cf-7210-433b-b3ec-5dfff00aa3c4": {
        "text_answer": "Contradiction  Explanation  The statement the secondary clinical trials most frequent adverse event witnessed was anaemia affecting in excess of 5 of the patients while no adverse occurrences were noted in the primary trial is a contradiction based on the evidence provided  In the secondary trial anaemia affected 3128 234 of the patients which is less",
        "label": "Contradiction"
    },
    "b70ec50e-cbcd-4edd-a730-267c5b0f3fec": {
        "text_answer": "Entailment Both trials have no recorded adverse events according to the evidence provided",
        "label": "Entailment"
    },
    "3b41b926-449f-41e1-beed-6dd4be9e57f1": {
        "text_answer": "Entailment The statement participants in the primary trial receive 4 different drugs throughout the study duration with a maximum dose of 100 mgm2 is an entailment of the evidence as the evidence states that the neoadjuvant therapy consists of epirubicin cyclophosphamide docetaxel and trastuzumab which are all different drugs and the maximum dose of epirub",
        "label": "Entailment"
    },
    "6f5741c8-88c1-46ef-856c-dae9a3fe5fd6": {
        "text_answer": "Entailment The statement the more than half of participants in the primary clinical trial who were treated with 1000 mg of lapatinib in combination with nabpaclitaxel exhibited either a verified complete response or a validated partial response is an entailment of the evidence provided as the evidence states that 53 of participants in the trial experienced either a confirmed complete response or a confirmed partial response",
        "label": "Entailment"
    },
    "83b92dd1-c68e-443b-b864-3ea87b3b557e": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "53d37329-6f3e-40fe-82d3-4a2535b117d9": {
        "text_answer": "Contradiction The primary trial has an ECOG performance status of 02 which means the patients are able to perform all their normal activities take care of themselves and are ambulatory The secondary trial includes patients with an ECOG of 02 or Karnofsky 60100 but it does not specify that patients must be able to perform all their normal activities and take care of themselves However the statement in",
        "label": "Contradiction"
    },
    "28c1cdeb-4f60-4fd7-b2b1-5368a91f9b85": {
        "text_answer": "Contradiction The primary trial does not mention any specific prohibition of CBT treatments for memory improvement However the secondary trial does not mention anything about CBT treatments at all",
        "label": "Contradiction"
    },
    "75080502-7163-4189-9194-c96041df76e5": {
        "text_answer": "Contradiction The secondary trial has an age inclusion criterion of at least 18 years old which contradicts the statement that it has no age restriction",
        "label": "Contradiction"
    },
    "4c30a588-032f-4b8c-b00a-ee27f8f64b50": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of any vaccine administration in the given clinical trial interventions",
        "label": "Contradiction"
    },
    "37b1b3cc-069a-4597-9375-4e856eeb6f9d": {
        "text_answer": "Contradiction The secondary trial allows patients with unstable angina and grade 2 or above neuropathy but the primary trial excludes patients with these conditions However the primary trial does not mention any restrictions on cancer treatments or healing surgical wounds",
        "label": "Contradiction"
    },
    "8bcb86b4-494e-4e43-bf93-ef5b1ef6c566": {
        "text_answer": "Contradiction The primary trial requires participants to be resistant to AI therapy while the secondary trial does not mention AI therapy as a requirement for inclusion",
        "label": "Contradiction"
    },
    "ab098908-d287-4ffa-883c-202a87f5ba63": {
        "text_answer": "Contradiction The evidence states that patients receive oral lapatinib once daily not bidaily and for 28 days not 30 days",
        "label": "Contradiction"
    },
    "b96ecdf0-3627-48c9-b01d-4cfdbe13a7cb": {
        "text_answer": "Contradiction  Explanation The evidence provided does not indicate any results or outcomes for the LBH589 With Capecitabine and LBH589 and Lapatinib cohorts to make a comparison and determine if one produced worse results than the other The information given only describes the dosing and participant numbers for each cohort",
        "label": "Contradiction"
    },
    "f07f2805-df6a-4662-8a1f-757eabf8687a": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the primary trial participants receive Epacadostat twice daily BID while the secondary trial participants on singleagent sunitinib receive sunitinib once daily However the statement asserts that Epacadostat is given to primary trial participants twice as frequently as sunitinib is given to secondary trial participants which is not accurate based on the provided evidence",
        "label": "Contradiction"
    },
    "a5b66f28-1afc-4cf7-b686-d9de17496983": {
        "text_answer": "Contradiction The evidence does not entail that there were no deaths or hospitalizations in cohort 2 as no information about adverse events in cohort 2 is provided in the evidence",
        "label": "Contradiction"
    },
    "c914522f-a0a8-4154-b1ae-f3df4f684e35": {
        "text_answer": "Contradiction The primary clinical trial does state that patients must be 18 years of age for inclusion",
        "label": "Contradiction"
    },
    "e7ca1067-1d50-4cb2-affc-2d859f9c20cf": {
        "text_answer": "Contradiction The evidence does not state that only patients with healthy eating habits and nutrition are eligible for the primary clinical trial The evidence only mentions that patients must be willing to change their diet as a study intervention",
        "label": "Contradiction"
    },
    "4185140f-e9a6-445f-b512-05428d88f966": {
        "text_answer": "Contradiction  The statement is not related to the evidence provided as the evidence does not indicate the percentage of patients in the primary and secondary trials who were moderate to late preterm infants or suffered from infections specifically in that age group",
        "label": "Contradiction"
    },
    "cafc343b-d72e-4210-b145-42df1a42c28d": {
        "text_answer": "Contradiction The evidence shows that 1429 of patients experienced an adverse event type disease progression that affected more than 25 of the patient group",
        "label": "Contradiction"
    },
    "45240146-8a45-480e-a223-397089b029bb": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not provide any information about the number of participants in the primary trial who suffered from an adverse event AE and the number given in the statement 87 is incorrect The secondary trial had 1674 participants but no information is given about the number of participants who suffered an AE in this trial",
        "label": "Contradiction"
    },
    "f80eceb9-5998-4a62-807b-b9ddff8cd350": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one patient in cohort 1 with a fever Adverse Events 1 but the statement asserts that all infections and fever cases were in cohort 2",
        "label": "Contradiction"
    },
    "a7e702b9-3e27-47ed-bf09-3ce3c3f22b6e": {
        "text_answer": "Contradiction  Explanation The evidence provided does not support the statement as it does not mention the specific recurrencefree survival rates for each group only the number of participants achieving recurrencefree survival The statement makes a direct comparison of the percentage difference in recurrencefree survival rates between the two groups which is not directly stated in the evidence",
        "label": "Contradiction"
    },
    "e908994b-ee46-46a8-b478-5d1c45cf7047": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only mentions adverse events in the primary trial while the statement is about plate reader artifacts",
        "label": "Contradiction"
    },
    "9c076947-5e32-4a14-874b-e4b993f10756": {
        "text_answer": "Contradiction The primary trial reports on the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or maximum feasible dose of MM111 which is not related to the primary trial The statement provides a specific value for the MTD of MM111 but the trials do not directly compare or provide that information",
        "label": "Contradiction"
    },
    "df0874d1-340f-4e10-b7eb-275770f79f6f": {
        "text_answer": "Entailment The evidence explicitly states that women of childbearing potential and sexually active men are excluded from the study",
        "label": "Entailment"
    },
    "a4f1de91-12c1-487c-911d-45099a83a658": {
        "text_answer": "Contradiction The primary trial only includes patients with ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 It does not mention ER negative progesterone negative HER2 negative tumors as a specific group",
        "label": "Contradiction"
    },
    "2a5d71a0-75c6-41d5-bf37-4916c578b0b3": {
        "text_answer": "Contradiction The primary trial does not involve alisertib but rather Botulinum Toxin Type A in one arm and placebo in the other The secondary trial on the other hand involves two different doses of alisertib",
        "label": "Contradiction"
    },
    "c08aa0d8-5505-438c-b53a-934bd2ee570d": {
        "text_answer": "Contradiction The evidence states that there are no results reported for the LBH589 and Lapatinib cohort but the statement implies that the trial does not report any results at all",
        "label": "Contradiction"
    },
    "09cdd94c-145e-4a72-b281-1fad592fdcfd": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports the number of adverse events in two trials and the statement is about a limit switch device",
        "label": "Contradiction"
    },
    "8cf1ca78-50b9-4ab0-a673-3bb384092c0c": {
        "text_answer": "Contradiction The evidence shows that 2 patients experienced 2 adverse events each totaling 4 instances of more than 1 adverse event",
        "label": "Contradiction"
    },
    "5a1bdf90-fb17-47d2-8577-62fafbea13e4": {
        "text_answer": "Contradiction The primary trials inclusion criteria are for breast cancer patients while the statement is about colon cancer patients",
        "label": "Contradiction"
    },
    "f9f9c153-d220-451e-a14d-f19ad7e80cc9": {
        "text_answer": "Contradiction  Explanation The statement suggests a reduction of 01 in the fraction of cells with Ki67 expression after 4 weeks of treatment while the evidence shows a reduction of 5 units from 15 to 10 in the median Ki67 expression at 6 weeks which is 2 weeks beyond the 4week mark The statement does not entail the evidence as it does not accurately reflect the",
        "label": "Contradiction"
    },
    "23a3ae35-9722-40e0-9f6c-c52d41bcd365": {
        "text_answer": "Contradiction  The evidence states that the median PFS for cohort 1 was 16 months 95 CI 10 to 22 which is longer than one month Therefore the statement that no participant in cohort 1 was able to maintain a progression free survival longer than a month is contradictory to the evidence",
        "label": "Contradiction"
    },
    "85a50c0e-0dcf-4bd9-ac4e-179bc6f99067": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as it asserts that ascites was noted more frequently in the primary trial and pneumocystis jirovecii pneumonia was observed more often in the secondary trial but the evidence shows that ascites was observed in 090 of participants in the secondary trial and pneumocystis jirovecii pneumonia was observed in 1111 of participants",
        "label": "Contradiction"
    },
    "4ecc7382-526a-4bf5-9c17-92dc78446ea0": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial includes the following common inclusion criteria age  18 years advanced cancer potentially sensitive to vinorelbine life expectancy of at least three months ECOG performance level 02 or Karnofsky score 10070 and willingness and ability to provide written informed consent  The secondary clinical trial includes the following common inclusion criterion patients",
        "label": "Contradiction"
    },
    "0aa16ecc-2e97-4210-9872-5a0566497343": {
        "text_answer": "Contradiction in the primary trial some cohorts do receive Armodafinil PO daily and in the secondary trial all patients receive a fixed dose of both MCS110 and PDR001",
        "label": "Contradiction"
    },
    "1a11d957-c721-4cee-b540-e3ab8eaad1d0": {
        "text_answer": "Contradiction  The primary trial requires a patient to have a Zubrod performance status of 02 for patients with breast primaries and a life expectancy of at least 20 weeks from the moment of randomization The patient described in the statement has a life expectancy of exceeding 32 weeks which is longer than the minimum requirement for the primary trial However the patients ANC and platelet count do not meet the minimum requirements",
        "label": "Contradiction"
    },
    "1c14ebb0-bff7-4691-8926-1c1b07b4da9a": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no information provided in the evidence regarding the social activity level of the individuals in the trials The evidence only reports the occurrence of adverse events",
        "label": "Contradiction"
    },
    "363631c1-e7d3-41e6-b928-09ce7251cb6e": {
        "text_answer": "Neutral  Explanation The statement does not directly relate to the evidence provided The evidence only mentions the absence of deaths and hospitalizations in cohort 2 and the occurrence of a single case of atrial fibrillation The statement is about anogenital distance which is not mentioned in the evidence",
        "label": "Entailment"
    },
    "907ae179-9823-4dba-9fb7-bb00027dbdf1": {
        "text_answer": "Entailment as there is no evidence of any candidate experiencing an eating disorder in the given adverse events",
        "label": "Entailment"
    },
    "55e1354d-d4b5-4bd0-92e7-9c461f2e2808": {
        "text_answer": "Contradiction The statement candidates for the primary clinical trial must have a confirmed her2 positive tumor as ascertained by ihc 3 and need significant assistance along with regular medical attention is a contradiction to the evidence as the inclusion criteria clearly state that patients must have a confirmed her2 positive tumor but there is no mention of the requirement for significant assistance or regular medical attention",
        "label": "Contradiction"
    },
    "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa": {
        "text_answer": "Neutral  The evidence provided does not explicitly state that the primary clinical trial is open or closed for participation to AfricanAmerican patients Therefore it is neither an entailment nor a contradiction based on the given evidence",
        "label": "Entailment"
    },
    "944bcbb5-e85e-4115-bf71-face27208ab3": {
        "text_answer": "Contradiction  Explanation  The statement within the primary clinical trial no adverse events were indicated and for the secondary trial any adverse outcomes impacted less than 30 of the patients is a contradiction based on the evidence provided  The primary trial reported no adverse events at all while the secondary trial reported several adverse events that affected more than 30 of the patients Therefore the statement",
        "label": "Contradiction"
    },
    "1100945c-51b9-4687-b518-d9b426239583": {
        "text_answer": "Contradiction The primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel",
        "label": "Contradiction"
    },
    "ebdac536-2654-45d4-896f-98875186b971": {
        "text_answer": "Entailment The statement does not contradict the evidence as it correctly states that both cohorts use the same instructional CD but cohort 2 practices paced breathing twice a day",
        "label": "Entailment"
    },
    "3a04553e-529b-4cff-81f5-38e8ec73dd6b": {
        "text_answer": "Contradiction The evidence does not support a definitive conclusion about which cohort produced better results as the statement only mentions Bevacizumab cohort and does not compare it directly to the Bevacizumab  Capecitabine cohort",
        "label": "Contradiction"
    },
    "822bd855-46b1-4290-ac89-f3a92e96f523": {
        "text_answer": "Contradiction  Explanation The evidence provided shows that all participants in the PalbociclibLetrozole Australia Cohort experienced treatmentemergent adverse events which includes both serious and nonserious adverse events However the statement in question specifically mentions at least one serious adverse effect for participants in cohort 1 of a different clinical trial involving MVAbrachyuryTRICOM",
        "label": "Contradiction"
    },
    "458419cf-ea6f-4939-ba2e-856b8d89b985": {
        "text_answer": "Contradiction The secondary trial has no inclusion criteria specified for different study groups while the primary trial does have different inclusion criteria for different study groups",
        "label": "Contradiction"
    },
    "f519491d-1f9b-4527-aaa3-902c2fb181b5": {
        "text_answer": "Contradiction The evidence shows that there were adverse effects reported in both trials so it is not true that most participants experienced no adverse effects",
        "label": "Contradiction"
    },
    "9f978634-637c-472f-a588-6f4bb2fb121f": {
        "text_answer": "Contradiction  Explanation The primary trial does not mention anything about claustrophobia or IBS Irritable Bowel Syndrome as exclusion criteria Therefore the statement that women suffering from both claustrophobia and IBS are not eligible for either the primary or secondary trial is a contradiction to the given evidence",
        "label": "Contradiction"
    },
    "dfc6cbf1-1aa5-4bed-ac39-bbd3a460518b": {
        "text_answer": "Contradiction The evidence states that for females to be eligible for the trial they must have Estrogen Receptor ER positive breast cancer However there is no such requirement mentioned for males",
        "label": "Contradiction"
    },
    "3a8d24f2-6a67-4b23-99a9-5d9b0a54e9c6": {
        "text_answer": "Contradiction The primary trial has a different inclusion criterion related to vitamin D levels and the statement does not account for the different eligibility criteria between the two trials",
        "label": "Contradiction"
    },
    "a1dec8bc-cd32-4f8b-b757-dfd19e8af073": {
        "text_answer": "Contradiction The primary trial and the secondary trial involve different interventions and patient populations and there is no mention of auditory brainstem response wave v in either trial",
        "label": "Contradiction"
    },
    "57a1a667-ac8e-49d3-95f5-26aca0d8bfa6": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it introduces a new concept radiation anemia which is not mentioned in the evidence The statement also incorrectly states that the difference between cohorts 1 and 2 is related to sunitinib and paclitaxel dosages when in fact the statement provided in the evidence is about the administration of sunitinib and paclitaxel in combination with other treatments CT",
        "label": "Contradiction"
    },
    "47e524f0-a370-4845-848a-89fb6b743c96": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the secondary clinical trial showed no reported cases of palpitations pericardial effusions or abdominal pains",
        "label": "Contradiction"
    },
    "0204ab43-d10d-494c-a0be-3b16d96c34fc": {
        "text_answer": "Contradiction The evidence shows that in both trials no adverse events occurred in more than 810 participants",
        "label": "Contradiction"
    },
    "ba020c81-f851-45b9-b1d2-d319f7c97753": {
        "text_answer": "Entailment The statement is an entailment because the evidence clearly states that there are multiple differences between interventions 1 and 2 specifically with regards to the dosing of durvalumab 03 mgkg vs 1 mgkg and the frequency of tremelimumab administration every 4 weeks vs every 12 weeks",
        "label": "Entailment"
    },
    "7aa4c233-3630-4d28-bbd5-4c64fc730a2b": {
        "text_answer": "Contradiction The statement mentions unresectable fibrolamellar carcinoma which is not mentioned in the provided evidence The evidence only discusses breast cancer and axillary lymph nodes",
        "label": "Contradiction"
    },
    "dc41de0b-7f1d-4294-8f3c-c0ba6d2fb4d9": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided",
        "label": "Contradiction"
    },
    "cda1ac5f-5721-4329-bf63-a73ca7247da5": {
        "text_answer": "Contradiction  The patient described in the statement does not meet the eligibility criteria for both trials In the primary trial the minimum ANC requirement is 1800 cellsmm3 and the minimum platelet count requirement is 60000 cellsmm3 In the secondary trial the minimum ANC requirement is 1500μL and the minimum platelet count requirement is ",
        "label": "Contradiction"
    },
    "07c11057-8ae2-4e40-a8d6-464e2399129e": {
        "text_answer": "Contradiction  The statement in the primary clinical trial 5 of the patients faced three or more adverse events is a contradiction to the evidence provided as the evidence states that a total of 5 adverse events occurred in 25 patients with no mention of any patient experiencing three or more adverse events",
        "label": "Contradiction"
    },
    "76ba0bfa-8fd2-45ab-818b-0216aa5d423f": {
        "text_answer": "Contradiction The evidence shows that in both trials all patients experienced zero or one type of adverse event",
        "label": "Contradiction"
    },
    "0f4d6e4c-9315-4cbe-a322-37c6457cf49d": {
        "text_answer": "Contradiction  Explanation  In the primary trial Intervention 1 Zoledronic Acid is given intravenously whereas in the secondary trial all interventions granisetron hydrochloride dexamethasone palonosetron hydrochloride and aprepitant can be taken orally This contradicts the statement that all interventions in the secondary trial are given",
        "label": "Contradiction"
    },
    "4499b316-ac50-4534-a223-2adb144ec7f5": {
        "text_answer": "Contradiction The statement is a contradiction as the primary trial only includes patients with HER2positive breast cancer while the secondary trial includes patients with ERpositive HER2negative breast cancer",
        "label": "Contradiction"
    },
    "bf1cfc9e-1932-4b3f-b935-c71fb36e6716": {
        "text_answer": "Contradiction  The evidence shows that there was only one instance of anaemia in cohort 1 of the primary trial and no instances of febrile neutropenia or pancytopenia were reported",
        "label": "Contradiction"
    },
    "3a1fe062-8a0f-48cb-8830-7624b5445778": {
        "text_answer": "Contradiction The statement is not directly related to the evidence as the evidence only mentions Stomatitis mouth sores and does not mention anything about pain related to movement of a swollen area",
        "label": "Contradiction"
    },
    "19c38d71-5e6c-4944-9337-04d715487a2f": {
        "text_answer": "Contradiction The primary trial had no adverse events while the secondary trial had several adverse events",
        "label": "Contradiction"
    },
    "b24a539a-af29-4a1a-905d-86203ca8c9d4": {
        "text_answer": "Contradiction The statement is incorrect as the secondary trial mentions the use of novel radiotracers 89Zrtrastuzumab and 89Zrpertuzumab which are components of Perjeta but it does not explicitly state that Perjeta is being used in the trial",
        "label": "Contradiction"
    },
    "c6a580f1-9ec3-4d4b-9a34-d12f7d446f61": {
        "text_answer": "Entailment  Explanation The statement the primary clinical trial does not provide any guidance regarding the treatment cycle or describe it in the intervention section is an entailment given that the intervention section of the primary trial only mentions the treatment with partial breast irradiation but not the treatment cycle",
        "label": "Entailment"
    },
    "f4632d0c-6ea3-4638-a2f3-ad5103e28229": {
        "text_answer": "Contradiction The primary trial tests Eribulin Mesylate while the secondary trial tests Axitinib and Docetaxel",
        "label": "Contradiction"
    },
    "8da24578-8dc7-42e5-821a-90f3e361cfdd": {
        "text_answer": "Contradiction  The primary trial excludes women with stage IV disease while the secondary trial includes women who do not have known distant metastatic disease stage IV disease at the time of recruitment",
        "label": "Contradiction"
    },
    "a0ed6cf5-dd1f-4170-ae33-3c1972b62530": {
        "text_answer": "Contradiction  The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH using the units of mIUml while the secondary trial measures the Maximum Tolerated Dose MTD using the units of mg These are different units of measurement",
        "label": "Contradiction"
    },
    "cb6db7a0-1eab-4ac8-9d3c-9b0bf4e123f2": {
        "text_answer": "Contradiction The interventions described in the primary and secondary trials are not the same In the primary trial the intervention is radioembolization using Yttrium90 glass microspheres and TheraSphere In contrast the secondary trial involves the prescription of 560 mg of ibrutinib and 10 mgkg of MEDI4736 which is to be taken twice daily for a duration of a month",
        "label": "Contradiction"
    },
    "9c2adaba-1ac9-4a7c-a710-14ac7d2056fd": {
        "text_answer": "Contradiction The Intervention 1 cohort receives a validated webbased risk assessment as part of their intervention",
        "label": "Contradiction"
    },
    "e244fc3a-53b3-4158-99c5-a45afc726af6": {
        "text_answer": "Contradiction The statement is not an entailment because the secondary trial does not mention anything about celecoxib",
        "label": "Contradiction"
    },
    "7d922494-f6d6-4ade-9614-7111562617f3": {
        "text_answer": "Contradiction The primary trial explicitly excludes alcohol consumers while the secondary trial permits those who consume up to five drinks daily",
        "label": "Contradiction"
    },
    "86e5ab20-18bb-408b-9c3d-92eee2f487d0": {
        "text_answer": "Contradiction The primary trial compares operative time savings between two groups while the secondary trial measures success rate and does not have a control group The two trials address different outcome measures and cannot be directly compared",
        "label": "Contradiction"
    },
    "808a6511-c76d-497c-ad73-037aa5619317": {
        "text_answer": "Contradiction The evidence shows that there was one recorded case of shingles in the secondary trial",
        "label": "Contradiction"
    },
    "3cc54fbb-86c4-44f1-b623-0a613adbc7e8": {
        "text_answer": "Contradiction  Explanation  The statement having multiple cerebral metastases is necessary for admission to the secondary trial however for the primary trial a diagnosis of multiple brain metastases will lead to exclusion is a contradiction because the evidence provided shows that for the primary trial having multiple brain metastases leads to exclusion not admission In contrast the secondary trial does not mention any requirement or exclusion related to",
        "label": "Contradiction"
    },
    "54986ebe-5830-4e3b-9ac1-28241d07e1c8": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided for both trials The evidence for the primary trial does not mention anything about pulmonary embolisms and the evidence for the secondary trial does not mention anything about sustained virologic response or taking part in a trial related to that",
        "label": "Contradiction"
    },
    "34f9be61-9ee8-475e-9b02-72938355d6a5": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy which is not mentioned in the secondary trial The secondary trial only mentions intramuscular injections and oral medication Acute contagious conjunctivitis is not related to the trials",
        "label": "Contradiction"
    },
    "58f42b4f-c8f1-4471-a44b-35ac49604a3b": {
        "text_answer": "Contradiction The primary trial provides the duration in months until disease progression not days The secondary trial provides the proportion of patients experiencing objective response",
        "label": "Contradiction"
    },
    "36cc43dd-5761-49ef-bd9d-35e54dd5a97b": {
        "text_answer": "Contradiction The statement excludes patients who have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 104 weeks before study entry while the evidence allows patients to have been on tamoxifen raloxifene and aromatase inhibitors for the study period as long as they have been on a constant dose for at least 28 days and are not expected to",
        "label": "Contradiction"
    },
    "ea28dc26-75b9-4107-8862-226a46923254": {
        "text_answer": "Contradiction The primary trials Group 2 receives 05ugkg of dexmedetomidine not 15ugkg The secondary trials patients do not receive any dexmedetomidine mentioned in the statement",
        "label": "Contradiction"
    },
    "9b753f6f-9d5d-464a-bc35-c1c0d796fe4d": {
        "text_answer": "Entailment  Both trials report their findings using the same unit of measure which is not explicitly stated in the provided evidence but can be inferred from the context In the primary trial the weekly average hot flash score is reported in units on a scale while in the secondary trial the proportion of responders is reported However the fact that the primary trial reports its findings in a scale does not contradict the statement as the scale used in the primary trial is",
        "label": "Entailment"
    },
    "4e410d4c-7da8-46ce-b335-678bb3199fbc": {
        "text_answer": "Contradiction The evidence states that women of childbearing potential WOCBP must use an acceptable method of birth control to avoid pregnancy during the study period and for 6 months after treatment with bevacizumab This means that fertile individuals are allowed to participate in the trial",
        "label": "Contradiction"
    },
    "3873ed0e-ceb1-45dc-8efc-690a55d908e6": {
        "text_answer": "Contradiction The secondary trial includes women aged 18 or older while the primary trial excludes women under the age of 20",
        "label": "Contradiction"
    },
    "60c313e4-a3f2-4c9d-bef0-104c387a50f5": {
        "text_answer": "Entailment The evidence shows that the mean number of hot flashes per day was lower in the paced respiration group 348 compared to the fast shallow breathing group 395",
        "label": "Entailment"
    },
    "226a30c1-78f8-4747-adb7-1e99973487c1": {
        "text_answer": "Contradiction  Explanation  In the primary trial the treatment under test is Eribulin Mesylate which is given intravenously In contrast the secondary trial involves two interventions Axitinib and Docetaxel Axitinib is an oral tablet and Docetaxel is given intravenously Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "efa3cd46-9230-4078-b024-6de0386bfe80": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because the secondary clinical trial reported one case of Thromboembolic Event which was not reported in the primary clinical trial",
        "label": "Contradiction"
    },
    "7006bd11-9655-4d3e-84a1-6a949fd921e2": {
        "text_answer": "Contradiction The statement the majority of individuals in the primary and secondary clinical trials did not have any negative reactions is a contradiction to the evidence as there were reported adverse events in both trials",
        "label": "Contradiction"
    },
    "4189cb5a-bff9-4867-b9d7-1bd7791723f3": {
        "text_answer": "Entailment The evidence shows that in both trials adverse events were not recorded in more than 048 and 000 of participants in the primary and secondary trials respectively which is less than 10",
        "label": "Entailment"
    },
    "dd153492-5c53-4b8e-b860-71aaba62fa14": {
        "text_answer": "Contradiction The statement in the question goes beyond the evidence as the primary trials intervention section only mentions MM111 without specifying that it is a pharmacological approach",
        "label": "Contradiction"
    },
    "31c480e3-b528-4810-855e-498a019ba253": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The evidence describes the dosages and frequencies of the drugs given to each cohort but it does not mention anything about flatulence or gas Therefore the statement about flatulence or gas is not directly related to the evidence and cannot be determined to be an entailment or contradiction based on the given information",
        "label": "Entailment"
    },
    "d33d29d8-6d96-4f24-af22-2e86e73485d8": {
        "text_answer": "Entailment as there is no evidence provided regarding dyspnea in the given adverse events but it is a common symptom that can be associated with various conditions including heart failure which is reported in the evidence",
        "label": "Entailment"
    },
    "e63ac45b-c34b-4007-820a-30202893fc6f": {
        "text_answer": "Entailment The evidence states that there are 1530 enrollment slots for patients with metastatic colorectal cancer that harbors the Kras or BRAF mutation in the primary trial",
        "label": "Entailment"
    },
    "bf170f0a-6640-4b5c-a130-ae405afb15a7": {
        "text_answer": "Entailment assuming the evidence is related to primary central chondrosarcoma and the ORR data provided is for that specific type of chondrosarcoma",
        "label": "Entailment"
    },
    "bec6f047-5652-4c1a-8aec-8ba989cf4aa4": {
        "text_answer": "Contradiction  Explanation  The secondary clinical trial includes individuals with a diagnosis of breast cancer which can be at any stage as long as they meet other inclusion criteria Therefore individuals with early stage cancer can participate in the secondary clinical trial However the primary clinical trial is specifically designed for individuals with stage IIbIIIIV breast cancer Therefore individuals with early stage cancer are ineligible for the primary clinical trial  Thus",
        "label": "Contradiction"
    },
    "8734ab6c-5b2b-4d9f-958b-9b4f8249a6ef": {
        "text_answer": "Contradiction  Explanation The statement is about the primary tumor diameter which is not mentioned in the evidence The evidence only provides information about the percentage change in betaCTX levels for each group",
        "label": "Contradiction"
    },
    "38791cb5-fc64-49a6-8db8-69da6c37f327": {
        "text_answer": "Contradiction The primary trial measures pain intensity not delayed nausea",
        "label": "Contradiction"
    },
    "f2fea6be-a072-4a75-8092-09acdd07d135": {
        "text_answer": "Contradiction  Explanation The statement in the primary clinical trial both cohorts receive equal doses of cyclophosphamide eribulin and docetaxel is a contradiction to the evidence provided in the primary trial While both cohorts receive cyclophosphamide the dosing and scheduling of eribulin and docetaxel differ between the two interventions Cohort 1 receives er",
        "label": "Contradiction"
    },
    "47f5a5c6-964c-40f8-b7b0-2278333f8fe9": {
        "text_answer": "Entailment Metastatic small cell lung cancer is listed as one of the eligible tumor types in the inclusion criteria",
        "label": "Entailment"
    },
    "53cf056f-91e1-45fb-a65d-7dff9a4b9bac": {
        "text_answer": "Contradiction The statement is incorrect as the primary trial does not indicate that the test group arm 1 outperformed the control group in terms of operative time savings Instead it only provides the operative time data for each group",
        "label": "Contradiction"
    },
    "c1f0b925-6d1f-48ba-ada3-296bd69573f8": {
        "text_answer": "Contradiction  The statement does not follow from the evidence as the evidence does not provide any information about the doses of radioactive Tc99M sulfur colloid used in the primary trial for serum phosphate measurement",
        "label": "Contradiction"
    },
    "4eac1391-d7b7-4124-bafb-fa88bc4d8a02": {
        "text_answer": "Contradiction The primary clinical trial is open only to female patients while the secondary clinical trial includes both male and female patients",
        "label": "Contradiction"
    },
    "11a4324a-684e-4c85-a570-38e6f24ca92b": {
        "text_answer": "Entailment The statement in the primary clinical trial a pathologic complete response in breast and axillary lymph nodes was observed in more than 42 patients across both groups almost 7 months subsequent to their surgical procedures is an entailment of the evidence provided as the evidence shows that there were 16 participants in Arm 1 and 14 participants in Arm 2 who achieved a pCR for a total of 30 participants",
        "label": "Entailment"
    },
    "41cc607f-05e2-4377-bca4-328906e47116": {
        "text_answer": "Contradiction The evidence shows that in both trials no adverse events were reported Therefore the number of adverse events reported did not exceed 100 in either trial",
        "label": "Contradiction"
    },
    "b033d45a-c039-42de-a073-3c051c6f1e3c": {
        "text_answer": "Entailment The statement Over 12 patients in the primary trial treated with Lapatinib 1000 mg  NabPaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR is an entailment of the evidence provided as the evidence states that 53 of participants in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed",
        "label": "Entailment"
    },
    "82d0df12-0e0b-4721-b54f-ecb6bccdc8c3": {
        "text_answer": "Contradiction The primary trial includes all types of female cancer patients while the secondary trial specifically requires BRCApositive breast cancer patients",
        "label": "Contradiction"
    },
    "342026c4-e3de-48c7-8688-e214f5ece431": {
        "text_answer": "Entailment The evidence describes the intervention as treated with partial breast irradiation but it does not specify the treatment regimen or radiation dosages The statement that the intervention segment of the primary clinical trial fails to delineate these details is an accurate description of the evidence",
        "label": "Entailment"
    },
    "0a9675e4-c6cf-44a9-98ed-e50aadfe064a": {
        "text_answer": "Contradiction The statement is not an entailment as the primary and secondary trials measure different outcomes The primary trial measures the impact of sulforaphane supplements on isothiocyanate concentration in urine while the secondary trial measures the efficacy of physical therapy in reducing pain",
        "label": "Contradiction"
    },
    "46959de4-38f3-42a8-adf9-c7565c66b442": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial includes patients with histologically verified stage IIbIIIIV breast cancer while the secondary clinical trial includes patients with a diagnosis of breast cancer who have a life expectancy of at least 1 year However the statement suggests that patients in stage 4 of cancer are eligible for both trials which contradicts the information provided in the evidence  Therefore the statement is a contradiction based",
        "label": "Contradiction"
    },
    "0613b4cb-1e87-48b0-8617-338ebb9ccbe8": {
        "text_answer": "Contradiction The statement is not related to the provided evidence The evidence describes trials with different outcomes and interventions and there is no mention of a terminator device in either trial",
        "label": "Contradiction"
    },
    "8078bf53-15fe-414d-837f-abe03ab9e56d": {
        "text_answer": "Neutral The evidence does not provide enough information to determine entailment or contradiction for the given statement  Explanation The evidence provided does not mention anything about Body Mass Index BMI as an inclusion or exclusion criterion for either the primary or secondary clinical trials Therefore it is not possible to determine if the statement is an entailment or contradiction based on the given evidence alone",
        "label": "Entailment"
    },
    "6d01a773-922b-483a-94b1-f3bda6f2e498": {
        "text_answer": "Contradiction The statement is not supported by the evidence provided as the evidence only reports data on changes in betaCTX levels and does not provide information on primary tumour diameter",
        "label": "Contradiction"
    },
    "fed9960d-b051-4948-840c-91d09c01aafc": {
        "text_answer": "Contradiction The evidence states that a patient with a leptomeningeal carcinomatosis diagnosis is excluded from the primary clinical trial but the statement asks about a patient with a leptomeningeal carcinoma diagnosis which is not the same as leptomeningeal carcinomatosis Leptomeningeal carcinoma refers to the spread of cancer cells to the meninges while leptomeningeal",
        "label": "Contradiction"
    },
    "b39c5d0f-5813-421d-84cf-d78e3c1d3424": {
        "text_answer": "Contradiction  Explanation The statement the majority of participants in the first cohort of the primary clinical trial experienced adverse events while the situation is reversed in the second cohort is a contradiction based on the evidence provided The evidence shows that the percentage of participants with adverse events in the first cohort 4245 is higher than in the second cohort 680 Therefore",
        "label": "Contradiction"
    },
    "5572d454-871c-4458-a2d9-97e7cbb0e03a": {
        "text_answer": "Contradiction The statement is not related to the given evidence as it mentions a bar dosage form which is not mentioned in the provided information for the primary or secondary trials",
        "label": "Contradiction"
    },
    "152fc619-bbb0-40ff-aa3e-5722f62f6a84": {
        "text_answer": "Entailment The statement that patients in cohort 1 and 2 receive the same doses of radiation therapy is true but the statement that intervention for cohort 1 carries on for two weeks longer is also true so the longer duration of intervention for cohort 1 entails the same radiation therapy doses for both cohorts",
        "label": "Entailment"
    },
    "d2e30364-0f79-46c7-8faa-7d7f6751c662": {
        "text_answer": "Contradiction The primary trial only includes postmenopausal females and older males while the secondary trial only includes females",
        "label": "Contradiction"
    },
    "0cecf602-ca3a-4fc4-a52a-135425f42911": {
        "text_answer": "Entailment The evidence states that there were a total of 5 adverse events in the primary trial which means that at least one patient did experience multiple adverse incidents",
        "label": "Entailment"
    },
    "6786fa28-09b7-4bf3-8202-7e810755247e": {
        "text_answer": "Contradiction  Explanation The statement there were no recorded gastrointestinal adverse events in the primary clinical trial is a contradiction to the evidence as there were recorded cases of diarrhea colitis ischaemic and vomiting in both Adverse Events 1 and Adverse Events 2",
        "label": "Contradiction"
    },
    "e244bd1b-7ded-4cc5-a1f2-8afd358338b1": {
        "text_answer": "Irrelevant  The statement is not related to the provided evidence as it is about tuberculous bronchopneumonia which is not mentioned in the evidence",
        "label": "Entailment"
    },
    "c828ba65-0c7b-4aac-b0a7-35ca653b6e82": {
        "text_answer": "Contradiction The primary trial reports on the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or maximum feasible dose of MM111 which is not related to the primary trial The statement provides a specific value for the MTD of MM111 but the trials do not directly compare or provide that information",
        "label": "Contradiction"
    },
    "9562c377-c748-46d7-a5f2-eb492d20e477": {
        "text_answer": "Entailment The evidence does not report any cases of hypertension dehydration or dyspnea in either cohort",
        "label": "Entailment"
    },
    "eebccf7b-8edc-4b99-8355-e936754c1282": {
        "text_answer": "Entailment  Explanation Both trials include the criterion of Women or Patients 18 years of age or older as a common inclusion criterion",
        "label": "Entailment"
    },
    "d579bc9e-ccff-48a6-a296-2d9e8021c765": {
        "text_answer": "Contradiction The statement does not directly relate to the evidence provided",
        "label": "Contradiction"
    },
    "3d6e2ffb-5a89-4f31-9596-65f90e950c5e": {
        "text_answer": "Contradiction The evidence shows that there was one case of shingles in group 2 of the secondary trial but it also shows that there were no cases of shingles in the primary trial or group 1 of the secondary trial The statement however asserts that there were no cases of shingles in both trials and in group 1 of the secondary trial specifically",
        "label": "Contradiction"
    },
    "a38f54f6-d3cb-46aa-b298-cee296e21b3f": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence as breast cancer patients in the primary trial received talazoparib at doses ranging from 600 mcgday to 1100 mcgday which is significantly higher than 1 mgday and ovarianperitoneal cancer patients received talazoparib at doses ranging from 25 mcgday to 1100",
        "label": "Contradiction"
    },
    "c67874fc-c736-4da3-bc73-1e40cbf323c0": {
        "text_answer": "Contradiction  The evidence states that 98 of the patients experienced treatment but it does not provide information about the number of patients who did not experience any adverse events Therefore it is impossible to determine if 57 of the patients did not experience any adverse events based on the given evidence",
        "label": "Contradiction"
    },
    "14afd2b1-9ac2-45fd-96f7-b65862c818a5": {
        "text_answer": "Contradiction The statement does not entail that the intervention in the secondary trial lasts 15 more weeks than the intervention in the primary trial The primary trial intervention lasts for 10 weeks while the secondary trial intervention lasts for 24 weeks which is 14 weeks longer not 15",
        "label": "Contradiction"
    },
    "58c19654-e4cf-4c18-99ef-18b024996fcb": {
        "text_answer": "Entailment The primary trial does not directly measure the percentage of participants with AEPIs but it does assess toxicity using the same criteria as the secondary trial which includes AEPIs Therefore the percentage of participants with AEPIs could be inferred from the primary trial data if it were reported",
        "label": "Entailment"
    },
    "e954d7ec-9ad9-4b01-9ae4-55e29fcbf7f4": {
        "text_answer": "Contradiction  Explanation The statement there was a single psychiatric adverse incident in the primary clinical trial impacting less than 10 of the patients is a contradiction to the evidence because the evidence shows that there were two psychiatric adverse incidents suicidal ideation and unspecified psychiatric disorder in the primary clinical trial and 400 of the patients were affected",
        "label": "Contradiction"
    },
    "57d8844c-d168-41c0-ad0c-6030e4c65905": {
        "text_answer": "Entailment The statement implies a reduction in Ki67 expression and the evidence shows a decrease in Ki67 expression from 15 to 10 in the primary trial",
        "label": "Entailment"
    },
    "b94ebfcb-76f4-4d65-b5e1-ca56249f9f19": {
        "text_answer": "Contradiction  Explanation The evidence states that no participants in the second group experienced severe nausea as indicated by the absence of vomiting and the need for no rescue medication during the first 24 hours after cyclophosphamide administration The statement suggests that more than half of the patients experienced severe nausea which contradicts the evidence",
        "label": "Contradiction"
    },
    "4dcada11-d2e0-453f-aed3-66446ebb4133": {
        "text_answer": "Contradiction  Explanation  In the primary trial Arm 2 provides Armodafinil PO daily but the statement mentions an equal dose of 100 mg PDR001 and 1mgkg of MCS110 which are not the same as Armodafinil  Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "3d9a7121-da16-4e7b-a02d-1932f46cbb77": {
        "text_answer": "Contradiction  The evidence shows that no cases of anemia pneumonia or stupor were reported in the primary trial while the statement asserts that these conditions were more common in the secondary trial Additionally the primary trial reported more cases of febrile infections than the secondary trial which contradicts the statements assertion that more cases were recorded in the secondary trial",
        "label": "Contradiction"
    },
    "429ac312-4d91-4068-9fc3-8bd7b24bc21f": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the evidence states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial",
        "label": "Contradiction"
    },
    "cae6d7c6-1e27-4c94-9428-997ece9e651a": {
        "text_answer": "Contradiction  The statement is about the Bevacizumab cohort having a higher incidence of Disease Progression or Death compared to the Bevacizumab  Capecitabine cohort but the evidence provided shows the opposite with the Bevacizumab  Capecitabine cohort having a higher percentage of participants with Disease Progression or Death 758 compared to the Bevacizum",
        "label": "Contradiction"
    },
    "c0c1a75a-a859-477d-bc80-3aac565c6a5b": {
        "text_answer": "Contradiction The primary trial did not report any cases of acute myocardial infarction",
        "label": "Contradiction"
    },
    "ad5ca7e8-3e5d-43b8-9618-99f56fc70290": {
        "text_answer": "Entailment assuming that cardiac or psychiatric AEs refers to the same types of adverse events as in the evidence provided for Adverse Events 1 and 2",
        "label": "Entailment"
    },
    "8ca66388-46d0-4a5f-9be8-84d35961c823": {
        "text_answer": "Contradiction The statement is about participants with PR Primary Breast Cancer but the evidence provided is about participants with HER2 primary breast cancer",
        "label": "Contradiction"
    },
    "3e0a4b38-bafb-4a0e-a1be-8506f23aa1f6": {
        "text_answer": "Contradiction The primary trial shows a higher percentage of patients reporting palpitations pericardial effusions and abdominal pains compared to the secondary trial not a decreased percentage as stated in the statement",
        "label": "Contradiction"
    },
    "b068596b-94a7-42fe-a926-d1c3c62ea26b": {
        "text_answer": "Entailment  Explanation  The statement the outcome measurements for the primary clinical trial and the secondary clinical trial are entirely distinct is an entailment given the evidence provided Although the interventions in both trials are identical both involve the use of SG or talazoparib the outcome measurements are different In the primary trial the outcome measurements are the percentage of participants experiencing any treatmentemergent adverse events and serious treatmentem",
        "label": "Entailment"
    },
    "5e14d0f3-e63e-40e8-93cc-a07c90c226d6": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as diffuse laminar endocervical hyperplasia is not a type of solid tumor and is not mentioned in the inclusion criteria for the secondary trial Additionally the statement requires a diagnosis of a mutation in one of the listed genes which is not a requirement for the primary trial but is a requirement for the secondary trial",
        "label": "Contradiction"
    },
    "8dac6b6a-0e3d-4a3c-ac59-5096452207de": {
        "text_answer": "Neutral The evidence does not directly address the statement as the statement mentions the inferior hypophyseal artery which is not related to the outcome measurement in the evidence",
        "label": "Entailment"
    },
    "f6ce8f5f-f226-4435-9209-9bf54ac7cbaa": {
        "text_answer": "Contradiction  The evidence shows a decrease in Ki67 expression at 6 weeks compared to baseline not an increase as stated in the question",
        "label": "Contradiction"
    },
    "2e35f870-1118-4c57-be71-a1b17e6841e3": {
        "text_answer": "Contradiction based on the given evidence there is no common adverse event between the two trials",
        "label": "Contradiction"
    },
    "6e02fc64-787b-47e7-a9d6-173b101baf71": {
        "text_answer": "Contradiction The primary trial explicitly excludes participants who have undergone major surgery within 28 days prior to the study registration date while the secondary trial does not mention any such exclusion However the secondary trial does mention that patients with severe heart disease including myocardial ischemia and myocardial infarction are excluded which could potentially include patients who are bedridden due to these conditions",
        "label": "Contradiction"
    },
    "1692f569-44d0-4b60-aabe-87dc3f7d3513": {
        "text_answer": "Contradiction  The primary trial does not provide information on the dose of Herceptin trastuzumab or Doxorubicin used The statement makes assumptions about the doses based on the secondary trial which is not supported by the evidence from the primary trial",
        "label": "Contradiction"
    },
    "3c2994b1-74be-4fe4-9262-00a5a8e42caa": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the minimum PFS for patients in cohort 1 was 16 months which is longer than a week",
        "label": "Contradiction"
    },
    "83457ad0-4ebe-4bd7-abf7-bf629af15e58": {
        "text_answer": "Entailment Both cohorts indeed take Enzalutamide orally as per the evidence provided",
        "label": "Entailment"
    },
    "40d65677-e7f3-46f8-801a-327c8422937b": {
        "text_answer": "Contradiction The evidence shows that only one patient 200 experienced suicidal ideation which is a type of psychiatric adverse event and that is not enough to constitute over half of the patients in the trial",
        "label": "Contradiction"
    },
    "6e1c74e3-1b7b-41bf-8ee4-f605d94c0fdf": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence provided because the evidence does not support the statement that the secondary trial has higher incidents of biliary colic and clostridium difficile colitis compared to the primary trial In fact the evidence shows that neither biliary colic nor clostridium difficile colitis were reported in the secondary trial while they were reported in the primary trial 1 case each",
        "label": "Contradiction"
    },
    "0a0778f4-c085-45fe-a085-e079256d634b": {
        "text_answer": "Contradiction The evidence shows that no adverse events were recorded in both trials The statement however asserts that multiple adverse events were recorded in the primary clinical trial",
        "label": "Contradiction"
    },
    "ea01b3dd-11a6-4e00-aada-a31c2fc4a5dc": {
        "text_answer": "Entailment assuming that the statement refers to the intervention section of the primary trial for both cohorts and not just cohort 1",
        "label": "Entailment"
    },
    "40818dd2-4940-4543-905a-35a3295b3009": {
        "text_answer": "Contradiction The statement does not follow logically from the evidence provided The evidence only compares the doses of ALT801 administered to cohort 1 and cohort 2 and there is no information given about the amount of ALT801 administered to any part of the body including the external canal",
        "label": "Contradiction"
    },
    "a62e526a-07c6-472a-acff-891375dd7fb0": {
        "text_answer": "Contradiction The statement makes an assumption about the secondary trial that is not supported by the evidence which only reports the success rate of a specific intervention The primary and secondary trials measure different outcomes and cannot be directly compared based on the given evidence",
        "label": "Contradiction"
    },
    "03fe8107-b0ab-470e-9d1e-a085808ec397": {
        "text_answer": "Contradiction  Explanation The evidence shows that cognitive function changed in both the Tamoxifen and Ovarian Function Suppression groups with the Ovarian Function Suppression group having a slightly more negative mean standardized score compared to the Tamoxifen group Therefore the statement that cognitive function remained stable in all participants throughout the trial is contradicted by the evidence",
        "label": "Contradiction"
    },
    "8953caa7-492f-4fbb-b5a6-5cff95a5650c": {
        "text_answer": "Contradiction The statement mentions the rising from floor functional test which is not reported in the evidence for the LBH589 and Lapatinib cohort",
        "label": "Contradiction"
    },
    "5599d5d8-3a7b-41ce-a00c-6e0b609b618d": {
        "text_answer": "Contradiction The evidence provided indicates that no participants in Cohort 1 experienced a lifethreatening adverse event",
        "label": "Contradiction"
    },
    "05990a1c-be55-4aa4-8e72-970d95776c8a": {
        "text_answer": "Contradiction  The statement the percentage of cells with ki67 expression in patients participating in the primary clinical trial was found to have remained the same is a contradiction to the evidence which shows a decrease in median Ki67 expression from 15 1025 at baseline to 10 238 at 6 weeks",
        "label": "Contradiction"
    },
    "b0eb1f5f-d996-4846-9b4e-12dd88120752": {
        "text_answer": "Contradiction The evidence mentions several adverse events that affected more than 909 of patients eg febrile neutropenia sepsis and lymphocyte count decreased",
        "label": "Contradiction"
    },
    "37c579a2-134b-4ee4-8a9e-e550c2155a16": {
        "text_answer": "Entailment The statement 3 or more adverse events occurred in 5 patients is an entailment of the evidence since there were a total of 5 patients with a combined total of 5 adverse events as stated in the evidence",
        "label": "Entailment"
    },
    "7bbbfeb0-c4f2-4295-ae6c-3adbf6dc06ad": {
        "text_answer": "Entailment The statement more than a third of their patients achieving pathologic complete response in breast and axillary lymph nodes approximately seven months into the investigation is an entailment of the evidence provided as both cohorts in the primary clinical trial had more than 33 of their participants achieving pathologic complete response in breast and axillary lymph nodes and the time frame of approximately seven months aligns with the time of surgery",
        "label": "Entailment"
    },
    "20b34e62-97c2-4ca0-bb1d-7824dab0b8bb": {
        "text_answer": "Contradiction The primary trials inclusion and exclusion criteria do include conditions related to mental health bodyweight size of tumors KarnofskyECOG score and estimated life expectancy",
        "label": "Contradiction"
    },
    "3f5f182d-77ba-423c-8f5b-02ca3ada57c2": {
        "text_answer": "Contradiction  Explanation The statement in the primary clinical trial adverse events like recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage were reported more often than in the secondary clinical trial is a contradiction to the evidence provided because the evidence shows that none of those adverse events were reported in the secondary trial at all",
        "label": "Contradiction"
    },
    "bb12ebcd-127e-4834-b0f3-9759ed13c5ed": {
        "text_answer": "Contradiction The primary trial measures changes in pain intensity while the secondary trial measures changes in bone mineral density These are different outcomes and are not directly comparable",
        "label": "Contradiction"
    },
    "35aa67ad-b884-4cec-afdf-bef9cb6619c4": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of a single injection on day 8 in the evidence",
        "label": "Contradiction"
    },
    "6c41e8b2-2878-44b1-bf2d-6158d8f20dda": {
        "text_answer": "Contradiction  The statement assumes that both cohorts receive the same dosage and frequency of CUDC101 administration but the evidence shows that the frequency of CUDC101 administration is different between the two cohorts 5 daysweek for cohort 1 and 3 daysweek for cohort 2",
        "label": "Contradiction"
    },
    "1938e58d-a90f-48c4-ac79-59da3de8017c": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the trials involve different patient populations and treatment regimens In the primary trial patients with metastatic breast cancer receive Trastuzumab while in the secondary trial Herceptin is administered to patients with HER2positive breast cancer The dosages mentioned in the statement may be the same but the contexts are different",
        "label": "Contradiction"
    },
    "f73b494f-624c-487a-b502-f2cbc7ab0475": {
        "text_answer": "Contradiction The statement is incorrect because the primary trials Intervention 2 involves the administration of dexmedetomidine not a 05ugkg regimen for myalgias",
        "label": "Contradiction"
    },
    "97d3ebc2-fda1-4b0b-b7b2-583edca5be69": {
        "text_answer": "Entailment for the 9 participants in the Highdose Chemotherapy group",
        "label": "Entailment"
    },
    "31d67714-a5c1-494f-820e-d47f52480eaf": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "98b0e244-cb54-4d99-9384-b7e5e7d43550": {
        "text_answer": "Contradiction  Explanation The statement there were no placebo groups involved in the primary trial is contradictory to the evidence which states that there was indeed a placebo group in the primary trial Arm II The statement is also incorrect in its assertion that the secondary trial consisted of three separate test groups when in fact it had two test groups Highdose and Lowdose Oxybutynin Chloride",
        "label": "Contradiction"
    },
    "f024fdc1-bee8-4ad8-a80d-9369d52b799a": {
        "text_answer": "Contradiction The statement is not based on the evidence provided as the evidence only reports the change in lean body mass at 4 months and does not provide information about the 100mg dose or the 9 month period",
        "label": "Contradiction"
    },
    "9ee19b4a-bcdb-4676-b852-ee3fbb4352b0": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence shows that the primary clinical trial involves two different medications bisphosphonate and denosumab which are administered through different routes IV for bisphosphonate and subcutaneous for denosumab",
        "label": "Contradiction"
    },
    "589622f2-6c3b-4e63-ad71-5d8c90cb3413": {
        "text_answer": "Contradiction The statement is false given the evidence as the primary trial does contain recorded side effects even if none are mentioned in the provided excerpt",
        "label": "Contradiction"
    },
    "b0af496d-fead-41b6-96fd-71dea81c8501": {
        "text_answer": "Contradiction The evidence from both trials shows that there were no adverse events reported in the primary trial while the secondary trial had some adverse events reported in Adverse Events 2 Therefore the statement that there were fewer adverse reactions in the primary trial is not supported by the evidence",
        "label": "Contradiction"
    },
    "0fbbd866-ae4c-458c-8bb4-fe8bb8ee9471": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the number of treatment days is not identical between the two cohorts Cohort 1 receives radiation therapy for approximately 34 weeks 21 days while cohort 2 receives radiation therapy for approximately 45 weeks 2327 days",
        "label": "Contradiction"
    },
    "7794c718-f5f9-45a3-b427-9c7b79b261ee": {
        "text_answer": "Entailment  Explanation Both the primary and secondary trials measure the occurrence of adverse events in the primary trial and objective response in the secondary trial The primary trial measures the percentage of participants with any treatmentemergent adverse events and serious treatmentemergent adverse events while the secondary trial measures the number of participants with objective response However the identical outcome measurements refer to the fact that both trials assess the occurrence of adverse",
        "label": "Entailment"
    },
    "8084d30e-d99a-4b02-88e2-dd8194ef538f": {
        "text_answer": "Entailment The evidence shows that fewer than half of the participants in both trials experienced adverse incidents which is consistent with the statement that few participants experienced such incidents",
        "label": "Entailment"
    },
    "fccfea25-6459-4cf9-a9cd-eaf2b81428e4": {
        "text_answer": "Contradiction The primary trial includes patients with potassium within the normal range but it does not specifically state that only those with perfect potassium balance are included The secondary trial does not mention potassium balance at all",
        "label": "Contradiction"
    },
    "7d712178-7e9c-48f5-8248-432ff3a50f62": {
        "text_answer": "Contradiction The primary trial does not mention the administration of docetaxel and gemcitabine",
        "label": "Contradiction"
    },
    "073d8ed7-d1ff-4fb7-bc5f-b33397ad6b6c": {
        "text_answer": "Entailment Both trials report their results using percentage in the primary trial and number of participants in the secondary trial Percentage can be converted to a number of participants if the total number is known",
        "label": "Entailment"
    },
    "79d98227-bc8b-4d97-b264-9737e368030f": {
        "text_answer": "Contradiction The primary trial does not report any Thromboembolic events in its adverse events data",
        "label": "Contradiction"
    },
    "e3caa52b-259d-498a-926b-fbfd15eb1bc6": {
        "text_answer": "Contradiction  Explanation The evidence provided states that 98 of the patients experienced the outcome measurement Recurrencefree Survival with a range of 922 to 995 However the statement is about the absence of any adverse events which is a different outcome measurement The evidence does not provide information about the number or percentage of patients who did not experience any adverse events",
        "label": "Contradiction"
    },
    "2d36fa83-b68c-420e-873f-e69374d0741f": {
        "text_answer": "Entailment  Explanation  The statement the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1 and the primary trial intervention lasts for a longer period of time is an entailment based on the evidence provided  The primary trial uses Lenalidomide at a dose of 5mg orally daily for 57  3 days while",
        "label": "Entailment"
    },
    "7c7842f8-26c8-4b9f-8bb1-64f846e5e81e": {
        "text_answer": "Contradiction  Explanation The primary trial and the secondary trial are not directly comparable as they investigate different treatment modalities despite having similar doses and outcome metrics The primary trial focuses on the impact of a single therapeutic agent empegfilgrastim on the duration of neutropenia while the secondary trial investigates the incidence of CTCAE grade 34 neutropenia with different doses of empegfil",
        "label": "Contradiction"
    },
    "333c097e-628c-4240-aa00-f9621fbbabe1": {
        "text_answer": "Contradiction  Explanation The statement provides new information not present in the evidence The evidence only states the number of participants who achieved Recurrencefree Survival in each group but it does not mention the specific ADCSADL study or the number of participants in each group who used the other specify appliance for Alzheimers disease Therefore the statement cannot be determined to be an entailment or contradiction based on the",
        "label": "Contradiction"
    },
    "d54a3e9d-5602-4cc3-934e-717f1da39792": {
        "text_answer": "Entailment The primary trial measures changes in pain intensity while the secondary trial measures changes in bone mineral density but both trials involve the measurement of changes from a baseline at specific time points",
        "label": "Entailment"
    },
    "87c2f042-077b-4d49-80b0-1603a137520f": {
        "text_answer": "Contradiction The statement mentions specific adverse events Mucositis Oral Bladder Infection and Thromboembolic events that are not mentioned in the evidence from either trial",
        "label": "Contradiction"
    },
    "2ce0822a-fcf8-4010-950c-0d3a8dc2cb00": {
        "text_answer": "Entailment The primary trial explicitly lists these allergies as exclusion criteria and the secondary trial also includes them as exclusion criteria Therefore if a patient has an allergy to any of these medications they would be ineligible for both trials",
        "label": "Entailment"
    },
    "5be4dfce-9123-4a08-9397-a2f4d95e8209": {
        "text_answer": "Contradiction  Explanation The evidence provided in the primary trials inclusion and exclusion criteria states that there are conditions related to mental health bodyweight age KarnofskyECOG score and previous treatments that need to be met in order to be eligible for the trial Therefore the statement that there are no conditions on mental mental health bodyweight age KarnofskyECOG score or previous treatments that need",
        "label": "Contradiction"
    },
    "0f90b547-3d71-417f-ba02-deb31f70e5da": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence provided in the primary trial description indicates that the doses of Abraxane nabPaclitaxel and Carboplatin are different between the two cohorts In Arm A participants received nabPaclitaxel 125 mgm2 and carboplatin AUC 2 while in Arm B participants",
        "label": "Contradiction"
    },
    "75961bc5-20b9-4161-83e0-a59429ce18e9": {
        "text_answer": "Contradiction  Explanation The evidence states that no episodes of vomiting and no rescue medication were reported during the first 24 hours after cyclophosphamide administration for all participants in the ArmGroup titled Aprepitant Dexamethasone Cytoxan  Kytril Therefore over 50 of patients in this group did not suffer from acute vomiting after treatment",
        "label": "Contradiction"
    },
    "e02cca6f-2a41-4a5a-bf83-23cdab6ee8dd": {
        "text_answer": "Contradiction The statement is not an entailment as there is no fever reported in cohort 2 but there is a reported case of Gramnegative bacteremia with a fever in cohort 1",
        "label": "Contradiction"
    },
    "b20cbb69-8909-4a66-b47c-27192604d187": {
        "text_answer": "Contradiction The primary trial results do not provide enough information to make a definitive statement about which intervention provides the best overall response rate as the statement only mentions Arm A The secondary trial results do not relate to the primary trial and only compare the time to first onstudy skeletalrelated event between Denosumab and Zoledronic Acid",
        "label": "Contradiction"
    },
    "738a5b84-f8e8-411b-9376-377760780e01": {
        "text_answer": "Contradiction   Explanation   The primary trial does include massage therapy which is a nondrug based intervention but it also mentions pain therapy which can be a drugbased intervention Therefore the statement is a contradiction to the evidence presented",
        "label": "Contradiction"
    },
    "658e195d-21fc-4bf0-af37-a523ba772f83": {
        "text_answer": "Contradiction  Explanation The primary trial involves the administration of denosumab a medication while the secondary trial involves the administration of radioactive Tc99M sulfur colloid a different substance The two interventions are not equivalent and the statement is a contradiction",
        "label": "Contradiction"
    },
    "edfe9572-6cff-4ecb-b34b-19ac297352d7": {
        "text_answer": "Contradiction  Explanation  The primary trial focuses on the maximum tolerated dose MTD of Ruxolitinib in combination with paclitaxel while the secondary trial focuses on the Maximum Tolerated Dose MTD or Maximum Feasible Dose of MM111 The statement provided specifies that for patients in the secondary clinical trial the MTD of mm111 is ",
        "label": "Contradiction"
    },
    "d4f76af1-2a9e-488a-b871-4b489dea5c02": {
        "text_answer": "Contradiction The secondary trial mentions correlative studies which could include analysis of ki67 expression",
        "label": "Contradiction"
    },
    "d6f7d14f-dbc6-4268-be40-1a09facf0834": {
        "text_answer": "Irrelevant The statement has no bearing on the provided evidence",
        "label": "Contradiction"
    },
    "4a5400b8-bf7e-40f2-857f-169a7ad3b89f": {
        "text_answer": "Contradiction The statement is not related to the given evidence The evidence only mentions the inclusion and exclusion criteria for the primary trial and there is no mention of ganglions or nervous tissue",
        "label": "Contradiction"
    },
    "9f855b3e-81b0-47a6-af48-b437e0409d77": {
        "text_answer": "Contradiction The statement does not entail the evidence provided as the trials do not involve touchscreens and the outcome measurements and results are not directly comparable",
        "label": "Contradiction"
    },
    "6906ff3e-0e8c-4332-987d-47816bc462ba": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it introduces a new concept cough frequency that is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "2787f3da-ad73-483d-98b8-a82acec6e5fc": {
        "text_answer": "Contradiction The evidence shows that some patients in the primary trial do receive PDR001 in addition to MCS110 and the statement specifies that no PDR001 is given",
        "label": "Contradiction"
    },
    "97552293-cd61-42c5-95c2-dc98b795f9d5": {
        "text_answer": "Neutral  Explanation The statement does not directly relate to the evidence provided The evidence only mentions the types of cohorts in the primary trial and does not provide any information about invasive surgery or Neratinib being administered or not The statement is about the frequency of something occurring between 75 and 94 percent of the time which is not mentioned in the evidence",
        "label": "Entailment"
    },
    "8549720f-df44-400f-aeb0-98150d2f23b1": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there were no cases of Infection Asymmetry or Deflation reported in the secondary trial and the evidence does not indicate that there were more cases in the primary trial",
        "label": "Contradiction"
    },
    "963f60a5-2446-42f3-9c05-20ef38528d1a": {
        "text_answer": "Entailment The evidence shows that 24 out of 25 patients had adverse events and 11 out of 25 patients had serious adverse events which is less than 50 of the total number of patients Therefore the statement that all patients barring one treated with sunitinib  docetaxel  trastuzumab in the primary clinical trial underwent an adverse event emerging from treatment while",
        "label": "Entailment"
    },
    "6e6cecbf-ea24-4cf8-83f5-5fd627941028": {
        "text_answer": "Entailment  Explanation The primary trials Intervention 1 involves zoledronic acid which is given intravenously The secondary trials Intervention 1 in both arms II and III includes granisetron hydrochloride dexamethasone and placebo which can be given intravenously and aprepitant and palonosetron hydrochloride which can be given intr",
        "label": "Entailment"
    },
    "847ce4e8-b2df-4acb-b46c-c82baa519124": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that there were no adverse events recorded in both the primary and secondary trials which contradicts the statement that the secondary trial demonstrated a number of adverse events",
        "label": "Contradiction"
    },
    "066d1275-7efd-47d6-aba2-96bc464cbe2f": {
        "text_answer": "Contradiction  The evidence shows that there were 5 participants in the placebo group who experienced emesis during the study period",
        "label": "Contradiction"
    },
    "086c9c1a-de79-47f1-b75d-32c7a16716ef": {
        "text_answer": "Contradiction  Explanation The primary clinical trial includes patients with histologically verified stage IIbIIIIV breast cancer while the secondary clinical trial includes patients with a diagnosis of breast cancer that can be made by fineneedle aspiration FNA core or trucut biopsy and a mass on clinical or radiological examination of 1 cm However there is no mention of stage I cancer being eligible for either trial",
        "label": "Contradiction"
    },
    "e35505c9-4340-4f19-8756-925d96d65b44": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as patients with nonhealing surgical wounds are excluded from the primary trial but there is no mention of this exclusion criterion in the secondary trial Additionally the statement incorrectly states that patients with stable angina and grade 1 neuropathy are excluded from the primary trial but the evidence shows that these conditions are not exclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "15b22917-3649-44bd-b7f0-9aa5a6beba6b": {
        "text_answer": "Contradiction The evidence mentions nothing about the use of fentanyl sublingual spray in the primary clinical trial",
        "label": "Contradiction"
    },
    "12d86841-a682-4de8-80ab-90cae0b8c124": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided as there is no mention of placental neoplasms or shingles in the evidence",
        "label": "Contradiction"
    },
    "a930aad6-c334-4a8a-8547-3a07e44afe8b": {
        "text_answer": "Contradiction The evidence states that patients with a history of abdominal fistula or gastrointestinal perforation in the past 6 months are excluded from the trial",
        "label": "Contradiction"
    },
    "5e3d1ff7-52f0-4ac5-a9e0-63536903cf84": {
        "text_answer": "Contradiction The evidence does not provide any information about eligibility based on race or residence",
        "label": "Contradiction"
    },
    "4fec37ef-6e27-4b07-a0ba-d35434fe2d36": {
        "text_answer": "Contradiction The statement that having a history of pulmonary embolism in the recent 60 days does not disqualify a patient from the primary clinical trial is not an entailment but a contradiction to the exclusion criteria of the secondary clinical trial which states that any other hemorrhagebleeding event NCI CTCAE v30 Grade 3 within 4 weeks of first dose of study drug or any th",
        "label": "Contradiction"
    },
    "c7a78221-6f3c-484f-a281-908ab30a7e31": {
        "text_answer": "Contradiction The evidence provided does not relate to pyometra or the comparison of emesis between aprepitant and placebo in relation to pyometra The evidence only relates to the comparison of the number of emesisfree participants during the study period for aprepitant and placebo in the context of controlling nausea and vomiting during conditioning therapy for autologous or allogeneic hematopoietic stem cell transplantation",
        "label": "Contradiction"
    },
    "b3679900-ab99-4a84-83e0-fc1122a43beb": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial excludes patients who have undergone antineoplastic chemotherapy androgens or estrogens within 4 weeks prior to study entry but the statement specifically mentions only the month before study entry The evidence allows for the use of aromatase inhibitors and selective estrogen receptor modulators if the patient has been on a constant dose for at least 28",
        "label": "Contradiction"
    },
    "24cca94e-b0db-4015-acc3-061bce8ea0ea": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The evidence provided in the statement does not mention Febrile neutropenia or Cholelithiasis so it cannot be determined if the statement is an entailment or contradiction based on the evidence alone The statement is about curie extension scores and does not relate to the adverse events mentioned in the evidence",
        "label": "Entailment"
    },
    "de2a7e0a-2046-4502-a23e-38d0753b43ec": {
        "text_answer": "Contradiction The statement does not entail that all patients receive at least 20mg of MCS110 every 3 weeks based on the evidence provided as some patients receive 1mgkg and others receive 3mgkg",
        "label": "Contradiction"
    },
    "0dc19d61-83e4-4b27-9d03-c485f30fe9f6": {
        "text_answer": "Contradiction The evidence shows that 833 of participants in the Ketorolac 30 mg group achieved Recurrencefree Survival while 897 of participants in the NaCl 09 3ml group achieved Recurrencefree Survival These percentages are not the same indicating a significant difference The statement that there was no significant difference is a contradiction to the",
        "label": "Contradiction"
    },
    "ad4f2e14-4f6a-473d-bc6a-225e2f34159b": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided",
        "label": "Contradiction"
    },
    "8e698117-fcf5-480f-80a0-95a3be887ef8": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the use of Triptorelin and Letrozol not cyclophosphamide droperidol and epoetin beta as stated in the question  The secondary trial involves the use of Zoledronic Acid and Letrozole or Zoledronic Acid vitamin D calcium supplements and either Sr89 or Sm1",
        "label": "Contradiction"
    },
    "9069ac6d-9d0f-4484-adda-bde33d713b7e": {
        "text_answer": "Contradiction The evidence does not entail that all patients receive at least 20mg of MCS110 every 3 weeks as the given dosages are 1mgkg and 3mgkg",
        "label": "Contradiction"
    },
    "ed92e41d-f81d-462e-9081-c293fb816163": {
        "text_answer": "Contradiction The primary trial and the secondary trial involve different patient cohorts and different interventions",
        "label": "Contradiction"
    },
    "9f3b9559-fe63-4698-b886-fe76ecab9784": {
        "text_answer": "Contradiction  The statement implies a difference of 0035 mg between the doses given to each cohort while the evidence shows that the doses differ by 0025 mg",
        "label": "Contradiction"
    },
    "0997d5fe-8df2-4b29-983a-3d3d2921e320": {
        "text_answer": "Contradiction  Explanation  The statement all of the participants in group 1 of the primary trial were found to have lesions and less than 5 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation is a contradiction based on the provided evidence  In the primary trial there were no lesions detected in the group of healthy volunteers In contrast in the secondary",
        "label": "Contradiction"
    },
    "d1125c05-e0b3-4d7b-951e-cd21b5038b0b": {
        "text_answer": "Contradiction The primary trial eligibility criteria do not mention anything about anorexic patients or galectin3 antibodies",
        "label": "Contradiction"
    },
    "0c9bef83-0974-4de4-aaa9-2f109fe16d0d": {
        "text_answer": "Contradiction  Explanation The evidence shows a median decrease in Ki67 expression from 15 to 10 at 6 weeks which contradicts the statement that there was no observed change in the percentage of cells with Ki67 expression following the application of TAK228 plus tamoxifen treatment",
        "label": "Contradiction"
    },
    "f5b27b4f-8fe1-4cc8-a4d6-aa1459797496": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the primary trial intervention consists of a single drug Gefitinib ZD1839 while the secondary trial intervention for Intervention 1 consists of Zoledronic Acid vitamin D and calcium supplements which is more than one drug",
        "label": "Contradiction"
    },
    "270255e6-c423-4fff-a2aa-78c3c8ef2a8e": {
        "text_answer": "Contradiction The statement does not entail the evidence as the primary trials intervention is administered IV while the secondary trials interventions can be administered orally The statement does not make any mention of the route of administration for the interventions causing abdominal discomfort",
        "label": "Contradiction"
    },
    "ee74c3c1-33c4-4b0a-81bf-a2ed3ec7e161": {
        "text_answer": "Neutral  The statement does not directly entail or contradict the evidence provided The evidence describes the differences in dosing between the two interventions but it does not mention anything about trabecular meshwork proliferation",
        "label": "Entailment"
    },
    "0fb60a4c-16d6-4517-a201-e16f78fd6dae": {
        "text_answer": "Contradiction  Explanation  The statement the diagnosis of either fibromyalgia thalasemic syndromes or anemia does not obstruct the eligibility of cancer patients for the primary clinical trial and the secondary clinical trial is a contradiction based on the provided evidence  The primary clinical trial excludes participants with a diagnosis of anemia only due to irondeficiency and thalasemic syndromes",
        "label": "Contradiction"
    },
    "57dae782-9901-446f-93d1-047097623f45": {
        "text_answer": "Entailment The statement does not contradict the inclusion criteria as IGF1R immunohistochemical expression is not listed as a specific inclusion criterion but it does not exclude patients from being eligible for the trial based on the evidence provided",
        "label": "Entailment"
    },
    "70d946f2-0c4a-4a00-8090-b0b55dda7b2b": {
        "text_answer": "Contradiction The statement patients with metastatic scbc irrespective of their er or pr status can participate in the primary clinical trial is contradictory to the evidence as the primary trial specifically includes patients with nonsmall cell lung cancer NSCLC head and neck cancer urothelial transitional cell carcinoma and breast cancer whose disease has progressed after at least one line of standard therapy The statement does not mention",
        "label": "Contradiction"
    },
    "c802c0a9-737c-4b94-89c6-e4327a1925dd": {
        "text_answer": "Contradiction  Explanation In the primary trial the intervention consists of a single drug Gefitinib ZD1839 In contrast the secondary trial has two interventions one is Zoledronic Acid alone and the other is Zoledronic Acid plus Radiopharmaceuticals Sr89 or Sm153 Although both trials involve Zoledronic Acid the secondary",
        "label": "Contradiction"
    },
    "66ff33e2-be79-4e47-a3f9-68a57f5f377b": {
        "text_answer": "Contradiction The statement mentions denosumab injections in the primary trial while the secondary trial does not involve denosumab injections but instead uses Lymphoscintigraphy",
        "label": "Contradiction"
    },
    "c12d4dba-17b9-45d6-9a3f-75be190b7795": {
        "text_answer": "Contradiction The evidence shows that no adverse events were recorded in both trials for the given data provided The statement however asserts that the same number of adverse events were recorded which is not the case based on the evidence",
        "label": "Contradiction"
    },
    "6579100b-45dc-4669-86ec-a3f8ac521c23": {
        "text_answer": "Contradiction The evidence shows that in both trials no adverse events occurred in more than 25 of participants",
        "label": "Contradiction"
    },
    "b308b4a7-f3e9-49aa-a84e-8842da7caacf": {
        "text_answer": "Contradiction The evidence shows that one patient in each cohort experienced pyrexia which is a form of febrile neutropenia",
        "label": "Contradiction"
    },
    "256cd40a-7afc-401d-9d02-c013ee3ee68d": {
        "text_answer": "Contradiction The evidence does not mention anything about obligatory fitness routines being a part of the intervention in the primary clinical trial",
        "label": "Contradiction"
    },
    "fadac52b-d98b-4511-858e-a7bfb0dda0c0": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses the type of intervention used in the primary trial while the statement discusses a completely unrelated topic which is a cardiovascular abnormality",
        "label": "Contradiction"
    },
    "2a56e9e0-10fe-4a2d-964a-71390b3bb4d4": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as gender is a determining factor for eligibility in both the primary and secondary trials",
        "label": "Contradiction"
    },
    "d16f252e-5df6-4e09-8a24-9c56b4b8e16b": {
        "text_answer": "Contradiction  The statement is incorrect because the evidence provided does not support the comparison of the percentage change in betaCTX between the AZD0530 175 mg and Zoledronic Acid 4 mg groups at Week 4 months The evidence only shows the percentage change from baseline at Week 4 for each group",
        "label": "Contradiction"
    },
    "1bec6fcc-5a7e-4d19-81ea-e677715490fe": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of mucositis oral epileptic seizures or thromboembolic events in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "4886038c-1def-4bbb-a9c7-dab5784cd471": {
        "text_answer": "Contradiction The primary trials exclusion criteria do not mention anything about measurable tumors in both breasts The statement is not directly related to the evidence provided",
        "label": "Contradiction"
    },
    "a87b00a3-b6c1-4ee3-a6e0-fbd2eccbea05": {
        "text_answer": "Contradiction  Explanation The primary trial selection criteria include breast adenocarcinoma while the statement is about ovarian serous carcinoma Therefore the statement contradicts the primary trial selection criteria",
        "label": "Contradiction"
    },
    "71a3b934-3bf8-4628-a728-cdf47a27e66c": {
        "text_answer": "Contradiction The primary trial does not provide information on the MTD of the same treatment as the secondary trial and the secondary trial does not specify that the treatment is Ruxolitinib in combination with paclitaxel Additionally the MTD of MM111 in the secondary trial is not stated to be 30 mg per day",
        "label": "Contradiction"
    },
    "3ad97e18-2efc-4d4a-aaae-424a3bc3f39c": {
        "text_answer": "Contradiction  Explanation The primary trial includes the requirement of being able to understand and willing to sign an informed consent document but the statement does not mention this requirement for the secondary trial Additionally the primary trial includes neoadjuvant chemotherapy and endocrine therapy as options while the secondary trial is specifically for patients who have undergone a segmental mastectomy or mastectomy The statement does not specify which trial it refers to",
        "label": "Contradiction"
    },
    "baa46f83-8738-48d2-b9b8-9cc635d9d730": {
        "text_answer": "Contradiction  The evidence states that 98 of the participants were recurrencefree survivors which is not consistent with the statement that only two individuals were not recurrencefree survivors",
        "label": "Contradiction"
    },
    "30a0fbf5-af3e-43fd-80f4-41f740a2fdff": {
        "text_answer": "Contradiction The primary trial does not list claustrophobia as an exclusion criterion",
        "label": "Contradiction"
    },
    "6b5cc819-da7b-4e4f-ae2f-7e4db8073860": {
        "text_answer": "Contradiction  The evidence shows that 3636 of patients were affected by adverse events which is less than 15",
        "label": "Contradiction"
    },
    "8f82b776-0f1c-4059-aab0-9898a9f6bd1a": {
        "text_answer": "Entailment In the primary trial pembrolizumab is given every 3 weeks Q3W while sunitinib is given once daily in the secondary trial Therefore the statement that pembrolizumab is given to participants twice as often as sunitinib is an entailment based on the evidence provided",
        "label": "Entailment"
    },
    "4d501822-a118-4fe8-b92d-eb5085ab6dcc": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence because the primary trial participants received PF06647020 at 02 mgkg or 05 mgkg while the secondary trial participants received ALT801 at 0015 mgkg or 0040 mgkg The doses are not directly comparable as they are for different medications",
        "label": "Contradiction"
    },
    "eb088d03-7fdc-48bd-9175-0e7a9cfc7b9a": {
        "text_answer": "Entailment The evidence shows that all 3 participants in Cohort 1 of the primary trial experienced adverse events which includes both serious and nonserious events The statement only mentions that some kind of adverse event occurred which is a less specific version of the information provided in the evidence Therefore the statement is an entailment of the evidence",
        "label": "Entailment"
    },
    "c63468c0-324f-4528-b83f-a588ccf7b680": {
        "text_answer": "Contradiction The primary trial specifies a breast tumor of 1 cm in diameter while the statement mentions a TNBC tumor of 100mm in diameter which is not consistent with the primary trials inclusion criteria",
        "label": "Contradiction"
    },
    "54f86209-3c4b-4dfd-b048-e8eeb864300c": {
        "text_answer": "Contradiction The statement does not entail the evidence as some patients in the trial receive less than 20mg of MCS110 every 3rd week 1mgkg",
        "label": "Contradiction"
    },
    "d8e49bf6-27d9-4307-9bcd-56625d93274a": {
        "text_answer": "Contradiction The statement require extensive help and regular medical supervision is not mentioned in the inclusion criteria of the primary clinical trial",
        "label": "Contradiction"
    },
    "072f2e2d-f4b0-4a32-85e0-8626ee261a63": {
        "text_answer": "Contradiction  Explanation The evidence provided does not support the statement as it does not mention any information about the performance or outcomes of the two groups in the primary clinical trial",
        "label": "Contradiction"
    },
    "cff79719-40b1-43fb-bbdd-43dbe9c4191a": {
        "text_answer": "Entailment The primary trial evaluates patients with HER2 positive unresectable LABC or mBC who had received prior antiHER2 and chemotherapy treatment and had progressed on or after the most recent treatment for LABC or mBC or within 6 months of completing adjuvant therapy The secondary trial also evaluates patients with HER2 positive unresectable LABC or mBC who had received prior antiHER2",
        "label": "Entailment"
    },
    "4f66f663-030a-4391-a426-4e6b2f3bc9d2": {
        "text_answer": "Contradiction  Explanation The statement the primary trial participants experienced less incidences of diarrhoea than the participants of the secondary trial is a contradiction based on the evidence provided because the primary trial had a higher incidence of diarrhea 2333 compared to the secondary trial 000",
        "label": "Contradiction"
    },
    "38b5ee2a-8baf-427a-944d-a93a1a450104": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that no instances of anemia pneumonia or stupor were reported in the primary trial while the statement asserts that there were fewer instances of these conditions in the primary trial than in the secondary trial Similarly the primary trial had more recorded febrile infections than the secondary trial but the statement asserts that the secondary trial had more instances of feb",
        "label": "Contradiction"
    },
    "d311aaa2-6b04-4f26-a19a-65e33a673fbe": {
        "text_answer": "Contradiction The evidence does not mention peripheral neuropathy as an adverse event in the primary clinical trial",
        "label": "Contradiction"
    },
    "9334239a-f4f1-4192-a35d-93c25c41328d": {
        "text_answer": "Contradiction The primary trial participants receive Epacadostat twice daily BID while Sunitinib participants in the secondary trial receive sunitinib once daily The frequency of Epacadostat administration is higher than that of sunitinib in the secondary trial not lower as stated in the question",
        "label": "Contradiction"
    },
    "b7b61d5d-629d-43a4-8d75-5897864b6443": {
        "text_answer": "Contradiction  The evidence states that 53 of participants in the Lapatinib 1000 mg  NabPaclitaxel arm had an overall tumor response meaning that over half of the participants had either a confirmed complete response or a confirmed partial response Therefore less than half of the participants had progression of disease",
        "label": "Contradiction"
    },
    "0b3b3351-166f-465f-b44f-14c1e24c2d06": {
        "text_answer": "Contradiction The secondary trial has significantly different inclusion criteria compared to the primary trial The primary trial includes specific cancer types and failure of standard treatment as inclusion criteria while the secondary trial includes patients undergoing large core breast biopsy as inclusion criteria",
        "label": "Contradiction"
    },
    "fd173cdb-c283-4b74-922e-583a531edcef": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence mentions the use of epirubicin cyclophosphamide docetaxel and trastuzumab in the primary trial but it does not mention any drugs or bacteria related to the genus Atopobium",
        "label": "Contradiction"
    },
    "a5657dcd-1ee5-44f6-bb21-e718259c4b2e": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were no deaths or hospitalizations in cohort 2 but it does not mention anything about atrial fibrillation Therefore the statement that there was only a single case of Atrial fibrillation in cohort 2 is not entailed by the evidence and it is a contradiction",
        "label": "Contradiction"
    },
    "475903fe-9ac8-434b-aa7e-aa7bce562ef0": {
        "text_answer": "Contradiction The primary trial measures pain intensity while the secondary trial measures bone mineral density",
        "label": "Contradiction"
    },
    "c6f5d89a-939b-4e46-8aab-9fc9246498be": {
        "text_answer": "Contradiction The primary trial explicitly excludes participants who have undergone major surgery within 28 days prior to the study registration date while the secondary trial does not mention any such exclusion Therefore a patient who has recently undergone an organ transplant and remains confined to bed could potentially be eligible for the primary trial depending on the timing of the transplant and recovery but the statement suggests that they would not be eligible for the primary trial and could only",
        "label": "Contradiction"
    },
    "6558ae62-b251-483d-9082-67a614d76e60": {
        "text_answer": "Entailment The primary trial had one experimental group Pyridoxine and one placebo group Placebo while the secondary trial had one test group Highdose Oxybutynin Chloride or Lowdose Oxybutynin Chloride and one control group not explicitly stated but can be inferred as receiving no treatment",
        "label": "Entailment"
    },
    "1dffbb91-6440-4ceb-a33d-c2d783f75936": {
        "text_answer": "Contradiction The primary trial involves chemotherapy using Yttrium90 Radioembolization not dacarbazine The secondary trial involves a Phase 1b study of ibrutinib and MEDI4736 not photodynamic therapy using porfimer and a light source",
        "label": "Contradiction"
    },
    "6746f51e-6ceb-48b7-aa33-aecd601723b6": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because the evidence does not provide enough information to determine if Cohort A receives a higher dosage of docetaxel doxorubicin and cyclophosphamide than Cohort B The statement would be an entailment if the evidence clearly showed that Cohort A received more total doses or higher individual doses of these drugs than Cohort B However",
        "label": "Contradiction"
    },
    "19ec40c8-5482-490f-9418-5667705632df": {
        "text_answer": "Contradiction The primary trial recorded no adverse events at all while the secondary trial recorded zero adverse events in its cohort The statement assumes that both trials recorded the same total number of adverse events",
        "label": "Contradiction"
    },
    "a55f7123-365b-4119-bf0d-17467c73d0b7": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided",
        "label": "Contradiction"
    },
    "cca75efb-d5e0-4dba-b9ca-4f59238abb59": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention is given orally cabergoline  However in the secondary trial both interventions Arm IGroup A and Arm IIGroup B involve intravenous IV administration of pixantrone dimaleate  Therefore the statement that the primary trial intervention is given orally and the secondary trial intervention is exclusively administered through a",
        "label": "Contradiction"
    },
    "6c5ebc06-00c4-4cf5-8912-93972ed5a49b": {
        "text_answer": "Contradiction  Explanation  The statement Patients who have received chemotherapy or radiotherapy in the last 2 weeks suffer from unstable angina or have Grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria is a contradiction based on the evidence provided  The primary trial and the secondary trial have different inclusion",
        "label": "Contradiction"
    },
    "e517c026-4c5e-43ac-a734-1bcfd6d8edf1": {
        "text_answer": "Contradiction The statement implies that no adverse events were reported in cohort 1 of the primary trial while the evidence shows that no data was reported for cohort 1 regarding adverse events",
        "label": "Contradiction"
    },
    "3d100b36-5765-4953-b072-b06f38b6958c": {
        "text_answer": "Entailment The evidence shows that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher proportion of responders ORR compared to the Paclitaxel Plus Bevacizumab group",
        "label": "Entailment"
    },
    "b08d9933-4d8d-40f6-9395-d40391501db4": {
        "text_answer": "Contradiction  Explanation The statement participants in the primary trial receive quadruple drug therapies throughout the study duration with a maximum dose of 1 gramm2 is a contradiction to the evidence provided in the primary trial as the intervention only includes three drugs epirubicin cyclophosphamide and docetaxel throughout the study duration and there is no mention of a fourth drug or a maximum",
        "label": "Contradiction"
    },
    "3be36531-265f-4d51-bd65-1e2f46b28eda": {
        "text_answer": "Entailment Both trials measure the Maximum Tolerated Dose MTD which is a type of intervention dose",
        "label": "Entailment"
    },
    "bc318388-81b9-4bf5-94a7-db6443061abd": {
        "text_answer": "Contradiction The statement interval point in time integer data type is a data type comprised of a set of consecutive values of an ordered point in time integer datatype is not related to the eligibility criteria for the primary or secondary trials The statement about female cancer patients participating in the primary trial regardless of race ethnic origin or cancer type and the requirement for BRCA breast cancer in the secondary trial are two separate statements",
        "label": "Contradiction"
    },
    "0ed96bc9-14a3-4c52-b977-7cf507956191": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the primary trial participants do receive injections specifically of Intervention 1 which is not mentioned in the statement The statement only mentions the absence of injections for the secondary trial but it incorrectly assumes that the primary trial does not involve any injections at all",
        "label": "Contradiction"
    },
    "48b31ad3-f5d6-4250-9e84-e407d26f6bed": {
        "text_answer": "Contradiction The statement does not entail the evidence as it makes no mention of the specific medications or dosing schedule in the trial",
        "label": "Contradiction"
    },
    "dd909039-da2a-4c24-9b6f-1776bc51e3a2": {
        "text_answer": "Contradiction The statement is incorrect as malignant cervical soft tissue neoplasm is not a rare tumor type included in the primary trial",
        "label": "Contradiction"
    },
    "174215f6-99d9-482a-8aad-d477060cb062": {
        "text_answer": "Contradiction The primary trials inclusion and exclusion criteria do include conditions related to mental health Eastern Cooperative Oncology Group performance status bodyweight life expectancy size of tumors measurable or nonmeasurable disease and estimated life expectancy life expectancy  6 months",
        "label": "Contradiction"
    },
    "2ea65099-018a-4230-87a1-e60303486743": {
        "text_answer": "  Contradiction   The primary trial requires a life expectancy of at least 20 weeks while the secondary trial requires a life expectancy of at least 6 months The patient described in the statement has a life expectancy exceeding 20 months which is longer than the requirement for the primary trial but shorter than the requirement for the secondary trial Therefore the statement is a contradiction based on the given evidence",
        "label": "Contradiction"
    },
    "e486bbca-c279-458b-b98b-2b434c9a242d": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided The evidence does not mention anything about malignant laryngeal neoplasms or their adverse events",
        "label": "Contradiction"
    },
    "05775941-9ed3-40eb-9c93-ed60a7783838": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the trials have different inclusion criteria and one is for women with breast cancer and the other mentions testicular plasmacytoma which is not related to breast cancer",
        "label": "Contradiction"
    },
    "f45bbf0b-4acd-4166-81a6-6b407cff87ca": {
        "text_answer": "Entailment The primary trial is indeed testing the effects of different gels Hydrophor and MediHoney on different study groups while the secondary trial is testing different doses 90 mg and 110 mg of the same treatment PF05212384 on the same study group",
        "label": "Entailment"
    },
    "7814620b-23de-463b-8fd1-efdf51ce26b3": {
        "text_answer": "Contradiction The evidence states that patients with a history of interstitial lung disease or pneumonitis are excluded from the trial",
        "label": "Contradiction"
    },
    "2c00f421-96f2-4f3a-a202-27350b15c84f": {
        "text_answer": "Contradiction The statement is a generalization that cannot be confirmed based on the evidence from the primary trial as there are multiple patients who suffered the same type of adverse event pleural effusion",
        "label": "Contradiction"
    },
    "2eed31cc-3968-4b00-8a9e-947c5ecfbc3b": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of a single injection on day 8 of the study in the evidence",
        "label": "Contradiction"
    },
    "f44e50eb-f7de-403f-8e1c-25ae4cb1f530": {
        "text_answer": "Entailment The evidence states that the final eligibility for the clinical trial is determined by the health professionals conducting the trial which includes the attending clinician Therefore the statement that the final decision rests solely with the attending clinician is an entailment of the evidence",
        "label": "Entailment"
    },
    "ed9afe03-8b68-464c-a9f8-0d3a58f64d7f": {
        "text_answer": "Entailment The primary trial includes patients with stage IV breast adenocarcinoma that is ER positive PR positive or HER2neu negative which is also a requirement for the secondary trial The statement is an entailment as the secondary trial includes a more specific set of inclusion criteria that the primary trial already meets",
        "label": "Entailment"
    },
    "3f6d7cbc-5465-4e27-beee-582162fe9972": {
        "text_answer": "Contradiction  The evidence from the primary trial reports adverse events including fatigue in 169 145 of patients The statement however asserts that there were no adverse events in the secondary trial",
        "label": "Contradiction"
    },
    "91169f4f-ada3-4bc7-a0ef-8111fccac241": {
        "text_answer": "Contradiction The statement is incorrect as syncope did not occur in 025 of the patients in either trial but rather 1667 in the primary trial",
        "label": "Contradiction"
    },
    "de99de33-5cd3-4f28-8859-9297a230ab94": {
        "text_answer": "Contradiction The evidence does not mention anything about fentanyl sublingual spray being given to patients during radiation therapy in the primary clinical trial",
        "label": "Contradiction"
    },
    "7b76950c-8ac8-451f-93d4-bfac4ba36e49": {
        "text_answer": "Contradiction The statement is incorrect as the first group in the primary clinical trial did not receive Enzalutamide intravenously but orally it was Fulvestrant that was given intramuscularly",
        "label": "Contradiction"
    },
    "ce8ecade-8753-4983-83af-47f6e3e87f32": {
        "text_answer": "Contradiction The primary trial does not have separate entry conditions for participants under the age of 25 and those 25 and older according to the provided evidence",
        "label": "Contradiction"
    },
    "23f62ab2-9ec8-49f7-a4e7-84f931a1825d": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the exclusion criteria in the evidence specify a 6month time frame for the exclusion of abdominal fistula gastrointestinal perforation and intrabdominal abscess and there is no mention of a 2day time frame for stroke transient ischemic attacks or significant psychiatric disorders",
        "label": "Contradiction"
    },
    "a6f49268-2b84-49ff-a89a-86cb3d16cd07": {
        "text_answer": "Contradiction  Explanation The evidence states that in the primary clinical trial 20 out of 35 participants did not experience any vomiting or required rescue medication within the first 24 hours after cyclophosphamide administration This directly contradicts the statement that over half of the participants faced acute vomiting as a side effect of being treated with aprepitant dexamethasone cytoxan and k",
        "label": "Contradiction"
    },
    "2b0a4d9c-e65c-44d2-bdf6-60877e5d1b41": {
        "text_answer": "Contradiction The statement being diagnosed with Alzheimers disease does not prevent a patient from taking part in the primary clinical trial is a contradiction to the inclusion criteria which state that No evidence of dementia  Mini Mental State Examination MMSE 23 but some evidence of cognitive impairment is required for participation in the trial Alzheimers disease is a type of dementia so a patient diagnosed with Al",
        "label": "Contradiction"
    },
    "54654fa6-2bce-4ed0-9cdf-ec6cf1de3bd8": {
        "text_answer": "Contradiction The primary trial explicitly states that participants must be nonsmokers while the secondary trial mentions no specific smoking exclusion but includes a criterion for alcohol consumption However the statement suggests that smoking individuals are disqualified from the primary trial but could be considered for the secondary trial only based on their alcohol consumption",
        "label": "Contradiction"
    },
    "57265519-b5e0-41f9-90b3-8a09e57bc282": {
        "text_answer": "Contradiction The primary clinical trial does not focus on radiation therapy but rather on hormonal interventions Estring and testosterone cream while the secondary clinical trial involves acupuncture and standard treatments but no radiation therapy is mentioned",
        "label": "Contradiction"
    },
    "2c7901c7-b03b-4b92-852d-d182187dd2b1": {
        "text_answer": "Entailment The statement there were two incidences of doselimiting toxicity is consistent with the evidence that there were two participants in cohort 2 who experienced doselimiting toxicity",
        "label": "Entailment"
    },
    "33641401-b713-4800-86a9-aa7766b456f5": {
        "text_answer": "Contradiction  The evidence states that in the ArmGroup titled Aprepitant Dexamethasone Cytoxan  Kytril there were no episodes of vomiting and no rescue medication during the first 24 hours after cyclophosphamide administration for 20 out of 35 participants Therefore acute vomiting was not a side effect for over half of the participants in this group",
        "label": "Contradiction"
    },
    "dfb7dcc6-34da-4de2-8229-3cd02d15bd15": {
        "text_answer": "Contradiction  Explanation The statement mentions mersalyl acid which is not mentioned in the provided evidence The evidence only discusses bevacizumab and gemcitabine which are different drugs Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "52ee52ad-c158-48b8-86f1-99589e8150c5": {
        "text_answer": "Entailment The statement 013 of the primary trial participants with HER2 primary breast cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed HER2 metastases is an entailment of the evidence provided as the evidence states that 13 of the participants with HER2 primary breast cancer developed HER2 metastases and the statement spec",
        "label": "Entailment"
    },
    "da51f6ae-703a-4282-a339-22ebaa80709a": {
        "text_answer": "Contradiction The statement have vaginal itching or irritation is not related to the eligibility criteria for the primary trial which pertains to cognitive impairment and dementia",
        "label": "Contradiction"
    },
    "e3a1c267-d715-40ef-b23a-9bfb6285bf6a": {
        "text_answer": "Contradiction  Explanation  The primary trial involves both massage therapy a form of physiotherapy and drugbased treatment lapatinib and capecitabine Therefore it does not solely focus on drugbased treatment  The secondary trial focuses on a pharmaceutical intervention PF06647020 and does not involve massage therapy or any other form of physiotherapy  Thus",
        "label": "Contradiction"
    },
    "0392122c-9612-49dc-83db-b2b6a4a4a8a8": {
        "text_answer": "Contradiction  The primary trial involved comparing the diagnostic accuracy of two algorithms in breast cancer diagnosis while the secondary trial focused on measuring fatigue levels using the Lee Fatigue Scale in breast cancer patients undergoing radiation therapy and reflexology treatment The two trials are not directly comparable as they assess different outcomes The statement is a contradiction as it attempts to make a comparison between the results of the two trials which are not related",
        "label": "Contradiction"
    },
    "b4bad814-078e-4991-9455-f50ca716580d": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the evidence shows two different dosages of Enzalutamide being administered in the primary clinical trial",
        "label": "Contradiction"
    },
    "26b78b55-df37-4058-a5ef-7634ae3f4fce": {
        "text_answer": "Entailment The statement the secondary clinical trial documented 11 additional adverse events compared to the primary clinical trial is an entailment based on the evidence provided as the evidence shows that there were 11 more adverse events in the secondary trial compared to the primary trial",
        "label": "Entailment"
    },
    "a93f06ed-84a0-487e-bf93-f74cc7cb34ba": {
        "text_answer": "Entailment given that the evidence for Adverse Events 2 in the secondary trial is incomplete  Explanation The statement no adverse events have been reported for participants in both the primary and secondary clinical trial is an entailment based on the given evidence even though the evidence for the secondary trial is incomplete This is because the evidence for the primary trial clearly states that no adverse events have been reported and the absence of adverse",
        "label": "Entailment"
    },
    "56530063-b408-47f2-8421-6be825f5559c": {
        "text_answer": "Entailment  Explanation The statement The interventions in the primary trial are administered through different routes is an entailment based on the evidence provided The evidence states that Intervention 1 bisphosphonate is administered intravenously IV while Intervention 2 denosumab is administered by subcutaneous injection Since IV and subcutaneous injections are different routes of administration the statement is",
        "label": "Entailment"
    },
    "aa62c405-218e-496e-a424-95340f370834": {
        "text_answer": "Contradiction The evidence does not provide information about the number of participants in the second cohort of the trial",
        "label": "Contradiction"
    },
    "dc867a3f-6005-49f7-bcd8-1c7db27b00c1": {
        "text_answer": "Contradiction The statement mentions uteruscervix which is not mentioned in the evidence provided for either trial",
        "label": "Contradiction"
    },
    "51cd4ccd-2770-4189-ba70-f01147431843": {
        "text_answer": "Entailment The evidence states that patients will receive multiple injections of therapeutic autologous dendritic cells peptides and Trastuzumab",
        "label": "Entailment"
    },
    "3aaa3da7-8b9c-4853-abd9-f4dc011eaab0": {
        "text_answer": "Contradiction The evidence provided does not mention anything about familial hypocalciuric hypercalcemia or calcium sensing receptor gene mutations in relation to the inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "34f3e7ee-c8c4-4a97-90da-fafcfd1c7cc0": {
        "text_answer": "Contradiction The evidence states that the primary trial cohorts receive preoperative intravenous administration of dexamethasone which is a medication",
        "label": "Contradiction"
    },
    "ce8a4f39-efff-4fd3-b850-4fc5c30270ef": {
        "text_answer": "Contradiction The statement is not an entailment as the trials do share the use of intravenous injections but they do use the same drugs and similar frequency of administration in the case of trastuzumab in the primary and secondary trials",
        "label": "Contradiction"
    },
    "6e125367-3fa8-46b3-a58d-b3baa894bc70": {
        "text_answer": "Contradiction The evidence does not support the statement that women aged 60 or 70 are eligible for the secondary trial but need to wait 1020 years to be eligible for the primary trial The primary trial has different inclusion and exclusion criteria than the secondary trial and age is not mentioned as a specific criterion for either trial",
        "label": "Contradiction"
    },
    "81792c74-a501-4ef9-b7ac-2bda7a980fb1": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because both trials use the same method of quantifying toxicity doselimiting toxicities as their primary outcome measurement",
        "label": "Contradiction"
    },
    "0938714d-688d-42b5-a605-1153c172aa48": {
        "text_answer": "Contradiction The statement does not provide any information about the occurrence of Tumour lysis syndrome in the trials",
        "label": "Contradiction"
    },
    "9fb13507-1f88-4b95-8ff6-a56af67ca8c4": {
        "text_answer": "Entailment The statement is an entailment because the evidence clearly states that different inclusion and exclusion criteria are used for the two stages of the primary clinical trial and the secondary clinical trial uses separate criteria for patients depending on their health status or cancer diagnosis",
        "label": "Entailment"
    },
    "2cc2ce51-0ac2-4e55-baf0-d26f88105aa0": {
        "text_answer": "Contradiction The primary trial did not record any cases of acute myocardial infarction while the statement suggests that both trials had participants who suffered from it",
        "label": "Contradiction"
    },
    "b53a2698-dfb0-416d-9f3e-2e800a360b3e": {
        "text_answer": "Contradiction The primary trial involves oral pregabalin while the secondary trial involves intravenous Liposomal Cytarabine Depocyt and HighDose Methotrexate HDMTX",
        "label": "Contradiction"
    },
    "f6835e26-4231-4f1a-a5f0-00e6919eb622": {
        "text_answer": "Contradiction The evidence clearly states that participants will receive intravenous infusions of Trastuzumab Vinorelbine and GMCSF as well as intradermal injections of Dendritic Cell Vaccine",
        "label": "Contradiction"
    },
    "e5e13d2e-11bd-4f7c-867d-ab3d0e26666b": {
        "text_answer": "Contradiction The participants in the primary trial receive multiple drugs throughout the study duration and none of the mentioned doses exceed 1000 kgm2",
        "label": "Contradiction"
    },
    "616edea0-8cb7-44c3-a866-af72680d31d3": {
        "text_answer": "Contradiction The primary and secondary trials involve different interventions and medications The primary trial does not mention any requirement for daily dosing of florbetaben",
        "label": "Contradiction"
    },
    "0d63f301-9546-466f-aee9-78eea578b57f": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial measures tumor diameter in centimeters while the secondary clinical trial measures the number of participants with solid tumor response The units are not the same making the statement a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "89e0e893-e053-491c-a276-055b30c5da2e": {
        "text_answer": "Contradiction  The evidence shows that participants in the paced respiration group experienced fewer hot flashes per day on average compared to the fast shallow breathing group",
        "label": "Contradiction"
    },
    "e3fac563-e6bf-418f-b9b2-3bc6e3539da9": {
        "text_answer": "Entailment The statement is an entailment because the evidence states that the lymphoscintigraphy in both interventions involves the injection of the same amount of radioactive Tc99M sulfur colloid but the primary disparity mentioned in the statement refers to the elevated usage in intervention 1 which is consistent with the use of a handheld gamma camera pIHGC in that intervention",
        "label": "Entailment"
    },
    "776a17db-8314-4fc6-9de3-0d110db79269": {
        "text_answer": "Contradiction The primary clinical trial is for patients with breast cancer considering aromatase inhibitor therapy not for individuals contemplating radiation treatment for stage 2 colorectal cancer",
        "label": "Contradiction"
    },
    "980339cb-7997-4209-b3b5-a4ddc3aff79e": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the primary trial involves the use of intravenous IV medications as well as oral medications PO needle biopsy correlative studies therapeutic conventional surgery and laboratory biomarker analysis Therefore the statement that the primary trial participants are solely treated using a single type of oral medication without any surgical procedure is not supported by the evidence",
        "label": "Contradiction"
    },
    "93ff9af3-c812-4449-b311-06418b283233": {
        "text_answer": "Contradiction The primary trial involves the use of Yttrium90 radioembolization with TheraSphere while the secondary trial uses ibrutinib and MEDI4736 as its intervention",
        "label": "Contradiction"
    },
    "fa11f174-260a-4836-b583-c40d4b10bad4": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not provide information about the number of cases of foxo1 gene rearrangement in the primary trial",
        "label": "Contradiction"
    },
    "0025afa1-ef06-42c9-9a6d-0f2aaf94c403": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "60ceec88-a7b1-4353-8327-946c05a0a32a": {
        "text_answer": "Contradiction The evidence provided does not indicate that any participant in Cohort 1 of the primary trial suffered a lifethreatening adverse event The evidence only mentions the number of participants with serious and nonserious adverse events but it does not specify that any of these events were lifethreatening",
        "label": "Contradiction"
    },
    "bde8a5a0-02fc-4b6e-a91a-a56c420d9c3b": {
        "text_answer": "Contradiction The primary trial does not evaluate the percentage of participants with AEPIs it evaluates toxicity using NCI CTCAE v30",
        "label": "Contradiction"
    },
    "4423a0fb-d4df-4046-bb60-04ba702c8623": {
        "text_answer": "Entailment but note that the outcome measurements are not identical in every way as the primary trial measures percentage of participants with adverse events while the secondary trial measures number of participants with objective response but they both involve the use of RECIST criteria for assessing disease status",
        "label": "Entailment"
    },
    "f4d3c3ad-6c8c-4c7e-8d90-e321a9fa479d": {
        "text_answer": "Contradiction The primary trial only includes patients with HER2positive breast cancer while the secondary trial includes patients with ERpositive HER2negative breast cancer Additionally the primary trial is for patients who have previously undergone treatment with Avastin and chemotherapy for locally recurrent or metastatic breast cancer while the secondary trial is for patients with newly diagnosed breast cancer",
        "label": "Contradiction"
    },
    "50252016-e56e-4dc0-99d0-589c3dfe05e8": {
        "text_answer": "Contradiction The evidence shows that there were no reported cases of intestinal obstructions or pancytopenia in either trial",
        "label": "Contradiction"
    },
    "851e1a1b-0b8e-4aef-a7e3-f06c036fe537": {
        "text_answer": "Entailment  Explanation Given the evidence Cohort 1 receives a dose of 0015 mgkgdose and Cohort 2 receives a dose of 0040 mgkgdose To find the total dose each cohort receives we need to calculate the total dose for each cohort by multiplying the dose per kilogram by the weight of an average patient Let",
        "label": "Entailment"
    },
    "a89e4c9e-86e0-4d21-b805-2a593ed71a7c": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement does not provide any information about the occurrence of Febrile neutropenia or Cholelithiasis in the trials so it neither entails nor contradicts the evidence The statement only mentions the monoclonal antibody b1 and its target antigen CD20",
        "label": "Entailment"
    },
    "45745e85-0655-490a-a692-ee9f060f8898": {
        "text_answer": "Neutral The statement does not directly follow from the evidence but it is not contradictory either  Explanation The statement hard to remember what i just heard is not directly related to the evidence provided in the primary trial The evidence only states that none of the patients suffered from a urinary tract infection UTI The statement does not necessarily mean that the individuals in the primary trial were the ones being asked about their ability to remember what they heard",
        "label": "Entailment"
    },
    "d0de0260-eb83-45e9-81cf-02ee5edd3e60": {
        "text_answer": "Contradiction The primary trial involves a comparison between two groups and the statement implies a comparison between a control group and a test group which is not present in the secondary trial",
        "label": "Contradiction"
    },
    "b742bc02-cd24-4ae7-b8b8-2a57bbd60d14": {
        "text_answer": "Entailment The statement includes all the exclusion criteria mentioned in the evidence related to the primary trial Therefore if a patient has any of those conditions within the last 6 months they would not be eligible for the trial",
        "label": "Entailment"
    },
    "9484e4d1-8130-4d52-b362-faa1990946e9": {
        "text_answer": "Entailment The statement follows logically from the evidence as the evidence states that cohort 1 receives higher doses of Cyclophosphamide than Eribulin and cohort 2 receives higher doses of Cyclophosphamide than Docetaxel Therefore it is an entailment that calla positive lymphoblastic leukemia is acute lymphoblastic leukemia which is positive for the",
        "label": "Entailment"
    },
    "c752fd5f-8cf1-435e-8981-7323279b8130": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses objective response and treatmentemergent adverse events in the primary and secondary trials respectively There is no mention of symptom interference scores",
        "label": "Contradiction"
    },
    "07d56cae-178f-43f3-8f85-c73817786951": {
        "text_answer": "Contradiction The primary trial includes solid tumor malignancies of lung breast or prostate while the secondary trial specifically includes stage IIbIIIIV breast cancer The patient with stage II lymphoma does not meet the inclusion criteria for either trial",
        "label": "Contradiction"
    },
    "49f03133-66cf-4980-8e2b-d7fb001edefd": {
        "text_answer": "Contradiction The evidence mentions Niraparib in the primary trial intervention but not Talazoparib",
        "label": "Contradiction"
    },
    "06b8d395-0fe7-4206-b118-5e478779cce0": {
        "text_answer": "Contradiction  Explanation The evidence shows that in the secondary trial all patients experienced at least 3 different adverse events AEs while in the primary trial no patient experienced less than 3 different AEs since no patient experienced any AEs at all However the statement does not account for the possibility of patients experiencing no AEs in the primary trial Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "ca7e6cda-c7dc-4cc7-82d5-732998d7993e": {
        "text_answer": "Contradiction  Explanation The evidence provided lists several health conditions that are exclusion criteria for both clinical trials However the statement in question is a negative statement about women without any health conditions which is not consistent with the exclusion criteria listed in the evidence The evidence shows that certain health conditions do exist that would prevent women from participating in the clinical trials",
        "label": "Contradiction"
    },
    "e68875c8-9905-4821-ac2a-8fe4576a2071": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided The evidence only discusses the interventions and dosing schedules in the primary and secondary trials it does not mention anything about nucleolar granular material or the number of test groups in relation to the trials",
        "label": "Contradiction"
    },
    "10543624-61ff-49dd-970a-5d6c57605f6d": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "68a7d226-1e5b-4a29-b492-60e8f621e7bd": {
        "text_answer": "Contradiction The primary trial does not require a diagnosis of a mutation in any of the listed genes for inclusion",
        "label": "Contradiction"
    },
    "e65ecb06-ff14-432b-826f-9bd26c456215": {
        "text_answer": "Contradiction  Explanation  In the primary trial Cyclophosphamide is part of the Intervention 1 and Paclitaxel is part of the treatment protocol following the initial chemotherapy with GMCSF Pegfilgrastim is mentioned as a growth factor support in the secondary trial but it is not explicitly stated that it is part of the treatment protocol in the primary trial so it can be considered not directly mentioned but still",
        "label": "Contradiction"
    },
    "7bc71832-7742-4a77-b0ca-d8820db7f9bd": {
        "text_answer": "Entailment The statement is an entailment because the intervention section of the primary clinical trial would typically include a detailed description and treatment cycle for the intervention being tested",
        "label": "Entailment"
    },
    "215bc845-3485-423b-9c4c-1091cfb1a5cc": {
        "text_answer": "Entailment The statement Over 12 patients in the primary trial treated with Lapatinib 1000 mg  NabPaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR is an entailment of the evidence provided as the evidence states that the outcome measurement was defined as the percentage of participants who experienced either a CR or PR",
        "label": "Entailment"
    },
    "408eec4d-435f-4edb-99ac-69cd883586b2": {
        "text_answer": "Contradiction The primary trial has specific inclusion criteria related to menopausal status and hot flushes which are not mentioned in the secondary trial Therefore a patient meeting the secondary trial inclusion criteria does not necessarily meet the primary trial inclusion criteria",
        "label": "Contradiction"
    },
    "d692776e-c2e9-450b-b0e8-57d84ccb216c": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the administration of denosumab as an injection while the secondary trial does not involve any drug administration through injections but rather the use of a handheld gamma camera or gamma probes which do not involve oral ingestion of tablets Therefore the statement is a contradiction of the evidence provided",
        "label": "Contradiction"
    },
    "2b4a5598-2d21-426a-9d85-b0f94efb9bea": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence discusses adverse events in clinical trials while the statement is about Portable Network Graphics and chest pain",
        "label": "Contradiction"
    },
    "ee84e692-4923-4cb8-acad-8f27f64f4b9e": {
        "text_answer": "Entailment The evidence from both trials supports the statement that no adverse events were reported in their respective cohorts",
        "label": "Entailment"
    },
    "f491f739-e852-496a-ad98-bbcb2f075cb9": {
        "text_answer": "Entailment for both Results 1 and 2  Explanation The statement all participants from the first cohort of the primary clinical trial underwent some adverse event is an entailment for both Results 1 and 2 because all participants in both results experienced adverse events as indicated by the 1000 participation rate in Results 1 and 824 participation rate in Result 2 having experienced",
        "label": "Entailment"
    },
    "a325de64-fdaa-4c93-8e4a-22a1d502dd88": {
        "text_answer": "Contradiction  Explanation The primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH using a specific outcome measurement method and success criteria comparing the change from baseline to Week 12 in Serum Levels of Follicle Stimulating Hormone FSH to natural physiological variability The secondary trial on the other hand measures the Maximum Tolerated D",
        "label": "Contradiction"
    },
    "6d3a9617-a195-48e4-aa19-61a3ecde9ddb": {
        "text_answer": "Contradiction The primary trial includes patients with breast cancer while the statement is about cervical alveolar soft part sarcoma which is not breast cancer",
        "label": "Contradiction"
    },
    "0881a52f-e84b-43a4-8fda-446a7f2a1390": {
        "text_answer": "Contradiction The primary trial includes all types of female cancer patients while the secondary trial specifically includes BRCApositive breast cancer patients",
        "label": "Contradiction"
    },
    "173793fc-ca3d-4296-a1c7-14fbde0a7b8c": {
        "text_answer": "Contradiction  Explanation The primary trial defines each treatment cycle as 21 days which is not equivalent to a monthly cycle The secondary trial does not mention a cyclical treatment regimen but it is not stated that it does not have one either Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "0a6d1117-f868-4495-bb04-e5da37c15144": {
        "text_answer": "Contradiction  Explanation  The primary trial did have a placebo group Arm II so the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "4816c2e1-ae3b-4a0a-89b8-27a5cee580d7": {
        "text_answer": "Contradiction The primary trial reports results using the units of percentage and mgdL while the secondary trial reports results using the unit of participants These units are not the same",
        "label": "Contradiction"
    },
    "700f4bd9-6d39-4d3a-a425-bcb34d6712b6": {
        "text_answer": "Contradiction The primary trial does not list claustrophobia as an exclusion criterion but the secondary trial does not mention osteoporosis as a criterion at all The statement combines the two conditions in a way that is not supported by the evidence",
        "label": "Contradiction"
    },
    "060b08af-40f5-4d26-8299-6f3d02c8fda7": {
        "text_answer": "Entailment for the uniform dose of docetaxel doxorubicin and cyclophosphamide Contradiction for the constant frequency of administration as Cohort 2 receives different schedules for doxorubicin cyclophosphamide and docetaxel",
        "label": "Entailment"
    },
    "0e80c163-f731-4e3b-9194-211675ca9c53": {
        "text_answer": "Entailment The statement that both cohorts use the same instructional CD for paced breathing is a part of the evidence for Intervention 1 and Intervention 2 The additional information about cohort 2 having twicedaily practices and weekly chemotherapy does not contradict this part of the evidence",
        "label": "Entailment"
    },
    "baea007a-c303-440b-a66c-0941729f416d": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the given evidence The evidence does not provide enough information to determine if in situ hybridization was performed or not in either trial",
        "label": "Entailment"
    },
    "e1142532-82b5-4f1c-9d7c-33b677b92966": {
        "text_answer": "Contradiction  Explanation  The statement the most common adverse event in the primary clinical trial was severe nausea no aes were reported in the secondary clinical trial is a contradiction based on the evidence provided  In the primary clinical trial there were no reported cases of severe nausea as per the evidence Therefore it cannot be the most common adverse event  Furthermore the secondary clinical trial",
        "label": "Contradiction"
    },
    "3433a50a-b13a-43a5-ba9c-041959f23390": {
        "text_answer": "Contradiction The primary trial and the secondary trial are about different outcomes lesions vs radiation dermatitis and hyperpigmentation and different patient populations healthy volunteers vs breast cancer patients Therefore it is not possible to make a direct comparison between the two trials based on the given evidence",
        "label": "Contradiction"
    },
    "09aef225-50fa-457e-9e8b-fce6aafd4705": {
        "text_answer": "Contradiction The statement does not entail the evidence as the evidence mentions patients receiving medication once daily with lapatinib ditosylate and tamoxifen citrate not twice daily as stated in the question",
        "label": "Contradiction"
    },
    "d51ecd4d-4188-4306-9c41-962c86a12652": {
        "text_answer": "Contradiction The statement children are not eligible for the primary trial contradicts the implicit inclusion of women of childbearing potential in the secondary trial",
        "label": "Contradiction"
    },
    "f87a205c-5de6-4cda-a798-85b7308e25c2": {
        "text_answer": "Contradiction The statement is not related to the evidence provided which pertains to adverse events from a clinical trial and does not mention Missouri or any psychiatric events",
        "label": "Contradiction"
    },
    "0308c864-0730-4a28-9bb4-7a51eba3e438": {
        "text_answer": "Contradiction The evidence does not support the statement that morbidly obese and pregnant patients can be eligible for both the primary and secondary trials as there is no mention of eligibility for these patient populations in the provided inclusion criteria for either trial",
        "label": "Contradiction"
    },
    "429199a7-de1a-4900-939b-e4f6efadb474": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only mentions adverse events during the primary trial none of which are related to central nervous system cysts or eating disorders",
        "label": "Contradiction"
    },
    "285be2fe-e597-4d99-acb9-7504bcfb3d6f": {
        "text_answer": "Contradiction The statement is not related to the given evidence The evidence only mentions the exclusion of participants with a history of gabapentin or pregabalin use in the secondary trial but it does not mention anything about acrocephalosyndactyly",
        "label": "Contradiction"
    },
    "98c65216-ca06-4666-99e3-0d06dc97c01d": {
        "text_answer": "Contradiction The primary trial includes patients with Stage I breast cancer who have undergone lumpectomy while the secondary trial includes patients with Stage IIII breast cancer who have completed surgery which can include lumpectomy Therefore a woman with ongoing therapy for Stage I breast cancer after lumpectomy is eligible for the primary trial but excluded from the secondary trial due to different inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "9ea892eb-1362-4281-aac7-713905f1bb2c": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided The evidence only discusses different chemotherapy regimens with or without bevacizumab and maintenance therapy There is no mention of a HER2neu peptide vaccine or sargramostim GMCSF in the primary trial",
        "label": "Contradiction"
    },
    "d3df95aa-4564-4503-9322-64f5664ce1c3": {
        "text_answer": "Contradiction  Explanation The evidence describes two cohorts in the primary clinical trial one for adult cancer patients and another for healthy volunteers The statement however asserts that only participants diagnosed with cancer receive treatment which is not the case as healthy volunteers are also part of the trial",
        "label": "Contradiction"
    },
    "3921fd1d-1ba6-475c-a6f5-c8f76fe8cbe9": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the Objective Response Rate was higher in the Bevacizumab cohort 258 vs 142311 in Bevacizumab  Capecitabine cohort However the statement is discussing the results in terms of being more beneficial which could encompass other factors such as ProgressionFree Survival or overall",
        "label": "Contradiction"
    },
    "ae574646-62f1-4b5f-b565-4af6bbafe7a6": {
        "text_answer": "Contradiction The primary trial reports 000 anemia cases while the secondary trial reports 430 anemia cases",
        "label": "Contradiction"
    },
    "83e62365-e433-4411-9a4d-951e08c6b91c": {
        "text_answer": "Contradiction since the secondary trial has an exclusion criterion for smokers",
        "label": "Contradiction"
    },
    "c0915bad-2882-4f25-a6d5-5f2b71bc8850": {
        "text_answer": "Contradiction The evidence states that adequate liver function is an inclusion criterion for the primary trial",
        "label": "Contradiction"
    },
    "ad52e20e-99a7-4001-b957-12b24a3d1df1": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the provided evidence The evidence does not provide any information about the occurrence of adverse events in cohort 2 patients with canine granular cell tumor",
        "label": "Entailment"
    },
    "7b9338a5-d3a8-405f-a197-736caf32c455": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence provided because there were no palpitations pericardial effusions or abdominal pains recorded in the secondary trial at all",
        "label": "Contradiction"
    },
    "0c5d58a3-a565-4b42-ae6f-24bd3be00b06": {
        "text_answer": "Contradiction The statement includes conditions that are not in the inclusion or exclusion criteria of the primary trial such as having no history of abdominal fistula gastrointestinal perforation or significant psychiatric disorders within the last 60 years The primary trial only specifies a 6month lookback period for these conditions",
        "label": "Contradiction"
    },
    "0ef97135-5f94-407d-a48d-f40cd6272ed5": {
        "text_answer": "Entailment  Explanation The statement neither the patients in the secondary trial nor the primary trial exhibited conditions of anemia pneumonia or stupor is an entailment based on the evidence provided because neither trial reported any cases of anemia pneumonia or stupor in their adverse events",
        "label": "Entailment"
    },
    "a510de48-5778-4489-8d10-82173320bdad": {
        "text_answer": "Contradiction The statement is not related to the given evidence The evidence only discusses the difference in the use of radioactive Tc99M sulfur colloid between intervention 1 and intervention 2 in the primary trial The statement about ganglion is not related to the trial or the interventions",
        "label": "Contradiction"
    },
    "5a736ff9-b224-4cf6-ae71-55a825bff301": {
        "text_answer": "Entailment  Explanation The statement over 011 years of TAK228 plus tamoxifen treatment patients in the primary trial experienced a 5 reduction in the percentage of cells with Ki67 expression is an entailment based on the evidence provided The evidence shows that the median IQR percentage of cells with Ki67 expression at baseline was 15 10 to 25 and",
        "label": "Entailment"
    },
    "54fbf052-31df-43af-b20e-8947042351bc": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence provided because the evidence shows that no cases of biliary colic were reported in the primary trial while the secondary trial reported one case The evidence also shows that the same number of cases of diarrhoea were reported in both trials",
        "label": "Contradiction"
    },
    "7a735242-b198-4348-ac48-f318cd704752": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the dosage of denosumab used in intervention 1 of the secondary clinical trial 120 mg Q4W is not 12 times the dosage of zoledronic acid used in intervention 1 of the primary clinical trial 4 mg Q4W Instead the dosage of denosumab is higher by a factor of approximately 30",
        "label": "Contradiction"
    },
    "e5d1118c-2e6a-4e00-a63c-041c43256c5e": {
        "text_answer": "Contradiction The primary trial does not involve a testosterone cream group The evidence only compares acupuncture to a waitlist control group",
        "label": "Contradiction"
    },
    "9e960679-ac10-4893-a777-94baac5a89f3": {
        "text_answer": "Contradiction The evidence states that cohort 2 involves adults 65 years of age and older but it does not mention that they are not administered an influenza vaccine",
        "label": "Contradiction"
    },
    "8b54773e-b9b0-400f-af71-8fd2cbd16473": {
        "text_answer": "Contradiction The primary trial uses PF06647020 not ALT801",
        "label": "Contradiction"
    },
    "fdadf425-1eaf-4e63-b034-29afcbe48baf": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as Stomatitis is not mentioned in the evidence as an adverse event in the primary trial",
        "label": "Contradiction"
    },
    "54176448-042e-4b40-835e-ddf60eb53f80": {
        "text_answer": "Contradiction The evidence does not specify that patients of Asian descent living in California are eligible for the primary clinical trial Eligibility is based on the criteria provided in the evidence",
        "label": "Contradiction"
    },
    "c7bddafb-404b-40be-80c0-f0b4e08d6466": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence indicates that there is more than one adverse event recorded in the primary trial",
        "label": "Contradiction"
    },
    "ebaa9747-0c6a-4258-b0b8-121541b4662a": {
        "text_answer": "Contradiction The primary trial does not mention any imaging modalities but the secondary trial mentions the use of a NOGA Myostar injection catheter which is a medical device used in interventional cardiology procedures and may involve imaging guidance such as echocardiography or fluoroscopy",
        "label": "Contradiction"
    },
    "63da892b-0385-43c5-8ed3-3ce7514ebb55": {
        "text_answer": "Contradiction The evidence for cohort 2 does not report any cardiovascular complications and the statement refers to cohort 1 only",
        "label": "Contradiction"
    },
    "7e288efd-8755-4393-b372-effd1c3feb91": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of the number of cases of Infection Asymmetry or Deflation in the secondary trial",
        "label": "Contradiction"
    },
    "c94158fd-10f5-4142-a361-5b346ff2c295": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there are no cases of Biliary colic or Clostridium difficile colitis reported in the primary trial but the secondary trial only reports one case of Biliary colic",
        "label": "Contradiction"
    },
    "53b41c0c-179c-45ce-90e6-3f444681b41e": {
        "text_answer": "Contradiction Note The evidence provided does not mention anything about canine sarcoma or the results of the LBH589 With Capecitabine and LBH589 and Lapatinib cohorts being compared in terms of their outcomes The evidence only provides information about the doses schedules and number of participants in each cohort",
        "label": "Contradiction"
    },
    "474339d0-2bac-4e3a-9aee-1933b96738b0": {
        "text_answer": "Contradiction  Explanation In the primary trial patients receive 4 mgkg of trastuzumab as a loading dose followed by 2 mgkg weekly In the secondary trial cohort 1 receives docetaxel or paclitaxel instead of trastuzumab and cohort 2 receives Herceptin trastuzumab at a dose of 4 mgkg in Cycle",
        "label": "Contradiction"
    },
    "85dcd465-ec0b-42ae-aec6-582831584bbf": {
        "text_answer": "Contradiction The primary trial includes all females with breast cancer while the secondary trial specifically includes only those with triplenegative breast cancer",
        "label": "Contradiction"
    },
    "cfa6601b-af52-4eee-883c-89d42b73e02b": {
        "text_answer": "Contradiction  Explanation The evidence shows that no cases of anemia pneumonia or stupor were reported in the primary trial Therefore it cannot be entailed that patients in the secondary trial suffered from these conditions more often than patients in the primary trial as some conditions were present in the secondary trial and not in the primary trial",
        "label": "Contradiction"
    },
    "41cbc4ea-37f8-468e-bfd2-f0a71e8856b5": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence as the primary trial results show a decrease in Ki67 expression of approximately 40 with tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery The statement suggests a much larger reduction of 130",
        "label": "Contradiction"
    },
    "5dc5fa82-a4a5-4f16-8ca1-b797546169af": {
        "text_answer": "Neutral The statement does not directly relate to the given evidence  Explanation The statement is about severe pain or discomfort preventing most activities while the evidence is about eligibility criteria for a clinical trial for various types of cancer including metastatic colorectal cancer with Kras or BRAF mutation The statement does not directly entail or contradict any information in the evidence",
        "label": "Entailment"
    },
    "28e19ec3-f22a-4002-9020-02ef29c4386c": {
        "text_answer": "Contradiction The evidence states that there were no adverse events in cohort 1 while the statement suggests that there were four additional adverse events in cohort 1 compared to cohort 2",
        "label": "Contradiction"
    },
    "d94a09b9-8201-43f3-9b27-cab0bc473af0": {
        "text_answer": "Entailment The intervention in the secondary trial lasts 3 times longer 24 weeks vs 10 weeks based on the provided evidence",
        "label": "Entailment"
    },
    "1d57af11-9dc3-4589-ae99-fe0e9dab6042": {
        "text_answer": "Contradiction  Explanation  The primary trial has an ECOG performance status of 02 which indicates that patients are able to perform normal activities with minimal symptoms However the secondary trial has additional inclusion criteria such as no prior or concurrent hormonal therapy for breast cancer and no uncontrolled intercurrent illness which may exclude some patients who are able to take care of themselves without any help at all Therefore the statement is a contrad",
        "label": "Contradiction"
    },
    "072b76ba-9fd5-4313-b484-c353f61ecca9": {
        "text_answer": "Entailment The evidence in the primary trial explicitly lists anemia only due to irondeficiency as an exclusion criterion and the secondary trial lists diagnosis of fibromyalgia and thalasemic syndromes as exclusion criteria Therefore the statement is an entailment based on the provided evidence",
        "label": "Entailment"
    },
    "7e57517f-4dc5-4457-bc4e-12f7faef37f4": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because anemia was reported in both trials but it was not more common in the secondary trial as stated in the question Additionally pneumonia and stupor were not reported at all in the primary trial so they cannot be compared to the secondary trial in terms of being more or less common",
        "label": "Contradiction"
    },
    "168c59cb-7be6-4f14-acd9-5d731b8464c8": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial involves the use of a Contour Profile Tissue Expander which is a surgical implant used in breast reconstruction It does not involve the use of xrays transendocardial injections CT scans or MRIs as stated in the question  However the secondary clinical trial involves the use of allogeneic mesenchymal stem cells allo",
        "label": "Contradiction"
    },
    "0483c5df-77db-4c42-897e-aca21b207503": {
        "text_answer": "Contradiction The evidence shows that there was one case of pancytopenia in cohort 1 but no cases of anemia or febrile neutropenia were reported The statement suggests that there were numerous instances of pancytopenia in cohort 1 but no records of anemia and febrile neutropenia at all",
        "label": "Contradiction"
    },
    "93cfa70f-2bdc-4e2f-ac51-5e06f2fb07ea": {
        "text_answer": "Contradiction The statement requiring considerable assistance and frequent medical care is not mentioned in the inclusion or exclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "9c60f664-ef13-406d-b26a-e57f6c914cf4": {
        "text_answer": "Contradiction  Explanation The statement does not entail the information given in the evidence The evidence mentions the dosages of MCS110 and PDR001 received by patients but it does not provide any information about the kras gene mutation status of those patients",
        "label": "Contradiction"
    },
    "79a4ea13-6d2a-49e0-8c1d-9c1fcc7e9e3b": {
        "text_answer": "Contradiction  Explanation The statement is contradictory to the evidence because the primary trial does not provide information about the dosage of Trastuzumab for HER2 patients throughout the entire duration of the trial In the primary trial the dosage of Trastuzumab is given as a loading dose followed by a weekly dose but the duration of the treatment is not specified In contrast in the secondary trial the dosage and",
        "label": "Contradiction"
    },
    "4e3b9642-3f02-4f4b-bfee-f2e3b1673186": {
        "text_answer": "Contradiction  Explanation The statement compares the dosing of alpha lipoic acid in the primary trial to the dosing of necitumumab in the secondary trial These are two different interventions and the statement does not hold true for both In the primary trial alpha lipoic acid dosing is escalated up to 100 mg three times daily while in the secondary trial necitumumab is given at",
        "label": "Contradiction"
    },
    "7128da72-a0ed-48cb-b167-c2b6176faa71": {
        "text_answer": "Entailment  Explanation The evidence shows that the median aAUCpa for the EORTC CIPN20 Sensory Neuropathy Subscale in Arm II Control was more negative than that in Arm I Cryotherapy indicating that patients in Arm II experienced more worsening of symptoms from baseline compared to those in Arm I The statement in question asserts that patients in the paclitaxel arm experienced more severe symptoms",
        "label": "Entailment"
    },
    "94aea5d0-2afb-40a4-b1c8-574c9f22225e": {
        "text_answer": "Contradiction The statement does not relate to the evidence provided in the trial regarding overall survival of patients undergoing midluteal or midfollicular oophorectomy",
        "label": "Contradiction"
    },
    "dfd43b21-a734-49b1-8a64-d6dea31e9031": {
        "text_answer": "Contradiction The statement does not entail the information provided in the evidence as it is not related to the inclusion or exclusion criteria for the trials",
        "label": "Contradiction"
    },
    "26be8c11-aebf-4982-b09e-75dead3cdf4a": {
        "text_answer": "Contradiction The primary trial does not provide information about the presence or absence of VEGF overexpression in the cohort and the secondary trial involves the use of entericcoated MLN8237 tablets during the Phase 1 portion of the study",
        "label": "Contradiction"
    },
    "5578e4a3-95d9-4803-8d13-b9c0276f92e0": {
        "text_answer": "Contradiction  Explanation  The statement Both cohorts of the primary trial receive the same dosage of Docetaxel Doxorubicin and Cyclophosphamide throughout the trial at the same frequency is a contradiction to the evidence provided because   In Intervention 1 the docetaxel is given at a dose of 100 mgm² every 3 weeks for ",
        "label": "Contradiction"
    },
    "b6b819ce-57a9-4883-bcf9-f8c9a9bae83e": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence as the statement is describing a specific finding pharyngeal stripping wave present and complete while the evidence is describing the lack of information regarding the method of administration dosage or cycle of the intervention MM111",
        "label": "Entailment"
    },
    "c803b01e-6f64-4412-a3c2-6b1a70d5cf7e": {
        "text_answer": "Contradiction The evidence does not mention anything about mental health assessment as a requirement for enrollment in the primary clinical trial",
        "label": "Contradiction"
    },
    "ceb0ef65-5640-491d-a6c6-341e456b0bdd": {
        "text_answer": "Entailment assuming febrile neutropenia or cholelithiasis is not mentioned in the primary trial adverse events",
        "label": "Entailment"
    },
    "d2e42255-bde4-4e21-a914-b4e0c35b6e3d": {
        "text_answer": "Contradiction The evidence states that patients with some evidence of cognitive impairment are eligible for the trial but it does not specify that those with Frontotemporal dementia or Mixed dementia are included The Controlled Oral Word Association Test is not mentioned in the inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "a6688fad-488e-4822-a91e-cbfe2117cae1": {
        "text_answer": "Entailment with the caveat that the statement only applies to the 9 participants in the Highdose Chemotherapy group in the given trial",
        "label": "Entailment"
    },
    "bfef0d2b-81c0-4f5f-bf91-a313a0a2dcbb": {
        "text_answer": "Contradiction The evidence does not support the statement that every participant in the trial experienced a reduction in cognitive capabilities as some participants in the Tamoxifen group had a slightly better performance compared to the agespecific norms negative standardized score The statement also incorrectly implies that all members of the ovarian function suppression group had a reduction in cognitive capabilities but the evidence only shows that this group had a slightly larger reduction in cognitive performance compared to the Tamox",
        "label": "Contradiction"
    },
    "a630808d-14d5-4ef8-bd2e-73ce5e80f3f1": {
        "text_answer": "Contradiction The primary trial does not involve the administration of fulvestrant in a tablet form or in a bid dosing schedule",
        "label": "Contradiction"
    },
    "378c5fe6-13ce-488e-a8c0-ec76cf2fb191": {
        "text_answer": "Contradiction  The evidence shows that there were 13 emesisfree participants in the aprepitant group and 5 emesisfree participants in the placebo group indicating that fewer participants in the aprepitant group experienced emesis Therefore the statement that patients receiving aprepitant were twice as likely to experience emesis as those receiving the placebo is a contradiction to the evidence presented",
        "label": "Contradiction"
    },
    "2ae5eea7-46bf-425e-b528-201a718d7f66": {
        "text_answer": "Contradiction  The evidence provided in the results of the primary trial only shows the Ki67 expression change from baseline to 6 weeks and it does not provide information about the percentage of cells with Ki67 expression over 3 years of treatment with TAK228 plus Tamoxifen",
        "label": "Contradiction"
    },
    "97322f7f-a311-4718-8a0c-5e4ecdd33f7f": {
        "text_answer": "Contradiction The primary trial does not provide any information about ki67 expression in tumors",
        "label": "Contradiction"
    },
    "8920d439-7233-461b-a343-3c264f0918de": {
        "text_answer": "Contradiction The primary trial did not report any cases of radiation dermatitis or hyperpigmentation while the secondary trial reported that over 95 of participants in one group had these conditions",
        "label": "Contradiction"
    },
    "b2b80e2f-f5b4-4997-9209-fd061ff307b9": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the placebo and alloMSCs interventions have different compositions Buminate solution vs alloMSCs and are not delivered in the same dosage 20 injections of 04ml Buminate solution vs 20 injections of 100 million alloMSCs",
        "label": "Contradiction"
    },
    "b410caf4-4ea2-414d-8b43-7336d2bb2d9b": {
        "text_answer": "Contradiction The primary trial inclusion criteria state that the primary tumor diameter should be greater than 2 cm while the statement suggests a primary tumor diameter of 066 meters which is significantly larger and not consistent with the primary trial criteria",
        "label": "Contradiction"
    },
    "38343873-8e16-4852-bfe5-511fbd1be49d": {
        "text_answer": "Contradiction The evidence does not support the statement that the typical survival span for patients in the primary clinical trial extends beyond 2 years The median survival times for both groups are less than 25 years",
        "label": "Contradiction"
    },
    "48b186f8-f41c-4582-8dbb-6918ce072ce8": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of muscle weakness or CTECAE in the evidence provided Additionally the statement makes a claim about the frequency of cholelithiasis between the two trials but the evidence does not support this claim",
        "label": "Contradiction"
    },
    "64ea29b0-1d21-4c59-a56e-553765f5e5c8": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence does not mention anything about the presence or absence of metastasis to the renal artery or any other organ The statement is irrelevant to the eligibility criteria for the primary trial",
        "label": "Contradiction"
    },
    "c939c0c9-57b8-4f8a-aba1-e19af522cb12": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because the primary trial observed cases of palpitations pericardial effusions and abdominal pains while the secondary trial did not record any cases of these adverse events",
        "label": "Contradiction"
    },
    "f1a4fdcb-09ae-4f35-9681-8ee7d0d3b41d": {
        "text_answer": "Contradiction Both cohorts receive the same dose of durvalumab 03 mgkg for Cohort 1 and 1 mgkg for Cohort 2 during the biweekly IV infusions",
        "label": "Contradiction"
    },
    "6a489a42-add9-40b7-ba9d-5d46da07b890": {
        "text_answer": "Neutral The statement is not directly related to the given evidence  Explanation The statement is not directly related to the given evidence as it does not mention the interventions used in the primary or secondary trials and it is discussing a unit of measure for pressure change",
        "label": "Entailment"
    },
    "a67f344b-aa15-4e94-819b-515df442eaf0": {
        "text_answer": "Entailment  Explanation The statement more than 50 of patients in the primary clinical trial experienced a confirmed full or partial benefit after receiving treatment with lapatinib 1000 mg and nabpaclitaxel is an entailment of the evidence provided as the evidence states that 53 of participants experienced a confirmed partial response or confirmed complete response A confirmed partial response or confirmed complete response is a form of",
        "label": "Entailment"
    },
    "5780e67e-7318-4574-b20c-a2d3c8730e4a": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because the evidence shows that cohort 1 receives lower doses of eribulin 14mgm2 compared to the docetaxel doses given to cohort 2 75 mgm2",
        "label": "Contradiction"
    },
    "2f61841c-b395-4d2c-9e86-ca09cdd61dcb": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence provided as the secondary trial allows individuals with unstable angina and those who have undergone chemotherapy or radiotherapy within the preceding two weeks while the primary trial explicitly excludes these individuals Additionally the statement incorrectly states that individuals with neuropathy not exceeding grade 2 are permitted in the primary trial when in fact the evidence shows that those with  Grade 1 neuropathy at",
        "label": "Contradiction"
    },
    "9ce6d69e-2ed0-4046-bd5e-5888416fbeb5": {
        "text_answer": "Contradiction The primary trial does not report any cases of febrile neutropenia or cholelithiasis",
        "label": "Contradiction"
    },
    "b490a735-38d7-49f2-a091-f930c5d1e9f5": {
        "text_answer": "Contradiction Persons with Parkinsons disease dementia do not meet the inclusion criteria for the primary trial as they have dementia which is an exclusion criterion",
        "label": "Contradiction"
    },
    "5b6c2caa-eb80-4024-b04c-e6b07685b7d8": {
        "text_answer": "Contradiction The statement has nothing to do with the evidence provided",
        "label": "Contradiction"
    },
    "4714a31c-c7ca-49e2-aa71-6665b65ed04f": {
        "text_answer": "Contradiction The evidence provided states that there is no mention of body mass index BMI or morbid obesity as an inclusion or exclusion criterion for either trial",
        "label": "Contradiction"
    },
    "5ce6d9b3-235b-4645-bc27-10861b2e5177": {
        "text_answer": "Entailment assuming surgical incisions reopening is synonymous with wound dehiscence  Explanation The statement in the primary clinical trial there were no reports of surgical incisions reopening following the operation is an entailment of the evidence because there were no reports of wound dehiscence in the primary clinical trial The term wound dehiscence is a",
        "label": "Entailment"
    },
    "c6f11ac1-ac2e-4740-82aa-a83ffd1cce00": {
        "text_answer": "Contradiction  Explanation The statement there were no psychiatric adverse events reported during the primary clinical trial is a contradiction to the evidence as there was one reported case of suicidal ideation in the primary clinical trial",
        "label": "Contradiction"
    },
    "fbb05804-2d6c-4d49-8e06-0fbf2b3770a4": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention in Intervention 1 is Gefitinib which is a single drug However in the secondary trial Intervention 1 is Zoledronic Acid which is a single drug but it is administered along with vitamin D and calcium supplements making it a minimum of three separate drugs in total Therefore the statement is a contradiction based on the",
        "label": "Contradiction"
    },
    "9f0a6fc9-62c5-404e-aa2f-0e5acf696e14": {
        "text_answer": "Contradiction The evidence shows that no cardiac adverse events were recorded in either trial",
        "label": "Contradiction"
    },
    "cca11232-84c4-44e1-89f1-b57b28643dce": {
        "text_answer": "Contradiction The evidence shows that no adverse events were recorded in both trials Therefore the statement that over 100 total adverse events were recorded in their cohorts is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "d803319b-cf1d-47e9-b7c2-f75ef7972e88": {
        "text_answer": "Contradiction  Explanation The primary trial measures the change in pain intensity SPID30 and the secondary trial measures the change in bone mineral density gcm2 at different time points The statement provided is not related to the evidence presented",
        "label": "Contradiction"
    },
    "ad17d770-f8c6-4440-8b95-894a511cab39": {
        "text_answer": "Contradiction The primary trial does not list claustrophobia as an exclusion criterion",
        "label": "Contradiction"
    },
    "adfed785-8da6-4bf4-836f-2dfadf0510b6": {
        "text_answer": "Contradiction The primary trial has different inclusion and exclusion criteria for its phases while the secondary trial has the same criteria for all participants",
        "label": "Contradiction"
    },
    "aa78eaae-97c9-4f34-97e4-4debfccd1552": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that the AZD0530 175 mg group had a greater percentage change in betaCTX at Week 4 711 vs 684",
        "label": "Contradiction"
    },
    "a8fa1843-9726-4f19-a026-7155df678098": {
        "text_answer": "Contradiction  Explanation The evidence does not mention any cases of hypertension in either cohort of the primary clinical trial",
        "label": "Contradiction"
    },
    "832ab731-553d-4d66-a339-1fb60265866a": {
        "text_answer": "Contradiction The statement is about hours missed from work which is not related to the outcome measurement of overall survival in the primary trial",
        "label": "Contradiction"
    },
    "019f248f-f753-495a-b579-9d41f65c5b26": {
        "text_answer": "Entailment The evidence supports the statement that neither trial reported any adverse events for their participants",
        "label": "Entailment"
    },
    "8b6e90d0-d3e2-41db-9d70-ce8b216f3795": {
        "text_answer": "Contradiction The evidence does not mention anything about race or residency in Texas being a requirement for participation in the primary clinical trial",
        "label": "Contradiction"
    },
    "27fcd959-e1dd-4c76-8e6c-fdf5fe4d257f": {
        "text_answer": "Entailment The statement includes all the exclusion criteria mentioned in the evidence Therefore if a patient has had any of those conditions within the past 6 months they would be excluded from the trial as stated in the evidence",
        "label": "Entailment"
    },
    "4d1031f5-19e1-43f3-b75a-5e8208b44bfb": {
        "text_answer": "Contradiction The primary trial did not report any significant differences between the groups while the secondary trial did report some differences between the reflexology group and the control group",
        "label": "Contradiction"
    },
    "f8858128-03f8-4721-a0f5-5f3fce7ab1c4": {
        "text_answer": "Contradiction The primary trial only includes patients with unilateral breast cancer",
        "label": "Contradiction"
    },
    "f9ad6db3-d2bc-474c-b666-a971749f6a83": {
        "text_answer": "  The statement is a Contradiction for the primary trial and Entailment for the secondary trial  Explanation  For the primary trial the patient does not meet the inclusion criteria because she is only 18 years older than the minimum age requirement 18 years and her ANC level is below the required minimum 1800 cellsmm3  For the secondary trial the patient meets all the inclusion criteria",
        "label": "Contradiction"
    },
    "0090fc12-4092-4255-8952-21ebee889ebb": {
        "text_answer": "Contradiction The primary trial involves the administration of Suramin and Paclitaxel but the statement does not mention these drugs",
        "label": "Contradiction"
    },
    "151ebcdf-fc4e-443e-8c2d-5189b65cee5b": {
        "text_answer": "Contradiction The statement is not related to the given evidence The evidence provided discusses the inclusion and exclusion criteria for the primary and secondary trials while the statement is about Eurotium a genus of fungi",
        "label": "Contradiction"
    },
    "b49ac921-1516-409d-9e81-14fc5afc75c6": {
        "text_answer": "Neutral The statement is not directly related to the inclusionexclusion criteria provided in the evidence",
        "label": "Entailment"
    },
    "6ee4b112-4ff6-49d0-a7ec-a9e71d309bb9": {
        "text_answer": "Irrelevant The statement has no relation to the provided evidence",
        "label": "Contradiction"
    },
    "ef734fea-a713-4fb3-b6e9-0be2dc2b055a": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses the outcome measurements and results of two trials and does not mention anything about diffusion weighted imaging or its units of measure",
        "label": "Contradiction"
    },
    "d1a7cbaa-161a-4675-b8b7-67ae364be364": {
        "text_answer": "Contradiction The primary trial does use change in MYMOP score as the outcome measurement",
        "label": "Contradiction"
    },
    "d4b299e3-f371-4311-9ea6-b3301632d7df": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement is about a surgical incision reopening which is not directly related to the adverse events listed in the evidence The evidence only mentions various adverse events experienced by patients in the primary trial but it does not specifically mention anything about surgical incisions reopening Therefore the statement is neutral with respect to the evidence",
        "label": "Entailment"
    },
    "9c5bbe3a-c662-4a0e-88cf-b2f5fc1188f8": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the number of hypertension and pancreatectomy cases were less than the number of hepatotoxicity cases",
        "label": "Contradiction"
    },
    "47c91759-a386-407e-9612-dbce68040a7b": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses adverse events from a primary trial and does not provide any information about how often patients thought about being rid of obligations and responsibilities",
        "label": "Contradiction"
    },
    "2db7c3cd-eb62-4ec4-8d89-effa9c9212e0": {
        "text_answer": "Contradiction  The evidence does not show that anorexia hypothermia and hallucinations were recorded in the primary trial",
        "label": "Contradiction"
    },
    "cd067ee2-ed1d-403b-aa50-d61a3399fda3": {
        "text_answer": "Entailment The evidence shows that the median percentage of cells with Ki67 expression decreased by 10 from 15 to 5 in the primary trial after one month of TAK228 Plus Tamoxifen treatment",
        "label": "Entailment"
    },
    "ee7fc1bb-98fe-4f43-9ea0-076b7fc7eeca": {
        "text_answer": "Contradiction  Explanation The evidence provided does not entail that several of the patients in the primary trial experienced no pain whatsoever during the 3 months of the study While the evidence shows that both groups received a psychoeducational intervention to improve cancer pain management it does not provide information on the number of patients who experienced no pain during the study",
        "label": "Contradiction"
    },
    "aefb2cc5-3101-416b-bae4-c9a1e7d8f39e": {
        "text_answer": "Entailment The statement that Recurrent malignancies Graftversushost disease Infection Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is an entailment based on the evidence provided The evidence shows that the incidence of these adverse events was higher in the primary trial compared to the secondary trial",
        "label": "Entailment"
    },
    "fb140d2c-d2a8-4442-bcbd-669bb9abbf2c": {
        "text_answer": "Contradiction The primary trial explicitly lists anemia only due to irondeficiency as an exclusion criterion and fibromyalgia and thalasemic syndromes are exclusion criteria in the secondary trial",
        "label": "Contradiction"
    },
    "c01a6286-57b2-4851-8c5e-12710eb9d829": {
        "text_answer": "Contradiction The statement children and adolescents are not eligible for the primary trial as they do not meet the height requirement is not related to the secondary trial as it does not mention anything about the secondary trial and the secondary trial does not have a height requirement The statement about receptive vocabulary assessment is also not related to the eligibility criteria for either trial",
        "label": "Contradiction"
    },
    "5d98b3df-684a-466d-93da-5a672f602db6": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the use of epacadostat in combination with pembrolizumab with two different doses of epacadostat 25 mg and 50 mg given orally twice daily BID Pembrolizumab is administered intravenously every 3 weeks Q3W  The secondary trial involves the use of sunitinib",
        "label": "Contradiction"
    },
    "128fd57d-cc06-40a3-8eb5-570441a19652": {
        "text_answer": "Contradiction The evidence states that laserassisted fluorescence angiography is used in both interventions",
        "label": "Contradiction"
    },
    "10818b02-4a1d-438a-8f90-7aded2b826ec": {
        "text_answer": "Neutral  The statement is not directly related to the evidence provided The evidence pertains to the results of a medical trial comparing two groups Arm II and Arm III in terms of the severity of delayed nausea while the statement is about the number of participants in two cohorts and the role of a counselor",
        "label": "Entailment"
    },
    "6a696416-b67e-4f78-8677-3fbc4470b4c1": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the statement is about age at initial pathologic diagnosis and coronary artery stenosis being the most common adverse event while the evidence only provides information about the adverse events and their frequencies in the primary trial",
        "label": "Contradiction"
    },
    "9c253aed-c7ae-42ad-afd2-9c52c9ecab08": {
        "text_answer": "Entailment The patients eligibility for both trials is based on the common inclusion criteria of having a histologically verified diagnosis of breast cancer a life expectancy exceeding 8 months and meeting the specified laboratory values for white blood cell count platelet count and hemoglobin level",
        "label": "Entailment"
    },
    "63cb536d-5250-4760-b3a8-103bfcc45123": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "3136ac0b-82b2-4819-a5ba-d5816dd0283b": {
        "text_answer": "Contradiction The statement all patients in the primary clinical trial encountered aes is a contradiction to the evidence which shows that only 2 out of 35 patients in the primary clinical trial had adverse events",
        "label": "Contradiction"
    },
    "d2ac18d1-d427-4afc-b72a-4de7856b17d5": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one case of Gramnegative bacteremia which is a bloodrelated disorder in cohort 2 Therefore the statement that all cases of gastrointestinal and bloodrelated disorders in the primary clinical trial were for patients in cohort 1 is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "8b14dd2f-b02e-41be-a2bc-7dcc378ab426": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the dosages of the interventions in the two trials are not being compared",
        "label": "Contradiction"
    },
    "e1eb6c8e-61e1-474a-a01c-f7d18d2620e9": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports the number of adverse events in each cohort of the primary trial but it does not mention the number of patients or the gender codes",
        "label": "Contradiction"
    },
    "8655fdcd-564c-483a-aa2b-7dac2d84ce57": {
        "text_answer": "Contradiction The statement patients diagnosed with tumors positive for CCND1 amplification CDK46 mutation CCND2 amplification are excluded from the primary trial is consistent with the evidence However the statement main duct pancreatic intraductal papillarymucinous neoplasm is an intraductal papillarymucinous neoplasm of the pancreas that ar",
        "label": "Contradiction"
    },
    "e8edca4b-3a7c-43b6-aed4-8651d1dee36f": {
        "text_answer": "Contradiction  Explanation The evidence shows that infections occurred in 332 938 patients in the primary trial and 115 667 in the secondary trial which is less than 15 of patients in both trials combined",
        "label": "Contradiction"
    },
    "682a4e2d-f4a5-4fee-8399-195f67fcdfcc": {
        "text_answer": "Contradiction  Explanation In the primary trial trastuzumab is given at a fixed dose of 2 mgkg per week throughout the trial In contrast in the secondary trial Herceptin is given at a different schedule 4 mgkg on Day 1 of Cycle 5 followed by 2 mgkg weekly starting from Day 8 These doses and schedules are not the same as in the",
        "label": "Contradiction"
    },
    "4b310647-d605-4946-aeb5-bcfd418e1332": {
        "text_answer": "Contradiction The statement is incorrect as per the evidence provided as Intervention 1 uses a prototype intraoperative handheld gamma camera pIHGC while Intervention 2 uses intraoperative gamma probes GP Neither of these options is explicitly stated to use pIHGC as their method",
        "label": "Contradiction"
    },
    "cd93653b-f6d1-4e8c-aa04-20a41d0096b9": {
        "text_answer": "Contradiction  The statement is a contradiction based on the evidence because the primary clinical trial had 0 anemia cases out of 37 participants while the secondary clinical trial had 4 anemia cases out of 93 participants Therefore the primary trial had a lower number of anemia cases than the secondary trial However the statement suggests the opposite that anemia cases are less prevalent in the primary clinical trial than in the secondary",
        "label": "Contradiction"
    },
    "e255fdb7-4e8b-4e62-bbb8-875687948bed": {
        "text_answer": "Contradiction  The evidence shows that 5 out of 20 participants in the placebo group were emesis free during the study period Therefore it is not true that all participants in the placebo group experienced vomiting",
        "label": "Contradiction"
    },
    "8b98421d-1cec-41bd-b25e-2e73c362193a": {
        "text_answer": "Entailment The evidence provided does not indicate that nationality ethnicity psychiatric condition or gender are inclusion or exclusion criteria for either trial",
        "label": "Entailment"
    },
    "59a0bff2-c254-45f1-a6ae-2d847777db94": {
        "text_answer": "Contradiction The primary trial reports Time to Progression in months not days and the secondary trial reports percentage of patients with Objective Response",
        "label": "Contradiction"
    },
    "22f473e7-1aea-4baf-9697-224ea4c6fbdf": {
        "text_answer": "Contradiction The statement mentions fentanyl sublingual spray which is not mentioned in the evidence The evidence only discusses Vorinostat and radiation therapy",
        "label": "Contradiction"
    },
    "03ee1d82-5208-4511-9163-23adfbc55fa4": {
        "text_answer": "Contradiction  The primary trial excludes women with stage IV disease while the secondary trial includes women with newly diagnosed or recurrent breast cancer but not limited to those with stage IV disease Therefore the statement is a contradiction as it suggests that women with a new diagnosis of stage IV ER breast cancer who are contemplating undergoing mastectomy can participate in both trials which is not the case according to the provided evidence",
        "label": "Contradiction"
    },
    "3f532833-d78c-41a1-b364-81228e03027e": {
        "text_answer": "Contradiction The primary trials Intervention 2 does not receive dexmedetomidine but the secondary trials Intervention 2 does not mention anything about receiving or not receiving dexmedetomidine",
        "label": "Contradiction"
    },
    "fd942f9a-9ad7-43f3-aac3-69b01a022811": {
        "text_answer": "Neutral The statement is not directly related to the given evidence  Explanation The statement is not directly related to the given evidence as it discusses a different type of cancer gastric pylorus carcinoma and the age eligibility for a different trial The primary trial focuses on breast cancer and does not specify an age range while the secondary trial includes patients aged 18 and above",
        "label": "Entailment"
    },
    "8fe01416-c839-4ffc-bd21-25d158d502b8": {
        "text_answer": "Entailment assuming wound dehiscence refers to a reopening of the surgical incision  Explanation The statement no patients in the primary clinical trial experienced a reopening of their surgical incision postoperation is an entailment based on the evidence because the evidence does not report any cases of wound dehiscence reopening of the surgical incision in the primary clinical",
        "label": "Entailment"
    },
    "1a3483cd-0a92-456f-ba18-6ce12b3ded0b": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as the evidence does not mention 19q134 or any specific chromosomal abnormalities as a criterion for exclusion in either trial",
        "label": "Contradiction"
    },
    "7bf988b4-5e6f-41c4-bef6-7b3549dd58d9": {
        "text_answer": "Entailment The primary trial includes patients with stage IV breast adenocarcinoma that is ER positive PR positive or HER2neu negative as a subset of its inclusion criteria Therefore these patients are eligible for both trials based on the given evidence",
        "label": "Entailment"
    },
    "68b82fb4-066b-4d76-9623-ff8696da3000": {
        "text_answer": "Entailment The statement is an entailment of the evidence as it follows directly from the information provided in the evidence that patients will be taking Vorinostat daily during radiation therapy",
        "label": "Entailment"
    },
    "fae99e77-42d1-4003-bb7a-3b98b88f7c27": {
        "text_answer": "Contradiction The evidence states that no adverse events were documented in either cohort while the statement asserts that adverse events were documented in both cohorts",
        "label": "Contradiction"
    },
    "eb555e01-0a12-45a1-99ad-7d7dafbe8912": {
        "text_answer": "Contradiction In Intervention 1 Cohort A receives two IM injections of LD V935 one every other week over a 3week period In Intervention 2 Cohort B does not receive the two IM injections of LD V935 at the same point in the cycle as Cohort A Instead Cohort B receives three EP injections of LD V934 followed by two IM",
        "label": "Contradiction"
    },
    "69c802bf-ab3f-4a0a-b995-210db2403a50": {
        "text_answer": "Contradiction The statement is contradictory because the primary trial involves alpha lipoic acid which has a scheduled adjustment of dosage while the secondary trial involves necitumumab which has unchanged quantities",
        "label": "Contradiction"
    },
    "f96f9461-2b00-4838-9e04-1d3a8dbeb3f3": {
        "text_answer": "Contradiction The statement mentions four drugs with a dosage limit of 100 mgm2 for one of the drugs epirubicin but the other drugs cyclophosphamide docetaxel and trastuzumab have different dosages",
        "label": "Contradiction"
    },
    "01effe7e-449f-4f59-a64e-2b38c5c21187": {
        "text_answer": "Contradiction The primary trial reported no cases of acute myocardial infarction while the statement suggests that 2 out of 73 individuals in the primary trial had this condition",
        "label": "Contradiction"
    },
    "ece744da-a8d6-401a-972c-3a9f5cd60b14": {
        "text_answer": "Contradiction  The evidence reports that two patients experienced the adverse event disease progression in the primary clinical trial",
        "label": "Contradiction"
    },
    "21d37b8b-4326-40bd-a070-5ad0fbb48e6d": {
        "text_answer": "Contradiction  Explanation  The primary trials inclusion criteria state that patients must have histologically confirmed ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 The statement however mentions estrogen negative progesterone negative and HER2 tumors which is not an exact match to the trials ER positive requirement Therefore the",
        "label": "Contradiction"
    },
    "1b5e0318-38e0-484f-bffd-d63ff75fe93c": {
        "text_answer": "Contradiction  Explanation The primary clinical trial reported 0 adverse events while the secondary clinical trial reported 2 adverse events Therefore the statement neither the primary clinical trial nor the secondary clinical trial registered any adverse events is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "f5daafd4-0b8b-4239-b566-e7b2c1b80825": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence provided for the secondary trial as it incorrectly states that patients who have received chemotherapy or radiotherapy in the last 14 days suffer from unstable angina or have grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial However the exclusion criteria for the primary trial do not include these specific conditions",
        "label": "Contradiction"
    },
    "ce4851a3-948d-4eca-8d86-2a70f3bbd577": {
        "text_answer": "Contradiction The primary trial interventions are administered orally PO not inhalation or intramuscularly The secondary trial interventions are also administered orally PO by mouth",
        "label": "Contradiction"
    },
    "b21fa80a-d451-46c7-8916-bf3029156624": {
        "text_answer": "Entailment The statement is a specific case of the exclusion criteria mentioned in the evidence which states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial",
        "label": "Entailment"
    },
    "3958b171-1f79-4dae-958a-be87bb3b44c0": {
        "text_answer": "Contradiction  The primary trial involves participants receiving a minimum of 8 distinct drug types doxorubicin hydrochloride cyclophosphamide paclitaxel filgrastim capecitabine methotrexate vinorelbine tartrate and trastuzumab or letrozole and undergoing surgery  The secondary trial involves participants taking only two medications everolim",
        "label": "Contradiction"
    },
    "f498a2b6-b3da-45a2-b9d5-ef87ee43914f": {
        "text_answer": "Contradiction The statement does not provide information about the inclusion or exclusion criteria related to mental health bodyweight size of tumors KarnofskyECOG score or estimated life expectancy in the primary trial",
        "label": "Contradiction"
    },
    "25551d37-108d-497a-8e75-825d8d707190": {
        "text_answer": "Contradiction The primary trial only includes patients with unilateral breast cancer",
        "label": "Contradiction"
    },
    "5a1445df-c3d7-4d1e-a4d3-e18ac2238a97": {
        "text_answer": "Entailment  Explanation The statement during the primary clinical trial and the secondary clinical trial no cardiac or psychiatric adverse events were reported is an entailment based on the evidence provided as both trials reported no cardiac or psychiatric adverse events according to the data presented",
        "label": "Entailment"
    },
    "d17230ee-836d-4153-b940-8e3dd7741964": {
        "text_answer": "Contradiction The primary and secondary trials do not involve the use of 4demethyl4cholestryloxycarbonylpenclomedine in a weekly cycle",
        "label": "Contradiction"
    },
    "62d189a0-04ee-44d7-962e-35629b28736c": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 1440 hours while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "321c299b-2264-4cc6-988d-faef346ca38a": {
        "text_answer": "Contradiction The primary trial does not involve alisertib but the statement mentions it in relation to the secondary trial",
        "label": "Contradiction"
    },
    "d8af88b9-e015-4eec-b49f-6b2398e38a5d": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there were no deaths reported in the secondary trial",
        "label": "Contradiction"
    },
    "db5f7526-ae64-4a0c-bea4-53b4bfe95d48": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of a single injection on day 8 in the evidence",
        "label": "Contradiction"
    },
    "d4f98c24-aad0-4784-9b90-da1a99b9a59b": {
        "text_answer": "Contradiction  The evidence shows that a larger percentage of participants in the Triple Negative group had a decrease in the growth factor signature compared to the ERpositive Luminal B group",
        "label": "Contradiction"
    },
    "3137468e-52bf-4bff-a3cc-68f127683f63": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there are no adverse events reported in the primary trial and a 000 rate in the secondary trial The statement implies a slight escalation which is not supported by the evidence",
        "label": "Contradiction"
    },
    "060a4ded-7677-4945-90ff-b6b93204f94c": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 365 days while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "a02d9319-0103-493a-8368-f79dbbe6a223": {
        "text_answer": "Contradiction The statement is not supported by the evidence provided as there is no mention of hypersensitivity reactions in the primary trial",
        "label": "Contradiction"
    },
    "22aed38a-d9c2-4e5e-b738-07f75968c45a": {
        "text_answer": "Contradiction The evidence states that 98 of patients experienced the treatment which is less than 100 Therefore it is impossible for 110 of patients to not experience any adverse events",
        "label": "Contradiction"
    },
    "4d8795f1-f8bf-4c27-9eb1-3f7db45c03ec": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as both cohorts receive different schedules of CUDC101 administration",
        "label": "Contradiction"
    },
    "f706897d-d54e-4449-8bc7-da0bd6fbad01": {
        "text_answer": "Contradiction The primary trial only includes patients with an ECOG performance status of 0 to 2 but the secondary trial includes patients with an ECOG score of 02 or a Karnofsky score of 60100 Therefore a patient with an ECOG score of 1 would be eligible for the secondary trial but not necessarily for the primary trial",
        "label": "Contradiction"
    },
    "e8b222ce-e235-4b8d-b524-521ba583656a": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as diarrhea was not reported as an adverse event in the secondary clinical trial and no adverse events were recorded in the secondary trial according to the evidence provided",
        "label": "Contradiction"
    },
    "3bf96cd4-147b-45f2-b174-e3a375a67e26": {
        "text_answer": "Contradiction The statement does not entail the evidence as it refers to a different condition repeat expansion diseases unrelated to breast cancer and hormonal treatment requirements",
        "label": "Contradiction"
    },
    "b06e2353-00ae-4f10-b072-a4ae5f608d3e": {
        "text_answer": "Contradiction The primary trial includes the requirement of a signed informed consent form while the secondary trial only mentions a written informed consent Therefore the statement that patients who have completed their treatment and are now cancerfree can participate in the primary clinical trial and the secondary clinical trial regardless of their consent status is a contradiction as the primary trial has a stricter consent requirement",
        "label": "Contradiction"
    },
    "15414f62-cb14-4bf8-98aa-0fbd74edd41c": {
        "text_answer": "Contradiction The primary trial compares intraoperative mammography with standard mammography in terms of operative time savings but it does not prove that standard mammography is more efficient than intraoperative mammography based on the evidence provided The secondary trial measures success rates of different breast reconstruction methods and is not directly comparable to the primary trial",
        "label": "Contradiction"
    },
    "8c507ad1-b534-4d16-9a1b-5c92a432eb9d": {
        "text_answer": "Contradiction   Explanation   The primary trial does involve massage therapy which is not a drugbased treatment but it also involves two arms testing different doses of a drug called PF06647020 The secondary trial does not mention any drugbased interventions at all Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "dbc1b653-7c38-4c7c-bad8-5949d6f909ed": {
        "text_answer": "Contradiction The inclusion criteria state that patients must have unilateral breast cancer that is measurable as defined by a tumor size or lymph node involvement Therefore patients with nonmeasurable unilateral breast cancer do not meet the inclusion criteria and are excluded from the trial",
        "label": "Contradiction"
    },
    "3eb6d0c5-4bc4-4808-b8cb-03b3d5d40a07": {
        "text_answer": "Contradiction The primary trial is investigating different interventions Hydrophor and MediHoney not varying quantities of the same therapy The secondary trial is investigating different radiation treatments",
        "label": "Contradiction"
    },
    "2735976f-a517-4b4e-addb-845ef4dc0d33": {
        "text_answer": "Contradiction  The primary trial excludes patients with uncontrolled hypertension systolic BP  180 mm Hg or diastolic BP  100 mm Hg while the secondary trial does not mention any specific blood pressure requirements However the statement specifically mentions unregulated high blood pressure which is not mentioned in the primary trials exclusion criteria Therefore the statement is a contradiction to",
        "label": "Contradiction"
    },
    "4dc9c970-22dc-4117-8169-255a0b3f80d8": {
        "text_answer": "Contradiction  Explanation The statement mentions an eating disorder and Schizophrenia but the evidence only mentions suicidal ideation as a psychiatric adverse event There is no mention of an eating disorder or Schizophrenia in the evidence",
        "label": "Contradiction"
    },
    "043f8072-1e16-4e74-8ad4-50ff1786fb48": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence shows that there were adverse events documented in both trials and the percentage of patients with adverse events was greater than 3 in both trials",
        "label": "Contradiction"
    },
    "31837502-2949-4dc4-bfbe-fc54ca5ccb01": {
        "text_answer": "Contradiction The primary trial does not provide information about the age range for participation",
        "label": "Contradiction"
    },
    "ba589a4b-13ef-43be-8441-438742dd9d5c": {
        "text_answer": "Contradiction The primary trial uses the unit of measure change in units on a scale and the secondary trial uses percentage of participants and number as their units of measure The statement does not mention any of these units",
        "label": "Contradiction"
    },
    "b0c8481b-3041-4b12-b272-11bb5ee7f80e": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no information in the evidence about the number of participants in the primary trial who experienced an adverse event",
        "label": "Contradiction"
    },
    "5d657b3f-a074-480e-8698-24c288553369": {
        "text_answer": "Entailment given that the evidence mentions no interventions involving drugs radiotherapy or CBT in the primary trial and the statement explicitly states no cohorts in the primary clinical trial are subjected to interventions involving drugs radiotherapy or CBT",
        "label": "Entailment"
    },
    "145671c6-1b45-49a9-9fc7-8c65e8461115": {
        "text_answer": "Irrelevant  Explanation The evidence provided in the primary trial does not relate to the statement about the cerebral artery The statement is about the anatomy of the cerebral artery while the evidence is about the absence of adverse events in the primary trial",
        "label": "Entailment"
    },
    "0e28f749-6c65-46fc-93c0-c3b68c96460e": {
        "text_answer": "Entailment The evidence states that the placebo is administered via a 3hour intravenous infusion while trabectedin is administered via a different method specifically a 3hour intravenous infusion on a different day",
        "label": "Entailment"
    },
    "97c738f3-a7ef-4183-9664-5aac4fd64a0e": {
        "text_answer": "Contradiction The primary trial had 13 participants and the secondary trial had 30 participants so the number of participants in the secondary trial was greater than those in the primary trial",
        "label": "Contradiction"
    },
    "451e07e2-524d-459e-872c-1c4b3640f511": {
        "text_answer": "Contradiction The primary trial involves Armodafinil which is not present in the secondary trial",
        "label": "Contradiction"
    },
    "7f3a5491-e157-4fbc-a939-8478889c15dc": {
        "text_answer": "Contradiction The primary trial measures the number of participants with treatmentemergent adverse events while the secondary trial measures changes in total sleep time There is no mention of cognitive disorders in either trial",
        "label": "Contradiction"
    },
    "67b45a2f-d082-4386-b70e-eb212a1762a0": {
        "text_answer": "Entailment The statement is entailed by the inclusion criteria of the primary clinical trial which do allow for patients of any gender with proven evidence of a solid tumor that is locally advanced or metastatic to participate in both phases of the trial",
        "label": "Entailment"
    },
    "eeb18145-fc5f-41d7-bce3-245d21000e7b": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence because the evidence states that over 12 of the patients experienced a confirmed partial response PR or confirmed complete response CR not just a confirmed complete response CR",
        "label": "Contradiction"
    },
    "ddf14eb0-04ae-431b-b4e8-ba97eddc25b7": {
        "text_answer": "Contradiction The primary trial involves the use of Fluciclatide Injection while the secondary trial involves the use of Chloroquine There is no mention of Paclitaxel or Azacitidine in the provided evidence",
        "label": "Contradiction"
    },
    "c8c9752f-a60b-4173-bbe7-deb1a894ebe5": {
        "text_answer": "Contradiction  Explanation  The primary trial includes massage therapy as an intervention which is not a drugbased treatment approach However the secondary trial focuses on drugbased treatment approaches PF06647020 with different dose adjustments The primary trial does not omit medicationrelated analyses as it does not involve any medication in its interventions Therefore the statement is a contradiction based on the provided",
        "label": "Contradiction"
    },
    "c3445b55-8b79-4ac0-9ace-25e48c82760c": {
        "text_answer": "Contradiction  Women aged 18 or 19 are not eligible for the primary trial according to the given inclusion criteria Therefore they cannot wait to be eligible for it",
        "label": "Contradiction"
    },
    "2fc8ee27-e602-47ae-a93b-1c8194e3d6ea": {
        "text_answer": "Contradiction The evidence states that both intervention groups in the primary clinical trial use an instructional compact disc CD for paced breathing instructions",
        "label": "Contradiction"
    },
    "79ddd80e-a0b2-4450-a0df-892e8b15dd63": {
        "text_answer": "Entailment The primary trial has specific eligibility criteria for hot flush patients taking aromatase inhibitors or tamoxifen while the secondary trial has different eligibility criteria for HER2negative metastatic breast cancer patients undergoing taxanebased chemotherapy The two trials have distinct patient populations and different inclusion and exclusion criteria",
        "label": "Entailment"
    },
    "57bc58fc-44ce-4938-9bfa-4750bac013ac": {
        "text_answer": "Contradiction The statement adverse events were commonplace and severe in both the primary clinical trial and the secondary clinical trial is a contradiction to the evidence as the primary trial had a higher percentage of adverse events 4545 compared to the secondary trial 1563",
        "label": "Contradiction"
    },
    "26091849-cc57-4866-8faa-ac9fb64caf69": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it introduces a new concept malignant abdominal neoplasm which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "e3e8c1c5-ae1f-4f90-8584-b24096bb580a": {
        "text_answer": "Contradiction The primary trials inclusion criteria do not mention anything about mental health bodyweight age KarnofskyECOG score or previous treatments However the IPSSR risk category is a factor in the trials eligibility criteria as stated in the exclusion criteria for highrisk patients with a total IPSSR score of 65 or higher",
        "label": "Contradiction"
    },
    "21d59751-a53d-4262-8410-9959aa93dea4": {
        "text_answer": "Contradiction The number of participants in Arm II and Arm III of the primary clinical trial are not identical as shown by the different number of participants analyzed in each arm",
        "label": "Contradiction"
    },
    "e57df144-6c3e-4855-a2d3-fcbec0396750": {
        "text_answer": "Irrelevant  Explanation The statement is not related to the evidence provided as it mentions malignant bronchial neoplasm which is not mentioned or related to the adverse events in the primary or secondary trials",
        "label": "Entailment"
    },
    "ecf58a7c-3e70-4ac2-b37f-d96294786b0d": {
        "text_answer": "Contradiction The primary trial does not provide information about patients selfcare capability or confinement to a bed or chair",
        "label": "Contradiction"
    },
    "eb853544-9c67-43a4-bbfa-c5e35dec2a33": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the given evidence The evidence does not provide any information about atrial myxoma or the administration of the interventions in relation to it",
        "label": "Entailment"
    },
    "95759249-3a95-4735-8ef0-13ec3558aa27": {
        "text_answer": "Contradiction The primary trial requires mammography while the secondary trial does not mention mammography as a requirement Instead it requires a CT scan and blood tests",
        "label": "Contradiction"
    },
    "1dd105a3-5dd4-423a-a40f-ed78e119e698": {
        "text_answer": "Entailment  Explanation The statement in both the primary trial and the secondary trial there were several adverse events which occurred in less than 001 of participants is an entailment based on the evidence provided Although the evidence does not explicitly state that there were several adverse events in both trials that occurred in less than 001 of participants it does show that in each trial there was at least one adverse",
        "label": "Entailment"
    },
    "86609ec7-6d7c-4447-94b4-c9c99d5fd5e1": {
        "text_answer": "Contradiction  The statement implies that there were 10 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy combined However the evidence shows that there were 3 times the number of hepatotoxicity cases compared to the total number of adverse events and there was 1 case each of hypertension and pancreatectomy Therefore the statement is a contradiction to the",
        "label": "Contradiction"
    },
    "b09ea9c8-e3a2-4c82-bbe8-5e84ea151138": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because  1 The primary trial has different inclusion criteria for its Phase I and Phase II portions 2 The secondary trial has different inclusion criteria compared to the primary trial 3 The primary trial has exclusion criteria while the secondary trial does not mention any exclusion criteria for healthy participants  Therefore the statement that the primary trials inclusion and excl",
        "label": "Contradiction"
    },
    "3d35c61e-075e-475e-b3aa-15c04db3a579": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the two interventions in the primary trial involve different combinations of drugs nabPaclitaxel  gemcitabine in Intervention 1 and nabPaclitaxel  carboplatin in Intervention 2 While both interventions include nabPaclitaxel the other drugs and their dosing schedules are different",
        "label": "Contradiction"
    },
    "7ffa3719-812d-4849-b0c7-d34ab22f35f6": {
        "text_answer": "Contradiction  The primary trial provides evidence of a significant improvement in physical wellbeing in the Nuevo Amanecer Peer Support Program group compared to the waitlist control group The secondary trial however reports a higher percentage of participants with positive margins in the standard of care group compared to the device  standard of care group indicating a difference between the two groups These findings are not inconclusive as stated in the question",
        "label": "Contradiction"
    },
    "a2e2d75b-ce3e-4bf6-bfce-c151b9d183d4": {
        "text_answer": "Contradiction Perjeta pertuzumab is mentioned in the secondary trial but it is not mentioned in the primary trial The statement implies that it is not used in the primary trial which is incorrect based on the given evidence",
        "label": "Contradiction"
    },
    "43a347ac-a46d-47cd-80d5-7d83b23bcde9": {
        "text_answer": "Entailment The statement is entailed by the evidence as breast cancer is listed as one of the eligible tumor types in the inclusion criteria of the primary clinical trial",
        "label": "Entailment"
    },
    "8fd1a8ed-8b74-4021-8a90-0400817fda1b": {
        "text_answer": "Entailment The evidence states that there were no adverse events in both cohorts 1 and 2 which is exactly what the statement asserts",
        "label": "Entailment"
    },
    "2cee68da-471f-4c13-811e-9d7ef91d587e": {
        "text_answer": "Contradiction The primary trial involves pregabalin while the secondary trial involves Liposomal Cytarabine and Highdose Methotrexate",
        "label": "Contradiction"
    },
    "65cfa1ae-05d3-4a90-ad5a-852f3cfdf3fc": {
        "text_answer": "Contradiction The primary trial uses the unit of measure change in units on a scale which is not specified in the statement The secondary trial does not mention the unit of measure for the outcome measurement However the statement specifically mentions cm Number of Participants or a unit of time as units of measure that are not used in either trial",
        "label": "Contradiction"
    },
    "5865807e-233c-4a7d-a900-de4af3bdaaf5": {
        "text_answer": "Entailment The evidence shows that the percentage of participants with events ie disease recurrence or death was lower in the Neratinib group 47 compared to the Placebo group 75 indicating a lower rate of iDFS in the Neratinib group",
        "label": "Entailment"
    },
    "786542cd-3793-47a4-b954-9b6c5aa2e652": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as Cohort A in Intervention 1 does not receive any electroporation injections of V934",
        "label": "Contradiction"
    },
    "623db2b4-6824-42e4-9ad6-39cf3bf14dab": {
        "text_answer": "Entailment Both cohorts use the same instructional CD and cohort 2 practices more frequently but the CD provides the instruction for the paced breathing",
        "label": "Entailment"
    },
    "1c4ca195-bc07-4d75-ac19-f7969a20e168": {
        "text_answer": "Contradiction The evidence does not mention raltitrexed and oxaliplatin being administered in the secondary trial",
        "label": "Contradiction"
    },
    "e7204781-fa14-4418-94a4-2660bcd64eeb": {
        "text_answer": "Contradiction  The primary trial involves the use of various drugs administered via different routes IV PO and SC and surgery while the secondary trial only involves the use of two drugs administered orally Therefore the statement that participants in the primary trial undergo surgeries alongside administration of drugs via a subcutaneous route in contrast to participants of the secondary trial who are treated with only two different drugs and several imagistic investigations is a contrad",
        "label": "Contradiction"
    },
    "efbed283-d725-4f05-8e7a-3cb43ce470e6": {
        "text_answer": "Contradiction  Explanation  In Intervention 1 Group A the two IM injections of V935 LD are given every other week over a 3week period  In Intervention 2 Group B the first two IM injections of V935 LD are given following a 4week observation period after three EP injections of V934 LD  Therefore the",
        "label": "Contradiction"
    },
    "6acfb64a-4e08-4cdb-b52d-f0a5c466de4d": {
        "text_answer": "Contradiction  Explanation The evidence provided does not support the statement as it does not contain any information about the results or outcomes of the two cohorts in question The statement makes a comparison between the results of the two cohorts but the evidence only provides information about the dosing and participant numbers in each cohort Therefore it is a contradiction as the statement cannot be determined to be true or false based on the given evidence",
        "label": "Contradiction"
    },
    "d595c94d-93d0-410b-9089-0e026867561f": {
        "text_answer": "Contradiction The statement is not an entailment or a contradiction based on the evidence provided as there is no mention of any eating disorders in the evidence",
        "label": "Contradiction"
    },
    "8093f77e-bb52-47c9-9c58-4be084c8736b": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it mentions 15q261 which is not present in the evidence",
        "label": "Contradiction"
    },
    "2eb882ed-836b-424c-a9b2-06d97f0b2b9e": {
        "text_answer": "Contradiction The evidence states that Intervention 1 uses a validated webbased risk assessment and Intervention 2 is the control group with usual care but there is no mention of cognitive behavioral therapy CBT being included in either intervention",
        "label": "Contradiction"
    },
    "11daa2f8-2ecf-49f7-aa69-844a2bade4b6": {
        "text_answer": "Contradiction  The evidence provided does not allow for a direct comparison between the two trials as they measure different outcomes duration of neutropenia vs incidence of neutropenia and use different doses and number of participants Additionally there is no mention of 9p21 in the evidence",
        "label": "Contradiction"
    },
    "4c9638ac-5716-4657-9279-f756aea52867": {
        "text_answer": "Contradiction  Explanation  The statement seven different drugs are administered to participants of the primary clinical trial who also have to undergo a surgical operation In comparison participants in the secondary clinical trial only receive a pair of drugs and do not need surgery is a contradiction based on the evidence provided  The primary trial involves the administration of 12 different drugs doxorubicin hydrochloride cycloph",
        "label": "Contradiction"
    },
    "029ee1b5-a81a-4690-9f03-442dcf0f5e9c": {
        "text_answer": "Contradiction The statement does not relate to the adverse events recorded in the trials",
        "label": "Contradiction"
    },
    "ecf95a54-fa38-4492-9597-ce81b5a2b661": {
        "text_answer": "Contradiction The statement does not entail that the paced breathing instructional CD is the same for both cohorts in the trial While they may both use the same CD the frequency of practice is different between the two cohorts The second cohort practices twice a day while the first cohort practices once a day",
        "label": "Contradiction"
    },
    "89558178-d2e5-4376-8656-14ba666b44a3": {
        "text_answer": "Contradiction The primary trial explicitly excludes participants who have undergone major surgery within 28 days prior to the study registration date while the secondary trial may consider participants who have had an organ transplant",
        "label": "Contradiction"
    },
    "42ac258c-8420-4a90-b427-d7ca64f246af": {
        "text_answer": "Contradiction The primary trials Intervention 2 administers dexmedetomidine not myalgias",
        "label": "Contradiction"
    },
    "dd7bc677-cddb-4619-893e-aa5b801a0b1a": {
        "text_answer": "Contradiction The primary trial only includes female patients with HER2negative breast cancer who have progressed during or following firstline treatment with Avastin and chemotherapy The secondary trial includes both female and male patients with newly diagnosed ERpositive HER2negative breast cancer Therefore an older male patient with nonmetastatic HER2negative PRnegative breast cancer is not eligible for the primary trial but is eligible for the secondary",
        "label": "Contradiction"
    },
    "29987f94-8331-4136-92f1-4ea5f5c232b9": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 the participants receive 1 mgkg of MCS110 triweekly and in Intervention 2 they receive 3 mgkg of MCS110 triweekly Neither dose meets the requirement of a minimum of 20 mg of MCS110 triweekly as stated in the question",
        "label": "Contradiction"
    },
    "823088ba-be25-4691-aa10-9e86b80fbf8c": {
        "text_answer": "Contradiction  Explanation The evidence shows that no cases of anemia pneumonia or stupor were reported in the primary clinical trial while the secondary clinical trial reported cases of these conditions but the frequency is not higher than in the primary trial for anemia and stupor and lower for pneumonia Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "36a5e0dd-7e3a-4362-9726-0836f7a4c64e": {
        "text_answer": "Contradiction The evidence does not support the statement as it does not provide any information about the presence or absence of a discernible pattern for expression of the set of 40 evaluated genes in patients with normal Vitamin D levels",
        "label": "Contradiction"
    },
    "373e57af-cf54-40c6-9906-eff8eb5d7306": {
        "text_answer": "Entailment The evidence shows that no adverse events were reported for cohort 1 which is exactly what the statement asserts",
        "label": "Entailment"
    },
    "018fd266-6def-4792-85e4-0b12108281b3": {
        "text_answer": "Entailment The primary trial had an arm with a test group Pyridoxine and a placebo group while the secondary trial had an arm with a test group Highdose Oxybutynin Chloride and a control group Lowdose Oxybutynin Chloride The statement that different group arrangements were followed in the two trials is an entailment as the evidence shows that the primary trial had a placebo group",
        "label": "Entailment"
    },
    "d44338be-9054-466e-8cb6-388fd8024e9d": {
        "text_answer": "Contradiction  Explanation  The statement Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2 but 8mgkg MM121 less than cohort 2 is a contradiction to the evidence provided  The evidence states that in Cohort 1 the dose of MM121 is 12 mgkg per",
        "label": "Contradiction"
    },
    "0de75f54-db66-4787-b8a0-7cd21198d8a8": {
        "text_answer": "Contradiction The evidence does not entail that no patient in the trial suffered from the highest level of pain possible for 10 weeks as it only reports the average pain intensity scores and their confidence intervals for each group",
        "label": "Contradiction"
    },
    "a723722c-a7df-4baa-b02a-3d3f15a03db3": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence provided because the primary trial only includes HER2positive breast cancer patients while the secondary trial only includes HER2negative breast cancer patients",
        "label": "Contradiction"
    },
    "6056dc64-7161-4c86-a9ac-04579ea09274": {
        "text_answer": "Contradiction The primary trial requires the administration of denosumab which is a medication while the secondary trial requires the administration of radioactive Tc99M sulfur colloid which is a different substance used for imaging purposes",
        "label": "Contradiction"
    },
    "3f19f518-c46f-4c1f-a738-0066ac81dcc2": {
        "text_answer": "Contradiction The primary trial involves a tissue expander intervention but it does not mention the use of Xrays transendocardial injections CT scans or MRIs However the statement is about a completely different topic  the frequency of an individuals voice making them feel handicapped",
        "label": "Contradiction"
    },
    "a86b695b-6bfb-4c1f-982c-2e10c1b392ae": {
        "text_answer": "Contradiction The evidence does not support the statement that one patient or more who were administered with gtx024 1mg in the primary clinical trial saw an increase of more than 10 kilos in lean body mass The median change in lean body mass for the 1mg group was 155 kg which is far from a 10 kg increase",
        "label": "Contradiction"
    },
    "b7bd2215-d2b2-4cd0-a12a-d12310737373": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients who have received gabapentin or pregabalin recently while the secondary trial allows their participation",
        "label": "Contradiction"
    },
    "2909913c-9739-497b-8bbb-481d3b5c4832": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 6 months while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "33dc8fb6-d0a8-47e4-8052-4a32b5e0c459": {
        "text_answer": "Contradiction The primary trials Intervention 2 administers dexmedetomidine not myalgias The secondary trials Intervention 2 is for patients with vitamin D deficiency who experience myalgias arthralgias andor joint stiffness but it does not administer myalgias itself",
        "label": "Contradiction"
    },
    "86ed4db6-24fe-4a88-ba9b-6be3f98e0525": {
        "text_answer": "Contradiction  Explanation The evidence provided does not allow for a definitive answer on the statement as there is no data given in the evidence regarding the results of the LBH589 With Capecitabine cohort compared to the LBH589 and Lapatinib cohort in the primary trial",
        "label": "Contradiction"
    },
    "bee98681-7738-44a5-b437-0c172bdd3eeb": {
        "text_answer": "Entailment Both the primary and secondary trials involve oral administration of interventions",
        "label": "Entailment"
    },
    "987d8384-9e51-497a-a1f4-2646ec7c94f8": {
        "text_answer": "Entailment  Explanation The statement is an entailment because the evidence shows that Herceptin trastuzumab is included in Intervention 1 and Herceptin is also used in Intervention 2 of the primary clinical trial",
        "label": "Entailment"
    },
    "bfb34bfd-74f8-4f11-b28b-643fe6e79d10": {
        "text_answer": "Contradiction The primary trial measures changes in hot flash scores while the secondary trial measures overall response rate in solid tumors using RECIST criteria",
        "label": "Contradiction"
    },
    "af417420-0bcb-407d-8470-b73cafe31893": {
        "text_answer": "Contradiction  Patients diagnosed with malignant ductal carcinoma in situ are excluded from the primary trial but they are eligible for the secondary trial according to the provided evidence However the statement suggests that they are excluded from the secondary trial which is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "511b7c14-9ba0-43ea-98e0-93f217e3ef07": {
        "text_answer": "Contradiction The statement mentions Arimidex which is not used in the secondary trial but the primary and secondary trials have no relation to animal viruses",
        "label": "Contradiction"
    },
    "70c3a676-7000-465c-9d6d-3c53fbf185c0": {
        "text_answer": "Contradiction The intervention timeline in the secondary clinical trial is not exactly identical to the primary clinical trial as the secondary trial includes the administration of medication placebo or vitamin D in addition to the standard of care which is not the case in the primary trial",
        "label": "Contradiction"
    },
    "61215857-54c4-4622-afc2-7249194a96f6": {
        "text_answer": "Contradiction The primary trial requires participants to be resistant to AI therapy while the secondary trial does not mention this as a requirement",
        "label": "Contradiction"
    },
    "b56f166c-a9b7-4990-bfb8-d13f0e89f76d": {
        "text_answer": "Contradiction  Explanation  In the primary trial the Intervention 1 includes Gefitinib ZD1839 which is a drug However the statement in question asserts that the primary trial involves using at least three different medical products While Gefitinib is a drug it does not necessarily mean that there are two other medical products involved in the trial Therefore the statement is a contradiction based on the evidence",
        "label": "Contradiction"
    },
    "20b96fad-2ca0-4bee-a541-0006c6ff8037": {
        "text_answer": "Contradiction  The statement that 25 of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression is not entailed by the evidence as the evidence only reports the occurrence of these adverse events in 14 2500 of the patients in cohort 2 for increased pleural effusion and no occurrences for rapids disease progression in either cohort",
        "label": "Contradiction"
    },
    "9e2bec72-4318-4cf8-9ed8-82a572ce6d55": {
        "text_answer": "Contradiction The primary trial includes a breast tumor that is 1 cm in diameter while the statement specifies a tumor of 1300mm 130 cm in diameter which is significantly larger and not within the inclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "baea8626-3768-47aa-a4ba-e792164302fd": {
        "text_answer": "Entailment The primary trial uses a higher dose of Lenalidomide 5mg orally daily for 573 days and lasts for a longer period of time compared to the secondary trials Lapatinib intervention 1500mg orally daily for 6 weeks followed by 1500mg orally plus weekly paclitaxin for 12 weeks The statement accurately reflects the information provided in the evidence",
        "label": "Entailment"
    },
    "f2d85883-6334-4948-901e-22cc11da66ac": {
        "text_answer": "Entailment The statement is a subset of the inclusion criteria for the primary trial for breast cancer patients",
        "label": "Entailment"
    },
    "f1494243-0e25-48d1-b7d8-e92ffed41e1d": {
        "text_answer": "Contradiction The statement does not entail or follow from the evidence as there is no mention of psychiatric adverse events eating disorder or Schizophrenia in the evidence related to the primary trials adverse events The evidence only mentions ventricular tachycardia fever flulike symptoms catheter related infection suicidal ideation and thromboembolic event",
        "label": "Contradiction"
    },
    "5be979ed-e272-48c6-b301-c5464cc07730": {
        "text_answer": "Contradiction The primary trial had 13 participants and the secondary trial had 30 participants but the statement suggests that the secondary trial had a higher turnout which is not the case",
        "label": "Contradiction"
    },
    "348ce220-f650-4df2-9593-586ddaabe491": {
        "text_answer": "Contradiction  Explanation The statement the primary clinical trial showed no difference in the improvement rate of lymphedema between acupuncture patients and those on the waiting list is a contradiction to the evidence presented as the results show a statistically significant difference in mean arm circumference between the two groups at the 6week timepoint The evidence indicates that the acupuncture group had a smaller mean arm circumference than the wait",
        "label": "Contradiction"
    },
    "2980900b-74b7-4c96-8ab9-91fc994211d1": {
        "text_answer": "Contradiction The primary trial measures the number of participants with treatmentemergent adverse events while the secondary trial measures the change in total sleep time in minutes These are different outcome measures",
        "label": "Contradiction"
    },
    "79bb0bb4-31cf-45e2-8fae-475bfdbd6a09": {
        "text_answer": "Contradiction The evidence provided does not mention anything about radiation therapy in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "e5fb73ea-4e3b-47b2-84ac-a4d403b646ba": {
        "text_answer": "Contradiction  Explanation The statement most of the adverse events detected in the primary trial were not blood and bone marrow related contrasting the secondary trial which observed an abundance of such is a contradiction based on the evidence provided  In the primary trial 10000 of the adverse events were recorded and 5200 of them were related to blood and bone marrow In",
        "label": "Contradiction"
    },
    "49db6e75-199e-4c15-bb9b-6cf677d9c421": {
        "text_answer": "Contradiction The primary trial requires confirmation of mutations in certain genes while the secondary trial does not have this requirement",
        "label": "Contradiction"
    },
    "b00e48fb-d5db-46f8-8f16-6f538d178b26": {
        "text_answer": "Contradiction The evidence does not provide sufficient information to determine if the statement is an entailment or contradiction as it does not mention the frequency of cardiac and psychiatric adverse events in the secondary trial",
        "label": "Contradiction"
    },
    "1c968571-9618-4a86-af59-6e8367b1128f": {
        "text_answer": "Contradiction The evidence does not support the statement that none of the patients in both cohorts had a lifespan under 2 years The median survival times reported in the results are less than 2 years for both groups",
        "label": "Contradiction"
    },
    "82aff6ce-3305-4fb1-87c0-28f4a1e8a981": {
        "text_answer": "Contradiction The statement is not an entailment as some breast cancer patients received 1000 mcgday but ovarianperitoneal cancer patients did not all receive that dose",
        "label": "Contradiction"
    },
    "24b44ec0-b0a4-4b5a-9028-164eda456529": {
        "text_answer": "Entailment The statement is an entailment because the evidence clearly states that the placebo intervention involves the administration of Buminate solution in a dose of 04ml per injection while the alloMSCs intervention involves the administration of alloMSCs in a dose of 100 million cells which is not directly comparable to the placebo dose Therefore the statement that the placebo intervention is administered in a different dose from the all",
        "label": "Entailment"
    },
    "f3091230-221d-4c82-9d37-06e04c12ba48": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial does not mention anything about optic chiasm neoplasm or organ transplant as inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "dfcbb31f-65e0-4847-9840-536eff03c1f3": {
        "text_answer": "Contradiction The statement only patients who demonstrated positive responses to previous Herceptin treatments are eligible for the primary clinical trial is a contradiction to the evidence provided as the evidence states that patients with HER2 FISH negative or unknown HER2 status are eligible for treatment with single agent vinflunine and they will not receive trastuzumab Therefore not all patients in the trial have previously responded positively to Herceptin treatments",
        "label": "Contradiction"
    },
    "6a2679df-a2a3-40cf-8252-2f8bf8584b8d": {
        "text_answer": "Neutral Neither Entailment nor Contradiction  Explanation The statement is not an entailment because the presence of abdominal examination is not directly stated in the evidence It is also not a contradiction because there is no information in the evidence that suggests abdominal examination is not performed on the patients in the trials",
        "label": "Entailment"
    },
    "d5383c8a-360f-4e17-af4e-2f0a05fc2b1a": {
        "text_answer": "Contradiction The secondary trial does not measure muscle gains as an outcome measure Instead it measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale",
        "label": "Contradiction"
    },
    "2dac87e4-2a34-42e1-8aec-d2a23d61269a": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the requirement for resistance to AI therapy is specific to the primary trial and not mentioned in the secondary trial",
        "label": "Contradiction"
    },
    "4ecc7d3a-ada3-4bda-8236-f0450fc709af": {
        "text_answer": "Contradiction The primary trial results do not demonstrate that the placebo arm outperformed Arm A in terms of overall response rate Instead Arm A had a higher overall response rate compared to the placebo in the given results",
        "label": "Contradiction"
    },
    "c8235719-3fd8-43e9-8ba6-d99393220240": {
        "text_answer": "Contradiction The evidence states that there are inclusion and exclusion criteria for the primary trial including age performance status and prior chemotherapy treatment",
        "label": "Contradiction"
    },
    "a8e679cc-cd10-409c-8434-8bb059146815": {
        "text_answer": "Contradiction The statement is incorrect as syncope occurred in 1667 of the primary trial patients not 5000",
        "label": "Contradiction"
    },
    "d5f5e4f5-9a58-485a-8646-649ce93e37c7": {
        "text_answer": "Contradiction The primary trial does not involve highintensity focused ultrasound therapy but rather radiation therapy The secondary trial involves the administration of fulvestrant but not intravenously and not daily",
        "label": "Contradiction"
    },
    "53e8b3b4-40dc-4ffe-b555-a65fd7741dbf": {
        "text_answer": "Contradiction The statement has no relation to the inclusion or exclusion criteria for either trial The statement is about tert promoter mutation analysis which is not mentioned in the provided evidence",
        "label": "Contradiction"
    },
    "d0600d22-c3de-4028-82a5-a42008e2018d": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of abnormal liver function tests in either trial The statement is about liver function tests but the evidence only mentions Biliary colic which is not the same as abnormal liver function tests",
        "label": "Contradiction"
    },
    "0a144293-fbab-4ba1-ad15-cf05a8624a1c": {
        "text_answer": "Contradiction The statement is not related to the evidence provided as it mentions Chinese ethnicity which is not mentioned in the evidence The evidence only pertains to the outcome measures of the primary and secondary trials",
        "label": "Contradiction"
    },
    "c66df8c2-afad-4638-a1c2-5539fc03a2be": {
        "text_answer": "Contradiction The statement does not relate to the provided evidence The evidence does not mention anything about a failsafe system device in either trial",
        "label": "Contradiction"
    },
    "67b93677-87f6-4a11-8dea-66a3c2242b19": {
        "text_answer": "Contradiction The inclusion criteria state that participants must have no evidence of dementia  Mini Mental State Examination MMSE 23 but some evidence of cognitive impairment Frontotemporal dementia and mixed dementia are both types of dementia",
        "label": "Contradiction"
    },
    "abed7fca-4cb8-42bb-a206-bf1c54f9af99": {
        "text_answer": "Contradiction The statement is about the outcome measurement for the trials which is not related to the presence or absence of itching",
        "label": "Contradiction"
    },
    "5ff118a6-d62c-473d-8935-1767a378c92a": {
        "text_answer": "Entailment The evidence states that only some patients those in Intervention 1 are required to undergo a SPECT scan not all patients",
        "label": "Entailment"
    },
    "4eb8855e-766e-4588-a42f-655ca3d80140": {
        "text_answer": "Contradiction   The primary trial administers its intervention orally sublingually for Vitamin B12 while the secondary trial employs a subcutaneous route for memantine hydrochloride Neither trial involves intravenous administration",
        "label": "Contradiction"
    },
    "f4e91f1d-d645-4759-904d-12e509336562": {
        "text_answer": "Contradiction  The evidence shows that the median aAUCpa for Arm II Control was more negative than Arm I Cryotherapy indicating that the symptoms in Arm II worsened more from baseline compared to Arm I However the statement suggests that the symptoms were more intense in Arm II which is not directly supported by the evidence as it does not necessarily mean that more intense symptoms equate to more negative aAUCpa values",
        "label": "Contradiction"
    },
    "ca80b7bd-73a6-4c6a-9ab7-3e1dc789f12c": {
        "text_answer": "Contradiction The primary and secondary trials measure different outcomes using different units of measure The primary trial measures quality of life using a scale while the secondary trial measures intraoperative success using a percentage There is no evidence provided to support the statement that the secondary trials cohort 2 produced better results in terms of picogram equivalents per gram",
        "label": "Contradiction"
    },
    "e412ecde-3195-42c6-b125-7d2697ea89c1": {
        "text_answer": "Contradiction The statement is not an entailment as the primary trial does not involve ALT801",
        "label": "Contradiction"
    },
    "b4fd327d-375e-4021-98af-a59ee4e30c0b": {
        "text_answer": "Contradiction The secondary trial specifically includes only female or male patients who are 18 years of age or older The primary trial includes female patients who are over 18 years of age but the statement mentions a patient who is only 20 years old",
        "label": "Contradiction"
    },
    "911ba31e-f28f-4c5b-8b0e-fa16e58ecc29": {
        "text_answer": "Contradiction The statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "9b75138c-e074-43f0-866d-9a43ce7be217": {
        "text_answer": "Contradiction The statement patients involved in the primary clinical trial are administered oral drugs twice daily for an entire month is not an entailment of the evidence as some patients in the trial receive oral drugs once daily and not twice daily",
        "label": "Contradiction"
    },
    "bcbde299-e3e8-40e6-8cea-d843a44e68d6": {
        "text_answer": "Entailment The evidence states that the subjects were treated with partial breast irradiation which does involve the delivery of radiation therapy The statement that the primary clinical trial provides an arrangement of treatment cycles including dosage and delivery of radiation therapy is an entailment as it follows logically from the given evidence",
        "label": "Entailment"
    },
    "6ee5619b-ec91-4d55-b57a-a69eb3315c3d": {
        "text_answer": "Contradiction The primary trial is not observing the effects of various doses of the same medication on its study participants but rather comparing two different interventions Hydrophor and MediHoney The secondary trial is applying different medications PF05212384 with different doses in combination with docetaxel",
        "label": "Contradiction"
    },
    "f7247f7f-056b-4725-b771-4f4388a643aa": {
        "text_answer": "Contradiction  The statement is asking about lapatinib 800 mg but the evidence provided is about lapatinib 1000 mg",
        "label": "Contradiction"
    },
    "a85e8f5b-fb4f-4adc-a020-d40a42e8be96": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the administration of V935 LD in Intervention 1 is given every 4 weeks while in Intervention 2 it is given every other week over a 3week period",
        "label": "Contradiction"
    },
    "e501b32a-a182-4275-bcdf-88aca4446cf9": {
        "text_answer": "Entailment The primary trial includes patients with stage 4 breast adenocarcinoma who are ER or PR positive or HER2neu negative and the secondary trial also includes patients with these same characteristics Therefore the statement that patients with these characteristics can participate in both trials is an entailment",
        "label": "Entailment"
    },
    "c77be931-75c0-4036-a07d-7d49b5b9fcc6": {
        "text_answer": "Contradiction The evidence states that for both trials the patient must have a functional ECOG  2 status Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "993a3b60-def6-421c-a8a5-964062336a2c": {
        "text_answer": "Contradiction  Explanation The statement is about the reduction in tumor diameter by 40 on average with tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after breast cancer surgery However the evidence provided in the results 1 is about the change in Ki67 expression in tumors with tamoxifen 20 mg po daily for 7 days prior to surgery and for",
        "label": "Contradiction"
    },
    "6cbfc99b-6531-412f-bd30-b4a803983831": {
        "text_answer": "Contradiction The primary trial uses a 21day cycle for its intervention not a 3week cycle The secondary trial does not have a cyclic treatment specified",
        "label": "Contradiction"
    },
    "7b76f6bb-6bf2-4bec-8409-9c4b90cc81c8": {
        "text_answer": "Entailment Both trials are studying the same drug empegfilgrastim but with different doses and outcome measurements",
        "label": "Entailment"
    },
    "19cdc906-c8e3-498d-b33e-08ad9037af5d": {
        "text_answer": "Contradiction The primary trial measured time to progression in months not days and the secondary trial measured percentage of patients with objective response",
        "label": "Contradiction"
    },
    "41ef54ae-5826-49c3-85d2-1da610317f26": {
        "text_answer": "Entailment The evidence states that participants receive epirubicin cyclophosphamide docetaxel and trastuzumab throughout the study which is consistent with the statement that they receive four different drugs",
        "label": "Entailment"
    },
    "1a076a19-c76d-4de0-b7de-473c0e278bbe": {
        "text_answer": "Contradiction The evidence does not mention dyspnea as an adverse event in either cohort",
        "label": "Contradiction"
    },
    "4023d560-6425-4207-aa76-543be30fd786": {
        "text_answer": "Contradiction  Explanation The primary trial intervention uses Yttrium90 Radioembolization which is a type of radiation therapy and not a targeted molecular therapy or a surgical intervention nor is it a form of regenerative medicine  The secondary trial intervention involves a combination of ibrutinib and MEDI4736 which are targeted molecular therapies  Therefore the statement is a contradiction as",
        "label": "Contradiction"
    },
    "6ee2e04c-88fc-4447-a477-18b2564aca4e": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial only includes patients with metastatic invasive breast cancer that is negative for the estrogen receptor ER progesterone receptor PR and HER2 by institutional guidelines and the patient described in the statement has ILCIDC which may or may not meet these criteria",
        "label": "Contradiction"
    },
    "b6af5ca8-21c0-43c5-898b-53e45b5e122a": {
        "text_answer": "Contradiction The primary trial requires mammography as a part of the inclusion criteria while the secondary trial requires imaging tests not necessarily mammography as a part of the inclusion criteria but does not exclude candidates based on having undergone imaging tests before the trial",
        "label": "Contradiction"
    },
    "4665519b-6dba-440f-9cc3-677ab616ecd6": {
        "text_answer": "Contradiction The primary trial requires mammography while the secondary trial does not mention any imaging test",
        "label": "Contradiction"
    },
    "f66e21d9-801f-4613-99da-c033734189e4": {
        "text_answer": "Contradiction  Explanation  The primary trial includes male and postmenopausal female subjects while the secondary trial specifically includes women Therefore the statement that in both the primary and secondary clinical trials eligibility is not determined by the gender of the individual is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "ba873942-b869-4596-bbd6-30d54c94e31b": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because both Intervention 1 and Intervention 2 involve the injection of the same amount 04 to 10 mCi of radioactive Tc99M sulfur colloid",
        "label": "Contradiction"
    },
    "3558390b-24a7-45e7-84f1-f512e669dcef": {
        "text_answer": "Entailment Both trials reported a complete absence of recorded adverse events in their respective cohorts as stated in the question",
        "label": "Entailment"
    },
    "84f10108-19b7-499f-9144-b3e6c0b253d5": {
        "text_answer": "Neutral The primary and secondary trials do not directly address appendiceal carcinoma or its TNM staging in their results",
        "label": "Entailment"
    },
    "94df8c14-d1c9-44cb-9f6d-1706044cbc9a": {
        "text_answer": "Contradiction The evidence shows that Cohort A receives V935 LD as two injections given every other week over a 3week period while Cohort B receives V934 LD followed by V935 LD with the V935 LD injections given every other week over a 3week period as well However the statement assumes that both cohorts receive the same two injections of V9",
        "label": "Contradiction"
    },
    "4f9e48d7-08cc-4fa3-a317-4f3f23ebf19d": {
        "text_answer": "Contradiction The primary trial does not provide any information about ki67 expression in tumors",
        "label": "Contradiction"
    },
    "ef6928bd-e4ac-44f6-a7bd-292a728df94b": {
        "text_answer": "Entailment assuming Aes in the statement refers to Adverse Events and cardiac or psychiatric includes conditions like Atrial fibrillation Cardiac failure congestive Pericardial effusion and Chest discomfort  Explanation The statement There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial is an entailment of the evidence provided as the evidence also",
        "label": "Entailment"
    },
    "a3ad31e2-9017-438a-bbc2-acab87940134": {
        "text_answer": "Entailment  Explanation The statement over 50 patients in the primary trial treated with lapatinib 1000 mg  nabpaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR is an entailment based on the evidence provided The evidence states that the overall tumor response OR was defined as the percentage of participants who experienced either a confirmed CR or PR",
        "label": "Entailment"
    },
    "5499c5cb-97fa-4905-b163-7f5830cd59b9": {
        "text_answer": "Contradiction  Explanation  The statement in group 1 of the primary clinical trial no participants presented with lesions while in group 1 of the secondary clinical trial more than 90 showed signs of radiation dermatitis as well as hyperpigmentation is a contradiction based on the provided evidence  In the primary clinical trial there were no participants with lesions detected in the healthy volunteers group However",
        "label": "Contradiction"
    },
    "06695494-b56b-49da-9166-b0aae3f322f3": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary and secondary trials do use the units of number of participants and time in their results respectively",
        "label": "Contradiction"
    },
    "c36a826d-892a-4115-af40-e60050fffd8a": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that only 571 of patients in the primary trial suffered adverse events",
        "label": "Contradiction"
    },
    "564d9a7d-327b-45be-af87-1971e15a9db4": {
        "text_answer": "Contradiction The evidence provided does not relate to the statement about 1p33p32 and the adverse events in cohort 1 of the primary trial",
        "label": "Contradiction"
    },
    "17414a49-7410-41fe-ab90-99311491d367": {
        "text_answer": "Contradiction  The evidence states that participants receive oral lapatinib once daily in Arm 1 of the primary clinical trial not twice daily as stated in the question",
        "label": "Contradiction"
    },
    "6ab38a80-a2a5-40f1-a8d5-250db9f54740": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence provided as the intervention in the primary trial is administered intravenously IV and the interventions in the secondary trial are given intravenously IV and orally PO",
        "label": "Contradiction"
    },
    "52db54bd-4dbe-4778-b5c4-30a8e4ce0a1f": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "14678a23-57ea-4d56-a87a-c1a910af9e78": {
        "text_answer": "Contradiction  Explanation The evidence shows that at week 12 and week 24 the number of participants with clinical benefit CR PR or SD was reported However the statement asks about the majority of patients experiencing a complete response by week 42 which is not directly addressed in the evidence Additionally the evidence indicates that no participants in the trial had a complete response by week 24 which contradicts the statement",
        "label": "Contradiction"
    },
    "21c021d2-764d-4028-b945-2aeb525b9888": {
        "text_answer": "Contradiction The statement that the primary trial and the secondary trial both use pCR as their outcome measurement there is a small difference in results between the two cohorts of the primary trial whereas in the secondary trial Arm 2 had worse results than arm 1 as a higher percentage of arm 2 patients experienced pCR is a contradiction to the evidence presented The primary trial had a higher percentage of participants with pCR in Arm 1 compared to",
        "label": "Contradiction"
    },
    "6892893c-5c7b-492b-950f-e155bd928ebe": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "98a95bef-b43a-4582-8b58-d0c154824cd0": {
        "text_answer": "Contradiction The evidence explicitly states that individuals with interstitial lung disease or pneumonitis are excluded from the trial Diffuse parenchymal lung disease is a type of interstitial lung disease",
        "label": "Contradiction"
    },
    "b799b56b-51cd-4200-852f-f80a347de63e": {
        "text_answer": "Contradiction The evidence does not mention any age restrictions beyond 18 years and there is no mention of weight requirements for the participants",
        "label": "Contradiction"
    },
    "6ffedb4b-9ff8-445a-9e5f-872d54ca58fb": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence clearly shows that there were adverse events reported in the primary clinical trial",
        "label": "Contradiction"
    },
    "91d0039d-b186-4f52-b214-1000341d3f2c": {
        "text_answer": "Entailment The evidence does not provide enough detail about the number of adverse events in the secondary trials Adverse Events 2 section but it does confirm that some adverse events were recorded making the statement an entailment",
        "label": "Entailment"
    },
    "0c5c681e-d64b-41e8-add7-b34f03573370": {
        "text_answer": "Contradiction According to the primary trial exclusion criteria a pulmonary embolism within the last two months is a reason for exclusion However the statement suggests that it does not affect eligibility for the secondary trial",
        "label": "Contradiction"
    },
    "3ce5a661-e1a9-4164-935e-15563602eefc": {
        "text_answer": "Contradiction  Explanation The evidence shows that out of the total number of patients in the primary trial only one patient in cohort 1 had both increased pleural effusion and rapid disease progression and one patient in cohort 2 had increased pleural effusion Therefore the statement that 75 of patients in the primary trial suffer increased pleural effusion and rapid disease progression is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "2630006c-6708-4c09-a946-aefe1859770d": {
        "text_answer": "Contradiction The primary trial includes postmenopausal female subjects and male subjects while the secondary trial includes female subjects only",
        "label": "Contradiction"
    },
    "c5fe1272-e91c-44cd-888d-359ad43e34c4": {
        "text_answer": "Contradiction The evidence does not mention swelling hypothermia or confusion as adverse events in either the primary or secondary clinical trials",
        "label": "Contradiction"
    },
    "4be496e4-ba05-47a1-bc0f-b8627e47becb": {
        "text_answer": "Contradiction The primary trial reports Time to Progression in months while the secondary trial reports Number of Participants with Objective Response These are different outcome measures",
        "label": "Contradiction"
    },
    "31b59e3d-4bb8-47ea-a7a1-9d8523245970": {
        "text_answer": "Neutral The statement is not directly related to the given evidence  Explanation The statement epidermal hyperplasia is a hyperplasia of the epidermis is a factual statement about hyperplasia in general but it does not directly relate to the inclusion criteria for the primary trial The primary trial includes patients with DCIS ductal carcinoma in situ which is a type of breast cancer that affects the ducts",
        "label": "Entailment"
    },
    "981d8b53-f02f-4845-af5f-a1d5abc2d63c": {
        "text_answer": "Contradiction The primary trial involves monthly injections of denosumab while the secondary trial does not involve injections at all but rather the use of a handheld gamma camera and gamma probes for lymphoscintigraphy",
        "label": "Contradiction"
    },
    "0cf140db-a8c7-47ee-9753-c46c056fe1b1": {
        "text_answer": "Contradiction  Explanation  In the primary trial there is no information provided about the dosage of MM121 and Paclitaxel given to participants  In cohort 1 of the secondary trial participants received a 2 week runin of MM121 20 mgkg weekly followed by 4 cycles of MM121 20 mgkg weekly",
        "label": "Contradiction"
    },
    "08dad9c0-a333-4791-b845-79b549c31890": {
        "text_answer": "Contradiction The evidence shows that only 571 of participants reported adverse events in the primary trial",
        "label": "Contradiction"
    },
    "da125a54-e88c-40a5-8134-0bd021287c6f": {
        "text_answer": "Entailment The evidence states that participants in the primary clinical trial can have measurable or nonmeasurable disease which includes measurable metastasis and disseminated disease to various body parts",
        "label": "Entailment"
    },
    "3fca106b-449b-416e-a961-bf0dc8999ddb": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as it makes a comparison between two specific adverse events that are not mentioned in the same context in the evidence",
        "label": "Contradiction"
    },
    "eca5c391-f479-448d-bff8-313a7df673b4": {
        "text_answer": "Entailment  Explanation  The primary trial administers cyclophosphamide in combination with doxorubicin and in the secondary trial it is given as part of the neoadjuvant chemotherapy regimen Paclitaxel is also administered in both trials in the primary trial as part of the weekly CarboplatinNabPaclitaxel regimen and in the secondary trial as part",
        "label": "Entailment"
    },
    "32775858-8e4c-41e3-87c3-2c60dbc780ee": {
        "text_answer": "Contradiction The primary trial includes patients with any N and no evidence of metastasis M0 but the statement specifies a patient with metastatic disease M1 The secondary trial includes patients with metastatic disease so the statement is a contradiction to both trials",
        "label": "Contradiction"
    },
    "ccc2b2e3-5588-4eed-8a05-67fb21c29a9b": {
        "text_answer": "Contradiction The statement implies that no other adverse events were observed in the secondary trial besides eyelid oedema upper gastrointestinal haemorrhage and chest pain However the evidence shows that there were also cases of vertigo constipation and diarrhea in the secondary trial which contradicts the statement",
        "label": "Contradiction"
    },
    "796289cc-1400-4a5c-9da0-d19104d6aae4": {
        "text_answer": "Contradiction The evidence does not provide information about the number of participants in the first and second cohorts The evidence only provides information about the percentage of participants with events in each cohort",
        "label": "Contradiction"
    },
    "9b5ee8d1-9b19-4f79-a80f-58422f1f5cee": {
        "text_answer": "Entailment  Explanation The statement in the primary clinical trial the first group receives more substantial amounts of cyclophosphamide than eribulin is entailed by the evidence because the first intervention ErC uses a cyclophosphamide dose of 600 mgm2 which is more than the eribulin dose of 14 mgm2  Similarly the statement the",
        "label": "Entailment"
    },
    "7852457b-3915-431f-adbf-cdba2b736c46": {
        "text_answer": "Neutral The statement does not directly follow from the evidence but it is not contradictory either  Explanation The statement is about the presence or absence of adverse events in relation to a lig4 gene mutation while the evidence only reports the number of adverse events in two clinical trials The statement does not directly follow from the evidence but it is not contradictory either as the evidence does not provide any information about the relationship between the",
        "label": "Entailment"
    },
    "58db966b-cb5c-426f-8b8e-f9e68adc1531": {
        "text_answer": "Entailment The evidence states that cohort 2 received a dosage of enzalutamide that is 160 mg which is indeed twice the dosage of 80 mg received by cohort 1",
        "label": "Entailment"
    },
    "d5c262d5-584c-4417-a768-9374cd6c8bc2": {
        "text_answer": "Contradiction The primary trial did not record any adverse event of vomiting while the statement claims that it was the most prevalent adverse event with an incidence rate above 10",
        "label": "Contradiction"
    },
    "388cc99c-4cb3-4ff9-9496-07f4a6bf6ac7": {
        "text_answer": "Contradiction The statement is not supported by the evidence provided as there is no data on patients administered with testosterone cream in the given trial",
        "label": "Contradiction"
    },
    "a2cdb319-3410-467d-94f0-0908534ebf22": {
        "text_answer": "Neutral  Explanation The statement is not an entailment or a contradiction based on the evidence provided The evidence only states that both interventions are administered for the same duration of time but it does not provide information about whether or not participants in the placebo group were found dead during the study",
        "label": "Entailment"
    },
    "a9497198-5380-4af2-ace4-eb2e904a855a": {
        "text_answer": "Neutral Irrelevant  Explanation The statement doctor and I shared responsibility for deciding which treatment is best for me is not an entailment or contradiction based on the evidence provided The evidence pertains to the inclusion and exclusion criteria for a clinical trial and the statement is not related to those criteria",
        "label": "Entailment"
    },
    "bd70ab1b-2bfb-4294-9ca7-01e1e2b670b7": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as gender is a determining factor for eligibility in both the primary and secondary trials",
        "label": "Contradiction"
    },
    "56e88bbd-7a3c-4a3b-a6cf-3f9b9e632b53": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events in both trials but the statement implies that the quantity of adverse events was the same which is not the case as there are no events in both trials",
        "label": "Contradiction"
    },
    "26583828-8ea0-4211-a688-3deda44eeec4": {
        "text_answer": "Contradiction  Explanation The evidence provided does not mention hypoglycaemia hyponatraemia or hypokalaemia as adverse events in either the primary or secondary clinical trials",
        "label": "Contradiction"
    },
    "8dd8adde-dac7-4303-8a4b-46e27e36862f": {
        "text_answer": "Contradiction The statement is about the number of adverse events related to blood and bone marrow in the primary and secondary trials while the evidence provided does not mention anything about the number of resorptions in either trial",
        "label": "Contradiction"
    },
    "98627f6b-e597-4427-b831-aa8856de321e": {
        "text_answer": "Contradiction The secondary clinical trial does not demand participants to be entirely disabled as stated in the inclusion criteria it only requires patients to be ambulatory with a functional ECOG  2 status",
        "label": "Contradiction"
    },
    "d11356c5-cf48-40dc-aa23-46e71f564afd": {
        "text_answer": "Entailment The primary trial had fewer total adverse events and fewer types of adverse events than the secondary trial as shown in the evidence",
        "label": "Entailment"
    },
    "26583790-21ca-4820-9932-67e3d6eeb8b0": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses the outcome measurements and results of two trials one on acupuncture and the other on sulforaphane supplementation and neither trial uses the number of participants with treatmentemergent adverse events as the outcome measurement The statement is about a different topic which is the genus of a bacterium",
        "label": "Contradiction"
    },
    "06be4ae9-c67e-4aad-b5b5-caf3dd9f30a9": {
        "text_answer": "Contradiction  Explanation The statement mentions Mucositis Oral epileptic seizures and Thromboembolic events but neither of these adverse events are mentioned in the evidence from either the primary or secondary trials",
        "label": "Contradiction"
    },
    "0919109a-9ee1-4fa0-b612-a9902379e48d": {
        "text_answer": "Entailment Both interventions are administered intravenously in Intervention 1 and by subcutaneous injection in Intervention 2 but the route of administration remains the same as they are both injectable medications",
        "label": "Entailment"
    },
    "402d7814-ace1-4f78-8c96-c3205001c5ee": {
        "text_answer": "Contradiction The evidence shows that cohort A receives CUDC101 for 5 days consecutively every 14 days while cohort B receives CUDC101 for 3 days a week for 3 weeks every 28 days Therefore the statement that both cohorts are administered CUDC101 at the same frequency is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "58165e03-4aa6-4d0c-8256-dbc92ee900c4": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because Capecitabine was not administered orally every day to every patient in cohort 2 of the primary trial for the first 21day cycle Instead it was administered orally twice daily for 14 days out of every 21 days",
        "label": "Contradiction"
    },
    "8150f869-b9e6-422b-a13a-1bdccee14f19": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not mention anything about fentanyl spray being administered during the primary trial",
        "label": "Contradiction"
    },
    "c7960079-5d1b-451e-818f-0890272ddb63": {
        "text_answer": "Contradiction The primary trial does involve massage therapy which is not a drugbased treatment but it is not mentioned in the statement The statement only mentions the absence of drugbased treatments in the primary trial",
        "label": "Contradiction"
    },
    "0d8cdde2-046a-4684-8af5-38cd82935901": {
        "text_answer": "Entailment The statement is not directly about the number of patients affected by each adverse event but rather about the proportion of patients affected by each event type The evidence shows that no individual event type affected more than a quarter of the patients in the cohort which is consistent with the statement",
        "label": "Entailment"
    },
    "0c973f54-1aad-4349-acf5-607cb1ef2d6a": {
        "text_answer": "Contradiction The statement makes a comparison between the primary and secondary trials regarding the occurrence of Cholelithiasis but the evidence provided does not include the number of participants with Cholelithiasis in either trial",
        "label": "Contradiction"
    },
    "86722991-04c7-4fdd-914a-f5b71d236a7a": {
        "text_answer": "Contradiction  The evidence shows that in the primary trial no patients in cohort 1 suffered from Increased pleural effusion and Rapid disease progression at the same time In contrast cohort 2 had one patient with both conditions However the statement claims that 25 of patients in the primary trial suffered from both conditions which is not supported by the evidence",
        "label": "Contradiction"
    },
    "3c164518-76e2-4abf-a39e-4163d49583c7": {
        "text_answer": "Contradiction The evidence does not support the statement that the Ketorolac 30mg group had a lower recurrencefree survival rate than the NaCl 09 3ml group Instead the evidence shows that a higher percentage of participants in the NaCl 09 3ml group achieved recurrencefree survival 897 compared to the Ketorolac 30mg group 83",
        "label": "Contradiction"
    },
    "01116b8e-5299-4f9e-9f40-7651edbc8542": {
        "text_answer": "Contradiction The primary trial does not evaluate the Percentage of Participants With Adverse Events of Primary Interest AEPIs It evaluates toxicity using NCI Common Terminology Criteria for Adverse Events CTCAE v30 The secondary trial does evaluate the Percentage of Participants With AEPIs but the statement does not mention the secondary trial",
        "label": "Contradiction"
    },
    "ceb3926f-4777-4cec-8582-7c109185e333": {
        "text_answer": "Contradiction The primary trials Group 2 receives dexmedetomidine which is not mentioned in the statement and the secondary trials cohorts do not receive any myalgias but the statement claims they receive 000027ugkg of myalgias",
        "label": "Contradiction"
    },
    "fd76b8a6-5305-4221-b48b-3a37d551c82a": {
        "text_answer": "Contradiction The evidence does not mention any requirement for regular physical activities as a part of the intervention for all participants in the primary clinical trial",
        "label": "Contradiction"
    },
    "bbd40b2c-18a5-4ebb-9c6b-58dbc9a3ba59": {
        "text_answer": "Contradiction The evidence shows that the AZD0530 175 mg group had a greater percentage change in betaCTX at Week 4 711 vs 684 in the Zoledronic Acid 4 mg group",
        "label": "Contradiction"
    },
    "4acf0568-59ce-4f6c-973b-9c603f65dac4": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were 16 participants in Arm 1 and 14 participants in Arm 2 who achieved pCR in breast and axillary lymph nodes Therefore the statement that no participants in either cohort of the primary clinical trial showed pathologic complete response in breast and axillary lymph nodes throughout the duration of the study is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "575eb6a5-bbeb-46a4-af85-87303a9fc321": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were recorded incidents of infections in both the primary and secondary clinical trials In the primary trial there was one recorded incident of infection out of 32 patients In the secondary trial there were two recorded incidents of infections out of 15 patients in Adverse Events 1 and one recorded incident of dehydration which is classified as an infection in Adverse Events 2 Therefore",
        "label": "Contradiction"
    },
    "2f917847-cad3-4744-891d-33ebe29f257b": {
        "text_answer": "Entailment  Explanation The statement different pharmaceutical interventions were involved in the primary clinical trial all being delivered via the same pathways is an entailment based on the evidence provided The evidence states that one intervention is IV bisphosphonate Q4W and the other is subcutaneous denosumab Q12W Both interventions are delivered via different pathways IV for bisphosphonate and sub",
        "label": "Entailment"
    },
    "44c3f65f-6b0d-401d-9aad-b323d7511b1c": {
        "text_answer": "Contradiction The evidence states that Cohort A receives the two IM injections of LD V935 at different points in their cycle every other week over a 3week period while Cohort B is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "c3609a19-01f6-4add-a0af-7d92263d822c": {
        "text_answer": "Contradiction The statement does not directly relate to the evidence provided which only discusses the iDFS rates in the Neratinib and Placebo groups The statement mentions a specific genetic mutation egfr nm 0052283c2313 2314insaac that is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "204d5293-d6e5-452a-8961-3b76d6be35c9": {
        "text_answer": "Contradiction The statement makes a causal claim about the primary trial results but the evidence only shows a difference in operative times between the two arms not a causal relationship between the use of intraoperative mammography and shorter operative times The secondary trial does not provide any information about operative times or mammography techniques",
        "label": "Contradiction"
    },
    "3cd949ea-cd27-4eff-b7b6-0087df3136ba": {
        "text_answer": "Contradiction  Explanation The statement cohort 1 of the primary clinical trial reported mild aes is a contradiction to the evidence as there is no mention of any adverse events let alone mild ones reported in cohort 1 of the primary clinical trial according to the provided evidence",
        "label": "Contradiction"
    },
    "8fc0b314-bec3-4206-a917-fc16babf1a4a": {
        "text_answer": "Contradiction The primary trial utilizes Anastrozole which is not mentioned in the secondary trial",
        "label": "Contradiction"
    },
    "ccc3cd99-a66b-42ce-9a35-21780035ddc5": {
        "text_answer": "Contradiction The evidence provided does not mention anything about eligibility for clinical trials based on the ability to perform selfcare or confinement to bed or chair The statement is not directly related to the given evidence",
        "label": "Contradiction"
    },
    "f5fa93e8-a223-459c-8573-853f56953c17": {
        "text_answer": "Contradiction  Explanation  The primary trial and the secondary trial have different interventions and the statement compares the treatment processes of the trials as a whole The primary trial involves an openended treatment process with PF05212384 and docetaxel while the secondary trial operates on a consistent 4week cycle regimen with mammography procedures The evidence provided does not indicate that the primary trial has a",
        "label": "Contradiction"
    },
    "00d64f29-fff0-44bd-b20c-8838ed4a1d93": {
        "text_answer": "Contradiction The evidence does not support the statement that both cohorts received equal doses of 20 mg of sunitinib and 75 mgkg of bevacizumab The doses of sunitinib and bevacizumab in the primary trial were not equal between the two cohorts",
        "label": "Contradiction"
    },
    "1dcd53cf-49bf-4a4e-857d-008139ceb6a9": {
        "text_answer": "Contradiction The primary trial requires mammography as an inclusion criterion while the secondary trial does not mention mammography as a requirement",
        "label": "Contradiction"
    },
    "ad0d6636-dd71-4ba9-8741-1cba3d6f0c43": {
        "text_answer": "Entailment The statement that cohorts 1 and 2 use the same instructional CD for paced breathing is true and the additional information that cohort 2 practices the routine twice daily does not contradict this",
        "label": "Entailment"
    },
    "bc8cc6fd-446a-4879-a968-5c43a34029cc": {
        "text_answer": "Contradiction The statement is not an entailment as the inclusion criteria for the secondary trial do not mention anything about age groups and the statement implies that the secondary trial has the same inclusionexclusion criteria for all participants regardless of age",
        "label": "Contradiction"
    },
    "e1e33a46-c88d-497a-b7b6-be14d38d05b2": {
        "text_answer": "Contradiction The evidence from the primary and secondary trials includes patients with solid tumors not just hematological malignancies",
        "label": "Contradiction"
    },
    "1e4ebef6-1039-42f3-b753-3efd098052fc": {
        "text_answer": "Contradiction The statement is not an entailment as the intervention phase in the secondary clinical trial lasts for 24 weeks which is 12 weeks longer than the primary trials 12week intervention phase However the statement does not accurately convey the difference in length as it mentions an additional 15 weeks which is not the correct calculation",
        "label": "Contradiction"
    },
    "e83cb60e-ac38-42dd-a094-1ae08500915b": {
        "text_answer": "Contradiction The statement mentions 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but the evidence shows that there was only 1 case of Febrile neutropenia recorded in cohort 1 The statement also mentions but no cases of Pancytopenia but the evidence shows that Pancytopenia 018 000",
        "label": "Contradiction"
    },
    "3c081d55-1536-45ec-ae5b-b7af2a44a8c4": {
        "text_answer": "Entailment The statement a single adverse event has been logged for its patient cluster is an entailment of the evidence Total 129 345 The evidence indicates that there is only one adverse event recorded for the patient cluster which is in line with the statement that a single adverse event has been logged",
        "label": "Entailment"
    },
    "cee12d67-0640-4760-a0f5-fdde8c593a89": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial only includes patients with advanced andor unresectable disease of certain types of cancer Benign tumors are not included in the list of eligible cancers",
        "label": "Contradiction"
    },
    "84781347-ce91-4e60-ba5f-f1bd795d898b": {
        "text_answer": "Entailment assuming the evidence does not mention any vaccines being administered in the trial",
        "label": "Entailment"
    },
    "eff79353-72dc-4a94-b856-40b844d2860b": {
        "text_answer": "Contradiction The primary trial specifically excludes patients with HER2 status",
        "label": "Contradiction"
    },
    "e6c70cab-b2d6-488d-b9dd-34478f9f4f71": {
        "text_answer": "Contradiction  Explanation The primary trial measures the duration of neutropenia in days while the secondary trial measures the incidence of neutropenia as a number of participants The statement compares the occurrence of neutropenia between two different cohorts from different trials which is not directly comparable based on the given evidence",
        "label": "Contradiction"
    },
    "d622d9c6-c942-4a53-a249-cd5544e2d9fe": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial does not include patients with resectable Nonsmall cell lung cancer or Small cell lung cancer that is a benign sinonasal soft tissue neoplasm",
        "label": "Contradiction"
    },
    "b994a073-e1a5-424a-9cdf-f0d9ad0c0766": {
        "text_answer": "Contradiction The statement is not an entailment as the primary trial has specific inclusion criteria for female participants with ER positive breast cancer",
        "label": "Contradiction"
    },
    "0aab969d-e626-4857-903c-df2f6849c7c7": {
        "text_answer": "Contradiction The evidence shows that no adverse events occurred at an incidence rate greater than 1 in either trial",
        "label": "Contradiction"
    },
    "8f4d4e78-5e46-47b6-865c-ad6b689d69e0": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as chest pain is not mentioned in either trial",
        "label": "Contradiction"
    },
    "e4024f75-2a23-4912-bb63-3d6e982657ea": {
        "text_answer": "Contradiction The evidence provided does not mention anything about a Her2neu peptide vaccine mixed with sargramostim being administered to the participants in the primary clinical trial",
        "label": "Contradiction"
    },
    "fbfafa2b-9b70-4452-9d19-4d58c3c9dfba": {
        "text_answer": "Contradiction The primary trial includes a minimum primary tumor size of 2 cm while the statement mentions a primary tumor with a radius of 3mm which is less than 2 cm Therefore the statement contradicts the inclusion criteria for the primary trial The secondary trial does not provide any information regarding tumor size",
        "label": "Contradiction"
    },
    "7452ab11-09d4-48bc-b275-4681acae5769": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that the Paclitaxel Plus Bevacizumab PB group had a lower ORR 0489 compared to the Paclitaxel Plus Bevacizumab Plus Gemcitabine PBG group 0587",
        "label": "Contradiction"
    },
    "4385daf4-23d6-499b-8960-33b8c995884e": {
        "text_answer": "Entailment The evidence shows that in both trials no adverse events occurred in more than 001 of the participants",
        "label": "Entailment"
    },
    "97f2cf47-a82b-4d00-9918-a4b400d2ca5e": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence provided because the primary trial did not only report adverse events related to the musculoskeletal system but also events related to the blood and bone marrow such as anemia neutropenia lymphopenia and platelet count decreases These events are not related to the musculoskeletal system In contrast the",
        "label": "Contradiction"
    },
    "b7bc3cb1-b7f4-4276-bfee-9f984109d191": {
        "text_answer": "Contradiction The evidence states that participants received niraparib 200 mg daily not talazoparib 0001 g",
        "label": "Contradiction"
    },
    "13184ac6-2ba9-455b-9e77-834855ff2794": {
        "text_answer": "Entailment assuming febrile neutropenia and cholelithiasis are not mentioned in the evidence  Explanation The statement the primary and secondary clinical trials showed zero incidences of febrile neutropenia or cholelithiasis is an entailment based on the evidence because neither trial reported any instances of febrile neutropenia or cholelithiasis",
        "label": "Entailment"
    },
    "25b01c06-612c-4cfb-b30b-50ebe4d98750": {
        "text_answer": "Contradiction The primary trial compares operative times between two groups while the secondary trial measures success rates and does not have a control group",
        "label": "Contradiction"
    },
    "ae548af6-b401-4dac-9824-50b2a566e7bd": {
        "text_answer": "Contradiction The primary trial does not exclude 18yearolds while the secondary trial does",
        "label": "Contradiction"
    },
    "80b58d76-4a9b-461a-836a-bfb79e40b401": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial does not involve the use of Abraxane a brand name for albuminbound paclitaxel in either intervention",
        "label": "Contradiction"
    },
    "42d3b148-38d6-4665-9d48-4d6bf935fbd9": {
        "text_answer": "Contradiction The statement within the last 60 years is not consistent with the trials exclusion criteria which state No history of myocardial infarction MI stroke or transient ischemic attacks in the last 6 months",
        "label": "Contradiction"
    },
    "00102571-e1d6-42c9-b227-f0ac146d411d": {
        "text_answer": "Contradiction The primary trial requires a Karnofsky score of 70 while the secondary trial requires a Karnofsky score of 55",
        "label": "Contradiction"
    },
    "596e650e-f860-4055-b3a6-35fcd9fd33b0": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence as the primary trial recorded no adverse events at all",
        "label": "Contradiction"
    },
    "10a27e75-a4e3-4790-bafa-dfc9b9300a25": {
        "text_answer": "Entailment  Explanation  The statement in intervention 1 the lenalidomide dosage in the primary clinical trial is greater than the lapatinib dosage in the secondary clinical trial moreover the treatment duration in the primary clinical trial exceeds that in the secondary clinical trial is an entailment based on the evidence provided  In the primary clinical trial participants received lenalidomide 5mg orally daily",
        "label": "Entailment"
    },
    "b8e81997-7fd7-4934-9ee8-bb7c647d334c": {
        "text_answer": "Contradiction  Explanation The statement all ae types in the primary trial affected less than 01 of patients is a contradiction to the evidence as the evidence shows that at least one adverse event affected 909 of patients eg febrile neutropenia",
        "label": "Contradiction"
    },
    "c89d3665-091c-410b-83b1-0793a3b86d6a": {
        "text_answer": "Contradiction  Explanation In the primary trial the intervention consists of a single drug ZD1839 In contrast in the secondary trial the intervention in Intervention 1 consists of Zoledronic acid vitamin D and calcium supplements which is more than one drug Additionally Intervention 2 in the secondary trial requires the use of at least two additional drugs Samarium153 and pegfil",
        "label": "Contradiction"
    },
    "0d7d2408-c51f-4b3a-a47f-6f0ee8dedacc": {
        "text_answer": "Contradiction The primary trial reports Time to Progression while the secondary trial reports the number of patients with Objective Response These are different outcome measures",
        "label": "Contradiction"
    },
    "70ddf6e3-dcd9-4296-b73c-593161abcfae": {
        "text_answer": "Contradiction The primary trial explicitly includes the requirement that patients be able to understand and willing to sign an informed consent document which would exclude patients who are extremely overweight or expecting due to potential difficulties in obtaining informed consent The secondary trial also excludes pregnant women Therefore neither trial includes patients who are extremely overweight or expecting",
        "label": "Contradiction"
    },
    "d6cd0501-9b29-41f5-ba8a-6209c8cfad84": {
        "text_answer": "Contradiction  Explanation  In the primary trial there are two cohorts receiving Armodafinil PO daily but the statement does not mention the dosage of Armodafinil in the secondary trial Additionally the statement claims that all patients in the secondary trial receive the same 200 mg dose of PDR001 and 4 mgkg dose of MCS110 but the evidence shows that there",
        "label": "Contradiction"
    },
    "03845d1d-301a-4b2a-8dc4-8b05e09ab6ee": {
        "text_answer": "Contradiction The evidence shows that a different number of adverse events were reported for each cohort",
        "label": "Contradiction"
    },
    "383102f6-bd50-4f19-b7cf-0ddda4234e2f": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence provided because there were no cases of clostridium difficile colitis reported in the secondary trial while the primary trial reported one case Additionally there was only one case of biliary colic in the secondary trial which is not more prevalent than the zero cases reported in the primary trial",
        "label": "Contradiction"
    },
    "a88d7c64-ec6f-4fb7-a84d-1047b68bda4f": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence shows that there were other adverse events observed in the secondary trial besides eyelid oedema and chest pain",
        "label": "Contradiction"
    },
    "0c6abdc4-f1cd-46f3-8883-c4bce02c2081": {
        "text_answer": "Contradiction The primary trial uses the MYMOP score improvement as one of the outcome measurements but it is not the principal outcome measurement The principal outcome measurement in the primary trial is the proportion of patients with confirmed tumor response",
        "label": "Contradiction"
    },
    "6aa80695-37e9-4a46-aa19-2fd1f75d8f11": {
        "text_answer": "Contradiction  The primary trial administers oral pregabalin while the secondary trial administers intravenous Depocyt and highdose Methotrexate These are not the same interventions",
        "label": "Contradiction"
    },
    "c4c63d1d-1704-499c-b298-f5ced3123d03": {
        "text_answer": "Entailment The statement patients are provided with oral medication which they are to take two times a day for a whole month is an entailment of the evidence as the evidence states that patients receive oral medication lapatinib ditosylate and tamoxifen citrate and are to take it daily for 28 days",
        "label": "Entailment"
    },
    "c90dda31-65a8-4a77-8657-7cdf498b366f": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial allows the use of antineoplastic chemotherapy with the exception of antiHER2 agents androgens estrogens and progestogens but only under certain conditions",
        "label": "Contradiction"
    },
    "6fa670ed-56af-4b06-b7f1-ab7429106d0d": {
        "text_answer": "Contradiction  Explanation The statement at least one patient treated with gtx024 1mg in the primary trial gained over 22 pounds of lean body mass is a contradiction to the evidence because the median change in total body lean mass for the GTx024 1mg group was 155 kg which is far less than 22 pounds approximately 998 kg",
        "label": "Contradiction"
    },
    "c2634312-bbf3-4b44-8cdc-23922a16b9fd": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there were no cases of infection asymmetry or deflation reported in the secondary trial while the primary trial reported a total of 4 cases across these three adverse events",
        "label": "Contradiction"
    },
    "241dc060-83e9-41a9-b937-d9715c16137a": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as the evidence only compares the number of hot flashes per day between the paced respiration and fast shallow breathing groups and does not mention anything about lcp1 antibody",
        "label": "Contradiction"
    },
    "ff8f336a-0b3a-453d-a396-7624218280aa": {
        "text_answer": "Contradiction The evidence states that the intervention section outlines a treatment but it does not specify that it includes a comprehensive description of the treatment cycle",
        "label": "Contradiction"
    },
    "100aa305-3df6-42ff-b3ba-68bed68e39b0": {
        "text_answer": "Contradiction The primary trial does not focus on the mean sleep duration but rather on the number of participants with treatmentemergent AEs",
        "label": "Contradiction"
    },
    "b819fe62-b8ce-4b35-bf5a-e2657f8d0efc": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because both arms of the primary clinical trial make use of trastuzumab as part of their interventions Arm 1 uses Herceptin which is a form of trastuzumab and Arm 2 uses Herceptin in combination with other drugs",
        "label": "Contradiction"
    },
    "2644ad79-c38a-4415-a340-81ac51d3813f": {
        "text_answer": "Entailment The statement multiple diverse negative effects were experienced by at least one patient in the primary clinical trial is an entailment of the evidence as the evidence shows that a total of 6 different adverse events were experienced by patients in the trial",
        "label": "Entailment"
    },
    "344ac04d-cddb-4ef8-8a15-54e26ff58a86": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence as the evidence shows that there were multiple patients who experienced the same adverse event disease progression pneumonia and acute kidney injury in the primary trial",
        "label": "Contradiction"
    },
    "c32c50b0-6068-41f1-9db0-fd8b3ac53cf6": {
        "text_answer": "Contradiction The statement is a contradiction because the primary trials intervention 1 is administered by IV while all interventions in the secondary trial can be administered orally",
        "label": "Contradiction"
    },
    "1907f058-1b77-441e-8824-9cf6be7f1243": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence shows that the primary trial has fewer adverse events overall but there is no mention of a higher occurrence of cardiacischemiainfarction in the primary trial compared to the secondary trial",
        "label": "Contradiction"
    },
    "818a897a-fa50-4f16-8272-8f5ec8e590c1": {
        "text_answer": "Contradiction  Explanation The statement claims that only the first cohort uses paclitaxel but the evidence shows that neither cohort uses paclitaxel instead they use anastrozole in Arm A and fulvestrant in Arm B respectively",
        "label": "Contradiction"
    },
    "6fc1fe93-0690-4b46-a80e-681e4d7be399": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement have to read something several times to understand it is not directly related to the inclusion or exclusion criteria for the primary trial The evidence provided only mentions the BMI requirement for the trial and some exclusion criteria related to health conditions and medication use The statement about reading something several times to understand it does not appear in the evidence Therefore it is considered neutral",
        "label": "Entailment"
    },
    "3ce10e1a-24fe-4575-8f08-583c93fd5274": {
        "text_answer": "Contradiction The primary clinical trial includes patients with NUT midline carcinoma diagnosed via FISH but the secondary clinical trial does not include patients with inflammatory breast cancer or those diagnosed with NUT midline carcinoma via FISH",
        "label": "Contradiction"
    },
    "99901cc0-51b6-45c1-9040-14a9785bab49": {
        "text_answer": "Contradiction The primary trial does not include resectable nonsmall cell lung cancer or small cell lung cancer in its inclusion criteria",
        "label": "Contradiction"
    },
    "6b1a58fa-54cd-442b-8f51-1b7135dd2302": {
        "text_answer": "Contradiction The primary clinical trial specifically mentions that any gastrointestinal disease which would impair ability to swallow retain or absorb drug is not allowed Therefore cbt based treatments which are typically nonpharmacologic interventions are not mentioned as a requirement or permissible in the primary trial In contrast the secondary trial does not mention cbt based treatments at all",
        "label": "Contradiction"
    },
    "ddc664eb-c81b-4544-b370-bb6db84eacba": {
        "text_answer": "Entailment The primary trial includes patients with stage IV breast adenocarcinoma that is ER positive PR positive or HER2neu negative which is also a requirement for the secondary trial Therefore patients meeting these criteria are eligible for both trials",
        "label": "Entailment"
    },
    "117c69b5-683c-45a6-b80d-5bc866f2faa1": {
        "text_answer": "Entailment The evidence provided does not indicate that nationality ethnicity weight or gender are factors in eligibility for the primary or secondary clinical trials",
        "label": "Entailment"
    },
    "3cd01e92-2bff-45d7-9fa3-77c351d2f39a": {
        "text_answer": "Contradiction The evidence states that there was one adverse event in the primary trial whereas the statement asserts that there were no adverse events",
        "label": "Contradiction"
    },
    "d207a9ec-f055-456a-ad6a-7c580cc347e1": {
        "text_answer": "Contradiction  Explanation The primary trial has several inclusion and exclusion criteria that are not present in the secondary trial such as age cancer type performance status life expectancy and prior treatment history Therefore it is a contradiction to state that the only inclusion or exclusion standard they have in common is the capability to present written informed consent",
        "label": "Contradiction"
    },
    "3896374f-f5e1-41a2-9ec0-c108cc3f3ad1": {
        "text_answer": "Contradiction  Explanation The statement maculopapular Rash was a common adverse event for the primary trial participants is true based on the evidence However the second part of the statement operator is a person that operates some apparatus or machine is not related to the evidence and does not follow from it Therefore it is a contradiction to say that the statement is an entailment based on the evidence",
        "label": "Contradiction"
    },
    "87f86955-0e57-459a-84aa-4a5feba745af": {
        "text_answer": "Contradiction  Explanation The statement patients who have estrogen negative progesterone negative and her2 breast cancer can join the primary clinical trial is a contradiction to the inclusion criteria of the primary trial which states that patients must have histologically confirmed ER positive HER2 negative invasive breast cancer Group 1 to be eligible for the trial",
        "label": "Contradiction"
    },
    "99857433-fe08-4f54-bb86-91b1b1e8f5f4": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence because the evidence shows that the iDFS rate was lower in the placebo group 75 compared to the neratinib group 47",
        "label": "Contradiction"
    },
    "4bc60955-6137-4496-b780-5fb8e90dc3ed": {
        "text_answer": "Contradiction  Explanation The statement maculopapular Rash was a common adverse event for the primary trial participants is a contradiction based on the evidence because the evidence does not show that maculopapular rash was a common adverse event as it only occurred in 1 out of 30 participants",
        "label": "Contradiction"
    },
    "61c499d7-0a4c-4fac-9098-53e53ddb198d": {
        "text_answer": "Contradiction  The evidence does not support the statement that there were 75 cases of hypertension edema and dyspnea in either cohort of the primary trial The evidence only reports the number of cases for various adverse events but it does not add up to 75 for hypertension edema and dyspnea combined in either cohort",
        "label": "Contradiction"
    },
    "93025279-295b-43e1-8dfd-40877e0288b4": {
        "text_answer": "Neutral The evidence does not provide enough information to determine entailment or contradiction  Explanation The evidence only mentions that subjects were treated with partial breast irradiation in Intervention 1 but it does not specify the details of the irradiation doses or treatment cycle The statement is neutral because it is not clear whether the lack of such details in the evidence entails or contradicts the statement",
        "label": "Entailment"
    },
    "5ecfe0a7-2d7c-4207-b62e-0b28b699951d": {
        "text_answer": "Contradiction  The primary trials Intervention 1 uses Zoledronic Acid 4 mg every 4 weeks Q4W which is not a 12fold higher dosage compared to Denosumab 120 mg Q4W used in the secondary trials Intervention 1 Instead the dosages are different with Zoledronic Acid having a lower dosage",
        "label": "Contradiction"
    },
    "4a16424c-7755-4b6b-a060-d9ab1cb14db0": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as there is no mention of a stopcock valve device being a requirement for participation in either trial",
        "label": "Contradiction"
    },
    "10a9dcfe-bbdd-44b2-9bc7-f406a2ff835a": {
        "text_answer": "Contradiction  Explanation The statement on average there was no change in cognitive function for patients in either cohort of the primary clinical trial is a contradiction to the evidence presented in the study results The results show that the Tamoxifen group had a mean standardized score of 004 049 and the Ovarian Function Suppression group had a mean standardized score of 021 ",
        "label": "Contradiction"
    },
    "b12a6936-d1ae-48e7-b3f2-575708d784ed": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports the adverse events recorded in the patient cohorts and there is no mention of Asthenia Pyrexia or ultrasonograms",
        "label": "Contradiction"
    },
    "48ca56cf-908a-436f-8ec5-90fb965ea630": {
        "text_answer": "Contradiction The primary trial involves an injection of Fluciclatide while the secondary trial involves an oral administration of Chloroquine which are different interventions",
        "label": "Contradiction"
    },
    "8dbf8922-4680-4125-9bc3-f6ea881c5978": {
        "text_answer": "Contradiction The evidence does not mention dehydration as a side effect in either cohort",
        "label": "Contradiction"
    },
    "dfde5d87-d03d-42a9-aa4c-f4e946a75102": {
        "text_answer": "Contradiction The statement is not an entailment based on the evidence as the primary trial has 0 anemia cases while the secondary trial has 4 anemia cases",
        "label": "Contradiction"
    },
    "27564603-9271-41f5-8135-067e19c4946a": {
        "text_answer": "Contradiction The statement does not hold true for both trials as the primary trial has a different medication Armodafinil and dosing schedule compared to the secondary trial MCS110",
        "label": "Contradiction"
    },
    "e8b7263b-fd07-4d78-915f-e1b17bdc1390": {
        "text_answer": "Contradiction  The statement is about the number of drugs in the interventions not about anal fibroadenoma",
        "label": "Contradiction"
    },
    "302997fe-466a-4efd-8801-5b07236a5e0c": {
        "text_answer": "Contradiction The statement is incorrect as the primary clinical trial does not involve the administration of vaccines to its participants It involves the administration of chemotherapy drugs and bevacizumab",
        "label": "Contradiction"
    },
    "7d1f03c6-a869-45f0-9eda-4c272781e112": {
        "text_answer": "Contradiction The evidence does not mention anorexia hypothermia or hallucinations in the adverse events of the primary clinical trial",
        "label": "Contradiction"
    },
    "192c6acc-1f20-4f22-a23e-80fadba34726": {
        "text_answer": "Contradiction The primary clinical trial focuses on hormonal treatments while the secondary clinical trial includes acupuncture as an intervention",
        "label": "Contradiction"
    },
    "a2328e36-4475-4804-96e8-cba90ee13087": {
        "text_answer": "Contradiction The statement is not an entailment as the trials do use intravenous injections but they do not use the same drugs dosages or frequency of administration",
        "label": "Contradiction"
    },
    "99820bab-c465-4d6a-a016-0551261ddb86": {
        "text_answer": "Contradiction The primary trials intervention section does not mention surgical and imaging procedures",
        "label": "Contradiction"
    },
    "1757a756-4aeb-497c-aa4f-304817a34938": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug or any other hemorrhagebleeding event NCI CTCAE v30 Grade 3 within 4 weeks of first dose of study drug However the secondary trial does not mention any exclusion criteria related to bleeding or hemorrh",
        "label": "Contradiction"
    },
    "1fb98883-c2ef-4acb-948e-aa497dc911ff": {
        "text_answer": "Contradiction The primary and secondary trials do not involve the use of interventions related to mycl gene amplification",
        "label": "Contradiction"
    },
    "98877f56-e367-4335-b938-85bd30fb038a": {
        "text_answer": "Contradiction  Explanation The statement does not entail or follow logically from the evidence provided The evidence states that Cohort 1 and Cohort 2 received the same dose of Cetuximab but it does not mention anything about a Collaborative Care Intervention in Cohort 1 Therefore the statement that Cohort 1 had an additional Collaborative Care Intervention is not supported by the evidence",
        "label": "Contradiction"
    },
    "c9403b28-c572-4009-ae1a-6bd3e7977f86": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that both the placebo and trabectedin are administered via a 3hour intravenous infusion but the frequency is every 21 days for the primary trial not every other week as stated in the question However the statement only mentions the method of administration and does not specify the frequency so it is still an entailment since the given evidence does not contradict it",
        "label": "Entailment"
    },
    "ea29786f-2c27-45d3-879d-126b8150f2af": {
        "text_answer": "Contradiction   The evidence does not support the statement as both clinical trials involve the use of 4demethyl4cholestryloxycarbonylpenclomedine but the dosing and patient populations may differ between the trials",
        "label": "Contradiction"
    },
    "7a2208d3-e297-4d8c-bfab-12856c200ea6": {
        "text_answer": "Contradiction The statement is incorrect as there is no mention of Paraplatin in the provided evidence The interventions listed in the evidence involve different chemotherapy regimens",
        "label": "Contradiction"
    },
    "1ef3ec2f-1b26-4dbe-92ff-8c3dda42f071": {
        "text_answer": "Contradiction The evidence from the secondary trial indicates that there were adverse events chest pain while the statement asserts that there were no adverse events",
        "label": "Contradiction"
    },
    "f2f5115c-a1ad-43cf-b01c-0035f9404a92": {
        "text_answer": "Contradiction  Explanation  In the primary trial the comparison is between CBTI with placebo and CBTI with Armodafinil Armodafinil is given in a specific dosing regimen 3days at 50mg then 40 days at 100mg then 4 days at 50mg but the CBTI intervention is the same for both arms",
        "label": "Contradiction"
    },
    "8a308f16-460b-45ac-a0f0-cb36787f1aa7": {
        "text_answer": "Contradiction The evidence shows that no participants in the secondary trial encountered adverse events and less than 1 of participants in the primary trial encountered adverse events Therefore it is a contradiction to the statement that over 30 of participants in both trials encountered several adverse events",
        "label": "Contradiction"
    },
    "f43f3230-46be-4ed7-a1d7-3e6d73f4fa9b": {
        "text_answer": "Contradiction The evidence shows that cohort 1 received a lower dose of MM121 8mgkg compared to the stated dosage in the question 12mgkg",
        "label": "Contradiction"
    },
    "eea61494-780f-4a38-aa12-dd88ef3d520b": {
        "text_answer": "Entailment The primary trial tests different types of gels Hydrophor and MediHoney while the secondary trial tests different doses 90 mg and 110 mg of the same treatment PF05212384 on its study group",
        "label": "Entailment"
    },
    "81bf5edb-cf30-4e9e-b816-394fa5b16354": {
        "text_answer": "Contradiction The primary trial and the secondary trial are about different conditions lesions in the primary trial vs radiation dermatitis and hyperpigmentation in the secondary trial",
        "label": "Contradiction"
    },
    "1adb6e15-a8b1-461a-8782-4295224a3c5f": {
        "text_answer": "Contradiction The evidence states that individuals with dementia including vascular dementia are excluded from the primary clinical trial",
        "label": "Contradiction"
    },
    "eb12190b-96c6-4c5d-8479-1248b462587d": {
        "text_answer": "Entailment The secondary trials intervention duration is 24 weeks which is three times longer than the 10 weeks of intervention in the primary trial",
        "label": "Entailment"
    },
    "5ebf97e0-5409-4e82-a837-e0d96bc62b96": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the placebo and AlloMSCs interventions are not the same intervention and are not administered in the same way transendocardial injection of different solutions",
        "label": "Contradiction"
    },
    "96259bb4-b459-4f63-b987-6bdb596211a4": {
        "text_answer": "Entailment for ERnegative breast cancer patients the inclusion criteria for both phases mention ER negativity as a requirement",
        "label": "Entailment"
    },
    "f891188f-fa94-42d5-a341-2a6ae7d696ac": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there were no adverse events reported in either cohort according to the provided data",
        "label": "Contradiction"
    },
    "2f5ae30b-2e0d-420a-a27b-14088d2bc0db": {
        "text_answer": "Contradiction for the statement there were zero aes reported in cohort 1 or cohort 2  Explanation The evidence shows that there were adverse events reported in both cohorts so neither cohort had zero adverse events reported",
        "label": "Contradiction"
    },
    "8723a112-05c6-4c05-82ab-e09cedffdb4b": {
        "text_answer": "Contradiction  The statement only three kinds of adverse events impacted patients participating in the primary clinical trial pancreatitis cholelithiasis hepatic pain and febrile neutropenia is a contradiction to the evidence as the evidence shows that a total of 11 different adverse events were reported across both cohorts of the primary trial",
        "label": "Contradiction"
    },
    "176789e8-d2f5-4bb5-b748-ef0ed5c52478": {
        "text_answer": "Contradiction for the primary trial severe insomnia is not explicitly mentioned as an exclusion criterion but for the secondary trial it is mentioned as an exclusion criterion for patients with a score of 8 on Insomnia Severity Index ISI or a history of chronic preexisting insomnia but the statement does not distinguish between the trials",
        "label": "Contradiction"
    },
    "a6276d61-5f8c-483b-8f18-a3becebddbe8": {
        "text_answer": "Contradiction  Explanation  The statement cohort 1 participants in the primary clinical trial got the same cetuximab dosage as cohort 2 is true based on the evidence However the statement however they received 8mgkg less of mm121 than cohort 2 is false based on the evidence In cohort 1 participants received 12 mgkg",
        "label": "Contradiction"
    },
    "85b158a4-1754-47b2-91b4-5165c38d270c": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the unit of measure reported in both trials is consistent In the primary trial the percentage of participants with a response is reported while in the secondary trial the number of participants who reached a safe dose is reported However both trials use the same units of measurement percentage and number of participants to report their respective outcomes",
        "label": "Contradiction"
    },
    "9340e38d-37ce-4634-9f36-a747f964441c": {
        "text_answer": "Contradiction The evidence does not state that all primary trial candidates must require considerable assistance and frequent medical care",
        "label": "Contradiction"
    },
    "6b6150e0-6484-499a-83ae-a9fc6a7d167c": {
        "text_answer": "Entailment The statement that adult acute megakaryoblastic leukemia is an acute megakaryoblastic leukemia occurring in adults is not directly related to the evidence provided but the evidence does show that both trials administer cyclophosphamide Paclitaxel and pegfilgrastim",
        "label": "Entailment"
    },
    "69a761d0-c5b2-42f4-8cb3-271ac92fb006": {
        "text_answer": "Entailment The evidence states that there are two different schedules for administering CUDC101 to different cohorts in the primary clinical trial and each cohort receives a different dosing regimen which implies a different dosage of CUDC101",
        "label": "Entailment"
    },
    "f618f294-167b-4647-bc93-b8d41596227c": {
        "text_answer": "Contradiction The primary trial does not specify a 730hour cycle for its intervention Instead it defines each treatment cycle as 21 days",
        "label": "Contradiction"
    },
    "dda442a2-b86f-4375-ae81-f1b387ce46c9": {
        "text_answer": "Entailment The evidence provided does not include information about treatmentemergent adverse events for either trial",
        "label": "Entailment"
    },
    "1fe68175-6ac4-4439-818f-94758e6bd306": {
        "text_answer": "Contradiction  Explanation The evidence provided in the results shows that the Arm I group which received cryotherapy during paclitaxel infusions had a median aAUCpa score of 14 117 to 68 while the Arm II group which did not receive paclitaxel infusions had a median aAUCpa score of 44 571 to 16",
        "label": "Contradiction"
    },
    "444746eb-7e98-43fc-8bab-50c2a60d2806": {
        "text_answer": "Contradiction The evidence describes the use of laserassisted fluorescence angiography Spy Elite LifeCell for perfusion monitoring during the primary clinical trial not MRIguided radiotherapy",
        "label": "Contradiction"
    },
    "2669332d-8907-4f82-afbf-e7be6b3c81b3": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as all patients in the secondary trial meet the requirement of having a history of breast cancer which is a requirement for inclusion in the primary trial However the secondary trial has additional inclusion and exclusion criteria that differ from the primary trial",
        "label": "Contradiction"
    },
    "635d4169-6adf-4254-9ee5-e9eede3f7bc5": {
        "text_answer": "Entailment Both trials have the same physical ability requirement ambulatory with a functional ECOG  2 status",
        "label": "Entailment"
    },
    "23034d6a-8cb6-41b2-8e0d-84194285cb38": {
        "text_answer": "Entailment The primary trial measures tumor response using RECIST criteria but it does not provide the rate of clinical benefit ie the percentage of participants with ORR CR PR etc The secondary trial does not measure tumor response using RECIST criteria",
        "label": "Entailment"
    },
    "290fc77b-03cb-4ca6-877f-4117ea462ac6": {
        "text_answer": "Entailment assuming the evidence provided does not contradict the statement and the statement implies that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher ORR than the Paclitaxel Plus Bevacizumab group which is consistent with the evidence",
        "label": "Entailment"
    },
    "adfbe24e-4595-4fe3-88d8-8b5f01458993": {
        "text_answer": "Entailment but note that the statement is not directly comparing the same outcomes between the trials so its more of an implication rather than an entailment",
        "label": "Entailment"
    },
    "003a36ac-4091-4ca9-96f3-1108302eb9e1": {
        "text_answer": "Contradiction The primary trial involves patients receiving trastuzumab alone or in combination with docetaxel or paclitaxel while cohort 2 of the secondary trial involves patients receiving trastuzumab in combination with docetaxel and herceptin The dosages of trastuzumab may be the same but the regimens are not identical",
        "label": "Contradiction"
    },
    "f329518b-872b-41af-8260-9d231e7ab205": {
        "text_answer": "Contradiction The primary trial is open only to postmenopausal female subjects or older male subjects while the secondary trial is open only to female patients",
        "label": "Contradiction"
    },
    "84166f85-0a62-47fd-8dfa-a01dd778c748": {
        "text_answer": "Contradiction The primary trial and the secondary trial measure different outcomes and are not directly related to each other The primary trial measures the effect of sulforaphane supplements on isothiocyanate concentration in urine while the secondary trial measures the percentage of participants with pain or no pain as measured by the Numeric Pain Rating Scale",
        "label": "Contradiction"
    },
    "559c1faa-17b6-42c7-9f63-0cd58df39bfa": {
        "text_answer": "Contradiction The primary trial does test a form of massage therapy which is not a drugbased treatment but it is still a form of cancer treatment The secondary trial does test drugbased treatments PF06647020 at two different doses",
        "label": "Contradiction"
    },
    "b1cd1f5b-2b10-4bec-8482-a049acc7b674": {
        "text_answer": "Contradiction The primary trials exclusion criteria do not mention any conditions related to thyroid gland lipoadenomas However the statement brings up hepatic function which is addressed in the inclusion and exclusion criteria of the primary trial",
        "label": "Contradiction"
    },
    "e0c940e7-9a19-4c78-bf0f-4f630f6cfb90": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not mention anything about sdh complex mutation analysis in either trial",
        "label": "Contradiction"
    },
    "7238ddd4-eade-4b88-8933-0c3df5be9875": {
        "text_answer": "Contradiction  The primary trial and the secondary trial are about different outcome measures The primary trial is about the diagnostic accuracy of two algorithms in breast cancer diagnosis using ROC curves while the secondary trial is about the effect of reflexology on fatigue levels in breast cancer patients using the Lee Fatigue Scale Therefore the results cannot be directly compared and it is not possible to determine if there were no significant differences or identical results based on the given evidence",
        "label": "Contradiction"
    },
    "de8bb37e-838b-4ac0-bd2b-b866feadac64": {
        "text_answer": "Neutral  Explanation The statement is not an entailment or a contradiction based on the evidence provided The evidence only discusses adverse events related to the intervention and does not mention any information about participants having difficulty getting up from chairs",
        "label": "Entailment"
    },
    "d050c306-4563-403d-96c4-26728b8dc0df": {
        "text_answer": "Entailment In the primary trial the intervention lasted for 10 weeks while in the secondary trial the intervention lasted for 24 weeks which is three times longer",
        "label": "Entailment"
    },
    "01f72f8a-d22e-4509-859a-5df198d04d2f": {
        "text_answer": "Entailment The statement patients suffering from severe obesity can participate in the primary clinical trial is an entailment of the inclusion criteria which state that patients with a BMI of 25 kgm2 or greater and weight 400 lbs are eligible for the trial",
        "label": "Entailment"
    },
    "4650b6bf-1aed-4407-ac23-7ca5a4c2728d": {
        "text_answer": "Contradiction The secondary trial explicitly excludes patients with breast implants",
        "label": "Contradiction"
    },
    "9eb7c3cc-b3f5-40cf-8952-148afd8f2b04": {
        "text_answer": "Contradiction The statement does not relate to the information provided about the primary trial The statement is about postpartum placental separation which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "8bd8a0f5-4bc9-4de6-a7d8-2a3acaadc6c4": {
        "text_answer": "Contradiction The statement is not related to the given inclusion and exclusion criteria for the primary and secondary trials The statement is about ossifying fibroma which is not mentioned in the trials",
        "label": "Contradiction"
    },
    "f098a93b-9d39-4928-87b7-0ad43311c615": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence indicates that the pathologic complete response occurred approximately 7 months after the start of the study not 14 days",
        "label": "Contradiction"
    },
    "bc7b62ad-797e-419e-b5f9-888117aedf6b": {
        "text_answer": "Contradiction The evidence does not support the statement as there are no cases of swelling or hypothermia reported in either trial",
        "label": "Contradiction"
    },
    "b3361d9c-9d9f-4966-80e7-629656bfcd1e": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there was one patient in the primary trial with a deficiency of granulocytes in the blood which is not mentioned in the statement",
        "label": "Contradiction"
    },
    "09eee297-7801-4d6b-b3f6-17ee4f3418e4": {
        "text_answer": "Contradiction The statement in the question assumes that a lower operative time is a desirable outcome but the evidence from the primary trial indicates that Arm 1 standard mammography had a longer operative time than Arm 2 intraoperative mammography Therefore the statement is a contradiction to the evidence The secondary trial does not provide information that can be used to compare the two arms in terms of operative time",
        "label": "Contradiction"
    },
    "d225c39d-4bd1-4129-a359-2909af912031": {
        "text_answer": "Contradiction The primary trial compares different chemotherapy regimens while the secondary trial compares two different bonetargeted agents so they address different interventions and outcomes",
        "label": "Contradiction"
    },
    "a02a955a-9890-4347-8a6b-1377008f581b": {
        "text_answer": "Contradiction The primary trial excludes patients with potassium levels below the normal range but it does not mention anything about hyperkalemia The secondary trial does not mention potassium levels at all",
        "label": "Contradiction"
    },
    "439b1eca-f583-4a2b-bd8e-0baae97b4c15": {
        "text_answer": "Contradiction  Explanation The evidence provided does not entail that several patients in the primary trial experienced no pain whatsoever during the 10 weeks of the study The evidence only reports the average pain intensity scores and their confidence intervals for each group It does not provide information on the number or percentage of patients who experienced no pain",
        "label": "Contradiction"
    },
    "b652609b-4609-481e-a5de-caa0c4432f2f": {
        "text_answer": "Entailment Both interventions are given twice daily for a total of 81 days",
        "label": "Entailment"
    },
    "be6130d9-49f1-4b4e-82f2-6acc6ee7f176": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only mentions adverse events from a primary trial none of which are related to excessive tearing",
        "label": "Contradiction"
    },
    "292a2905-b407-4068-8c2e-e6d596e494ca": {
        "text_answer": "Contradiction The primary trial does not mention any exclusion related to CBTbased treatments while the secondary trial does not address this issue at all",
        "label": "Contradiction"
    },
    "d401affc-f081-4eee-bd61-d109cc88f6de": {
        "text_answer": "Contradiction The primary trial and secondary trial have different inclusion criteria and there is no mention in the primary trials exclusion criteria that patients in the secondary trial are excluded",
        "label": "Contradiction"
    },
    "72f49bc3-1624-437d-bf75-e37a24a9c19f": {
        "text_answer": "Contradiction The statement age at menarche is a risk factor for breast cancer is not mentioned in the inclusion or exclusion criteria for either the primary or secondary trial The other factors listed such as nationality ethnicity psychiatric condition or gender are not mentioned as eligibility criteria for either trial",
        "label": "Contradiction"
    },
    "002bd33d-4038-4b2b-9f56-1bd8e8978d64": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because the primary trial explicitly excludes patients with cerebral metastases within 5 mm of the optic chiasm or within the brainstem whereas the secondary trial excludes patients with cerebral metastases located within the brainstem",
        "label": "Contradiction"
    },
    "25d927c2-92be-405f-950a-e275c4d00e38": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that there was one case of recurrent malignancy and one case of anemia in the primary trial but there were no cases of these conditions in the secondary trial However the statement asserts that these conditions were more often associated with adverse events in the primary trial",
        "label": "Contradiction"
    },
    "fd2a59ea-6b33-4b24-ae04-32a2a40b4029": {
        "text_answer": "Neutral  The statement does not directly entail or contradict the evidence provided The evidence only specifies the dosage and timing of Dexamethasone administration for each cohort but it does not mention anything about vitamin K measurement or the diet of the patients",
        "label": "Entailment"
    },
    "883cad2c-dee5-4530-bdde-5d616d4570ad": {
        "text_answer": "Contradiction The primary trial does not mention any criteria related to schizophrenia so it cannot entail or contradict the statement about the secondary trial which does mention schizophrenia as an exclusion criterion for that trial",
        "label": "Contradiction"
    },
    "81694850-fb70-4062-8dab-a52dd8083ebb": {
        "text_answer": "Contradiction  Explanation The statement four unique adverse events impacted patients in cohort 2 of the primary clinical trial is a contradiction to the evidence provided as there are only three unique adverse events Fatigue and Pyrexia that impacted patients in cohort 2 according to the evidence",
        "label": "Contradiction"
    },
    "cf45d975-0c29-4cf3-8f21-c245482a2b32": {
        "text_answer": "Contradiction The primary trial measures treatmentemergent adverse events while the secondary trial measures objective response These are not the same outcome measurements",
        "label": "Contradiction"
    },
    "4fc29a51-2cd7-4c8c-8000-58bd9cb4858d": {
        "text_answer": "Entailment  Explanation The evidence shows that no adverse events have been reported in both the primary and secondary clinical trials The statement that no adverse events have been reported in either the primary clinical trial or the secondary clinical trial is an entailment of the evidence as it is a stronger statement that includes the evidence but does not add any new information",
        "label": "Entailment"
    },
    "64cc1bfb-d23f-47e1-bfcb-7d69cd8458ad": {
        "text_answer": "Contradiction  Explanation The statement there was a single psychiatric adverse event in the primary trial which affected fewer than 1 in 10 patients is a contradiction to the evidence because the evidence shows that there were two psychiatric adverse events suicidal ideation and unspecified psychiatric disorders in the primary trial and the total number of patients was 50 Therefore the statement that which affected fewer than",
        "label": "Contradiction"
    },
    "48a0cb8b-d7c5-42e0-8adc-abd0b8f17301": {
        "text_answer": "Contradiction The statement is not related to the given evidence as it mentions Leptospiraceae a taxonomic family of bacteria while the evidence pertains to breast cancer patients eligibility for clinical trials",
        "label": "Contradiction"
    },
    "dc55e21c-534b-4045-9c6c-f13919efde18": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial involves the use of FMX and MM398 with different dosing schedules while the secondary clinical trial employs the combination of lapatinib and paclitaxel with a different dosing frequency Therefore the statement is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "21afdaec-2db5-42b3-b201-b2dee4e23cb7": {
        "text_answer": "Contradiction The statement is not entirely true as the trials do share the use of intravenous injections and MRIs but they do not have identical drugs dosages or frequency of administration",
        "label": "Contradiction"
    },
    "d6381c6b-a7d6-406a-9d52-a660c27c2d49": {
        "text_answer": "Entailment given the provided evidence the statement is true because there are no recorded adverse events in both trials",
        "label": "Entailment"
    },
    "3159e9e4-c8a2-4333-b24c-250698ae8ffd": {
        "text_answer": "Contradiction  The evidence shows that all three participants in Cohort 1 of the primary clinical trial experienced adverse events",
        "label": "Contradiction"
    },
    "2cde3c46-f21a-4177-afc8-94f851854b98": {
        "text_answer": "Entailment The evidence shows that there were a total of 5 gastrointestinal adverse events diarrhea gastritis hemorrhagic and vomiting in Adverse Events 1 and 1 gastrointestinal adverse event dyspepsia in Adverse Events 2 Therefore the statement There was at least 1 recorded gastrointestinal adverse event in the primary trial",
        "label": "Entailment"
    },
    "70bfa3c4-2199-4d07-84c9-f41cac594ed4": {
        "text_answer": "Contradiction  Explanation The statement mentions nothing about the use of a mixer device in the primary trial so it is not related to the evidence provided and cannot be determined to be an entailment or contradiction based on the evidence alone However the evidence shows that Cohort 1 received a lower dose of MM121 than Cohort 2 but the same dose of Cetuximab Therefore the",
        "label": "Contradiction"
    },
    "97fe92c7-779d-4de8-8834-60ed8fe3178f": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "5829a465-2f7e-4a15-a746-24e4c0f53200": {
        "text_answer": "Contradiction The evidence for the primary trial does not state that there are no age limits only that there are no age restrictions specified",
        "label": "Contradiction"
    },
    "88fbd986-643d-4086-8091-e535d1970ab9": {
        "text_answer": "Contradiction The primary trial and secondary trial have some similar inclusion and exclusion criteria but they also have significant differences For example the primary trial includes patients with advancedmetastatic solid tumors while the secondary trial includes patients with a history of breast cancer or a perceived increased risk of breast cancer The primary trial also includes patients with measurable or nonmeasurable disease while the secondary trial only includes patients with bothersome hot flashes for one month",
        "label": "Contradiction"
    },
    "0ed8370b-00c3-41d9-9d12-0c0f1259cbf1": {
        "text_answer": "Contradiction The evidence states that cohort 2 practices paced breathing once daily but the statement specifies no antineoplastic treatments weekly which is not related to the paced breathing intervention",
        "label": "Contradiction"
    },
    "a06d2404-8265-4baf-907d-ddba1bb223d0": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement is about the length of time that not feeling like eating occurred which is not directly related to the adverse events reported in the evidence The evidence only provides the number of adverse events and their percentages in the primary trial but it does not mention the duration of any of those events",
        "label": "Entailment"
    },
    "df8f9622-e361-4283-bc4a-fef7eaa101b1": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence shows that there were no adverse events recorded in the primary trial while the secondary trial recorded 0 adverse events per 15 patients 000 The statement assumes that both trials recorded the same total number of adverse events but the evidence does not support this assumption",
        "label": "Contradiction"
    },
    "8b50bdc1-1722-403b-a854-adeaacd02acb": {
        "text_answer": "Contradiction  The evidence states that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the trial The statement provided in the question suggests that patients with a history of severe anaphylactic reactions to herceptin trastuzumab are eligible for the trial which contradicts the exclusion criteria in the evidence",
        "label": "Contradiction"
    },
    "1f742130-d274-4857-bc92-af652963c07b": {
        "text_answer": "Entailment  Explanation The statement none of the primary trial participants and none of the 1674 secondary trial participants experienced an adverse event is an entailment of the evidence provided as the evidence shows that no adverse events were reported in either trial",
        "label": "Entailment"
    },
    "3cd90294-f295-4725-82d4-e185d03cc2b7": {
        "text_answer": "Contradiction The evidence does not mention anything about diffuse parenchymal lung disease as an exclusion criterion for the primary trial",
        "label": "Contradiction"
    },
    "0cacd90a-ae93-47cb-b9f2-fa7e03d75270": {
        "text_answer": "Contradiction The evidence does not mention anything about talazoparib or mouth discomfort with toothpaste in the primary trial",
        "label": "Contradiction"
    },
    "9a137ed3-f905-4367-988c-002fabb77140": {
        "text_answer": "Contradiction The evidence shows that 2500 of patients in cohort 2 reported increased pleural effusion",
        "label": "Contradiction"
    },
    "71268387-6e9d-4875-b193-b60b4e3e7033": {
        "text_answer": "Contradiction  Explanation In the primary trial patients receive 4 mgkg as a loading dose followed by 2 mgkg weekly In the secondary trial cohort 2 receives Herceptin at 4 mgkg on Day 1 of Cycle 5 and 2 mgkg weekly starting from Day 8 However the dosages are not identical throughout the trials making the statement a contradiction",
        "label": "Contradiction"
    },
    "54a1eab3-1e8e-4c1c-a30f-f4d677a84c71": {
        "text_answer": "Contradiction The primary trial compares two interventions Arm A and Arm B against each other while the secondary trial compares two different treatments Denosumab and Zoledronic Acid The statement attempts to make a comparison between the results of the two trials which is not valid",
        "label": "Contradiction"
    },
    "79f436e1-8238-4d99-824f-6b19bfbd4ec4": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that both trials involve the use of trastuzumab which is a monoclonal antibody drug making the drugbased cures in the primary and secondary trials not utterly diverse in nature",
        "label": "Contradiction"
    },
    "5a181517-dbdc-4598-8955-ca1bfa380fa9": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention in Intervention 1 consists of a single drug ZD1839  In the secondary trial Intervention 1 consists of Zoledronic acid vitamin D and calcium supplements This is not a single drug but rather a combination of three different drugs  However Intervention 2 in the secondary trial does require at least ",
        "label": "Contradiction"
    },
    "1cb125fb-0be1-49c6-b68b-64b525278c9c": {
        "text_answer": "Entailment  Explanation The statement Across both the primary trial and the secondary trial only one death was recorded in the adverse events is an entailment based on the evidence provided The evidence shows that in the primary trial one death was recorded and in the secondary trial no deaths were recorded Therefore the statement that only one death was recorded across both trials is a logical conclusion from the evidence",
        "label": "Entailment"
    },
    "726add6d-9f17-4e3e-a43e-8b391fbb953b": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because  1 In the primary trial the dose of Alpha Lipoic Acid is not fixed and will be escalated until a maximum tolerated dose is found 2 In the secondary trial the dose of Necitumumab is fixed at 800 mg for the entire duration of the trial  Therefore the statement that Patients",
        "label": "Contradiction"
    },
    "333e2178-1944-4771-9ce5-6c89a1386f5a": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the two interventions in the primary trial have different dosing schedules for doxorubicin cyclophosphamide and docetaxel In Intervention 1 doxorubicin and cyclophosphamide are given in the same doses and frequency for all participants during the first 4 cycles but docetaxel is given at",
        "label": "Contradiction"
    },
    "c8633493-4879-4e97-9fcf-5e59ca22a79a": {
        "text_answer": "Contradiction The primary trial specifically states that patients must have a breast tumor 1 cm in diameter while the statement suggests a tumor size of 082 cm",
        "label": "Contradiction"
    },
    "a003e152-72e6-4c28-9f7d-1d2086174992": {
        "text_answer": "Contradiction  The statement under half of the patients in the primary clinical trial treated with lapatinib 1000 mg  nabpaclitaxel experienced a confirmed complete response CR or a confirmed partial response PR is a contradiction to the evidence provided which states that 53 of participants experienced a confirmed complete response CR or a confirmed partial response PR",
        "label": "Contradiction"
    },
    "594bf055-6c27-4319-b7b6-11ef47fab70c": {
        "text_answer": "Entailment The statement one instance each of anaemia and febrile neutropenia was documented while pancytopenia was not observed is entailed by the evidence Anaemia 118 556 Febrile neutropenia 118 556 Pancytopenia 018 000 The evidence confirms that",
        "label": "Entailment"
    },
    "174a00b4-2d77-4734-b02a-3603133fa8fe": {
        "text_answer": "Entailment The evidence shows that the percentage of participants with iDFS events was lower in the Neratinib group 47 compared to the Placebo group 75",
        "label": "Entailment"
    },
    "055374e1-939d-4366-835a-edf8e587f45c": {
        "text_answer": "Contradiction The statement excludes patients who have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 730 days before study entry but the primary trial exclusion criteria state that any of these therapies are excluded if they are currently  4 weeks prior or planned",
        "label": "Contradiction"
    },
    "292a7346-b4f6-4fc1-92a7-80297532eeff": {
        "text_answer": "Entailment Both cohorts use the same instructional CD for paced breathing but cohort 2 practices more frequently twice daily than cohort 1 once daily The statement correctly conveys this relationship",
        "label": "Entailment"
    },
    "892ac2e3-f5f8-42eb-957c-b3ca6af18d3a": {
        "text_answer": "Contradiction  The primary trial administers 150 mg of oral pregabalin twice daily for 6 weeks which is not equivalent to 015 grams of oral pregabalin every 14 days over 42 days  The secondary trial administers different treatments specifically Liposomal Cytarabine Depocyt and Highdose Methotrexate HDMTX",
        "label": "Contradiction"
    },
    "6c12493c-9eab-4206-aacc-bbb3dc398050": {
        "text_answer": "Contradiction The statement no single type of adverse event noted in the primary clinical trial impacted over 25 of the patient population is a contradiction to the evidence as the adverse event disease progression impacted 1429 of the patients in the primary clinical trial",
        "label": "Contradiction"
    },
    "753d23e6-333c-4ec1-8bc2-a853c29a20e9": {
        "text_answer": "Contradiction The primary trial uses radioembolization with Yttrium90 glass microspheres while the secondary trial uses a systemic therapy with ibrutinib and MEDI4736",
        "label": "Contradiction"
    },
    "c1e836e2-ad18-40b1-b8c4-0f05168d5104": {
        "text_answer": "Contradiction  Explanation The statement suggests that cohort 2 receives 0035 mg less ALT801 than cohort 1 However the evidence shows that cohort 1 receives a dose of 0015 mgkgday and cohort 2 receives a dose of 0040 mgkgday To determine if the statement is an entailment",
        "label": "Contradiction"
    },
    "2c817052-b2e7-4199-8b5c-77d285e2231c": {
        "text_answer": "Contradiction The statement the primary clinical trial mandate is that all participants possess an IHC 3 confirmed Her2 positive tumor and necessitate substantial aid and frequent healthcare support is a contradiction to the evidence as the evidence does not state that all participants require substantial aid and frequent healthcare support The inclusion criteria only state that participants must have a histologically confirmed Her2 positive breast cancer",
        "label": "Contradiction"
    },
    "561a11dc-abb5-4a2b-9211-4e27419cfc43": {
        "text_answer": "Entailment The evidence shows that 53 of participants in the Lapatinib 1000 mg  NabPaclitaxel arm had an overall tumor response which includes both complete and partial responses Therefore the statement that over 50 of those treated with lapatinib 1000 mg and nabpaclitaxel displayed either a verified complete or partial response is an entailment of the evidence",
        "label": "Entailment"
    },
    "9eb119ec-3ef7-4de4-ab36-5e8d63fdb984": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction as the primary and secondary trials address different conditions and populations",
        "label": "Entailment"
    },
    "9e31c420-01cc-4232-9793-a3a4b7201fa6": {
        "text_answer": "Irrelevant The statement is not related to the inclusion or exclusion criteria for either trial",
        "label": "Entailment"
    },
    "6fa15cf5-6fc4-48f3-a800-5e4699952ddb": {
        "text_answer": "Contradiction The evidence does not mention anything about obesity as an inclusion or exclusion criterion for either trial",
        "label": "Contradiction"
    },
    "54c7e880-a1bf-4206-9573-1c994932ba15": {
        "text_answer": "Contradiction  Explanation  The statement Patients who have received chemotherapy or radiotherapy in the last 2 weeks suffer from unstable angina or have Grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial unless they have nonhealing surgical wounds is a contradiction based on the evidence provided  The primary trial exclusion criteria state that",
        "label": "Contradiction"
    },
    "804742bb-2d69-45a8-a7a9-b6a269bf8d58": {
        "text_answer": "Neutral The statement is not directly entailed or contradicted by the evidence provided  Explanation The evidence provided in the primary trials inclusion and exclusion criteria does not mention anything about a specific level of hepatic enzymes in the blood being required to participate in the trial Therefore the statement is neither an entailment nor a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "a8932849-e870-422e-a81a-1b43d9622082": {
        "text_answer": "Contradiction The evidence does not provide information on the difference in Recurrencefree Survival percentage between the two groups",
        "label": "Contradiction"
    },
    "05b6b24d-8753-4029-9464-c825cb52b9f4": {
        "text_answer": "Contradiction The statement does not entail the evidence as it incorrectly states that the distinction between the first and second cohorts is based on the dosage of sunitinib and paclitaxel alone when in fact the first cohort receives sunitinib and the second cohort receives bevacizumab in addition to paclitaxel",
        "label": "Contradiction"
    },
    "e34d6b72-e842-4cd8-a0f4-08c8f4d33be9": {
        "text_answer": "Contradiction The evidence states that patients must have a BMI of 25 kgm2 or greater to participate in the trial",
        "label": "Contradiction"
    },
    "0bba5705-e808-4f90-b434-a951027f4d0f": {
        "text_answer": "Contradiction The primary trial follows a treatment regime based on a 3week cycle while the secondary trial does not have a set cycle for its intervention However the statement there is no set cycle for the intervention in the secondary clinical trial is an accurate description of the evidence so the statement is not a contradiction to the evidence but rather a correct statement based on the evidence The statement while the primary clinical trial follows a treatment regime based on a three",
        "label": "Contradiction"
    },
    "746f0f7a-c7e2-4ac9-a0ca-db2783eec9fa": {
        "text_answer": "Contradiction The evidence shows that 24 out of 25 participants in the Sunitinib  Docetaxel  Trastuzumab arm of the primary trial experienced treatmentemergent adverse events",
        "label": "Contradiction"
    },
    "9e02f276-1bd0-4373-a049-9a67ee3eac87": {
        "text_answer": "Contradiction The statement is not related to the evidence provided which only reports the number of adverse events in each cohort of the primary trial The statement is about a genetic syndrome",
        "label": "Contradiction"
    },
    "7e0f7c16-59ff-4a80-833a-7bb82748e80a": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because the evidence shows that both cohorts received the same dose of MM121 8mgkg but cohort 1 received a lower dose of Cetuximab 200 mgm2 compared to cohort 2 400 mgm2",
        "label": "Contradiction"
    },
    "00f4aa60-c89a-496d-aa2d-9535fcc79ff0": {
        "text_answer": "Entailment Note The statement provided in the question is not related to the evidence given in the primary trial The statement provided in the question is about a dosage form which is not mentioned in the evidence The answer is based on the evidence given regarding the comparison of hot flash frequency between the paced respiration and fast shallow breathing groups",
        "label": "Entailment"
    },
    "65edf675-63e7-4b5f-b131-9e5cdf9eeec4": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the dosages of interventions in the two trials are not directly comparable",
        "label": "Contradiction"
    },
    "a116a540-abca-478e-94ea-9997b0434c8b": {
        "text_answer": "Entailment The statement does not directly mention the inppl1 gene mutation in the evidence but the evidence does show a reduction in Ki67 expression which is a marker of cell proliferation during TAK228 Plus Tamoxifen treatment The statement is entailed by the evidence as it implies a potential effect of the treatment on cell proliferation",
        "label": "Entailment"
    },
    "ed50607e-8c46-4565-9192-4d5c4ca5fea5": {
        "text_answer": "Contradiction The statement is about cohort 2 of the primary trial suffering from acute vomiting but the evidence provided states that no episodes of vomiting and no rescue medication were reported during the first 24 hours after cyclophosphamide administration for cohort 2",
        "label": "Contradiction"
    },
    "321d4cba-47ee-4c74-85b9-072814b6fe6b": {
        "text_answer": "Entailment The primary and secondary trials both exclude pregnant patients so if a patient is not pregnant they meet the eligibility criteria for both trials",
        "label": "Entailment"
    },
    "1f4fe504-06a7-40e6-ad0e-76c903ea80a2": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not report the number of cases for hypertension and pancreatectomy to be compared to hepatotoxicity in the primary clinical trial",
        "label": "Contradiction"
    },
    "6c3ebd57-b814-49df-bade-ad46362eaa2b": {
        "text_answer": "Contradiction  The evidence states that cohort 1 is for triplenegative and HER2positive patients while cohort 2 is for HER2amplified patients The statement suggests that cohort 1 is for ER PR and HER2 patients while cohort 2 is for ER PR and HER2 patients which is not consistent with the evidence",
        "label": "Contradiction"
    },
    "83c979cb-fb3a-4792-8a63-8f7e544bb8a8": {
        "text_answer": "Contradiction The statement is about a patient with diffuse parenchymal lung disease being excluded from the primary trial while the evidence provided lists interstitial lung disease or pneumonitis as an exclusion criterion However diffuse parenchymal lung disease is a type of interstitial lung disease Therefore the statement is a contradiction to the evidence as it is more specific than the exclusion criterion provided",
        "label": "Contradiction"
    },
    "f203176f-3d6f-4e37-a07b-9bcf409ed538": {
        "text_answer": "Contradiction The evidence does not state that AfricanAmerican participants in the primary clinical trial must remain inhabitants of Texas for the entirety of the study",
        "label": "Contradiction"
    },
    "c467ce7a-d234-4542-909b-ac94393314ce": {
        "text_answer": "Contradiction The evidence states that the educational DVD is used in Intervention 1 but not in Intervention 2 Therefore the statement that the educational DVD will not be used in any of the interventions is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "60431d29-7e80-4a3e-b433-83f886ea73b6": {
        "text_answer": "Contradiction The statement makes assumptions about the number of adverse events in each trial that are not supported by the evidence provided",
        "label": "Contradiction"
    },
    "afc5437d-4c34-46e3-bcb0-742a23ba35e6": {
        "text_answer": "Contradiction The secondary trial participants have HER2negative metastatic breast cancer which is an exclusion criterion for the primary trial",
        "label": "Contradiction"
    },
    "aa861098-a5f8-473e-be7d-eba94ccb4ab1": {
        "text_answer": "Contradiction The patient described in the statement does not meet the inclusion criteria for the primary trial as they have a life expectancy of less than 3 months",
        "label": "Contradiction"
    },
    "1f8901ea-ca2d-4771-95e5-8b75fa7e9994": {
        "text_answer": "Contradiction The evidence mentions that subjects were treated with partial breast irradiation which implies a treatment cycle",
        "label": "Contradiction"
    },
    "4869e50d-ccc3-4200-b2e0-bf706fc99488": {
        "text_answer": "Contradiction  Patients with benign ductal carcinoma in situ are included in the primary trial but they are not explicitly mentioned in the secondary trials inclusion criteria However the secondary trial does include patients with a history of breast cancer which could potentially include ductal carcinoma in situ Therefore the statement is a contradiction as it incorrectly states that patients with benign ductal carcinoma in situ are eligible for the",
        "label": "Contradiction"
    },
    "22cf6f40-f022-4482-acdf-eef98748b946": {
        "text_answer": "Contradiction The primary trial measures changes in pain intensity not BMD of the lumbar spine",
        "label": "Contradiction"
    },
    "b4a7bcbe-6c7b-4e37-be25-35f2dd042bce": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence does not report any complete responses by week 2",
        "label": "Contradiction"
    },
    "97a8ede9-e46f-4b17-be7d-b05e9bd2f86e": {
        "text_answer": "Entailment The evidence does not report any cases of tumour lysis syndrome in either trial",
        "label": "Entailment"
    },
    "59c8ac7f-504b-46db-a840-b84fd9969b3d": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence does not provide any information about responses in the LBH589 and Lapatinib cohort of the primary clinical trial The evidence only provides information about the planned dosing and number of participants for this cohort",
        "label": "Contradiction"
    },
    "d08f014d-7d1b-45a1-b1c2-f68f12591f15": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the number of participants in each arm of the trial is different 1420 in each arm but not the same total number",
        "label": "Contradiction"
    },
    "6a0e68b7-6099-4fb9-bf11-35885b715348": {
        "text_answer": "Contradiction  Explanation The statement for the primary clinical trial patients with a successful response to previous hormonal therapies could be considered for participation is a contradiction to the inclusion criteria of the primary trial which states Breast Cancer has continued to grow after having received treatment with an antiestrogen hormonal treatment such as tamoxifen or an aromatase inhibitor  Therefore patients with a successful response to previous horm",
        "label": "Contradiction"
    },
    "f53c5344-36d7-459f-9f84-300e19decced": {
        "text_answer": "Contradiction  The evidence shows that 5 out of 20 patients in the placebo group were emesisfree during the study period",
        "label": "Contradiction"
    },
    "cf4c4c98-b8b0-4ab8-85a8-1269da4d9fd8": {
        "text_answer": "Contradiction  Explanation  The primary trial has several inclusion criteria related to cancer diagnosis stage sensitivity to vinorelbine and life expectancy It also has several exclusion criteria related to pregnancy previous vinorelbine treatment infection and prior anticancer therapy  The secondary trial on the other hand only includes patients undergoing large core breast biopsy in the Radiology Department at the Beth Israel Deacon",
        "label": "Contradiction"
    },
    "ebe5f6c9-355c-4d69-8b0d-5ac8d5f861a1": {
        "text_answer": "Contradiction  Explanation The statement mentions an eating disorder and Schizophrenia as psychiatric adverse events in the primary trial However the evidence only mentions suicidal ideation as a psychiatric adverse event There is no mention of an eating disorder or Schizophrenia in the evidence",
        "label": "Contradiction"
    },
    "90e72a43-b0ee-4656-b679-a6025ef5d4c2": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial measures tumor diameter in centimeters while the secondary clinical trial measures the number of participants with solid tumor response These are different units of measurement making the statement an contradiction",
        "label": "Contradiction"
    },
    "89f8f42e-0ac7-4fc4-bbd3-d58ffb933005": {
        "text_answer": "Contradiction  The statement makes a comparison between the primary trial and the secondary trial regarding the doses of MM121 and Paclitaxel but it does not mention anything about Herceptin or Doxorubicil The primary trial does not provide information about the doses of these drugs",
        "label": "Contradiction"
    },
    "7af1ab1f-5170-496e-ba41-61d54113c9c6": {
        "text_answer": "Contradiction The evidence states that sexually active fertile men and women of childbearing potential are excluded from the study",
        "label": "Contradiction"
    },
    "70b8c9a1-dcd5-459b-b138-d341132d2b5e": {
        "text_answer": "Contradiction  The statement is about the change in tumor diameter while the evidence provided is about the change in Ki67 expression These two measures are not directly related",
        "label": "Contradiction"
    },
    "91ce9f54-322f-4796-930e-0f85cf65d115": {
        "text_answer": "Contradiction The statement mentions oral doses of V935 but the evidence provided does not mention any oral administration of V935 in either Intervention 1 or Intervention 2 The given information is about intramuscular IM injections of V935 in Intervention 1 and intramuscular injections of V934 followed by V935 in Intervention 2",
        "label": "Contradiction"
    },
    "2c4fbaa0-f62c-4a7b-9d9d-7b61a8383ec4": {
        "text_answer": "Contradiction The statement does not directly relate to the evidence provided as the evidence only discusses iDFS rates and does not mention anything about granuloma assessment",
        "label": "Contradiction"
    },
    "23cb11b4-6a85-4a6f-9e72-920eff085459": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the evidence provides the median PFS for each group not the longest PFS for an individual patient",
        "label": "Contradiction"
    },
    "33b59cbc-c52d-4e5c-8f77-f2d8a6fa491c": {
        "text_answer": "Contradiction The evidence shows that no adverse events were recorded in the secondary trial The statement implies that there were several recorded adverse events",
        "label": "Contradiction"
    },
    "e9e1b48b-55a2-479b-93cd-33db74d3053c": {
        "text_answer": "Irrelevant The statement is not related to the evidence provided",
        "label": "Entailment"
    },
    "cb418196-3bf8-4a86-9c90-819eb43ede13": {
        "text_answer": "Entailment The evidence shows that there were reported adverse events for cohort 1 patients in the primary clinical trial",
        "label": "Entailment"
    },
    "d16039bf-c0d3-488f-8890-cb5b5d909ab8": {
        "text_answer": "Contradiction  Explanation  In the primary trial only the Intervention 2 group receives Armodafinil daily PO but in the secondary trial neither Intervention 1 nor Intervention 2 mentions daily Armodafinil administration Instead Intervention 1 in the secondary trial mentions the use of MCS110 and PDR001 without specifying their dosing frequency or duration Therefore the statement",
        "label": "Contradiction"
    },
    "eb3891b2-5320-4b6e-9a9f-08c7aa8bdd29": {
        "text_answer": "Contradiction The primary trial does not exclude patients with cerebral metastases within the brainstem while the secondary trial does",
        "label": "Contradiction"
    },
    "0c9b06e1-9dab-4937-b22e-0d372a5fd92d": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the primary trial involves the administration of alpha lipoic acid while the secondary trial involves the administration of necitumumab The two interventions are not the same and the statement does not hold true for both interventions",
        "label": "Contradiction"
    },
    "4a56cd2d-ce04-4515-a033-f140e44cf955": {
        "text_answer": "Contradiction The statement mentions that there was a single case of anaemia and febrile neutropenia in the first cohort but the evidence shows that there was only one case of anaemia in the first cohort and no cases of febrile neutropenia",
        "label": "Contradiction"
    },
    "284bab9f-a986-4a27-9fe3-ac989cefcf4e": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence does not support the claim that weekly subcutaneous injections are designed for those enrolled in the secondary clinical trial In the primary trial there is no mention of weekly subcutaneous injections as a procedure for any arm of the study In contrast the secondary trial involves the use of epoetin beta through weekly subcutaneous injections but it is not",
        "label": "Contradiction"
    },
    "e5746ae9-641d-4549-a164-811aa126a2e5": {
        "text_answer": "Entailment  Explanation The statement over 05 patients in the primary trial treated with lapatinib 1000 mg  nabpaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR is an entailment of the evidence provided in the trial results as the evidence states that 53 of the participants in the lapatinib 1000 mg  n",
        "label": "Entailment"
    },
    "510ae9ab-feae-4c57-a8c3-02e8764e6faa": {
        "text_answer": "Contradiction The evidence provided does not mention anything about claustrophobia being a criterion for inclusion or exclusion in either the primary or secondary trial Osteoporosis is mentioned as an exclusion criterion in the primary trial but there is no mention of it in the secondary trial",
        "label": "Contradiction"
    },
    "539adaf8-43ce-4c8f-9ed5-df5b030132c3": {
        "text_answer": "Contradiction The evidence states that participants receive oral medication daily for 28 days not intravenous medication once a week for six months",
        "label": "Contradiction"
    },
    "df3a590c-02f9-4dc2-84da-da4d5534c542": {
        "text_answer": "Entailment  Explanation The evidence states that both Intervention 1 and Intervention 2 are part of a primary trial and each intervention has its specific cohorts Phase 2 Triple Negative and Phase 2 HER2 respectively The statement does not mention any invasive surgery or Neratinib for any of the cohorts which is in line with the evidence Therefore the statement is an entailment based on",
        "label": "Entailment"
    },
    "f995d440-b2ff-491e-bc11-038f63b8681e": {
        "text_answer": "Contradiction The primary trial only includes patients with HER2positive breast cancer while the secondary trial includes patients with ERpositive HER2negative breast cancer",
        "label": "Contradiction"
    },
    "d6cde3f8-ef3c-4d8a-8afb-d3e9f8c5c1f8": {
        "text_answer": "Contradiction The evidence states that the inclusion criteria include no evidence of dementia  Mini Mental State Examination MMSE 23 but some evidence of cognitive impairment Alzheimers disease is a type of dementia so patients with Alzheimers disease would not be eligible for the trial according to the given evidence However the statement in the question specifically mentions Alzheimers disease whereas the evidence ment",
        "label": "Contradiction"
    },
    "dbb49ce0-7aed-4573-9b13-1db31e9df94d": {
        "text_answer": "Contradiction The secondary trial does not measure range of motion for yoga but rather measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale The primary trial studies the effect of mineral supplements on electrolyte balance in blood using isothiocyanate in urine samples",
        "label": "Contradiction"
    },
    "198d43b9-ed80-463e-bbdc-d2d565fb61aa": {
        "text_answer": "Contradiction  Women aged 18 or 19 are not eligible for the primary trial according to the given inclusion criteria Therefore they cannot be eligible for a 1224 month wait to be eligible for the primary trial",
        "label": "Contradiction"
    },
    "679f8ab4-38a4-4c6c-b85f-800e645e5bb8": {
        "text_answer": "Irrelevant  The statement is not related to the provided evidence as it mentions an electrocardiographic finding undetermined rhythm that is not mentioned or relevant to the given data",
        "label": "Entailment"
    },
    "93850158-9371-4320-aefc-c31e15a5d983": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction to the evidence provided because  1 The primary trial has different inclusion and exclusion criteria for its Phase I and Phase II portions 2 The secondary trial has the same inclusion criteria for all participants but the exclusion criteria were not provided in the evidence 3 The statement mentions a unit of concentration but there is no mention of this unit in the evidence",
        "label": "Contradiction"
    },
    "7bdf850e-2f84-40f0-9b80-5bf9984be081": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The evidence describes the details of the primary trial including the dosing schedule for Vorinostat and radiation therapy The statement on the other hand makes a general statement about the electrocardiographic finding of a QRS complex and the requirement for patients to swallow a capsule of Vorinostat daily during radiation therapy While the two pieces of information are related",
        "label": "Entailment"
    },
    "10acc981-00c5-4c74-b2ce-58bc69406955": {
        "text_answer": "Entailment The statement the primary clinical trial has a multitude of adverse events recorded for its patient cohort is an entailment of the evidence Adverse Events 1 Total 129 345 Although the evidence only reports one type of adverse event it does not contradict the statement which uses the term a multitude in a general sense and does not specify that all types of adverse events",
        "label": "Entailment"
    },
    "e42e5fc5-cdf8-40c3-9cf7-44ff5bdff413": {
        "text_answer": "Contradiction The primary trial does impose an age restriction 2555 years old",
        "label": "Contradiction"
    },
    "5a90093d-2964-4935-b8af-236bfff8d4de": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there is no mention of paclitaxel in the given interventions ANA and FULV of the primary clinical trial",
        "label": "Contradiction"
    },
    "1cda1a1d-3ca1-4838-9054-bcab763bb5d0": {
        "text_answer": "Contradiction The evidence provided does not support the statement as it mentions several adverse events related to cardiac and hematologic conditions which are not related to mental health",
        "label": "Contradiction"
    },
    "15d7d028-69c2-4e01-b85c-cff568f34cc1": {
        "text_answer": "Contradiction The evidence states that patients with uncontrolled medical conditions that may limit compliance with the study interventions are excluded Anorexia is a medical condition characterized by a persistent lack of appetite and significant weight loss which could potentially limit compliance with the study requirements related to diet and weight changes",
        "label": "Contradiction"
    },
    "0bc4c4b5-bdb3-4b4b-9122-e52dcb57ec61": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only mentions the interventions given in each trial it does not mention anything about gynecologic cancer affecting sexual relationships",
        "label": "Contradiction"
    },
    "5d04737b-c113-4934-94b6-ea9d8dd6318b": {
        "text_answer": "Contradiction The primary trial does not provide information about neonatal culture positive sepsis as an adverse event",
        "label": "Contradiction"
    },
    "9d9fc91e-b6a2-4ab8-bb28-a0a182574d90": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as Sunitinib was not administered orally every day to every patient in the primary trial for the entire duration of the study The evidence states that Sunitinib was administered orally from Day 1 at a continuous daily dosing schedule in 21day cycles while Capecitabine was administered orally from Days 1 to 14 every 21 days This",
        "label": "Contradiction"
    },
    "e6b528a8-9d23-420b-b1a1-63bd831b7c03": {
        "text_answer": "Contradiction The evidence shows that there were cases of wound dehiscence and seroma which are complications related to surgical incisions",
        "label": "Contradiction"
    },
    "205bc80b-db03-469f-85b8-290a4be79af8": {
        "text_answer": "Entailment  Explanation In the primary trial there is no information provided about the doses of MM121 and Paclitaxel However in the secondary trial Cohort 1 receives a weekly dose of 20 mgkg for MM121 and 80 mgkg for Paclitaxel while in the primary trial there is no mention of these doses Therefore the statement",
        "label": "Entailment"
    },
    "1a15db80-85f2-4d35-b325-1e01fdfb453d": {
        "text_answer": "Contradiction  Explanation The evidence provided does not support the statement as it does not mention any results or outcomes related to the inferiority of the LBH589 with Capecitabine cohort compared to the LBH589 and Lapatinib group The evidence only provides information about the dose levels dosing schedules and number of participants analyzed for each group",
        "label": "Contradiction"
    },
    "52ae60f0-ea78-473d-9e82-78f2d1fc81bf": {
        "text_answer": "Contradiction The statement about having poor or reduced appetite is not mentioned in the evidence for either the primary or secondary trials",
        "label": "Contradiction"
    },
    "f008bad4-fa46-4187-b784-434238a5992b": {
        "text_answer": "Contradiction The primary trial uses PF06647020 not ALT801",
        "label": "Contradiction"
    },
    "0ebc75cd-f87b-46a6-aaa3-9b511cdb90ae": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial does not include patients with resectable Nonsmall cell lung cancer or Small cell lung cancer",
        "label": "Contradiction"
    },
    "f52235c3-a9c6-4eb2-a9c6-929afe1bf49a": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one case of Gramnegative bacteremia with a fever in Cohort 1 of the primary trial However there were no infections or infestations reported in Cohort 2 Therefore the statement that all infections and infestations cases in the primary clinical trial were evenly distributed among all cohorts is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "6bf5cffc-eb10-45ae-9e9f-b5b5d60be392": {
        "text_answer": "Irrelevant The statement is not related to the provided evidence",
        "label": "Entailment"
    },
    "62c8e736-58fd-472f-bef0-c957b8055237": {
        "text_answer": "Contradiction  The statement implies that there were 3 cases of hepatotoxicity and 0125 cases each of hypertension and pancreatectomy in the primary trial which is not supported by the evidence The evidence shows that there were 3 cases of hepatotoxicity 1 case of hypertension and 1 case of pancreatectomy",
        "label": "Contradiction"
    },
    "cc369e33-07e2-441d-b4fd-8233478ba98a": {
        "text_answer": "Contradiction The evidence does not state that patients with severe malnutrition are ineligible for the primary clinical trial However it does list specific medical conditions and circumstances that would exclude individuals from participating Severe malnutrition is not explicitly mentioned in the exclusion criteria",
        "label": "Contradiction"
    },
    "77f689bc-c9fc-45ab-9966-aea06482863a": {
        "text_answer": "Contradiction The evidence does not explicitly state whether children are eligible for the secondary clinical trial",
        "label": "Contradiction"
    },
    "fc35b082-3d3c-4ccc-971b-1f008c224a28": {
        "text_answer": "Contradiction  The evidence mentions the use of 7 different drugs in the primary trial epirubicin cyclophosphamide docetaxel trastuzumab epirubicin cyclophosphamide docetaxel and trastuzumab which is less than the stated 14 different drugs in the question Additionally the maximum dose of epirubicin is 10",
        "label": "Contradiction"
    },
    "28efc57b-6732-4778-84e9-81d1cea1a43e": {
        "text_answer": "  Contradiction The statement aggravated malignant neoplasm is a malignant neoplasm that shows clinical andor pathologic progression Only 2 patients in the primary trial did not have Recurrencefree Survival is a contradiction to the evidence provided The evidence states that 98 of the patients had Recurrencefree Survival which is not the same as stating that only 2",
        "label": "Contradiction"
    },
    "a4ddb589-176d-4a2f-bdf2-3c5973a09a4d": {
        "text_answer": "Contradiction The evidence states that there was one adverse event recorded in the primary trial which contradicts the statement that no adverse events were recorded for the patient cohort",
        "label": "Contradiction"
    },
    "47ff584c-f344-45ab-afec-1c1561453a36": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was at least one case of anaemia and one case of febrile neutropenia in cohort 1 of the primary clinical trial as per Adverse Events 1 Therefore the statement that the primary clinical trial found no traces of anaemia febrile neutropenia or pancytopenia in cohort 1 is a",
        "label": "Contradiction"
    },
    "0f0501ba-557e-4111-8473-ec54b624a47f": {
        "text_answer": "Contradiction  The statement suggests that breast cancer patients received 200 mcgday and ovarianperitoneal cancer patients received 500 mcgday but the evidence shows that breast cancer patients received a range of doses from 600 mcgday to 1100 mcgday and ovarianperitoneal cancer patients received a range of doses from 25 m",
        "label": "Contradiction"
    },
    "825832eb-2b69-42a2-80b1-f210915da77c": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement does not directly relate to the adverse events reported in the primary trial The statement is about polycythemia excluding polycythemia vera and the absence of certain conditions Hypertension Dehydration and Dyspnea in the trial while the evidence provided is about the adverse events observed",
        "label": "Entailment"
    },
    "9a337e6e-70b7-420d-9679-cc0baf5a5ba8": {
        "text_answer": "Contradiction The evidence does not provide any information about tumour lysis syndrome in either trial",
        "label": "Contradiction"
    },
    "9cc10a0d-5cb3-49b0-99c9-586837640270": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The evidence describes the use of different imaging modalities pIHGC and GP in the context of lymphoscintigraphy for breast cancer while the statement refers to a different type of meningioma choroid plexus meningioma These two pieces of information are not directly related to each other",
        "label": "Entailment"
    },
    "bde45f5a-8909-48eb-b331-715583659654": {
        "text_answer": "Contradiction The evidence shows that 11 out of 25 participants had serious treatmentemergent adverse events which is less than 75 of the participants",
        "label": "Contradiction"
    },
    "ac50c12b-4055-428b-8d8b-0136aca85f10": {
        "text_answer": "Contradiction  Explanation The statement a higher percentage of patients suffered from adverse events in cohort a compared to cohort b during the primary clinical trial is a contradiction based on the evidence provided because the evidence does not show that cohort a had a higher percentage of patients with adverse events than cohort b In fact the evidence shows that the percentage of patients with adverse events was the same in both coh",
        "label": "Contradiction"
    },
    "1023b3b0-b190-4ad2-b849-a7ba384be1f8": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as cohort 1 received a lower dose 0015 mgkgdose of ALT801 than cohort 2 0040 mgkgdose",
        "label": "Contradiction"
    },
    "be705668-6d11-46eb-bd96-9d20f01b936d": {
        "text_answer": "Irrelevant The statement is not related to the provided evidence The evidence only reports the adverse events for each trial and there is no information about whether or not CSF cytology was completed at diagnosis for any of the participants",
        "label": "Contradiction"
    },
    "beff7121-1697-41a7-bf43-998005d5c68e": {
        "text_answer": "Contradiction The primary trial includes Perjeta pertuzumab in Intervention 1 while the secondary trial excludes it entirely",
        "label": "Contradiction"
    },
    "cd250e97-c2b4-48cd-bcbe-55ea06fa9662": {
        "text_answer": "Entailment with the condition that the woman has completed surgery for breast cancer and meets the other criteria for the secondary trial or is undergoing immediate tissue expander reconstruction following mastectomy by any of the surgeon coinvestigators for the primary trial",
        "label": "Entailment"
    },
    "c4e967e1-c656-4d32-b8b5-c0b74a94bf02": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the evidence shows that the primary trial used lenalidomide in a dose of 5mg orally daily for a total of 573 days while the secondary trial used lapatinib in a dose of 1500mg orally daily for 6 weeks The total amount of lenalidomide used in the primary trial cannot be directly compared",
        "label": "Contradiction"
    },
    "9c15d42d-2fcc-4c69-86b2-f75e29d732d4": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The statement is about a blood substitute while the evidence is about adverse events in the primary trial",
        "label": "Entailment"
    },
    "1641b323-b136-4104-81e5-744ceac933de": {
        "text_answer": "Contradiction The statement all ae types witnessed in the primary clinical trial affected less than a tenth of the patients is a contradiction to the evidence as some adverse events affected more than 909 of the patients eg febrile neutropenia and sepsis each affected 909 of the patients",
        "label": "Contradiction"
    },
    "6033e8d9-c7d5-4b36-b6da-80fdb98de034": {
        "text_answer": "Contradiction The primary trial includes patients with a breast tumor that is 1 cm in diameter while the secondary trial does not mention any specific tumor size requirement",
        "label": "Contradiction"
    },
    "e8702a99-36bb-4f4f-b2ff-3fa6d49d034e": {
        "text_answer": "Contradiction The statement is incorrect as the first cohort is treated with 90 mgm2 paclitaxel not 25 mg sunitinib",
        "label": "Contradiction"
    },
    "961aaf91-e07d-4723-860e-23593727c303": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as zoledronic acid in the primary trial is given intravenously while some drugs in the secondary trial granisetron hydrochloride dexamethasone aprepitant and palonosetron hydrochloride can be given orally or intravenously",
        "label": "Contradiction"
    },
    "45e2f6cb-6ab2-424e-bd21-c2086ab6def3": {
        "text_answer": "Contradiction  The evidence provided shows that the percentage of participants with disease progression or death was lower in the Bevacizumab only cohort 883 compared to the Bevacizumab  Capecitabine cohort 758 Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "526f99de-e377-42e4-a7ae-a42b797aa536": {
        "text_answer": "Contradiction  Explanation  The evidence shows that there were 5 participants in the placebo group who did not experience any emesis during the study period Therefore the statement that every participant of the primary clinical trial who received a placebo intervention went through episodes of emesis is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "f8f0d036-16aa-4a9f-816e-c52940709126": {
        "text_answer": "Irrelevant  The statement is not related to the evidence provided in the primary trial results The trial results only report on the correlation of Vitamin D levels prognostic factors and gene expression profile in patients with breast cancer and do not mention anything about mouth sensitivity",
        "label": "Entailment"
    },
    "b6902408-8d60-438b-bb38-416d4a4d76fb": {
        "text_answer": "Entailment assuming the evidence provided does not contradict any information given about the interventions in the primary trial  Explanation The evidence describes the patient population and eligibility criteria for the primary trial but it does not mention any requirement for regular exercise as part of the interventions described in Intervention 1 Arm I or Intervention 2 Arm II Therefore the statement that none of the primary trial candidates have to perform regular exercise as part",
        "label": "Entailment"
    },
    "449b619f-902b-446d-ac1e-f73be62ac2ab": {
        "text_answer": "Contradiction The primary trial recorded no adverse events at all while the secondary trial recorded a high incidence of adverse events",
        "label": "Contradiction"
    },
    "c114301e-f64f-468b-95f7-8debdc840a74": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as per the given trial design cohort 1 and cohort 2 receive different schedules of CUDC101 administration and there is no mention of PD0332991 in the evidence",
        "label": "Contradiction"
    },
    "7d60c7dd-fb79-4e95-a662-32de2036683f": {
        "text_answer": "Entailment The statement two patients suffered an Incidence of Doselimiting Toxicity is entailed by the evidence since the evidence reports that two patients from cohort 2 experienced doselimiting toxicities",
        "label": "Entailment"
    },
    "99a6cb19-b6d8-4cb7-84e1-be559854caa6": {
        "text_answer": "Contradiction The statement does not entail the evidence as some patients receive less than 20mg of MCS110 every 3 weeks 1mgkg",
        "label": "Contradiction"
    },
    "06024cb1-ce64-432e-b1d9-f3df2f95b025": {
        "text_answer": "Contradiction  Explanation  The statement suggests that both cohorts receive the same three electroporation injections of LD V934 However the evidence shows that in Intervention 1 Cohort A the three electroporation injections of LD V934 are given as part of Part A while in Intervention 2 Cohort B the three electroporation injections of LD V",
        "label": "Contradiction"
    },
    "e4cdcf39-a01c-45f5-a382-d0e8a96a0be6": {
        "text_answer": "Contradiction The primary trial does not divide its subjects into healthy and cancer patients with separate sets of rules for each phase The secondary trial does",
        "label": "Contradiction"
    },
    "fb758700-bd95-4857-a58e-1ee8d88c0d71": {
        "text_answer": "Contradiction The primary trial does provide information on the MTD of Ruxolitinib in combination with paclitaxel as stated in the outcome measurement section",
        "label": "Contradiction"
    },
    "4a64f808-b518-4666-9f78-56a2d6dd7093": {
        "text_answer": "Contradiction The evidence does not provide information about the number of participants in each arm of the trial only the number analyzed",
        "label": "Contradiction"
    },
    "2e42ac97-e353-4bbc-b61e-391e0c092689": {
        "text_answer": "Entailment The statement correctly identifies that the only difference between the two interventions is the dosage of durvalumab given in the biweekly IV infusions",
        "label": "Entailment"
    },
    "36cb2716-6b66-49bd-bb22-7119bd022e28": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement is not directly related to the evidence provided as it does not make a claim about the number of participants in each group but rather about the detail of the number of participants in each group being provided in the primary clinical trial",
        "label": "Entailment"
    },
    "88951a9e-179e-4284-9f98-141eb3d76369": {
        "text_answer": "Entailment  Explanation The statement Aes were not recorded for the primary trial or the secondary trial is an entailment based on the evidence provided because both trials have no reported adverse events in their respective Adverse Events 1 sections",
        "label": "Entailment"
    },
    "1027bd72-7cce-4903-9838-733046143102": {
        "text_answer": "Contradiction The evidence does not support the statement that generally patients from the primary clinical trial have a life expectancy that exceeds 2 years as the median survival times for both groups were less than 25 years",
        "label": "Contradiction"
    },
    "effa7535-9810-4bf3-92bd-64aba7878bf6": {
        "text_answer": "Contradiction The statement implies that more than two participants experienced doselimiting toxicity but the evidence shows that only one participant experienced doselimiting toxicity in each arm of the trial",
        "label": "Contradiction"
    },
    "eeb1a073-304f-41e4-b1f7-e2381eabf50f": {
        "text_answer": "Contradiction The primary trial does not involve radiation therapy at all",
        "label": "Contradiction"
    },
    "666c3ebb-3f79-4795-b5e7-4584815f498d": {
        "text_answer": "Contradiction  Explanation The primary trial measures changes in pain intensity while the secondary trial measures changes in bone mineral density These are different outcomes and are not directly comparable",
        "label": "Contradiction"
    },
    "9e8aeaf6-36db-4f09-b7a6-7a5e41d14215": {
        "text_answer": "Irrelevant The statement does not relate to the evidence provided",
        "label": "Entailment"
    },
    "811978a1-2715-4174-84af-07a0ca3686e8": {
        "text_answer": "Contradiction The statement is not related to the inclusionexclusion criteria of the trials",
        "label": "Contradiction"
    },
    "bed73866-02e7-49d2-a66a-215e0a0d1b83": {
        "text_answer": "Contradiction  The primary trial recorded one death but the statement assumes that both trials recorded only one death for an adverse event attributed to the disease However the secondary trial did not report any deaths in the adverse events section",
        "label": "Contradiction"
    },
    "910d3110-1fa1-4488-a481-085a18d1670a": {
        "text_answer": "Entailment The statement that both cohorts undergo the same intensity of radiation therapy is entailed by the evidence as the radiation therapy dosages and schedules are identical for both groups The difference lies only in the duration of the intervention due to the addition of the Active Breathing Coordination in the first cohort",
        "label": "Entailment"
    },
    "da901268-f433-47ff-9119-69d36ce3c4d0": {
        "text_answer": "Contradiction The primary trial involves denosumab injections while the secondary trial involves intraoperative gamma camera procedures with radioactive Tc99M sulfur colloid injections These are not the same interventions",
        "label": "Contradiction"
    },
    "c8109cb7-4cf5-469b-ba02-5d610579cc89": {
        "text_answer": "Entailment assuming that by similar results the statement refers to the fact that both trials involve the assessment of safety and efficacy outcomes in cancer patients even though the interventions and patient populations may differ",
        "label": "Entailment"
    },
    "3a85c9cb-b4e8-46cb-84c5-e618f0307b26": {
        "text_answer": "Contradiction  Explanation The evidence provided does not support the statement as it does not include any data or results related to the performance of the two cohorts in question The statement is making a comparison between the two cohorts but the evidence only describes the design and participant numbers for each cohort Therefore it is a contradiction based on the available evidence",
        "label": "Contradiction"
    },
    "d0168033-35eb-4032-b6e5-f81d9d3a9f7a": {
        "text_answer": "Contradiction  Explanation The evidence provided shows that the median aAUCpa for the Arm I Cryotherapy group was 14 117 to 68 while the median aAUCpa for the Arm II Control group was 44 571 to 162 A negative value indicates that symptoms have worsened from baseline However the statement suggests that patients in",
        "label": "Contradiction"
    },
    "90783994-6867-4dfe-bbd0-71c4004d9a20": {
        "text_answer": "Contradiction The statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "5d1e61bb-42f4-430c-843a-c6e80d121655": {
        "text_answer": "Contradiction  Explanation The statement assumes that cohort 1 and 2 receive the same dosage of CUDC101 but the evidence shows that cohort 1 receives CUDC101 more frequently which means they receive a higher total dose over the course of the trial Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "a9e1aa54-a19a-47d1-8d55-caef2035160e": {
        "text_answer": "Contradiction The statement mentions specific adverse events that are not documented in the evidence",
        "label": "Contradiction"
    },
    "c6ff494c-5fa8-414d-8a32-15713193c9a3": {
        "text_answer": "Contradiction  The evidence shows that the mean arm circumference in the waitlist group was actually slightly smaller at 6 weeks compared to baseline while the acupuncture group had a slightly smaller mean arm circumference at 6 weeks compared to baseline as well but the difference was greater in the acupuncture group However the statement implies that the improvements in the acupuncture group were more notable which is not directly supported by the evidence",
        "label": "Contradiction"
    },
    "1b48209c-3fcd-40d3-a647-f54b7e6179d2": {
        "text_answer": "Entailment  Explanation The statement is an entailment because if all the inclusion and exclusion criteria are met the healthcare professionals have the final say on participation which is already stated in the evidence",
        "label": "Entailment"
    },
    "7fb4b7a6-dee2-404f-a55f-18c8db378060": {
        "text_answer": "Entailment The patient meets the inclusion criteria for both trials based on the provided information",
        "label": "Entailment"
    },
    "61acc1f3-e02a-49ca-8ac8-42453619e78c": {
        "text_answer": "Contradiction  Explanation The statement mentions no unexpected fatalities or hospital admissions were reported in both the primary clinical trial and the secondary clinical trial but the evidence shows that there was one reported incident of lymphoma in the primary trial that resulted in a hospital admission which is considered an unexpected event according to the statements criteria Therefore the statement is a contradiction of the evidence",
        "label": "Contradiction"
    },
    "bf233363-7c05-475d-b248-d71303dec4e2": {
        "text_answer": "Contradiction The primary trial includes only ER HER2 patients Group 1 and ER PR HER2 patients Group 2 It does not include patients with ER PR HER2 tumors",
        "label": "Contradiction"
    },
    "8203056c-37a1-4fbf-a3cf-ddf28608d1ad": {
        "text_answer": "Contradiction The evidence states that there should be no meningeal carcinomatosis which is a type of meningitis caused by cancer cells",
        "label": "Contradiction"
    },
    "e8cc1118-7a1a-46ba-aa08-cfb7f414a753": {
        "text_answer": "Contradiction The statement does not entail that the primary trial excludes patients based on kat6a gene rearrangement but rather excludes those with a pulmonary embolism within the last 3 years The secondary trial does not mention anything about kat6a gene rearrangement as an exclusion criterion",
        "label": "Contradiction"
    },
    "b73bde4f-21c4-48bd-82d3-0447d22cbd1c": {
        "text_answer": "Contradiction  Explanation  The primary trial includes the requirement that patients have potassium within the normal range of 3553 mEqL as an inclusion criterion The secondary trial does not mention potassium levels as a criterion for inclusion or exclusion Therefore the statement that hypokalemic patients are most welcomed to participate in the primary clinical trial while those with normal potassium levels",
        "label": "Contradiction"
    },
    "68bae1de-1bee-486e-a50e-30ab9a4c705a": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions no occurrences of cardiac and psychiatric adverse events in either trial",
        "label": "Contradiction"
    },
    "664a5c0e-406c-4050-85d3-f2f489e5098b": {
        "text_answer": "Entailment as the evidence does not mention any vaccines being given to the participants",
        "label": "Entailment"
    },
    "90eca162-5617-44e3-909b-c8304af0d763": {
        "text_answer": "Contradiction The statement is contradictory because patients with NUT midline carcinoma or Castrateresistant prostate cancer as determined by fluorescence In situ hybridization are eligible for the primary trial according to the given inclusion criteria but they are not eligible for the secondary trial as per its exclusion criteria NUT midline carcinoma is listed as an exclusion criterion in the secondary trial Inflammatory breast",
        "label": "Contradiction"
    },
    "a8268e5e-d758-4dcf-8dd9-78c2016bc7f6": {
        "text_answer": "Entailment The evidence shows that both cohorts receive preoperative intravenous administration of Dexamethasone and the statement asserts that both cohorts receive preoperative Dexamethasone",
        "label": "Entailment"
    },
    "1480180d-d754-4fbd-bed9-70a50835c098": {
        "text_answer": "Contradiction  Explanation The statement in primary clinical trial the bevacizumab  capecitabine cohort demonstrated more positive outcomes compared to the bevacizumab cohort is a contradiction based on the evidence provided The evidence shows that the percentage of participants with disease progression or death was lower in the Bevacizumab cohort 883 compared to the Bevac",
        "label": "Contradiction"
    },
    "d8896ee9-9d44-485b-9b75-e25f4a56aa8d": {
        "text_answer": "Contradiction The evidence states that only 571 of patients in the primary trial suffered adverse events",
        "label": "Contradiction"
    },
    "57d27d0b-626b-474b-9e10-60cbdd237d92": {
        "text_answer": "Entailment Both the placebo and memantine interventions are indeed given orally on a daily basis as stated in the evidence",
        "label": "Entailment"
    },
    "2e054c61-23f1-46df-9c49-44e5f076163d": {
        "text_answer": "Contradiction The statement does not entail or follow logically from the evidence provided The evidence only mentions Herceptin trastuzumab being used in one of the interventions but it does not mention its use in the other intervention or any relation to paranemin",
        "label": "Contradiction"
    },
    "ac4e121f-e159-49e0-84cb-83218232ebbb": {
        "text_answer": "Contradiction The statement is about a completely different topic cell biology and medical history of patients for a clinical trial The first part of the statement is not related to the inclusionexclusion criteria for the primary trial mentioned in the evidence",
        "label": "Contradiction"
    },
    "a0d99371-52e5-4d30-81d5-ad65feba2e4e": {
        "text_answer": "Contradiction The primary trial inclusion criteria only mention unilateral breast cancer",
        "label": "Contradiction"
    },
    "8e205d62-f220-45ba-9324-f8ee359236b1": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial had two intervention groups Pyridoxine and Placebo but the statement incorrectly asserts that it had only one test group  The secondary clinical trial did indeed have two test groups Highdose Oxybutynin Chloride and Lowdose Oxybutynin Chloride as stated in the question  Therefore the statement is a contrad",
        "label": "Contradiction"
    },
    "e493c4b0-1bd6-446f-a432-2703b7775620": {
        "text_answer": "Contradiction The statement is not an entailment based on the evidence as some participants in the 1mg GTx024 group had a loss in lean body mass during the 4month period",
        "label": "Contradiction"
    },
    "23ccac08-3764-496a-a790-4a1f5079909e": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the secondary trial does not require candidates to be completely disabled",
        "label": "Contradiction"
    },
    "9ae8aa57-7196-4f5b-9911-33233705eac8": {
        "text_answer": "Contradiction The primary trial requires a primary tumor greater than 2 cm in diameter while the statement describes a primary tumor that is only 3mm in size",
        "label": "Contradiction"
    },
    "91a4429b-767a-493a-b1f3-f3a1ccf5ab6c": {
        "text_answer": "Entailment The evidence states that some patients receive MCS110 at a dosage of 1 mgkg which is less than 20 mg",
        "label": "Entailment"
    },
    "5f294eee-f332-4c58-a43f-076a06a04dd5": {
        "text_answer": "Contradiction The statement is incorrect as both cohorts receive Enzalutamide orally not by IV",
        "label": "Contradiction"
    },
    "03d015fe-1903-4b94-b495-4f23c40862db": {
        "text_answer": "Contradiction The evidence states that participants received niraparib 200 mg daily not talazoparib 200 mcg",
        "label": "Contradiction"
    },
    "63aa9e40-98df-4f09-a508-d0b03b9f93f1": {
        "text_answer": "Contradiction The evidence states that 571 of patients in the primary trial suffered adverse events which is greater than 0050",
        "label": "Contradiction"
    },
    "dcfb970a-f5b0-41c1-a5ec-99d17734c17c": {
        "text_answer": "Entailment The statement that patients with Histologically or cytologically confirmed metastatic andor advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial entails the statement that resolution of findings following intervention for kawasaki disease is an indication that findings were resolved following treatment for kawasaki disease as the eligibility criteria for the trials do not mention any specific",
        "label": "Entailment"
    },
    "0e935403-0cb2-40ff-b78b-6ba7eaf9621e": {
        "text_answer": "Irrelevant The statement is not related to the evidence provided The evidence only discusses the percentage of participants with HER2 Primary Breast Cancer who developed imagable HER2 Metastases during the trial and does not mention sweat gland neoplasms",
        "label": "Entailment"
    },
    "277c0ee2-5d34-4c87-80eb-6f5b630109ec": {
        "text_answer": "Contradiction The statement is about medulloblastoma which is a type of brain tumor while the evidence is about breast cancer patients",
        "label": "Contradiction"
    },
    "ef02754d-00ec-4f2d-bf7a-0a6d414b2476": {
        "text_answer": "Contradiction The evidence does not mention any cases of cutaneous fistulas in either trial",
        "label": "Contradiction"
    },
    "6848420c-ff9c-4003-bf9c-894b993c6720": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial has 0 anemia cases while the secondary trial has 4 anemia cases",
        "label": "Contradiction"
    },
    "481d1201-72b1-41b4-82cc-78b79ea8938a": {
        "text_answer": "Contradiction  Explanation  In the primary trial there is a comparison between two interventions Arm 1 CBTI  Placebo and Arm 2 CBTI  Armodafinil In Arm 2 Armodafinil is given daily for 47 days  However in the secondary trial there are two different interventions Ph Ib MCS110 1",
        "label": "Contradiction"
    },
    "c6039c02-dcb4-433b-a0a5-4d6beb33b8fa": {
        "text_answer": "Entailment The primary trial had a total of 0 adverse events and a variety of 0 while the secondary trial had a total of 623 adverse events and a variety of 1379 The primary trial having a lower total count and variety of adverse events is an entailment based on the evidence",
        "label": "Entailment"
    },
    "ee74199e-c159-41f6-9130-8410b237c32f": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that there was one case of biliary colic in the secondary trial and none in the primary trial Similarly there was one case of diarrhea in the secondary trial and four cases in the primary trial However the statement suggests that there are more cases of biliary colic and diarrhea in the secondary trial than in the primary trial which is not true",
        "label": "Contradiction"
    },
    "93bb8a0e-e84c-4730-b559-22d912103993": {
        "text_answer": "Contradiction  The primary trial uses a daily dose of lenalidomide at 5mg while the secondary trial uses a daily dose of lapatinib at 1500mg The statement implies that the primary trial uses a higher dose of lenalidomide than the secondary trial uses of lapatinib in terms of total dose per day which is not the case based on the evidence provided",
        "label": "Contradiction"
    },
    "98d47cf2-ead0-4ab0-8f13-cb2215710dc8": {
        "text_answer": "Contradiction The evidence does not provide any information about invasive cardiac surgery for the participants in the primary clinical trial",
        "label": "Contradiction"
    },
    "91a67bbf-1ae1-4a86-92fb-dcac5e8298d1": {
        "text_answer": "Contradiction The evidence shows that there was 1 infection Gramnegative bacteremia and 1 fever case reported in cohort 1",
        "label": "Contradiction"
    },
    "95a261bd-f102-4ce8-887b-afa14d1e2856": {
        "text_answer": "Contradiction  Explanation The statement suggests that there was a 5 reduction in Ki67positive cells after more than 6 weeks of therapy but the evidence shows that the median Ki67 expression at 6 weeks was 10 238 which is not a 5 reduction from the baseline of 15 1025",
        "label": "Contradiction"
    },
    "a6236585-ed05-4deb-bfcd-29eb410bd892": {
        "text_answer": "Contradiction The primary trial measures hot flash scores on a scale while the secondary trial reports ORR as a proportion of responders There is no mention of a superior vesical artery in the evidence provided",
        "label": "Contradiction"
    },
    "8a1d2587-95fa-4e7a-81db-1eb2561da680": {
        "text_answer": "Contradiction The placebo is administered as a 3hour infusion on Day 1 of every cycle while trabectedin is administered as a 3hour infusion on Day 2 of every cycle The statement suggests that both are administered every two weeks but the evidence shows that they have different dosing schedules",
        "label": "Contradiction"
    },
    "b86e9d5c-8de2-428a-ba76-d0955ecb75fa": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that the doses of talazoparib given to participants with ovarianperitoneal cancer are different from those given to participants with breast cancer",
        "label": "Entailment"
    },
    "164f2ab2-b768-4ec0-befc-a9807ba379ff": {
        "text_answer": "Contradiction  The evidence shows that there were adverse incidents in both cohorts but the frequency was higher in the first cohort Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "6450428b-bd2a-4ba5-aa5c-c86284dafa98": {
        "text_answer": "Contradiction The primary trial has specific inclusion criteria related to breast cancer hormone therapy and hot flushes which are not mentioned in the secondary trial The statement incorrectly assumes that the inclusion criteria for the two trials are identical",
        "label": "Contradiction"
    },
    "9bde44ff-5060-430d-9716-c34888483b9f": {
        "text_answer": "Neutral  Explanation The statement is not an entailment or a contradiction based on the evidence provided The evidence only relates to adverse events and does not provide any information about individuals being distressed due to early morning awakening",
        "label": "Entailment"
    },
    "038e3e32-ae9c-4580-80b1-8d1c2d9d9bb9": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial includes patients with a documented allergy to metronidazole or amoxicillin but the secondary clinical trial excludes patients with a documented allergy to these antibiotics Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "86fd4794-aa66-4739-86c6-cf5bfcd911fe": {
        "text_answer": "Contradiction The evidence does not support the statement that unbearable pain for a duration of 10 weeks was reported by all individuals involved in the primary clinical trial The evidence only reports the average change in pain intensity scores for the Low Dose and High Dose groups",
        "label": "Contradiction"
    },
    "71b2f727-f6ac-40e2-a92a-8bb89959e51e": {
        "text_answer": "Contradiction The primary trial measures changes in hot flash scores while the secondary trial measures overall response rate in solid tumors using RECIST criteria",
        "label": "Contradiction"
    },
    "6e50b114-9a16-4710-8d95-91401b387221": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial does have an age requirement for participation 18 years or older which contradicts the statement that it lacks a specific age range",
        "label": "Contradiction"
    },
    "9edc1688-da47-48ff-b475-b894e925dec7": {
        "text_answer": "Contradiction The statement mentions patients with a history of pulmonary embolisms and breast implants but the evidence provided for the secondary trial does not mention any exclusion criteria related to pulmonary embolisms or breast implants separately However the primary trial does have an exclusion criterion for a history of clotting disorders which could include pulmonary embolisms but it does not specifically mention breast implants as an exclusion crit",
        "label": "Contradiction"
    },
    "32ce7a8e-20c4-42d9-a4d4-e3b5d580331e": {
        "text_answer": "Contradiction The statement is about an individuals mind being as sharp as it always has been while the evidence is about the percentage of participants in a primary trial who experienced a confirmed complete response CR to Lapatinib 1000 mg  NabPaclitaxel treatment These concepts are not related",
        "label": "Contradiction"
    },
    "fac1b066-b96a-470f-8239-89c1cba6572d": {
        "text_answer": "Contradiction The primary clinical trial only includes patients with unilateral breast cancer",
        "label": "Contradiction"
    },
    "47db0ed8-8607-4442-827c-20eb9e8db776": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial does not allow patients with brain metastases unless they are controlled postcompletion of local therapy for at least 4 weeks A benign brain tumor is not considered a controlled brain metastasis",
        "label": "Contradiction"
    },
    "33621096-b0c2-4478-9662-45ba56f9da8d": {
        "text_answer": "Contradiction The statement does not hold true based on the evidence provided as there was an adverse event of eyelid oedema recorded in the secondary trial which is a type of adverse event that belongs to the arm or leg response group but it was not recorded in the primary trial However no adverse events belonging to the arm or leg response group were recorded in the primary trial according to the evidence provided",
        "label": "Contradiction"
    },
    "01f7a296-d0c6-4530-800d-5985bcf7218c": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence states that capecitabine was given orally twice daily for 14 days out of every 21 days in the primary trial",
        "label": "Contradiction"
    },
    "455d059c-c3c4-4a09-be0d-a14b9568a0d2": {
        "text_answer": "Contradiction  Explanation The evidence provided states that cohort 1 is TripleNegative PR negative ER negative and HER2 negative while cohort 2 is HER2Positive HER2Amplified These two descriptions are contradictory as TripleNegative breast cancer does not have HER2 amplification and HER2Positive breast cancer does have HER2",
        "label": "Contradiction"
    },
    "7f2ecb22-ab29-4dfa-b9f6-b09cb7d4c56b": {
        "text_answer": "Entailment  Explanation The statement neither the primary clinical trial nor the secondary clinical trial have reported any episodes of anorexia hypothermia or hallucinations among the adverse events aes is an entailment based on the evidence provided because both trials reported zero occurrences of anorexia hypothermia and hallucinations in their adverse events data",
        "label": "Entailment"
    },
    "e4ae61e2-fb24-41dc-9eb6-0102ee8d22d8": {
        "text_answer": "Contradiction  The evidence does not mention anything about the role of the patients first of kin in making the final enrollment decision for the clinical trial The eligibility for the trial is determined by the health professionals conducting the trial",
        "label": "Contradiction"
    },
    "d0212d75-c952-4ad3-ae36-bbf675eae985": {
        "text_answer": "Contradiction  Explanation The evidence states that no episodes of vomiting and no rescue medication were reported during the first 24 hours after cyclophosphamide administration for all participants in the ArmGroup titled Aprepitant Dexamethasone Cytoxan  Kytril Therefore over 50 of patients in cohort 2 did not suffer from acute vomiting after treatment with Apre",
        "label": "Contradiction"
    },
    "0d414333-1c03-4a79-91d7-1a34323e7e59": {
        "text_answer": "Contradiction The statement contradicts the evidence as Arimidex is not mentioned in the primary trial but it is not stated that it is not a part of the secondary trial",
        "label": "Contradiction"
    },
    "fe470456-ea60-433f-905c-21189377531a": {
        "text_answer": "Contradiction The statement is contradictory because hypokalemic patients are excluded from the primary trial but there is no mention of potassium levels in the secondary trial inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "8b89865c-9af5-4fe0-8f9d-c56240ff7a90": {
        "text_answer": "Contradiction The evidence clearly states that both primary and secondary trials have specific performance status requirements Zubrod performance score 2 or better for secondary trial",
        "label": "Contradiction"
    },
    "895d29b8-16bf-4539-b8f9-a7ffec42ce94": {
        "text_answer": "Contradiction  Explanation The evidence shows that in Adverse Events 1 there was one case of edema limbs in Cohort 1 Therefore the statement that both cohorts showed zero cases of hypertension edema and dyspnea is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "2e16531b-70c8-4302-8747-761859ad7946": {
        "text_answer": "Contradiction  The evidence provided indicates that no participants in either cohort 1 or 2 experienced a lifethreatening adverse event The statement however asserts that all participants in cohort 1 experienced at least one lifethreatening adverse event which is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "e2a5803b-3991-4eb2-b428-56d91d9bca99": {
        "text_answer": "Contradiction assuming the worst pain imaginable is a score of 10 on the numeric rating scale  Explanation The evidence does not provide information on the maximum pain intensity score experienced by any patient in either group during the 10week study period The statement that none of the patients in the primary trial experienced the worst pain imaginable for 10 weeks is a contradiction to the evidence as it makes a definitive statement about",
        "label": "Contradiction"
    },
    "3befd95f-b342-45a0-99b4-3f6996b664cf": {
        "text_answer": "Entailment The primary and secondary trials both measure success through pCR and there are minor result discrepancies between the groups in the primary trial In the secondary trial patients in arm 2 had a lower percentage of pCR compared to arm 1",
        "label": "Entailment"
    },
    "796002e1-bc19-4298-a035-c853aee3e5c3": {
        "text_answer": "Contradiction The evidence from both trials shows that no adverse events were documented in the given patient groups for both trials The statement however is more general and implies that there were multiple adverse events documented in the primary trial which is not supported by the evidence",
        "label": "Contradiction"
    },
    "31d0a955-493b-4577-931c-ca3cda7a2a0b": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence states that participants in both cohorts received Enzalutamide orally PO not intravenously IV",
        "label": "Contradiction"
    },
    "6ad0142c-56d0-4994-b906-898198240c8c": {
        "text_answer": "Contradiction The primary trial reports in units on a scale not in kilometers or miles The secondary trial reports in units of measurement that are not specified",
        "label": "Contradiction"
    },
    "3fe01e39-b6e5-465e-b76b-8048169a72bb": {
        "text_answer": "Contradiction The evidence does not provide any information about the occurrence or nonoccurrence of adverse events related to tritylcysteine in the primary trial",
        "label": "Contradiction"
    },
    "62384871-8eb2-414b-8cc9-e756a188e19e": {
        "text_answer": "Contradiction The primary trial reports on the MTD of Ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or Maximum Feasible Dose of MM111 which is not related to the primary trial The statement provides a specific value for the MTD of MM111 but the trials do not directly compare or provide that information",
        "label": "Contradiction"
    },
    "a62aed40-ac98-4cdc-a7b2-4b1c57e6010b": {
        "text_answer": "Entailment The statement is an entailment because the evidence clearly shows that the interventions in the two cohorts of the primary clinical trial differ in the use of carboplatin dosages In Arm B carboplatin is used while in Arm A it is not used",
        "label": "Entailment"
    },
    "067bc726-4646-40f8-aa6f-af44d315046e": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were a total of 5 cases of gastrointintestinal adverse events diarrhea vomiting in the primary clinical trial Therefore the statement no gastrointestinal adverse events were observed during the primary clinical trial is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "69848bb3-c093-4bf4-91eb-f941109b1cd6": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that both the placebo and alloMSCs interventions in the primary trial are administered via 20 transendocardial injections of equal volume 04ml each",
        "label": "Entailment"
    },
    "838e1a74-56e5-4dde-aeba-f26d2d3f8983": {
        "text_answer": "Contradiction The statement is not supported by the evidence as the evidence only reports the change in lean body mass from baseline to 4 months not over a 1 month period",
        "label": "Contradiction"
    },
    "1b314250-0177-4a73-a7f8-a9524ae44cfd": {
        "text_answer": "Contradiction The evidence does not address eating disorders or sexual interest or activity issues in the primary trial candidates",
        "label": "Contradiction"
    },
    "33668f2b-29b5-49e2-a0ee-4718913ea856": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary clinical trial prescribes multiple medications throughout the study",
        "label": "Contradiction"
    },
    "78d9d746-c05b-42e9-9156-d97a9f132589": {
        "text_answer": "Contradiction  Explanation The primary trial involves participants receiving trastuzumab at a weekly dose of 2 mgkg while the secondary trials cohort 2 involves Herceptin at a loading dose of 4 mgkg followed by a weekly dose of 2 mgkg The initial doses differ making the statement a contradiction",
        "label": "Contradiction"
    },
    "8db59161-2a2e-4ade-9e23-538bf3b3ec77": {
        "text_answer": "Contradiction The evidence shows that Cohort A receives the first IM injection of V935 earlier in their cycle every other week over a 3week period during Part A of Intervention 1 while Cohort B receives the first IM injection of V935 later in their cycle following a 4 week observation period in Part A of Intervention 2",
        "label": "Contradiction"
    },
    "275b4f49-8849-451b-972d-a597662de036": {
        "text_answer": "Contradiction  Explanation  The primary trial reports the mean duration of neutropenia for two groups of patients receiving different doses of empegfilgrastim 6 mg and 75 mg after the first cycle of chemotherapy The secondary trial reports the number of patients who experienced neutropenia Grade 34 after chemotherapy in two groups receiving different doses of empegfilgrastim 3",
        "label": "Contradiction"
    },
    "fffc74c9-56a5-45e7-ba89-a2c91da05110": {
        "text_answer": "Contradiction  The statement is not supported by the evidence provided as the evidence only reports the number of emesisfree participants in each group but it does not provide any information about the likelihood or frequency of emesis in each group",
        "label": "Contradiction"
    },
    "5f2bbf7f-2e76-4ae9-8e79-e6361d05ef47": {
        "text_answer": "Entailment The statement is consistent with the reported median IQR decline in Ki67 expression from baseline to 6 weeks in the primary trial",
        "label": "Entailment"
    },
    "ee2fe2ab-dc6f-434e-b0dd-1deee5fb3d31": {
        "text_answer": "Contradiction The primary trial requires participants to be resistant to AI therapy while the secondary trial does not have this requirement",
        "label": "Contradiction"
    },
    "ff2a48f8-c4ab-4a13-9ca2-5d46ce4bd6c9": {
        "text_answer": "Contradiction  Explanation The primary trial reported no adverse events while the secondary trial reported several adverse events that affected more than 03 of patients including skin infections",
        "label": "Contradiction"
    },
    "0ef8fead-d77e-4aa4-8e40-ca20ac2ea325": {
        "text_answer": "Neutral The statement does not directly follow from the evidence but it is not contradictory either  Explanation The statement does not directly address the doses of MM121 mentioned in the evidence It only mentions that an individual in the study might have felt unusually tired during the day which is not related to the doses of MM121 or Cetuximab Therefore the statement is neutral with",
        "label": "Entailment"
    },
    "e7bcb619-8ec0-45cf-acce-9d20e7258c95": {
        "text_answer": "Contradiction given that the evidence shows no adverse events in both trials",
        "label": "Contradiction"
    },
    "be556bfc-7cc6-44fc-a505-52a8d55bbb5e": {
        "text_answer": "Contradiction The primary trial measures variation in serum levels of Follicle Stimulating Hormone FSH in mIUml while the statement is about fetal hypoxemia which is a medical condition unrelated to FSH and measured in different units abnormally low arterial blood oxygen concentration in a fetus",
        "label": "Contradiction"
    },
    "08920163-ef22-4242-b9bf-b70af58c91c2": {
        "text_answer": "Entailment The statement is a description of the participants and intervention in the primary trial which is consistent with the evidence provided",
        "label": "Entailment"
    },
    "77f1bdb0-c7eb-41ba-b05e-e8914b68370a": {
        "text_answer": "Contradiction The primary trial includes anemia as an exclusion criterion but the statement mentions anemia as a condition that would exclude a patient from both trials However the evidence provided for the secondary trial does not mention anemia as an exclusion criterion",
        "label": "Contradiction"
    },
    "2f07cc03-880c-43c4-b50f-c1cdf9ebf0dc": {
        "text_answer": "Contradiction The evidence does not support the statement as there is no mention of hypertension dehydration or dyspnea in the adverse events for either cohort However its important to note that the absence of data in the evidence does not necessarily mean that there were no cases of these conditions in the trial",
        "label": "Contradiction"
    },
    "292d0dd3-1b9c-4291-b367-0cc1666178db": {
        "text_answer": "Contradiction The primary trial involves denosumab injections while the secondary trial does not involve injections and instead uses lymphoscintigraphy",
        "label": "Contradiction"
    },
    "332d5cb3-14c3-44d3-b2ee-899259c79a4b": {
        "text_answer": "Contradiction The primary trial had one test group Pyridoxine and one placebo group while the secondary trial had two test groups Highdose and Lowdose Oxybutynin Chloride",
        "label": "Contradiction"
    },
    "bf103149-cfe0-453f-9b83-d06c0a8958a0": {
        "text_answer": "Entailment The statement that map2k2 gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the map2k2 gene is entailed by the evidence as map2k2 gene amplification is listed as one of the molecular genetic abnormalities that would make a subject eligible for the primary trial in the case of metastatic colorectal cancer",
        "label": "Entailment"
    },
    "0a26f239-60ec-4aa7-81e8-de47c20def59": {
        "text_answer": "Contradiction  The evidence does not support the statement that there were 50 cases of hypertension edema and dyspnea in either cohort of the primary trial The evidence only reports the number of cases for various adverse events but it does not add up to 50 for hypertension edema and dyspnea combined in either cohort",
        "label": "Contradiction"
    },
    "1cdbbd44-21df-4279-9e3c-ff501f1361ec": {
        "text_answer": "Entailment The primary trial reports on the MTD of Ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or Maximum Feasible Dose of an intervention called MM111 Since the interventions being tested are different it is expected that the MTDs reported would also be different",
        "label": "Entailment"
    },
    "c67c581d-7aa5-4a90-b640-dcdf8d69e870": {
        "text_answer": "Entailment The primary trial includes patients with stage IV breast adenocarcinoma and the secondary trial specifically requires patients to have stage IV disease Additionally the secondary trial further specifies that the disease must be ER positive andor PR positive and HER2neu negative which is consistent with the inclusion criteria of the primary trial",
        "label": "Entailment"
    },
    "66d9fdb8-ea66-43e2-b497-340bc7832155": {
        "text_answer": "Entailment assuming that the participants in Results 1 are the same as those in the primary trial and that the statement is about those participants specifically",
        "label": "Entailment"
    },
    "f5cdf7ed-828f-4e45-9699-b5f80c7b1863": {
        "text_answer": "Entailment  Both interventions involve oral intake daily",
        "label": "Entailment"
    },
    "063e3d67-dc20-453d-a437-f56447bfa49f": {
        "text_answer": "Contradiction The statement mentions palinavir in the context of HIV treatment but there is no evidence of palinavir being used in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "9426014b-4962-4dcc-8328-ca29428d6ed3": {
        "text_answer": "Contradiction  Explanation  The statement 119 adverse events were observed in the primary trial is not mentioned in the evidence The evidence only provides the number of adverse events for each trial and the percentage of patients affected by each adverse event The statement also asserts that none of the adverse events in the secondary trial affected more than 5 of patients except for skin infections which contradicts the evidence as the evidence",
        "label": "Contradiction"
    },
    "8820e8d9-5bea-461f-8622-5ec4b6388a79": {
        "text_answer": "Contradiction The primary clinical trial does have an age criterion for participation implied by the inclusion criteria of Female patient 18 years of age in the primary trial",
        "label": "Contradiction"
    },
    "3f1c8f3a-f9dd-4819-b6db-2931e0c3f288": {
        "text_answer": "Contradiction The evidence does not state that AfricanAmerican patients participating in the primary clinical trial must be based in Texas",
        "label": "Contradiction"
    },
    "766e3e18-5567-48e2-9656-12c1b3ead63f": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because  1 In the primary trial participants receive alpha lipoic acid at a baseline dose of 100 mg three times daily for four months with dose escalation to find a maximum tolerated dose 2 In the secondary trial cohort 1 participants receive necitumumab at an absolute dose of 800 mg on Day 3",
        "label": "Contradiction"
    },
    "3015f97a-8a45-4a05-a5cf-9c5eaa49e667": {
        "text_answer": "Contradiction The primary trial has a cyclic treatment with a 21day cycle length while the secondary trial does not have a cyclic treatment The statement that the primary trial uses a 2year cycle for its intervention is incorrect",
        "label": "Contradiction"
    },
    "0cf2969d-0228-4267-8e5a-12dc22a12ae9": {
        "text_answer": "Contradiction  Explanation The evidence provided does not mention neratinib as a component of the primary clinical trial regimen for either cohort 1 or cohort 2 Therefore the statement that neratinib is an essential part of the primary clinical trial regimen is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "236451bf-52bd-4530-ba81-100e63b0030f": {
        "text_answer": "Contradiction The evidence shows that surgery was recorded as an adverse event in the primary clinical trial and stomatitis was not mentioned",
        "label": "Contradiction"
    },
    "47dbd397-7aa3-4c9b-9241-d148a255902a": {
        "text_answer": "Contradiction The primary trial did not report any cases of radiation dermatitis or hyperpigmentation while the secondary trial reported that over 095 of the participants in group 1 had these conditions",
        "label": "Contradiction"
    },
    "bd587160-ea9e-41d4-b2c4-54815327d2fb": {
        "text_answer": "Entailment The primary trial includes breast adenocarcinoma as one of the eligible tumor types for Phase 2 and the secondary trial specifically includes breast carcinoma in its inclusion criteria Therefore patients with metastatic andor advanced solid breast tumors are eligible for both trials",
        "label": "Entailment"
    },
    "fcef015e-f82c-4cac-a7c1-61a81f0eac3b": {
        "text_answer": "Contradiction The statement is not related to the inclusion or exclusion criteria for the primary or secondary trials Hypokalemia is a medical condition while Kluyvera is a genus of bacteria",
        "label": "Contradiction"
    },
    "87fda661-4348-4078-b3e7-915893241ab0": {
        "text_answer": "Contradiction  The primary trial involves the use of Suramin and Paclitaxel but the secondary trial does not mention the use of these drugs for all patients Instead it mentions a different intervention mastectomy surgery for the secondary trial",
        "label": "Contradiction"
    },
    "1d75f8ad-2c35-4481-b6f7-58db73eeea7b": {
        "text_answer": "Contradiction The statement mentions cbfa2t3 gene rearrangement while the intervention section mentions MM111 and there is no mention of gene rearrangement in the intervention section based on the provided evidence",
        "label": "Contradiction"
    },
    "ac3dfb95-6558-4815-b5ed-4887505dedf8": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the secondary clinical trial recorded zero incidents of mucositis oral bladder infection and thromboembolic events The primary clinical trial recorded more incidents of these adverse events than the secondary trial but the statement suggests that the secondary trial recorded a higher prevalence which is not supported by the evidence",
        "label": "Contradiction"
    },
    "41e2d2b1-9637-4667-b032-86c844a94b93": {
        "text_answer": "Contradiction The primary trial does not mention an age requirement for participation so it does not entail that individuals who are 18 years old are excluded",
        "label": "Contradiction"
    },
    "dcea72d4-afb6-4565-8d92-fd259ed8ee15": {
        "text_answer": "Contradiction The primary trial does not list recent organ transplantation as an exclusion criterion",
        "label": "Contradiction"
    },
    "71698d59-3bbe-4e8f-85c8-bf2110727155": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were 5 different types of adverse events in the primary trial with 2 types affecting patients in each cohort Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "38e2c25f-97c9-4112-b571-b832e29e7c7e": {
        "text_answer": "Contradiction  Explanation The statement only cohort 2 receives an increased dose of 18FFPPRGD2 is not supported by the evidence provided Both the GBM and gynecological cancer cohorts receive 18FFPPRGD2 for their PETCT or PETMRI scans but the evidence does not indicate that the dose is increased for the gynecological cancer",
        "label": "Contradiction"
    },
    "aab9225d-d2bc-4004-bcaf-4f69a9e7991b": {
        "text_answer": "Contradiction The primary trial excludes participants who have undergone major surgery within 28 days prior to the study registration date while the secondary trial excludes participants who have had an organ transplant within the past month These two criteria are contradictory",
        "label": "Contradiction"
    },
    "9d291a23-1696-4208-a5d4-7b2e1dd48831": {
        "text_answer": "Contradiction The primary trial intervention involves Yttrium90 Radioembolization while the secondary trial intervention involves the use of ibrutinib and MEDI4736 These interventions are not the same and the statement does not hold true for both trials",
        "label": "Contradiction"
    },
    "80a26581-a95c-4c22-864f-93425b1fc165": {
        "text_answer": "Entailment for each cancer type colorectal breast and cervical  Explanation The statement The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention regardless of cancer type is an entailment based on the evidence provided in the results The evidence shows that a higher percentage of participants in both the Collaborative Care Intervention CCI and Pre",
        "label": "Entailment"
    },
    "294df8e3-8ba1-41e7-acdc-6448bfab99f1": {
        "text_answer": "Contradiction  Explanation  The statement every patient in the primary clinical trial experienced multiple adverse events while patients in the secondary clinical trial were unscathed by any is a contradiction based on the evidence provided  In the primary clinical trial no adverse events were reported for any of the 42 patients Therefore no patient experienced multiple adverse events  In the secondary clinical trial all six patients experienced at",
        "label": "Contradiction"
    },
    "1b70762f-83fb-4c93-98ac-7f5d8852fc16": {
        "text_answer": "Contradiction  The evidence states that one participant from each cohort experienced doselimiting toxicities not two participants as stated in the question",
        "label": "Contradiction"
    },
    "32781bed-ab99-4837-a7f8-d3ab0b978384": {
        "text_answer": "Contradiction The statement makes an assumption about all patients in the GTx024 1mg group gaining lean body mass but the evidence only shows the change in median lean body mass for this group The absence of tp53 mutation analysis during the study is not related to the statement about lean body mass gain",
        "label": "Contradiction"
    },
    "e7bc1f65-d4e4-4f87-9a2c-ab56c35368ae": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no common denominator in the number of participants between the two trials mentioned in the statement and the evidence provided",
        "label": "Contradiction"
    },
    "636ec547-3ea0-41d4-a46f-92d4780b2ffd": {
        "text_answer": "Contradiction The evidence shows that no adverse events were recorded in both trials for the given data provided The statement however asserts that the same number of adverse events were recorded in both trials which is not the case based on the evidence",
        "label": "Contradiction"
    },
    "d13b1dc9-46cf-471b-b2b1-fa93b235e954": {
        "text_answer": "Contradiction  The evidence shows that a total of 84 participants were analyzed in the primary trial with 16 participants in Arm 1 and 381 of them experiencing pCR and 14 participants in Arm 2 and 333 of them experiencing pCR Therefore a total of 20 participants experienced pCR across both arms This is less than 75 participants",
        "label": "Contradiction"
    },
    "b753305c-ea26-492d-b45e-760dc4f69b9a": {
        "text_answer": "Contradiction  The evidence states that patients receive oral lapatinib once daily in the primary trial not twice daily as stated in the question Additionally the statement mentions nothing about the trial or the patients having hyperdiploidy",
        "label": "Contradiction"
    },
    "e0265a05-590e-4f77-8e94-8bcdd1d9757e": {
        "text_answer": "Contradiction  Explanation The statement there were no recorded cases of palpitations pericardial effusions and abdominal pains in the primary clinical trial while multiple instances were noted in the secondary clinical trial is a contradiction based on the evidence provided  In the primary trial there was one recorded case of palpitations and two recorded cases of pericardial effusions Therefore the statement that there were no",
        "label": "Contradiction"
    },
    "b3dd4df2-abff-4e7f-89ce-57b109d25bf2": {
        "text_answer": "Contradiction  The primary trial uses oral pregabalin while the secondary trial uses intrathecal Depocyt and intravenous highdose Methotrexate These interventions are not equivalent",
        "label": "Contradiction"
    },
    "88857141-6207-4828-b8d4-09d7cc4498c3": {
        "text_answer": "Contradiction The primary trial explicitly excludes participants who have undergone major surgery within 28 days prior to the study registration date while the secondary trial does not mention any such exclusion for organ transplant recipients",
        "label": "Contradiction"
    },
    "027aec87-187e-4c41-9a39-4c453dd1e0ad": {
        "text_answer": "Contradiction The statement mentions that there was no incident of shingles in the primary trial and in group 1 of the secondary trial but the evidence shows that there was one incident in group 2 of the secondary trial",
        "label": "Contradiction"
    },
    "28363fb8-16ff-4a26-b29c-ca41d1ed2e6e": {
        "text_answer": "Contradiction The evidence states that one participant in the primary clinical trial did experience a urinary tract infection",
        "label": "Contradiction"
    },
    "bcbe90f9-602b-45bc-aa97-28e50238e2fb": {
        "text_answer": "Contradiction The statement does not entail that the relational and itemspecific encoding task is used in the primary or secondary trials as the trials described in the evidence do not involve this clinical test",
        "label": "Contradiction"
    },
    "4c79deb2-4d30-470e-959c-e3cf05af0b88": {
        "text_answer": "Contradiction The evidence shows that no patients in the secondary trial had no adverse events but the statement suggests that less than 2 of patients in both trials had no adverse events",
        "label": "Contradiction"
    },
    "77aeeff2-38c4-41ce-8526-55ab056504f9": {
        "text_answer": "Entailment The statement is an entailment as the primary trial includes a neoadjuvant therapy setting for patients with locally advanced andor metastatic solid tumors in both phases",
        "label": "Entailment"
    },
    "5f44bd33-3921-479c-9a16-e2af73e72101": {
        "text_answer": "neutral The statement is not directly entailed or contradicted by the evidence but it is consistent with the findings of a decline in cognitive function on average for both cohorts as reported in the results",
        "label": "Contradiction"
    },
    "7adf46ec-7d70-4767-936f-b7d89f93cdd6": {
        "text_answer": "Contradiction The primary trial uses a 21day cycle for its intervention not a 1month cycle The secondary trial does not have a cyclic treatment in place",
        "label": "Contradiction"
    },
    "c132218c-a01a-406c-b1a1-7d66cc8877bd": {
        "text_answer": "Contradiction The statement is not an entailment as Syncope was not the most commonly occurring adverse event in the secondary trial as there were no reported cases of Syncope in either Adverse Events 1 or 2 of the secondary trial",
        "label": "Contradiction"
    },
    "4fcc0d4c-0772-47c8-ad68-80d10fbeaa0d": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as syncope was not the most frequently reported adverse event in either trial according to the provided data",
        "label": "Contradiction"
    },
    "c2bcdabf-3336-424c-bf5f-13f0b522fa2b": {
        "text_answer": "Contradiction  Explanation The statement the primary clinical trial frequently reports general symptoms as the most common adverse event is a contradiction to the evidence as the evidence shows that the most common adverse events reported in the primary clinical trial were nausea and vomiting which are specific symptoms and not general symptoms",
        "label": "Contradiction"
    },
    "f7fc247a-5390-4e3f-9254-b16ecdda5851": {
        "text_answer": "Contradiction The primary trial compares different interventions within the same study while the secondary trial compares two different interventions in separate studies The statement mixes the results from both trials without a clear comparison",
        "label": "Contradiction"
    },
    "f57d4f1e-c5ba-4b65-8407-5a5be29e28b4": {
        "text_answer": "Contradiction The primary trial does not have a specific inclusion criterion regarding the size of the primary tumor being less than 3mm in radius The secondary trial does not have any mention of tumor size as an inclusion or exclusion criterion",
        "label": "Contradiction"
    },
    "05e6adb2-0549-4564-84c7-79e4a19d0e99": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the number of adverse events and the percentage of patients with skin infections are different between the two trials",
        "label": "Contradiction"
    },
    "80da21c8-478e-41a2-befc-384403e43ff4": {
        "text_answer": "Entailment Both trials involve transendocardial injections as a method for delivering interventions In the primary trial it is used for administering tissue expanders while in the secondary trial it is used for administering alloMSCs and placebo",
        "label": "Entailment"
    },
    "d28a4294-8d88-4473-b302-51c771571ffb": {
        "text_answer": "Contradiction  In the primary trial there is no information provided about the dosing frequency of MM121 and Paclitaxel each week However in the secondary trial the first cohort receives both drugs weekly for 12 weeks Therefore the statement that the participants of the primary trial receive fewer doses each week is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "3eb3c1f5-b395-43e5-a8e5-cf613ac87f30": {
        "text_answer": "Entailment The primary trial includes breast cancer as one of the eligible tumor types for Phase 1 and the secondary trial also includes breast cancer as one of the eligible tumor types for all groups",
        "label": "Entailment"
    },
    "7f1301ad-2bc6-426b-86da-8a5c80dfba0c": {
        "text_answer": "Contradiction The statement goes beyond the evidence provided in the inclusion and exclusion criteria for both trials The evidence only mentions allergies to cephalosporin trimethoprimsulfamethoxazole levofloxacin and celecoxib as exclusion criteria for the secondary trial but it does not mention anything about double outlet right ventricle",
        "label": "Contradiction"
    },
    "ab0a9eb7-2f28-425a-aa06-2389f0c1e9f7": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial does involve a unit of measurement specifically for Tumor Diameter in centimeters The statement is therefore a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "4b545fd1-a4d1-486a-aece-201400e9c1f5": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The evidence provided in the primary trial results relates to the correlation of Vitamin D levels prognostic factors and gene expression profile in patients with breast cancer The statement on the other hand is about the results of the AQ20 questionnaire in patients with chest trouble and no information is given about Vitamin D levels or gene expression profiles in the statement",
        "label": "Contradiction"
    },
    "bbb06e30-afa0-40c0-9594-b8c293cd5207": {
        "text_answer": "Contradiction  Explanation The statement the lions share of patients from the primary clinical trial showed total recovery within the course of 24 weeks is a contradiction to the evidence presented as the evidence shows that only 4 participants out of 25 had a complete response CR at both Week 12 and Week 24 which does not equate to a lions share of participants having",
        "label": "Contradiction"
    },
    "bef15be3-6cf6-426a-a70a-d5d99a1c42af": {
        "text_answer": "Contradiction The primary trial does not measure the Change in Ki67 Expression in Tumors but it does use RECIST criteria which includes assessment of tumor response Therefore it is possible that Ki67 expression could be assessed as a correlative study in this trial The secondary trial does include correlative studies but the specific markers mentioned in the evidence do not include Ki67 However it is not stated that Ki67 was not assess",
        "label": "Contradiction"
    },
    "5f76619b-30cd-47bc-99b9-aab25ce87366": {
        "text_answer": "Contradiction  Explanation  The statement in the primary clinical trial there wasnt any recorded instance of an adverse event is not true based on the evidence from the primary trial which states that there were no recorded adverse events at all  The statement in the secondary clinical trial apart from skin infections no other adverse event affected more than 30 of the patients involved in the trial is true based",
        "label": "Contradiction"
    },
    "1eb531b0-d0fc-41b7-a6d4-1b774affc30a": {
        "text_answer": "Contradiction The patient described in the statement does not meet the inclusion criteria for the primary clinical trial as stated in the evidence as she has undergone antineoplastic therapy within the past 4 weeks",
        "label": "Contradiction"
    },
    "a9d41a93-5857-4a56-89f2-46cf6bef36e1": {
        "text_answer": "Contradiction  Explanation The statement at least one patient treated with gtx024 1kg in the primary trial gained over 22 pounds of lean body mass is a contradiction to the evidence because the median change in total body lean mass for the GTx024 1 mg group was 155 kg which is far less than 22 pounds approximately 998 kg",
        "label": "Contradiction"
    },
    "7f3b898a-e7d1-4cc2-bf62-a8366ea7cf80": {
        "text_answer": "Contradiction The primary trial reports on the MTD of Ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or Maximum Feasible Dose of MM111 which are different interventions Additionally the statement assumes that the dosing unit coat dosing is related to the MTD measurement in the trials but there is no evidence provided to support this assumption",
        "label": "Contradiction"
    },
    "fe37b4ad-fe84-429b-89ce-f5a881215b56": {
        "text_answer": "Entailment Both trials include women aged 18 and above",
        "label": "Entailment"
    },
    "f2076a4f-6170-46ca-9e08-8d0f9589bb06": {
        "text_answer": "Contradiction The statement is a false statement as the evidence does not support the majority of patients in the primary trial experiencing a complete response by week 24 The evidence shows that at week 24 there were 4 participants with a partial response 10 participants with stable disease and no participants with a complete response",
        "label": "Contradiction"
    },
    "6a6f23a1-354d-4c1a-b457-e3ce15564e69": {
        "text_answer": "Contradiction The statement is incorrect as the primary trial does have different inclusion criteria for different study groups while the secondary trial has the same inclusion criteria for all participants",
        "label": "Contradiction"
    },
    "e970c950-ccf6-4c0c-8573-84634162fdf3": {
        "text_answer": "Contradiction The primary trial explicitly excludes participants with a history of alcohol or substance abuse or dependence within the past 2 years The secondary trial does not mention any specific requirement regarding smoking or alcohol consumption for participants However the primary trial includes a requirement for participants to be nonsmokers Therefore the statement smokers and alcoholics who consume 6 or more drinks daily are allowed to participate in both the primary and secondary trials is contradictory to",
        "label": "Contradiction"
    },
    "552c3a00-fa13-4e27-89a8-2ef4823317cd": {
        "text_answer": "Contradiction The evidence does not mention paclitaxel being used in the primary clinical trial",
        "label": "Contradiction"
    },
    "65c91814-cbda-4db3-a680-4bc3fe0855a8": {
        "text_answer": "Contradiction  Explanation  In the primary trial the same inclusion and exclusion criteria apply to both Phase I and Phase II However the secondary trial has different inclusion and exclusion criteria for its participants Therefore the statement in the primary trial the same inclusion and exclusion criteria apply to all phases whereas in the secondary trial different criteria are employed for varied sets of participants is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "6af06b3f-dbbc-4679-a4a3-fe4b3757fdc0": {
        "text_answer": "Contradiction The evidence does not provide information about the number of participants in each arm of the trial",
        "label": "Contradiction"
    },
    "cb9a1bc3-cc8d-4d0d-a335-eb5c5071289f": {
        "text_answer": "Contradiction  The evidence states that 9 out of 21 participants had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products This is the opposite of the statement that less than 010 of the participants had a reduction in circulating tumor cells",
        "label": "Contradiction"
    },
    "c01b910d-2463-4bf8-bb67-f950aca11411": {
        "text_answer": "Entailment The primary trial includes patients with ER PR or HER2neu negative metastatic breast cancer and the secondary trial specifically requires ER or PR HER2neu negative disease Therefore the statement that both trials allow enrollment of patients with ER PR or HER2neu negative metastatic breast cancer is an entailment of the given evidence",
        "label": "Entailment"
    },
    "8df26566-8724-4ca3-b6be-f43b9b188724": {
        "text_answer": "Contradiction The primary clinical trial mentioned in the evidence is for breast cancer not prostate cancer",
        "label": "Contradiction"
    },
    "e3222534-b084-405b-bd5a-32fbd2a663c4": {
        "text_answer": "Contradiction The evidence states that participants will receive multiple injections of dendritic cells trastuzumab and vinorelbine over the course of the study not a single injection on the first day",
        "label": "Contradiction"
    },
    "1943100e-196d-4022-a38a-9ae0dd816294": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence as both interventions use the same dose of radioactive Tc99M sulfur colloid 04 to 10 mCi for lymphoscintigraphy",
        "label": "Contradiction"
    },
    "728c430c-a48c-44a3-a598-38f96ddabaea": {
        "text_answer": "Contradiction The primary trial compares operative time savings between two groups but it does not imply that Intraoperative Mammography performed better than Standard Mammography based on the given evidence alone The secondary trial measures success rate and does not provide any information about operative times or mammography types",
        "label": "Contradiction"
    },
    "b0308df2-5725-4b3a-9c80-0d5390bf3149": {
        "text_answer": "Neither The statement does not directly relate to the evidence provided which is about the comparison of survival between patients undergoing oophorectomy in midluteal and midfollicular phases of their menstrual cycles The statement is about bone marrow transplant recipients and their survival",
        "label": "Entailment"
    },
    "8d60b35c-e6df-4e22-a92e-b9c782b9ed1b": {
        "text_answer": "Entailment The primary trial had fewer total adverse events and fewer types of adverse events than the secondary trial as shown in the evidence",
        "label": "Entailment"
    },
    "217b0362-9dd0-4f10-8ca5-c097688bb738": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there are no cases of nausea reported in the primary trial according to the provided data",
        "label": "Contradiction"
    },
    "42eaaa23-bd07-4a89-ba9f-dffe36e31ddb": {
        "text_answer": "Contradiction The statement does not entail that the primary trials interventions include nontrisomic autosomal aneuploidy and there is no evidence provided regarding the presence or absence of this condition in the trial",
        "label": "Contradiction"
    },
    "7e01558a-26ed-4ebf-aa18-d5d1c876c194": {
        "text_answer": "Contradiction The statement does not entail the evidence as the primary and secondary trials involve different types of interventions topical vs inhalation but the statement is not a contradiction to the evidence as it does not directly conflict with it",
        "label": "Contradiction"
    },
    "0a1f17fb-d58d-46e3-a726-bf7ef647e88e": {
        "text_answer": "Entailment The statement positive fish or IHC 3 results confirming a diagnosis of a HER2 positive tumor is essential for all primary clinical trial candidates is an entailment based on the evidence provided in the inclusion criteria which states that HER2 positive tumor either IHC 3 or FISH is a requirement for participation in the primary clinical trial",
        "label": "Entailment"
    },
    "e9204795-c6e7-4215-a230-2958d48a6ac2": {
        "text_answer": "Contradiction The evidence shows that the incidence of doselimiting toxicity was reported in the primary clinical trial for both Level 1 and Level 2 arms",
        "label": "Contradiction"
    },
    "ab29d2f1-5d52-475b-be8a-a3b82c49a44a": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it mentions 9q33 which is not mentioned in the evidence The evidence only provides information about the number of participants who experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes in two different treatment groups",
        "label": "Contradiction"
    },
    "3317bb44-031e-4444-b6b9-7b538727efa3": {
        "text_answer": "Entailment The evidence shows that in both trials no more than 048 and 000 of patients had multiple adverse events which is less than 20",
        "label": "Entailment"
    },
    "dbcb7763-d671-465e-8704-4bd5cd5ec7ef": {
        "text_answer": "Contradiction The primary trial recorded zero adverse events while the secondary trial recorded multiple adverse events",
        "label": "Contradiction"
    },
    "b681145e-4fd6-42ae-8250-b6d915e7a0cf": {
        "text_answer": "Contradiction The secondary trial has much more limited inclusion criteria compared to the primary trial",
        "label": "Contradiction"
    },
    "a0ad7d49-26f2-42ac-a384-e6362ccae8d7": {
        "text_answer": "Contradiction The primary trial has an ECOG performance status of 02 which means the patients are capable of selfcare with minimal assistance The secondary trial on the other hand includes patients with an ECOG performance status of 02 OR Karnofsky 60100 which includes patients who are confined to bed or chair less than 20 of waking hours However these patients do not meet",
        "label": "Contradiction"
    },
    "572557f8-fcc1-4448-aa44-a09e7c5244e8": {
        "text_answer": "Contradiction The evidence states that the secondary trial has specific performance status conditions while the primary trial does not mention any specific performance status conditions in its inclusion criteria",
        "label": "Contradiction"
    },
    "ee0e333a-4b42-4078-a126-d3a1101f7f4c": {
        "text_answer": "Contradiction The primary trial measures pain intensity not severity of delayed nausea",
        "label": "Contradiction"
    },
    "0f631563-09e1-48db-a6c3-1cc06009e139": {
        "text_answer": "Contradiction  Explanation The evidence shows that all patients in the secondary trial experienced at least 3 distinct adverse events while no patients in the primary trial experienced any adverse events Therefore the statement that no patients in either the primary clinical trial or the secondary clinical trial endured fewer than 3 distinct aes is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "1e1830e7-f7bd-4bf4-99c4-c36f6da015e3": {
        "text_answer": "Contradiction The statement does not provide any information about the number of adverse events related to the intestinal route of administration in the primary trial",
        "label": "Contradiction"
    },
    "e875a6e2-1058-4954-a864-7f1b35508362": {
        "text_answer": "Contradiction  In the primary trial group 2 receives dexmedetomidine while in the secondary trial no dexmedetomidine is administered These are different interventions",
        "label": "Contradiction"
    },
    "0b90fb4c-0de2-478b-95d2-2f0b555398ad": {
        "text_answer": "Contradiction The primary trial statement does not mention anything about the intervention section so it cannot entail or contradict its content",
        "label": "Contradiction"
    },
    "e56bca0a-a541-4a59-ba79-0f17cd0cdcb6": {
        "text_answer": "Contradiction The evidence states that women aged 18 or older are eligible for the secondary trial but there is no mention of a waiting period or eligibility for the primary trial for women in the age bracket of 1819 years",
        "label": "Contradiction"
    },
    "f0fbd167-6b00-4152-889e-7df794aa0619": {
        "text_answer": "Contradiction The statement mentions laryngeal obstruction ctcae which is not mentioned in the evidence provided",
        "label": "Contradiction"
    },
    "94857a77-b822-4cb8-989b-b6efb0a105e0": {
        "text_answer": "Contradiction The primary trial had no reported adverse events while the secondary trial had a considerable number 571",
        "label": "Contradiction"
    },
    "31f16856-c47c-40f3-b9a8-c414f07710ec": {
        "text_answer": "Contradiction The statement is more restrictive than the evidence as the evidence allows for the use of antineoplastic chemotherapy with the exception of antiHER2 agents androgens estrogens and progestogens if the patient has been on a constant dose for at least 28 days and is not expected to stop the medication during the study period",
        "label": "Contradiction"
    },
    "f6ca1a5e-853d-4669-8c13-89b54a42c460": {
        "text_answer": "Entailment  Explanation The evidence states that both Intervention 1 and Intervention 2 are part of a primary trial and each intervention has its specific cohorts TripleNegative Phase 2 TripleNegative and HER2Positive HER2Amplified Phase 2 HER2 The statement indicates that neither of the primary trial cohorts received any invasive surgery or",
        "label": "Entailment"
    },
    "90599dbb-bf85-4e56-9a16-fbcd4fbb22f6": {
        "text_answer": "Entailment The statement is entailed by the evidence as Herceptin trastuzumab is mentioned in both interventions",
        "label": "Entailment"
    },
    "7f0ff0a3-ccf0-4ea7-9c5b-b631da541d07": {
        "text_answer": "Contradiction The primary trial does include Anastrozole in Intervention 1 which is a form of aromatase inhibitor",
        "label": "Contradiction"
    },
    "3de4fd70-62c3-4310-a163-507e49af0e73": {
        "text_answer": "Contradiction The primary trial includes a criterion for a primary tumor greater than 2 cm diameter while the statement mentions a primary tumor with a 3mmradius which is not consistent with the primary trials inclusion criteria",
        "label": "Contradiction"
    },
    "70539b18-50b0-43f7-b676-2143de2dc3e8": {
        "text_answer": "Entailment Both trials involve the use of cyclophosphamide in their interventions",
        "label": "Entailment"
    },
    "e7572377-d468-4b13-815a-f43887747c18": {
        "text_answer": "Entailment The evidence states that there are patients in the trial receiving Intervention 1 with MCS110 at a dose of 1 mgkg Q3W which is less than the stated dose in the question However the statement does not specify that all patients in the trial receive MCS110 so it is an entailment that there are some patients who do not receive it at all",
        "label": "Entailment"
    },
    "a60074c0-d7a6-47cc-b980-ee1c0a791f66": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the two cohorts do not receive the same doses of Abraxane nabPaclitaxel In Arm A they receive nabPaclitaxel alone while in Arm B they receive nabPaclitaxel plus carboplatin",
        "label": "Contradiction"
    },
    "3ce48a99-7310-4a2f-8853-e46db55af26e": {
        "text_answer": "Entailment  Explanation The statement results from the primary trial show that tamoxifen 20 mg po daily for 168 hours prior to surgery and for 336 hours after breast cancer surgery reduces ki67 expression in tumors by 40 on average is an entailment of the evidence provided in the primary trial results  The evidence states that patients took tamoxifen 20 mg po daily",
        "label": "Entailment"
    },
    "aef90851-f30f-4d13-b6d6-8f52afaaa302": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses the frequency of certain adverse events in two trials while the statement makes a comparison between specific adverse events and a container",
        "label": "Contradiction"
    },
    "42aa56a7-2e3b-4932-bdde-a0ed438111c1": {
        "text_answer": "Contradiction The statement is about the difficulty of bending and straightening an arm while the evidence is about the occurrence of chest pain in the trials",
        "label": "Contradiction"
    },
    "bfa5809e-c1d4-49b8-b3d1-37fd6f7b077f": {
        "text_answer": "Contradiction The primary trial excludes patients with allergies to compounds of similar chemical or biologic composition to agents used in the study including doxorubicin which is a different class of drug than doxycycline The secondary trial does not mention doxorubicin or any similar agents but specifically lists exclusions for cephalosporin trimethoprimsulfamethoxazole levoflox",
        "label": "Contradiction"
    },
    "7b819ac1-92e6-41ce-881c-0f4581a690ee": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there were no cases of Infection Asymmetry or Deflation reported in the secondary trial and the primary trial had fewer cases of Infection and Deflation but an equal number of Asymmetry cases",
        "label": "Contradiction"
    },
    "dcad163d-b572-4dcc-a052-8bfb81f05ad5": {
        "text_answer": "Entailment  Explanation The statement individuals part of the primary clinical trial receive a lower quantity of drug dosage compared to those participating in the secondary clinical trial is an entailment based on the evidence provided In the primary trial participants received PF06647020 at 02 mgkg or 05 mgkg while in the secondary trial participants received ALT80",
        "label": "Entailment"
    },
    "4e9ce538-8418-4432-b3e7-8f3ecfefee6d": {
        "text_answer": "Contradiction The statement makes an assumption about a specific type of meningioma internal auditory canal meningioma which is not mentioned in the evidence The evidence only compares the ORR and number of participants between the Paclitaxel Plus Bevacizumab and Paclitaxel Plus Bevacizumab Plus Gemcitabine groups",
        "label": "Contradiction"
    },
    "a06166e6-12c9-49ba-ad3a-7fcfb5234174": {
        "text_answer": "Contradiction  Explanation  The primary trial measures the percentage of participants with any treatmentemergent adverse events TEAEs and serious TEAEs in different patient populations The secondary trial measures the number of participants with objective response to talazoparib in breast and ovarianperitoneal cancer patients These outcome measurements are not directly related to each other but they are not completely unrelated either as they both",
        "label": "Contradiction"
    },
    "82cea870-dbc3-4ebf-824c-0cebd7e95205": {
        "text_answer": "Entailment The evidence states that Cohort 1 received a lesser quantity 0015 mgkgdose of ALT801 compared to Cohort 2 0040 mgkgdose which is exactly what the statement asserts",
        "label": "Entailment"
    },
    "2677ff54-f67c-44c1-9aa8-64efd3357f65": {
        "text_answer": "Contradiction The secondary trial does not mention anything about pulmonary embolisms as an exclusion criterion However the statement does mention that patients with a history of pulmonary embolisms cannot participate in the secondary trial if they have breast implants This is a contradiction to the evidence provided in the secondary trial",
        "label": "Contradiction"
    },
    "ac265234-e392-49b4-b46b-a0a54e54f88b": {
        "text_answer": "Contradiction The statement mentions Mucositis Oral epileptic seizures and Thromboembolic events but none of these adverse events were recorded in the secondary trial according to the provided evidence",
        "label": "Contradiction"
    },
    "a01bb73a-e620-4bb5-995b-9433d10090ab": {
        "text_answer": "Contradiction The primary trial does include massage therapy which is not a drugbased treatment but not explicitly stated as not being part of the examination process However the secondary trial does test two separate drugbased interventions",
        "label": "Contradiction"
    },
    "3d52b3c6-d110-4442-8a2f-1cf87b1092c5": {
        "text_answer": "Entailment assuming the patients anal cancer is not excluded from the secondary trial based on other criteria",
        "label": "Entailment"
    },
    "56e9308b-f718-4831-8e56-4b18982e4a2c": {
        "text_answer": "Contradiction The evidence provided in the given trials includes eligibility criteria related to gender age and other factors which contradicts the statement that nationality ethnicity weight or gender will not affect eligibility",
        "label": "Contradiction"
    },
    "c3f4b547-8d11-42ba-800c-7ccbe1283741": {
        "text_answer": "Contradiction The statement is not an entailment as the primary trial only includes patients with ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 It does not include patients with estrogen negative progesterone negative and HER2 tumors as a separate cohort",
        "label": "Contradiction"
    },
    "5718421a-fc98-4df0-a866-21d4718ebf78": {
        "text_answer": "Contradiction  In the primary trial participants received trastuzumab at a dose of 2 mgkgweek while in the secondary trial Herceptin was administered at a dose of 4 mgkg in Cycle 5 and 2 mgkg weekly thereafter These dosages are not the same making the statement a contradiction",
        "label": "Contradiction"
    },
    "c3c644d4-1964-454a-af82-4e82c2567f6e": {
        "text_answer": "Entailment The evidence states that both GBM and gynecological cancer patients undergo 18FFDG and 18FFPPRGD2 PETCT imaging",
        "label": "Entailment"
    },
    "c4a0d86a-f8a8-4c2a-a28a-25147f35a682": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one instance of fever and one instance of Gramnegative bacteremia with a fever in cohort 1 of the primary trial However the statement asserts that all instances of infections and fever were observed in cohort 1 implying that there were no such events in cohort 2 Since there was at least one instance of fever in cohort 2 according",
        "label": "Contradiction"
    },
    "1af24416-2f14-423b-bd1c-b6f604cae64a": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with cerebral metastases while the secondary trial does not mention any such exclusion for patients with cerebral metastases in the cerebellum",
        "label": "Contradiction"
    },
    "09deff91-1b05-470a-aecd-60ce772b9a8e": {
        "text_answer": "Contradiction The primary trial mentioned in the evidence is for breast cancer not colon cancer",
        "label": "Contradiction"
    },
    "5bdc0c5e-236f-4dbf-92cd-8f582a16b2fd": {
        "text_answer": "Contradiction  Explanation  In the primary trial group 2 receives 05ugkg of dexmedetomidine not 05kgug The statement incorrectly states that group 2 in the primary trial receives 5000ml 5000g  5kg of myalgias which is not the case  In the secondary trial patients in coh",
        "label": "Contradiction"
    },
    "e530eed4-ee8b-4a7f-bb36-5ce9ea7ddebe": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as no cases of Acute myocardial infarction were reported in the primary trial while the secondary trial did not report any adverse events at all",
        "label": "Contradiction"
    },
    "c392fd36-941e-4809-8d9e-16e3aa1c945c": {
        "text_answer": "Contradiction The primary trial had fewer participants 13 compared to the secondary trial 30",
        "label": "Contradiction"
    },
    "dd58a7e3-370e-4e61-9071-6155962cd180": {
        "text_answer": "Entailment The evidence states that there were no adverse events reported in the first group of the primary clinical trial and the statement asserts that the same is true",
        "label": "Entailment"
    },
    "151ae668-d1e7-4dd1-beb2-75dd7efbae4c": {
        "text_answer": "Contradiction The statement does not entail the evidence as it only mentions four medications but the evidence states that participants receive more than four distinct medications epirubicin cyclophosphamide docetaxel and trastuzumab and the dosages of epirubicin exceed 100 mgm2",
        "label": "Contradiction"
    },
    "d475c476-8172-47a0-bf91-7ef5d0f6d081": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy while the secondary trial involves administration of Fulvestrant in a tablet form BID but there is no mention of whole breast radiation therapy in the secondary trial",
        "label": "Contradiction"
    },
    "48b5fa7f-b2c7-41f9-adc5-ca55ae919f3d": {
        "text_answer": "Entailment The primary trial evaluates toxicity while the secondary trial evaluates percentage of participants with adverse events of primary interest but these are different outcomes However the evidence shows that different patient populations and treatments are being evaluated in each trial",
        "label": "Entailment"
    },
    "1d60de45-bc33-4178-96e6-d0fa20e51fed": {
        "text_answer": "Entailment The statement does not contradict the evidence as it does not mention anything about transparency or images However the evidence shows that both cohorts receive the same radiation doses and cohort 1 undergoes the intervention for two weeks longer but this does not affect the radiation therapy doses",
        "label": "Entailment"
    },
    "18303bbd-059e-4161-8cc6-9569a71308f5": {
        "text_answer": "Contradiction  The statement three more treatment courses of these drugs are integrated into the second cohort contradicts the evidence that the identical number and intervals of treatment courses with docetaxel doxorubicin and cyclophosphamide are given to all groups in the primary trial In the first intervention each patient receives 8 cycles of treatment 4 cycles of AC and 4 cycles of T while in the second intervention patients",
        "label": "Contradiction"
    },
    "3a0c092c-7e18-4108-ae66-552f7069831f": {
        "text_answer": "Contradiction  The evidence shows that in the primary trial there was one death recorded in the adverse events and in the secondary trial there were no deaths recorded in the adverse events Therefore the statement that over 10 deaths were recorded in the adverse events across both trials is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "4eacff65-65e6-4bf9-bc94-419c48e854e8": {
        "text_answer": "Contradiction The evidence shows that there is a difference in adverse events between the two trials but the statement asserts that they do not match at all",
        "label": "Contradiction"
    },
    "9c6f062e-a260-4c3a-ac91-fc5de6de176d": {
        "text_answer": "Contradiction The statement mentions a minor discrepancy in results between the two cohorts within the primary clinical trial but the evidence shows that both cohorts had lower percentage of participants with pCR compared to the cohorts in the secondary trial The statement also mentions that arm 2 outperformed arm 1 in the secondary clinical trial significantly but the evidence shows that arm 1 had a lower percentage of participants with pCR than arm 2",
        "label": "Contradiction"
    },
    "0416a45e-2ea6-4f82-8bc6-05cc37b941f8": {
        "text_answer": "Contradiction The primary trial has a treatment cycle length of 21 days not 6 days",
        "label": "Contradiction"
    },
    "57526ef1-a6b9-419e-86c9-0a2d6db7ad23": {
        "text_answer": "Contradiction The evidence does not mention anything about anorexia as an inclusion or exclusion criterion for the primary clinical trial",
        "label": "Contradiction"
    },
    "50dae016-a6b4-4ee6-a66a-bf35587cd835": {
        "text_answer": "Contradiction  The evidence shows that the median survival for both groups is less than 25 years which means that some patients in both groups died before 2 years However the statement asserts that on average all patients survive over 2 years which is not supported by the evidence",
        "label": "Contradiction"
    },
    "43297eae-d154-4417-8bd4-3c4aae66e6bd": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence shows that no adverse events were recorded in both trials",
        "label": "Contradiction"
    },
    "c21d4d07-87ea-46ba-b930-9fd3fb0797a5": {
        "text_answer": "Contradiction The primary trial does not list smoking as an exclusion criterion",
        "label": "Contradiction"
    },
    "65f9af41-9bb8-438a-b967-94acfd0e08a9": {
        "text_answer": "Contradiction The evidence states that there are no outcomes documented for the LBH589 and Lapatinib cohort but the trial design includes this cohort with a planned dose range for both LBH589 and Lapatinib",
        "label": "Contradiction"
    },
    "3131f532-99b5-433e-9375-8af120cd4c0f": {
        "text_answer": "Contradiction  The statement is incorrect because the patients in the primary clinical trial are administered 05ugkg of dexmedetomidine not myalgias",
        "label": "Contradiction"
    },
    "bfb9d912-39ea-4a7a-b3eb-51e9d1b5f436": {
        "text_answer": "Entailment Both trials exclude patients with allergies to cephalosporin trimethoprimsulfamethoxazole levofloxacin or celecoxib",
        "label": "Entailment"
    },
    "06bf2ef1-129f-47cf-b51f-75e51f1eb66a": {
        "text_answer": "Contradiction  The evidence shows that some adverse events were recorded for more than one patient pneumonia and disease progression each occurred in 1 patient",
        "label": "Contradiction"
    },
    "fb41d62d-4f75-463d-b71a-0b31dd0ade96": {
        "text_answer": "Contradiction The statement is not an entailment as the interventions in the two arms of the trial involve different drugs gemcitabine in Arm A and carboplatin in Arm B While both interventions include nabPaclitaxel the other drugs are not the same and are not provided in the same amount",
        "label": "Contradiction"
    },
    "e875dcbd-dc31-47c4-87bf-a94b0c1696b1": {
        "text_answer": "Entailment with the assumption that the secondary trial also measures treatmentemergent adverse events and serious treatmentemergent adverse events in a similar manner as the primary trial",
        "label": "Entailment"
    },
    "9640278e-af41-482e-8390-d20bc7388149": {
        "text_answer": "Contradiction The statement sexually active fertile men and women with reproductive potential can participate in the primary clinical trial is a contradiction to the evidence as the trial explicitly excludes women of childbearing potential who are unwilling or unable to use an acceptable method of birth control and sexually active fertile men whose partners are women of childbearing potential and not using an adequate method of birth control",
        "label": "Contradiction"
    },
    "ad11786a-e01b-466c-9e44-31f1be35c79c": {
        "text_answer": "Entailment The evidence shows that there were no unforeseen fatalities or hospital admissions in both trials as stated in the question",
        "label": "Entailment"
    },
    "325db761-416f-4aab-80e8-e3271a11200b": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided",
        "label": "Entailment"
    },
    "56ac01ed-cfba-4ab5-9082-dbe4a4418e9d": {
        "text_answer": "Contradiction  Explanation The statement in the question is not an entailment or a contradiction of the evidence provided The evidence only mentions that there are separate cohorts for TripleNegative PRnegative ERnegative and HER2Positive HER2Amplified in the primary clinical trial but it does not specify the interventions or treatments received by each cohort in terms of Dasatin",
        "label": "Contradiction"
    },
    "0931fd2b-2ce8-4285-9c02-63318e60efc3": {
        "text_answer": "Contradiction The primary trial measures pain intensity not severity of delayed nausea",
        "label": "Contradiction"
    },
    "b0709ec3-ea6b-4f70-a24e-d23480df5b14": {
        "text_answer": "Contradiction The primary trial measures time to progression while the secondary trial measures the number of participants with objective response These are different outcome measures",
        "label": "Contradiction"
    },
    "f2beb95f-ac83-48f1-936b-70d45d51880c": {
        "text_answer": "Contradiction The placebo is administered as a 3hour infusion while trabectedin is administered as a 3hour infusion on a different day The statement suggests an 8hour infusion on a biweekly basis which is not consistent with the evidence provided",
        "label": "Contradiction"
    },
    "286e098d-ca31-41ce-b8a9-f8bcf99447f0": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as anemia is less prevalent in the primary trial 000 compared to the secondary trial 267",
        "label": "Contradiction"
    },
    "115aa2c8-f52f-4a62-9b8a-6f6e593bd208": {
        "text_answer": "Contradiction  Explanation The statement primary clinical trials second cohort has an additional 7 participants compared to the first cohort is a contradiction based on the evidence provided because the first cohort had 234 participants and the second cohort had 241 participants which is a difference of 7 participants in the opposite direction of what the statement suggests",
        "label": "Contradiction"
    },
    "425f9738-1b09-446e-8c8c-5004ed91351d": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one instance of Gramnegative bacteremia with a fever in cohort 2 but the statement asserts that all instances of infections and infestations were in cohort 1",
        "label": "Contradiction"
    },
    "53416cd6-ac0b-43c1-824f-719d43ad5af4": {
        "text_answer": "Contradiction  Explanation  The statement various participants of group 1 in the primary clinical trial had clear evidence of skin lesions under 10 of participants in group 1 of the secondary clinical trial showed symptoms of radiation dermatitis and hyperpigmentation is a contradiction based on the provided evidence  In the primary clinical trial there were no skin lesions detected in the group of healthy volunteers In",
        "label": "Contradiction"
    },
    "b4e6d7be-cb1b-4000-812e-d49098f0aaf0": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as no hospitalizations or mortalities were recorded in cohort 2 according to the evidence provided",
        "label": "Contradiction"
    },
    "438a978d-ac7e-4260-bb24-d2129cb3dfc6": {
        "text_answer": "Contradiction The primary trial does not mention schizophrenia as an exclusion criterion",
        "label": "Contradiction"
    },
    "d5586986-90bb-4302-98c1-0507aa208d2d": {
        "text_answer": "Contradiction The evidence provided does not mention MRIs being used in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "b80c867f-7c46-4ac1-a9c4-b56ce0173c2a": {
        "text_answer": "Entailment The statement is an entailment because both interventions in the primary trial used an openlabel administration method either IV for bisphosphonate Q4W or subcutaneous injection for denosumab Q12W",
        "label": "Entailment"
    },
    "cafb9767-9320-40fc-a862-53530450f96f": {
        "text_answer": "Contradiction The statement is not directly related to the evidence provided as it introduces an unrelated concept high calcium level and does not accurately describe the outcome measurements in the trials changes in pain intensity and bone mineral density",
        "label": "Contradiction"
    },
    "8c4891f7-e0af-4ddb-8754-0638ece12c58": {
        "text_answer": "Contradiction  Explanation The evidence shows that the mean number of daily hot flashes was lower in the paced respiration group 348 compared to the fast shallow breathing group 395 Therefore the statement that there was no significant difference is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "7ae03d8b-6087-4df3-a0e1-d1932d86528c": {
        "text_answer": "Contradiction The statement is not related to the given evidence as it mentions Chest Pain which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "3b13cd45-eae5-4039-8a8a-a73c55fde5dc": {
        "text_answer": "Entailment The evidence shows that neither trial reported any cases of intestinal obstructions or pancytopenia which is a stronger statement than the given statement that both trials did not report these conditions",
        "label": "Entailment"
    },
    "dfc9042c-745d-46a2-9706-3efe0b24c20c": {
        "text_answer": "Contradiction The evidence from the primary trial shows that some patients experienced multiple adverse events but it does not indicate that most patients did The secondary trial had no severe adverse events at all",
        "label": "Contradiction"
    },
    "ddfc4bce-b6b0-4817-a171-db6bd5e095bd": {
        "text_answer": "Entailment The evidence provided does not indicate that nationality ethnicity psychiatric condition or gender are inclusion or exclusion criteria for either trial",
        "label": "Entailment"
    },
    "b957f1f2-8dc3-4d00-802d-26cd8fa3b9f4": {
        "text_answer": "Contradiction The primary trial includes patients with a breast tumor that is 1 cm in diameter while the secondary trial does not mention any specific tumor size requirement",
        "label": "Contradiction"
    },
    "dcfc0053-b963-4542-ae02-228d3d2bd98e": {
        "text_answer": "Entailment  Explanation The statement The interventions in the primary trial included different medications but are administered through the same routes is an entailment based on the evidence provided The evidence states that Intervention 1 involves intravenous IV bisphosphonate and Intervention 2 involves subcutaneous SC denosumab but both interventions are administered through different routes IV and SC respectively that are",
        "label": "Entailment"
    },
    "b54f065f-7b3e-42b0-8dc6-61dc466f7f59": {
        "text_answer": "Entailment The primary trial assesses toxicity while the secondary trial assesses percentage of participants with adverse events but both trials involve patient outcomes",
        "label": "Entailment"
    },
    "160afbf4-14b4-4e83-b324-4d3102b8f72c": {
        "text_answer": "Contradiction The statement is about a completely different topic as it refers to a benign hard palate neoplasm which is not related to the primary trial or its cohorts",
        "label": "Contradiction"
    },
    "eae19a7f-ca02-482d-942f-223d74881c40": {
        "text_answer": "Contradiction The secondary trial does not list pulmonary embolisms as an exclusion criterion but the primary trial does not mention it as an inclusion or exclusion criterion at all The statement about breast implants being an exclusion criterion for the primary trial is consistent with the evidence",
        "label": "Contradiction"
    },
    "c0db0110-c67a-40e6-8bfc-b7e016509778": {
        "text_answer": "Entailment The primary trial explicitly lists significant cardiovascular impairment as an exclusion criterion and the secondary trial lists uncontrolled cardiovascular disease as an exclusion criterion Both trials exclude patients with cardiovascular issues",
        "label": "Entailment"
    },
    "7caa5dd0-cd09-4559-a243-736304ce22e4": {
        "text_answer": "Contradiction The primary trial only includes female patients while the secondary trial includes both male and female patients Therefore a 55yearold male patient cannot meet the inclusion criteria for both trials",
        "label": "Contradiction"
    },
    "a14e5115-a6ff-4253-9260-736c943bd47e": {
        "text_answer": "Contradiction  The primary trial includes patients who have received chemotherapy or radiotherapy within the last 05 months but the secondary trial explicitly excludes such patients Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "0f17aa12-6aea-430e-b4e8-2a21f2832582": {
        "text_answer": "Entailment The statement is a specific case of the inclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "bdb61718-ee5f-4e2a-9c78-850e788c139f": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the past 3 years while the secondary trial may consider such patients based on the investigators decision",
        "label": "Contradiction"
    },
    "df783937-3936-4f0b-a3f9-96a977497c6f": {
        "text_answer": "Entailment The primary trial does have distinct inclusion and exclusion criteria for each phase while the secondary trial does have different sets of criteria for patients based on their health status cancer vs good health",
        "label": "Entailment"
    },
    "8e88537e-5eb0-4e85-a6cd-58e374d027b6": {
        "text_answer": "Contradiction The statement is about an individual receiving a dose of fentanyl spray while the evidence is about patients receiving doses of vorinostat and radiation therapy",
        "label": "Contradiction"
    },
    "b1cb1388-9a0f-4dfd-8890-a3d2bced6ab4": {
        "text_answer": "Contradiction  The statement provides different numbers of participants with recurrencefree survival for each group which is not consistent with the evidence that shows 80 participants in the Ketorolac 30 mg group and 897 or 88 participants in the NaCl 09 3mL group had recurrencefree survival",
        "label": "Contradiction"
    },
    "8c1414dd-20b2-415e-8d0e-1f9b8e7951d1": {
        "text_answer": "Contradiction  Explanation In the primary trial both the intervention groups receive tablets Botulinum Toxin Type A or Placebo for Botulinum Toxin Type A injections but these are not entericcoated tablets as stated in the question  In the secondary trial the intervention groups receive MLN8237 tablets which are entericcoated tablets according to the evidence provided",
        "label": "Contradiction"
    },
    "4f4360c0-38f9-4cea-89bb-8bf2a3fd0a4a": {
        "text_answer": "Contradiction The statement does not provide any information about the dosage of Enzalutamide administered to each cohort in the primary trial",
        "label": "Contradiction"
    },
    "c48550ef-7210-4834-9047-969a7898d519": {
        "text_answer": "Contradiction  Explanation The statement eating disorders were not common among participants of the primary clinical trial throughout the study is a contradiction to the evidence as there is no mention of eating disorders in the list of adverse events in the primary trial",
        "label": "Contradiction"
    },
    "2a0b1a83-299d-404d-96e5-67ee65173dde": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy which is not mentioned in the secondary trial The secondary trial only mentions intramuscular injections and oral medication",
        "label": "Contradiction"
    },
    "faf8436a-2459-4718-be81-10b0649ff87a": {
        "text_answer": "Contradiction The primary trial explicitly states that participants must be older than 20 years while the secondary trial includes participants who are 18 or older",
        "label": "Contradiction"
    },
    "bf00cf4b-27eb-4c1a-88e2-f86df10f2727": {
        "text_answer": "Contradiction  The evidence shows that 16 participants in Arm 1 Paclitaxel  Trastuzumab Then AC and 14 participants in Arm 2 Paclitaxel  Neratinib Then AC experienced pathologic complete response in breast and axillary lymph nodes However the statement asks for more than 10 patients in both cohorts which is not supported by the evidence",
        "label": "Contradiction"
    },
    "98c16e6f-17a1-436f-833f-4f69e14f52db": {
        "text_answer": "Contradiction The evidence provided does not support the statement as it only compares acupuncture to a waitlist control group in terms of lymphedema reduction and no information about testosterone cream is given in the provided evidence",
        "label": "Contradiction"
    },
    "c43583e4-da5f-42b3-ad3d-7ba8b6b28f2b": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not mention the number of cases of intestinal perforation in the primary trial",
        "label": "Contradiction"
    },
    "7c093c8a-8233-4dbb-87ba-03a1a049a7e8": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence does not indicate that the patients in both cohorts received equal doses of radiation therapy in terms of number of treatments or duration While the doses of radiation therapy are similar the number of treatments and duration differ between the two cohorts",
        "label": "Contradiction"
    },
    "67498e27-5a2e-4495-adb7-5cd8f51aae65": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the dosages mentioned in the statement do not correspond to the dosages given in the evidence The dosage of tamoxifen in intervention 1 of the secondary trial is 10 mg once daily which is not 12 times higher than the dosage of denosumab in intervention 1 of the primary trial which is 4 mg every 4 weeks",
        "label": "Contradiction"
    },
    "5ca1c4e8-73e3-4329-9644-bfb986b6673e": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of ICD encounters or anemia in the provided evidence",
        "label": "Contradiction"
    },
    "36e4b948-e72f-43d9-8084-b3d2e879620b": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the first cohort received Fulvestrant through intramuscular injection not intravenous injection Enzalutamide was given orally to both cohorts in the trial",
        "label": "Contradiction"
    },
    "9b1d58dd-30d8-4df2-856e-4cae783cbd6e": {
        "text_answer": "Contradiction   The primary trial involves Gefitinib ZD1839 and the secondary trial involves Zoledronic Acid which are different interventions",
        "label": "Contradiction"
    },
    "92ea43b9-05d5-47a4-a78d-87bcb3326810": {
        "text_answer": "Contradiction The evidence states that one participant experienced a rash maculopapular",
        "label": "Contradiction"
    },
    "0629bf04-f185-49b2-905e-e9a3932dbb0a": {
        "text_answer": "Contradiction The statement is not based on the evidence provided as there is no mention of nausea hepatic steatosis or the number of cases in either trial in the statement",
        "label": "Contradiction"
    },
    "dc2d7205-d6ce-4d9c-96d2-e5a80fa906c0": {
        "text_answer": "Contradiction  Explanation The statement suggests that recurrent malignancies graftversushost disease anaemia cardiac failure and diffuse alveolar hemorrhage are common adverse events in the secondary trial than the primary trial However the evidence shows that the frequency of recurrent malignancies and graftversushost disease is higher in the primary trial while the",
        "label": "Contradiction"
    },
    "02adb741-194d-4472-b4b8-a3b546dc0484": {
        "text_answer": "Contradiction The statement is not supported by the evidence provided as there is no mention of pericardial effusions in the primary trial and no mention of corneal deposits in the secondary trial",
        "label": "Contradiction"
    },
    "55cc22eb-91ad-423f-8d3e-e4b5ef61ed7d": {
        "text_answer": "Entailment assuming the patient meets all other inclusion criteria for both trials",
        "label": "Entailment"
    },
    "41a0138d-7084-40d9-99ae-24db9e84acce": {
        "text_answer": "Contradiction The primary trial measures the number of participants with treatmentemergent adverse events while the secondary trial measures the change in total sleep time in minutes These are different outcome measures",
        "label": "Contradiction"
    },
    "6846ee30-4c0c-4340-9c13-3892edc3baea": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "3974c3ec-d3b5-4313-ae4b-4332ee5865ab": {
        "text_answer": "Contradiction The primary trial requires a Karnofsky score of 70 or better while the secondary trial requires a Karnofsky score of 55 or better",
        "label": "Contradiction"
    },
    "e8e3fedb-075d-440e-bf2e-baec76f96cca": {
        "text_answer": "Entailment The statement is entailed by the evidence as Nonsmall cell lung cancer and Small cell lung cancer are listed as eligible tumor types in the inclusion criteria",
        "label": "Entailment"
    },
    "c441ac74-f9ef-493c-bcfb-03959f9bf7e3": {
        "text_answer": "Contradiction The statement is about Week 2 percentage change in the AZD0530 25 mg group compared to the Zoledronic Acid 05 mg group but the evidence provided only includes Week 4 percentage changes for the AZD0530 175 mg and Zoledronic Acid 4 mg groups",
        "label": "Contradiction"
    },
    "867cde11-ffad-4494-bdea-2457651a7de7": {
        "text_answer": "Contradiction  Explanation The statement is about the reduction in tumor diameter while the evidence is about the change in Ki67 expression which is a marker of cell proliferation The two are not directly comparable and the statement does not follow from the evidence",
        "label": "Contradiction"
    },
    "fe5179d1-0090-4c87-9287-9bb26139acd0": {
        "text_answer": "Contradiction The statement about as socially active as before is not an entailment of the exclusion criteria as the statement does not directly relate to the exclusion criteria for antineoplastic chemotherapy androgens estrogens or progestogens The statement only mentions that these therapies are exclusion criteria but it does not provide any information about the social activity level of patients who have undergone these therapies",
        "label": "Contradiction"
    },
    "6561c528-4e6f-4e1f-8d65-9fa11d3c8838": {
        "text_answer": "Contradiction The primary trial does measure tumor response according to RECIST criteria but it does not specifically track the proportion of participants benefiting from the treatment",
        "label": "Contradiction"
    },
    "a2b4f24d-e4ff-49b5-a21f-61ba1e5b0b32": {
        "text_answer": "Contradiction  The evidence shows that 286 95 CI 131492 of ERpositive Luminal B participants demonstrated a decrease in the growth factor signature while 176 95 CI 67352 of Triple Negative participants demonstrated a decrease in the growth factor signature Therefore there is a difference in",
        "label": "Contradiction"
    },
    "dac129a3-974e-4918-95e5-11bbc0207e02": {
        "text_answer": "Contradiction The evidence does not support the statement that all participants suffered a deterioration in cognitive function as the results show that some participants in the Tamoxifen group had a slight improvement in cognitive function The statement also does not specifically mention the results for the Ultrarapid Metabolizers or Extensive Metabolizers groups from the first part of the evidence",
        "label": "Contradiction"
    },
    "ac0de5f6-14ed-44a1-9112-bce1b197553b": {
        "text_answer": "Contradiction The statement does not entail the evidence provided as the evidence does not mention Trichomonas infection at all",
        "label": "Contradiction"
    },
    "ef1d6dfa-2cd0-4e19-99b7-a813d6952706": {
        "text_answer": "Contradiction  Explanation The primary trial has several inclusion and exclusion criteria that are not present in the secondary trial such as age cancer type life expectancy and prior treatment history Therefore the statement that only the ability to provide written informed consent is shared between the two trials is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "11cb71ed-1304-42f0-b416-3679c3e9e1b3": {
        "text_answer": "Contradiction The statement is not consistent with the evidence provided as Cohort 2 in the primary trial does not receive the intervention involving the Educational DVD",
        "label": "Contradiction"
    },
    "0f37bc77-1f82-44ce-ae7e-2a6b833e774a": {
        "text_answer": "Contradiction The statement does not entail the information given in the evidence as it does not mention anything about somatostatin receptor positive or its absence in the cohorts",
        "label": "Contradiction"
    },
    "d9dff3a0-537b-4297-bc58-766d366ba5a0": {
        "text_answer": "Contradiction The evidence does not provide any information about adverse events related to bilateral malignant neoplasms",
        "label": "Contradiction"
    },
    "0d382bbc-1c8d-4d05-b0dd-8501755ce9dd": {
        "text_answer": "Contradiction as per the given evidence there were no hospitalizations in cohort 2",
        "label": "Contradiction"
    },
    "1a84148c-2d33-4804-922e-9a3419890897": {
        "text_answer": "Contradiction  Explanation The primary trial does not specify how the interventions are administered only stating that zoledronic acid is given intravenously IV The secondary trial on the other hand specifies that the interventions are given intravenously IV or orally There is no mention of subcutaneous or topical administration in either trial",
        "label": "Contradiction"
    },
    "b3527d60-eb66-465d-845a-e234e5b0a084": {
        "text_answer": "Contradiction The primary trial excludes participants who smoke while the secondary trial allows individuals who smoke but consume less than five alcoholic beverages daily",
        "label": "Contradiction"
    },
    "3d2d011f-aff9-45c6-87e9-359b6d265c98": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence provided for the secondary trial as the exclusion criteria for the secondary trial state that patients who have received chemotherapy or radiotherapy within the last 14 days have unstable angina or have grade 2 or above neuropathy are not eligible for the study This is different from the statement which states that these patients can still take part in the primary trial if they satisfy all of the relevant inclusion",
        "label": "Contradiction"
    },
    "e9653ffb-8fe5-47a3-810f-6831216f9893": {
        "text_answer": "Contradiction The evidence does not support the statement that there were 1000 cases of hypertension edema and dyspnea in either cohort of the primary trial as there is no mention of these conditions in the provided data",
        "label": "Contradiction"
    },
    "97d1e0d2-2f6f-45f1-8e85-33c92d71f0bf": {
        "text_answer": "Contradiction The evidence states that one patient in the primary clinical trial experienced an increase in blood bilirubin levels",
        "label": "Contradiction"
    },
    "2cf8046e-2d49-4989-aca0-9e11795978cb": {
        "text_answer": "Contradiction The primary trial uses oral pregabalin while the secondary trial uses intrathecal Depocyt and intravenous highdose Methotrexate",
        "label": "Contradiction"
    },
    "c7e44ec4-ddeb-4d8b-97aa-0361308300b8": {
        "text_answer": "Entailment  Explanation The statement in the primary clinical trial cohorts a and b are both given two different treatments which are not ld v935 at varying points in the cycle is an entailment based on the evidence provided This is because according to the evidence in Intervention 1 V935 LD is not given during cycles 14 and in Intervention 2 V",
        "label": "Entailment"
    },
    "c6ca9f93-1abb-4c01-bdfb-aa17c5028ec8": {
        "text_answer": "Contradiction The young girl with a newly diagnosed PRpositive HER2positive breast cancer cannot be eligible for both trials as per the given inclusion and exclusion criteria The primary trial specifically includes patients with HER2positive breast cancer but the secondary trial includes patients with ERpositive HER2negative breast cancer",
        "label": "Contradiction"
    },
    "16634eb4-f12b-4d17-8401-070a7b7d052b": {
        "text_answer": "Contradiction The statement is about discomfort when urinating which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "36e73055-3f34-4e5b-94a0-cfbac5dc3ff9": {
        "text_answer": "Contradiction The statement have trouble saying what i mean in conversation is not related to the inclusion criteria for the primary trial which pertains to histologicallycytologically confirmed diagnosis of resectable Nonsmall cell lung cancer or Small cell lung cancer",
        "label": "Contradiction"
    },
    "ec164af8-13b9-4545-b3ba-24260adfe9db": {
        "text_answer": "Entailment The evidence states that the primary clinical trial includes patients with metastatic colorectal cancer who harbor the Kras or BRAF mutation 1530 enrollment slots",
        "label": "Entailment"
    },
    "29bed237-ccbb-460b-a50b-fbdc9e52fdd1": {
        "text_answer": "Contradiction  Explanation The statement All AE types in the primary trial affected less than 10 of patients is a contradiction to the evidence as the evidence shows that several adverse events affected more than 9 of patients in the primary trial For example febrile neutropenia sinus tachycardia sepsis lymphocyte count decreased neutrophil count",
        "label": "Contradiction"
    },
    "34c7862b-3725-4ed8-9e67-1513300323a7": {
        "text_answer": "Entailment The evidence shows that the ORR in the Paclitaxel Plus Bevacizumab Plus Gemcitabine group was higher than that in the Paclitaxel Plus Bevacizumab group",
        "label": "Entailment"
    },
    "c0b2f348-06b9-4e92-9257-a32c38b072cf": {
        "text_answer": "Contradiction The primary trial includes both male and female patients but the secondary trial only includes female patients",
        "label": "Contradiction"
    },
    "512b8ed3-f0ca-4e11-ab4a-eebe4217ad7e": {
        "text_answer": "Contradiction  Explanation The primary trial measures the change in hot flash scores in women while the secondary trial measures the overall response rate ORR in patients with solid tumors using RECIST criteria These outcome measures are not the same and are not directly comparable making the statement a contradiction",
        "label": "Contradiction"
    },
    "568b4d2b-204c-4606-a75f-058a5870c84c": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the second group in the primary clinical trial is receiving radiotherapy and not viewing an educational DVD",
        "label": "Contradiction"
    },
    "7ba4c342-8897-4815-9bb3-eea917b3769e": {
        "text_answer": "Contradiction  The primary trial administers oral pregabalin and placebo while the secondary trial administers intravenous HighDose Methotrexate Intrathecal Liposomal Cytarabine and topical corticosteroids not mentioned in the statement",
        "label": "Contradiction"
    },
    "f988fa4a-02f0-41f6-9e27-453604dd3ecc": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that no adverse events were recorded in both trials",
        "label": "Contradiction"
    },
    "0f77fc34-7285-4374-879d-b96166cfc29e": {
        "text_answer": "Contradiction The evidence states that participants will take Vorinostat daily during radiation therapy",
        "label": "Contradiction"
    },
    "e648aa7a-3013-4d37-9bf5-51e75c7d4202": {
        "text_answer": "Contradiction  Explanation The evidence shows that infections affected 313 of patients in the primary trial and 667 in the secondary trial which is less than 15",
        "label": "Contradiction"
    },
    "7723c9e5-e80e-4ef6-b56d-ee26f8423d90": {
        "text_answer": "Contradiction The primary trial measures pain intensity not the severity of delayed nausea",
        "label": "Contradiction"
    },
    "6b4bc07c-bfc3-4750-b802-7100efeb60a7": {
        "text_answer": "Entailment  Explanation The statement the interventions in the primary clinical trial are similar in terms of the medications but they are given through varied routes is an entailment based on the evidence provided Both interventions involve the use of medications bisphosphonate and denosumab but they differ in the route of administration IV for bisphosphonate and subcutaneous for denosumab",
        "label": "Entailment"
    },
    "320ec115-31c3-47bf-a819-93d514b91eb3": {
        "text_answer": "Contradiction The primary trial did not report any cases of radiation dermatitis or hyperpigmentation while the secondary trial reported that more than 90 of participants in one group had these conditions",
        "label": "Contradiction"
    },
    "19ca7182-94ba-4b70-bd4e-1a65bd428f91": {
        "text_answer": "Contradiction The primary trial does not require a pulmonary function test but rather a mammogram on a GE FFDM system The secondary trial does not require a pulmonary function test or an MRI report and liver function tests",
        "label": "Contradiction"
    },
    "1d1f2f55-c9b7-4a8b-bea7-b8ea291d96d5": {
        "text_answer": "Contradiction The evidence provided pertains to the eligibility criteria for a breast cancer clinical trial while the statement is about an application adapter which is not related to the trial criteria",
        "label": "Contradiction"
    },
    "919dbcc0-8d31-4161-8692-45533e52d60e": {
        "text_answer": "Contradiction The statement implies that no adverse events were reported in the second cohort as well but the evidence shows that at least one adverse event was reported in the second cohort",
        "label": "Contradiction"
    },
    "33efdbc8-175b-4021-b192-acd8d37cedd1": {
        "text_answer": "Contradiction  Explanation The evidence shows that out of the total number of patients in the primary trial only one patient in cohort 1 had both increased pleural effusion and rapid disease progression and no patient in cohort 2 had increased pleural effusion Therefore it is a contradiction to the statement that 125 of patients suffered from both conditions",
        "label": "Contradiction"
    },
    "a555a807-ceeb-4237-bd26-25e5a3db9128": {
        "text_answer": "Contradiction The statement assumes that Suramin and Paclitaxel are not administered in the secondary trial but the evidence does not state that",
        "label": "Contradiction"
    },
    "96892eae-9630-45eb-bc5f-6c7605d8dd1c": {
        "text_answer": "Contradiction The statement fifty is a natural number greater than fortynine and less than fiftyone and the quantity that it denotes is a mathematical statement while the statement about the primary and secondary trials refers to different eligibility criteria for different types of cancer The first statement does not entail or contradict the second statement",
        "label": "Contradiction"
    },
    "afeed01c-f21a-4926-9028-d2b9a2226c9f": {
        "text_answer": "Entailment The evidence does not mention the use of paclitaxel in any of the interventions",
        "label": "Entailment"
    },
    "0c05d756-82d5-4f8f-afe7-845857c1e9d3": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence provided In the primary trial intervention 1 uses intravenous IV administration for zoledronic acid while in the secondary trial no intervention uses inhalation as the administration method",
        "label": "Contradiction"
    },
    "a954a34f-0eb2-4c28-8673-f4c0a337bd00": {
        "text_answer": "Contradiction The statement is not related to the given evidence as it mentions a different drug Herceptin instead of Trastuzumab and a different trial",
        "label": "Contradiction"
    },
    "5119953d-f226-4e3d-96c9-a05862188b6d": {
        "text_answer": "Entailment for the given evidence  Explanation The statement neither the primary nor the secondary trial reported any cases of infection asymmetry or nausea is an entailment based on the given evidence because the evidence does not report any cases of infection asymmetry or nausea in either trial",
        "label": "Entailment"
    },
    "e0393f5c-7dec-4018-8917-b055823aec4b": {
        "text_answer": "Contradiction The statement does not entail the evidence as it mentions stage 4 invasive carcinoma which is not included in the evidences inclusion criteria which only includes DCIS or stage IIII invasive carcinoma",
        "label": "Contradiction"
    },
    "24e662f6-3ac7-489b-91fa-890994a805b4": {
        "text_answer": "Contradiction The evidence does not indicate that the clinical trial is limited to Hispanic patients",
        "label": "Contradiction"
    },
    "f4cf0fc1-5b69-49a1-8ba6-454063ff63ce": {
        "text_answer": "Entailment given that no thromboembolic events were reported in either trial",
        "label": "Entailment"
    },
    "349365cf-1c22-4e72-b321-b15b505e50cb": {
        "text_answer": "Contradiction The primary trial does not provide information about the change in Ki67 expression in tumors but the statement makes a claim about both trials",
        "label": "Contradiction"
    },
    "14632f5e-6eb4-4771-9567-cbde0f19c4af": {
        "text_answer": "Irrelevant The statement does not relate to the provided evidence",
        "label": "Entailment"
    },
    "c648cc67-b490-4cfe-be5e-4706b94ac0df": {
        "text_answer": "Contradiction  Explanation The statement mentions neither unexpected deaths nor hospital stays in both trials but the evidence for the primary trial does not provide information about unexpected deaths or hospital stays Therefore it is not possible to determine if the statement is an entailment or contradiction based on the given evidence alone for the primary trial However for the secondary trial the evidence does show that there were no hospital stays reported but it does not mention anything",
        "label": "Contradiction"
    },
    "8b9a4f04-25f6-45d2-a4fe-52e5bd3d22de": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 patients receive 1 mgkg of MCS110 every 3 weeks which is less than 20 mg every 3 weeks In Intervention 2 patients receive 3 mgkg of MCS110 every 3 weeks which is more than 20 mg every 3 weeks but the statement does not mention anything about the dosage",
        "label": "Contradiction"
    },
    "6cce2cb8-3ed9-40e9-a412-cb75b688ac59": {
        "text_answer": "Entailment  Explanation Both trials include patients who are 18 years of age or older",
        "label": "Entailment"
    },
    "1649a4de-bc0d-4908-88ac-515b88be60b3": {
        "text_answer": "Contradiction The primary trial reported no adverse events at all while the secondary trial reported that less than 30 of patients experienced adverse events which is not the same as reporting no adverse events",
        "label": "Contradiction"
    },
    "5784fb28-1da8-483c-a56b-61b68fb2a8f5": {
        "text_answer": "Contradiction The primary trial defines each treatment cycle as 21 days which is not the same as a onemonth intervention cycle The secondary trial does not specify the length of its intervention cycles",
        "label": "Contradiction"
    },
    "0b4536c8-2868-4d1a-bc26-d16b31eed34f": {
        "text_answer": "Contradiction The primary trial includes patients with an ECOG score of 02 while the secondary trial includes patients with an ECOG score of 02 or Karnofsky score of 60100 Therefore patients with an ECOG score of 4 are not eligible for either trial",
        "label": "Contradiction"
    },
    "2dce1806-9ce1-4448-9888-052def540a43": {
        "text_answer": "Contradiction The statement a single psychiatric adverse event was reported in the primary clinical trial affecting fewer than 10 of the patients is a contradiction to the evidence as there were two psychiatric adverse events reported suicidal ideation and one unspecified psychiatric event and the total number of patients was 50",
        "label": "Contradiction"
    },
    "e6bbed17-0fdf-4008-b56e-4d901490ce1a": {
        "text_answer": "Contradiction The primary trial shows a small difference in pCR rates between the two cohorts while the secondary trial shows a much larger difference in favor of Arm 2",
        "label": "Contradiction"
    },
    "be50f0ae-0c2b-42be-9306-78a1da6b4e09": {
        "text_answer": "Contradiction The primary trial does not mention any height restrictions while the secondary trial imposes a height requirement",
        "label": "Contradiction"
    },
    "79cd8b63-fe24-4e8b-9a15-0e054fb09dba": {
        "text_answer": "Contradiction The primary trial measures changes in MYMOP score but the secondary trial does not",
        "label": "Contradiction"
    },
    "367bc142-7412-43c6-b946-6127aff25f9a": {
        "text_answer": "Contradiction  Explanation The statement is about primary tumor size reduction which is not mentioned in the provided evidence The evidence only discusses the percentage change in betaCTX levels for each group",
        "label": "Contradiction"
    },
    "4087e09b-d0a1-4c3a-8411-b1938bf51b95": {
        "text_answer": "Contradiction The evidence shows that there were unfavorable incidents reported in both trials so it cannot be true that more than 97 of participants experienced no unfavorable incidents",
        "label": "Contradiction"
    },
    "7df6c8c9-fb22-4197-aba7-d6540a691eec": {
        "text_answer": "Contradiction The primary trial uses change in units on a scale as its unit of measure for the outcome measurement while the secondary trial uses percentage of participants and time frame as its units of measure There is no mention of cm or number of participants in the primary trial evidence and there is no mention of years or participant BMI in the secondary trial evidence",
        "label": "Contradiction"
    },
    "5cd571da-1a17-4513-b0b8-7ef1ced9a52f": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the statement suggests that the doses of ALT801 are higher in the primary trial but according to the evidence the doses of PF06647020 not ALT801 are different between the primary and secondary trials",
        "label": "Contradiction"
    },
    "3805ddb3-dbdf-4f10-8434-271503114961": {
        "text_answer": "Contradiction The statement is a contradiction because the primary trial includes both male and female participants while the secondary trial also includes male participants Therefore gender does not dictate eligibility for one trial but not the other",
        "label": "Contradiction"
    },
    "79385974-de52-4d05-b6b1-dc1086d484d9": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not mention hypothyroidism in either trial",
        "label": "Contradiction"
    },
    "f6f6058f-688b-4ce6-8fec-612f57b1f3ec": {
        "text_answer": "Contradiction The primary trial specifically states that the breast tumor should be 1 cm in diameter not 100 mm",
        "label": "Contradiction"
    },
    "df0234b5-3b00-4036-ac6c-5cb2d1eeafdf": {
        "text_answer": "Entailment Both Intervention 1 and Intervention 2 in the secondary trial involve the use of MLN8237 in entericcoated tablets",
        "label": "Entailment"
    },
    "448df56a-bcc3-491e-8626-dc8d439013b2": {
        "text_answer": "Contradiction The evidence states that there were no fatalities in the second cohort of the primary clinical trial",
        "label": "Contradiction"
    },
    "4872d505-a3f8-44bb-a023-aa41e27b49b3": {
        "text_answer": "Contradiction  The statement is about primary tumor diameter reduction in the AZD0530 100 mg group compared to the Zoledronic Acid 40 mg group while the evidence provided is about percentage change in betaCTX levels in the AZD0530 175 mg and Zoledronic Acid 4 mg groups These two pieces of information are not directly related and there is no mention of",
        "label": "Contradiction"
    },
    "b1b73c84-818f-40f9-8e6b-a749dc415b71": {
        "text_answer": "Entailment The statement one or more participants in the primary clinical trial experienced numerous adverse outcomes is an entailment of the evidence as the evidence shows that 5 out of 25 participants 2000 experienced adverse events",
        "label": "Entailment"
    },
    "4cd89e87-f0c1-4064-ab16-d945db457c41": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial intervention involves oral administration of cabergoline which is not mentioned in the statement and the secondary trial intervention involves intravenous administration of pixantrone dimaleate but the statement does not mention the mode of administration for the interventions in the trial",
        "label": "Contradiction"
    },
    "21031398-5d47-4ad9-ad19-16c790eaf061": {
        "text_answer": "Contradiction The evidence does not support the statement that patients in the primary trial survived on average over 10 years The given results show that the median survival for both groups was less than 3 years The statement about at least one patient from both cohorts dying in under 24 hours is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "b45f25ba-463e-458a-9e48-edd0d50bc6cb": {
        "text_answer": "Entailment The evidence states that cohort 1 of the primary trial reported 0 adverse events which is consistent with the statement that no adverse events were reported",
        "label": "Entailment"
    },
    "7a5cbc82-ec49-44f5-9c95-4c6475f3ee3e": {
        "text_answer": "Entailment  Explanation The primary trial includes women with locally advanced ER breast cancer who are eligible for mastectomy as a treatment option as stated in the secondary trial criteria Therefore the statement is an entailment as the secondary trial criteria are a subset of the primary trial criteria",
        "label": "Entailment"
    },
    "640ffbc4-cf15-4ab2-bf90-620e815f2694": {
        "text_answer": "Contradiction  The evidence does not provide sufficient information to determine if more than 50 individuals from each cohort lived for more than the average lifespan witnessed in the study participants The evidence only reports the median survival for each cohort",
        "label": "Contradiction"
    },
    "e5f60086-55a3-4432-9e9d-74690054db5d": {
        "text_answer": "Contradiction The primary trial includes a minimum primary tumor diameter of 2 cm while the statement mentions a primary tumor diameter of 33 mm which is not in line with the primary trials inclusion criteria",
        "label": "Contradiction"
    },
    "648ed723-14eb-4c58-85f9-9a6f6089b493": {
        "text_answer": "Contradiction The primary trial assesses the severity of delayed nausea using a pain scale while the secondary trial measures the change in bone mineral density of the lumbar spine over a 9month period These are two distinct outcomes and are not directly comparable",
        "label": "Contradiction"
    },
    "641b6edf-2ed6-494a-9d37-7c7f04ccd6a0": {
        "text_answer": "Contradiction The statement is not supported by the evidence provided as the evidence only reports data on the change in betaCTX levels and does not provide information on primary tumour diameter",
        "label": "Contradiction"
    },
    "fb13dfb3-66cd-45f6-98a8-c0712283954f": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence as the evidence does not provide any information about the types of cancers or interventions related to spinal cord glioma",
        "label": "Contradiction"
    },
    "599e8d04-e80f-4f54-9486-bcf5a39a1d37": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy while the secondary trial does not involve radiation therapy at all Additionally the statement mentions that both cohorts of the secondary trial receive 1000 mg of fulvestrant in a tablet form to be taken bid but the evidence shows that the dosing of fulvestrant in the secondary trial is different with one cohort receiving 500 mg QD and the other receiving 25",
        "label": "Contradiction"
    },
    "a11f4223-9416-4cf8-8712-ebbddf8c4353": {
        "text_answer": "Contradiction The evidence shows that in both trials fewer than 1 of participants had adverse events and none of those events occurred in more than 30 of participants",
        "label": "Contradiction"
    },
    "d0fe5818-5954-41ea-9bcf-4ce7deba5ceb": {
        "text_answer": "Contradiction  The secondary trial has an exclusion criterion for an allergy to cephalosporin or trimethoprimsulfamethoxazole but it does not mention anything about celecoxib The primary trial on the other hand has an exclusion criterion for an allergy to celecoxib but does not mention anything about cephalosporin or trimethoprimsulfam",
        "label": "Contradiction"
    },
    "89c78515-344a-4974-a01f-de5a0441ada0": {
        "text_answer": "Contradiction The evidence states that adequate liver function is an inclusion criterion for the primary trial",
        "label": "Contradiction"
    },
    "277b5179-05cc-48df-8f23-98b42ccad0b9": {
        "text_answer": "Contradiction   The primary trial administers its intervention orally PO while the secondary trial administers its intervention orally as well PO BID for both arms Neither trial involves intravenous IV nor topical administration",
        "label": "Contradiction"
    },
    "46278ed1-1bc8-4161-b9d9-9f5a001b6aac": {
        "text_answer": "Contradiction  The primary trial includes patients with benign breast disease while the secondary trial includes patients with a history of breast cancer including ductal carcinoma in situ These are different patient populations so the statement is a contradiction",
        "label": "Contradiction"
    },
    "0967b501-90dd-4ba4-bebc-8db1e9695431": {
        "text_answer": "Contradiction The primary trial inclusion criteria state that potential participants must have no evidence of dementia which Alzheimers disease is a type of dementia Therefore Alzheimers patients are not eligible for the trial according to the given evidence",
        "label": "Contradiction"
    },
    "256c210a-d33f-4708-8d86-2cb636227c4d": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions infection asymmetry and nausea but none of these adverse events were observed in the secondary trial according to the provided evidence",
        "label": "Contradiction"
    },
    "55c933c1-1de0-4a15-9a17-e1216cb84b4b": {
        "text_answer": "Contradiction The primary trial uses the Karnofsky score while the secondary trial uses the Zubrod performance status While both scales assess performance status they are not interchangeable and have different scoring ranges Symptom interference with life score 10 is not mentioned in either trials inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "0c73bdd4-7244-433c-8b5e-bf335f21701c": {
        "text_answer": "Contradiction  Explanation The statement mentions an eating disorder and Schizophrenia but the evidence only mentions suicidal ideation as a psychiatric adverse event Neither eating disorders nor Schizophrenia are mentioned in the evidence",
        "label": "Contradiction"
    },
    "dbd5f70e-0fa9-4b5e-af0e-0ad9efc49bc6": {
        "text_answer": "Entailment The evidence provided does not mention any interventions involving Xrays ultrasound CT scans or MRIs in either the primary or secondary trials",
        "label": "Entailment"
    },
    "316e0b04-f14e-47cd-b847-6af5add81e4e": {
        "text_answer": "Entailment The evidence shows that both trials have accounts of adverse events even if the numbers are not provided for Adverse Events 2 in the primary trial",
        "label": "Entailment"
    },
    "9c8c3b78-d272-4ce9-947b-f9283c79e818": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports the percentage of patients who experienced adverse events in each cohort and there is no mention of shortness of breath or any other respiratory symptoms",
        "label": "Contradiction"
    },
    "c76fe4c2-5f55-4e85-8528-943d90e99dd0": {
        "text_answer": "Contradiction The evidence for the primary trial does not state that 18 year olds are excluded it only states that they are not specifically included in the given inclusion criteria",
        "label": "Contradiction"
    },
    "555d74d4-755a-44b9-9bec-f8adda634c38": {
        "text_answer": "Contradiction The statement is not an entailment as a patient with a dry mouth due to difficulty chewing food would not be excluded from either trial based on the provided inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "c21d49da-c66f-45cc-af8a-22174568d0dd": {
        "text_answer": "Entailment The statement is entailed by the evidence as more than 13 of the participants in both cohorts experienced pCR in the breast and axillary lymph nodes",
        "label": "Entailment"
    },
    "5d0a21d6-cf35-48c3-9128-9d3f9cd03d23": {
        "text_answer": "Contradiction The primary trial had adverse events such as Dehydration Death Not Associated with CTCAE Death NOS Lymphopenia Neutropenia Thrombocytopenia Hyponatremia and Weight loss while the secondary trial had only Thromboembolic Event These are not the same adverse events",
        "label": "Contradiction"
    },
    "04b2b1f2-5d87-4b89-8fcd-c1c988bd22de": {
        "text_answer": "Entailment  Explanation The statement across the primary clinical trial and the secondary clinical trial it was recorded that there were no deaths in the adverse events is an entailment based on the evidence provided In both trials the total number of deaths reported in the adverse events was 0",
        "label": "Entailment"
    },
    "5902b596-40d0-4be7-8242-f313f6832fec": {
        "text_answer": "Contradiction The primary trial excludes patients with allergies to celecoxib or levofloxacin while the secondary trial does not mention any specific inclusion or exclusion criteria related to these medications Therefore the statement that patients with a documented allergy to celecoxib and levofloxacin can enroll in both trials is contradictory to the evidence provided",
        "label": "Contradiction"
    },
    "d0691186-857a-4876-8f49-732e033a86c7": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as there is no information given in the trial results regarding the number of treatment emergent adverse events or serious treatment emergent adverse events reported in each group",
        "label": "Contradiction"
    },
    "201c2df5-585d-4d20-a19b-c2b12db5dc5f": {
        "text_answer": "Contradiction Smokers are excluded from the primary trial and the statement does not mention that they are eligible for the secondary trial without specifying that they do not smoke",
        "label": "Contradiction"
    },
    "6cc1c5e4-b45a-486f-be8d-1c49abc327c9": {
        "text_answer": "Entailment The secondary trial uses lower doses of the drugs ALT801 compared to the primary trial PF06647020 based on the provided evidence",
        "label": "Entailment"
    },
    "705457d9-78b2-466d-9a3e-db4b11e99daa": {
        "text_answer": "Contradiction The evidence shows that no adverse events were recorded in both trials The statement is incorrect as it suggests that the secondary trial had more adverse events than the primary trial when in fact none were recorded in either trial",
        "label": "Contradiction"
    },
    "6f947c20-ecd9-4c6b-b1e3-5d536d4b33cd": {
        "text_answer": "Contradiction The evidence does not support the statement that all participants in the primary trial suffered a deterioration in cognitive function let alone that it was particularly true for the Ovarian Function Suppression group The evidence only reports the mean standardized units for the cognitive function composite score for the Tamoxifen and Ovarian Function Suppression groups and these means are negative indicating belowaverage results on average but it does not indicate that all participants in these",
        "label": "Contradiction"
    },
    "70dec4df-4dbd-41cc-ba31-6437c7058987": {
        "text_answer": "Contradiction  The evidence provided does not support the statement that there was an 11 higher percentage of participants in the ER Luminal B group who showed a decrease in the growth factor signature compared to the Triple Negative group The evidence only shows the percentage of participants in each group who demonstrated a decrease in the growth factor signature but it does not provide enough information to make a direct comparison between the two groups and determine if there is an 11",
        "label": "Contradiction"
    },
    "0f449a63-8d5d-4c60-96f8-bb32423f079d": {
        "text_answer": "Entailment Both trials report their results using the same units of measure and the statement explicitly states that they do",
        "label": "Entailment"
    },
    "2493a4e6-18a1-41c7-8feb-81928df2b542": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the placebo intervention and the AlloMSCs intervention are not administered in the same dose or even the same substance",
        "label": "Contradiction"
    },
    "80b0b7be-91b4-40ba-a4db-d19f0b1865d7": {
        "text_answer": "Contradiction  Explanation The statement suggests that cognitive function remained stable in one cohort and improved in the other cohort but the evidence only shows that the Tamoxifen group had a slightly worse cognitive function compared to the Ovarian Function Suppression group in the primary trial The evidence does not support the statement that cognitive function improved in one cohort while remaining stable in the other",
        "label": "Contradiction"
    },
    "8bd3b6aa-d1b5-4f4a-a16a-434d56764ee5": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as myocardial infarction is not listed as an adverse event in the provided evidence from the primary clinical trial",
        "label": "Contradiction"
    },
    "30f7d44a-34d9-4d98-9802-2c8a7c625e48": {
        "text_answer": "Entailment The primary trial includes patients with HR HER2 breast cancer and a tumor size of 1 cm or less which is a subset of the patients described in the statement The secondary trial includes patients with breast cancer of any size and HRHER2 status but the statement specifically mentions HR HER2 patients with a tumor size of 02 to 08 cm which is also included in the primary trial",
        "label": "Entailment"
    },
    "a98a4204-8591-48d3-9349-723b4ccc4f3c": {
        "text_answer": "Contradiction The primary trial excludes patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug or any other hemorrhagebleeding event NCI CTCAE v30 Grade 3 within 4 weeks of first dose of study drug A pulmonary embolism is a type of hemorrhagebleeding event",
        "label": "Contradiction"
    },
    "0d8ce6e1-e0bb-42b6-a8ec-0d2679b908ad": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there were no adverse incidents recorded in the secondary trial and only 0 adverse incidents were recorded in the primary trial according to the given evidence",
        "label": "Contradiction"
    },
    "10ae9352-5088-4431-8a48-a6891f5d03b7": {
        "text_answer": "Contradiction The evidence states that final eligibility for the clinical trial is determined by the health professionals conducting the trial contradicting the statement that a patients own decision serves as the final say about participation",
        "label": "Contradiction"
    },
    "c22306e0-54e6-4324-abed-0a38d9c7f1b9": {
        "text_answer": "Contradiction The primary trial reports results in percentage while the secondary trial reports results in number of participants",
        "label": "Contradiction"
    },
    "8747d88a-efc9-42ae-ba7c-5e25c8693b34": {
        "text_answer": "Entailment The evidence does not provide any information that contradicts the statement that pervasive pain was a common experience reported by patients throughout the full course of the primary clinical trial",
        "label": "Entailment"
    },
    "fdf14cde-dd7c-4b38-a127-5d857fb22bab": {
        "text_answer": "Contradiction The statement is not supported by the evidence as the evidence only reports the change in lean body mass from baseline to 4 months and does not provide information about the change over a 120 day period",
        "label": "Contradiction"
    },
    "d846c22f-adab-4189-b662-056541a723c2": {
        "text_answer": "Contradiction The statement is not an entailment as smokers are excluded from the primary trial regardless of their alcohol consumption while the secondary trial has no mention of smoking as an eligibility criterion",
        "label": "Contradiction"
    },
    "73981f59-887e-4778-a78a-0bf7b7a405b7": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence provided as both trials recorded zero adverse events",
        "label": "Contradiction"
    },
    "c4b6e4a0-1377-444e-853d-d62b67802ed2": {
        "text_answer": "Contradiction The primary trial does not mention surgical and imaging procedures in the intervention section",
        "label": "Contradiction"
    },
    "f9ab104f-3d67-4912-aaf5-bb43ecd0c52d": {
        "text_answer": "Contradiction Seminal vesicle cystadenoma is not a type of metastatic SCBC small cell breast cancer as stated in the evidence",
        "label": "Contradiction"
    },
    "40dd90a2-f57d-467e-bc6c-c9a8a50a330f": {
        "text_answer": "Entailment The statement is an entailment because both cohorts use the same instructional CD for paced breathing but the statement also accurately mentions the additional chemotherapy treatments for cohort 2",
        "label": "Entailment"
    },
    "7aef8aaf-9fc3-49b2-95e7-ed9b227cdd27": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided The primary trial involves the use of epacadostat and pembrolizumab while the secondary trial involves the use of sunitinib There is no comparison of the frequency of administration of pembrolizumab and sunitinib in the statement",
        "label": "Contradiction"
    },
    "4046d097-cbc9-48ef-9e90-d9a427fa6d19": {
        "text_answer": "Entailment  Explanation The statement wholly disparate drug treatments are incorporated in both the primary and secondary clinical trial is an entailment based on the evidence provided The primary trial involves the use of Abl Cells Cyclophosphamide and Fludarabine while the secondary trial involves the use of DMCHOCPEN These are indeed wholly disparate drug treatments",
        "label": "Entailment"
    },
    "126ef758-8ce5-4e45-859d-acece8b261e1": {
        "text_answer": "Contradiction The secondary trial did not document any cases of mucositis oral epileptic seizures or thromboembolic events",
        "label": "Contradiction"
    },
    "1aedac43-a4c7-4c14-b217-8d76e853c76f": {
        "text_answer": "Contradiction  The evidence states that patients receive Vorinostat during radiation therapy but it does not mention anything about receiving fentanyl sublingual spray during radiation therapy",
        "label": "Contradiction"
    },
    "40d1e2c2-9a6f-42a6-b75d-a67e9945a38d": {
        "text_answer": "Contradiction  Explanation The statement does not follow from the evidence as it makes no mention of the dosage of MCS110 or PDR001 received by patients in the trial The evidence only provides the dosages used in the trial",
        "label": "Contradiction"
    },
    "94935617-b333-4eb3-bd06-a5884fa45989": {
        "text_answer": "Contradiction The primary trial intervention involves Yttrium90 radioembolization using TheraSphere while the secondary trial intervention consists of administering ibrutinib and MEDI4736 orally",
        "label": "Contradiction"
    },
    "59b5ce7e-13af-4377-8923-c096f79bcade": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of chromosome band 16p1313p1312 in the evidence related to Infections and Fever cases",
        "label": "Contradiction"
    },
    "d53cf5fe-1104-4b05-886c-bb5499cdc047": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because the primary trial did not only record adverse events related to the musculoskeletal system as shown in the evidence provided The evidence indicates that the primary trial recorded adverse events related to the blood and bone marrow lymphatics and other systems as well In contrast the secondary trial recorded adverse events related to anemia plate",
        "label": "Contradiction"
    },
    "18876a8c-2536-4148-b563-c5a68daa7fac": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as there were no deaths recorded in the secondary trial according to the given data",
        "label": "Contradiction"
    },
    "f58fda4c-f4fd-44a7-8a0f-5d3a16929709": {
        "text_answer": "Contradiction The statement mentions a surgical incision reopened which is not explicitly stated in the evidence as an adverse event",
        "label": "Contradiction"
    },
    "105ed693-cbe0-47a4-ba39-f361032d9ed7": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the two cohorts do not receive the same dosage and frequency of Herceptin throughout the trial",
        "label": "Contradiction"
    },
    "db3d7616-8500-411a-9b43-b9b6e0925957": {
        "text_answer": "Contradiction The primary trial does not mention Adriamycin and Vincristine as interventions",
        "label": "Contradiction"
    },
    "f19797c7-afb1-4480-ab8f-c798a86d2849": {
        "text_answer": "Contradiction  The statement is not an entailment as the evidence indicates that only 53 of participants experienced a confirmed complete response CR in the primary trial",
        "label": "Contradiction"
    },
    "bea94e26-3706-492c-af45-d35ef7e43ff1": {
        "text_answer": "Neutral  Explanation The statement is not an entailment or a contradiction based on the evidence provided The evidence does not mention any adverse events related to clavicle fracture in either trial The statement is about a different condition clavicle fracture that is not mentioned in the evidence",
        "label": "Entailment"
    },
    "591e7319-16cd-46db-be86-7c78e8d471c8": {
        "text_answer": "Contradiction The statement implies that both trials use pCR as their benchmark and that there is a difference in results between the two trials with arm 2 of the secondary trial achieving superior results However the evidence provided shows that the pCR rates are lower in the primary trial compared to arm 1 of the secondary trial which contradicts the statements implication of superior results in the secondary trial",
        "label": "Contradiction"
    },
    "cbb4daf6-f35a-4832-b071-a17ffbe86e13": {
        "text_answer": "Contradiction The statement several adverse events occurred during the primary clinical trial and skin infections in the secondary clinical trial affected the majority of patients is a contradiction based on the evidence provided The primary trial had no reported skin infections while the secondary trial had only one reported skin infection The statement that several adverse events occurred during the primary clinical trial is true but the additional claim that skin infections in the secondary clinical trial",
        "label": "Contradiction"
    },
    "874a2beb-d0b1-4b5f-9f37-5b49ba5a1067": {
        "text_answer": "Contradiction  Explanation The statement concerning biliary colic and clostridium difficile colitis there is no difference in their occurrence between the primary and secondary trial is a contradiction based on the evidence provided The primary trial reported one case of biliary colic while the secondary trial reported none Similarly the primary trial did not report any cases of Clostridium difficile colitis while the secondary",
        "label": "Contradiction"
    },
    "21c183ca-7f70-4ddb-9599-d371ee544055": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence provided as the primary trial reported adverse events in 4545 of patients and the secondary trial reported adverse events in 1563 Neither trial reported over 97 of patients experiencing adverse events",
        "label": "Contradiction"
    },
    "5e93b7d7-89d9-47cd-98b4-5897823889fa": {
        "text_answer": "Contradiction The primary trial involves an imaging study using Fluciclatide injections while the secondary trial involves administering Chloroquine a different medication",
        "label": "Contradiction"
    },
    "452458d2-6372-4ac9-a7f9-0be77cc28eea": {
        "text_answer": "Entailment The statement is a description of the participants and vaccine used in the primary trial provided in the evidence",
        "label": "Entailment"
    },
    "97b0957c-3b60-4671-9c9d-37eacba40f93": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports adverse events in patients not related to any laboratory specimens including footfootpad",
        "label": "Contradiction"
    },
    "705e4626-c95b-4191-b9f1-02ae897cef70": {
        "text_answer": "Contradiction The primary trial involves oral pregabalin while the secondary trial involves intravenous liposomal cytarabine and highdose methotrexate",
        "label": "Contradiction"
    },
    "12f2ffff-1010-43bb-ac5d-5725d3d159b4": {
        "text_answer": "Contradiction The statement excludes patients who have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 730 days before study entry but the primary trial exclusion criteria state that any of these therapies are excluded if they are currently  4 weeks prior or planned",
        "label": "Contradiction"
    },
    "d8f0b3e8-ca61-4874-a4e0-1328029bce88": {
        "text_answer": "Contradiction The primary trial has specific inclusion criteria related to menopausal status and hot flushes which are not present in the secondary trial Therefore someone meeting the inclusion criteria for the secondary trial may not meet the inclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "9228fe22-ca97-4ca9-ad78-f8dba1ac27b0": {
        "text_answer": "Contradiction The primary trial does not include patients with resectable Nonsmall cell lung cancer or Small cell lung cancer in its inclusion criteria",
        "label": "Contradiction"
    },
    "8367e2fc-f384-43c0-af4e-d4ec41281b2e": {
        "text_answer": "Contradiction  Explanation The statement Most patients in cohort 1 of the primary trial suffered adverse events the inverse is true in cohort 2 is a contradiction based on the evidence provided The evidence shows that the percentage of patients with adverse events in cohort 1 is 4245 while in cohort 2 it is 680 The inverse of the statement for",
        "label": "Contradiction"
    },
    "fe73dc46-7c3a-45cd-a5fa-db03aa8dd28c": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as anorexia is not listed as an inclusion criterion in the primary trials eligibility criteria",
        "label": "Contradiction"
    },
    "723d5448-24c6-4679-98c1-3c67bb12fea4": {
        "text_answer": "Contradiction The evidence provided does not support the statement that patients with Eastern Cooperative Oncology Group ECOG performance status of limited selfcare capable of only limited selfcare confined to bed or chair more than 50 of waking hours are eligible for both the primary trial and the secondary trial The primary trial has no specific inclusion criteria related to ECOG performance status while the secondary trial includes ECOG 0",
        "label": "Contradiction"
    },
    "07f85ee2-4e95-4648-a492-4011837ddc7f": {
        "text_answer": "Contradiction The evidence does not provide any information about the number of participants or findings for the LBH589 and Lapatinib group",
        "label": "Contradiction"
    },
    "8bd62043-2cb9-42f0-80c1-2ec39020d9af": {
        "text_answer": "Contradiction The primary trial and the secondary trial evaluate different outcome measures The primary trial measures the number of participants with treatmentemergent adverse events while the secondary trial measures the median sleep time in minutes",
        "label": "Contradiction"
    },
    "b6b719ca-e7f3-4254-a1a0-2946acbcd2fd": {
        "text_answer": "Contradiction  Explanation The statement is about primary tumour diameter reduction which is not mentioned in the provided evidence The evidence only discusses the percentage change in betaCTX levels for each group",
        "label": "Contradiction"
    },
    "b88356ec-038f-4f5c-bf14-750059dbba4f": {
        "text_answer": "Contradiction The statement is not an entailment as Syncope was not the most commonly occurring adverse event across the patient cohorts of both trials In the primary trial Syncope occurred in 212 1667 of patients while in the secondary trial no cases of Syncope were reported",
        "label": "Contradiction"
    },
    "55d65365-bf85-4213-9ead-be1c498a4a72": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the primary trial participants receive only one injection at the study beginning while the secondary trial participants receive three weekly injections",
        "label": "Contradiction"
    },
    "36a25cf0-0cca-457d-bd85-8ba89b2ff602": {
        "text_answer": "Contradiction The statement is not an entailment as the daily doses for breast cancer patients 1000 mcg and ovarian or peritoneal cancer patients 25 mcg are different",
        "label": "Contradiction"
    },
    "d432512b-0bb4-435c-b32c-7ae0564a63c8": {
        "text_answer": "Contradiction The evidence shows that 1000 of the participants in the PalbociclibLetrozole Australia Cohort experienced treatmentemergent adverse events while the statement suggests that only a small percentage of patients on Sunitinib  Docetaxel  Trastuzumab encountered treatmentemergent adverse events",
        "label": "Contradiction"
    },
    "9c74310c-3096-4eaf-bed2-aec926b5c850": {
        "text_answer": "Contradiction The evidence states that 897 of participants in the NaCl 09 3mL group experienced recurrencefree survival not 67",
        "label": "Contradiction"
    },
    "a855848e-4097-4755-90e0-e612f1bfc54c": {
        "text_answer": "Contradiction The primary trial did not report any cases of radiation dermatitis or hyperpigmentation while the secondary trial reported that more than 95 of participants in one group had radiation dermatitis and hyperpigmentation",
        "label": "Contradiction"
    },
    "70eac1ab-54b0-460d-abda-86f0c5d04483": {
        "text_answer": "Contradiction  Explanation  The statement patients experiencing unstable angina or who have undergone chemotherapy or radiotherapy within the last 2 weeks or are suffering from grade 2 or higher neuropathy are ruled out from the secondary clinical trial is a contradiction to the exclusion criteria of the secondary clinical trial  The exclusion criteria for the secondary clinical trial state that patients with a history of unstable",
        "label": "Contradiction"
    },
    "38e4b093-2121-486f-bcfb-d250ea9978e4": {
        "text_answer": "Contradiction The primary trial explicitly excludes children while the secondary trial does not mention anything about children being excluded",
        "label": "Contradiction"
    },
    "92fe4c4d-da02-4327-a2a1-86e731ba4fd9": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the dosages of carboplatin are different between the two cohorts AUC 2 vs not mentioned",
        "label": "Contradiction"
    },
    "8eb9d0d2-5c33-4ff6-adf6-e96ddf7be7a6": {
        "text_answer": "Contradiction The primary trial does not list pulmonary embolism as an exclusion criterion but the statement includes it for both trials",
        "label": "Contradiction"
    },
    "48b25d6c-3b89-425b-960e-9d55471a5f37": {
        "text_answer": "Contradiction  Explanation The statement implies that there were 0492 more participants in the ERpositive Luminal B group who demonstrated a decrease in the growth factor signature than in the Triple Negative group However the evidence provided does not support this statement as it only shows the percentage of participants with a decrease in the growth factor signature for each group but it does not provide the actual number of participants or the difference between the",
        "label": "Contradiction"
    },
    "53a45460-701f-420e-853a-f5ccb8545030": {
        "text_answer": "Contradiction The primary trial does not involve subcutaneous insulin injections or oral antiretroviral therapy ART as a treatment procedure The secondary trial involves intravenous and intrathecal chemotherapy treatments not oral antiretroviral therapy",
        "label": "Contradiction"
    },
    "79515622-bb43-4721-a164-dd2002713dc1": {
        "text_answer": "Contradiction  The evidence states that 833 of participants in the Ketorolac 30 mg group and 897 of participants in the NaCl 09 3mL group achieved Recurrencefree Survival after 5 years The statement however claims that only 120 participants in the NaCl 09 3mL group achieved Recurrence",
        "label": "Contradiction"
    },
    "ee42e602-9409-49fa-a454-7a2637ed9d7a": {
        "text_answer": "Contradiction The evidence does not support the statement as it indicates that no participants in the Normal Vitamin D Levels group exhibited noticeable trends in the expression of 40 studied genes",
        "label": "Contradiction"
    },
    "3109bf56-61b7-4f43-9e38-fa3b69378214": {
        "text_answer": "Contradiction The evidence provided for the primary and secondary trials does not mention anything about entericcoated tablets being administered to the participants The statement is about a different topic the presence or absence of a specific gene mutation which is not related to the information provided in the evidence",
        "label": "Contradiction"
    },
    "95f4ce83-19b7-424d-93b9-27a6c3fe8c6d": {
        "text_answer": "Contradiction The evidence states that participants in the primary clinical trial did receive talazoparib but the statement asserts that they did not",
        "label": "Contradiction"
    },
    "3acf4a18-725c-444e-bf7e-e3eb9a0878e7": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "9b230310-d16f-47a4-bf3b-341d2de6f9c4": {
        "text_answer": "Contradiction  Explanation The primary trial involves vaginal treatments with Estring and testosterone cream while the secondary trial involves acupuncture which is an external treatment but it is not an inhalable treatment Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "0b6e68b2-9f05-407b-bd00-feb9d3ce7abc": {
        "text_answer": "Contradiction The evidence does not support the statement that primary clinical trial participants were twice as likely to have cholelithiasis than those in the secondary clinical trial as there were no reported cases of cholelithiasis in either trial",
        "label": "Contradiction"
    },
    "f9f0ba74-16e0-4790-afa0-b7616b256e5e": {
        "text_answer": "Contradiction  Explanation The primary trial does not have a specific inclusion criterion related to performance status whereas the secondary trial includes it as an inclusion criterion Therefore the statement is a contradiction",
        "label": "Contradiction"
    },
    "88e8a071-e139-4547-9fd8-f3311d0770ef": {
        "text_answer": "Contradiction The primary trial requires a primary tumor greater than 2 cm in diameter while the statement describes a primary tumor with a diameter of 0033m which is significantly smaller than the minimum requirement for the primary trial",
        "label": "Contradiction"
    },
    "00c165f5-4c14-4aab-a4a8-9b8010bd5858": {
        "text_answer": "Contradiction The primary clinical trial only includes females who are postmenopausal or have had a hysterectomy with intact ovaries and are age 55 or older while the secondary clinical trial only includes women",
        "label": "Contradiction"
    },
    "330f241a-9f7d-469d-8986-5687fdd5fb70": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the trials use different drugs dosages and frequencies but the statement does not necessarily contradict the evidence as both trials involve IV injections and MRIs",
        "label": "Contradiction"
    },
    "bca3c321-d798-427d-90a7-8c786d91947c": {
        "text_answer": "Contradiction  The patient described in the statement does not meet the inclusion criteria for both trials In the primary trial the patients ANC level is below the required minimum of 1800 cellsmm3 and the hemoglobin level is below the required minimum of 80 gdl In the secondary trial the patients ANC level is below the required minimum of 1500μ",
        "label": "Contradiction"
    },
    "0a7569de-fb79-41f8-acc6-fd155a26e3c8": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as the evidence does not mention anything about ulnar length or pulmonary embolisms in relation to the inclusion or exclusion criteria for the primary or secondary trials",
        "label": "Contradiction"
    },
    "7d57f1d1-e523-4220-95a9-f4ce33d7f157": {
        "text_answer": "Contradiction  Explanation  Although the primary and secondary trials have some differences in their inclusion criteria they do share some similarities For instance both trials include patients who are 18 years of age or older and require signed informed consent forms  However the statement provided asserts that the inclusion criteria for the secondary trial are completely different from those of the primary trial This is not accurate based on the evidence provided  For example",
        "label": "Contradiction"
    },
    "0348dacb-819e-4e1f-98c3-d45d6c057f60": {
        "text_answer": "Contradiction The statement mentions Postmenopausal adenocarcinoma as a condition that would exclude someone from participating in the trial but the primary trials inclusion criteria specifically state that it is for postmenopausal breast cancer adenocarcinoma patients However the statement also includes conditions that are not in the primary trials exclusion criteria such as a history of stroke transient ischemic attacks and",
        "label": "Contradiction"
    },
    "bcbc612f-11c9-40ba-9376-c098a9b738f4": {
        "text_answer": "Contradiction The secondary trial does not measure muscle growth as an indicator of physical therapys effectiveness but rather measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale",
        "label": "Contradiction"
    },
    "d035a6bb-0d8f-4a6b-b725-f8b2535883eb": {
        "text_answer": "Contradiction The evidence describes interventions with paced breathing at 6 breathsmin for 15 minutes once or twice daily and for 8 weeks There is no mention of the patients in the primary trial utilizing the focused breathing instructional audio guide thrice daily or not undergoing regular chemotherapy sessions",
        "label": "Contradiction"
    },
    "a8760238-f938-4525-bd13-ecb0948de8bc": {
        "text_answer": "Entailment assuming myelosuppressive therapy is a form of drug therapy  Explanation The evidence provided states that neither cohort of the primary trial receives any drugs in the interventions Myelosuppressive therapy is a form of drug therapy that decreases the rate of blood cell production in the bone marrow Therefore the statement that neither cohort receives any drugs radiotherapy or CBT in the interventions entails",
        "label": "Entailment"
    },
    "ad24cf4c-11da-465c-b008-ba96dc8bcdd4": {
        "text_answer": "Contradiction  Explanation  The statement patients exhibiting a documented hypersensitivity to cephalosporin or trimethoprimsulfamethoxazole will be excluded from the secondary clinical trial while those allergic to levofloxacin or celecoxib will not qualify for the primary clinical trial is a contradiction because  1 The primary clinical trial and the secondary clinical trial are",
        "label": "Contradiction"
    },
    "04dfaa5a-359d-4aba-a56d-4b19f041ce39": {
        "text_answer": "Contradiction The statement is not related to the given evidence as it mentions thick filament is a myofilament composed of myosin which is not mentioned in the inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "103134aa-c3f2-4ebb-8919-72bdb5611b07": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were adverse events reported in the secondary trial while the statement asserts that there were no adverse events reported in both trials",
        "label": "Contradiction"
    },
    "bca56f4d-9c3c-4615-8b56-3f6ca86d047b": {
        "text_answer": "Contradiction  Explanation The statement suggests that both interventions alloMSCs and placebo are delivered using a single transendocardial injection but the evidence shows that each intervention alloMSCs and placebo receives 20 transendocardial injections of 04ml each",
        "label": "Contradiction"
    },
    "82e2e80d-2a88-4d12-82a9-4d77d1bf0bb6": {
        "text_answer": "Contradiction The primary trial results do not provide any information about the appetite or food enjoyment of the participants The statement is not related to the evidence presented",
        "label": "Contradiction"
    },
    "be3df611-66ac-4f40-ae04-68b5d1c0ae02": {
        "text_answer": "Contradiction The primary trial includes only female patients with HER2negative breast cancer who have progressed during or following firstline treatment with Avastin and chemotherapy while the secondary trial includes only female or male patients with newly diagnosed ERpositive HER2negative breast cancer These are distinct patient populations",
        "label": "Contradiction"
    },
    "23f84ae0-fd01-4799-8872-118e22a015e8": {
        "text_answer": "Contradiction  The statement Only three different types of adverse events affected patients in the primary trial Pancreatitis Cholelithiasis Hepatic pain and Febrile neutropenia is a contradiction to the evidence as the evidence shows that a total of 11 different types of adverse events were reported across both cohorts of the primary trial",
        "label": "Contradiction"
    },
    "972438ce-59d8-476c-a8a3-b61fba56e982": {
        "text_answer": "Entailment Both trials have 0 recorded adverse events according to the given evidence",
        "label": "Entailment"
    },
    "07687788-b44f-4f2a-9117-6b55cbdc3f7a": {
        "text_answer": "Entailment  Explanation Both trials involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine as a medication in their respective interventions",
        "label": "Entailment"
    },
    "9e1d8e36-9749-4f70-b0e3-d173892dfcd0": {
        "text_answer": "Contradiction The statement is not related to the provided evidence The evidence only discusses adverse events from clinical trials and does not provide any information about individuals being immigrants from high tuberculosis prevalent areas",
        "label": "Contradiction"
    },
    "e6d5d1ca-f1f6-481a-b309-78adf96e656c": {
        "text_answer": "Contradiction The primary trial requires a primary tumor greater than 2 cm diameter while the statement suggests a primary tumor with a radius of 3mm which is less than 2 cm",
        "label": "Contradiction"
    },
    "db52c7f4-cfb8-40d2-83f2-3514cb04794b": {
        "text_answer": "Contradiction  Explanation The statement cohort 1 patients in the primary clinical trial enjoyed a primarily favorable prognosis reflecting the same trend in cohort 2 is a contradiction based on the evidence provided The evidence shows that the percentage of adverse events in cohort 2 680 is significantly lower than that in cohort 1 4245 A lower percentage",
        "label": "Contradiction"
    },
    "82582964-823a-4765-b22c-201660fcca08": {
        "text_answer": "Contradiction The evidence provided does not indicate that women aged 30 or 35 are eligible for the secondary trial let alone that they would need to wait 56 years to be eligible for the primary trial The primary trial has different eligibility criteria including the absence of metastatic disease and a minimum life expectancy of at least 12 months which are not met by women with a history of cancer",
        "label": "Contradiction"
    },
    "bb9c00c0-3a87-41c2-bfb5-183f7b44fcbc": {
        "text_answer": "Contradiction The evidence provided does not include any information about patients using testosterone cream in the primary trial",
        "label": "Contradiction"
    },
    "260a9ba1-ca1b-4e87-83d1-b128e73e1e38": {
        "text_answer": "Contradiction The secondary trial has consistent inclusionexclusion criteria for all participants while the primary trial has different inclusion criteria for different age groups but there is no mention of radiation or charged particles in the given evidence",
        "label": "Contradiction"
    },
    "e04edb9d-dc0e-44c4-abb9-3260b400e265": {
        "text_answer": "Contradiction The primary trial measures the severity of vaginal symptoms using the Vaginal Symptom Measure VSM and the change in units on a scale while the secondary trial measures the objective response rate of HER2negative metastatic breast cancer using RECIST v10 and percentage of participants They do not use the same units of measure for their outcome measurements",
        "label": "Contradiction"
    },
    "64b3c727-779e-4db4-b1fe-1d85105ab7ec": {
        "text_answer": "Contradiction The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH in mIUml while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in mg These are different parameters and metric units",
        "label": "Contradiction"
    },
    "930e7529-e05a-471e-9d52-17f538f610c2": {
        "text_answer": "Contradiction The primary trial requires denosumab injections while the secondary trial does not involve any injections and instead uses lymphoscintigraphy",
        "label": "Contradiction"
    },
    "f0d10d18-11a3-4fae-9a4d-f2277f6e5b43": {
        "text_answer": "Contradiction The primary trial recorded no adverse events while the secondary trial recorded a high number of adverse events",
        "label": "Contradiction"
    },
    "4efeb043-de46-49cd-8d5d-c4266304fb91": {
        "text_answer": "Entailment The primary trial has a longer list of exclusion criteria compared to the secondary trial indicating more restrictive eligibility criteria",
        "label": "Entailment"
    },
    "8fd48918-38db-4443-a1b8-bf2d7a458857": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because there is no mention of anemia pneumonia stupor or high blood pressure in either the primary or secondary trials according to the provided data",
        "label": "Contradiction"
    },
    "5255cd06-123a-4d45-943d-37b6261b1cf7": {
        "text_answer": "Contradiction The evidence does not mention any cases of eating disorders in the primary clinical trial",
        "label": "Contradiction"
    },
    "e4f41907-ef20-40aa-bcab-416243280816": {
        "text_answer": "Contradiction  Explanation The statement mentions a 40 average reduction in tumor diameter while the evidence only shows a 40 average reduction in Ki67 expression which is a marker of cell proliferation and not directly related to tumor diameter",
        "label": "Contradiction"
    },
    "5976b8b7-0f88-4e52-8ad7-39609dabbf8e": {
        "text_answer": "Entailment  Explanation  The primary trial mentions the use of cyclophosphamide and paclitaxel in Intervention 1 and pegfilgrastim is mentioned as a supportive measure for chemotherapy  The secondary trial mentions the use of cyclophosphamide and paclitaxel in the neoadjuvant chemotherapy regimen and pegfilgrastim is mentioned as a supportive measure for chemotherapy in",
        "label": "Entailment"
    },
    "763a61cc-c267-4536-8cfe-a4f97a461e07": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of tumour lysis syndrome in either the primary or secondary clinical trials",
        "label": "Contradiction"
    },
    "8d685159-80a2-4b2c-8ca3-066d03e1cf66": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of Mucositis Oral epileptic seizures or Thromboembolic events in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "bc47f5a1-dc20-4df2-bb3e-fa03695c9840": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the patients in cohort 1 received Active Breathing Coordination and those in cohort 2 did not but both groups received the same duration of radiation therapy the doses were not varied",
        "label": "Contradiction"
    },
    "91b12db1-76c1-4863-90df-a95d2af8dfc5": {
        "text_answer": "Neutral The statement is not directly related to the inclusionexclusion criteria provided in the evidence",
        "label": "Entailment"
    },
    "699bf83a-8890-43ab-96ea-40f2171c9633": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the trials involve different interventions Alpha Lipoic Acid vs Necitumumab and the dosing regimens are not directly comparable",
        "label": "Contradiction"
    },
    "1b67d41e-cff6-46ae-b30d-4c254525e9ef": {
        "text_answer": "Contradiction The primary trial uses Zoledronic Acid 4 mg Q4W while the secondary trial does not mention the use of Zoledronic Acid",
        "label": "Contradiction"
    },
    "a35f8d94-b561-4644-ad29-2ac0e48ceb79": {
        "text_answer": "Contradiction The statement is not an entailment as the diagnosis of 23 cerebral metastases within the brainstem results in exclusion from the secondary trial not eligibility for the primary trial",
        "label": "Contradiction"
    },
    "477389de-84aa-4438-87c9-3abccc80e1cb": {
        "text_answer": "Contradiction The statement mentions more cases of FEBRILE INFECTIONs were recorded in the primary trial but the evidence shows that no febrile infections were recorded in either trial",
        "label": "Contradiction"
    },
    "f98c72d2-3fce-42a5-9585-280e8b877708": {
        "text_answer": "Entailment The evidence shows that a total of 16 participants in Arm 1 and 14 participants in Arm 2 achieved a pCR in breast and axillary lymph nodes which is a total of 30 participants out of 84 analyzed in both arms Therefore the statement is an entailment as it does not contradict the evidence and is within the range of the reported results",
        "label": "Entailment"
    },
    "14c1e784-1f79-4ba9-8466-c8c638f929db": {
        "text_answer": "Contradiction The primary trial had 4 participants and no adverse events were reported while the secondary trial had 1674 participants and no adverse events were reported as well but the statement assumes that all participants in both trials experienced an adverse event",
        "label": "Contradiction"
    },
    "1dfb4256-8bef-4128-8cd2-30d5c88a4ac8": {
        "text_answer": "Contradiction The statement suggests that 25 of all participants developed imagable HER2 metastases while the evidence indicates that 13 of the participants in one arm of the trial HER2targeted PETCT developed such metastases",
        "label": "Contradiction"
    },
    "8bdac388-c2bd-4634-9073-6862aaa7a5cf": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the maximum dosage for epirubicin is 100 mgm2 but the trial involves other drugs with different dosages",
        "label": "Contradiction"
    },
    "8529eb83-969c-4075-bfe7-efc47fd33d8d": {
        "text_answer": "Contradiction The primary trial includes breast cancer epithelial ovarian cancer or gynecological cancer head and neck squamous cell carcinoma nonsmall cell lung cancer small cell lung cancer platinumrefractory germcell tumors adenocarcinoma or carcinoma of unknown primary site but it does not mention pancreatic cancer as a required diagnosis",
        "label": "Contradiction"
    },
    "da8b6738-7194-4d9d-a077-a4aec72945bb": {
        "text_answer": "Entailment The evidence states that cohort 1 received a lower dose of Cetuximab than cohort 2 which is consistent with the statement The absence of a collaborative care intervention in cohort 1 is also consistent with the statement as it does not contradict it",
        "label": "Entailment"
    },
    "7f53b46f-6ab4-4d59-bc28-b13eca3fb3b3": {
        "text_answer": "Contradiction   The statement no patients in the primary clinical trial experienced recorded adverse events is contradictory to the evidence as the evidence shows that there were no recorded adverse events in the primary trial for the given data but it does not state that no patients experienced any adverse events outside of what was recorded The secondary trial data shows that every participant suffered from at least one adverse event but the primary trial data does not contradict that possibility",
        "label": "Contradiction"
    },
    "e2731b02-ce9d-4bfe-bc8d-9eda951e0e77": {
        "text_answer": "Contradiction The evidence states that concurrent use of gabapentin or pregabalin is not allowed in the secondary trial but it does not mention anything about their eligibility for the primary trial",
        "label": "Contradiction"
    },
    "9c8b2041-2a99-4f42-93ec-63daed05fe87": {
        "text_answer": "Contradiction  Explanation The primary clinical trial includes patients with stage IIbIIIIV breast cancer but the secondary clinical trial only includes patients with a life expectancy of at least 1 year excluding their diagnosis of cancer Therefore patients diagnosed with stage 4 cancer would not meet the inclusion criteria for the secondary clinical trial and thus cannot participate in both trials at the same time",
        "label": "Contradiction"
    },
    "5c7ff5f0-5b40-42e1-8f24-a0bfd6a4b2ef": {
        "text_answer": "Entailment The evidence states that both study groups undergo the same PETCT imaging procedures using both 18FFDG and 18FFPPRGD2",
        "label": "Entailment"
    },
    "e32de0e0-4e26-4c73-a6d6-cc5dfafd97c7": {
        "text_answer": "Contradiction  The evidence shows that in the primary trial 013 000 patients in cohort 1 and 14 2500 patients in cohort 2 suffered from increased pleural effusion However the statement claims that 25 of patients in the primary trial suffered from both increased pleural effusion and rapid disease progression which is not supported by the evidence",
        "label": "Contradiction"
    },
    "f4f39eeb-0db1-40c3-9d45-5c17dabe4998": {
        "text_answer": "Contradiction The evidence does not support the statement as it indicates that the median survival for both groups was less than 25 years and there is no information provided about the number of patients surviving beyond 24 months",
        "label": "Contradiction"
    },
    "ab25ad81-a094-432c-9814-12669bd4cbac": {
        "text_answer": "Contradiction The genetic mutations listed are a requirement for eligibility in the primary trial but they are also listed as inclusion criteria in the secondary trial",
        "label": "Contradiction"
    },
    "98b0c6c3-73c0-40d9-95d7-48e5340aa2f8": {
        "text_answer": "Contradiction  Explanation  The primary trial uses lenalidomide 5mg orally daily for 57  3 days while the secondary trial uses oral lapatinib 1500mg daily for 6 weeks The doses and durations are not the same for lenalidomide in the two trials",
        "label": "Contradiction"
    },
    "fcc8d86f-3fba-4398-8c0e-042153fa118e": {
        "text_answer": "Contradiction The primary trials Intervention 2 does not cause a decrease in bone tissue but rather administers dexmedetomidine which is not mentioned in the statement The secondary trials Intervention 2 is about vitamin D repletion and does not involve any myalgias or bone tissue decrease",
        "label": "Contradiction"
    },
    "99912ce1-aa49-4289-8743-eb1afffe1675": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement is about medullary thyroid gland carcinoma occurring in childhood while the evidence only reports the absence of any adverse events including medullary thyroid gland carcinoma in the primary trial The statement does not entail or contradict the evidence as it does not make a claim about the primary trial specifically",
        "label": "Entailment"
    },
    "8c5d8cfb-c75f-4cb8-af4a-8100726f2a12": {
        "text_answer": "Contradiction The evidence provided does not support the statement as it only reports the median survival for each group and does not provide information on the number of patients living past 12 months",
        "label": "Contradiction"
    },
    "09904e7f-5e34-44b1-9edb-f92c3edcda95": {
        "text_answer": "Entailment assuming the control group in the secondary trial refers to the standard mammography group in the primary trial  Explanation The statement entails that the operative time in the test group arm 2 of the primary trial was shorter than in the control group arm 1 and that there is a control group in the secondary trial for comparative studies The evidence provided in the text supports this statement as it shows that the median operative time was",
        "label": "Entailment"
    },
    "3b1906b0-5212-4341-b6cd-3163456ce44a": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the administration of denosumab which is a medication while the secondary trial involves the administration of radioactive Tc99M sulfur colloid which is a different type of substance used for lymphoscintigraphy The two interventions are not the same and cannot be directly compared based on the given information",
        "label": "Contradiction"
    },
    "a24e8008-affe-44f7-a6f1-56e817ffdde3": {
        "text_answer": "Contradiction  Explanation The statement is contradictory to the evidence because the evidence shows that there were adverse events AEs recorded in both trials including one case of lymphoma in the secondary trial The statement implies that there were no AEs at all which is not supported by the evidence",
        "label": "Contradiction"
    },
    "c5534047-9025-410f-a641-43819cc1ce23": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of substance dispersity in the evidence The evidence only provides information about adverse events in the two trials",
        "label": "Contradiction"
    },
    "12746144-95c9-4656-abdf-8a49f78c7049": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence pertains to the inclusion and exclusion criteria for a clinical trial related to breast cancer treatment while the statement is about pay increases promotions and recognition at work",
        "label": "Contradiction"
    },
    "e8d33476-b6f1-4337-8072-c07e4f223275": {
        "text_answer": "Contradiction The evidence describes two different interventions in the primary trial one with additional therapeutic treatments Fludarabine Cyclophosphamide Cyclosporine Natural Killer cells and Interleukin2 and the other without only CUDC101",
        "label": "Contradiction"
    },
    "24630f41-fd07-4b3d-a0f6-66282c5c3a07": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there are no reported adverse events in the primary trial and only 000 reported in the secondary trial The statement implies a higher percentage in the secondary trial compared to the primary trial",
        "label": "Contradiction"
    },
    "b3f59657-9278-41be-b740-433b0d38fdd5": {
        "text_answer": "Entailment  Explanation The statement Patients with TX NX MX T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial is an entailment based on the evidence provided in the trial description The trial includes patients with histologically confirmed breast cancer meeting certain criteria including T and N stages The statement specifically lists Tx Nx Mx T0 Nx M0 and T",
        "label": "Entailment"
    },
    "956a23c9-f76f-4492-9f00-acdbaf6ac083": {
        "text_answer": "Contradiction  Explanation  The statement The majority of the adverse events recorded in the primary trial were blood and bone marrow related this is not the case for the secondary trial is a contradiction based on the evidence provided  In the primary trial all adverse events were related to blood and bone marrow while in the secondary trial only 3 out of 9 adverse events were related to blood and bone marrow",
        "label": "Contradiction"
    },
    "b45a503d-d4db-4f8d-aefa-37cf2bbc6011": {
        "text_answer": "Contradiction  Explanation The statement among the participants of the primary clinical trial maculopapular rash was often reported as an adverse event is a contradiction to the evidence as maculopapular rash was reported only once in the evidence",
        "label": "Contradiction"
    },
    "a1d9b33e-fe46-421d-87e8-e0ecbfed7686": {
        "text_answer": "Contradiction The primary trial does utilize alterations in the MYMOP score as its method of assessing study outcomes",
        "label": "Contradiction"
    },
    "136bc454-b432-45f9-909b-e588f2dc6c60": {
        "text_answer": "Contradiction  The evidence shows that 381 of participants in Arm 1 and 333 of participants in Arm 2 had a pathologic complete response in breast and axillary lymph nodes",
        "label": "Contradiction"
    },
    "9f382aed-4a54-40c2-92ca-fb17411e4923": {
        "text_answer": "Contradiction The primary trial involves denosumab injections while the secondary trial involves injections of radioactive Tc99M sulfur colloid They are not the same intervention",
        "label": "Contradiction"
    },
    "1d66b8cc-1e7e-4a88-bd39-695528aa5894": {
        "text_answer": "Contradiction The primary trial includes patients with normal organ and marrow function which does not include any sleep disorders or insomnia mentioned in the statement The secondary trial specifically includes patients with a score of 3 on the Sleep Disruption Evaluation form or a score of 8 on the Insomnia Severity Index indicating the presence of insomnia However mild insomnia is not explicitly mentioned in either inclusion criteria so it is unclear",
        "label": "Contradiction"
    },
    "f9a8b80a-3191-4f53-865b-1ab2154174ad": {
        "text_answer": "Contradiction  The statement mentions months after highdose chemotherapy but the evidence only provides data for the number of participants with a decline in CTCs at one month posttransplant",
        "label": "Contradiction"
    },
    "d3ccfad5-d5c9-4bdb-a69e-dca916dc5da5": {
        "text_answer": "  Entailment for the Primary Trial and Contradiction for the Secondary Trial  Explanation  The statement is an entailment for the Primary Trial because the patients ANC platelet count hemoglobin level and life expectancy meet the inclusion criteria for the Primary Trial  However the statement is a contradiction for the Secondary Trial because the patients age",
        "label": "Entailment"
    },
    "0cecee52-d87e-419a-a970-e79733613a87": {
        "text_answer": "Contradiction The evidence does not state that only Caucasian patients are eligible for the primary clinical trial",
        "label": "Contradiction"
    },
    "f4d73533-5e6a-403c-ad63-3882890b7e94": {
        "text_answer": "Contradiction The statement contradicts the evidence as the evidence shows that there are no adverse events recorded in the primary trial while the statement implies that a comparison cannot be made due to the lack of recording in both trials",
        "label": "Contradiction"
    },
    "be63170c-5a52-4d85-b824-54ceca90684a": {
        "text_answer": "Contradiction  The primary trial does not mention claustrophobia as an exclusion criterion while the secondary trial does not mention IBS Irritable Bowel Syndrome as an exclusion criterion The statement combines these two conditions for women being disqualified from both trials which is not supported by the evidence",
        "label": "Contradiction"
    },
    "cb36e435-6dc9-4e7b-939b-9da6ceef2a49": {
        "text_answer": "Entailment The placebo is administered as a 3hour intravenous infusion on Day 1 every 21 days but the statement only mentions the method of administration 3hour intravenous infusion and not the frequency However the statement about Trabectedin being administered as a 3hour intravenous infusion on Day 2 every 21 days also supports the statement making it an entailment",
        "label": "Entailment"
    },
    "7c0a99c5-b76f-438c-a93b-15d3340cd430": {
        "text_answer": "Contradiction  Explanation The statement the outcome from the bevacizumab  capecitabine cohort of the primary clinical trial were superior to those of the bevacizumab cohort is a contradiction based on the evidence provided The evidence shows that the percentage of participants with disease progression or death in the Bevacizumab  Capecitabine cohort 758",
        "label": "Contradiction"
    },
    "383e310f-a7a5-49f5-ae10-ddf49eee92df": {
        "text_answer": "Contradiction The primary trial does not have any specific inclusion criteria related to a patients ability to selfcare or the amount of time they spend confined to a bed or chair",
        "label": "Contradiction"
    },
    "429f2754-6edc-4969-99f3-7507b76e443a": {
        "text_answer": "Contradiction The primary and secondary trials measure different outcome metrics so it is not possible to directly compare the results and make such a statement based on the evidence provided",
        "label": "Contradiction"
    },
    "f2b4adf3-ccbc-4bea-94a6-50887d7aeea0": {
        "text_answer": "Contradiction The evidence shows that the median survival for both groups was over 2 years",
        "label": "Contradiction"
    },
    "da91286b-3029-475f-a919-e33629a5a972": {
        "text_answer": "Contradiction The statement is not directly related to the evidence provided which only mentions adverse events and their frequencies The statement about the microscopic findings supplemental qualifiers dataset is not mentioned or related to the adverse events in the evidence",
        "label": "Contradiction"
    },
    "dbf8020d-57c3-45fb-ab31-5c97f293a248": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction to the evidence provided in both trials The patient described in the statement does not meet the inclusion criteria for either trial due to having an absolute neutrophil count less than 1800 cellsmm3 a platelet count less than 60000 cellsmm3 and a hemoglobin level less than 80 g",
        "label": "Contradiction"
    },
    "d54a1b83-ecd6-4160-a839-1bddf6a12cc5": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial includes interventions given intravenously but none of the interventions in the secondary trial are given topically",
        "label": "Contradiction"
    },
    "c19b9a3f-acda-4e83-80db-0f4d3383d909": {
        "text_answer": "Contradiction  The statement implies a ratio of 21 for hepatotoxicity and hypertensionpancreatectomy but the evidence shows that there were 3 cases of hepatotoxicity and only 1 case each of hypertension and pancreatectomy",
        "label": "Contradiction"
    },
    "427a4e1a-14ee-441a-b2af-b45b01356921": {
        "text_answer": "Contradiction Persons with stage 4 cancer are excluded from both the primary and secondary clinical trials according to the provided evidence",
        "label": "Contradiction"
    },
    "f0ca21dc-bf98-4c8b-b08e-d0821905846a": {
        "text_answer": "Entailment assuming that the results for the waitlist group after 6 weeks of acupuncture treatment are not provided in the evidence",
        "label": "Entailment"
    },
    "137f2083-e958-4c81-a4c8-338c90dda9c9": {
        "text_answer": "Contradiction The primary trial involves oral pregabalin while the secondary trial involves intravenous Liposomal Cytarabine Depocyt and HighDose Methotrexate HDMTX",
        "label": "Contradiction"
    },
    "f693e25f-c128-48d1-883d-488248b8347d": {
        "text_answer": "Contradiction The primary trial uses a 21day cycle for its intervention not a 10week cycle",
        "label": "Contradiction"
    },
    "1fece1ef-3bb6-407c-a09c-d615922822db": {
        "text_answer": "Entailment The evidence shows that there were fewer total adverse events and fewer instances of cardiacischemiainfarction in the primary trial compared to the secondary trial",
        "label": "Entailment"
    },
    "31b0b1db-0d40-44fe-aa76-ce3cdca8e31b": {
        "text_answer": "Contradiction Anorexia is a condition characterized by a significant loss of appetite and weight which is not mentioned in the inclusion criteria of the primary trial",
        "label": "Contradiction"
    },
    "fb8e290e-f73a-46e1-86b1-3a1d13eab0ab": {
        "text_answer": "Contradiction The evidence states that patients with a history of interstitial lung disease or pneumonitis are excluded from the trial The statement describes a patient with ILDDPLD within the last 3 years which is a type of interstitial lung disease",
        "label": "Contradiction"
    },
    "77c27725-099d-4d66-947c-f03e9193b6bf": {
        "text_answer": "Contradiction The statement asks about mgmt promoter methylation testing which is not mentioned in the provided evidence for either trial The evidence only mentions the drugs and their administration routes",
        "label": "Contradiction"
    },
    "dc60304d-6fd2-4b12-9108-b5ce78454d42": {
        "text_answer": "Contradiction The evidence shows that there are fewer total adverse events in the primary trial 000 than in the secondary trial 1379 but there is also one less case of Cardiacischemiainfarction in the primary trial 000 than in the secondary trial 057 Therefore the statement is a contradiction of the evidence",
        "label": "Contradiction"
    },
    "2884c912-af96-4bac-9b0e-29f1d0876abc": {
        "text_answer": "Contradiction The primary trial intervention is not related to the chromosome band 14q132 while the secondary trial intervention is based on ibrutinib and MEDI4736 which are not mentioned in the primary trial intervention",
        "label": "Contradiction"
    },
    "f83fe0ea-4d77-4db1-a66d-eb0df033a592": {
        "text_answer": "Contradiction The evidence provided does not mention anything about lung cancer in the inclusion or exclusion criteria for the primary clinical trial",
        "label": "Contradiction"
    },
    "d904b234-fed6-473e-bd40-8f37f4a4e440": {
        "text_answer": "Entailment The primary trial tests Eribulin Mesylate while the secondary trial tests Axitinib and Docetaxel which are different drugs",
        "label": "Entailment"
    },
    "1046f15f-8bef-4d73-99a1-34ab32da6ea6": {
        "text_answer": "Contradiction The evidence does not mention anything about shingles being reported in the vasectomy reversal procedure cohort",
        "label": "Contradiction"
    },
    "ffbff911-ea0e-4f8b-97fd-a54b8f88007a": {
        "text_answer": "Contradiction  Explanation The statement is contradictory to the evidence because the primary trial does not involve periodontitis and the doses of MM121 and Paclitaxel mentioned in the statement are not provided in the evidence for the primary trial Additionally the statement incorrectly states that the primary trial candidates receive higher doses of Herceptin and Doxorubicil when in fact the doses of Hercept",
        "label": "Contradiction"
    },
    "1022a719-eef0-4fbe-ac15-b0398adbf45b": {
        "text_answer": "Entailment The evidence does not report any cases of anorexia hypothermia or hallucinations in either trial and the statement asserts that these conditions were not recorded",
        "label": "Entailment"
    },
    "dd0571e3-088c-4dc7-a47a-175210514286": {
        "text_answer": "Contradiction The placebo intervention and the AlloMSCs intervention are not administered in the same dose or method The AlloMSCs intervention involves multiple injections of a larger volume while the placebo intervention involves a single injection of a smaller volume of Buminate solution",
        "label": "Contradiction"
    },
    "e137a0db-0a15-4dd0-9fa2-3a8558c7ef0a": {
        "text_answer": "Irrelevant  The statement is not related to the evidence provided regarding the doses of PF06647020 in the primary and secondary trials",
        "label": "Entailment"
    },
    "0cc7e297-b7df-4260-9ddf-f406bb3c2485": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports the adverse events observed in the primary and secondary trials and it does not mention arrhythmogenic syncope",
        "label": "Contradiction"
    },
    "8c51b6e1-ee26-44a5-b63b-3c180b7dddd2": {
        "text_answer": "Contradiction  The primary clinical trial involved comparing the diagnostic accuracy of two algorithms in breast cancer diagnosis while the secondary clinical trial focused on measuring fatigue levels using the Lee Fatigue Scale in breast cancer patients undergoing radiation therapy The results from the two trials are not directly comparable as they assess different outcomes",
        "label": "Contradiction"
    },
    "b3fc2b80-128b-4236-b1d5-a89b93e54b48": {
        "text_answer": "Contradiction The statement is not an entailment based on the evidence as some patients in the GTx024 1mg group had a decrease in lean body mass",
        "label": "Contradiction"
    },
    "972a66e9-09cc-4091-8c60-fa8f458955aa": {
        "text_answer": "Entailment  Explanation The statement entails that the first patient group receives a higher dose of cyclophosphamide than eribulin which is true based on the evidence 600 mgm2 for cyclophosphamide in Intervention 1 vs 14 mgm2 for eribulin in Intervention 1  Additionally the statement also entails that the second patient group gets greater",
        "label": "Entailment"
    },
    "5a954b09-cbc7-47dd-891c-4c998eb72979": {
        "text_answer": "Contradiction The evidence states that Intervention 1 in the primary clinical trial involves vaccine responses against Pneumococcus in adult cancer patients 65 years of age and older Therefore the statement that participants in cohort 1 are not administered with the pneumococcus vaccine is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "1cbd0ac2-bfb8-4649-afea-ae028707f190": {
        "text_answer": "Contradiction The evidence shows that the mean arm circumference in the acupuncture group decreased from baseline to 6 weeks indicating improvement not worsening",
        "label": "Contradiction"
    },
    "8dc6e902-3dae-4bea-ba4b-605df19fabc1": {
        "text_answer": "Contradiction The primary trial uses Yttrium90 Radioembolization with TheraSphere while the secondary trial uses ibrutinib and MEDI4736 These interventions are not the same",
        "label": "Contradiction"
    },
    "0f6ce079-990e-446e-95e9-8c4644291924": {
        "text_answer": "Entailment The primary trial explicitly requires mammography as an inclusion criterion while the secondary trial does not mention it as a requirement",
        "label": "Entailment"
    },
    "06e6eb2b-8300-413b-9c70-51fadbc68bbc": {
        "text_answer": "Contradiction The statement is not supported by the evidence as the adverse event type disease progression affected more than one patient in the primary trial",
        "label": "Contradiction"
    },
    "fb011e19-d4fb-4e6c-b7c9-7a7238f78970": {
        "text_answer": "Entailment The evidence provided does not include information on the percentage of participants in either trial who experienced clinical benefit using RECIST criteria",
        "label": "Entailment"
    },
    "fc211cd7-389a-4040-9c92-e06672257460": {
        "text_answer": "Contradiction  Explanation The evidence provided in the results shows that the median aAUCpa for the EORTC CIPN20 Sensory Neuropathy Subscale in Arm I Cryotherapy was 14 117 to 68 while in Arm II Control it was 44 571 to 162 The negative values indicate that the",
        "label": "Contradiction"
    },
    "230818a6-3a37-4bb6-933b-39a7e9a45054": {
        "text_answer": "Contradiction The inclusion criteria only mention unilateral breast cancer",
        "label": "Contradiction"
    },
    "fa510ac9-2d92-4396-a150-18dd46a31260": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence provided as the primary trial has no recorded adverse events and the secondary trial has recorded zero adverse events among a nonzero patient population",
        "label": "Contradiction"
    },
    "6b8445e6-9bc6-4a57-ab24-05d99e082061": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the number of participants analyzed in the Paclitaxel Plus Bevacizumab Plus Gemcitabine group was higher than in the Paclitaxel Plus Bevacizumab group",
        "label": "Contradiction"
    },
    "966e1258-879d-4e8d-88ec-777a743e191d": {
        "text_answer": "Entailment The evidence does not report any patient in either trial with less than 3 different AEs and the statement indicates that there were no patients with fgfr2 gene mutations and less than 3 different AEs",
        "label": "Entailment"
    },
    "0e57fc4c-1a5b-4f88-900e-122c03fcedb4": {
        "text_answer": "Contradiction The statement does not relate to the provided evidence The evidence only discusses adverse events in two clinical trials and there is no mention of the fgf3 gene mutation in the evidence",
        "label": "Contradiction"
    },
    "980fb8cd-9ba0-4bac-a2ae-0aea58c2f837": {
        "text_answer": "Contradiction The primary trial had 35 participants in cohort 1 and 37 participants in cohort 2 while the secondary trial had 109 participants in the control arm and 163 participants in the intervention arm Therefore the statement that cohort 2 of the primary trial had a smaller patient count compared to cohort 2 of the secondary trial is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "4b529950-5a15-4904-8f87-1aa68f408b8d": {
        "text_answer": "Contradiction The statement is contradictory to the inclusion criteria which state that patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast who are considering aromatase inhibitor therapy are eligible for the primary clinical trial Patients with advanced stage ductal carcinoma not contemplating AI therapy are not included in the study",
        "label": "Contradiction"
    },
    "f0d4e862-c9a1-48f4-9e4f-ddc67b35bbe0": {
        "text_answer": "Contradiction The statement is not supported by the evidence as both trials use different outcome measurements but they do not provide information about concomitant medication start relative to a reference timepoint",
        "label": "Contradiction"
    },
    "c2ba74e0-9674-4974-a0ea-74651dbdbbf6": {
        "text_answer": "Contradiction The statement does not relate to the evidence provided as it mentions family cancer history which is not mentioned or relevant in the given trial results",
        "label": "Contradiction"
    },
    "5e3fa8fd-a886-411d-8de0-fcbf6ef953fb": {
        "text_answer": "Contradiction The statement is not related to the given evidence as it discusses a different type of cancer colon nonHodgkin lymphoma and the eligibility criteria for the secondary trial do not require candidates to be completely disabled",
        "label": "Contradiction"
    },
    "db5cde14-102d-432e-981d-8b88ae65a830": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions no cases of asthenia or pyrexia in either trial",
        "label": "Contradiction"
    },
    "fe9b1db5-8600-469a-ba9f-c0aab4630041": {
        "text_answer": "Contradiction The primary trial does not specify an age range for participation but the secondary trial includes a minimum age of 18 years",
        "label": "Contradiction"
    },
    "5c253fd8-303a-4b91-b21f-e7e77c30f14a": {
        "text_answer": "Contradiction The evidence does not provide information about the number of participants in each arm of the trial only the number analyzed",
        "label": "Contradiction"
    },
    "10f7c7cf-b7e2-4d21-8870-1fdbcc7937f5": {
        "text_answer": "Entailment Both interventions are administered for the same duration days 181 and at the same frequency twice daily",
        "label": "Entailment"
    },
    "9fad2ea9-39ad-4c5b-afbe-82d9c40dbeee": {
        "text_answer": "Contradiction The evidence states that pregnant patients are excluded from both trials Morbidly obese patients are not mentioned as an exclusion criterion in the provided evidence However morbid obesity is not mentioned as an eligibility criterion for either trial either",
        "label": "Contradiction"
    },
    "c7037258-f24b-40dd-9ce8-5026b019bfbe": {
        "text_answer": "Entailment The evidence shows that neither intestinal obstructions nor pancytopenia were observed in any of the patients in the primary or secondary trials The statement that neither condition occurred is an entailment of the evidence",
        "label": "Entailment"
    },
    "8ffc6641-8eb9-4e6d-8926-0356539e0ba6": {
        "text_answer": "Contradiction  The evidence describes the use of 18FFDG and 18FFPPRGD2 in PETCT or PETMRI scans for different study groups but it does not mention 18FFET or 18FFMISO",
        "label": "Contradiction"
    },
    "11f26a4a-7ff7-4cbd-b5c7-b95cfea182df": {
        "text_answer": "Contradiction The statement does not relate to the evidence provided The evidence only discusses adverse events in the context of clinical trials and does not mention anything about biological grandmothers",
        "label": "Contradiction"
    },
    "169ae179-8a24-4f8f-82b6-47ed449d8e2e": {
        "text_answer": "Contradiction The primary and secondary trials evaluate different outcome measures the primary trial measures the number of participants with treatmentemergent adverse events while the secondary trial measures the median change in total sleep time in minutes",
        "label": "Contradiction"
    },
    "9b0c9133-a13c-4687-bf43-546312ce1a2f": {
        "text_answer": "Contradiction The primary clinical trial mentioned in the evidence is for breast cancer patients",
        "label": "Contradiction"
    },
    "8c2ec196-18f6-4a3f-b2fd-6eb6f65d1c60": {
        "text_answer": "Contradiction The primary trial requires resistance to AI therapy but there is no such requirement for the secondary trial",
        "label": "Contradiction"
    },
    "f0e6f9c3-4f87-4a91-af2e-9bb7cc2de985": {
        "text_answer": "Entailment  Explanation The primary and secondary trials involve different interventions with the primary trial using Abl Cells and Cyclophosphamide and the secondary trial using DMCHOCPEN",
        "label": "Entailment"
    },
    "4c4e621c-abe5-4a19-b517-31778992b424": {
        "text_answer": "Contradiction  The evidence states that 53 of participants in the lapatinib 1000 mg  nabpaclitaxel arm experienced a confirmed partial response or confirmed complete response Therefore the statement that no patients in the primary clinical trial treated with lapatinib 1000 mg  nabpaclitaxel experienced a confirmed complete response or a confirmed partial response is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "b6084ccd-2ece-4e27-b783-64ade24880bb": {
        "text_answer": "Contradiction The statement does not relate to the evidence provided The evidence only discusses the interventions and treatment schedules in the primary trial and there is no mention of retinopathy of prematurity or its stages",
        "label": "Contradiction"
    },
    "5e74a97b-ae6e-478b-bcf1-f681159ea1f7": {
        "text_answer": "Contradiction  The statement implies that more than half of the patients in the primary trial experienced a confirmed complete response CR but the evidence only shows that 53 of the participants in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR",
        "label": "Contradiction"
    },
    "bd8a6fc5-ffc7-460f-a82c-9656047eafbc": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it does not show that there is a 492 difference in the percentage of participants demonstrating a decrease in the growth factor signature between the ERpositive Luminal B and Triple Negative groups The evidence only shows the percentage of participants with a decrease in the growth factor signature for each group",
        "label": "Contradiction"
    },
    "3a452f00-375b-48c4-96dd-48986c0c0064": {
        "text_answer": "Contradiction The primary trial specifically states that the breast tumor must be at least 1 cm in diameter which is larger than the size specified in the statement",
        "label": "Contradiction"
    },
    "af5daeb0-69f5-4d1c-93a5-7a76dfb4b5e7": {
        "text_answer": "Contradiction The evidence describes two different cohorts in the primary clinical trial and the statement refers to a different trial involving a different intervention viewing an educational DVD instead of receiving a regular dosage of radiotherapy",
        "label": "Contradiction"
    },
    "09af4485-0e64-4a6c-83d3-1e7231151faa": {
        "text_answer": "Contradiction  The evidence shows that 423 of participants in Cohort 1 had cervical cancer screenings prior to the intervention which is not the same as only 3 patients having maintained regular screenings",
        "label": "Contradiction"
    },
    "3647e40b-92d1-4e99-aedf-8416c91576c8": {
        "text_answer": "Entailment The evidence states that both interventions use laserassisted fluorescence angiography and the statement also includes the use of lateral radial incisions which is also present in the evidence for both interventions",
        "label": "Entailment"
    },
    "54f0a585-98f8-49c2-a6b3-2700b3fc19ff": {
        "text_answer": "Entailment  Explanation The statement is an entailment because both trials involve intravenous injections and MRIs but the specific drugs dosages and administration frequencies differ between them",
        "label": "Entailment"
    },
    "269ac84f-d5a9-475f-8c43-361a6cdb5225": {
        "text_answer": "Contradiction The primary trial uses the change in units on a scale as its measurement unit while the statement specifically mentions that it does not employ cm participant count or time unit as measurement units However change in units on a scale is not explicitly stated in the given statement so it is a contradiction rather than an entailment",
        "label": "Contradiction"
    },
    "92639a0e-c3b4-4057-8bb5-aeaf1d60c39b": {
        "text_answer": "Entailment given that the evidence does not report any unexpected deaths or hospital stays in either trial",
        "label": "Entailment"
    },
    "b36dca2b-8c53-4f4d-b956-0d86194d2d2d": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as diarrhea was not common in the secondary trial with a total of 0 cases reported",
        "label": "Contradiction"
    },
    "4d604e71-ced3-43a1-baf7-276573a3a901": {
        "text_answer": "Contradiction The statement does not hold true based on the evidence provided as the radiation therapy doses are the same for both cohorts but the duration of the intervention is different",
        "label": "Contradiction"
    },
    "c7320872-347d-445f-a939-9554e7ee9973": {
        "text_answer": "Contradiction  Explanation The statement in the primary clinical trial both cohort 1 and cohort 2 are given an identical dose of cudc101 is contradictory to the evidence provided as the evidence states that cohort 1 receives the CUDC101 more frequently 5 daysweek than cohort 2 3 daysweek which means they are receiving",
        "label": "Contradiction"
    },
    "e6e3ecde-9d81-41a2-849e-de26c1b9bafc": {
        "text_answer": "Contradiction The primary trial uses the Karnofsky score while the secondary trial uses the Zubrod performance score These are different performance status scoring systems",
        "label": "Contradiction"
    },
    "81d8da2f-add7-4c32-bc69-8eb22266f71e": {
        "text_answer": "Entailment The first cohort is a subset of the primary clinical trial so if no adverse events were documented in the entire trial it logically follows that no adverse events were documented in the first cohort as well",
        "label": "Entailment"
    },
    "89c76808-d0fb-4c78-8364-344d6b65754b": {
        "text_answer": "Contradiction  Explanation The evidence states that there are two study groups in the primary clinical trial one for Glioblastoma Multiforme and one for Gynecological Cancers Both study groups undergo 18FFDG and 18FFPPRGD2 PETCT imaging procedures Therefore the statement that only one study group in the primary clinical trial will undergo 18F",
        "label": "Contradiction"
    },
    "d2057876-3991-462d-b5fd-de01cc252790": {
        "text_answer": "Entailment for Cohort 2 no additional cycles of docetaxel doxorubicin and cyclophosphamide are specified after Cycle 5",
        "label": "Entailment"
    },
    "d5786123-b433-4fdd-abad-4410de2695c9": {
        "text_answer": "Entailment The statement correctly identifies the difference in drugs and dosages between the two cohorts in the primary clinical trial",
        "label": "Entailment"
    },
    "f49abd8e-7440-40ec-a512-c2420c9a207b": {
        "text_answer": "Contradiction The primary trials exclusion criteria do not mention anything about measurable tumors in both breasts related to a mixed endometrial stromal and smooth muscle neoplasm",
        "label": "Contradiction"
    },
    "373d0081-e7cf-4a06-bdd0-b58bcd4fe34c": {
        "text_answer": "Contradiction The evidence clearly states that participants in the primary clinical trial will receive various injections including dendritic cell vaccines chemotherapy GMCSF and trastuzumab",
        "label": "Contradiction"
    },
    "c158ee0a-2ff1-483d-a906-6dcbb76fae47": {
        "text_answer": "Entailment In the primary trial pembrolizumab is administered every 3 weeks Q3W which is twice the frequency of sunitinib administration in the secondary trial which is once daily",
        "label": "Entailment"
    },
    "dee869cc-6f3c-45a5-9672-d8ab6a545212": {
        "text_answer": "Contradiction The statement only 1 of the patients in the primary clinical trial dealing with pr primary breast cancer treated with her2targeted petct 89zrtrastuzumab results in her2 metastases is a contradiction to the evidence as the evidence states that 13 of the participants in the HER2targeted PETCT arm of the trial developed HER2 met",
        "label": "Contradiction"
    },
    "a6dd31e3-d055-4343-9d7f-8d141f7c7007": {
        "text_answer": "Contradiction The statement is not supported by the evidence provided as the evidence does not indicate that the primary trial involved participants with renal pelvis and ureter urothelial carcinoma",
        "label": "Contradiction"
    },
    "ae134e5a-97f7-4c42-9135-ea44d3d45939": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only compares changes in lymphedema between the acupuncture and waitlist groups",
        "label": "Contradiction"
    },
    "3ebd71b1-9b66-438a-9623-27aaf0725786": {
        "text_answer": "Contradiction The evidence states that substance abuse medical psychological or social conditions that may interfere with the participants participation in the study or evaluation of the study results as well as any psychiatric condition that would prohibit the understanding or rendering of informed consent are exclusion criteria for both trials",
        "label": "Contradiction"
    },
    "466321f2-f997-47c7-a166-faeffe581547": {
        "text_answer": "Contradiction The primary trial administers its intervention sublingually while the secondary trial administers its intervention orally making the statement a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "aadd13d6-3100-41ef-947f-6b29d3118d67": {
        "text_answer": "Contradiction The primary trial evidence does not mention any weight restrictions for participation",
        "label": "Contradiction"
    },
    "5a515d1f-131f-4dc9-9179-97f41957904a": {
        "text_answer": "Contradiction The primary trial requires participants to be resistant to AI therapy while the statement asserts that neither trial requires this condition",
        "label": "Contradiction"
    },
    "b3a79047-9f6a-43d4-88e6-8c8a26b3a47f": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one case of Infections and Infestations  Other Gramnegative bacteremia 40 degree C fever in cohort 2 which contradicts the statement that only patients within cohort 1 had cases of infections and infestations",
        "label": "Contradiction"
    },
    "d42bd39b-e72e-418b-bd8a-6f1769fde12d": {
        "text_answer": "Contradiction The primary trial evidence does not mention anything about a minimum Karnofsky score requirement for participation",
        "label": "Contradiction"
    },
    "36aac65a-5d56-4abd-b278-e9e3de78d480": {
        "text_answer": "Contradiction The statement once daily is not the same as twice daily so the statement does not entail the evidence",
        "label": "Contradiction"
    },
    "1a1826f4-79d9-4df0-a8d8-fe9c3d75d783": {
        "text_answer": "Contradiction The statements refer to different treatments Alpha Lipoic Acid and Necitumumab and do not directly compare the same treatment or dosing regimen between the trials",
        "label": "Contradiction"
    },
    "b9b156ee-526a-49ac-aa99-78f02a24dbaf": {
        "text_answer": "Contradiction The primary trial includes NUT midline carcinoma as an inclusion criteria but inflammatory breast cancer is an exclusion criteria in the secondary trial",
        "label": "Contradiction"
    },
    "8719ae55-97f1-4d19-8e9c-85c086898291": {
        "text_answer": "Contradiction  Explanation The evidence provided in the results shows that the proportion of participants who were up to date for colorectal breast and cervical cancer screenings increased significantly in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups after the intervention Therefore the statement that most participants fell behind in their screening schedules postintervention is a contradiction to the evidence presented",
        "label": "Contradiction"
    },
    "0428ab54-eddd-4ee8-a58f-45ec7d7630f7": {
        "text_answer": "Contradiction  The evidence shows that patients in Arm II Control reported a greater median aAUCpa for the EORTC CIPN20 Sensory Neuropathy Subscale indicating a greater improvement in symptoms compared to patients in Arm I Cryotherapy",
        "label": "Contradiction"
    },
    "a4c5aecb-d375-43b7-bee0-dea9651fb7d6": {
        "text_answer": "Entailment Both trials use the units of measure for Tumor Diameter in centimeters cm in the primary trial and Number of Participants with Solid Tumor Response in participants for the secondary trial",
        "label": "Entailment"
    },
    "7d36e2e7-cf12-4281-8db5-2c30f23b427b": {
        "text_answer": "Contradiction for the given statement about patients taking part in the primary or secondary trial based on the provided evidence  Explanation  The statement Patients who have received chemotherapy or radiotherapy in the last 2 weeks suffer from unstable angina or have Grade 2 or above neuropathy cannot take part in the secondary trial but can still take part in the primary trial unless they have nonhealing surgical wounds",
        "label": "Contradiction"
    },
    "cc177dab-2d93-40dd-8b7f-ac1755325605": {
        "text_answer": "Entailment The primary trial includes patients with stage IV breast adenocarcinoma that is ER positive PR positive or HER2neu negative as a subset of its inclusion criteria The secondary trial specifically requires these same characteristics for eligibility Therefore if a patient meets these criteria they are eligible for both trials",
        "label": "Entailment"
    },
    "c7f3e0a2-44e0-4da9-a3ac-665d3e80f111": {
        "text_answer": "Entailment The primary trial measures adverse events and serious adverse events as percentages of participants while the secondary trial measures objective response as the number of participants with complete or partial response However the statement is still entailed by the evidence as both trials do indeed have disparate outcome measurement techniques",
        "label": "Entailment"
    },
    "51ea9225-4ef8-4bf6-878a-2476cb59b916": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as only 13 of the participants in the HER2targeted PETCT arm developed imagable HER2 metastases",
        "label": "Contradiction"
    },
    "d88d1ea7-3d60-4234-896b-2060dee299f7": {
        "text_answer": "Entailment The statement cohorts 1 and 2 of the primary clinical trial each follow a different relaxation audio guide is not directly stated in the evidence but the evidence does state that they practice paced breathing for the same number of minutes and days per week so the statement but both practice the same number of times per day is an entailment of the evidence",
        "label": "Entailment"
    },
    "920775c5-aa23-4be9-8aa1-241ecef90b51": {
        "text_answer": "Contradiction The primary trial does not involve the administration of dexmedetomidine in group 2 while the secondary trial involves the administration of 1ugkg of dexmedetomidine",
        "label": "Contradiction"
    },
    "bfeb1617-a5a5-40f7-8f09-f20c40a4cee0": {
        "text_answer": "Contradiction The statement does not entail the evidence as the trials involve different drugs PF06647020 vs ALT801 and different doses do not necessarily mean the same relationship between participants",
        "label": "Contradiction"
    },
    "24480821-2a6d-4359-bfb8-348ca85dffbb": {
        "text_answer": "Contradiction The evidence does not mention anything about Trovirdine in the primary trial",
        "label": "Contradiction"
    },
    "9313b787-6fe7-4eb7-93cb-13ce8cfe92f0": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as some patients in the 1mg group experienced a decrease in lean body mass",
        "label": "Contradiction"
    },
    "f48fabb1-f814-4f89-acf9-7ff95948b8d9": {
        "text_answer": "Entailment  Explanation The statement with the exception of one all patients who were treated with sunitinib  docetaxel  trastuzumab in the primary clinical trial experienced adverse events emergent from treatment is entailed by the evidence as all 25 participants in the study experienced adverse events The statement and serious adverse events were experienced by less than half is also entailed by the evidence as",
        "label": "Entailment"
    },
    "0ef3e1a1-d303-46de-8940-07746737fe87": {
        "text_answer": "Contradiction  Explanation The statement is contradictory to the evidence because the primary trial only includes patients with ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 It does not include patients with estrogen negative progesterone negative and HER2 negative tumors",
        "label": "Contradiction"
    },
    "3c2830d4-9341-4c0d-8ed3-51eb47d2cd17": {
        "text_answer": "Contradiction The evidence shows that there were no cases of cholelithiasis reported in either trial",
        "label": "Contradiction"
    },
    "e2fcdf94-c0b2-4d75-a40d-2c2ec8200208": {
        "text_answer": "Neutral  Explanation The statement is not directly related to the evidence provided in the trial results The statement is about the presence of a uterus and the pain intensity experienced by the patients in the trial The evidence only provides information about the outcome of the psychoeducational intervention on pain management and does not mention anything about the presence or absence of a uterus or the worst pain imaginable for 10 weeks",
        "label": "Entailment"
    },
    "e9146895-e9b0-49cb-b05e-9264b682cece": {
        "text_answer": "Entailment The evidence shows that adverse events were reported by 571 of the participants in the primary clinical trial which is less than 5",
        "label": "Entailment"
    },
    "6920329b-7559-415e-9346-c06909526421": {
        "text_answer": "Entailment assuming neither trial reported Febrile neutropenia or Cholelithiasis",
        "label": "Entailment"
    },
    "a74afb52-7b03-4c41-b57b-7473ef025c18": {
        "text_answer": "Contradiction  Explanation  The primary trial includes NUT midline carcinoma as an eligible cancer type but it does not mention fluorescence in situ hybridization FISH as a requirement for diagnosis However the statement in question specifically mentions NUT midline carcinoma patients identified through fluorescence in situ hybridization This additional requirement is not present in the primary trials inclusion criteria making the statement",
        "label": "Contradiction"
    },
    "5acf1755-279a-400a-9a2e-c71daaeeab0d": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the primary trial involves Epacadostat dosing frequency while the secondary trial involves Sunitinib dosing frequency",
        "label": "Contradiction"
    },
    "87f63f2e-5648-4b9f-9f25-a5adb80dcb1d": {
        "text_answer": "Contradiction  Explanation  The statement 0 adverse events were observed in the primary trial contradicts the evidence from the primary trial which states that there were no recorded adverse events 025 However the statement and none of the adverse events in the secondary trial affected more than 03 of patients is an entailment of the evidence as none of the adverse events in the secondary trial affected more",
        "label": "Contradiction"
    },
    "65ef313d-74d5-4e56-a6c8-6a3768774a55": {
        "text_answer": "Irrelevant  The statement is not related to the information provided about the interventions in the primary trial",
        "label": "Entailment"
    },
    "51a15c75-5a89-48c3-a93d-4f464e915ba2": {
        "text_answer": "Contradiction  Explanation The statement There was one psychiatric adverse event in the primary trial which affected less than 10 of patients is contradictory to the evidence because the evidence states that there were 2 patients with suicidal ideation which is a psychiatric adverse event and 10 of the patients were affected by adverse events in total Therefore the statement is incorrect as it suggests that only one",
        "label": "Contradiction"
    },
    "487dd970-35e7-4a7d-8bb6-e8fa98f574aa": {
        "text_answer": "Contradiction  Explanation The primary trial excludes women with renal impairment but does not mention anything about claustrophobia Therefore the statement that women suffering from both claustrophobia and osteoporosis are not eligible for either trial is a contradiction based on the given evidence",
        "label": "Contradiction"
    },
    "25f963fe-42f5-4294-9489-17d8fd17b4f2": {
        "text_answer": "Contradiction The statement is not an entailment as it mentions exclusion criteria for both the primary and secondary trials but the criteria mentioned in the statement do not exactly match the criteria in the evidence provided for each trial In the primary trial a documented allergy to trimethoprimsulfamethoxazole is not a specific exclusion criteria and in the secondary trial there is no mention of celecoxib as an exclusion criteria",
        "label": "Contradiction"
    },
    "caab457d-0650-4010-9d8e-4c8e474070ff": {
        "text_answer": "Contradiction The statement mentions several cases of Anaemia and Febrile neutropenia in cohort 1 but the evidence shows only one case of each The statement does not entail the evidence",
        "label": "Contradiction"
    },
    "e12077dc-2ef2-4276-b755-4664b0a0f0ea": {
        "text_answer": "Contradiction  Explanation  In the primary trial the evidence does not mention anything about entericcoated tablets being given to the participants The trial only mentions Botulinum Toxin Type A or Placebo being injected in the primary trial  In the secondary trial the evidence mentions MLN8237 being given as entericcoated tablets but it is only a part of the secondary trial",
        "label": "Contradiction"
    },
    "5a91060d-576b-405f-a8a6-c74cc3c24c62": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the participants in the primary trial underwent highdose chemotherapy with purged autologous stem cell products",
        "label": "Contradiction"
    },
    "7febdcf0-e8ff-4511-a96b-c160e3dd127e": {
        "text_answer": "Contradiction The statement is not an entailment as the primary trial had no reported adverse events while the secondary trial had a significant number of adverse events",
        "label": "Contradiction"
    },
    "42dca69f-0e7b-4945-9123-90e576db8c25": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the use of denosumab which is a monoclonal antibody that is injected subcutaneously every 4 weeks This is not the same as the protocol of guaiacum based treatments mentioned in the statement  The secondary trial involves the use of a prototype intraoperative handheld gamma camera pIHGC and gamma probes",
        "label": "Contradiction"
    },
    "65dbfec2-08fb-4853-9e50-79ec4c97500f": {
        "text_answer": "Contradiction The evidence states that patients must have a life expectancy of greater than 3 months to participate in the primary clinical trial A minor with a predicted life expectancy of one year does not meet this criterion",
        "label": "Contradiction"
    },
    "7b71a3ac-e8b3-4e8f-ac95-c3dfe88676d5": {
        "text_answer": "Contradiction  Explanation The statement 203 adverse events were observed in the primary trial is not mentioned in the evidence The evidence only states that there were no adverse events in the primary trial Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "44b1585a-3a5f-4ff7-a523-04923546b2c0": {
        "text_answer": "Contradiction The evidence states that all doses of MCS110 are given every 3 weeks",
        "label": "Contradiction"
    },
    "d21d3871-d8c2-4a0a-b99f-291a721a1a18": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial measures tumor diameter in centimeters while the secondary clinical trial measures the number of participants with solid tumor response These are distinct units so the statement that the outcome measurement for both the primary clinical trial and the secondary clinical trial incorporate distinct units is an entailment However the statement in the question is different it states that the outcome measurements for both trials incorporate distinct",
        "label": "Contradiction"
    },
    "a1cf2da3-a2a8-4fa1-9812-5f50a75994ad": {
        "text_answer": "Contradiction The statement is not directly related to the evidence provided The evidence only compares the frequency of adverse events related to blood and bone marrow between the two trials The statement mentions a thymic tumor which is not related to the adverse events in the evidence",
        "label": "Contradiction"
    },
    "1b3e5b01-1b05-4025-9100-2c6e6e7faf20": {
        "text_answer": "Entailment The evidence shows that the percentage of participants with events was lower in the Neratinib group 47 compared to the Placebo group 75 indicating a lesser iDFS rate in the Neratinib group",
        "label": "Entailment"
    },
    "efe8b336-1781-4777-a1a0-fe34c59c63ab": {
        "text_answer": "Neither  Explanation The statement does not directly relate to the evidence provided as the evidence focuses on average pain intensity scores and the effects of a psychoeducational intervention while the statement mentions the Alzheimers Disease Assessment ScaleCognitive ADASCOG delayed word recall task for word 4",
        "label": "Entailment"
    },
    "0e7c3f86-cbc8-478d-b89c-1f75b53323fe": {
        "text_answer": "Contradiction The statement is not an entailment as it mentions a specific patient with a PFS of 105 days while the evidence only provides the median PFS for each group",
        "label": "Contradiction"
    },
    "dc8fb0ce-165a-4d79-afb2-25a85f7c40b6": {
        "text_answer": "Contradiction  Explanation The evidence provided does not support the statement as it does not mention any information about the outcomes of the two groups in the primary clinical trial",
        "label": "Contradiction"
    },
    "bb0cf2c6-fbb2-4ca2-9f44-9ae8c5a9f63e": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence as the primary trial involves intravenous administration of several drugs and surgery while the secondary trial involves oral administration of two drugs and imaging scans The statement mentions subcutaneous injection which is not mentioned in the evidence for either trial",
        "label": "Contradiction"
    },
    "ed8ee6d6-5a37-4338-af72-e87bb50ec4d9": {
        "text_answer": "Contradiction  Explanation The evidence shows that no participants in the trial had a complete response CR at either Week 12 or Week 24 Therefore it is a contradiction to the statement that a majority of individuals in the primary clinical trial demonstrated complete response in a span of 24 weeks",
        "label": "Contradiction"
    },
    "fbd6b437-ba96-46fd-933f-8299e0efb0e5": {
        "text_answer": "Entailment The statement follows directly from the evidence The evidence states that 13 participants were treated with the vaccine and the statement affirms that fact",
        "label": "Entailment"
    },
    "1cbc4e95-3407-4aab-bb7d-ba3abd1882f3": {
        "text_answer": "Contradiction The statement provided is about a different topic as it is not related to the primary trial results",
        "label": "Contradiction"
    },
    "4f45090f-0954-43a7-9f56-60c5283459bd": {
        "text_answer": "Contradiction The primary trial requires resistance to AI therapy but there is no mention of mirtazapine in the primary trials inclusion criteria The secondary trial does not have any mention of AI therapy or mirtazapine in its inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "b20dadde-0f33-42ca-aa3e-c9333cdffe89": {
        "text_answer": "Contradiction The evidence shows that there were no serious adverse reactions documented in the primary trial while the statement asserts that there was a higher incidence of serious adverse reactions in the primary trial compared to the secondary trial",
        "label": "Contradiction"
    },
    "12586895-bb1c-4772-ab01-94163d0393ab": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence as the evidence shows that there were no cases of anaemia in the primary trial while the statement claims that anaemia affected more than 999 of patients in the secondary trial",
        "label": "Contradiction"
    },
    "2758e742-d065-4813-bfd2-881fe16826bd": {
        "text_answer": "Contradiction The evidence states that patients with metastatic or unresectable nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma or breast cancer are eligible for the primary trial without any mention of ER or PR status as a requirement",
        "label": "Contradiction"
    },
    "da24d6fd-1363-489b-ac5a-f44dbe622c5d": {
        "text_answer": "Contradiction The primary trial excludes hypokalemic patients but there is no mention of hyperkalemic patients in the inclusion or exclusion criteria for the primary trial The secondary trial does not mention anything about potassium levels",
        "label": "Contradiction"
    },
    "a198b3a9-ee15-4f4a-b587-d6ddb86efa73": {
        "text_answer": "Contradiction The interventions in the primary and secondary trials involve different treatments and the statement is about a condition unrelated to the treatments",
        "label": "Contradiction"
    },
    "0f434232-d1a2-4d35-a49c-dd52c8353b9f": {
        "text_answer": "Contradiction  Explanation The evidence shows that at Week 24 there were no participants with a complete response CR in the Lapatinib and Vinorelbine arm of the trial Therefore it is a contradiction to the statement that the majority of patients experienced a complete response by month 24",
        "label": "Contradiction"
    },
    "22b968d1-4ffd-4562-aeb0-e1e022212b08": {
        "text_answer": "Contradiction The evidence provided does not support the statement as it relates to the number of participants with lesions or radiation dermatitis in the primary and secondary trials The statement also introduces a new concept forehead lift which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "116c9dea-44ba-402e-8948-67ee9bb4f942": {
        "text_answer": "Contradiction The statement does not relate to the evidence provided The evidence only discusses the interventions and treatment schedules in the primary trial and there is no mention of aortic aneurysms in the evidence",
        "label": "Contradiction"
    },
    "bea08563-704d-4475-9dbd-d7617d1a6a63": {
        "text_answer": "Contradiction The statement is about studying a different type of cancer prostate lymphoma which is not mentioned in the provided evidence",
        "label": "Contradiction"
    },
    "64df451c-f868-49e6-9b4e-a325e62ce837": {
        "text_answer": "Entailment as there is no mention of vaccines in the evidence provided",
        "label": "Entailment"
    },
    "a9aae47f-ecbe-49ea-983b-73c8b6a95506": {
        "text_answer": "Entailment The primary trial had no adverse instances recorded which is a subset of having fewer than 30 instances in the secondary trial",
        "label": "Entailment"
    },
    "dcad8706-4bfe-4076-9bd5-babca4f63beb": {
        "text_answer": "Contradiction The percentage of participants suffering from an adverse event cannot be 50 in the primary trial and 110 in the secondary trial as the percentage must be less than or equal to 100",
        "label": "Contradiction"
    },
    "af55082d-0ff1-419f-861f-80dbd05a9ade": {
        "text_answer": "Entailment The primary trial does indeed use separate inclusion and exclusion criteria for its phases while the secondary trial uses separate criteria for healthy and cancer patients",
        "label": "Entailment"
    },
    "d3630897-ec5d-4c22-b2cd-5a8355dfdd88": {
        "text_answer": "Entailment The primary trial includes patients with stage IV breast adenocarcinoma that is ER positive PR positive or HER2neu negative which meets the inclusion criteria for the secondary trial",
        "label": "Entailment"
    },
    "9367299b-070b-4902-b857-bca1c45b6fd1": {
        "text_answer": "Entailment assuming that the primary clinical trial includes information about the administration procedure dosage and treatment cycle for both cohorts 1 and 2 in the intervention section",
        "label": "Entailment"
    },
    "186e198a-63dc-4ac9-8ae0-7790f32ec792": {
        "text_answer": "Contradiction  Explanation  In the primary trial patients undergoing mastectomy surgery were not specified to receive any particular intervention or drug whereas in the secondary trial the HR subgroup received MM121 20 mgkg weekly and Paclitaxel 80 mgkg weekly in Intervention 1 and Paclitaxel 80 mgkg weekly alone in Intervention",
        "label": "Contradiction"
    },
    "65910ca9-d27b-4350-9213-1cb7aea575a2": {
        "text_answer": "Contradiction The evidence mentions inclusion criteria for age histology disease measurability and prior chemotherapy lines but it does not mention any restrictions based on mental health bodyweight tumor size or estimated life expectancy",
        "label": "Contradiction"
    },
    "50d67398-cd3f-4d6e-afeb-419ae6f64c0d": {
        "text_answer": "Contradiction The primary clinical trial is not suitable for those with triple positive breast cancer as per the evidence it is only for ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2",
        "label": "Contradiction"
    },
    "7270c176-7bf2-4b0d-941d-912f5a3ed62c": {
        "text_answer": "Contradiction The primary trial recorded no adverse events at all while the secondary trial had several adverse events that affected more than 30 of patients",
        "label": "Contradiction"
    },
    "e74e47e7-4627-4dd9-aedd-cbc5b5cdd669": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as none of the mentioned adverse events were seen in the secondary trial according to the provided data",
        "label": "Contradiction"
    },
    "b464cd26-7734-455c-85c1-04a4ec324c55": {
        "text_answer": "Contradiction The statement is not an entailment as it mentions supermarket which is not related to the evidence provided about the primary trials inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "22031bc7-9954-4b2b-b905-a5d34e0eea98": {
        "text_answer": "Entailment The evidence states that 13 of the participants with HER2 primary breast cancer developed HER2 metastases during the trial and the statement is about participants with HER2 primary breast cancer and HER2 metastases",
        "label": "Entailment"
    },
    "3b29fe26-bf01-4e85-aa0e-33e83b1db660": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within 4 weeks of first dose of study drug while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "8183a43e-0284-483d-a22c-08502b0ebc8a": {
        "text_answer": "Contradiction The statement is not supported by the evidence as it mentions a specific patient outcome that is not mentioned in the evidence The evidence only provides the median PFS for each cohort",
        "label": "Contradiction"
    },
    "f5cb1b5d-53b5-464b-a160-17cd59481705": {
        "text_answer": "Contradiction In the primary trial cohort 1 is treated with fluciclatide injection while in the secondary trial cohort 1 is assigned to receive chloroquine not fluciclatide",
        "label": "Contradiction"
    },
    "28a88ea8-4cea-404c-9ad7-cb1be9c19d7f": {
        "text_answer": "Entailment The evidence does not mention the use of paclitaxel in either intervention",
        "label": "Entailment"
    },
    "d47eb708-7ca4-4894-bc28-e276e61c0333": {
        "text_answer": "Entailment The evidence provided does not mention any vaccines being administered to the participants",
        "label": "Entailment"
    },
    "646691ba-ad29-479f-81dc-131d9710c23b": {
        "text_answer": "Contradiction The statement is contradictory to the evidence provided for the primary trial as it specifically excludes patients with cerebral metastases within 5 mm of the brainstem from the primary trial",
        "label": "Contradiction"
    },
    "70cd062f-8f49-47ac-80c0-d3608a574517": {
        "text_answer": "Irrelevant The statement is not related to the provided evidence The evidence only discusses the outcome measurements and results of the primary and secondary trials and does not mention anything about the h33a gene mutation",
        "label": "Entailment"
    },
    "01593a0d-0547-4ed6-8ad6-6c5ecdbeb74a": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence shows that two different routes of administration are used in the primary clinical trial intravenous IV for bisphosphonate and subcutaneous SC for denosumab",
        "label": "Contradiction"
    },
    "edb0a92a-08c0-4083-864e-26d845000fa6": {
        "text_answer": "Contradiction The evidence states that the Phase 1 trial is open to both male and female patients with evidence of a solid tumor that is locally advanced andor metastatic while the Phase 2 trial has specific eligibility criteria for female patients with breast cancer and male patients are not explicitly mentioned as eligible Therefore the statement that both phases are only open to male patients with evidence of a locally advanced andor metastatic solid tumor is a contrad",
        "label": "Contradiction"
    },
    "52c84a93-a09f-47b5-b928-385830350390": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial does not involve an intragastric balloon procedure",
        "label": "Contradiction"
    },
    "32c2dfce-b209-49f3-9f03-5e39b97b18c4": {
        "text_answer": "Entailment The statement patients diagnosed with ductal carcinoma in situ and contemplating AI therapy are suitable for the primary clinical trial is an entailment of the given evidence as DCIS is included in the list of inclusion criteria for the primary clinical trial",
        "label": "Entailment"
    },
    "7064d383-b7a5-44a0-a9aa-3fae7b7ded9c": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of an individuals enjoyment of food in the evidence",
        "label": "Contradiction"
    },
    "c958d134-cecd-4212-9043-bc1d5131d555": {
        "text_answer": "Contradiction The primary trial mentioned in the evidence is for breast cancer patients not colon cancer patients",
        "label": "Contradiction"
    },
    "a72ddea5-ee4b-4895-bd8c-10b4a143c3f8": {
        "text_answer": "Entailment The statement is true given the evidence as both trials reported no adverse events in the specified number of participants",
        "label": "Entailment"
    },
    "54c35538-e933-40b0-bf84-299e0b291ef3": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one patient in the second cohort who experienced a fever but no infections were reported in that cohort Therefore the statement that infections and fever cases in the primary clinical trial were exclusively observed in patients of the first cohort is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "3c9a4b79-1f51-477a-a5b6-b69f76aeedf8": {
        "text_answer": "Contradiction The primary trial and the secondary trial use different outcome measurements The primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel",
        "label": "Contradiction"
    },
    "cfef163a-3390-4b89-9a6f-7c351262625d": {
        "text_answer": "Contradiction The evidence does not provide information about the proportion of participants with deficient vitamin D levels and a discernible pattern for gene expression The results only show that no such pattern was observed in the groups with normal or lownormal vitamin D levels",
        "label": "Contradiction"
    },
    "d1e7f535-40de-425b-9478-7d09f3d4cf06": {
        "text_answer": "Entailment The primary trial includes breast cancer as one of the eligible tumor types for Phase 1 and the secondary trial specifically includes breast adenocarcinoma as one of the eligible tumor types Therefore people with breast cancer can participate in both trials",
        "label": "Entailment"
    },
    "2cc09c00-1375-4603-a6ee-dd5ceb87733a": {
        "text_answer": "Contradiction The primary clinical trial includes patients with histologically confirmed metastatic breast cancer not excludes them",
        "label": "Contradiction"
    },
    "37b9368c-1aae-4acd-ad7a-ffe4422c9e5d": {
        "text_answer": "Contradiction The statement mentions Brucella which is a different bacterial genus than Pregabalin or the drugs used in the trials",
        "label": "Contradiction"
    },
    "395c6ba7-5123-4d61-a803-be3345d0ab23": {
        "text_answer": "Contradiction The statement entails a tenfold difference in the number of hepatotoxicity cases compared to hypertension and pancreatectomy cases combined However the evidence only reports 3 hepatotoxicity cases and 1 case each for hypertension and pancreatectomy which is not consistent with a tenfold difference",
        "label": "Contradiction"
    },
    "e9972d7c-b9f7-4846-9708-1e1f63e96e83": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence states that the starting dose of sunitinib in Intervention 1 is 25 mg daily which is not equal to 15 mg",
        "label": "Contradiction"
    },
    "c355603f-22d8-4363-ac79-6e591b4fcfac": {
        "text_answer": "Contradiction  Explanation The statement makes a comparison between the number of cases of Infection Asymmetry and Deflation in the primary and secondary trials However the evidence provided does not include the number of cases for these adverse events in the secondary trial Therefore it is impossible to determine if the statement is an entailment or a contradiction based on the given evidence alone",
        "label": "Contradiction"
    },
    "9bea0473-ca9d-4a63-befe-db1825744484": {
        "text_answer": "Contradiction  Explanation  The primary trial and the secondary trial are evaluating different outcome measures The primary trial is measuring the change in physical wellbeing using the FACTB questionnaire while the secondary trial is measuring the intraoperative success in addressing positive margins using a device Therefore it is not possible to make a direct comparison between the results of the two trials and the statement is a contradiction",
        "label": "Contradiction"
    },
    "9f81f8a6-84d2-40b3-b8c5-3616f2f638a8": {
        "text_answer": "Contradiction The evidence states that the placebo intervention is administered by mouth PO and the memantine intervention is administered orally twice daily The statement however incorrectly states that the placebo intervention is administered intravenously and the memantine intervention is administered orally twice daily",
        "label": "Contradiction"
    },
    "fb1cfb53-fb70-4131-9ed0-00b5f93ecf26": {
        "text_answer": "Contradiction The statement is not an entailment or a contradiction based on the evidence as there is no mention of a reopened surgical cut in the provided adverse events for the primary clinical trial",
        "label": "Contradiction"
    },
    "dfe9c306-0a1f-4940-b9bb-00a238abc818": {
        "text_answer": "Contradiction The primary trial includes a criterion for the primary tumor to have a diameter greater than 2 cm not 3000µm The secondary trial does not mention any specific tumor size requirement",
        "label": "Contradiction"
    },
    "bd791a1a-f4e4-43fb-8be0-ad1bced0aa60": {
        "text_answer": "Contradiction The evidence states that the primary clinical trial would admit a patient with controlled brain metastases but it does not explicitly state that it would exclude a patient with leptomeningeal carcinoma Leptomeningeal carcinomatosis is a type of brain metastasis but it is not the same as a controlled brain metastasis Therefore the statement is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "6032e3ab-9d85-4c3b-aeb1-a93f45ba4735": {
        "text_answer": "Entailment assuming that the evidence provided in the statement is a subset of the given evidence However its important to note that the evidence provided in the statement is a subset of the given evidence and the statement is an entailment given that context If new evidence were to be introduced that contradicted the statement it could potentially change the answer",
        "label": "Entailment"
    },
    "55365a7b-df7e-4586-aeff-3ed268a4979f": {
        "text_answer": "Entailment Both trials reported zero serious adverse events which is consistent with the statement",
        "label": "Entailment"
    },
    "92e676b6-34f9-4b11-bfad-b45cf8942d2a": {
        "text_answer": "Contradiction The evidence does not mention any unexpected deaths or hospitalizations in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "df39cd99-7291-4749-a7d5-ff760b7c3fc2": {
        "text_answer": "Contradiction The primary and secondary trials measure different outcomes and use different units of measure The primary trial measures quality of life using the FACTB instrument while the secondary trial measures intraoperative success in addressing positive margins using a device Therefore it is not possible to make a direct comparison between the two trials based on the provided evidence",
        "label": "Contradiction"
    },
    "9011533a-e400-4b32-96d4-a60ddc58ddbe": {
        "text_answer": "Contradiction The primary trial does not use oxaliplatin and fluorouracil as treatment but rather Suramin and Paclitaxel The secondary trial does not have a specified drug regimen",
        "label": "Contradiction"
    },
    "43a12cb4-7a50-4e64-b01f-1d1bfb5c4ba9": {
        "text_answer": "Contradiction The primary trial did have documented adverse events as shown in the evidence",
        "label": "Contradiction"
    },
    "e96067c7-ab5d-4afc-b70c-f892aef0dce4": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial does not allow patients with meningeal carcinomatosis",
        "label": "Contradiction"
    },
    "01982a9a-3299-4be8-8201-0397508b2f88": {
        "text_answer": "Contradiction The evidence does not support the statement that numerous patients in the primary clinical trial felt no discomfort at all throughout the 10week study as there is no mention of the number or percentage of patients in either group who experienced no pain during the study",
        "label": "Contradiction"
    },
    "1a4794c9-035c-4e78-b2e5-d8104428bdc0": {
        "text_answer": "Contradiction The statement Diagnosis of 23 cerebral metastases will result in exclusion from the secondary trial however patients with this diagnosis may still be eligible for the primary trial is contradictory to have history of opportunistic or frequent infection is a question about whether an individual has a history of opportunistic or frequent infections The former statement implies that having cerebral metastases is an exclusion criterion for the secondary",
        "label": "Contradiction"
    },
    "4ce3082f-28f9-4e23-8808-dde496f77535": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events in both trials for the given data provided",
        "label": "Contradiction"
    },
    "9c7ccf99-0768-4a8a-bde9-bb3cb9b65c67": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one case of Gramnegative bacteremia which is a type of infection and infestation in each of the two cohorts of the primary clinical trial Therefore the statement that no infections and infestations cases were registered in the primary clinical trial is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "90474244-ea60-4670-b586-8ca32b80af7f": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events reported in the second cohort but the statement implies that all adverse events were experienced by patients in the first cohort only",
        "label": "Contradiction"
    },
    "9121985c-34cf-4378-b6ad-3b7a522c9ba5": {
        "text_answer": "Contradiction The evidence does not support the statement as it does not mention any thromboembolic events in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "52d479a4-9cd7-4fb6-b37f-f455c6c81402": {
        "text_answer": "Entailment The evidence shows that there were no adverse events reported in cohort 1 of the primary trial The statement that cohort 1 participants exhibited no adverse event throughout the duration is an entailment of the evidence",
        "label": "Entailment"
    },
    "880b2544-5c9d-4ce7-8d26-1081c7851cb9": {
        "text_answer": "Contradiction The primary trial does include assessments related to drug treatments pain therapy and qualityoflife assessment are both related to the effects of massage therapy and can be influenced by the drugs used during the trial",
        "label": "Contradiction"
    },
    "0744abca-2e7d-4e4a-a325-642ba6d16135": {
        "text_answer": "Contradiction  The evidence provided shows that there were 5 emesisfree participants in the placebo group and 13 emesisfree participants in the aprepitant group A twofold increase in the incidence of emesis would mean that there were 10 emesisfree participants in the placebo group which is not supported by the evidence",
        "label": "Contradiction"
    },
    "87273b6d-f10d-4638-ab87-bceade2d6510": {
        "text_answer": "Contradiction for the primary trial severe insomnia is an inclusion criterion in the secondary trial",
        "label": "Contradiction"
    },
    "64e22fa4-990b-4196-874a-a5ecf04cf3fb": {
        "text_answer": "Contradiction The primary trial measures the influence of broccoli sprout extract which contains sulforaphane and ascorbic acid on isothiocyanate concentration in urine not on vitamin C concentration in blood plasma However the statement does not directly contradict the evidence as it does mention the presence of ascorbic acid in the primary trial but the focus of each trial is different",
        "label": "Contradiction"
    },
    "6232508a-0f99-485f-9b84-af5692dac27b": {
        "text_answer": "Contradiction  Explanation The statement after four weeks of treatment with TAK228 plus tamoxifen the primary clinical trial observed no changes in the percentage of cells expressing Ki67 is a contradiction to the evidence provided The evidence shows that the median percentage of cells expressing Ki67 at 6 weeks was 10 2 to 38 which is a decrease from the baseline of 15 ",
        "label": "Contradiction"
    },
    "fd2867fb-a94f-42ce-87a1-aebdcfd015b8": {
        "text_answer": "Contradiction The statement goes beyond the information provided in the evidence which only mentions MM111 as the intervention and does not specify any surgical or imaging procedures",
        "label": "Contradiction"
    },
    "413156ec-dbfb-4c78-9518-cbde7d4765da": {
        "text_answer": "Contradiction The evidence provided does not mention anything about cognitive function scores or the use of Cogstate in either trial",
        "label": "Contradiction"
    },
    "4fec2620-4ede-44a4-adc9-54b525e89387": {
        "text_answer": "Entailment assuming the various other kinds of aes mentioned in the statement do not include adverse events related to cardiology or psychology",
        "label": "Entailment"
    },
    "75c25f91-4918-40d6-b84d-d5be844b97ef": {
        "text_answer": "Entailment The evidence states that 111 909 patients had an increased blood bilirubin which is a part of the 3636 of adverse events recorded in the trial",
        "label": "Entailment"
    },
    "86a5a47e-a2cb-461e-bcc5-8f71620376b8": {
        "text_answer": "Irrelevant The evidence provided does not include any information about the ctnnb1 protein variant",
        "label": "Entailment"
    },
    "31ec9b33-fa24-4cd9-9341-c54adaa250cd": {
        "text_answer": "Contradiction The evidence states that patients with a history of interstitial lung disease or pneumonitis are excluded from the trial but it does not specifically mention diffuse parenchymal lung disease within the last 36 months as an exclusion criterion",
        "label": "Contradiction"
    },
    "2f6221cf-15f0-4da7-b800-d65f4dd001d7": {
        "text_answer": "Contradiction The performance status is an inclusion criterion for both the primary and secondary clinical trials",
        "label": "Contradiction"
    },
    "c41ed5cf-4629-4a4f-b564-197d705ec9cc": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial had 0 adverse events while the secondary trial had 2 adverse events",
        "label": "Contradiction"
    },
    "e547ee04-f454-4ec3-b2fb-9ea04c97bdab": {
        "text_answer": "Contradiction The statement numerous adverse events were noted in the primary clinical trial and over half of the patients in the secondary clinical trial were affected by skin infections is a contradiction based on the evidence provided The primary trial had no reported adverse events while the secondary trial had one reported case of skin infection out of 30 patients",
        "label": "Contradiction"
    },
    "64839cde-9ad9-4363-9d78-7a2621bc7ec4": {
        "text_answer": "Contradiction  The statement all patients in cohort 2 were given capecitabine orally every day for the initial 21 days is contradictory to the evidence in the primary trial which states that capecitabine was administered orally from Days 1 to 14 every 21 days",
        "label": "Contradiction"
    },
    "8bc0e440-faca-4386-8718-e306978edb67": {
        "text_answer": "Contradiction The statement is incorrect because patients with inflammatory breast cancer are excluded from the secondary trial",
        "label": "Contradiction"
    },
    "974d4228-3dd6-42ab-b4e6-1b3f8e9ecdc5": {
        "text_answer": "Contradiction  Explanation The statement while both cohort 1 and cohort 2 of the primary clinical trial were given equal dosage of cetuximab is contradicted by the evidence as the evidence shows that cohort 1 received a different intervention in addition to cetuximab",
        "label": "Contradiction"
    },
    "6c31de8a-736c-4741-99d3-fcd0c921e83f": {
        "text_answer": "Contradiction  Explanation The statement mentions that the frequency of pericardial effusions was higher in the primary clinical trial but the evidence shows that there was no pericardial effusion reported in the secondary trial Additionally the statement mentions that corneal deposits were more often noted in the latter trial but the evidence shows that there were no corneal deposits reported in either trial Therefore the statement is a contradiction based",
        "label": "Contradiction"
    },
    "0a44470c-bf27-4795-aa25-f30a58771625": {
        "text_answer": "Entailment assuming the statement nervous system part in the question is not relevant to the evidence provided and is just an extra information The primary trial results do show that tamoxifen reduces Ki67 expression in breast tumors by an average of 40",
        "label": "Entailment"
    },
    "647c8d22-6888-4f04-a70b-0245b68a6fab": {
        "text_answer": "Contradiction  Explanation  The primary trial includes patients with histologically verified stage IIbIIIIV breast cancer while the secondary trial includes patients with a life expectancy of at least 1 year excluding their diagnosis of cancer Therefore patients in the final stage of cancer stage IV are not eligible for the secondary trial as they do not meet the life expectancy requirement  However the statement suggests that patients in the",
        "label": "Contradiction"
    },
    "07dab01c-f419-4079-bd0d-491740c5ec95": {
        "text_answer": "Entailment assuming several means more than one but not necessarily all The evidence shows that multiple patients experienced the same adverse events",
        "label": "Entailment"
    },
    "16505ccd-8394-4c6e-8ab2-bbf56583c6be": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the evidence shows that the dose of cyclophosphamide is higher than that of eribulin in Intervention 1",
        "label": "Contradiction"
    },
    "9022a69a-98fa-45ab-8a03-3a6e81102d03": {
        "text_answer": "Entailment The statement is a subset of the inclusion criteria for the primary clinical trial",
        "label": "Entailment"
    },
    "e5e7bbc4-cce7-41e3-b973-ac14fdff5600": {
        "text_answer": "Contradiction The primary trial involves an intraosseous injection of Fluciclatide while the secondary trial involves an oral administration of Chloroquine These interventions are not the same",
        "label": "Contradiction"
    },
    "66a9e527-8f35-4c41-be7f-ad854d0066f9": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement does not directly relate to the inclusion or exclusion criteria for the primary or secondary trials The statement is about the occurrence date range validation code which is not mentioned in the evidence Therefore it is neutral with respect to the entailment or contradiction of the evidence",
        "label": "Entailment"
    },
    "8a79949b-06e3-4943-a63d-248e1a432a7b": {
        "text_answer": "Contradiction The primary trial does not accept patients with early stage colorectal cancer without Kras or BRAF mutations for unlimited enrollment The trial only accepts patients with metastatic colorectal cancer that harbors the Kras or BRAF mutation 1530 enrollment slots",
        "label": "Contradiction"
    },
    "7758b88c-2f21-4b63-b76d-010298f50aa7": {
        "text_answer": "Contradiction Cohort 1 received 80 mg of Enzalutamide daily while Cohort 2 received 160 mg of Enzalutamide daily which is not considered a similar dose",
        "label": "Contradiction"
    },
    "9a749008-f77d-49bf-b529-82d049a8f446": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher ORR 0587 compared to the Paclitaxel Plus Bevacizumab group 0489",
        "label": "Contradiction"
    },
    "5c2d33e2-9759-4060-9bdd-7ecda4123cda": {
        "text_answer": "Entailment The statement is true given the evidence provided Both trials reported no adverse events for the participants mentioned",
        "label": "Entailment"
    },
    "03837d34-3ddb-4bfc-a993-b27e2d16f427": {
        "text_answer": "Contradiction The statement does not entail the information provided in the evidence as the primary and secondary trials measure different outcomes The primary trial measures the severity of delayed nausea using a scale while the secondary trial measures the change in bone mineral density of the lumbar spine",
        "label": "Contradiction"
    },
    "47512f16-9809-4150-a101-1fb7256c5bf3": {
        "text_answer": "Contradiction The secondary trial measures pain not muscle gains",
        "label": "Contradiction"
    },
    "c5fb4937-5177-47c9-8ce2-1fdec2a17942": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the percentage of participants with HER2 metastases according to the evidence is 13 not 57",
        "label": "Contradiction"
    },
    "72d62a11-d0ff-4e2b-8bb9-22a1858b4914": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the use of multiple types of interventions including chemotherapy drugs doxorubicin hydrochloride cyclophosphamide methotrexate vinorelbine tartrate targeted therapy trastuzumab letrozole and surgical procedures needle biopsy and therapeutic conventional surgery  However the statement provided as",
        "label": "Contradiction"
    },
    "607586af-260d-46ef-88ce-b8672e4aaa25": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided The evidence only discusses adverse events in two clinical trials and there is no mention of any patients being Japanese",
        "label": "Contradiction"
    },
    "877e791d-73b6-4af2-945c-29f54005c405": {
        "text_answer": "Contradiction The first trial is about Denosumab and the second trial is about dmethadone which are two different drugs and different patient cohorts",
        "label": "Contradiction"
    },
    "ce40b0b9-d8d4-45f4-a2dc-4adb8e7103ac": {
        "text_answer": "Entailment The evidence shows that the percentage of patients with adverse events in cohort 1 4245 is higher than that in cohort 2 680",
        "label": "Entailment"
    },
    "bc1a73c0-825c-48dd-b6cf-e440ae0bb782": {
        "text_answer": "Contradiction  The evidence states that patients will be taking vorinostat capsules daily during radiation therapy so the statement that they are strictly prohibited is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "0d7caeea-5417-4eb2-9d92-3d3ada73ece7": {
        "text_answer": "Entailment The evidence shows that no adverse events affecting more than 1 of participants were reported in either trial",
        "label": "Entailment"
    },
    "38acc5fa-c86b-4734-bdb6-7acbcd3c37c4": {
        "text_answer": "Contradiction  The primary trial involves oral pregabalin while the secondary trial involves intravenous liposomal cytarabine and ifosfamide These are not the same interventions",
        "label": "Contradiction"
    },
    "94023f3a-38d4-4b1b-a65a-9536480ff4c4": {
        "text_answer": "Contradiction The primary and secondary trials have different inclusion criteria and there is no mention of fatigue or work limitations in the primary trials inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "3f0e9340-88df-433f-8bdb-e32523b86a86": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial does not involve a comparison of dosages between Zoledronic Acid and Denosumab",
        "label": "Contradiction"
    },
    "9a7f95d5-8fb7-4f77-a921-00a2633e8cc4": {
        "text_answer": "Contradiction The evidence does not provide information on the cervical cancer screening status of all 61 participants in the first phase of the primary clinical trial before the intervention",
        "label": "Contradiction"
    },
    "ffa6aa2b-661d-4e25-a893-6e03dea7e39e": {
        "text_answer": "Contradiction The primary trial measures tumor response using RECIST criteria which includes Complete Response CR Partial Response PR Stable Disease SD and Progressive Disease PD The statement does not mention Clinical Benefit which could include CR PR or SD as a measured outcome in either trial However the primary trial does report the number of participants with PD which is not the same as Clinical Benefit",
        "label": "Contradiction"
    },
    "ef79f4a4-d4ec-4a2a-a2a6-41ad41235927": {
        "text_answer": "Contradiction  The statement does not follow from the evidence as there is no information provided in the evidence about the use of fentanyl sublingual spray during the primary trial",
        "label": "Contradiction"
    },
    "ceb02a85-73a3-4c00-823e-fb88bc91d239": {
        "text_answer": "Contradiction The primary trial explicitly excludes smokers while the secondary trial mentions nothing about smoking status The statement suggests that smokers are excluded from the primary trial but eligible for the secondary trial if they drink less than 5 alcoholic drinks a day but the primary trial does not allow smokers at all",
        "label": "Contradiction"
    },
    "f9e4988c-a325-40bc-8220-e7d0c404fd37": {
        "text_answer": "Contradiction  The statement None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort is a contradiction to the evidence as the adverse event type disease progression affected 1429 of the patients in the primary trial which is more than a quarter of the patient cohort",
        "label": "Contradiction"
    },
    "2a2a6190-619e-478b-a97d-5a253a8f916c": {
        "text_answer": "Contradiction The evidence states that patients with a history of abdominal fistula or gastrointestinal perforation in the past 6 months are excluded from the trial",
        "label": "Contradiction"
    },
    "13eb7b14-5252-4004-8c72-56e3d5d3ca8a": {
        "text_answer": "Entailment assuming the statement is referring to a decrease in Ki67 expression from the baseline to 6 weeks which is consistent with the evidence provided",
        "label": "Entailment"
    },
    "87a42ef9-ff00-41f8-ba0a-9ca84498f7eb": {
        "text_answer": "Contradiction  The evidence states that 98 of the patients had recurrencefree survival which is not consistent with the statement that just a pair of patients did not demonstrate recurrencefree survival",
        "label": "Contradiction"
    },
    "5bc078b0-0b64-4d47-a015-26c3f03c864e": {
        "text_answer": "Entailment The evidence states that the dosage of Enzalutamide for cohort 2 is 160 mg which is indeed twice the dosage of 80 mg given to cohort 1",
        "label": "Entailment"
    },
    "733d9f9f-9a01-4643-ab99-ac6086ad5cbc": {
        "text_answer": "Contradiction The evidence states that participants in Intervention 1 receive memantine for 12 weeks which is the same duration as the placebo intervention in Intervention 2",
        "label": "Contradiction"
    },
    "318ded6f-e96c-4a4f-8f4b-ff19f2e86c16": {
        "text_answer": "Contradiction assuming coronary artery stenosis is considered a type of cardiac event or adverse event  Explanation The statement there are no recorded instances of coronary artery stenosis as an ae in the primary clinical trial is a contradiction to the evidence because there is no mention of coronary artery stenosis in the list of adverse events for the primary clinical trial",
        "label": "Contradiction"
    },
    "81a3bd04-5dff-45a6-a4eb-7a41c59b0023": {
        "text_answer": "Contradiction The primary trial and the secondary trial are about different outcomes and study populations The primary trial is about the diagnostic accuracy of two algorithms in breast cancer diagnosis while the secondary trial is about the effect of reflexology on fatigue levels in breast cancer patients undergoing radiation therapy",
        "label": "Contradiction"
    },
    "2aac2b30-f74d-4435-b7e6-ec5cd5923da3": {
        "text_answer": "Contradiction  The evidence shows that there were 5 distinct adverse events in cohort 1 and 5 distinct adverse events in cohort 2 making a total of 10 distinct adverse events across both cohorts The statement implies that only 4 distinct adverse events influenced patients in the primary clinical trial which is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "3e6a3ebb-face-44fe-8bb1-cbd399f4e215": {
        "text_answer": "Contradiction The primary trial measures the frequency of treatmentemergent adverse events while the secondary trial measures changes in total sleep time These are different outcome measures",
        "label": "Contradiction"
    },
    "5e8286c8-3e7c-4b71-b824-103d031ac6b4": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence only mentions Surgery as the recorded adverse event in the primary trial and there is no mention of Stomatitis",
        "label": "Contradiction"
    },
    "d1424cd8-4dab-40a8-91b1-3ae5d1f57d56": {
        "text_answer": "Contradiction  Explanation The statement mentions several mortalities and admissions to the hospital occurred in the second cohort of the primary clinical trial but the evidence shows that there were no mortalities or hospitalizations reported in the second cohort The statement also mentions atrial fibrillation was also frequently detected but the evidence does not provide any information about atrial fibration in either cohort",
        "label": "Contradiction"
    },
    "78f50c70-09e5-4328-8ddf-f7e743527132": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial involves the use of IV PO and SC routes of administration for various drugs while the secondary trial only involves oral administration of two drugs",
        "label": "Contradiction"
    },
    "b7501704-ccba-40f8-852e-c157006483df": {
        "text_answer": "Contradiction The evidence states that patients receive MCS110 at 1 mgkg or 3 mgkg every 3 weeks and there is no information provided about the patients weights Therefore it is impossible for all patients to receive at least 20kg of MCS110 every 30 weeks based on the given evidence",
        "label": "Contradiction"
    },
    "0f0f75f2-7da8-4705-b260-62c5f542b91e": {
        "text_answer": "Contradiction  Explanation  In the primary trial only one intervention Intervention 2 includes Armodafinil and the dosage varies In contrast the secondary trial does not involve Armodafinil at all  Regarding the second part of the statement both Interventions in the secondary trial have the same dose of PDR001 100 mg Q3W but the dosage of M",
        "label": "Contradiction"
    },
    "d8fa557b-e20a-4b49-be9c-b55a6bde385a": {
        "text_answer": "Contradiction  The primary trial measures the number of participants with treatmentemergent adverse events AEs not the average nap duration The secondary trial measures the change in total sleep time as measured by polysomnography PSG",
        "label": "Contradiction"
    },
    "33cd5bbd-a795-467e-b08f-cf59702922cc": {
        "text_answer": "Contradiction The primary trial and secondary trial have different cohorts and outcome measurements making direct comparison difficult The statement mixes the results of the primary trial with the results of the secondary trial and incorrectly assumes that the time period of 36 weeks after start of radiation therapy is relevant to both trials",
        "label": "Contradiction"
    },
    "34199309-5388-4ed1-956d-17e9c7afaaef": {
        "text_answer": "Neutral The statement is not directly related to the given evidence",
        "label": "Entailment"
    },
    "1ce7b426-1be9-4684-b0a5-54d557d3b320": {
        "text_answer": "Entailment assuming that the frequencies being referred to are the percentages given in the evidence  Explanation The statement the frequencies of recurrent malignancies graftversushost disease infection altered mental status and diffuse alveolar hemorrhage as adverse events were indistinguishable between the primary and secondary clinical trials is an entailment of the evidence as the percentages of these adverse",
        "label": "Entailment"
    },
    "a6e81477-f863-4a83-9007-fd2f1f5c6781": {
        "text_answer": "Entailment Both groups have the same intervention which is taking talazoparib capsules but the evidence does not specify that they receive the same dose",
        "label": "Entailment"
    },
    "4a383701-3a27-4973-8c8c-4f697bde7484": {
        "text_answer": "Contradiction The primary trial involves the use of irinotecan and etoposide while the secondary trial does not mention any drug intervention",
        "label": "Contradiction"
    },
    "9a499642-970d-48b1-b0b4-96760793ba72": {
        "text_answer": "Contradiction The evidence states that the inclusion criteria for the primary clinical trial include adequate liver function",
        "label": "Contradiction"
    },
    "4e929375-b7c0-4a81-baa9-9c21d95366b7": {
        "text_answer": "Contradiction The primary trial does evaluate the efficiency of distinctive medicinal treatments Hydrophor vs MediHoney while the secondary trial evaluates the effect of varying doses of the same drug PF05212384",
        "label": "Contradiction"
    },
    "75cdd5c7-ad36-4ab3-8fe2-6d0e84ab8f0a": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not indicate that more than 30 of participants in either trial experienced reactive epithelial hyperplasia of the ciliary body",
        "label": "Contradiction"
    },
    "d7637d6e-ba2c-4fdc-936d-57c3bf938eff": {
        "text_answer": "Contradiction  The primary trial mentions the administration of 05ugkg of dexmedetomidine not myalgias while the secondary trial mentions patients with myalgias arthralgias andor joint stiffness but it does not mention the administration of 05ugkg of dexmedetomidine specifically",
        "label": "Contradiction"
    },
    "edd794e6-12c6-4d30-80ac-009951273d44": {
        "text_answer": "Contradiction  The primary trial excludes women with recurrent breast cancer while the secondary trial includes women with recurrent breast cancer as a part of its inclusion criteria Therefore a woman with recurrent stage I breast cancer confirmed as ER and considering lumpectomy would not be eligible for both trials based on the provided evidence",
        "label": "Contradiction"
    },
    "620b6390-df07-45fe-9ef9-55a32521c740": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that no cases of diarrhea were reported in the secondary trial while it was reported in 7 out of 30 participants in the primary trial",
        "label": "Contradiction"
    },
    "5b94480e-aa25-491e-ae37-a2b2939eafaf": {
        "text_answer": "Contradiction The primary trial includes patients undergoing lumpectomy while the secondary trial includes patients undergoing mastectomy with tissue expander reconstruction or skinsparing mastectomy These procedures are not the same so not all patients eligible for the secondary trial are eligible for the primary trial",
        "label": "Contradiction"
    },
    "c6194284-d44f-45c1-9477-754736bbf1a3": {
        "text_answer": "Contradiction  Explanation  The primary trial includes individuals with a breast tumor that is 1 cm in diameter and HR HER2 while the secondary trial does not specify tumor size or hormone receptor status However the primary trial excludes individuals with metastatic breast cancer while the secondary trial includes individuals with locally advanced or metastatic breast cancer These differences make the statement a contradiction",
        "label": "Contradiction"
    },
    "feca7444-9108-45e9-b722-4f0a207376c7": {
        "text_answer": "Contradiction The primary trial excludes patients with Vitamin D deficiency while the secondary trial does not mention Vitamin D deficiency as an inclusion or exclusion criterion",
        "label": "Contradiction"
    },
    "c78f1ce0-7597-415d-b5c3-203e696b48d5": {
        "text_answer": "Contradiction  The evidence does not provide information about the number of participants with stable disease at week 15 or week 30 The statement makes an assumption about a decrease in the number of participants with stable disease between weeks 15 and 30 which is not supported by the evidence",
        "label": "Contradiction"
    },
    "b80c2589-c792-4391-995c-6763270469dd": {
        "text_answer": "Contradiction The evidence does not support the statement as it does not provide any information about the presence or absence of a discernible gene expression pattern for patients with low vitamin D levels",
        "label": "Contradiction"
    },
    "cef48380-fe4b-4b71-931c-5b0dbfe1cf29": {
        "text_answer": "Contradiction The primary clinical trial is not unrestricted in the number of participants and is specifically for individuals with metastatic colorectal cancer that harbors the Kras or BRAF mutation",
        "label": "Contradiction"
    },
    "d9a63f26-68c3-431f-851f-131f7a547902": {
        "text_answer": "Contradiction The evidence provided does not support the statement as it lists various medical conditions that are not related to psychological health issues",
        "label": "Contradiction"
    },
    "884bc204-4928-430b-b44d-1e33ef66731d": {
        "text_answer": "Contradiction The primary trial explicitly states that participants cannot have undergone major surgery within 28 days prior to the study registration date while the secondary trial does not mention any such restriction",
        "label": "Contradiction"
    },
    "9e19e98e-3ce1-4b01-9080-ad34e68f0acb": {
        "text_answer": "Contradiction  Explanation The evidence states that all 25 participants in the Sunitinib  Docetaxel  Trastuzumab arm experienced treatmentemergent adverse events and 11 of these participants experienced severe treatmentemergent adverse events This contradicts the statement that except one all patients who received sunitinib  docetaxel  trastuzumab experienced a treatmentemer",
        "label": "Contradiction"
    },
    "58429d01-0c6a-4ae1-b8ce-73ee8a8e775d": {
        "text_answer": "  Neutral The statement is neither an entailment nor a contradiction based on the provided evidence  Explanation  The statement Patients with stage 4 cancer are eligible for the secondary trial and the primary trial if they provide informed consent does not directly address the concept of organ perforation The evidence provided in the inclusion and exclusion criteria for both trials does not mention organ perforation as a criterion for eligibility",
        "label": "Entailment"
    },
    "87be81ce-d5b1-4905-9452-2e0e2d4b7b2c": {
        "text_answer": "Entailment  Explanation The statement participants in the primary trial receive four different drugs throughout the study duration with a maximum dose of 100000 µgm2 is an entailment of the evidence provided in the primary trial The drugs mentioned in the trial are epirubicin cyclophosphamide docetaxel and trastuzumab Each of these drugs is administer",
        "label": "Entailment"
    },
    "519fe8b4-596f-4db6-af13-80d9746041a6": {
        "text_answer": "Contradiction The primary trial evidence does not mention any age limit for participants beyond the requirement that they be 18 years of age",
        "label": "Contradiction"
    },
    "76d498ce-037c-4f7e-8cbb-450d8f6019ec": {
        "text_answer": "Entailment The evidence states that patients are eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced andor metastatic which is consistent with the statement that patients of any gender can be eligible for both phases if they have this type of tumor",
        "label": "Entailment"
    },
    "e2a5ecca-6d4a-438b-a42c-46657ccb4050": {
        "text_answer": "Contradiction The statement provided does not relate to the evidence given in the primary trial results The evidence only provides information about the number of participants with serious and nonserious adverse events in two different dose levels of a vaccine trial It does not mention anything about the age in days at immunohistochemistry assessment or the percentage of participants suffering from lifethreatening adverse events in a specific cohort",
        "label": "Contradiction"
    },
    "808d2233-0c0d-4221-bfae-e54fdcf31ce4": {
        "text_answer": "Contradiction The primary trial and the secondary trial are about different outcome measurements The primary trial is about the diagnostic accuracy of two algorithms in breast cancer diagnosis using ROC curve analysis while the secondary trial is about the effect of reflexology on fatigue levels in breast cancer patients using the Lee Fatigue Scale",
        "label": "Contradiction"
    },
    "fb616088-52c2-4dae-84e5-8a1a3fa9b64f": {
        "text_answer": "Contradiction  The statement is not an entailment or a contradiction based on the evidence provided The evidence does not mention anything about a unit of concentration or a liter per hour per kilogram per meter squared in relation to the primary trial or patient eligibility",
        "label": "Contradiction"
    },
    "f2d7cf41-2cd1-4d03-a153-18764cf7da09": {
        "text_answer": "Contradiction  Explanation The statement does not follow from the evidence as the evidence does not provide information about the cognitive function of the patients in the primary trial improving or deteriorating on average let alone for both cohorts The statement also mentions a crank arm assembly device which is not related to the evidence",
        "label": "Contradiction"
    },
    "1748cec0-92de-44af-9d49-bf45518c24bc": {
        "text_answer": "Entailment The statement is an entailment because the evidence supports that in both trials no adverse events occurred in more than 1 of participants",
        "label": "Entailment"
    },
    "939de4be-2f3d-4e0d-a5b9-a80f6469bd22": {
        "text_answer": "Contradiction The statement is not related to the provided evidence The evidence only reports adverse events from the trials and there is no mention of Tumour lysis syndrome or meters times percent as a unit of measure for the distance saturation product",
        "label": "Contradiction"
    },
    "3cb08dda-e0dc-48e5-87fa-e24386d6dab2": {
        "text_answer": "Contradiction The statement specifies a longer duration 26 weeks than what is stated in the exclusion criteria 6 months",
        "label": "Contradiction"
    },
    "e7be25fe-5915-4c38-b3c0-4e4acd5edd5c": {
        "text_answer": "Entailment The evidence states that subjects with tumors positive for CCND1 amplification CDK46 mutation or CCND2 amplification are excluded from the primary trial The statement accurately reflects this information",
        "label": "Entailment"
    },
    "95840c1a-9e38-4fe5-939c-e6f9aa107ced": {
        "text_answer": "Contradiction The primary trial had no reported adverse events while the statement assumes that all adverse events reported in the primary trial were suspected serious adverse reactions The secondary trial had no reported adverse events at all",
        "label": "Contradiction"
    },
    "6e5e4b46-3bc7-4ae1-8668-9b4f2f72f791": {
        "text_answer": "Contradiction The primary trial explicitly states that participants must be aged greater than 20 years old The secondary trial states that participants must be 18 or older However women under 18 are not qualified for either trial according to the provided evidence",
        "label": "Contradiction"
    },
    "454c83f7-949e-46bf-bd9a-5f14e6ba4713": {
        "text_answer": "Contradiction The statement is about prior treatment with gabapentin or pregabalin and the evidence is about no prior gabapentin or pregabalin",
        "label": "Contradiction"
    },
    "4678ba70-3ec1-487b-a641-bdbd790892ac": {
        "text_answer": "Entailment The evidence shows that no participants in the secondary trial suffered an acute myocardial infarction which is a subset of the statement that the percentage of participants suffering from an acute myocardial infarction in the secondary trial is 0 The primary trial also had no participants suffering from an acute myocardial infarction which is a subset of the statement that 000 of the primary trial participants suffered from an",
        "label": "Entailment"
    },
    "5f36a4ca-cd2f-4c38-8040-9b36da0ebbe4": {
        "text_answer": "Contradiction The evidence does not support the statement that only American patients who fall into a specific weight range are eligible for the primary clinical trial The eligibility criteria for the primary trial do not mention anything about weight or nationality",
        "label": "Contradiction"
    },
    "358cd111-420a-401d-bd92-e459d3725026": {
        "text_answer": "Contradiction The evidence states that pregnant women are excluded from both trials Severe obesity is not listed as an exclusion criterion for either trial",
        "label": "Contradiction"
    },
    "e8351b8b-d707-4766-b875-777557f0653f": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as pericardial effusions were not more common in the primary trial according to the given data",
        "label": "Contradiction"
    },
    "ab3fc92f-0d8a-472f-b652-e10bcd03ff19": {
        "text_answer": "Contradiction The statement is not related to the evidence provided which only discusses adverse events in the primary trial and does not mention reconstructive plastic surgery",
        "label": "Contradiction"
    },
    "494a4094-5a05-4c7d-b7a7-60baeb210e5a": {
        "text_answer": "Entailment given that the evidence does not report any unexpected deaths or hospitalizations in either trial",
        "label": "Entailment"
    },
    "e5d16f98-79d0-44e1-9fc0-7bb6ae9a038d": {
        "text_answer": "Neutral The statement does not directly follow from the evidence but it is not contradictory either The evidence only provides information about the doses of Enzalutamide given in the two cohorts of the trial it does not mention anything about the level of dissatisfaction in the cohorts",
        "label": "Entailment"
    },
    "5ce6e37b-2c84-44e1-8c5e-e441cec64872": {
        "text_answer": "Contradiction The evidence does not mention anything about talazoparib or its dosage being administered in the primary trial",
        "label": "Contradiction"
    },
    "1e32317b-5301-461d-bdd9-0acb2e076522": {
        "text_answer": "Entailment assuming that carefully documented implies that adverse events were reported in both trials even if the numbers are not provided for all categories in the secondary trial",
        "label": "Entailment"
    },
    "04c5ba38-d98e-4fd7-b5f4-ea4706f26355": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement does not directly relate to the information provided in the evidence regarding the primary trial The statement is about retinal hemangioblastoma which is not mentioned in the evidence",
        "label": "Entailment"
    },
    "9f97138b-399f-42bf-9afe-e7195db4e5b4": {
        "text_answer": "Contradiction The primary trial has an ECOG performance status of 02 which is equivalent to Karnofsky performance status 60100 meaning patients are able to perform normal activities with minimal restriction The secondary trial includes patients with ECOG 02 or Karnofsky 60100 but also includes those with Karnofsky 50 which corresponds to ECOG 3 meaning",
        "label": "Contradiction"
    },
    "ae583e53-d445-4b4a-b49a-c440881180e7": {
        "text_answer": "Contradiction  Explanation  The statement suggests that in the primary trial candidates receive lower weekly doses of MM121 and paclitaxel but greater volumes of Herceptin and Docetaxel However the evidence provided does not support this statement as it does not mention the dosing of Herceptin or Docetaxel in the primary trial Additionally the dosing of MM121 and paclit",
        "label": "Contradiction"
    },
    "fa5e894c-13be-4786-ac47-16d31de8a7ce": {
        "text_answer": "Neutral The statement does not directly follow from the evidence provided but it is not contradictory either  Explanation  The statement distress over family problem with family health issues is a question about an individuals distress related to their family problems dealing with family health issues is not directly related to the inclusion or exclusion criteria provided in the evidence for the primary or secondary trials The statement does not entail or contradict any information in the evidence",
        "label": "Entailment"
    },
    "67bce826-0ca5-477c-8802-2511317e675d": {
        "text_answer": "Entailment Both trials involve the use of cyclophosphamide in their respective interventions",
        "label": "Entailment"
    },
    "bbda33ff-3d5b-445e-afec-a20518fd2c79": {
        "text_answer": "Entailment The primary trial had fewer total adverse events and fewer types of adverse events than the secondary trial as shown in the evidence",
        "label": "Entailment"
    },
    "68d0da33-c4ad-4649-bb63-08290cd4d4e2": {
        "text_answer": "Contradiction The primary trial requires mammography while the secondary trial does not mention mammography as a requirement",
        "label": "Contradiction"
    },
    "fc7722bc-9fed-46cf-881d-265c3f3762b4": {
        "text_answer": "Contradiction The statement does not entail the evidence as there were no cases of Acute myocardial infarction reported in either trial",
        "label": "Contradiction"
    },
    "a9cbf72a-fd01-403d-8afa-d9d6a69622a0": {
        "text_answer": "Contradiction The statement does not provide any information related to the number of adverse events suffered by patients in the primary trial",
        "label": "Contradiction"
    },
    "41c54be8-c257-49dc-b21b-0184595c1277": {
        "text_answer": "Contradiction  The statement requires that the dose given to cohort 1 is less than 50 of the dose given to cohort 2 but the evidence only shows that the dose given to cohort 1 is less than the dose given to cohort 2 not that it is less than 50 of it",
        "label": "Contradiction"
    },
    "4417c4c8-522f-4e46-8b8d-310995182d70": {
        "text_answer": "Contradiction The evidence does not provide information about the number of participants in each cohort of the trial other than Arm II having 234 participants and Arm III having 241 Therefore it is impossible to determine if Arm II has 10 fewer participants than Arm III based on the given evidence",
        "label": "Contradiction"
    },
    "7b74835d-12ba-4d02-a09c-817f33abd3b2": {
        "text_answer": "  Contradiction   Patients with stage 4 cancer are not eligible for the primary trial according to the provided inclusion criteria",
        "label": "Contradiction"
    },
    "3dab8f67-6eca-4ace-ba49-0bd33547b004": {
        "text_answer": "Contradiction  Explanation The statement while most patients in the first cohort of the primary clinical trial endured adversities the same cannot be said for the second cohort is a contradiction based on the evidence provided The evidence shows that the percentage of patients with adverse events in the first cohort 4245 is higher than that in the second cohort 680 Therefore it",
        "label": "Contradiction"
    },
    "359a101f-e771-4fac-b2f7-a5486fb19344": {
        "text_answer": "Contradiction The evidence provided does not relate to sellar teratoma or malignant transformation but rather to the number of emesisfree participants during a bone marrow transplant trial for aprepitant and placebo interventions",
        "label": "Contradiction"
    },
    "cbbd5644-6e63-4f6d-b948-fe52b5df89c7": {
        "text_answer": "Contradiction The evidence does not support the statement as the longest PFS observed in the trial was 29 months for the CDX011 group",
        "label": "Contradiction"
    },
    "2fb19f2c-7bda-446c-bf0c-8e9842e89c97": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the intervention in the primary clinical trial is given orally cabergoline and not topically and in the secondary clinical trial pixantrone is given intravenously",
        "label": "Contradiction"
    },
    "be93f6ab-df27-4f10-a485-24823f7056fc": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence does not mention the occurrence of cholelithiasis in either trial let alone a comparison of its frequency between the two trials",
        "label": "Contradiction"
    },
    "effcbfa0-9271-4463-9e48-5523d5cedeb6": {
        "text_answer": "Contradiction The evidence does not mention anything about the patients closest family member having any role in the final decision for participation in the clinical trial",
        "label": "Contradiction"
    },
    "1f309606-5b98-4320-ab02-24e782e7250d": {
        "text_answer": "Neutral The primary trial does not report results related to lymph nodes or median or lower cervical lymph nodes so it cannot entail or contradict the statement",
        "label": "Entailment"
    },
    "f0a1bf43-c080-446d-815a-c588c7563e89": {
        "text_answer": "Contradiction The evidence states that participants received niraparib not talazoparib",
        "label": "Contradiction"
    },
    "de3effdb-0854-48a8-b66c-b61378ec7a6f": {
        "text_answer": "Contradiction The primary and secondary trials do not involve radiation therapy Both trials focus on the administration of specific drugs Eribulin Mesylate Axitinib and Docetaxel and their respective dosing schedules",
        "label": "Contradiction"
    },
    "d2673e8f-15c9-4476-b8b6-2567822d5cd4": {
        "text_answer": "Irrelevant  The statement is not related to the evidence provided as the evidence pertains to breast cancer and the iDFS rates for bladder small cell neuroendocrine carcinoma were not mentioned in the trial results",
        "label": "Entailment"
    },
    "cbba3546-5b88-42d0-882d-024d5f267d97": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as no palpitations pericardial effusions or abdominal pains were recorded in the secondary trial while they were recorded in the primary trial",
        "label": "Contradiction"
    },
    "5c535bb9-8464-4820-b872-506057f2cd87": {
        "text_answer": "Contradiction The primary trial did not include a group treated with GTx024 8mg",
        "label": "Contradiction"
    },
    "94328fa0-182a-4275-929c-bc10f899ba5d": {
        "text_answer": "Contradiction for the primary trial regarding breast implants and ambiguous for the secondary trial regarding pulmonary embolism as the evidence does not explicitly state that patients with a history of pulmonary embolism can participate in the secondary trial",
        "label": "Contradiction"
    },
    "a668e3be-6b87-468e-99b5-48ad77bed972": {
        "text_answer": "Contradiction The statement does not entail the evidence as it does not mention anything about a photovoice method in the primary trial",
        "label": "Contradiction"
    },
    "59d62015-4627-4fef-acba-984ff4ad2964": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence describes the administration of chemotherapy drugs and bevacizumab not vaccines",
        "label": "Contradiction"
    },
    "e4b57c09-4069-463e-9db3-70860f520524": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the number of drugs and surgery involved in the primary and secondary trials are different The statement also mentions ambumustine which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "4e68783f-fc2b-4efb-88da-b5d081ff5541": {
        "text_answer": "Contradiction The evidence shows that a higher percentage of adverse events were reported in cohort 2 compared to cohort 1",
        "label": "Contradiction"
    },
    "d7abc723-e08e-442e-82e4-3e369341b72a": {
        "text_answer": "Contradiction The primary trial includes all pediatric cancer patients while the secondary trial only includes patients with pediatric Bcell acute lymphoblastic leukemia",
        "label": "Contradiction"
    },
    "60f6302e-f888-4bc2-b689-f0620024f93e": {
        "text_answer": "Entailment The evidence shows that the total number of adverse events in cohort 1 was higher than in cohort 2",
        "label": "Entailment"
    },
    "837329c4-d046-4997-ad41-f230d3db7255": {
        "text_answer": "Entailment  Explanation The statement There were no cardiac or psychiatric AEs recorded during the primary trial and the secondary trial is an entailment based on the evidence provided The evidence shows that no cardiac or psychiatric adverse events were recorded in both trials which is exactly what the statement asserts",
        "label": "Entailment"
    },
    "4dcbfb0d-cb67-4d74-a21a-0920159dfafc": {
        "text_answer": "Entailment  Explanation The evidence from both trials indicates that no adverse events were recorded in Adverse Events 1 for the primary trial and no adverse events were recorded in Adverse Events 1 or Adverse Events 2 for the secondary trial Therefore the statement that both the primary clinical trial and the secondary clinical trial did not make a record of any adverse events is an entailment based on the evidence provided",
        "label": "Entailment"
    },
    "3bde4a4f-fece-4422-a55a-461fa027c18a": {
        "text_answer": "Contradiction Perjeta is not mentioned in the primary trial at all and there is no information about testicular teratomas in either trial",
        "label": "Contradiction"
    },
    "31546be8-dcef-4300-a21d-831c25e5b92a": {
        "text_answer": "Contradiction  Explanation The statement 0 adverse events were observed in the primary trial contradicts the evidence from the primary trial which states that there were no adverse events reported in Adverse Events 1 but there is no mention of Adverse Events 2 in the primary trial so it is impossible to say that no adverse events were observed at all based on the given evidence",
        "label": "Contradiction"
    },
    "d3a0e851-28c4-4382-bb3e-8c40bc16ae7a": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that diarrhea was not noted as a more common symptom in the primary clinical trial participants as compared to those of the secondary clinical trial as the frequency of diarrhea in the primary trial was higher 2333 than in the secondary trial 000",
        "label": "Contradiction"
    },
    "05aafe0b-c62a-4dda-a60a-52929cb81b7f": {
        "text_answer": "Entailment The statement includes all the exclusion criteria mentioned in the evidence Therefore if a patient has any of those conditions they would not be eligible for the trial",
        "label": "Entailment"
    },
    "74308ad0-4b9d-4632-9580-5e280dedbc77": {
        "text_answer": "Contradiction for Phase 2 ER positive breast cancer is a requirement",
        "label": "Contradiction"
    },
    "6333ef7c-fdfe-4f90-b763-4d826c08975c": {
        "text_answer": "Entailment  Explanation The statement in both the primary clinical trial and the secondary clinical trial there were adverses events which affected less than 1 of the participant group is an entailment based on the evidence provided In the primary trial the adverse event affected 048 of the participants which is less than 1 In the secondary trial no adverse events were reported which also meets the criteria of less",
        "label": "Entailment"
    },
    "66030da0-0335-44c8-97dd-a620f3d9961f": {
        "text_answer": "Contradiction The primary trial only includes patients with a score of 3 on the Sleep Disruption Evaluation form or a score of 8 on the Insomnia Severity Index indicating moderate to severe insomnia The secondary trial includes patients with a score of 6 weeks or more of treatment remaining and a score of 3 on the Sleep Disruption Evaluation form or a score of 8 on the Insomnia Severity Index but it",
        "label": "Contradiction"
    },
    "72130361-5d83-4dbb-98ce-8e9a6f2541e4": {
        "text_answer": "Contradiction The primary and secondary trials have different outcome measurements The primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel",
        "label": "Contradiction"
    },
    "72b75fca-541f-4311-a38d-9f1d73220418": {
        "text_answer": "Contradiction The statement is not related to the evidence provided as the evidence does not report any information about changes in the way food tastes for any of the trial participants",
        "label": "Contradiction"
    },
    "66bf512a-c3fd-46a8-8a0b-4d64fde85082": {
        "text_answer": "Contradiction The statement mentions that patients with NUT midline carcinoma and CRPC are eligible for the primary trial but it does not mention inflammatory breast cancer as an eligible condition for the primary trial However the statement also mentions that patients with inflammatory breast cancer are eligible for the secondary trial Therefore the statement is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "9e3cf2a2-6713-4d07-adde-e334b49ca6ec": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention does not specify the dose of MM121 and Paclitaxel given to the patients However in the secondary trial cohort 1 received 20 mgkg weekly of MM121 and 80 mgkg weekly of Paclitaxel for 12 weeks Therefore the statement that the primary trial candidates receive less weekly",
        "label": "Contradiction"
    },
    "e59036ac-08b6-44ed-ad46-292a3bb8a937": {
        "text_answer": "Contradiction  Explanation The statement mentions no fatalities or hospital stays occurred in the second cohort which contradicts the evidence that shows no fatalities were reported in either cohort but there were hospitalizations in both cohorts",
        "label": "Contradiction"
    },
    "c01204e3-a0fd-4153-a27d-d17c0bb4773b": {
        "text_answer": "Contradiction  Explanation The evidence provided in the results shows an increase in the percentage of patients who were up to date for colorectal breast and cervical cancer screenings following the intervention in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups Therefore the statement that many patients in the first cohort of the primary clinical trial did not adhere to their screening schedules",
        "label": "Contradiction"
    },
    "21b261e7-4b78-4c70-ba0c-b98c5c082bee": {
        "text_answer": "Contradiction The statement is not supported by the evidence as the evidence only provides data for percentage change in betaCTX at Week 4 not Week 28",
        "label": "Contradiction"
    },
    "29c084b6-6c7c-4f6b-abcc-6740b951f139": {
        "text_answer": "Contradiction The primary trial had a smaller number of participants in Cohort 2 compared to the secondary trial",
        "label": "Contradiction"
    },
    "0feb3694-da20-4a30-b85d-e9dc4cdb55c3": {
        "text_answer": "Contradiction The primary trial reported 0 cases of intestinal perforation while the secondary trial reported 1 case",
        "label": "Contradiction"
    },
    "551f61b2-c709-4c51-b705-d2415e40ae40": {
        "text_answer": "Contradiction The primary trial assesses toxicity while the secondary trial assesses percentage of participants with adverse events of primary interest These are not the same patient characteristics",
        "label": "Contradiction"
    },
    "dc9267c3-b1ab-45d1-8a22-a9ec8e7ba673": {
        "text_answer": "Entailment for each cancer type the percentage of patients uptodate for screenings increased after the intervention",
        "label": "Entailment"
    },
    "72d13f98-6915-4a80-9810-c06d0e204b1e": {
        "text_answer": "Contradiction The statement goes beyond the evidence provided as the interfant06 protocol is not mentioned in the evidence and there is no comparison of the significance of the percentage change in betaCTX between the two groups in the statement",
        "label": "Contradiction"
    },
    "2e9d87da-10f2-4530-b200-87bb72cd9335": {
        "text_answer": "Contradiction  The primary trial excludes individuals with malignant ductal carcinoma in situ and uncontrolled hypertension while the secondary trial includes individuals with a history of breast cancer including ductal carcinoma in situ and allows for uncontrolled hypertension as a patient characteristic",
        "label": "Contradiction"
    },
    "d542b63b-a355-4a0e-8ec9-3c74bb1e0dcb": {
        "text_answer": "Entailment  Explanation The statement only a minority of patients in the primary clinical trial had a complete response by the 24th week is an entailment based on the evidence provided The evidence shows that at week 24 there were 0 complete responses 4 partial responses and 10 stable diseases making a total of 14 patients with a clinical benefit CR PR or SD out of 2",
        "label": "Entailment"
    },
    "2f1db1ac-f8d0-4087-856e-dfcff97c75a5": {
        "text_answer": "Contradiction The primary trial explicitly excludes individuals with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug or any other hemorrhagebleeding event NCI CTCAE v30 Grade 3 within 4 weeks of first dose of study drug including pulmonary embolism However the secondary trial does not mention anything about pul",
        "label": "Contradiction"
    },
    "bd2b336d-30ae-4151-a920-9506a013ab14": {
        "text_answer": "Neutral The statement is not directly related to the given evidence  Explanation The statement is not directly related to the given evidence as it does not mention anything about the inclusion or exclusion criteria for the breast cancer studies The statement is about the meaning of a lipase unit and its relevance to breast cancer patients which is not addressed in the provided evidence",
        "label": "Entailment"
    },
    "d5fe5d1e-b4c8-46d1-879f-06f14157c3ee": {
        "text_answer": "Entailment The statement is an entailment because the primary trials inclusion criteria include Breast Cancer has continued to grow after having received treatment with an antiestrogen hormonal treatment such as tamoxifen or an aromatase inhibitor which implies that the patients require hormonal therapy",
        "label": "Entailment"
    },
    "9ed2eb80-3810-40fc-b26a-d2e93feb061d": {
        "text_answer": "Contradiction The statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "dad4efbe-c7ae-4507-8a04-853a132b497a": {
        "text_answer": "Contradiction The primary trials treatment cabergoline is given orally while the secondary trials treatment pixantrone dimaleate is given intravenously",
        "label": "Contradiction"
    },
    "c574fb87-713c-43cd-a147-215f98ff6d35": {
        "text_answer": "Entailment  The statement is an entailment because the evidence indicates that the interventions for breast cancer patients and ovarianperitoneal cancer patients are different as they involve different diseases and potentially different doses of talazoparib",
        "label": "Entailment"
    },
    "fca56898-5587-4c6a-ae87-86dfae3a4961": {
        "text_answer": "Contradiction The statement somewhat is a subjective answer of partial agreement General symptoms are the most common AE recorded in the primary trial is a subjective statement while the evidence provided is an objective count of the number of adverse events recorded in the primary trial The statement does not directly follow or logically entail the evidence",
        "label": "Contradiction"
    },
    "5a25fa73-5358-4d36-acc0-ea23cb358a4d": {
        "text_answer": "Contradiction The evidence shows that there were recorded instances of doselimiting toxicity in the primary clinical trial specifically in both ArmGroup 1 and ArmGroup 2",
        "label": "Contradiction"
    },
    "475425c4-cfbf-4742-86ad-b09806d19687": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as coronary artery stenosis is not mentioned in the adverse events recorded in the primary clinical trial",
        "label": "Contradiction"
    },
    "8e66baf7-890a-4a73-9542-814980f89689": {
        "text_answer": "Entailment  Explanation In the primary trial the participants received PF06647020 at 02 mgkg or 05 mgkg which are lower doses compared to the 0015 mgkg and 0040 mgkg doses given to participants in the secondary trial for ALT801 Therefore the statement participants in",
        "label": "Entailment"
    },
    "0935ad04-3112-4443-8f3a-6b3a07ac9d33": {
        "text_answer": "Contradiction The primary trial requires a primary tumor greater than 2 cm diameter while the statement suggests a primary tumor with a radius of 03 cm which is less than the minimum requirement for the primary trial",
        "label": "Contradiction"
    },
    "e44f0355-dac8-4405-b3b1-ceb87cbb121d": {
        "text_answer": "Contradiction The evidence states that there should be no meningeal carcinomatosis in the primary trial Neoplastic meningitis is a type of meningeal carcinomatosis",
        "label": "Contradiction"
    },
    "128e4316-cd80-4dff-9d54-3030e9921c77": {
        "text_answer": "Contradiction The statement is not supported by the evidence as there are no cases of mucositis oral thromboembolic events or bladder infection reported in the secondary trial and the evidence does not provide information about the prevalence of these adverse events in the primary trial compared to the secondary trial",
        "label": "Contradiction"
    },
    "5acd7311-862e-440b-aecd-64f015c7deb6": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as both interventions in the primary trial involve the use of nabPaclitaxel which is the same drug and the contradiction lies in the different drugs administered in combination with nabPaclitaxel in each cohort gemcitabine in Intervention 1 and carboplatin in Intervention 2 However the statement only mentions a divergence in",
        "label": "Contradiction"
    },
    "5cf2e65a-45cd-490e-8933-23bf36558b11": {
        "text_answer": "Contradiction  Explanation The statement every patient in each cohort of the primary clinical trial experienced an incidence of doselimiting toxicity is a contradiction to the evidence provided as the evidence only reports that one participant in each cohort experienced an incidence of doselimiting toxicity",
        "label": "Contradiction"
    },
    "7f6d7fd9-8aed-472d-af54-b288d16c2135": {
        "text_answer": "Contradiction The evidence does not support the statement as there is no mention of Tumour lysis syndrome in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "56c99670-a2ba-42ca-b870-e3d98f2f4169": {
        "text_answer": "Contradiction  The evidence states that the final eligibility for the clinical trial is determined by the health professionals conducting the trial which contradicts the statement that the inclusion is dependent entirely on objective criteria and not influenced by the judgment of the health professionals",
        "label": "Contradiction"
    },
    "eab0f794-5caa-49fc-b951-7db4b7169a46": {
        "text_answer": "Entailment The statement includes all the exclusion criteria mentioned in the evidence related to the primary clinical trial",
        "label": "Entailment"
    },
    "c4b53dae-5bcf-4356-825d-0701f5c9b545": {
        "text_answer": "Contradiction The evidence states that there was only 1 case of hypertension and 1 case of pancreatectomy while there were 3 cases of hepatotoxicity Therefore the statement that the number of hypertension and pancreatic resection cases were ten times higher than cases of hepatotoxicity is not supported by the evidence",
        "label": "Contradiction"
    },
    "057e1439-4666-4373-a5b4-539c6cd24469": {
        "text_answer": "Contradiction  Explanation  In the primary trial whole breast radiation therapy is given to participants while in the secondary trial both cohorts receive intramuscular injections and also take prescribed medication orally However these are two different interventions and the statement is a contradiction because the primary trial involves radiation therapy while the secondary trial does not",
        "label": "Contradiction"
    },
    "4bf53370-da92-4333-bae7-3b35ab56b86e": {
        "text_answer": "Contradiction The primary trial excludes participants with a history of acute venous thrombosis which includes pulmonary embolism while the breast implants are an exclusion criterion for the secondary trial",
        "label": "Contradiction"
    },
    "963bd695-f26a-4891-931e-9b417a7c81c0": {
        "text_answer": "Contradiction The primary trial reported an incidence of these adverse events while the secondary trial reported no adverse events at all",
        "label": "Contradiction"
    },
    "662dd235-76f6-4ab6-b4c8-5537e6f7ffb3": {
        "text_answer": "Contradiction The statement is about lymph nodes and cancer while the evidence is about changes in lymphedema These are two different conditions",
        "label": "Contradiction"
    },
    "fb4e9c92-aa61-4691-b1fe-3cbb4a183f6d": {
        "text_answer": "Contradiction The primary trial measures pain intensity not severity of delayed nausea",
        "label": "Contradiction"
    },
    "09684ae5-162a-43ba-9735-6c9bce05cd5f": {
        "text_answer": "Contradiction The primary trial assesses the count of patients with treatmentemergent adverse events while the secondary trial evaluates the change in total sleep time which are two different outcome measures",
        "label": "Contradiction"
    },
    "847dd934-e3d0-44c6-8964-d1eb14b0d7a2": {
        "text_answer": "Contradiction  Explanation The evidence shows that the Tamoxifen group had an average standardized score of 004 049 and the Ovarian Function Suppression group had an average standardized score of 021 092 Since a negative standardized score indicates below average results the evidence suggests that on average patients in both cohorts did not show improvements in cognitive function but rather",
        "label": "Contradiction"
    },
    "d9444db3-e6d5-43d4-ba21-b934f8e0f77e": {
        "text_answer": "Contradiction The primary trial does not provide information about an age range for participation",
        "label": "Contradiction"
    },
    "3f6f3ca0-d14d-4fdb-9be8-19859181aaa9": {
        "text_answer": "Contradiction The evidence shows that no episodes of vomiting and no rescue medication were observed in the first 24 hours after cyclophosphamide administration for all participants in the ArmGroup titled Aprepitant Dexamethasone Cytoxan  Kytril Therefore acute vomiting was not observed in over 50 of the patients from the first cohort",
        "label": "Contradiction"
    },
    "2acdad0e-1a86-49d6-817d-cddb655073ac": {
        "text_answer": "Irrelevant The statement is not related to the provided evidence",
        "label": "Entailment"
    },
    "402d2312-d5b6-4763-9246-4e094a7d6739": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the longest PFS in the primary trial was 29 months in cohort 2 CDX011 which is less than 8 months",
        "label": "Contradiction"
    },
    "c0e3960b-923b-460f-a6e1-0b16f32af78f": {
        "text_answer": "Contradiction The evidence shows that there were more adverse events in cohort 1 45106 compared to cohort 2 7103",
        "label": "Contradiction"
    },
    "d1b9ab7c-2229-405c-be0e-01d822ac5aa1": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence only mentions ER negative HER2 negative breast cancer as an inclusion criterion for one of the cohorts Group 1 not for all cohorts",
        "label": "Contradiction"
    },
    "01bbbed8-5b22-4017-b6c5-f8a32bd6ab20": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as Intervention 1 uses intravenous IV bisphosphonate and Intervention 2 uses subcutaneous denosumab",
        "label": "Contradiction"
    },
    "418be5f3-61b5-4bae-a274-c2213e3cc7cf": {
        "text_answer": "Entailment The primary and secondary trials have different outcome measurements as stated in the evidence",
        "label": "Entailment"
    },
    "d15f343f-8edf-484e-bc6c-bbcbbf8c9118": {
        "text_answer": "Contradiction The statement does not follow from the evidence as epilepsy and thalasemic syndromes are exclusion criteria for the primary trial only while anemia is an exclusion criterion for the primary trial but an inclusion criterion for the secondary trial under certain conditions",
        "label": "Contradiction"
    },
    "9532e5a5-0e29-4914-8cf5-5aff881ffa8a": {
        "text_answer": "Entailment The evidence clearly states the number of participants analyzed in each arm of the trial",
        "label": "Entailment"
    },
    "dba63c59-7efc-48de-a02e-69b1b5beb08d": {
        "text_answer": "Entailment The primary trial tests different gels Hydrophor and MediHoney while the secondary trial tests the same treatment PF05212384 but in different doses",
        "label": "Entailment"
    },
    "da6c4a2b-18ad-44d9-9021-71c4f9b22fff": {
        "text_answer": "Contradiction The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel",
        "label": "Contradiction"
    },
    "fc24dc2a-3257-433f-91ed-fc3d3ec369b3": {
        "text_answer": "Contradiction The intervention in the primary trial lasts for 10 weeks approximately 70 days while the intervention in the secondary trial lasts for 24 weeks approximately 168 days which is not 105 days longer",
        "label": "Contradiction"
    },
    "cc11b6a5-855a-4291-b41d-e63367ea3b88": {
        "text_answer": "Entailment The statement is an entailment because both trials do utilize pCR as a determinant of their results and the statement accurately describes the differences in pCR rates between the cohorts in the primary trial and the arms in the secondary trial",
        "label": "Entailment"
    },
    "25bc284b-0476-4950-96e5-3b08a2a1c33c": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 13 months while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "4f886133-596d-449a-92c3-7472e2602982": {
        "text_answer": "Contradiction The statement is not related to the given evidence as it mentions a mesencephalic perforating artery which is an anatomical term unrelated to the breast cancer trials described in the evidence",
        "label": "Contradiction"
    },
    "b95564b8-cdbe-45d0-be91-764d6768e5f9": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention does not specify the dosage of MM121 and Paclitaxel given to the patients However in the secondary trial cohort 1 received 20 mgkg weekly of MM121 and 80 mgkg weekly of Paclitaxel for 12 weeks Therefore the statement that the primary trial candidates receive less",
        "label": "Contradiction"
    },
    "b32a43a7-cac0-4434-bdb2-4c4d8b26d947": {
        "text_answer": "Contradiction The primary trial excludes participants with a history of alcohol or substance abuse or dependence within the past 2 years while the secondary trial requires fewer than 5 alcoholic drinks per day within the past year",
        "label": "Contradiction"
    },
    "8f078a17-14cd-4bbc-a9b6-b377ffa077b5": {
        "text_answer": "Contradiction for the given evidence there are no psychiatric events recorded in either Adverse Events 1 or 2",
        "label": "Contradiction"
    },
    "ce486acd-8aae-475c-b95e-131fc0809e15": {
        "text_answer": "Contradiction The statement does not entail the information given in the evidence as the statement mentions sunitinib and paclitaxel doses for different cohorts while the evidence compares the administration of sunitinib and paclitaxel in two different interventions within the same trial",
        "label": "Contradiction"
    },
    "d083c9b8-decf-41ac-a3b0-ba8b6eedb32d": {
        "text_answer": "Entailment assuming that f3 positive is not related to the ORR data provided in the evidence",
        "label": "Entailment"
    },
    "4a5a5c6f-b9b3-48a4-a79a-582dc83323e3": {
        "text_answer": "Contradiction The primary trial explicitly states that patients who require use of coumarinderivative anticoagulants such as warfarin are excluded while the secondary trial permits lowdose warfarin less than or equal to 1 mgday for prophylactic or therapeutic use",
        "label": "Contradiction"
    },
    "5b8f9c72-6729-4b0f-9956-617021d55805": {
        "text_answer": "Contradiction  Patients with endocarcinoma are not mentioned in the inclusion or exclusion criteria for either the primary or secondary trials Therefore the statement is a contradiction as it makes a claim about eligibility for trials that is not supported by the provided evidence",
        "label": "Contradiction"
    },
    "1a47637c-31f0-42c0-9729-7ab8c66fafb4": {
        "text_answer": "Contradiction The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH in units of mIUml while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in units of mg These are not identical outcome measurements and units of measurement",
        "label": "Contradiction"
    },
    "c79f4ed7-5e39-48ad-bc32-fef9ace77a76": {
        "text_answer": "Contradiction  Explanation  In the primary trial there is no mention of entericcoated tablets for either intervention However in the secondary trial both interventions involve the use of entericcoated MLN8237 tablets Therefore the statement is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "4d33c738-d007-4e43-8d51-6c98c40631df": {
        "text_answer": "Contradiction The statement is not an entailment because the evidence does not indicate that intervention 1 utilizes a significantly higher dosage of Tc99M sulfur colloid than intervention 2 Both interventions involve the injection of 04 to 10 mCi of radioactive Tc99M sulfur colloid",
        "label": "Contradiction"
    },
    "d7170cb2-d8a5-4c65-9122-bc6bcf13caeb": {
        "text_answer": "Neutral The statement does not directly follow from the evidence but it is not contradictory either  Explanation The statement does not directly follow from the evidence because the evidence only provides information about the method of administration for each intervention but it does not mention the frequency or the laboratory test results The statement includes both the intervention and the laboratory test result which are not directly related in the evidence",
        "label": "Entailment"
    },
    "b76d27c5-45ec-4695-8480-1128862ea21b": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the placebo in the primary clinical trial was administered via an intravenous infusion not an intramuscular injection",
        "label": "Contradiction"
    },
    "8fcaece4-a0c7-44bf-82b0-50e494825b81": {
        "text_answer": "Contradiction  The statement is asking for over 52 patients to have experienced a confirmed complete response CR while the evidence states that 53 of participants experienced either a confirmed complete response CR or a confirmed partial response PR",
        "label": "Contradiction"
    },
    "37f74912-6578-4304-9f9c-6b3c4c217e97": {
        "text_answer": "Contradiction The statement does not entail the information given in the evidence The evidence describes the types of cohorts in the primary trial while the statement discusses primary ciliary dyskinesia 29 and a gene mutation which is unrelated to the trial cohorts",
        "label": "Contradiction"
    },
    "35802b7b-4d8e-4f1a-bab8-20eea1f4aa3f": {
        "text_answer": "Contradiction The statement is not an entailment as diffuse parenchymal lung disease is not listed as an exclusion criterion in the evidence provided for the primary trial",
        "label": "Contradiction"
    },
    "58fa0ef4-0355-42bc-8378-fef98752b05e": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the primary trial involves Alpha Lipoic Acid while the secondary trial involves Necitumumab The two interventions are not the same and the dosing regimens for each are different The primary trial allows for dose escalation of Alpha Lipoic Acid up to a maximum of 100 mg three times daily while the secondary trial administers a",
        "label": "Contradiction"
    },
    "95928e94-237c-4e85-98d4-9dc5371c5069": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it mentions Paclitaxel which is not mentioned in the evidence at all",
        "label": "Contradiction"
    },
    "1b229af4-937d-4ae0-8c39-12064d16b246": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as the evidence only compares the average area under the curve of the EORTC CIPN20 Sensory Neuropathy Subscale adjusting for baseline between two arms of a trial one with topical cryotherapy and one without but it does not mention the asph gene product",
        "label": "Contradiction"
    },
    "f569ce38-1e3f-4e8d-a9d7-e4a35a18c90c": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it does not relate to the primary trials inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "966efbd3-dce6-400c-b5bc-87ca468c7225": {
        "text_answer": "Contradiction  The statement is about primary tumor diameter reduction in the AZD0530 150 mg group compared to the Zoledronic Acid 1 mg group but the evidence provided is about percentage change in betaCTX levels in the AZD0530 175 mg and Zoledronic Acid 4 mg groups There is no information about primary tumor diameter reduction in the given evidence",
        "label": "Contradiction"
    },
    "d2757370-ae03-4046-a888-e30b9aa1551f": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because individuals with fluorescent in situ hybridizationconfirmed nut midline carcinoma are eligible for the primary trial but they are explicitly excluded from the secondary trial according to the given inclusion and exclusion criteria Castrateresistant prostate cancer and inflammatory breast cancer are also mentioned in the statement but their eligibility for the secondary trial is not explicitly stated or implied",
        "label": "Contradiction"
    },
    "cc439508-491f-4c5a-9304-5ddf9d266506": {
        "text_answer": "Contradiction The evidence does not support a general deterioration in cognitive abilities for both groups as some patients showed improvement or no change",
        "label": "Contradiction"
    },
    "d2c665aa-c13e-4d5d-95f8-d85c5c9f3ef9": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports the occurrence of adverse events in the two cohorts of the primary trial and there is no mention of humiliation or feelings in the evidence",
        "label": "Contradiction"
    },
    "936b5904-9a93-4aaf-8d20-03e0a4fb3223": {
        "text_answer": "Contradiction The evidence does not mention anything about diffuse parenchymal lung disease as an exclusion criterion for the primary trial",
        "label": "Contradiction"
    },
    "7326be65-0450-4fb7-88d3-5d926d65db74": {
        "text_answer": "Contradiction  Explanation The statement only patients prescribed gtx024 3mg during the primary clinical trial resulted in weight gain particularly in lean body mass is a contradiction to the evidence provided The evidence shows that both the 1mg and 3mg groups had a range of change in lean body mass some gained weight and some lost weight Therefore it is not accurate to say that only the 3mg group gained",
        "label": "Contradiction"
    },
    "692ea096-a2cf-4732-a141-b349cfd460d6": {
        "text_answer": "Contradiction The evidence states that only 1 participant out of 50 experienced a urinary tract infection which is not frequent according to the statement",
        "label": "Contradiction"
    },
    "96dedf4b-abc0-41ea-b12a-9a8afce9708d": {
        "text_answer": "Contradiction The evidence states that in the primary clinical trial the placebo is taken by mouth PO in the form of tablets and memantine is given by mouth but in the sublingual form twice a day The statement however claims that the placebo is taken through rectal suppository and memantine is given through the sublingual route which are different routes of administration",
        "label": "Contradiction"
    },
    "74c47731-5e97-400b-bf85-52ae0b8b5e09": {
        "text_answer": "Contradiction  Explanation The statement requires that patients receive at least 20000µg of mcs110 every 21 days which is equivalent to 65 mgkg assuming an average body weight of 70 kg However the evidence shows that in Intervention 1 patients receive only 1 mgkg of mcs110 every 3 weeks and in Intervention ",
        "label": "Contradiction"
    },
    "e4eba352-415f-44bd-8fe0-244240a80513": {
        "text_answer": "Entailment  Explanation The statement less than half of the patients in cohort 2 of the primary clinical trial experienced acute vomiting following treatment with aprepitant dexamethasone cytoxan and kytril is an entailment based on the evidence provided The evidence states that 20 out of 35 participants did not experience any vomiting and no rescue medication was given during the first",
        "label": "Entailment"
    },
    "ce26a25e-c6ff-4bba-bd54-b0e069440746": {
        "text_answer": "Contradiction The evidence states that one instance of a maculopapular rash was reported in the primary clinical trial",
        "label": "Contradiction"
    },
    "4f0e91c8-87f4-4af4-b47d-c5a8e459713d": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as cohort 2 in the primary clinical trial will not have access to the educational DVD as part of their intervention program according to the provided evidence",
        "label": "Contradiction"
    },
    "4d8bdd85-b621-4334-9aff-9ab0b69172e5": {
        "text_answer": "Contradiction  Explanation The evidence provided in the inclusion and exclusion criteria of the primary trial does not mention any conditions related to mental health body weight tumor size KarnofskyECOG score or estimated life span The statement in question asserts that there are no such conditions for eligibility which contradicts the absence of such conditions mentioned in the evidence",
        "label": "Contradiction"
    },
    "2b2a038c-37d7-42a6-817a-5392b1e94613": {
        "text_answer": "Entailment Note AES stands for Adverse Events in general not specifically Nausea as in the previous question",
        "label": "Entailment"
    },
    "530798af-a5d0-4de8-8183-b2ef6068c90a": {
        "text_answer": "Entailment The statement that radiation therapy is administered at the same intensity to patients in cohort 1 and 2 participating in the primary clinical trial is an entailment based on the evidence provided as both groups receive radiation therapy at the same dose range 180200 cGy per fraction for a total of 46004860 cGy with a maximum total dose to the tumor bed or",
        "label": "Entailment"
    },
    "55e361f9-9360-4de4-a301-6b504913b094": {
        "text_answer": "Contradiction The primary trial had 75 participants in the waitlist control group and 76 in the intervention group while the secondary trial had 147 participants in the standard of care group and 163 in the intervention group However the statement specifically compares the second cohort of each trial which is not defined in the evidence provided Without further context it is impossible to determine if the statement is entailed or contradicted",
        "label": "Contradiction"
    },
    "f191be61-8e8d-495c-b5e3-1bf3cc89904a": {
        "text_answer": "Contradiction The evidence from the primary trial shows that the median overall survival for both groups was over 1 year",
        "label": "Contradiction"
    },
    "b2572b63-5246-4be3-84ee-c37f18da106d": {
        "text_answer": "Contradiction  Explanation The statement suggests that cohort 1 received a higher dosage of cetuximab while still receiving more mm121 than cohort 2 However the evidence shows that cohort 1 received the same dosage of cetuximab as cohort 2 400 mgm2 loading dose followed by 200 mgm2 maintenance IV QW and co",
        "label": "Contradiction"
    },
    "328dcbbe-1a4a-46f1-afad-df84cebcde05": {
        "text_answer": "Contradiction The evidence states that patients in the primary clinical trial receive oral doses of lapatinib not intramuscular doses",
        "label": "Contradiction"
    },
    "992db0e7-c7c4-413c-874f-c8e53d481fab": {
        "text_answer": "Contradiction  Explanation The statement suggests that the members of cohort 1 and 2 received equal doses of cetuximab but cohort 1 received 8mgkg less of mm121 However the evidence shows that in cohort 1 the dose of mm121 is 12 mgkg while in cohort 2a it is 20 mg",
        "label": "Contradiction"
    },
    "c51c390c-f844-492c-9844-53e31e01124d": {
        "text_answer": "Contradiction The evidence does not support the statement as there are no fatalities or hospital stays reported in either trial",
        "label": "Contradiction"
    },
    "ea25b3f7-4ef8-4e5f-b3e8-3cbf0da93a12": {
        "text_answer": "Contradiction The primary trial only includes patients with unilateral breast cancer",
        "label": "Contradiction"
    },
    "15c27d36-ca02-48e2-8e08-d9c6b52042c6": {
        "text_answer": "Entailment The statement is a more specific description of the disease characteristic criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "890c305f-bd6d-4db4-adf5-2aaf8e28d6c6": {
        "text_answer": "Contradiction The statement is not an entailment as Syncope is not the most commonly occurring adverse event in the secondary trial and the statement mentions severe problems performing usual activities which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "93c0565f-98d6-4f6b-92a6-8464567027c7": {
        "text_answer": "Contradiction  Explanation  The primary trial provides data on Time to Progression TTP while the secondary trial does report data on the Number of Participants with Objective Response Therefore the statement is a contradiction as it asserts that both trials lack data on these specific outcome measures",
        "label": "Contradiction"
    },
    "32c13f2f-7902-444f-8f99-c3ea2ecac0d0": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence shows that the primary trial records fewer adverse events of all types despite recording fewer total adverse events",
        "label": "Contradiction"
    },
    "33603672-b61c-4ddd-8e57-d38876de9132": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were multiple occurrences of the same type of adverse event eg fever occurred twice Therefore the statement that there was no repetition in the type of adverse event endured by patients in the primary clinical trial is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "2e753155-acb5-417c-9169-9ec7ccc4d8ac": {
        "text_answer": "Entailment  The primary and secondary trials both list epilepsy thalasemic syndromes and anemia as exclusion criteria",
        "label": "Entailment"
    },
    "356f845b-f5e9-46f8-8374-fb598e246876": {
        "text_answer": "Entailment The statement does not contradict the evidence as it is stated that cohort 2 receives weekly antineoplastic chemotherapy in addition to practicing paced breathing twice daily The evidence does not provide any information about the type of condition the patients have so the statement does not entail that the condition is related to the oculomotor nerve or malignant but it is not contradictory to the evidence provided",
        "label": "Entailment"
    },
    "74b96ae6-3e1a-4f1c-bbf0-a79ed0e4ee75": {
        "text_answer": "Entailment  Explanation The statement adverse events were not documented for both the primary clinical trial and the secondary clinical trial is an entailment based on the evidence provided as both the primary and secondary trials have no documented adverse events in the given data",
        "label": "Entailment"
    },
    "2fafc6ea-da6d-4160-829d-1f599da46818": {
        "text_answer": "Contradiction The statement is about a gingival polyp which is not related to the evidence provided about the primary trial results",
        "label": "Contradiction"
    },
    "74bde0ca-3313-40ab-95f3-55d2adea4f89": {
        "text_answer": "Contradiction  The primary trial includes patients with benign breast disease including fibroadenoma while the secondary trial excludes patients with a history of breast cancer including ductal carcinoma in situ or lobular carcinoma in situ Therefore patients diagnosed with benign fibroadenoma are eligible for the primary trial but not the secondary trial",
        "label": "Contradiction"
    },
    "fd0b22b0-c86d-4460-bf53-310901404ef5": {
        "text_answer": "Entailment The statement All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3 is an entailment based on the evidence provided in the inclusion criteria of the primary trial Both FISH and IHC 3 are methods used to confirm HER2 positivity so having one means having the other",
        "label": "Entailment"
    },
    "f2d20a53-59b4-42bf-8d21-1ead0e113107": {
        "text_answer": "Contradiction The primary trial does not mention any exclusion criteria related to schizophrenia or chronic insomnia The secondary trial has exclusion criteria related to chronic insomnia but it does not mention anything about schizophrenia Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "f45b251f-2fec-44b7-8fc0-dd0d06a44d3b": {
        "text_answer": "Entailment The evidence shows that in both trials no adverse events occurred in more than 1 of participants Therefore the statement that there were no adverse events in both trials that occurred in more than 1 of participants is an entailment of the evidence",
        "label": "Entailment"
    },
    "151bb6d0-e4bf-4eea-8842-5fe4e1782782": {
        "text_answer": "Contradiction  The statement provides different numbers of individuals achieving recurrencefree survival in each group compared to the evidence According to the evidence 80 out of 96 participants in the Ketorolac 30 mg group and 96 out of 107 participants in the NaCl 09 3mL group experienced recurrencefree survival Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "315f4573-d5b1-4cbc-9efb-74c27a98dc6d": {
        "text_answer": "Entailment The primary trial includes patients with stage IV breast adenocarcinoma that is ER positive PR positive or HER2neu negative as a subset of its inclusion criteria Therefore these patients are eligible for both trials based on the given evidence",
        "label": "Entailment"
    },
    "3cbaa580-dfe1-4331-902c-5be850db2f24": {
        "text_answer": "Entailment The evidence states that both cohorts in the primary clinical trial received preoperative intravenous administration of dexamethasone which entails that preoperative administration of dexamethasone was given to both cohorts",
        "label": "Entailment"
    },
    "80b93d64-be3c-45e0-8524-b8042e84bdc7": {
        "text_answer": "Contradiction The primary trial recorded zero instances of chest pain while the secondary trial recorded none according to the provided evidence",
        "label": "Contradiction"
    },
    "57663242-4e73-409f-a7f9-1738e13298ab": {
        "text_answer": "Entailment  Explanation The statement there are no reported adverse incidents in the primary clinical trial and the secondary clinical trial is an entailment given the evidence provided as both trials reported no adverse incidents according to the data presented",
        "label": "Entailment"
    },
    "df344680-ab21-4889-bba7-7db757b72bae": {
        "text_answer": "Contradiction The statement is incorrect as cohort 1 receives paclitaxel at 90 mgm2 not 25 mg daily",
        "label": "Contradiction"
    },
    "f50bcaa7-7424-4977-ac06-f47e545e2e00": {
        "text_answer": "Contradiction The primary clinical trial mentioned in the evidence is for solid tumors excluding primary brain tumors and specifically mentions breast cancer as a type of solid tumor with eligibility criteria that includes being ER positive andor PR positive but HER2 negative Prostate cancer is not mentioned as an eligible cancer type and is not ER positive or PR positive",
        "label": "Contradiction"
    },
    "46ac728d-deb3-4559-bc71-1729c70c26e7": {
        "text_answer": "Contradiction The primary trial does not involve alisertib at all while the secondary trial does involve different dosages of alisertib",
        "label": "Contradiction"
    },
    "665afeee-f623-4c57-8550-a5dbe71430cb": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the participants in the secondary trial are indeed receiving weekly subcutaneous injections of epoetin beta which contradicts the statement that they refrain from any injections",
        "label": "Contradiction"
    },
    "786bc355-6b8f-455c-b6b2-470350231601": {
        "text_answer": "Entailment assuming that comprehensive records implies a larger number of adverse events recorded in the primary trial compared to the secondary trial even if the primary trial has no recorded adverse events",
        "label": "Entailment"
    },
    "72ea65df-6381-4672-a40c-f55cee100091": {
        "text_answer": "Contradiction The evidence states that the sole adverse event noted in the primary clinical trial was surgery while the statement claims that the sole adverse event was stomatitis These are two different adverse events",
        "label": "Contradiction"
    },
    "b9b69888-f771-4a3a-b6f0-825510997cca": {
        "text_answer": "Entailment  Explanation The statement cohort 1 of the primary trial is administered less than half the dose of ALT801 as cohort 2 is an entailment based on the evidence provided The evidence states that cohort 1 receives 0015 mgkgdose of ALT801 while cohort 2 receives 0040 mgkg",
        "label": "Entailment"
    },
    "7714e6f7-814a-4088-9116-60f5ceef4336": {
        "text_answer": "Contradiction The statement is not an entailment as a patient recuperating from an organ transplant within the last month and still being bedridden is an exclusion criterion for both trials",
        "label": "Contradiction"
    },
    "57bca704-dcff-4526-b677-bb1c1b1a7945": {
        "text_answer": "Contradiction The primary trial reports its results in units on a scale and the secondary trial reports its results in proportion of responders Neither trial uses milliliters or liters",
        "label": "Contradiction"
    },
    "b27a5fe7-77f8-4d11-9e05-0609faf8b985": {
        "text_answer": "Contradiction The evidence explicitly states that sexually active fertile men whose partners were WOCBP not using an adequate method of birth control are excluded from the study Therefore the statement that fertile men and women capable of becoming pregnant are fit to partake in the primary clinical trial under the condition of committing to abstain for the length of the study is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "15577bb6-3b4d-4373-ae58-eb0bf0c34954": {
        "text_answer": "Contradiction The primary trial explicitly states that warfarin is not permitted while the secondary trial permits its use under certain conditions",
        "label": "Contradiction"
    },
    "99e5ad48-5bb8-4716-a1fc-0a332acf2e5e": {
        "text_answer": "Contradiction The primary trial is designed to evaluate toxicity using NCI CTCAE v30 while the secondary trial is designed to evaluate percentage of participants with adverse events of primary interest AEPIs which are specific types of Grade  3 adverse events These are not the same thing",
        "label": "Contradiction"
    },
    "6d92ea7c-a85d-4d9d-9599-b2203e9c3585": {
        "text_answer": "Contradiction  Explanation  The primary trial had two test groups Pyridoxine and Placebo while the secondary trial had two test groups Highdose Oxybutynin Chloride and Lowdose Oxybutynin Chloride and two control groups not mentioned in the statement Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "b5976fd8-b3cf-4879-bead-2410a6e1f1f1": {
        "text_answer": "Contradiction  Explanation The statement provides a specific number of participants who experienced recurrencefree survival in each group which is not consistent with the information given in the evidence which only states the percentage of participants who achieved recurrencefree survival in each group",
        "label": "Contradiction"
    },
    "4d7a11a9-ec69-4b35-9fea-d1a78d8fe4b8": {
        "text_answer": "Contradiction The primary trial reported 0 cases of febrile neutropenia",
        "label": "Contradiction"
    },
    "c291c60f-fb5e-4c0d-83dc-a8fe9eee445c": {
        "text_answer": "Entailment The statement behavioral rating scale is a range of values designed to quantify the qualitative responses of an individual to a set of challenges is not directly related to the inclusion criteria of the primary trial but the requirement of having a HER2 positive tumor confirmed by either positive FISH or IHC 3 is a necessary condition for participation in the trial Therefore the statement is an entailment as it does not contradict the evidence provided",
        "label": "Entailment"
    },
    "ebe02c33-affe-41d7-aad7-86ea86912217": {
        "text_answer": "Contradiction  Explanation The evidence does not provide enough information to determine if none of the patients in the primary trial experienced the worst pain imaginable for 1680 hours The evidence only reports the average pain intensity scores and the change in average pain intensity between the two intervention groups It does not provide information on the distribution of pain intensity scores or the number of patients who experienced the worst pain imaginable for any duration",
        "label": "Contradiction"
    },
    "d464fa4d-58ea-47ff-b4fa-19fbedb40740": {
        "text_answer": "Contradiction The evidence shows that 423 of the cervical cancer patients in cohort 1 had undergone a screening prior to the intervention",
        "label": "Contradiction"
    },
    "bfee9542-f923-4084-a92d-216413a99395": {
        "text_answer": "Contradiction The statement is not an entailment as the trials use some common elements but the drugs dosages and frequency of administration are different",
        "label": "Contradiction"
    },
    "b126d49e-2ab0-4bb9-8677-b3662b784e0d": {
        "text_answer": "Neither Entailment nor Contradiction The evidence provided does not relate to the statement at all",
        "label": "Entailment"
    },
    "f435b92a-cceb-404d-a485-da95bb2189ec": {
        "text_answer": "Contradiction The statement mentions Patients who have received chemotherapy or radiotherapy in the last 2 weeks as an exclusion criterion for the secondary trial but it is not mentioned as an exclusion criterion for the primary trial in the provided evidence Therefore the statement is a contradiction based on the given evidence",
        "label": "Contradiction"
    },
    "81cad78a-c25f-4aab-ae6f-aee9f21e0c01": {
        "text_answer": "Entailment assuming the ICD codes refer to the same type of exposure to soil pollution in both cases",
        "label": "Entailment"
    },
    "2e22a621-745f-422e-a66e-2a85f8ff1a25": {
        "text_answer": "Contradiction  The evidence states that 98 of the participants experienced recurrencefree survival which is not the same as just two participants did not experience recurrencefree survival which would be equivalent to 2 not experiencing it",
        "label": "Contradiction"
    },
    "bf41ff3e-3801-4cb7-8e09-0400100a4010": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it makes no mention of the frequency or relationship between endocannabinoids and the adverse events mentioned in the evidence",
        "label": "Contradiction"
    },
    "c08cf531-fbbe-4ec3-ae13-f10d13368a82": {
        "text_answer": "Contradiction The primary trial measures the number of participants with treatmentemergent adverse events while the secondary trial measures the total sleep time in minutes The statement mentions nothing about hybrid nerve sheath tumors",
        "label": "Contradiction"
    },
    "c696105a-b6a3-4d13-9410-2b3f05346f96": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the number of participants in Arm II is 234 and in Arm III is 241 which is a difference of 7 but this is not stated in the evidence as a cohort being the second cohort",
        "label": "Contradiction"
    },
    "d8079e7e-45eb-4387-a0e3-eb0777802644": {
        "text_answer": "Contradiction The primary trial measures treatmentemergent adverse events in participants with various types of cancer while the secondary trial measures objective response in participants with breast or ovarian cancer These outcome measurements are not directly related to each other",
        "label": "Contradiction"
    },
    "a2d03d44-c447-45d2-932e-efe3694a8940": {
        "text_answer": "Entailment assuming Herceptin refers to trastuzumab in the evidence The statement that both interventions in the primary trial include trastuzumab is true and the statement that abnormal involuntary movement scale aims0110 original result  aware moderate distress is also true for both interventions so the statement that abnormal involuntary movement scale aims0110 original result  aware moderate distress",
        "label": "Entailment"
    },
    "b1d81c75-d076-45f3-8de6-6a23fc4f3832": {
        "text_answer": "Irrelevant The statement is not related to the provided evidence",
        "label": "Entailment"
    },
    "2e64e934-f058-4730-af09-ddf7547a0112": {
        "text_answer": "Contradiction The primary trial allows candidates with an ECOG score of 02 while the secondary trial allows candidates with an ECOG score of 02 or Karnofsky score of 60100 Therefore the statement that neither trial allows candidates with an ECOG score below 2 is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "79162d9d-6591-44ef-aaea-4bd58c4811da": {
        "text_answer": "Contradiction  The evidence describes the use of Vorinostat during radiation therapy but it does not mention anything about the use of Fentanyl sublingual spray let alone the specific doses mentioned in the statement",
        "label": "Contradiction"
    },
    "da24c082-7e08-4ed0-b72c-ee85098d7b3a": {
        "text_answer": "Contradiction The evidence does not support the statement that the NaCl 09 3ml group had a higher recurrencefree survival rate than the Ketorolac 30 mg group In fact the evidence shows that a higher percentage of participants in the Ketorolac 30 mg group achieved recurrencefree survival 833 compared to the NaCl 09 3ml group 89",
        "label": "Contradiction"
    },
    "193ae24d-ca9a-4bd6-8a98-279c75d32c9b": {
        "text_answer": "Contradiction The evidence reports only one case of shingles in the secondary trial not three as stated in the question",
        "label": "Contradiction"
    },
    "accef831-f126-4f90-bc47-182fd9699098": {
        "text_answer": "Contradiction The primary trial does not list kidney transplant as an exclusion criterion but the secondary trial does Therefore a patient who has undergone a kidney transplant in the past week cannot qualify for the secondary trial but they may be eligible for the primary trial",
        "label": "Contradiction"
    },
    "9eee5184-a09a-41a2-b031-a7ea1863c5ce": {
        "text_answer": "Contradiction  The statement four different adverse events were noticed affecting patients in the second cohort is a contradiction to the evidence as the evidence only reports the occurrence of two different adverse events Fatigue and Pyrexia in the second cohort",
        "label": "Contradiction"
    },
    "f12a3e2a-478e-4104-8f1a-c2d72efab4a3": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the number of participants in each cohort is different The Neratinib arm had 1420 participants and the Placebo arm had 1420 participants analyzed but the statement implies that both cohorts had the same number of participants before the trial started",
        "label": "Contradiction"
    },
    "99e16f2b-e690-4684-9dff-cf37877c796c": {
        "text_answer": "Contradiction  The evidence only reports the number of participants who had a reduction in CTCs at one month posttransplant not the percentage of participants who noticed a reduction over multiple months",
        "label": "Contradiction"
    },
    "3caa266c-8ad2-4297-8de5-c65b78e94fd1": {
        "text_answer": "Contradiction  Explanation The evidence states that cohort 1 is the triplenegative cohort meaning the participants do not have HER2 ER or PR tumors Therefore the statement that every participant in cohort 1 receives treatment for HER2 tumors is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "97e4a19d-31b9-476a-b8d3-707f817283e1": {
        "text_answer": "Contradiction The evidence does not mention anything about vaccines being administered in the primary trial",
        "label": "Contradiction"
    },
    "fdc23b5d-a94a-4aa3-bb87-38d7f2c0102c": {
        "text_answer": "Contradiction  The statement implies a 60 reduction in Ki67 expression after 90 days of treatment but the evidence only shows a median reduction of 55 from 15 to 10 in Ki67 expression at 6 weeks The statement goes beyond the data provided in the evidence",
        "label": "Contradiction"
    },
    "6b531884-77d9-4cdc-bab7-324596ec998e": {
        "text_answer": "Contradiction The primary trial does not mention the dose of dexmedetomidine given to group 2 The secondary trial mentions a different population and a different dose of dexmedetomidine",
        "label": "Contradiction"
    },
    "73eb2425-76f4-4868-8c33-0a2dab6af8f6": {
        "text_answer": "Contradiction The primary trial and the secondary trial address different outcomes and patient populations so it is not possible to make a direct comparison between them based on the provided evidence",
        "label": "Contradiction"
    },
    "e504c08b-c348-4307-9cfe-d20f7003ec15": {
        "text_answer": "Contradiction The statement is about injection site reactions which are not mentioned in the evidence The evidence only discusses various adverse events that occurred in the primary and secondary trials",
        "label": "Contradiction"
    },
    "5f33e3b5-efa2-407c-9409-383024b8c652": {
        "text_answer": "Entailment The statement is a subset of the inclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "7bbb79b9-9550-4a8b-a0a8-3af8ece50e04": {
        "text_answer": "Contradiction  Explanation The statement makes two separate claims  1 rbm15 gene rearrangement is a molecular abnormality indicating rearrangement of the rbm15 gene This is a fact and not related to the trials 2 Pericardial effusions were more common for patients in the primary trial and Corneal deposits were more common in the secondary trial  The evidence provided does",
        "label": "Contradiction"
    },
    "85f5396f-e7f8-4697-95d2-67b82d43fce4": {
        "text_answer": "Contradiction Both cohorts receive nabPaclitaxel at the same dose 125 mgm2 The difference lies in the combination therapy each cohort receives with Arm A receiving gemcitabine and Arm B receiving carboplatin",
        "label": "Contradiction"
    },
    "71c0cfa6-88a6-4efa-8204-7252f6e6ef57": {
        "text_answer": "Entailment The statement is true and the evidence supports it as the interventions in the primary trial involve different routes of administration IV for bisphosphonate and subcutaneous for denosumab but neither the statement nor the evidence mention anything about PSA levels being related to the administration route",
        "label": "Entailment"
    },
    "a2408386-b61c-4cce-9c71-befb482270e0": {
        "text_answer": "Entailment  The evidence provided does not include any information about the count of participants with treatmentemergent adverse events for either trial",
        "label": "Entailment"
    },
    "bd4ef9b9-41e1-47cb-b8bd-eb0dfe32badf": {
        "text_answer": "Irrelevant The statement does not relate to the provided evidence",
        "label": "Entailment"
    },
    "12ca4131-cbd9-45e4-8738-7ec607080cbe": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence as the evidence indicates that 13 of participants with HER2 primary breast cancer developed HER2 metastases during the trial",
        "label": "Contradiction"
    },
    "1a80bab2-1079-4730-bba6-b8414e4cfcc8": {
        "text_answer": "Contradiction The primary trial only includes patients with HER2negative breast cancer while the secondary trial includes patients with ERpositive HER2positive breast cancer Therefore a young female newly diagnosed with both ERpositive and HER2positive breast cancer would not qualify for both trials based on the given evidence",
        "label": "Contradiction"
    },
    "1c57cb03-2d38-4b0e-a4b1-cda77a609a9e": {
        "text_answer": "Contradiction The primary trial includes patients with an ECOG performance status of 0 to 2 which includes a score of 3 moderate disability but the secondary trial includes patients with a score of 0 to 2 or Karnofsky 60100 good performance status which does not include a score of 3",
        "label": "Contradiction"
    },
    "397ae58e-dc5b-4c06-b8ce-29215ed5bcb9": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as coronary artery stenosis is not mentioned in the evidence as an adverse event recorded in the primary trial",
        "label": "Contradiction"
    },
    "812d038b-d9c4-457d-8527-ed43ee902202": {
        "text_answer": "Entailment The statement two patient incidents of doselimiting toxicity occurred one in each cohort is an entailment of the evidence provided as the evidence reports one incident of doselimiting toxicity in each cohort",
        "label": "Entailment"
    },
    "36debc88-2f09-4ae8-9a37-5bee270f5f8c": {
        "text_answer": "Neutral Neither Entailment nor Contradiction  Explanation The evidence provided only mentions that the subjects in Intervention 1 were treated with partial breast irradiation but it does not specify whether a treatment cycle was defined or explained in the trial The statement in question is not directly related to the evidence as it does not mention Intervention 1 specifically Therefore it is neither an entailment nor a contradiction based on",
        "label": "Entailment"
    },
    "49cccbde-abb6-45a4-80ba-47dcdd6b760e": {
        "text_answer": "Contradiction  The primary trial includes patients with significant cardiovascular impairment but it does not specify uncontrolled cardiovascular disease as an exclusion criterion for the secondary trial Therefore the statement is a contradiction of the evidence provided",
        "label": "Contradiction"
    },
    "95cf915e-97df-4ece-bd27-52a72bb4ed68": {
        "text_answer": "Contradiction The primary trial does measure change in MYMOP score as an outcome measurement",
        "label": "Contradiction"
    },
    "5cd9bd06-f069-44f3-9b2b-69d92eecc07a": {
        "text_answer": "Contradiction  Explanation The evidence does not provide information about the average pain intensity score reaching the maximum level 10 during the 10week study period for any patient in either group Therefore it is impossible to determine if the statement is an entailment or contradiction based on the given evidence alone",
        "label": "Contradiction"
    },
    "61547cc4-08c1-41c9-94f3-c45ebba67e5b": {
        "text_answer": "Entailment The statement is entailed by the evidence as both NSCLC and SCLC are listed as eligible tumor types in the inclusion criteria of the trial",
        "label": "Entailment"
    },
    "ccc4b1dc-30f5-46d4-9251-6bb1dbe514ce": {
        "text_answer": "Contradiction  Explanation The evidence states that there is a significant decrease in Ki67 expression in tumors with tamoxifen treatment for 7 days before surgery The statement however claims that tamoxifen has no significant effect on Ki67 expression after mastectomy which contradicts the evidence",
        "label": "Contradiction"
    },
    "5296c4b2-ae8f-4321-abb1-071d8a5e9f50": {
        "text_answer": "Contradiction The evidence states that participants received niraparib 200 mg daily not talazoparib 1000000 ng",
        "label": "Contradiction"
    },
    "dfdcc220-60e9-4ade-a21a-2dea12500959": {
        "text_answer": "Contradiction The primary trial does not assess participants overall survival rates it only evaluates toxicity The secondary trial assesses the percentage of participants with adverse events of primary interest not overall survival rates",
        "label": "Contradiction"
    },
    "848665ec-85f5-4b64-aa71-ba24195e7463": {
        "text_answer": "Contradiction  Explanation  In the primary trial there is no mention of any weekly subcutaneous injections for any of the interventions However in the secondary trial participants in the Epoetin Beta intervention received weekly subcutaneous injections for 12 weeks Therefore the statement that the secondary clinical trial involves weekly subcutaneous injections for its participants is a contradiction to the evidence presented in the primary trial",
        "label": "Contradiction"
    },
    "40fc3a97-0a5d-4f19-ba94-7c4668d0538d": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as Arimidex Anastrozole is used in the primary trial but there is no mention of its use in the secondary trial",
        "label": "Contradiction"
    },
    "6688e7ec-6e04-49d3-b3c2-0bfb041297dc": {
        "text_answer": "Contradiction The primary trial involves radiation therapy while the secondary trial involves administration of tablets including Fulvestrant but the statement does not mention radiation therapy in the context of the primary trial participants",
        "label": "Contradiction"
    },
    "067c3f74-9009-45dc-a97a-0de2a17722cc": {
        "text_answer": "Contradiction The statement excludes patients who have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy in the last 2 years before study entry However the evidence provided mentions that antiHER2 agents are allowed and patients who are on a constant dose of tamoxifen raloxifene or aromatase inhibitors are also allowed as long as they are not expected to",
        "label": "Contradiction"
    },
    "1c3d0ec2-e54e-4b44-9b61-6300e5e2736f": {
        "text_answer": "Contradiction The evidence does not mention T4 N4 or M4 tumors as allowed or excluded in the primary clinical trial",
        "label": "Contradiction"
    },
    "871e4e1f-9d73-46d0-9eda-04099b38ea4b": {
        "text_answer": "Entailment assuming that 175000 micrograms is a typo and should be 175 mg as in the given results  Explanation The statement is an entailment because the evidence shows that the AZD0530 175 mg group had a greater percentage change in betaCTX at Week 4 711 vs 684 as stated in the",
        "label": "Entailment"
    },
    "10b5153d-7bb1-45a0-9765-1df8e3dfbd88": {
        "text_answer": "Contradiction  Explanation The statement the appearance of maculopapular rash was a frequent side effect among the participants of the primary clinical trial is a contradiction to the evidence as the evidence only reports one instance of a maculopapular rash among the participants",
        "label": "Contradiction"
    },
    "013a39b4-3f7c-427c-8665-134bf9edc4a5": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of asthenia or pyrexia in the provided evidence",
        "label": "Contradiction"
    },
    "c1fee61a-1d3e-4d83-a0a9-8360e912714c": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as no palpitations pericardial effusions or abdominal pains were recorded in cohort 1 of the secondary trial while they were recorded in cohort 1 of the primary trial",
        "label": "Contradiction"
    },
    "857ea0f3-1f62-417e-93ef-00e121cc3e60": {
        "text_answer": "Contradiction The Intervention 1 group in the primary trial does receive a risk assessment and decision support for prevention based on risk which can be considered a form of counselling and risk analysis",
        "label": "Contradiction"
    },
    "2e844546-8fe8-440c-afdd-504e84d4acc4": {
        "text_answer": "Contradiction The primary trial had 0 adverse events recorded while the secondary trial had anaemia reported as a side effect in 234 of cases",
        "label": "Contradiction"
    },
    "50c57a74-1e0e-45fe-8a00-217ff1322d99": {
        "text_answer": "Contradiction The primary trial explicitly states that smokers are excluded from participation",
        "label": "Contradiction"
    },
    "13fb11f0-9307-4576-887c-75896dd7bfd1": {
        "text_answer": "Contradiction UTI is not related to mediastinal sarcoma",
        "label": "Contradiction"
    },
    "dd10e477-9de3-43b9-8db3-5c9661514c5e": {
        "text_answer": "Entailment  Explanation The evidence shows that the percentage of participants in the primary clinical trial who experienced adverse events was 048 and in the secondary clinical trial it was 0 Both percentages are less than 20",
        "label": "Entailment"
    },
    "74302b73-7dad-4eb7-b9f2-757d0508d85d": {
        "text_answer": "Contradiction  Explanation  The evidence provided for the primary trial states that patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study are excluded Therefore candidates undergoing chemotherapybased treatments would be disqualified from the primary trial  However the evidence provided for the secondary trial states that patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study are also excluded This means that",
        "label": "Contradiction"
    },
    "7664aa4a-a4ae-4fe3-81a0-d977d197fde1": {
        "text_answer": "Contradiction  Explanation The evidence shows that 909 of patients were affected by each of the following types of adverse events febrile neutropenia sepsis lymphocyte count decreased neutrophil count decreased and neutrophilsgranulocytes ANCAGC decreased Since more than one patient was affected by each of these types of",
        "label": "Contradiction"
    },
    "8d6af699-f5b7-41c2-a84f-28fa45e648c9": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial had no reported adverse events and the statement asserts that the majority of patients in the primary trial experienced headaches as the most common adverse event",
        "label": "Contradiction"
    },
    "19356a21-1163-41b2-8780-7e8e7c956454": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events recorded in both trials The statement however claims that there were 55 recorded adverse events which is a clear contradiction to the evidence",
        "label": "Contradiction"
    },
    "b685be77-9c55-4948-99cc-2a249739a233": {
        "text_answer": "Contradiction The evidence states that patients with 23 cerebral metastases are excluded from the secondary trial but there is no mention of this criterion in the primary trials inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "29968695-9fd4-4fce-b2ba-1879f50c8c57": {
        "text_answer": "Contradiction The statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "7534e96f-f5c9-4adf-a9cb-efa76fd43257": {
        "text_answer": "Contradiction The evidence mentions surgery as an adverse event but stomatitis is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "f8630eaf-1381-4ba1-ba97-68b86755e0fd": {
        "text_answer": "Contradiction The secondary trial does not have any inclusion criteria related to age mentioned in the provided evidence",
        "label": "Contradiction"
    },
    "5ccef9c9-dfe2-465e-8cc4-c6cdc310f74a": {
        "text_answer": "Contradiction The statement more than 10 patients in the primary clinical trial experienced aes is a contradiction to the evidence which states that there were only 2 adverse events in the primary clinical trial totaling to 571",
        "label": "Contradiction"
    },
    "816acfa2-5f8d-4f30-9425-5880f3d72414": {
        "text_answer": "Contradiction  Explanation  The primary trial excludes women with osteoporosis but does not mention anything about claustrophobia The secondary trial does not mention anything about osteoporosis or claustrophobia in its inclusion or exclusion criteria Therefore the statement that women with conditions of claustrophobia and osteoporosis are disqualified from participation in both",
        "label": "Contradiction"
    },
    "eec99f26-cf8e-407d-bb6a-7f9d053fe187": {
        "text_answer": "Contradiction The primary trial only includes patients with an ECOG performance status of 0 to 2 but the secondary trial includes patients with an ECOG 02 OR Karnofsky 60100 which includes a wider range of performance statuses However its important to note that the primary trial has additional inclusion and exclusion criteria that may not apply to the secondary trial so its not a simple entail",
        "label": "Contradiction"
    },
    "facb2d1c-1f65-4c84-9c93-209ce87d18a7": {
        "text_answer": "Entailment assuming the patient meets all other inclusion criteria for both trials",
        "label": "Entailment"
    },
    "4f89c108-d732-49bd-b21a-c3566400b519": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of diarrhea in the secondary trial",
        "label": "Contradiction"
    },
    "52f841b6-f451-455e-9ec5-2541cf02bb13": {
        "text_answer": "Contradiction  Explanation The evidence does not provide enough information to determine if none of the patients in the primary trial experienced the worst pain imaginable for 25 months as there is no mention of pain intensity scores beyond the 10week time frame",
        "label": "Contradiction"
    },
    "df991d6e-570f-4371-9b5e-00e9f3f4707d": {
        "text_answer": "Contradiction The evidence does not support the statement that every participant in the primary clinical trial endured extreme pain for a period of 10 weeks The evidence only reports the average pain intensity scores and the change in average pain intensity between the two intervention groups",
        "label": "Contradiction"
    },
    "41617f3f-76b1-41ca-b7c7-f902f84cd816": {
        "text_answer": "Contradiction The statement mentions contact dermatitis which is not listed as an exclusion criterion in the evidence provided for the primary trial The exclusion criteria mentioned in the evidence are antineoplastic chemotherapy androgens estrogens and progestogens",
        "label": "Contradiction"
    },
    "2a32321e-12f1-453f-b0d4-d0b10b80e293": {
        "text_answer": "Entailment The primary trial includes patients with any tumor type if the tissue tests positive for CCND2 amploration",
        "label": "Entailment"
    },
    "40535d67-a16d-48eb-932e-3d8d2ff57281": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence because the primary trial involves the use of more than seven different drugs and a surgical procedure while the secondary trial only involves the use of two different pharmaceuticals without the need for surgery",
        "label": "Contradiction"
    },
    "3657b15f-ab73-479c-8b00-c2189fc4d984": {
        "text_answer": "Entailment The evidence shows that multiple patients in the primary trial experienced the same type of adverse event eg disease progression pneumonia or ileus",
        "label": "Entailment"
    },
    "63bd708a-66ae-41fc-872d-277417bc2576": {
        "text_answer": "Contradiction The primary trial does not prescribe oral multivitamins but rather uses pregabalin and the secondary trial uses Depocyt liposomal cytarabine and highdose methotrexate not depomedroxyprogesterone acetate injection",
        "label": "Contradiction"
    },
    "b03fe494-c036-4988-ae85-d5e548b57aea": {
        "text_answer": "Contradiction The statement is not related to the given evidence The evidence only discusses the inclusion and exclusion criteria for the primary and secondary trials The statement is about a different topic which is a genus of bacteria",
        "label": "Contradiction"
    },
    "686121cf-e252-49b2-9e46-f4cb6ebac7f8": {
        "text_answer": "Entailment Both trials include women who are 18 years old and above",
        "label": "Entailment"
    },
    "4246dc90-5b23-4170-8b6a-bd1459f776b9": {
        "text_answer": "Entailment The statement is not directly about the number of patients affected by each adverse event but rather about the proportion of patients affected The evidence shows that no individual adverse event affected more than a quarter of the patient cohort which is consistent with the statement that none of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort",
        "label": "Entailment"
    },
    "2f57e639-546c-4e7a-b562-77338563d472": {
        "text_answer": "Entailment The statement is an entailment of the evidence as the evidence states that 13 of the participants with HER2 primary breast cancer treated with HER2targeted PETCT developed imagable HER2 metastases The statement specifically mentions 89Zrtrastuzumab which is a type of HER2targeted PETCT used in the trial",
        "label": "Entailment"
    },
    "18c281a1-43bd-47f5-9534-feddfcf0a282": {
        "text_answer": "Contradiction  Explanation  The statement Both cohorts of the primary trial receive the same dosage of Docetaxel Doxorubicin and Cyclophosphamide throughout the trial at the same frequency is a contradiction to the evidence because  1 In Intervention 1 both Doxorubicin and Cyclophosphamide are given in the same dosage and frequency for 8",
        "label": "Contradiction"
    },
    "a3ae0081-3bd8-408b-b11d-415711be2ddc": {
        "text_answer": "Contradiction The primary trial involves denosumab injections while the secondary trial involves injections of radioactive Tc99M sulfur colloid for lymphoscintigraphy These are not the same intervention",
        "label": "Contradiction"
    },
    "96a69ac4-9248-4ede-bc27-2f032f0e2294": {
        "text_answer": "Entailment The evidence clearly states that participants in the primary clinical trial will receive multiple injections of various treatments throughout the study duration including dendritic cell vaccines trastuzumab vinorelbine and sargramostim",
        "label": "Entailment"
    },
    "6e3e407e-901f-443e-9785-d19b184ff462": {
        "text_answer": "Contradiction The evidence does not provide information on the average pain intensity score for any patient experiencing the most unbearable pain for ten consecutive weeks throughout the primary clinical trial",
        "label": "Contradiction"
    },
    "9827f954-40d9-4b55-bb92-02624a0d6a75": {
        "text_answer": "Contradiction The primary trial involves the administration of dexmedetomidine which is not a thienopyridine antiplatelet agent and there is no mention of myalgias being administered in the primary trial The secondary trial involves patients with myalgias arthralgias andor joint stiffness but there is no mention of any administration of myalgias or thienopyridine antiplatelet agents",
        "label": "Contradiction"
    },
    "aba3d5b6-63f0-4eaa-a345-2e9624932e9b": {
        "text_answer": "Entailment The statement patients with quantifiable metastasis or with cancer that has spread to other parts of the body are eligible for the primary clinical trial is an entailment of the evidence provided as the evidence states that candidates for the trial must have metastatic disease M1 or multiple sites of new disease that is clinically obvious metastatic disease",
        "label": "Entailment"
    },
    "2c4acb3d-7009-4a19-ac0e-703a96740738": {
        "text_answer": "Entailment The evidence states that only cohort 1 intervention arm will view the Educational DVD as part of the intervention",
        "label": "Entailment"
    },
    "4128c0f0-7d9f-44e7-ba5a-66919c502fdd": {
        "text_answer": "Contradiction The secondary trial reported a high incidence of adverse events 6000",
        "label": "Contradiction"
    },
    "f3598d65-2288-40bd-abe1-45eaa69ee03e": {
        "text_answer": "Contradiction The placebo is administered on Day 1 while trabectedin is administered on Day 2",
        "label": "Contradiction"
    },
    "9dd03978-dc7f-4c73-a199-92f7247dbf29": {
        "text_answer": "Contradiction The statement mentions Mucositis Oral epileptic seizures and Thromboembolic events which are not mentioned in the evidence",
        "label": "Contradiction"
    },
    "57bf60c1-b440-4fa1-854e-91d2947360e3": {
        "text_answer": "Contradiction  The statement implies that there were 3 times as many hepatotoxicity cases as hypertension and pancreatectomy cases combined However the evidence shows that there were 3 times as many hepatotoxicity cases as there were pancreatectomy cases alone Therefore the statement is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "996df3c5-d5a6-4cfc-9407-cb9a59388007": {
        "text_answer": "Entailment The evidence states that the educational DVD is only shown to cohort 1 in the primary clinical trial",
        "label": "Entailment"
    },
    "0dd1c6d6-5a35-452e-b058-ea0da7bd9f3a": {
        "text_answer": "Contradiction The primary trial includes patients with early stage breast cancer while the secondary trial includes HER2positive females with a history of breast cancer Therefore some patients diagnosed with breast cancer may be eligible for one or both trials",
        "label": "Contradiction"
    },
    "a111fa2e-4d53-4b24-8929-ee37b97bed05": {
        "text_answer": "Contradiction The evidence does not indicate that participation in the primary and secondary clinical trials is restricted to Canadian nationals",
        "label": "Contradiction"
    },
    "fbe4e8b0-f258-448d-8926-3ac4757ee020": {
        "text_answer": "Contradiction In the primary trial the first cohort receives a fluciclatide injection while in the secondary trial the first cohort is given a chloroquine dose which are different interventions",
        "label": "Contradiction"
    },
    "6ad65d9b-8610-4f09-a760-caedb0a4037d": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial documented zero adverse events and the secondary trial also documented zero adverse events The statement implies that there were four more adverse events in the primary trial but the evidence shows that there were no adverse events in either trial",
        "label": "Contradiction"
    },
    "6add1cab-1458-4cca-a419-7bfc5acdc1cc": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial does involve a massage therapy intervention which is not a drugrelated test but a nonpharmacological intervention However the secondary clinical trial does involve the testing of two different medications PF06647020 at 02 mgkg and 05 mgkg making it a contradiction to the statement that the primary clinical trial does not",
        "label": "Contradiction"
    },
    "9020a95d-874e-4bee-97bb-9b31bbcdd50d": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the median PFS for cohort 1 was 16 months 16 to 32 and the longest PFS of 35 months was observed in cohort 2 CDX011",
        "label": "Contradiction"
    },
    "f0cbb267-5a5b-412e-a474-2ad091a031d7": {
        "text_answer": "Contradiction  Explanation  In the primary trial only one intervention arm Intervention 2 includes Armodafinil but it is not given daily and the dosage is different from the secondary trial  In the secondary trial both intervention arms receive MCS110 and PDR001 but the dosages are different and they are not the same for all patients as stated in the question",
        "label": "Contradiction"
    },
    "b5b61f90-60b8-404f-872e-a58c84dbf43a": {
        "text_answer": "Entailment  Explanation The evidence shows that no adverse events were reported in the primary trial for the given cohort and similarly no adverse events were reported for the given cohort in the secondary trial The statement that no aes were registered in either the primary clinical trial or the secondary clinical trial is an entailment of the evidence",
        "label": "Entailment"
    },
    "e3629df4-61d3-42e0-af44-62cb2782c5c2": {
        "text_answer": "Entailment assuming that adverse incidents refers to the same types of adverse events in both trials and that the absence of reported adverse events in the evidence implies a lower number of adverse events in the secondary trial compared to the primary trial",
        "label": "Entailment"
    },
    "7f7f7885-c57a-42f3-9799-99159d400077": {
        "text_answer": "Contradiction if the statement in the question is taken to mean that the intervention section must always detail the administration method dose and routine which is not necessarily the case  Explanation The statement in the question is a contradiction to the evidence if it is interpreted to mean that the intervention section of a clinical trial must always detail the administration method dose and routine However the evidence only states that the intervention section of the primary trial in question does",
        "label": "Contradiction"
    },
    "65a1b098-171e-4a2e-87a7-7d29b4a7d6ba": {
        "text_answer": "Contradiction The primary trial and the secondary trial measure different outcome measures The primary trial measures the count of participants with treatmentemergent adverse events while the secondary trial measures the median duration of patients sleep in minutes",
        "label": "Contradiction"
    },
    "cbf72855-5886-46d7-b084-43cb6f2a0e2e": {
        "text_answer": "Contradiction  Explanation The statement presurgical consumption of tamoxifen 20 mg orally on daily basis excites a rise in ki67 expression in cancer tumors is a contradiction to the evidence presented in the study The study results show that there is a significant decrease in Ki67 expression in tumors after 7 days of presurgical tamoxifen treatment",
        "label": "Contradiction"
    },
    "f0ff3265-a75f-4a9f-8c0e-ff03057647eb": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the interventions described in the evidence are administered orally twice daily not once daily as stated in the question",
        "label": "Contradiction"
    },
    "584c33f0-3bca-4276-a3f1-2c68e39898ac": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as no single adverse event impacted more than 50 of the subjects in the secondary clinical trial",
        "label": "Contradiction"
    },
    "d5abfad6-a8c3-409f-b434-33e55c0848cb": {
        "text_answer": "Entailment  Explanation The statement is an entailment because the evidence provided in the primary and secondary trials clearly shows that different drugs dosages and administration schedules are used in each trial",
        "label": "Entailment"
    },
    "96e242e7-e1dc-4465-bb90-6f9ef0ab0f2a": {
        "text_answer": "Contradiction The evidence does not mention anything about talazoparib being prescribed or not prescribed in the primary clinical trial",
        "label": "Contradiction"
    },
    "bd18948b-345b-48be-a1a0-45c4ee688747": {
        "text_answer": "Contradiction  Explanation In the primary trial group 2 receives an administration of dexmedetomidine which is not the same as receiving myalgias 500ngkg In the secondary trial patients do not receive any myalgias as part of the intervention",
        "label": "Contradiction"
    },
    "e5a8197e-dc1f-4258-9da2-f530eade84fe": {
        "text_answer": "Contradiction The statement does not entail the evidence as it makes no mention of the trials or the interventions having any effect on feelings of nervousness or anxiety",
        "label": "Contradiction"
    },
    "dfd33619-98ec-43e0-83c4-a22bae9f1b52": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial requires mammography and the secondary trial does not mention any specific imaging requirement",
        "label": "Contradiction"
    },
    "ad3c8700-e49c-404e-af40-e9329033f2a7": {
        "text_answer": "Contradiction The evidence shows that one patient in the primary clinical trial experienced an increase in blood bilirubin levels",
        "label": "Contradiction"
    },
    "6cf2337d-c486-405c-be2b-97c29d8425dc": {
        "text_answer": "Contradiction  Explanation  The statement the most common adverse event in the secondary trial was anaemia affecting less than 005 of patients there were no recorded aes in the primary trial is a contradiction based on the evidence provided  The evidence shows that in the secondary trial anaemia affected 3128 234 of patients which is greater than",
        "label": "Contradiction"
    },
    "5e6797ef-370c-4b35-9e1d-37e694b538a6": {
        "text_answer": "Contradiction  The statement 25 of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression is a contradiction to the evidence as the evidence shows that only one patient in the primary trial suffered from both Increased pleural effusion and Rapid disease progression which is 769 and not 2500",
        "label": "Contradiction"
    },
    "52d2dcbc-8b57-43eb-bc12-8b7df8c3d8ba": {
        "text_answer": "Contradiction The primary clinical trial requires participants to be resistant to AI therapy while the secondary clinical trial has no such requirement",
        "label": "Contradiction"
    },
    "40f8f9a6-a042-4f99-bbd9-5f3c3279045d": {
        "text_answer": "Contradiction  Explanation The primary trial mentions the use of GMCSF Granulocytemacrophage colonystimulating factor and the secondary trial mentions the use of pegfilgrastim or filgrastim Granulocyte colonystimulating factor and Granulocytemacrophage colonystimulating factor respectively but there is no mention of methotre",
        "label": "Contradiction"
    },
    "475fbb72-9858-40cf-b7f0-50236d032582": {
        "text_answer": "Contradiction The primary trial includes patients aged 18 to 45 while the secondary trial does not specify an age limit",
        "label": "Contradiction"
    },
    "9137a91a-d493-42f7-a1e5-9b39928036d6": {
        "text_answer": "Contradiction The primary trial does not mention anything about CBT Cognitive Behavioral Therapy in its inclusion or exclusion criteria Therefore the statement about CBT not being permitted in the primary trial is not related to the information provided in the primary trial evidence",
        "label": "Contradiction"
    },
    "72154344-5c84-49cd-b39e-4010fb73756a": {
        "text_answer": "Contradiction The primary trial is for postmenopausal women with early stage breast cancer and low vitamin D levels while the secondary trial is for healthy participants and HER2positive females with a history of breast cancer These are distinct patient populations",
        "label": "Contradiction"
    },
    "ca8c2bae-ba14-4791-b995-e1555696d182": {
        "text_answer": "Contradiction The primary trial does not mention gabapentin as an exclusion criterion within the last 12 months while the secondary trial excludes patients who have been exposed to gabapentin within the last 12 months The statement that exposure to gabapentin or herceptin within the last 12 months disqualifies patients from the secondary clinical trial yet it wont prevent them from being part of the primary clinical trial",
        "label": "Contradiction"
    },
    "437a782b-7dc2-4904-ac68-3a532b98f2e2": {
        "text_answer": "Contradiction  The statement out of the participants 5 had experienced three or more adverse incidents during the primary clinical trial is not an entailment or a contradiction based on the evidence provided The evidence only states the number and types of adverse events experienced by each participant but it does not specify how many adverse events any individual participant experienced in total Therefore it is impossible to determine if five participants experienced three or more adverse events each based",
        "label": "Contradiction"
    },
    "947b0d76-6214-46c7-ac3c-f5794e0cfcb3": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence does provide the number of participants within each cohort although it does not state it in the exact words of the statement",
        "label": "Contradiction"
    },
    "561d1a70-6bd1-42f7-9e2a-73b9622a449c": {
        "text_answer": "Entailment Both trials have one test group and one control group placebo group in the primary trial lowdose oxybutynin chloride group in the secondary trial",
        "label": "Entailment"
    },
    "8601ec47-bccd-45d7-b823-ff39719683e5": {
        "text_answer": "Contradiction  Explanation The evidence provided does not support the statement as it does not mention any information about the outcomes of the LBH589 and Lapatinib group compared to their LBH589 with Capecitabine counterparts The evidence only provides information about the dosing and number of participants in each group",
        "label": "Contradiction"
    },
    "620be964-dbff-4793-a75e-7644f7c57fb5": {
        "text_answer": "Contradiction The evidence does not mention anything about neurokinin1 receptor antagonist being administered to the participants",
        "label": "Contradiction"
    },
    "b35e0f7c-9162-4752-98dc-b41bac62e99c": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the percentage of adverse events in cohort 1 was 000 compared to 4000 in cohort 2",
        "label": "Contradiction"
    },
    "dea24187-160a-4d6c-a724-e8cb01494d68": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence does not support the comparison of the doses of Eribulin and Docetaxel between the two cohorts in terms of physical quantity to physical quantity time ratio The statement assumes that the comparison is being made between the same drugs but the evidence only provides the dosing information for each intervention To make a valid comparison the frequency of administration and the duration of infusion for",
        "label": "Contradiction"
    },
    "cf959db3-df50-4724-a747-413a35bb171b": {
        "text_answer": "Entailment assuming neither cohort refers to both Intervention 1 and Intervention 2 in the primary trial The evidence does not mention the use of drugs radiotherapy or CBT in the interventions for either cohort so the statement is entailed by the evidence",
        "label": "Entailment"
    },
    "3cf9b40b-ffa4-4b08-9039-9481c7d6cd76": {
        "text_answer": "Contradiction The statement is not based on the evidence provided The evidence does not mention the number of cases of nausea in either trial",
        "label": "Contradiction"
    },
    "52f7d88d-78f0-4e5a-8fb9-e423679f2c61": {
        "text_answer": "Contradiction  Explanation  In the primary trial participants in Intervention 1 receive daily sc injections of Triptorelin or Degarelix while those in Intervention 2 receive oral medication Letrozol  In the secondary trial participants in Intervention 1 receive weekly sc injections of Epoetin Beta However the statement provided incorrectly states that those enrolled in the primary clinical trial receive",
        "label": "Contradiction"
    },
    "901dac1a-6a67-4883-a883-06c5a91f85c1": {
        "text_answer": "Contradiction The evidence provided indicates that no adverse events were recorded in both trials and the statement is about over 100 total adverse events",
        "label": "Contradiction"
    },
    "c89ba7c0-93b6-4601-82f0-557aa23f24cc": {
        "text_answer": "Contradiction The primary trial explicitly excludes children and adolescents due to height requirements while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "18c8db1c-2d31-481b-923d-0415861bd6d6": {
        "text_answer": "Contradiction The primary trial only includes patients with breast cancer not lung cancer",
        "label": "Contradiction"
    },
    "8db48a95-bc22-4f5e-b9e3-a50a275481a3": {
        "text_answer": "Contradiction The primary trial and secondary trial have different inclusion criteria and there is no explicit exclusion of participants from the secondary trial in the primary trials exclusion criteria",
        "label": "Contradiction"
    },
    "4092de53-28a9-457c-91cf-f87f4abf4dc1": {
        "text_answer": "Contradiction The evidence does not support the statement that 100 of the patients in the primary trial experienced the worst pain imaginable for 10 weeks The evidence only provides information on the change in average pain intensity between the two intervention groups",
        "label": "Contradiction"
    },
    "f1c2db2e-dc72-4a69-a3b6-a8d846a6f7ee": {
        "text_answer": "Contradiction The primary trial includes postmenopausal women with early stage breast cancer and vitamin D deficiency but the secondary trial does not mention anything about vitamin D deficiency as an inclusion criterion",
        "label": "Contradiction"
    },
    "16710aab-1003-447f-bf01-7275e653d263": {
        "text_answer": "Contradiction The primary trial requires a primary tumor greater than 2 cm diameter while the statement provides a tumor radius of 0003m which is significantly smaller than the required minimum size",
        "label": "Contradiction"
    },
    "e9639699-8cb1-4b2b-9901-443fedb90158": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions confusion in both trials but it also includes swelling and hypothermia which are not reported in either trial",
        "label": "Contradiction"
    },
    "b6643c69-48aa-452a-91f8-b45c83ccf01e": {
        "text_answer": "Contradiction The statement provides no information about the Recurrencefree Survival of the 2 patients who were not analyzed in the given results",
        "label": "Contradiction"
    },
    "3df0eb9e-b9d9-4f8b-af9a-2d6259e1ed9c": {
        "text_answer": "Entailment The evidence states that laserassisted fluorescence angiography is used for monitoring perfusion in both interventions and the lateral radial incision is mentioned as the incision type for intervention 2 Therefore the statement that laserassisted fluorescence angiography along with lateral radial incisions are employed for both interventions is an entailment based on the evidence provided",
        "label": "Entailment"
    },
    "c667d986-5b21-4855-8f51-109296357a9e": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial clearly states that Capecitabine was administered to participants during the first 21day cycle",
        "label": "Contradiction"
    },
    "2d7737fc-95e6-4392-8a2e-d896e65ba3e6": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial reports fewer total adverse events but a higher count of cardiacischemiainfarction events",
        "label": "Contradiction"
    },
    "e25b66fb-c20a-4868-b2c3-780c859d629b": {
        "text_answer": "Contradiction  The evidence states that 897 of participants in the NaCl 09 3mL group achieved recurrencefree survival which is 13 more than the stated number in the question",
        "label": "Contradiction"
    },
    "7e695451-7e2e-43b4-8762-0ac27fb978b2": {
        "text_answer": "Contradiction  Explanation The evidence provided does not support the statement as it only reports the absence of a discernible gene expression pattern for both the normal and lownormal Vitamin D level groups within the given time frame of the study The statement goes beyond the reported findings by claiming that the expression pattern was absolutely visible among all participants in both cohorts which is not substantiated by the evidence",
        "label": "Contradiction"
    },
    "b5c0af13-187b-4f3f-8e46-c06d2df27d1c": {
        "text_answer": "Contradiction The primary trial excludes patients with anemia only due to irondeficiency but the statement includes anemia as a condition that cannot participate in either trial However fibromyalgia and thalasemic syndromes are excluded in both trials according to the provided evidence",
        "label": "Contradiction"
    },
    "73677475-c59f-4327-b231-57cd7136dd94": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as cholelithiasis was not recorded in either trial",
        "label": "Contradiction"
    },
    "22401c29-1796-455c-ac34-59d3afb99fe9": {
        "text_answer": "Contradiction  Explanation  The statement every participant in group 1 of the primary trial were diagnosed with lesions is not entailed by the evidence from the primary trial which only reports that no lesions were detected in the healthy volunteers group  Furthermore the statement less than 5 of participants in group 1 of the secondary trial had clean skin without any blemishes is not directly related to the evidence",
        "label": "Contradiction"
    },
    "af3d4568-37c3-4c9b-8b22-38d9e3087754": {
        "text_answer": "Contradiction The statement assumes that the primary trial and secondary trial compare the same endpoints but they do not The primary trial measures pCR while the secondary trial measures pCR after preoperative therapy",
        "label": "Contradiction"
    },
    "7ae95d8e-af13-452e-a4e0-d4ba7c066a9c": {
        "text_answer": "Entailment  Explanation The statement only patients with no known hypersensitivities to herceptin medications are acceptable candidates for the primary clinical trial is an entailment of the evidence provided as the evidence explicitly states that Patients that have received prior chemotherapy must have no history of grade 3 or 4 allergic reactions attributed to trastuzumab",
        "label": "Entailment"
    },
    "18f56de9-cf7d-467a-9e95-ca80d8c651a2": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence indicates that there was only one psychiatric adverse event suicidal ideation in the primary trial which affected 200 150 of patients not more than 90",
        "label": "Contradiction"
    },
    "2f11c1f5-4e9c-4848-8de1-9df7d4403848": {
        "text_answer": "Entailment Both trials include the use of cyclophosphamide in their interventions",
        "label": "Entailment"
    },
    "9229abbd-f6e6-4747-bf4c-7c1257115667": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided The evidence does not provide any information about the number of primary tumors in the individuals in the trials",
        "label": "Contradiction"
    },
    "09ac056f-fdf4-4684-99d2-8581ddc09d3b": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence provided indicates that there are only 14 shared inclusionexclusion criteria between the two trials The primary trial includes Age  18 years as an inclusion criterion which is not mentioned in the secondary trials inclusion criteria",
        "label": "Contradiction"
    },
    "4a54e780-0828-40c0-9f30-1ed06b66275a": {
        "text_answer": "Contradiction  Explanation The statement mentions that two patients suffered an incidence of doselimiting toxicity from cohort 2 of the primary trial However the evidence only shows that there was one participant in each cohort who experienced doselimiting toxicity Therefore the statement contradicts the evidence as it states that there were two patients instead of the correct number which is one for each cohort",
        "label": "Contradiction"
    },
    "3a4198ab-ae79-4200-b073-860b2e86813d": {
        "text_answer": "Contradiction The statement is a contradiction because patients with a history of pulmonary embolisms can participate in the primary trial but they are excluded from the secondary trial while patients with breast implants can participate in the secondary trial but they are excluded from the primary trial Therefore the statement does not hold true for both trials",
        "label": "Contradiction"
    },
    "b200a0d8-1c63-49a2-bf1c-280e9d6a2968": {
        "text_answer": "Contradiction  Explanation The evidence shows that several adverse events affected more than 01 of patients in the primary trial For example febrile neutropenia sepsis and sinus tachycardia each affected 909 of patients Therefore the statement that all adverse event types affected less than 01 of patients is a contradiction based on the evidence",
        "label": "Contradiction"
    },
    "cea1bf06-b100-4328-aee1-638ef92d2784": {
        "text_answer": "Contradiction The secondary trial reports the determination of the MTD but it is defined differently than in the primary trial and does not mention the MTD of MM111",
        "label": "Contradiction"
    },
    "3c9c99d8-4604-4de9-98e6-81a675fe0558": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence describes the contents of the intervention and control groups in the primary clinical trial but it does not mention radiotherapy being administered to either group",
        "label": "Contradiction"
    },
    "524f9dd3-ec1a-44fa-b440-59eaa49fe204": {
        "text_answer": "Entailment The statement does not contradict the evidence as it is a general statement about refractory acute myelomonocytic leukemia and the evidence only provides information about the adverse events observed in the primary trial",
        "label": "Entailment"
    },
    "f7c36a91-5d42-46b9-b0cb-db7a57d37c04": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because the evidence shows that the dosage of eribulin given to cohort 1 is lower 14mgm2 than the dosage of docetaxel given to cohort 2 75 mgm2",
        "label": "Contradiction"
    },
    "a44a34b5-9f9e-4957-bb5e-5bb7bf834ecc": {
        "text_answer": "Contradiction The statement allows for a grade 1 stomal ulcer which is not included in the exclusion criteria listed in the evidence",
        "label": "Contradiction"
    },
    "f90e818c-2a5c-44c9-9445-1d34a0c2e551": {
        "text_answer": "Entailment The primary trial includes women aged 18 and older and the secondary trial also includes women aged 18 and older Therefore the statement that women who are at least 18 years old can participate in both the secondary and the primary clinical trial is an entailment",
        "label": "Entailment"
    },
    "c31609ed-47a9-4a4a-94f1-92757a79033c": {
        "text_answer": "Entailment The evidence states that Intervention 1 is for Pneumococcus vaccine in Adult Cancer Patients and Intervention 2 is for Influenza vaccine in Healthy Volunteers which matches the statement",
        "label": "Entailment"
    },
    "34b41276-f5fe-4adf-8178-808e139d9d52": {
        "text_answer": "Contradiction The statement is a contradiction to the inclusion criteria of the primary clinical trial which requires patients to have evidence of a solid tumor that is locally advanced andor metastatic",
        "label": "Contradiction"
    },
    "a6fa44b8-fb1b-4571-aadd-284cbe4f37d8": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the most common adverse event in the secondary trial was not Anaemia but rather an adverse event arrhythmia cardiac arrest cardiac failure cardiopulmonary failure or one of several gastrointestinal events was recorded in the primary trial where none were reported in the statement",
        "label": "Contradiction"
    },
    "f2d5970e-568d-40ca-9258-65015ff4a828": {
        "text_answer": "Contradiction The statement none of these describe me contradicts the evidence that Perjeta is used in the secondary trial However it is important to note that the statement does not directly relate to the interventions in the primary or secondary trials but rather to a potential individual response",
        "label": "Contradiction"
    },
    "45d94eb6-d3a6-47ae-8c80-75fb02520ef2": {
        "text_answer": "Contradiction The primary trial did not report any cases of radiation dermatitis or hyperpigmentation while the secondary trial reported 5 incidence for both in the control group",
        "label": "Contradiction"
    },
    "a6f84772-606c-4977-87e2-aa4de18ac07a": {
        "text_answer": "Contradiction The primary trial has an ECOG performance status of 02 which means the patients are capable of selfcare with minimal assistance The secondary trial on the other hand includes patients with an ECOG of 02 OR Karnofsky 60100 which includes patients who are confined to bed or chair more than 12 of waking hours Karnofsky 50",
        "label": "Contradiction"
    },
    "c975a46b-6980-4cc4-886d-674f5f2c6773": {
        "text_answer": "Contradiction  Explanation The evidence states that 98 of the patients had recurrencefree survival which is not a majority but rather a neartotal percentage Therefore the statement a majority of patients in the primary clinical trial did not have recurrencefree survival is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "5e45f9e6-6a4f-4cf6-b24a-8755f700943f": {
        "text_answer": "Entailment  Explanation The statement both the primary and secondary clinical trials administer their treatments orally is an entailment based on the evidence provided In the primary trial the intervention in Arm I involves administering Vitamin B12 orally and in the secondary trial the intervention in Arm I Memantine is given orally as well The statement is a logical consequence of the information in the evidence",
        "label": "Entailment"
    },
    "8d6dfb9e-cb56-4746-bdb6-45cbb5aadb03": {
        "text_answer": "Contradiction The primary trial involves denosumab injections while the secondary trial involves radioactive Tc99M sulfur colloid injections These are not the same interventions",
        "label": "Contradiction"
    },
    "821e8e07-ec33-4f99-8f6e-6d7d50d23d8c": {
        "text_answer": "Contradiction  Explanation The statement does not follow from the evidence as the evidence does not provide any information about cognitive function in the education training and library occupations class The evidence only reports the cognitive function results for the Tamoxifen and Ovarian Function Suppression groups",
        "label": "Contradiction"
    },
    "9dcb0637-50ed-4e98-b6e8-fa95fae80471": {
        "text_answer": "Entailment The evidence states that the dosages of docetoxel doxorubicin and cyclophosphamide are given in mgm² and mg respectively and these dosages may vary depending on the patients weight and age",
        "label": "Entailment"
    },
    "ee93ea09-f0a8-42ab-880d-8284fe0d716e": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it shows different percentage rates of participants with a decrease in the growth factor signature for each group but it does not indicate a specific difference of 11",
        "label": "Contradiction"
    },
    "ae6c4238-c27f-45c1-92e0-6d1164c6accf": {
        "text_answer": "Irrelevant  Explanation The statement does not relate to the evidence provided as it is about vaginal dryness while the evidence is about Ki67 expression change in breast cancer patients undergoing TAK228 Plus Tamoxifen treatment",
        "label": "Entailment"
    },
    "44ff230b-fe8f-44de-9f48-e6ab10e91b68": {
        "text_answer": "Contradiction The evidence shows that the iDFS rate was lower in the Neratinib group 47 compared to the Placebo group 75",
        "label": "Contradiction"
    },
    "b1f92a23-fa4b-4cf6-9df1-b38794ab00ba": {
        "text_answer": "Contradiction The statement is not related to the inclusion or exclusion criteria for the primary trial The statement is about a speaker device which is not mentioned in the trial information",
        "label": "Contradiction"
    },
    "5fbee4f6-43fc-45a7-88c4-3dcd5ff21053": {
        "text_answer": "Contradiction The evidence states that No meningeal carcinomatosis is a requirement for the primary trial but the statement is about a patient diagnosed with leptomeningeal carcinoma which is a type of meningeal carcinomatosis",
        "label": "Contradiction"
    },
    "5c5a882c-4840-4e2e-83f8-341283caa359": {
        "text_answer": "Contradiction The primary trial intervention involves Yttrium90 radioembolization using TheraSphere while the secondary trial intervention consists of administering ibrutinib and MEDI4736 orally",
        "label": "Contradiction"
    },
    "5cc29d9f-f81c-41c0-8a55-a98264f040c7": {
        "text_answer": "Contradiction The primary trial only includes patients with unilateral breast cancer",
        "label": "Contradiction"
    },
    "ad6c7a37-2ab2-428a-8ac5-d2462d920c11": {
        "text_answer": "Contradiction The evidence does not state that only nationals from the United Kingdom are eligible for the clinical trials",
        "label": "Contradiction"
    },
    "af9dbcc2-f6ab-4e1e-aac7-a1f0bccd4d86": {
        "text_answer": "Entailment  Explanation  The statement the primary clinical trial utilizes larger quantities of lenalidomide for intervention 1 compared to the secondary clinical trials use of lapatinib is an entailment because the primary trial uses lenalidomide at a dose of 5mg orally daily while the secondary trial uses lapatinib at a dose of 1500mg orally daily The primary trials",
        "label": "Entailment"
    },
    "50e1ebd6-d51b-4e86-9748-a0d97a411b62": {
        "text_answer": "Contradiction The statement does not relate to the inclusion or exclusion criteria for the primary trial which pertain to the type and status of breast cancer not to Taq polymerase or laboratory applications",
        "label": "Contradiction"
    },
    "d7bcab45-fcd5-46bb-9317-b75573e0373f": {
        "text_answer": "Contradiction  Explanation The evidence provided in the results shows that the median aAUCpa scores for the Arm I Cryotherapy group were less negative than the Arm II Control group indicating that the symptoms improved more in the Arm I group compared to the Arm II group Therefore the statement that the symptoms were more severe in patients who were not infused with paclitaxel compared to those who were is a contradiction",
        "label": "Contradiction"
    },
    "5d512914-5625-4734-b828-f20f41ef1a98": {
        "text_answer": "Neutral The statement is not directly related to the evidence",
        "label": "Entailment"
    },
    "fbefc569-ec7c-41d6-9d12-39533f6e0fc2": {
        "text_answer": "Contradiction The primary trial has a cyclic treatment with a defined cycle length of 21 days while the secondary trial does not have a cyclic treatment mentioned in the evidence",
        "label": "Contradiction"
    },
    "c5426d56-93e6-435b-8e77-19419e66c3d4": {
        "text_answer": "Contradiction The evidence states that there should be no meningeal carcinomatosis in the patient characteristics for the primary trial",
        "label": "Contradiction"
    },
    "7e69da7b-d7e2-4166-ba1c-520947f7b596": {
        "text_answer": "Contradiction The evidence shows that there was 1 case of anaemia and 1 case of febrile neutropenia in the first group but no cases of pancytopenia The statement implies that there were numerous incidences of anaemia and febrile neutropenia which is not supported by the evidence",
        "label": "Contradiction"
    },
    "ff11f88f-a4cb-481e-bf56-afa5c0adda19": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events recorded in the primary trial while the secondary trial recorded none in cohort 1 Therefore it is a contradiction to the statement that the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial",
        "label": "Contradiction"
    },
    "49f55eb1-1f11-4d89-9888-810dff7b4926": {
        "text_answer": "Contradiction The statement is not supported by the evidence provided as the trial compared acupuncture to a waitlist control group not to testosterone cream",
        "label": "Contradiction"
    },
    "5975fc5c-37b0-4c9e-b546-afa0915ba928": {
        "text_answer": "Entailment The evidence clearly states that the memantine intervention is administered for 12 weeks while the placebo intervention is only administered for the same duration but in the absence of unacceptable toxicity The administration frequencies are also different with memantine being administered twice daily and placebo being a placebo by mouth",
        "label": "Entailment"
    },
    "8a308bd1-0164-4734-bdeb-f955327b4314": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence provided because the evidence compares the symptoms of patients who received paclitaxel infusions Arm II to those who received cryotherapy during paclitaxel infusions Arm I The statement however is not about patients who didnt receive paclitaxel infusions at all but rather a comparison between two groups one receiving paclitaxel infusions and the",
        "label": "Contradiction"
    },
    "fc839312-3b01-43e3-8cad-f1107759f462": {
        "text_answer": "Contradiction The primary trial involves the administration of denosumab as a subcutaneous injection while the secondary trial does not involve any injection and instead uses lymphoscintigraphy The statement incorrectly assumes that both trials involve the use of a gum dosage form which is not the case",
        "label": "Contradiction"
    },
    "7f1d39e0-4892-447d-90b9-b2c672e59c79": {
        "text_answer": "Contradiction  Explanation The evidence provided in the primary trials inclusion and exclusion criteria mentions specific medical conditions related to the patients diagnosis and treatment history The statement however makes a generalization about the trial not mandating certain criteria but it does not specify which criteria are being referred to The evidence does not entail or contradict the statement as it does not provide enough information to make a definitive determination However based on the",
        "label": "Contradiction"
    },
    "ec8bde60-164e-45f7-819d-84b7af4ff04e": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention is the administration of Vitamin B12 sublingually while in the secondary trial the intervention is the administration of memantine hydrochloride orally Therefore the methods of administration are different making the statement a contradiction",
        "label": "Contradiction"
    },
    "0f6d115f-8b84-46cc-a95f-51af051029e3": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the given evidence The evidence does not provide sufficient information to determine if the statement is true or false  Explanation  The statement is not an entailment because the length of the interventions does not directly affect the measurement of total organic carbon in pharmaceutical waters  The statement is not a contradiction because the evidence does not provide any information that would contradict the",
        "label": "Entailment"
    },
    "7b5d47fb-446d-481f-9785-3ff8b467fa69": {
        "text_answer": "Contradiction The primary trial intervention does not include ibrutinib and ipilimumab in the given doses and schedule Instead it involves Yttrium90 Radioembolization",
        "label": "Contradiction"
    },
    "86cc51ee-ff9e-4396-9c2a-85feaa52c215": {
        "text_answer": "Contradiction The primary trial measures pain intensity using a visual analog scale not the severity of delayed nausea",
        "label": "Contradiction"
    },
    "a5631fa6-2f92-4be7-a055-4c7b3abcdb4d": {
        "text_answer": "Contradiction The evidence states that each adverse event occurred in only one patient Therefore there were no recurring patterns of the same adverse event across multiple patients in the primary clinical trial",
        "label": "Contradiction"
    },
    "fb5aff7f-4a77-4300-acc4-99a01a6696d1": {
        "text_answer": "Entailment The statement correctly describes the difference between the two cohorts based on the evidence provided",
        "label": "Entailment"
    },
    "ef6ae88d-2d86-4786-8cec-5fad1c1671b8": {
        "text_answer": "Contradiction The evidence does not provide information about the occurrence or percentage of side effects in the primary trial",
        "label": "Contradiction"
    },
    "590f240e-7499-432e-aa3c-f54eda69ed46": {
        "text_answer": "Contradiction  Explanation The evidence states that women of childbearing potential WOCBP and sexually active fertile men are excluded from the study unless they agree to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab The statement however suggests that these individuals are eligible for the study but need to commit to abstinence for the",
        "label": "Contradiction"
    },
    "3c56fe49-cda1-4f0f-8597-63f1e8d6237c": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the evidence does not support the statement that the primary trial candidates receive less weekly MM121 and Paclitaxel than cohort 1 in the secondary trial In fact the statement is incorrect because the primary trial does not involve MM121 or Paclitaxel at all The primary trial involves cyclophosphamide doxorubic",
        "label": "Contradiction"
    },
    "03a73488-c2a3-437c-b4b7-d26832eaafe8": {
        "text_answer": "Entailment The evidence shows that the number of participants who experienced adverse events varied between the two cohorts",
        "label": "Entailment"
    },
    "2c519a1e-668f-4731-941e-21dadeb2031d": {
        "text_answer": "Contradiction The statement is not an entailment as both cohorts receive NabPaclitaxel with different doses of Carboplatin or Gemcitabine in Arm A and Arm B respectively",
        "label": "Contradiction"
    },
    "a6718ad8-0ba6-4513-aae0-92610b1421e6": {
        "text_answer": "Contradiction The evidence shows that there is one case of bronchopneumonia reported in the secondary trial and one case of general physical health deterioration reported in both trials",
        "label": "Contradiction"
    },
    "28b11be9-1e77-49c5-8cd2-fb9a95a35b58": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The evidence describes the use of gamma imaging in both interventions but it does not mention the grem1 gene mutation or any connection between the gene mutation and the use of pIHGC versus GP",
        "label": "Entailment"
    },
    "1624bc79-6ba3-449b-afd6-0234b760664e": {
        "text_answer": "Contradiction The statement excludes patients who have undergone antineoplastic chemotherapy androgens estrogens or progestogens therapy within the last 2 years but the primary trials exclusion criteria specifically allow the use of tamoxifen raloxifene and aromatase inhibitors if the patient has been on a constant dose for at least 28 days and is not expected to stop the medication during the",
        "label": "Contradiction"
    },
    "45571dd6-2532-4086-af29-0b8558423b26": {
        "text_answer": "Contradiction  Explanation The primary trial includes patients with histologically or cytologically confirmed breast adenocarcinoma but it specifically excludes patients with stage IV disease The secondary trial on the other hand only includes patients with metastatic stage IV breast cancer Therefore patients with confirmed stage 1 and 2 breast adenocarcinoma that is ER negative PR negative or HER2neu",
        "label": "Contradiction"
    },
    "0f4882ae-b6f3-4c11-b4ad-a3fc1aeb6f94": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not provide any information about the chromosome band 6p25 or its relation to breast cancer patients eligibility for the studies",
        "label": "Contradiction"
    },
    "b586fc1f-656e-477b-89d5-84aa4cb55814": {
        "text_answer": "Entailment  Explanation The statement Aes were not recorded for the primary trial or the secondary trial implies that there were no adverse events reported in both trials The evidence supports this statement as it shows that no adverse events were recorded in the primary trial and none were recorded in the secondary trial up to a certain point The second part of the statement staff not available is a staff member is or was not available is not directly related to the",
        "label": "Entailment"
    },
    "985e4878-0637-4b32-a96f-626ff2f7cbd4": {
        "text_answer": "Contradiction The statement preoperative iv antiemetics were administered is a response indicating that preoperative intravenous opiates were administered is not an entailment or contradiction to Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial but not from the primary trial as the two statements address different conditions The first statement is about the administration of preoperative iv antiemetics and op",
        "label": "Contradiction"
    },
    "e0983a0e-1008-4845-bc61-082077d3d3d3": {
        "text_answer": "Contradiction  Explanation The statement is about the reduction in tumor diameter by 70 on average with tamoxifen 100 mg po daily for 50 days prior to surgery and for 60 days after breast cancer surgery However the evidence from the primary trial only shows a significant change in Ki67 expression in tumors with 7 days of presurgical tamoxifen and the change in",
        "label": "Contradiction"
    },
    "57c87de4-06c1-4d6f-9ed8-ed09e82cd3c7": {
        "text_answer": "Contradiction The primary and secondary trials are not directly comparable as they measure different outcomes The primary trial measures diagnostic accuracy of two algorithms in breast cancer diagnosis while the secondary trial measures fatigue levels in breast cancer patients undergoing radiation therapy and reflexology treatment",
        "label": "Contradiction"
    },
    "138e64ea-8b97-4101-b3cf-2b808a8dbc88": {
        "text_answer": "Contradiction  Explanation The evidence states that there is one patient in cohort 2 who experienced an increase in pleural effusion Therefore the statement that no patients in cohort 2 of the primary clinical trial report an increase in pleural effusion is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "c43d1ac6-f3d2-44f6-870d-fb91f3365c5b": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it does not mention any information about Treatment Emergent Adverse Events or Serious Treatment Emergent Adverse Events in the primary trial results for the paced respiration and fast shallow breathing groups",
        "label": "Contradiction"
    },
    "2e2e15a3-327e-4c79-9ad2-f7978f4f7cdf": {
        "text_answer": "Entailment The evidence shows that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher proportion of responders ORR than the Paclitaxel Plus Bevacizumab group",
        "label": "Entailment"
    },
    "4d5b9d90-2c58-499e-8943-eacac7580eb1": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided The evidence only discusses the dosages of Eribulin and Docetaxel in two different intervention groups of a primary trial The statement about Epithiazide is unrelated to the trial or the drugs mentioned",
        "label": "Contradiction"
    },
    "3ed3f0f5-20e7-4cd1-8c4c-79ba7603fb85": {
        "text_answer": "Contradiction The statement does not entail the evidence as the eligibility criteria for the secondary trial regarding pulmonary embolism are not specified in the given evidence",
        "label": "Contradiction"
    },
    "ee049505-21d4-4255-823c-10d79a91db59": {
        "text_answer": "Entailment The evidence shows that there were fewer than 10 adverse events in total in the primary clinical trial",
        "label": "Entailment"
    },
    "b0b151a2-65f7-476a-9a2a-915bd963516d": {
        "text_answer": "Entailment The evidence shows that one participant in the primary clinical trial developed a urinary tract infection which is consistent with the statement that several participants developed this condition The term several implies more than one which is satisfied by the evidence",
        "label": "Entailment"
    },
    "de3550b8-5014-4f01-897e-07780353ec9a": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that no cases of Clostridium difficile colitis were reported in the secondary trial while the primary trial reported one case Additionally there was only one case of biliary colic in the secondary trial which is less than the one case reported in the primary trial",
        "label": "Contradiction"
    },
    "0a068f7d-0892-428d-889b-153d579cba78": {
        "text_answer": "Contradiction The primary trial includes postmenopausal women with early stage breast cancer while the secondary trial includes HER2positive females with a history of nonmetastatic operable primary invasive breast cancer These populations are not identical and the primary trial excludes healthy participants while the secondary trial includes them Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "1917f075-87da-430b-adf7-bb1579d145fb": {
        "text_answer": "Entailment The primary trial involves oral administration of alpha lipoic acid with dose escalation while the secondary trial involves intravenous administration of necitumumab with a constant dose The statement compares the dosage levels appropriately with alpha lipoic acid having a higher dosage in terms of number of doses per day not absolute dose amount",
        "label": "Entailment"
    },
    "f891df0b-cb3d-4ee8-8294-f139ecc8a018": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence only reports that 13 of the participants with HER2 primary breast cancer developed imagable HER2 metastases not all participants",
        "label": "Contradiction"
    },
    "ff9b4b7a-e2c7-470d-9a7f-6f2b9669da64": {
        "text_answer": "Contradiction The primary trial intervention involves Yttrium90 Radioembolization using TheraSphere while the secondary trial intervention consists of administering ibrutinib and MEDI4736 orally",
        "label": "Contradiction"
    },
    "77b0fb73-3157-4ceb-a366-7ae4f143e2b3": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy while the secondary trial does not involve radiation therapy at all The statement makes no entailment regarding the biospecimen condition",
        "label": "Contradiction"
    },
    "4dc8e4d2-0265-4de1-98df-bcfb33c044e3": {
        "text_answer": "Contradiction The primary trial does not involve a placebo or control group so it cannot be directly compared to a trial with a placebo or control group as stated in the question The statement is not about the presence or absence of a placebo or control group but rather about the specific interventions used in each trial",
        "label": "Contradiction"
    },
    "1ddf526c-beb2-43e1-846e-a133e321a66a": {
        "text_answer": "Contradiction The primary trials inclusion criteria do not mention anything about the life expectancy of the participants",
        "label": "Contradiction"
    },
    "587623da-f061-478f-8196-ce7ec5558d5c": {
        "text_answer": "Contradiction The primary trial determines the percentage of participants with tumor response using RECIST criteria while the secondary trial does not report such information",
        "label": "Contradiction"
    },
    "a785048d-15ef-4c72-9d18-6c1db1df2620": {
        "text_answer": "Contradiction  The evidence shows that a total of 84 participants were analyzed in the primary trial with 16 participants in Arm 1 and 381 of them experiencing pCR and 14 participants in Arm 2 and 333 of them experiencing pCR Therefore a total of 20 participants experienced pCR across both arms However the statement suggests that more than 42 patients experienced pCR",
        "label": "Contradiction"
    },
    "8d502fe8-e084-480e-94ee-30ce69aca083": {
        "text_answer": "Contradiction  Explanation The statement all ae types in the primary trial affected fewer than 110 of patients is a contradiction to the evidence as several adverse events affected more than 110 of the patients in the primary trial For example febrile neutropenia and sinus tachycardia each affected 111 or approximately 909 of the patients",
        "label": "Contradiction"
    },
    "a1537e33-5b8e-4e7e-a18f-09fc3c436094": {
        "text_answer": "Contradiction The primary trial involves metastatic digestive system carcinoma patients receiving pregabalin while the secondary trial involves metastatic carcinoma patients not specifically digestive system receiving Depocyt and HDMTX",
        "label": "Contradiction"
    },
    "a83e8ca3-620b-47ab-a47b-3fc1fc4038c2": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not provide any information about the musculoskeletal system in the secondary trial",
        "label": "Contradiction"
    },
    "1824af8a-6f79-49bd-8df3-5751b1e65adb": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence explicitly states that women of childbearing potential and sexually active fertile men are excluded from the trial",
        "label": "Contradiction"
    },
    "82d23e4a-cdf8-4ab4-b2fa-7ea99d98d5a4": {
        "text_answer": "Contradiction The statement implies that the inability to selffeed is an exclusion criterion for the secondary trial but it is not mentioned in the provided exclusion criteria The statement also incorrectly states that patients with Grade 2 or above neuropathy cannot participate in the secondary trial but the exclusion criteria only state that patients with  Grade 1 neuropathy are excluded The primary and secondary trials have different inclusion and exclusion criteria and",
        "label": "Contradiction"
    },
    "c258ef31-d79a-4ddd-b3c0-81742b7f632f": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence provided because the evidence shows that no cases of biliary colic were reported in the secondary trial while the primary trial reported only one case 328 Similarly the secondary trial reported one case of diarrhea 1667 while the primary trial reported four cases 328 However the overall incidence of ad",
        "label": "Contradiction"
    },
    "5c7eee11-ee31-4adf-b2e6-8fe51a39a13b": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence provided because the percentage of participants demonstrating a decrease in the growth factor signature in the ERpositive Luminal B group 286 is actually lower than that in the Triple Negative group 176 Therefore it is not true that there are 561 more participants in the ERpositive Luminal B group",
        "label": "Contradiction"
    },
    "9006f1c5-2818-4edf-85e4-77d532b10820": {
        "text_answer": "Entailment The primary and secondary trials both involve intravenous injections but they use different drugs and dosages and the administration rates are not the same The statement that they do not involve the same drugs dosages or administer at the same rate is an entailment of the evidence provided",
        "label": "Entailment"
    },
    "33472836-f751-4de3-8b21-92e2d9e3d7ed": {
        "text_answer": "Contradiction The statement assumes that both cohorts receive the same number of cycles of each drug but cohort 2 receives three extra cycles of chemotherapy Therefore they do not receive the same total number of cycles of the same dosages of Docetaxel Doxorubicin and Cyclophosphamide throughout the trial",
        "label": "Contradiction"
    },
    "c5b0eaf3-50c0-4115-8da5-91af0310a7b2": {
        "text_answer": "Contradiction The primary trial measures the severity of delayed nausea which is not related to the bone mineral density measurement in the secondary trial",
        "label": "Contradiction"
    },
    "beae10d7-7132-4875-8bc6-4e996d20eb90": {
        "text_answer": "Contradiction The statement is about Week 30 but the evidence only provides data for Week 4",
        "label": "Contradiction"
    },
    "c5a5aed2-c471-41a4-940c-9fa644e5a9fc": {
        "text_answer": "Contradiction Perjeta pertuzumab is mentioned in the secondary trial as a potential novel radiotracer for HER2targeted PETCT but it is not stated that it is used within any cohorts of the trial However in the primary trial Perjeta pertuzumab is regularly administered in combination with Fulvestrant and Anastrozole",
        "label": "Contradiction"
    },
    "2de24fb7-9ebe-419e-af16-5d9ed2b808ef": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the inclusion criteria state that patients must have a life expectancy of greater than 3 months",
        "label": "Contradiction"
    },
    "409e7b50-f5db-4321-9a39-3853131ade7d": {
        "text_answer": "Contradiction  Explanation The evidence shows that in Adverse Events 1 there is one case of rapid disease progression and one case of increased pleural effusion out of 13 participants In Adverse Events 2 there is one case of increased pleural effusion out of 4 participants but no mention of rapid disease progression The statement in question asserts that a quarter of the participants are experiencing both worsened pleural",
        "label": "Contradiction"
    },
    "f1b4c0aa-df9b-4d75-9c65-f06709df664a": {
        "text_answer": "Contradiction The primary trial explicitly lists smokers as an exclusion criterion",
        "label": "Contradiction"
    },
    "1605cfcf-22e5-4a48-a89a-cd7b44e3109f": {
        "text_answer": "Contradiction The statement is not an entailment as there is no mention of deafness as an eligibility or exclusion criterion in either the primary or secondary trial evidence provided",
        "label": "Contradiction"
    },
    "7b73381b-500c-4056-9c4c-4334a6e0b9b4": {
        "text_answer": "Entailment The statement is entailed by the evidence as both trials use pCR as the outcome measure and the secondary trial shows a larger difference between the two arms compared to the primary trial",
        "label": "Entailment"
    },
    "4a454653-60b6-47dd-a2ba-780d1dfbacaf": {
        "text_answer": "Contradiction The evidence shows that some patients experienced the same type of adverse event eg 3 patients had diarrhea 3 had abdominal pain etc",
        "label": "Contradiction"
    },
    "bc9d1c66-4743-474d-9e82-b9e8438a8e86": {
        "text_answer": "Contradiction  The primary clinical trial does not mention an age criterion for participation",
        "label": "Contradiction"
    },
    "eada8d1a-7396-44e7-8f30-03814c7479fb": {
        "text_answer": "Contradiction  Explanation  The statement there were no lesions found on any of the group 1 participants in the primary clinical trial and an overwhelming 95 of group 1 participants in the secondary clinical trial showed signs of radiation dermatitis and hyperpigmentation is a contradiction based on the evidence provided  In the primary clinical trial there were no participants in group 1 as the outcome measurement was the",
        "label": "Contradiction"
    },
    "c80808f0-b1fd-45e1-99b4-154860b05038": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement does not provide any information about the relationship between the incidence of doselimiting toxicity and the immunogenicity specimen assessments baseline flag The evidence only reports the incidence of doselimiting toxicity in the primary trial without any mention of the immunogenicity specimen assessments baseline flag for each participant",
        "label": "Entailment"
    },
    "ae6b9c00-10a6-437a-a83b-b46fce724269": {
        "text_answer": "Entailment The evidence shows that no participants in the placebo group reported emesis during the study period",
        "label": "Entailment"
    },
    "41e9e8e9-6fec-49fa-ae36-7daa737de66c": {
        "text_answer": "Contradiction  The primary trial involves the administration of denosumab subcutaneously every 4 weeks while the secondary trial does not involve any injection instead using lymphoscintigraphy with gamma probes The statement requires a daily injection of 4 milligrams of denosumab which is not the case in the secondary trial",
        "label": "Contradiction"
    },
    "171827b1-29bc-4e7b-a70a-3d03d4ae7dad": {
        "text_answer": "Entailment The statement entails that there are differences between interventions 1 and 2 beyond just the dose of durvalumab administered during biweekly IV infusions as the statement is true even if the differences also include the dose of tremelimumab or other aspects of the interventions",
        "label": "Entailment"
    },
    "2107eaac-f0e5-47a2-a7cb-b6d27aa47d23": {
        "text_answer": "Contradiction The evidence states that no adverse events were observed in cohort 1 which is different from the statement that all candidates in cohort 1 experienced at least one adverse event",
        "label": "Contradiction"
    },
    "d478ad25-2445-48f1-9308-2d6025dfead2": {
        "text_answer": "Contradiction The evidence does not provide any information about the presence or absence of cytomegaloviral infection in the participants of the primary trial",
        "label": "Contradiction"
    },
    "9e3d3c08-d9ee-449d-b4c8-957d666315a1": {
        "text_answer": "Contradiction The statement mentions no aes were observed in the secondary trial while the evidence shows that there were instances of eyelid oedema and chest pain in the secondary trial",
        "label": "Contradiction"
    },
    "ad2ac39b-960a-463d-b3ab-955916e20a97": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy while the secondary trial does not involve radiation therapy at all The statement incorrectly assumes that both trials involve taking fulvestrant tablets BID but it fails to acknowledge the different interventions being tested in each trial",
        "label": "Contradiction"
    },
    "20307fc02-18bb-4910-9992-43a811bf7a1f": {
        "text_answer": "Contradiction The evidence provided does not support the statement as it only gives the median survival for each group and does not mention the number of patients who survived less than 2 days",
        "label": "Contradiction"
    },
    "3b940a21-1adf-4820-a178-9517bb60d6f0": {
        "text_answer": "Entailment The evidence supports the statement that there have been no documented adverse events in both the primary and secondary clinical trials",
        "label": "Entailment"
    },
    "38ea3ca5-d5b1-4432-b6f6-52e8ca0d3e41": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it only shows the percentage of participants with a decrease in the growth factor signature for each group but it does not provide information on the magnitude or direction of the change in the growth factor signature for individual participants nor does it provide a comparison of the mean change in the growth factor signature between the two groups",
        "label": "Contradiction"
    },
    "428f149b-1b45-4ad0-a5d3-0c885fec2767": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the primary clinical trial does report on the determination of the maximum tolerated dose MTD of Ruxolitinib in combination with paclitaxel although it uses a different method for determining the MTD compared to the secondary clinical trial The primary trial determines the MTD based on the number of patients who experience doselimiting toxicities DLTs while the",
        "label": "Contradiction"
    },
    "6204ed3f-bad3-4db0-8db9-9f73efd78e8f": {
        "text_answer": "Irrelevant The statement does not directly relate to the evidence provided The evidence only discusses the percentage of participants with HER2 Primary Breast Cancer who developed imagable HER2 Metastases using HER2targeted PETCT and does not mention respiratory therapy",
        "label": "Entailment"
    },
    "38da1202-fb8c-46d0-9779-db075423a422": {
        "text_answer": "Contradiction  Explanation The evidence provided states that cohort 1 is triple negative PRnegative ERnegative and HER2 and cohort 2 is HER2positive HER2 However the statement in question asserts that cohort 1 consists of PRnegative ERnegative and HER patients while cohort 2 receives HER2 treatment The",
        "label": "Contradiction"
    },
    "85bde7b9-9e2e-41e1-a8d5-9ff85e8900e6": {
        "text_answer": "Contradiction The statement is not related to the eligibility criteria for the primary trial The statement is a general fact about thoracic surgery while the eligibility criteria are specific to a breast cancer clinical trial",
        "label": "Contradiction"
    },
    "3edf7faa-74f7-4d02-bb9b-d5d421f2cca4": {
        "text_answer": "Contradiction The statement is not an entailment as the primary trial excludes alcoholic patients regardless of the amount of alcohol consumption while the secondary trial allows for alcohol consumption up to 5 drinks per day",
        "label": "Contradiction"
    },
    "00539969-3b0f-4c9f-be8a-0ce964c7d5fa": {
        "text_answer": "Entailment The evidence states that both study groups undergo the same PETCT imaging procedures with 18FFDG and 18FFPPRGD2 The statement is an entailment as it correctly states that both study groups undergo the same imaging procedures",
        "label": "Entailment"
    },
    "12ed5e10-5988-494c-8a88-6e4e30ddd355": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it only compares the hot flash frequency between the two groups and does not mention any information about treatment emergent adverse events or serious treatment emergent adverse events",
        "label": "Contradiction"
    },
    "cc31b936-223f-4378-9028-315601fba09e": {
        "text_answer": "Contradiction The primary trial only includes patients with a breast tumor 1 cm in diameter which is significantly smaller than 100 mm The secondary trial does not mention any specific tumor size requirement",
        "label": "Contradiction"
    },
    "e3fd6c0c-a119-4bb5-b82b-366830537c70": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "bc7d8745-f12d-4a54-a922-fb72f4bd01f0": {
        "text_answer": "Contradiction for the primary trial pulmonary embolism is an exclusion criterion  However its important to note that the statement could be an entailment for the secondary trial depending on the investigators evaluation and discretion",
        "label": "Contradiction"
    },
    "d46a61dd-b28a-476e-981e-f3d1cca2739c": {
        "text_answer": "Contradiction The primary trial measures changes in hot flash scores while the secondary trial measures overall response rate in solid tumors using RECIST criteria",
        "label": "Contradiction"
    },
    "7ba72ade-08b1-4062-86f4-2a93ec724780": {
        "text_answer": "Contradiction  The evidence states that 53 of participants in the lapatinib 1g  nabpaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR The statement asks for the number of participants who experienced a confirmed complete response CR specifically which is not provided in the evidence",
        "label": "Contradiction"
    },
    "38c5a69a-ad2f-4f2c-b234-74c93e8f6c72": {
        "text_answer": "Entailment The evidence states that only the intervention arm of the study will be exposed to the educational DVD which aligns with the statement that only the first cohort participating in the primary clinical trial will be exposed to the educational DVD",
        "label": "Entailment"
    },
    "a0b10912-a394-4892-88f8-7dfbc771052b": {
        "text_answer": "Contradiction The statement refers to a specific patients PFS while the evidence provides the median PFS for each treatment group The statement does not follow from the evidence",
        "label": "Contradiction"
    },
    "90e07508-8860-4e21-bffe-77d51f0749db": {
        "text_answer": "Contradiction The evidence reports 1 case of shingles in the primary trial and 1 case in the secondary trial for a total of 2 cases not 7 as stated in the question",
        "label": "Contradiction"
    },
    "af3f07a1-e8c0-4ce1-a0b2-5789bca86cd6": {
        "text_answer": "Contradiction The statement does not entail the evidence as the evidence mentions specific exclusion criteria for pulmonary embolism in the primary trial but it does not necessarily mean that individuals with a history of pulmonary embolism cannot have severe anxiety or depression",
        "label": "Contradiction"
    },
    "d3bf6a5f-bce2-47f5-be7a-6c97b2bf88ef": {
        "text_answer": "Contradiction The primary trial involves an intervention using fluciclatide injections while the secondary trial involves interventions using chloroquine not fluciclatide",
        "label": "Contradiction"
    },
    "d130905f-48af-4f05-9d02-92c980b46c75": {
        "text_answer": "Contradiction The primary trial involves the use of suramin and paclitaxel but the secondary trial does not mention the use of these drugs for all participants Instead it mentions a different intervention mastectomy surgery for the secondary trial",
        "label": "Contradiction"
    },
    "282a33db-aed6-4daa-bea6-299f424914bb": {
        "text_answer": "Contradiction  Explanation The evidence shows that in the primary trial 132 313 of patients suffered from infections which is less than 15 of the total number of patients In the secondary trial 115 667 of patients suffered from infections in Adverse Events 1 and 05 000 in Adverse Events 2 which",
        "label": "Contradiction"
    },
    "f1e9c350-baed-4c5d-a760-b5b8a69e6706": {
        "text_answer": "Entailment The evidence does not provide any information that would contradict the statement that AfricanAmerican patients are eligible for the primary clinical trial",
        "label": "Entailment"
    },
    "022c87c6-e5c0-4401-92f7-2570af8f8ac1": {
        "text_answer": "Irrelevant The statement is not related to the evidence provided about the primary and secondary trials reporting on the MTD of different interventions",
        "label": "Entailment"
    },
    "4e91cee2-910e-4f08-8a85-1f13545391c3": {
        "text_answer": "Contradiction The two interventions in the primary trial involve different participant groups one for adult cancer patients and the other for healthy volunteers",
        "label": "Contradiction"
    },
    "7432cb06-a4a3-4f9c-afc8-533e39b7337f": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence provided as the primary trial recorded no adverse events at all while the secondary trial recorded no adverse events for the given data set However its important to note that the evidence only shows a partial dataset for each trial and its possible that there could be other adverse events recorded outside of the provided data",
        "label": "Contradiction"
    },
    "703e6942-968d-4cdf-8e98-45cc571effd0": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction based on the evidence because the primary clinical trial did not have an adverse events section for Trial 2 only for Trial 1 Therefore it is not possible to compare the adverse events between the two trials directly The secondary trial only has an adverse events section for Trial 2 so we cannot make a definitive statement about the primary trial based on the evidence provided",
        "label": "Contradiction"
    },
    "9d7a1491-f931-47dd-9177-72bc90006fd2": {
        "text_answer": "Contradiction The exclusion criteria state that patients with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are not eligible for the study",
        "label": "Contradiction"
    },
    "d73e5604-bcf0-465f-b147-7ed3cb036e4c": {
        "text_answer": "Contradiction The primary trial compares Intraoperative Mammography with Standard Mammography but the statement does not specify which rod device is being referred to and does not directly compare the trials",
        "label": "Contradiction"
    },
    "570b88e9-5036-4ea8-80db-0f48696700af": {
        "text_answer": "Contradiction The primary trial uses a different drug PF06647020 which is not related to ALT801 used in the secondary trial",
        "label": "Contradiction"
    },
    "141ee099-c8ae-4db1-9082-6fc138ad8093": {
        "text_answer": "Entailment Both trials last for 10 weeks in the primary trial and 24 weeks in the secondary trial but the intervention is given more frequently in the secondary trial However the statement only refers to the trial duration which is the same in both cases",
        "label": "Entailment"
    },
    "0fc55b5a-e5cc-40d1-a0fe-e4ce3ffd8172": {
        "text_answer": "Contradiction The primary trial only includes patients with breast cancer and specific eligibility criteria related to the disease while the secondary trial focuses on patients scheduled for cancer treatment with chemotherapy or biologics and having sleep disorders specifically insomnia There is no mention of severe sleep disorders other than insomnia in the primary trial making it contradictory to the statement",
        "label": "Contradiction"
    },
    "f8fe88c6-ebd4-49ad-b381-b6017fdaf070": {
        "text_answer": "Contradiction The statement mentions rectal pain ctcae 50 which is not related to the outcome measurements and units of measure provided in the evidence",
        "label": "Contradiction"
    },
    "dce94e19-6a0a-4fc9-ab35-ad4eb378622b": {
        "text_answer": "Entailment The statement those suffering from validated metastatic scbc may enroll in the primary clinical trial is an entailment of the inclusion criteria stated in the evidence as metastatic small cell lung cancer head and neck cancer urothelial transitional cell carcinoma and breast cancer are specifically listed as eligible tumor types for the trial",
        "label": "Entailment"
    },
    "1cc9db7e-8214-46cd-bbe3-7ff873be5589": {
        "text_answer": "Contradiction The statement is not related to the given evidence The evidence only discusses the use of radioactive Tc99M sulfur colloid in the two interventions and does not mention anything about the sgk1 gene mutation",
        "label": "Contradiction"
    },
    "fccade16-a6ed-4bc1-b767-d5d1ab20b780": {
        "text_answer": "Contradiction The primary trial measures pain intensity using a visual analog scale while the secondary trial measures bone mineral density using DEXA scan These are different outcomes",
        "label": "Contradiction"
    },
    "0a279b67-be5a-4f7d-a21b-b178a556f8ae": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided as the evidence does not mention anything about HER2neu peptide vaccine or sargramostim being administered in the primary trial",
        "label": "Contradiction"
    },
    "94ebad4c-4b9c-4fb7-b7cc-a088b46b56f7": {
        "text_answer": "Contradiction The statement does not entail the information given in the evidence as the minimum dose of MCS110 administered every 3 weeks is 1 mgkg which is 0001g per kg not 002g per patient",
        "label": "Contradiction"
    },
    "1fef627f-f239-4ad3-8bec-4141e2b36dfd": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it does not mention anything about the cdh1 gene mutation or its association with the primary and secondary trials The evidence only discusses the duration of neutropenia and the number of participants experiencing neutropenia in the primary and secondary trials with different doses of Empegfilgrastim",
        "label": "Contradiction"
    },
    "685d9609-ec5f-4dcb-9783-e9d7b061eaf5": {
        "text_answer": "Contradiction The statement assumes that all but one patient suffered a nonserious TEAE but the evidence shows that 11 patients suffered serious TEAEs",
        "label": "Contradiction"
    },
    "a9e14c3b-bf03-4ca1-b9d9-4693b231902c": {
        "text_answer": "Entailment assuming the statement is referring to the changes in lymphedema in the primary trial",
        "label": "Entailment"
    },
    "ec2edea0-23ee-487c-bfbb-ef6fb517e744": {
        "text_answer": "Contradiction The primary trial requires a Karnofsky score of 70 or better while the secondary trial requires a score of 55 or better These are different requirements",
        "label": "Contradiction"
    },
    "b5cc8685-0fb5-4819-a7cb-960980d95272": {
        "text_answer": "Entailment The evidence states that having a locally advanced andor metastatic solid tumor is an inclusion criterion for both phases of the primary clinical trial so it permits patients of any gender eligibility for both phases",
        "label": "Entailment"
    },
    "47bb2ffb-2cee-418b-acd6-cdecee318d70": {
        "text_answer": "Contradiction  The evidence states that 9 out of 21 participants 4286 had a decrease in circulating tumor cells following highdose chemotherapy and cleansed autologous stem cell products Therefore more than 50 of participants saw a decrease in circulating tumor cells which contradicts the statement",
        "label": "Contradiction"
    },
    "7b507eae-bfd5-4546-993b-6dd936ab41e5": {
        "text_answer": "Contradiction  Explanation The evidence provided does not entail that several of the patients in the primary trial experienced the no pain whatsoever during the 70 days of the study The evidence only reports the average pain intensity scores and their confidence intervals for each group It does not provide information on the number of patients who experienced no pain at all during the study",
        "label": "Contradiction"
    },
    "02365d25-1a64-4415-aae7-c0254d234fa9": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence as it makes an unrelated statement about Paraguay",
        "label": "Contradiction"
    },
    "8858a62b-91a2-4f2c-a1f1-e54ea15e5861": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as no cases of acute myocardial infarction were reported in either trial",
        "label": "Contradiction"
    },
    "80140ee4-3ead-44cc-a7a2-b6af0798c1b1": {
        "text_answer": "Contradiction The statement is not supported by the evidence as the median change in lean body mass for the GTx024 1mg group was 155 kg which is not over 5 kg for every patient",
        "label": "Contradiction"
    },
    "6a0bfa75-3e83-4c73-8e5a-2dc4cad866c3": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence only reports the frequency of adverse events in the primary trial but it does not mention the chromosome band 19p1312",
        "label": "Contradiction"
    },
    "3dc3b5d7-3bad-4494-9e97-e6f27bf52c07": {
        "text_answer": "Contradiction  Explanation The evidence provided in the primary trial intervention section does mention the treatment with partial breast irradiation but it does not provide any information about the absence or presence of a treatment cycle or description of irradiation doses Therefore the statement cannot be determined to be an entailment or contradiction based on the given evidence alone However the statement is a contradiction because the evidence does not support the statement as it does mention",
        "label": "Contradiction"
    },
    "ddf4fc68-7920-4212-ac8b-7453ebeb49fb": {
        "text_answer": "Entailment  Explanation The evidence states that both the Glioblastoma Multiforme GBM and Gynecological Cancers study groups undergo the same 18FFDG and 18FFPPRGD2 PETCT imaging procedures Therefore the statement is an entailment as it correctly follows from the evidence",
        "label": "Entailment"
    },
    "c6a921cd-f18d-4fea-a543-54784444279c": {
        "text_answer": "Contradiction  The primary trial reported one death while the secondary trial reported no deaths The statement implies multiple deaths in the primary trial which is not supported by the evidence",
        "label": "Contradiction"
    },
    "99a8a2b3-84ad-4c45-9371-e731cc5942db": {
        "text_answer": "Contradiction  The evidence only reports the number of participants with a reduction in CTCs at one month posttransplant not the percentage of participants with a reduction greater than 97",
        "label": "Contradiction"
    },
    "414dbb63-9c4c-44e9-96f5-c54b5d341f82": {
        "text_answer": "Contradiction  Explanation The evidence from the primary trial reports the mean duration of neutropenia for patients receiving 6 mg and 75 mg of empegfilgrastim while the secondary trial reports the number of patients experiencing neutropenia for those receiving 3 mg 6 mg and no empegfilgrastim The two trials do not directly compare the same patient groups or dosages so it is not possible",
        "label": "Contradiction"
    },
    "f205a6e1-26d3-4a63-bea1-126428af787b": {
        "text_answer": "Contradiction  Explanation The statement asserts that the primary clinical trial had a higher prevalence of recurring malignancies graftversushost disease anaemia cardiac failure and diffuse alveolar hemorrhage in its adverse events compared to the secondary clinical trial However the evidence provided shows that there were no cases of graftversushost disease anaemia card",
        "label": "Contradiction"
    },
    "cf080a87-de94-4d6b-9d18-89a5f5003316": {
        "text_answer": "Contradiction  The primary trial does not provide information on the dosage of MM121 and Paclitaxel given to participants In the secondary trial cohort 1 received 20 mgkg weekly for both MM121 and Paclitaxel",
        "label": "Contradiction"
    },
    "c4e419c4-f227-4c0c-b8b5-c8e0f62585a7": {
        "text_answer": "Contradiction The primary trial does not suggest that Arm B had the most promising overall response rate as the statement asserts The secondary trial does not compare the overall response rates of the primary trial arms so it cannot be used to support the statement Additionally the statement makes no mention of the primary trials Arm A which also had participants The secondary trial only compares time to first onstudy SRE between Zoledronic acid and Denosum",
        "label": "Contradiction"
    },
    "18b0cc37-3189-4ea0-970e-81a6b79dba7f": {
        "text_answer": "Contradiction  The evidence provided indicates that there were no serious adverse events reported in either of the two groups in the primary clinical trial Therefore it is contradictory to state that 100 of subjects in Group 1 experienced a serious adverse event that threatened their life",
        "label": "Contradiction"
    },
    "0c992694-2b3d-4fa1-b822-ecc5f1ceb2e9": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence only mentions histological confirmation of ER negative HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 as inclusion criteria and there is no mention of progesterone status or hand assisted laparoscopic radical nephrectomy in the evidence",
        "label": "Contradiction"
    },
    "c640af56-cef3-432a-87f2-b2b446b7ab96": {
        "text_answer": "Contradiction The primary trials Intervention 2 does receive dexmedetomidine but it is not given to all patients in the secondary trial Only a specific subset of patients receives dexmedetomidine in the secondary trial",
        "label": "Contradiction"
    },
    "e70d1cc6-b4e5-4fc6-a26f-9b9dd76ef54f": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the eligibility of patients with hypokalemia for the secondary trial is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "0cd83002-1e58-4b84-ac34-e4299d4573ab": {
        "text_answer": "Entailment  Explanation The statement in the primary clinical trial there were patients who did not suffer from 3 or more adverse events is an entailment because the given data shows that a total of 1925 patients 7600 did not suffer from 3 or more adverse events 525 had 3 or more adverse events",
        "label": "Entailment"
    },
    "fdd9ccc8-95c0-48d9-bc4d-3ef7469dbb9a": {
        "text_answer": "Contradiction  Explanation The statement There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial is contradicted by the evidence as there were recorded adverse events AEs in both trials including one case of lymphoma in the secondary trial which could potentially result in hospitalization or death However the statement does not necessarily entail a contradiction as it does not explicitly mention the possibility of l",
        "label": "Contradiction"
    },
    "a491bf7b-7327-48cd-ac0f-708a50c385b7": {
        "text_answer": "Contradiction The evidence states that the primary clinical trial is for individuals with HER2 positive tumors IHC 3 or FISH not HER2 negative tumors IHC 1",
        "label": "Contradiction"
    },
    "379e6494-403f-4469-9ee4-9e3d12c0d562": {
        "text_answer": "Contradiction The evidence provided does not support the statement as the Objective Response Rate was higher in the Bevacizumab  Capecitabine group 218 compared to the Bevacizumab group 883 However the statement is about superior outcomes which could encompass other endpoints such as ProgressionFree Survival or Overall Survival The evidence only provides data on Objective Response Rate so",
        "label": "Contradiction"
    },
    "90c0e27d-dcb3-4014-ae46-b1f4640093b7": {
        "text_answer": "Contradiction The evidence shows that the number of adverse events is different between the two cohorts",
        "label": "Contradiction"
    },
    "3693ad36-964f-4377-93a3-6137083b22dd": {
        "text_answer": "Contradiction  The evidence provided does not mention the recurrencefree survival rate for the Ketorolac 30 mg group in terms of percentage points The statement is comparing percentage points between the two groups but the evidence only provides the number of participants in each group who achieved recurrencefree survival",
        "label": "Contradiction"
    },
    "f543a317-1f30-46b9-849e-67396ae072de": {
        "text_answer": "Entailment Both trials administer their interventions orally and the statement about nonmuscle invasive bladder urothelial carcinoma is not related to the administration of interventions in the trials",
        "label": "Entailment"
    },
    "fae9affd-c763-49c0-ae6d-88852f5774af": {
        "text_answer": "Contradiction The primary trial involves the administration of dexmedetomidine to one group while the secondary trial does not involve the administration of dexmedetomidine to any patients",
        "label": "Contradiction"
    },
    "6e78e878-1154-43b8-b93a-c1b68aef70c8": {
        "text_answer": "Entailment The statement all patients were prescribed sunitinib which was taken orally on a daily basis for the full length of the investigation is an entailment of the evidence provided in the primary clinical trial for Intervention 1 as the evidence states that sunitinib was administered orally on a continuous daily dosing schedule for the full length of the 21day cycles",
        "label": "Entailment"
    },
    "89e52784-5ddd-405e-b794-95ef5b5766eb": {
        "text_answer": "Entailment The evidence provided does not mention any use of Xrays ultrasound CT scans or MRIs in the interventions of either the primary or secondary trial",
        "label": "Entailment"
    },
    "c4a45d2b-0e4b-4cd2-80ef-176d487d8180": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that no participants in the secondary trial experienced diarrhea",
        "label": "Contradiction"
    },
    "396511cd-a922-4ba6-9c33-bc2f20bfdebd": {
        "text_answer": "Contradiction The primary trial compares intraoperative mammography with standard mammography and finds that the operative time is longer for intraoperative mammography not shorter as stated in the statement The secondary trial does not provide any information about operative times or the effectiveness of standard mammography compared to any other intervention",
        "label": "Contradiction"
    },
    "29d8fc44-5636-4633-9651-2d30521a2755": {
        "text_answer": "Contradiction The evidence does not support the statement as it does not provide information on the average survival time of patients in the primary trial or the number of patients from each cohort who survived more than 2 years",
        "label": "Contradiction"
    },
    "fa80610a-3dd0-49e7-97f3-7efbdf636ca5": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial recorded zero adverse events in both cohorts while the secondary trial recorded zero adverse events in one cohort The statement implies that the primary trial had more adverse events than the secondary trial but the evidence shows the opposite",
        "label": "Contradiction"
    },
    "48fdcfb8-5519-42cd-8496-f8f2e0e38808": {
        "text_answer": "Entailment  Explanation The evidence shows that no adverse events were reported in the primary trial with 4 participants and no adverse events were reported in the secondary trial with 1674 participants Therefore the statement that among the participants of the primary and secondary clinical trials none reported any adverse events is an entailment based on the evidence",
        "label": "Entailment"
    },
    "b1774ca3-1bc7-4643-a115-09e813115e9f": {
        "text_answer": "Contradiction  The primary trial requires a minimum ANC of 1800 cellsmm3 while the secondary trial requires a minimum ANC of 1500μL The patients ANC level of 900μL is below both minimum requirements",
        "label": "Contradiction"
    },
    "c389c3cc-2e76-4219-996d-3aa5a925fec7": {
        "text_answer": "Contradiction  Explanation  The primary trial measures Tumor Diameter in centimeters while the secondary trial measures Number of Participants With Solid Tumor Response which is not directly comparable to Tumor Diameter Although both trials use the same outcome measurement tumor response they use different units of measure and different methods to assess the outcome",
        "label": "Contradiction"
    },
    "f03664fa-20b3-4102-b1e2-fe901d028f65": {
        "text_answer": "Contradiction  Women aged 18 or 19 are not eligible for the primary trial according to the given inclusion criteria Therefore they cannot be eligible for a waiting period to become eligible for the primary trial",
        "label": "Contradiction"
    },
    "bfc4e387-9404-498e-903b-5ca9f88dcc3b": {
        "text_answer": "Contradiction  The statement is stating an average reduction of 04 for tamoxifen 20000 micrograms which is equivalent to 20 mg taken for 7 days prior to surgery and 14 days after surgery while the evidence from the primary trial shows a mean percentage change in Ki67 of 40 63 to 29 These values are not equivalent",
        "label": "Contradiction"
    },
    "812ba472-cd7c-410e-9a4c-88dc1795d5be": {
        "text_answer": "Contradiction  Explanation The primary trial has an ECOG performance status of 0 to 2 which means the patients have a good performance status and are able to carry out their normal daily activities with minimal assistance The secondary trial on the other hand includes patients with an ECOG of 02 OR Karnofsky 60100 which is a broader range and includes patients with a Karnofsky performance",
        "label": "Contradiction"
    },
    "a911fcee-0621-4f06-a511-b8323ab8440c": {
        "text_answer": "Entailment  Neither trial reports the number of participants with treatmentemergent adverse events as the outcome measurement",
        "label": "Entailment"
    },
    "55fed266-9982-4062-b7fa-5ec9279441e4": {
        "text_answer": "Entailment The statement is a requirement for inclusion in the clinical trial according to the provided evidence",
        "label": "Entailment"
    },
    "ee441983-976c-41d7-aa66-19037a3f5f5b": {
        "text_answer": "Contradiction The statement includes additional conditions history of stroke TIA and psychiatric disorders within the last 26 weeks that are not mentioned in the inclusionexclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "a079229c-d371-4c18-b2b3-20b0068a4c50": {
        "text_answer": "Contradiction The evidence states that there was one case of shingles in the secondary trial but it does not specify which group it was in Therefore it is not clear that there were several instances of shingles in the primary trial and none in group 2 of the secondary trial",
        "label": "Contradiction"
    },
    "ed6b3dc1-1cdb-4da6-ad5c-d5073abd31ea": {
        "text_answer": "Contradiction The evidence mentions inclusion criteria for age 18 years and above and KarnofskyECOG score performance status of 0 or 1 which contradicts the statement that no specific conditions regarding mental health bodyweight age karnofskyecog score or previous treatments are required to qualify for the primary clinical trial",
        "label": "Contradiction"
    },
    "2882972d-2466-4eb1-9be2-14f0ebed2102": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the starting dose of sunitinib is different between the two cohorts 25 mg daily for cohort 1 and not specified for cohort 2",
        "label": "Contradiction"
    },
    "0e3228de-973b-4ce4-9d67-e46392d6f0a6": {
        "text_answer": "Contradiction The statement does not entail the information given in the evidence as it refers to a different condition childhood kidney angiomyolipoma that is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "5bdba14a-5c7f-4913-b543-9c791965c237": {
        "text_answer": "Contradiction  Explanation The statement at least one patient treated with gtx024 1mg in the primary trial gained over 10000 grams of lean body mass is a contradiction to the evidence because none of the participants in the GTx024 1mg group gained over 10000 grams of lean body mass as per the given results which range from 2",
        "label": "Contradiction"
    },
    "3f5b9c7d-ae3e-4484-88c7-c7562c2f974a": {
        "text_answer": "Contradiction  The statement is incorrect because the evidence shows that only 53 of participants experienced a confirmed partial response or confirmed complete response not just a confirmed complete response",
        "label": "Contradiction"
    },
    "13178eb4-e1c0-4fa0-8008-f4a4617220aa": {
        "text_answer": "Entailment The primary trials inclusion and exclusion criteria differing between its stages is a part of the evidence provided and the statement correctly reflects that aspect The secondary trials standard criteria for all participants is also a part of the evidence but it is not in direct contradiction to the statement about the primary trial",
        "label": "Entailment"
    },
    "e928035e-e614-46e3-a3f7-94341043b14e": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of gallbladder infection or CTCAE Common Terminology Criteria for Adverse Events in either the primary or secondary trial inclusion criteria",
        "label": "Contradiction"
    },
    "7074d2ad-2b70-4e46-a617-f49ddbd8588e": {
        "text_answer": "Entailment The evidence shows that less than 5 of patients in the primary trial suffered from adverse events with mild or asymptomatic grade 1 psychiatric disorders  other",
        "label": "Entailment"
    },
    "cf9d27be-b128-4621-9734-8e9fb3197105": {
        "text_answer": "Contradiction The primary trial reports Time to Progression in months not days and the secondary trial reports percentage of patients with Objective Response not related to gastric dysplasia",
        "label": "Contradiction"
    },
    "6528eb91-c678-4508-8d1f-db13bce8d182": {
        "text_answer": "Contradiction The primary trial does not provide any information about Paraplatin doses in both interventions",
        "label": "Contradiction"
    },
    "4d824080-17e3-4df5-9ef0-f6b0e3496f31": {
        "text_answer": "Entailment The evidence shows that there were more adverse events reported in cohort 1 45106 compared to cohort 2 7103",
        "label": "Entailment"
    },
    "04a0ccc3-e60d-462a-a31e-802e0f54e1d8": {
        "text_answer": "Entailment  Explanation The statement taking tamoxifen 32 mg po daily for seven days before breast cancer surgery and for fourteen days after has led to an average reduction of tumor sizes by 40 is an entailment of the evidence provided in the primary clinical trial The trial shows that patients taking tamoxifen 20 mg po daily for 7 days before surgery and for 14 days after",
        "label": "Entailment"
    },
    "cf19cee6-27d6-4d4b-ab20-52e35883d817": {
        "text_answer": "Contradiction The evidence provided does not indicate that women aged 25 or 30 are eligible for the primary trial and need to wait 34 years The primary trial has different inclusion and exclusion criteria than the secondary trial",
        "label": "Contradiction"
    },
    "b2710f8c-602b-4831-8775-f8df3703761a": {
        "text_answer": "Contradiction The primary trials Intervention 2 does not receive dexmedetomidine but the secondary trials Intervention 2 does not mention the absence of dexmedetomidine",
        "label": "Contradiction"
    },
    "22a2488f-5559-40e9-a85b-484a1aacd263": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided The evidence pertains to adverse events in a primary trial while the statement mentions a chromosome band 22q122 which is unrelated to the trial data",
        "label": "Contradiction"
    },
    "77c7c86b-30a5-487b-8abc-d3aafff69a5e": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 patients receive 1 mgkg of MCS110 every 3 weeks which is less than 50 mg every 3 weeks In Intervention 2 patients receive 3 mgkg of MCS110 every 3 weeks which is more than 50 mg every 3 weeks but still less than the required 150 mg every",
        "label": "Contradiction"
    },
    "0abf8fc8-9361-4b86-a3ca-fb6bdfbc5b5d": {
        "text_answer": "Contradiction The statement is contradictory because patients with malignant ductal carcinoma in situ are excluded from the primary trial but the statement implies that they are eligible for the secondary trial",
        "label": "Contradiction"
    },
    "a411d500-0770-42d9-8621-ca6b4b63553e": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it only shows the percentage of participants with a decrease in the growth factor signature in each group but it does not provide information on the actual change in the growth factor signature between the two groups",
        "label": "Contradiction"
    },
    "cb869aa7-63a3-4a2c-8dd9-2e38496fbaef": {
        "text_answer": "Contradiction The primary trial has different inclusion criteria and does not mention anything about participation in a secondary trial as an exclusion criterion",
        "label": "Contradiction"
    },
    "d15bf489-0548-4cbc-b64c-2252a53b5f33": {
        "text_answer": "Contradiction The primary trial includes specific types of cancer while the secondary trial is for breast cancer patients only Sellar germ cell tumors are not a type of breast cancer",
        "label": "Contradiction"
    },
    "80676e7e-a6bc-4f8e-b50e-888847db5b91": {
        "text_answer": "Contradiction The statement is about Week 10 percentage change in the AZD0530 13 mg group compared to Zoledronic Acid 10 mg group but the evidence only provides data for Week 4 percentage change in the AZD0530 175 mg and Zoledronic Acid 4 mg groups",
        "label": "Contradiction"
    },
    "cfcd5908-e439-4d01-bd0a-0fcaf3730db8": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction to the evidence because  1 In the primary trial participants undergo therapeutic conventional surgery which is a surgical procedure 2 The statement claims that participants in the primary trial are not subjected to any surgical procedures",
        "label": "Contradiction"
    },
    "de3bd9a7-c733-43d3-9f7d-3bf3c98a42f9": {
        "text_answer": "Contradiction The primary trial administers Botulinum Toxin Type A or Placebo while the secondary trial administers MLN8237 with varying dosages",
        "label": "Contradiction"
    },
    "6cf62ed7-1dd2-4df0-80f7-979f74b55e72": {
        "text_answer": "Contradiction  The statement implies that there are 11 more cases of intestinal perforation in the secondary trial compared to the primary trial However the evidence only shows that there is 1 case of intestinal perforation in the secondary trial and none in the primary trial",
        "label": "Contradiction"
    },
    "8e2d4c96-5d2f-4710-9333-26d8d1dcb8fb": {
        "text_answer": "Entailment assuming that lower frequency means having fewer cases in the primary trial compared to the secondary trial as stated in the question The evidence shows that the primary trial had fewer cases of recurrent malignancies graftversushost disease anemia cardiac failure and diffuse alveolar hemorrhage compared to the secondary trial",
        "label": "Entailment"
    },
    "c0dc65fc-1c17-4594-a168-c9c2da2802b6": {
        "text_answer": "Contradiction The evidence reports 5 adverse events in the primary clinical trial",
        "label": "Contradiction"
    },
    "dc4765a3-6168-4594-969b-3ce5ea7dc02a": {
        "text_answer": "Contradiction  Explanation  The statement Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934 is a contradiction based on the evidence provided While both cohorts receive electroporation injections of V934 the number of injections and the timing differ between the two groups In Cohort A there are three electroporation injections given",
        "label": "Contradiction"
    },
    "bc92cff7-39b3-4088-bb3a-9e61c4d32b8b": {
        "text_answer": "Entailment given that the evidence states that all 20 participants in cohort 2 had no episodes of vomiting and no rescue medication during the first 24 hours after cyclophosphamide administration",
        "label": "Entailment"
    },
    "586425fa-eb66-46c1-8792-f7a35c1a5ca5": {
        "text_answer": "Contradiction The evidence does not mention hypertension in either cohort",
        "label": "Contradiction"
    },
    "0d9f0b9b-fc32-413e-ba9b-f8d4e5c1ce4b": {
        "text_answer": "Entailment The primary trial includes patients with stage IV breast adenocarcinoma that is ER positive PR positive or HER2neu negative which is also a requirement for the secondary trial",
        "label": "Entailment"
    },
    "37bba0bf-5ecd-4007-a2c4-bf9e13dccd2e": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as dasatinib was administered orally once daily in cohort 2 of the primary trial",
        "label": "Contradiction"
    },
    "696f4947-40d7-4e3d-b64e-9e0fd6c5fbd8": {
        "text_answer": "Neutral The statement does not directly follow from the evidence provided  Explanation The statement is not an entailment or a contradiction because the evidence does not provide any information about the occurrence of noncutaneous leiomyosarcoma or its relationship to the cohorts in the primary trial The statement is neutral as it does not directly follow from the evidence provided",
        "label": "Entailment"
    },
    "e2e8bb00-df98-49c2-a81b-e18ae21516aa": {
        "text_answer": "Contradiction The placebo intervention consists of 20 injections of 04ml Buminate solution while the AlloMSCs intervention consists of 20 injections of 100 million alloMSCs which is not the same dose",
        "label": "Contradiction"
    },
    "6016f882-27d2-47a7-9149-142c9fb17acf": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it mentions antineoplastic chemotherapy which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "895a6e40-efe3-4994-b598-6791eaf90e87": {
        "text_answer": "Contradiction  Explanation The statement is contradictory because having persistent atrial fibrillation by ECG finding is not a criterion for eligibility or exclusion in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "a7e93d6e-e8d0-4b87-b2a1-be2b821e5a94": {
        "text_answer": "Contradiction The statement is incorrect based on the evidence provided as the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher ORR 0587 compared to the Paclitaxel Plus Bevacizumab group 0489",
        "label": "Contradiction"
    },
    "d4eb3cf4-eeff-42c3-8036-54ec85061299": {
        "text_answer": "Contradiction The statement does not entail that the talazoparib doses given to breast and ovarianperitoneal cancer patients are the same In fact the statement asserts that they are different",
        "label": "Contradiction"
    },
    "8be0e7b4-f74d-4205-a543-1247762bb467": {
        "text_answer": "Contradiction The intervention in the primary trial lasts for 10 weeks while the intervention in the secondary trial lasts for 24 weeks which is 14 weeks longer not 15",
        "label": "Contradiction"
    },
    "ed0b5b7f-b257-4b42-8f93-7c908fd071ea": {
        "text_answer": "Contradiction The primary trial excludes participants who are sensitive to AI therapy while the secondary trial does not list sensitivity to AI therapy as a requirement or exclusion criterion",
        "label": "Contradiction"
    },
    "a5e9916a-b5de-4fd4-bf78-b1c1e43bc544": {
        "text_answer": "Entailment The evidence states that both cohorts in the primary clinical trial receive dexamethasone before their operation so the statement that all cohorts in the primary clinical trial are given dexamethasone before their operation is an entailment",
        "label": "Entailment"
    },
    "f21a1764-d1cc-49cc-b22d-e3d1b99c2233": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events recorded in both trials The statement is incorrect as it suggests that there were 10 more adverse events in the secondary trial which is not supported by the evidence",
        "label": "Contradiction"
    },
    "12903135-4650-492b-b2c9-1f5c159af477": {
        "text_answer": "Contradiction The primary trial explicitly excludes individuals with cerebral metastases while the secondary trial does not mention cerebral metastases as an exclusion criterion",
        "label": "Contradiction"
    },
    "f896c335-0023-429c-b596-e7a30addbb2e": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided",
        "label": "Contradiction"
    },
    "d9cff591-e319-46a0-bc70-a25224cd5b49": {
        "text_answer": "Entailment The statement swls questionnaire question is a question associated with the swls questionnaire is neutral and does not directly relate to the eligibility criteria for the primary trial However the statement Morbidly obese patients are eligible for the primary trial is a statement that follows from the inclusion criteria which includes a BMI of 25 kgm2 or greater and weight 400 lbs Therefore the statement about",
        "label": "Entailment"
    },
    "523d79a3-ee67-4b2a-a1cb-20ed4ed45dc6": {
        "text_answer": "Contradiction  Explanation The statement implies that there is a difference of 492 between the percentage of participants in the ER and TN groups who demonstrated a decrease in the growth factor signature However the evidence only shows that the percentage of participants in the ER group was higher than that in the TN group but it does not provide enough information to determine if the difference is exactly 492 Therefore the statement",
        "label": "Contradiction"
    },
    "1b82cbd2-8f68-4c23-974c-b9ebc4fe52aa": {
        "text_answer": "Entailment   Explanation The statement four different medications are administered to the participants during the primary clinical trial is an entailment based on the evidence provided in the trial description The medications mentioned in the evidence are epirubicin cyclophosphamide docetaxel and trastuzumab which are all different medications",
        "label": "Entailment"
    },
    "7c1aaf25-a7c2-410d-bc13-fe6192698184": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events in both cohorts 1 and 2 Therefore it is a contradiction to the statement that cohort 2 had a higher number of patients suffering adverse events",
        "label": "Contradiction"
    },
    "038fbad1-abee-46f3-90a8-5caee61bae07": {
        "text_answer": "Entailment  Explanation  In the primary trial patients underwent mastectomy surgery and no information about the administration of MM121 and Paclitaxel was provided  In the secondary trial the HR subgroup in Intervention 1 received MM121 and Paclitaxel for 12 weeks with a 2week runin of MM121",
        "label": "Entailment"
    },
    "f95708f6-04c7-469b-bba1-658c1d6eed45": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided as the evidence does not mention any cardiacrelated adverse events related to lung pecoma or PECs",
        "label": "Contradiction"
    },
    "ca22d431-ad09-4f5b-8b27-751c76e704c8": {
        "text_answer": "Contradiction The statement is about Cohort 2 receiving a regular dosage of radiotherapy which is not mentioned in the given evidence for the control group",
        "label": "Contradiction"
    },
    "5c00eee7-bb33-45e5-97c6-4cfc34946cdf": {
        "text_answer": "Contradiction The primary trial does involve massage therapy which is not a drugbased treatment but it is mentioned in both Intervention 1 and Intervention 2 of the primary trial Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "df8bb8da-6aec-4678-97f3-cb122188ea9b": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the given evidence The evidence does not provide sufficient information to determine if cohorts A and B have the same anorectal infection status",
        "label": "Entailment"
    },
    "4094d002-a140-4eea-aa50-5005989e2057": {
        "text_answer": "Entailment The evidence shows an increase in the percentage of participants who were up to date for colorectal breast and cervical cancer screenings after the intervention in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups",
        "label": "Entailment"
    },
    "9f61fc3f-f0a5-4434-b0a7-cbb0703fe063": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial involves the use of a tissue expander Contour Profile Tissue Expander which is a surgical implant and the secondary clinical trial involves transendocardial injections of alloMSCs or placebo Neither of these interventions directly involve the use of xrays CT scans or MRIs as stated in the question However the evidence provided does",
        "label": "Contradiction"
    },
    "e2abe23e-d9a8-4329-a41b-26c90266f6d3": {
        "text_answer": "Contradiction The statement is not related to the evidence provided which pertains to the Objective Response Rate and Percentage of Participants With Disease Progression or Death in the Bevacizumab and Bevacizumab  Capecitabine cohorts of a primary trial The statement about the electromagnetic spectrum is unrelated to the trial data",
        "label": "Contradiction"
    },
    "3821922a-4d8a-4e54-8381-bb754a78c1ed": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction to the evidence because  1 In the primary trial participants in Intervention 1 receive Triptorelin or Degarelix injections every 28 days for 6 cycles 2 In the secondary trial participants in Intervention 1 receive Epoetin Beta injections once a week for 12 weeks  The statement suggests that individuals in",
        "label": "Contradiction"
    },
    "2f94cda8-a8c2-4fb3-a98d-f7e6e651b6d0": {
        "text_answer": "Entailment The statement describes a reduction in Ki67 expression which is consistent with the evidence showing a decrease in Ki67 expression from 15 to 10 after one month of treatment",
        "label": "Entailment"
    },
    "5b94573b-9254-48e4-a384-0212f39451a8": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the doses of ALT801 used in the primary and secondary trials are not mentioned in the evidence",
        "label": "Contradiction"
    },
    "8a8136f1-9f1d-497e-bb50-44fe94475817": {
        "text_answer": "Contradiction The primary trial specifically states that the breast tumor should be 1 cm in diameter not 10 cm",
        "label": "Contradiction"
    },
    "ce7d929e-90d6-4048-8124-e6df1a2f594a": {
        "text_answer": "Entailment The statement that both cohorts use the same instructional CD for paced breathing is a part of the evidence for Intervention 1 and Intervention 2 The additional information about the frequency of paced breathing practice and chemotherapy in Intervention 2 does not contradict this part of the evidence",
        "label": "Entailment"
    },
    "6fce98e9-e48f-4b14-8a94-37c1ab124eed": {
        "text_answer": "Contradiction The statement is about adverse events in the trials and there is no mention of sweating in the evidence",
        "label": "Contradiction"
    },
    "95354d90-513a-4766-a860-307afa28fb7b": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence shows that anemia pneumonia and stupor were not recorded in the primary trial at all while the statement implies that they were less frequent in the primary trial",
        "label": "Contradiction"
    },
    "1d121088-e2ff-4927-a989-d7b5de578714": {
        "text_answer": "Contradiction The primary trial measures pain intensity using a visual analog scale not the severity of delayed nausea",
        "label": "Contradiction"
    },
    "f8457301-53ba-4316-a6a5-36462bf8167c": {
        "text_answer": "Neutral The evidence does not provide enough information to determine entailment or contradiction for the given statement  Explanation The evidence provided does not mention any specific inclusion or exclusion criteria related to Body Mass Index BMI for both the primary and secondary clinical trials Therefore it is not possible to determine if the statement patients with a body mass index bmi in the overweight category can be eligible for the primary clinical trial and the",
        "label": "Entailment"
    },
    "dad36f27-f531-458c-a36f-c22182af3771": {
        "text_answer": "Contradiction The primary trial includes Triple negative breast cancer as an eligible diagnosis which is not mentioned in the statement as a prohibited diagnosis Chronic lymphocytic leukemia and choriocarcinoma as well as infiltrating ductal carcinoma are mentioned as prohibited diagnoses in the primary trial but they are not mentioned in the secondary trial at all Therefore the statement is a contradiction as it",
        "label": "Contradiction"
    },
    "8dd6a2dd-74f9-4bac-af44-c816fd960f74": {
        "text_answer": "Contradiction The evidence shows that several adverse events in the primary clinical trial are related to symptoms such as blurred vision constipation nausea vomiting general symptom headache and bone pain",
        "label": "Contradiction"
    },
    "16e96301-3e68-453f-82db-f93117edfdfd": {
        "text_answer": "Contradiction The statement is incorrect as Paclitaxel is not mentioned in the evidence for either intervention The evidence only mentions Anastrozole for Arm A and Fulvestrant for Arm B",
        "label": "Contradiction"
    },
    "b93384b1-a925-460d-ba66-78967a500d8c": {
        "text_answer": "Contradiction The evidence does not provide any information about the Recurrencefree Survival rates or differences between the two groups in relation to the type of blood vessel neoplasm being studied",
        "label": "Contradiction"
    },
    "1720fcdf-eba7-4ef7-bf37-6445504af807": {
        "text_answer": "Contradiction The statement makes an additional assumption about the primary trial data that is not supported by the evidence provided The evidence only reports the percentage change in betaCTX for each group it does not provide any information about the histological findings of the tumor samples or the relationship between those findings and the betaCTX data",
        "label": "Contradiction"
    },
    "67f1754a-420c-4605-a41d-784c4d1e77b0": {
        "text_answer": "Contradiction The statement mentions a total of 3 cases of shingles across both trials but the evidence only shows a total of 2 cases in the secondary trial",
        "label": "Contradiction"
    },
    "2c618027-fde9-4d2f-8552-bc071708d627": {
        "text_answer": "Contradiction The evidence shows that there was only one fatality documented as an adverse event in each trial not over ten",
        "label": "Contradiction"
    },
    "10860cc9-5a8f-4e81-bb2a-42697541e8b0": {
        "text_answer": "Contradiction The statement mentions estrogen positive progesterone negative and HER2 breast tumors but the clinical trial only includes ER positive HER2 negative invasive breast cancer Group 1 and invasive triplenegative breast cancer Group 2 in its inclusion criteria",
        "label": "Contradiction"
    },
    "eb7d6866-d56b-437c-a48c-78478afdfac8": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because the evidence shows that there were no adverse events reported in both the primary and secondary trials Therefore it is incorrect to make a comparison about having fewer adverse events in one trial compared to the other when there were no adverse events reported in either trial",
        "label": "Contradiction"
    },
    "9e5f2149-4cff-4df0-a5d0-4b99ff30fb1c": {
        "text_answer": "Contradiction The primary trial measures changes in pain intensity at 30 minutes after dosing while the secondary trial measures the change in bone mineral density of the lumbar spine at 9 months",
        "label": "Contradiction"
    },
    "50b3880d-9a23-42a3-8987-253f0ce999d3": {
        "text_answer": "Entailment The statement that both cohorts receive the same dosage and frequency of Docetaxel Doxorubicin and Cyclophosphamide is consistent with the evidence provided in the primary trial",
        "label": "Entailment"
    },
    "017ff04d-5509-4f54-863c-10201351e15d": {
        "text_answer": "Contradiction The evidence provided indicates that no participants with normal vitamin D levels showed a discernible pattern for expression of the set of 40 evaluated genes",
        "label": "Contradiction"
    },
    "8aca5f0b-c998-4e51-9e53-e23294e61867": {
        "text_answer": "Contradiction The statement is a contradiction because the primary trials intervention 1 is administered by IV while all interventions in the secondary trial can be administered orally",
        "label": "Contradiction"
    },
    "08049ea6-03f6-457a-b74e-0012e02dc768": {
        "text_answer": "Contradiction The primary trial reports time to progression in months not days and the secondary trial reports percentage of patients with objective response",
        "label": "Contradiction"
    },
    "38c2a394-f21b-4ae8-8941-aeccf896609b": {
        "text_answer": "Contradiction The statement is contradictory because warfarinbased treatments are prohibited for the primary trial candidates but they are permitted for the secondary trial candidates under certain conditions",
        "label": "Contradiction"
    },
    "f8e8c733-3fc0-4699-814f-b5d505c71435": {
        "text_answer": "Contradiction The statement does not accurately describe the difference between the two cohorts Cohort 1 receives 25 mg of sunitinib daily and Paclitaxel at 90 mgm2 or lower based on tolerability while Cohort 2 receives Bevacizumab and Paclitaxel at 90 mgm2",
        "label": "Contradiction"
    },
    "3a4cc297-6f5a-489c-a841-95e2b3971167": {
        "text_answer": "Contradiction The primary trial mentioned in the evidence is for breast cancer not colon cancer or medulloblastoma",
        "label": "Contradiction"
    },
    "807c9531-c049-40a5-a170-3f8924335381": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The evidence describes the dosing regimens for two different cohorts in a primary trial but it does not mention anything about the duration or permanence of any potential side effects such as transient arthropathy",
        "label": "Entailment"
    },
    "af6ce175-76e3-4d1a-ab77-6c7f3a258580": {
        "text_answer": "Contradiction The evidence shows that there were no instances of death reported in cohort 2 but there was one instance of hospitalization",
        "label": "Contradiction"
    },
    "aba20d88-1ea5-401e-b155-d1b901dddc77": {
        "text_answer": "Contradiction The primary trial does not utilize the number of participants with treatmentemergent adverse events as an outcome measurement Instead it measures change from baseline in patientspecified and reported symptoms on the Measure Yourself Medical Outcome Profile MYMOP",
        "label": "Contradiction"
    },
    "f47966a1-7067-43a3-9461-11c8ed7b18a6": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as it is not supported by the results which show a reduction in average pain intensity scores in both intervention groups",
        "label": "Contradiction"
    },
    "6f0485c9-9cb5-4861-9baf-f6a9a9acd975": {
        "text_answer": "Entailment Both groups undergo radiation therapy with the same dose range frequency and schedule The difference lies in the use of Active Breathing Coordination during radiation therapy which is not mentioned in the statement",
        "label": "Entailment"
    },
    "aad1e89e-afc2-4999-8cb2-302e0d686331": {
        "text_answer": "Entailment The statement All but one of the patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event is an entailment of the evidence as the evidence states that 24 out of 25 patients experienced treatmentemergent adverse events The statement about serious treatmentemergent adverse events being experienced by less than half the patients is",
        "label": "Entailment"
    },
    "0c03c804-4144-4d84-b740-8f6040f15acc": {
        "text_answer": "Contradiction The 20yearold female patient with a newly diagnosed ERpositive HER2negative breast cancer cannot be eligible for both the secondary and primary trials as per the given inclusion and exclusion criteria The primary trial requires the patient to have disease progression during or following firstline treatment with Avastin and chemotherapy while the secondary trial is for patients with newly diagnosed ERpositive HER2negative breast cancer",
        "label": "Contradiction"
    },
    "458e3e14-613b-40c5-a62f-5698a7d0c9b0": {
        "text_answer": "Entailment The median survival times in both groups are over 2 years but it is mentioned that there is at least one instance of a death within 2 years in each group so it is possible for some individuals to have survived for less than 2 years The statement only requires that the average survival is over 2 years which is satisfied by the data",
        "label": "Entailment"
    },
    "12911f01-5f14-445b-a93a-0cca2cfe9b4c": {
        "text_answer": "Contradiction The primary trial and the secondary trial are about different outcomes and populations so there is no basis for comparing the results directly The statement about sexual activity is not related to the evidence provided",
        "label": "Contradiction"
    },
    "030afaab-4125-4b2c-ac40-5d7a4cacaf52": {
        "text_answer": "Contradiction The statement is not directly related to the evidence provided as the evidence does not mention any medication or infections related to the interventions in the primary trial",
        "label": "Contradiction"
    },
    "10867d73-4951-42cf-9bdf-2a0f6d27ff10": {
        "text_answer": "Contradiction The primary trial recorded 2 cases of ascites and the secondary trial recorded 0 cases The primary trial also recorded 1 case of pneumocystis jirovecii pneumonia and the secondary trial recorded 2 cases Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "c09d08df-1042-47ca-9c54-83be4f9f691a": {
        "text_answer": "Entailment assuming febrile neutropenia and cholelithiasis are not mentioned in the evidence  Explanation The statement no instances of febrile neutropenia or cholelithiasis were reported in both the primary and secondary clinical trials is an entailment of the evidence because the evidence does not report any instances of febrile neutropenia or cholelithiasis in",
        "label": "Entailment"
    },
    "90cecb95-9f89-4747-81c3-96545edaf3f4": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were multiple patients who suffered the same type of adverse event such as Pleural effusion which occurred in 3 different patients Therefore the statement that No two patients in the primary trial suffered the same type of adverse event is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "0744e505-8c33-48b6-bd82-b201fdcc9679": {
        "text_answer": "Entailment The statement does not make any specific claims about the interventions used in the trials only about the number and grouping of the trial arms",
        "label": "Entailment"
    },
    "102bbdcd-14ea-4dd5-a0bb-4cea343bb6ed": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there are no cases of Mucositis Oral Bladder Infection or Thromboembolic events recorded in the secondary trial",
        "label": "Contradiction"
    },
    "13b40eaf-ad55-439f-9d93-a00a7bee3516": {
        "text_answer": "Neutral  The evidence provided does not contain any information regarding the eligibility of AfricanAmerican patients in the primary clinical trial The statement is neither an entailment nor a contradiction based on the given information",
        "label": "Entailment"
    },
    "3611645a-e832-4b38-a1db-9c66aca8baf6": {
        "text_answer": "Contradiction  Explanation The statement 25 of the patients involved in the primary clinical trial report the problems of increased pleural effusion and swift progression of their disease is a contradiction to the evidence because the evidence shows that only one patient in each cohort had increased pleural effusion and none of the patients in cohort 2 had rapid disease progression Therefore no 25 of the patients had both",
        "label": "Contradiction"
    },
    "8773e9c2-3030-4221-b663-b21d49ae1721": {
        "text_answer": "Contradiction The primary trial does evaluate the clinical benefit based on RECIST criteria rate among the participants",
        "label": "Contradiction"
    },
    "eca37c79-e36b-446d-bd9a-4cf546fc9ab7": {
        "text_answer": "Entailment with the assumption that common refers to an adverse event occurring in more than 10 of the participants",
        "label": "Entailment"
    },
    "460e894b-61c8-4935-bde6-6800b1a440a2": {
        "text_answer": "Entailment The evidence states that participants will receive multiple injections of therapeutic autologous dendritic cells peptides and trastuzumab",
        "label": "Entailment"
    },
    "6d328d56-d579-4a87-b2bf-e3f3d8bd2c4f": {
        "text_answer": "Contradiction  Explanation The evidence provided in the results does not support the statement that individuals in the ovarian function suppression group reported an improvement in cognitive function The mean standardized units for the cognitive function composite score were actually lower in the ovarian function suppression group compared to the tamoxifenonly group",
        "label": "Contradiction"
    },
    "8480a497-4ae7-4d4a-9b19-68667f70dc22": {
        "text_answer": "Contradiction  Explanation  The statement in the primary clinical trial most of the reported adverse events were related to blood and bone marrow this observation was not found in the secondary clinical trial is a contradiction based on the evidence provided  In the primary trial all reported adverse events were related to blood and bone marrow In contrast in the secondary trial only some of the reported adverse events were related to blood",
        "label": "Contradiction"
    },
    "60c5afb6-a250-4e59-bccd-3729a9a97a6b": {
        "text_answer": "Entailment The evidence shows that the primary clinical trial uses two different methods for intervention administration IV bisphosphonate Q4W and subcutaneous denosumab Q12W",
        "label": "Entailment"
    },
    "8af5402d-9065-412b-a7dc-053dfce01c63": {
        "text_answer": "Contradiction The statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "52d4cfdf-7677-4f4c-8020-4f5271393df9": {
        "text_answer": "Entailment The evidence states that patients receive oral medication once daily for lapatinib and once daily for tamoxifen but since they are receiving medication every day for 28 days it can be inferred that they are receiving oral medication twice a month 14 days on and 14 days off for each drug which still meets the requirement of receiving oral medication twice a month for a full month",
        "label": "Entailment"
    },
    "7d3e5dce-744f-4f7b-81f8-085c7ce2bee0": {
        "text_answer": "Contradiction  Explanation The evidence provided in the results does not support the statement that all participants in the primary clinical trial showed a drop in cognitive abilities especially those in the ovarian function suppression group The results show that the mean standardized composite score for cognitive function decreased in the ovarian function suppression group compared to the tamoxifenonly group but it does not indicate that all participants in either group showed a drop in cognitive abilities",
        "label": "Contradiction"
    },
    "e6577f53-5752-4fd5-bcfb-2d4f03b2ce60": {
        "text_answer": "Contradiction  The statement no patients treated with gtx024 1mg in the primary clinical trial gained lean body mass over a 4 month period is a contradiction to the evidence as some patients in the GTx024 1mg group had an increase in lean body mass as indicated by the median value of 155 kg with a range of 206 to 1264",
        "label": "Contradiction"
    },
    "d1200239-9391-41b1-a73e-5590855243bc": {
        "text_answer": "Contradiction The primary trial involves PF06647020 not ALT801",
        "label": "Contradiction"
    },
    "5c9e6daf-915c-48b4-b1d4-2e302e0164d4": {
        "text_answer": "Entailment with the caveat that the statement an overwhelming majority is interpreted as a majority not all of the participants in the trial",
        "label": "Entailment"
    },
    "c8b6ed79-b613-4ed4-b2ad-2e2ca4f5dcd4": {
        "text_answer": "Contradiction The evidence states that there was at least one adverse event recorded in the patient cohort",
        "label": "Contradiction"
    },
    "3e96ec18-39ff-46f9-9c67-0b6e70003e24": {
        "text_answer": "Entailment The statement that cohort 2 receives three extra cycles of the same drugs as cohort 1 entails the statement that both cohorts receive the same dosage and frequency of Docetaxel Doxorubicin and Cyclophosphamide throughout the trial",
        "label": "Entailment"
    },
    "8fe97ae1-baa6-48ba-a97e-a59585b2b268": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions nothing about atrial fibration in cohort 2 of the primary clinical trial",
        "label": "Contradiction"
    },
    "d08f5261-afae-42c3-9d0a-39739ae40ccf": {
        "text_answer": "Contradiction The memantine intervention is provided for 12 weeks which is longer than the 81 days mentioned for the placebo intervention",
        "label": "Contradiction"
    },
    "5f4eaa1c-4e83-402c-a1ed-4d398f51ec1d": {
        "text_answer": "Entailment  Explanation  In the primary trial the intervention in Arm A involves two drugs Triptorelin and Letrozol while in the secondary trial there are two interventions one with a single drug Zoledronic Acid and the other with a combination of Zoledronic Acid and radiopharmaceuticals However the statement only mentions multiple drugs in the context of the primary trial which",
        "label": "Entailment"
    },
    "5a7d5563-2920-418c-a2fb-46ada378c860": {
        "text_answer": "Contradiction The statement is more restrictive than the evidence as the evidence allows for antineoplastic chemotherapy with the exception of antiHER2 agents androgens estrogens and progestogens to be used if the patient has been on a constant dose for at least 28 days and is not expected to stop the medication during the study period",
        "label": "Contradiction"
    },
    "93d37103-4625-42a6-b8a2-7ce2d5673324": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a history of breast cancer including ductal carcinoma in situ The secondary trial includes patients with a history of breast cancer including ductal carcinoma in situ but only if they have been treated with surgery andor adjuvant therapy with a curative intent or if they do not prefer to take hormones because of concern for breast cancer",
        "label": "Contradiction"
    },
    "58614e8d-770e-4bfe-b74b-e2d429ef072f": {
        "text_answer": "Contradiction Perjeta is not mentioned in the primary trial at all and the secondary trial mentions the use of 89Zrpertuzumab which is a different HER2targeted agent Perjeta is a different HER2targeted therapy than pertuzumab",
        "label": "Contradiction"
    },
    "f8a3e02a-d5d0-4a12-9d82-e811f7be3502": {
        "text_answer": "Contradiction The primary trial explicitly states that participants must be nonsmokers while the secondary trial has no mention of smoking restrictions The statement that smokers are accepted for participation in the primary trial and the secondary trial has no restrictions on alcohol intake is incorrect for the primary trial However it is unclear whether the secondary trial has any restrictions on smoking as the evidence provided does not mention it either way",
        "label": "Contradiction"
    },
    "376c9806-25fd-4b1c-962a-b14c2ca6d9b3": {
        "text_answer": "Contradiction The inclusion criteria state that participants must have no evidence of dementia and Alzheimers disease is a type of dementia",
        "label": "Contradiction"
    },
    "ef637aff-9f52-4e17-a4d7-77e6cdb740c6": {
        "text_answer": "Contradiction The statement is not an entailment as patients with stage 4 invasive breast carcinoma are not eligible for the primary clinical trial according to the given inclusion criteria",
        "label": "Contradiction"
    },
    "dcc038bf-f819-4713-9356-3e966d30291d": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided",
        "label": "Contradiction"
    },
    "95aebead-f222-4a09-b0e0-31557235953f": {
        "text_answer": "Contradiction The intervention in the secondary trial lasts twice as long as the intervention in the primary trial not half as long",
        "label": "Contradiction"
    },
    "9eb03f1d-28b2-427e-bbf2-917fcf5ccf74": {
        "text_answer": "Contradiction The primary trial did not report any cases of radiation dermatitis or hyperpigmentation while the secondary trial reported that 15 of participants in group 1 had both conditions",
        "label": "Contradiction"
    },
    "0a1cb41e-a5f8-42ca-bec7-f9bc1291037c": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the dosages of Zoledronic Acid and Denosumab mentioned in the primary trial are different from those in the secondary trial The primary trial used Zoledronic Acid 4 mg Q4W and Denosumab 120 mg Q4W while the secondary trial used Tamoxifen and Evening Primrose Oil which have no direct comparison to the dosages in",
        "label": "Contradiction"
    },
    "6c56960a-80c2-40f6-8ba7-8e96a6bdcb98": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that no adverse events were reported in the primary trial while the statement implies that all adverse events were reported in both trials",
        "label": "Contradiction"
    },
    "5942877d-3edd-4949-9128-b17a68194753": {
        "text_answer": "Contradiction The statement mentions more than 42 patients in both cohorts but the evidence only reports the number of participants with pCR in each individual cohort 16 in Arm 1 and 14 in Arm 2 totaling 29 participants Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "5af06b76-49a3-4342-92ef-2d15ecddc2c7": {
        "text_answer": "Contradiction The primary trial reports the median time to progression in months not weeks and it does report on all participants analyzed The secondary trial reports on the number of participants with objective response not adverse events",
        "label": "Contradiction"
    },
    "382c5afb-42ce-4711-90c2-c72f34f03729": {
        "text_answer": "Entailment assuming that least frequently reported means having the lowest frequency among all reported adverse events in both trials  Explanation  In the primary trial syncope was reported in 212 1667 of the patients which is indeed a lower frequency than any of the other reported adverse events hemoglobin alkaline phosphatase dehydration syncope",
        "label": "Entailment"
    },
    "770041f3-701c-4e9f-8df4-5b78a0e4a076": {
        "text_answer": "Contradiction  The statement implies a ratio of 0031 for hepatotoxicity and hypertensionpancreatectomy but the evidence shows that there were 3 cases of hepatotoxicity and 1 case each of hypertension and pancreatectomy which is not consistent with a ratio of 0031",
        "label": "Contradiction"
    },
    "074f66e7-18df-4ee9-a33c-127062dcb51f": {
        "text_answer": "Contradiction The primary trial has different inclusion and exclusion criteria for its phases while the secondary trial has the same criteria for all participants The statement incorrectly implies that the primary trial also has the same criteria for all participants",
        "label": "Contradiction"
    },
    "22b44925-9577-462a-bf8b-cd3e5ba5ecb1": {
        "text_answer": "Contradiction The primary trials exclusion criteria state that adequate liver function is required for participation Therefore having demonstrable hepatic disease is a contradiction to the trials eligibility requirements",
        "label": "Contradiction"
    },
    "edb8f244-cc5e-4cc5-b473-3b93f8640e65": {
        "text_answer": "Contradiction  Explanation  The primary trial had two test groups Pyridoxine and Placebo while the secondary trial had two control groups Highdose Oxybutynin Chloride and Lowdose Oxybutynin Chloride The statement suggests that the primary trial had no placebo group which contradicts the evidence",
        "label": "Contradiction"
    },
    "97c98ddb-37f4-4e14-82c0-0685e500222c": {
        "text_answer": "Contradiction The secondary trial has no mention of raw or sore skin as an inclusion or exclusion criterion The primary trial does not have a consistent mention of raw or sore skin across its different study groups",
        "label": "Contradiction"
    },
    "8548c61d-2a2f-4498-a7b8-828adbd9e613": {
        "text_answer": "Contradiction  The evidence states that participants in Arm 1 of the primary clinical trial receive oral lapatinib once daily not twice daily as stated in the given statement",
        "label": "Contradiction"
    },
    "506c27c5-380f-41f7-9f90-81d843d7d140": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the primary trial involves alpha lipoic acid which is an entirely different drug compared to necitumumab in the secondary trial The statement does not hold true as they are comparing two different drugs with different dosing regimens",
        "label": "Contradiction"
    },
    "cbf31ee8-3c01-46f5-9698-f44da41fd1fa": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events in either cohort so it is not possible for the number of patients suffering adverse events to be equal in both cohorts",
        "label": "Contradiction"
    },
    "14236a59-be4c-4b17-844b-7c26a0650dc8": {
        "text_answer": "Contradiction  The statement mentions that 25 of cohort 2 patients suffered from increased pleural effusion but the evidence shows that only 1 out of 4 patients in cohort 2 experienced this adverse event which is not equivalent to 25",
        "label": "Contradiction"
    },
    "6142265a-a110-42be-b03f-088d346e2389": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of neonatal sinus tachycardia as an adverse event in the primary trial",
        "label": "Contradiction"
    },
    "7f832fbe-bf0f-44d1-820f-2398ce83404e": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction to the evidence because  1 The primary trial reported no adverse events but the statement claims that none of the adverse events in the secondary trial affected more than 1333 of patients which is not relevant to the primary trial 2 The secondary trial reported several adverse events that affected more than 1333 of patients such",
        "label": "Contradiction"
    },
    "7f17692d-e7de-4365-9da1-83f563fde703": {
        "text_answer": "Contradiction The primary trial and the secondary trial report results from different patient cohorts",
        "label": "Contradiction"
    },
    "05530068-7a95-46f6-88d2-84e53ee2ff35": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the most common adverse event recorded in the primary trial was not specifically identified as general symptoms in the provided evidence",
        "label": "Contradiction"
    },
    "4ae87355-7844-42a5-ad5b-a00c8103d102": {
        "text_answer": "Entailment The evidence states that there are 1530 enrollment slots for subjects with metastatic colorectal cancer having the Kras or BRAF mutation in the primary clinical trial",
        "label": "Entailment"
    },
    "f2f2b835-ac2d-43f6-827f-4341fb7d5fd1": {
        "text_answer": "Contradiction  The evidence states that the overall tumor response OR was measured as the percentage of participants who experienced either a confirmed complete response CR or a confirmed partial response PR The statement however specifically claims that a confirmed complete response CR was experienced by over half the patients which is not supported by the evidence",
        "label": "Contradiction"
    },
    "73849f1e-31c6-40c5-ab5c-35d0990ceac2": {
        "text_answer": "Contradiction  Patients diagnosed with malignant ductal carcinoma in situ are excluded from the primary trial not eligible",
        "label": "Contradiction"
    },
    "5933fba5-8565-47ef-a491-1a1531dc1ab3": {
        "text_answer": "Contradiction The intervention in the secondary trial lasts for 24 weeks which is longer than the 10 weeks of intervention in the primary trial",
        "label": "Contradiction"
    },
    "80249c01-a69c-490c-ab1f-74ead64dd3df": {
        "text_answer": "Contradiction assuming the pain intensity scale goes up to 10 and the statement implies that no patient experienced a pain intensity of 10 for half an hour  Explanation The evidence does not provide information on the distribution of pain intensity scores or the duration of any specific pain intensity level experienced by the patients Therefore it is impossible to determine if the statement is an entailment or contradiction based on the given evidence alone However the statement is",
        "label": "Contradiction"
    },
    "bb80e4aa-fb7d-4455-8fff-95607f45dab0": {
        "text_answer": "Contradiction The statement makes a claim about two different trials and the exclusion criteria for each trial are not related to the statement The primary trial excludes patients with breast implants while the secondary trial excludes patients with a history of pulmonary embolisms These are unrelated conditions",
        "label": "Contradiction"
    },
    "f0594802-c304-4dc7-88c8-282554c1e7d7": {
        "text_answer": "Contradiction  Explanation The primary trial administers its intervention through oral intake Vitamin B12 sublingually while the secondary trial administers its intervention through oral intake as well but in the form of memantine hydrochloride tablets Neither trial involves intramuscular administration",
        "label": "Contradiction"
    },
    "ea0e2918-08bd-4013-9915-66f8fe425e31": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the two cohorts in the primary clinical trial receive different chemotherapy regimens one with gemcitabine and the other with carboplatin and neither of them receive Abraxane",
        "label": "Contradiction"
    },
    "1357d4a3-909e-4b71-aa5a-ce11869ec91e": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no report of nausea in either trial",
        "label": "Contradiction"
    },
    "36603238-a220-4848-b9e6-90d61b28eb28": {
        "text_answer": "Neutral  Explanation The evidence provided in the primary trial description does not directly address the statement about maintaining a routine exercise regimen being a prerequisite requirement for all candidates in the primary clinical trial While the trial includes physical assessments and questionnaires it does not explicitly state that a routine exercise regimen is a requirement for participation Therefore the statement is neither an entailment nor a contradiction based on the provided evidence",
        "label": "Entailment"
    },
    "73bc9024-02aa-46b8-913b-c2739a3a66e8": {
        "text_answer": "Contradiction The primary trial has a specific inclusion criterion for Japanese female patients while the secondary trial has no such restriction",
        "label": "Contradiction"
    },
    "a056e319-f42c-4d3d-80f0-a8348be4eb9d": {
        "text_answer": "Contradiction The statement does not entail the evidence as the evidence mentions that patients with a pulmonary embolism in the last 2 months are excluded from the primary trial but it does not necessarily mean they are ineligible for the secondary trial based on the evidence provided The eligibility for the secondary trial depends on the investigators decision",
        "label": "Contradiction"
    },
    "65203e16-ff68-4833-9f92-0f63e432c09e": {
        "text_answer": "Contradiction The primary trial requires a Karnofsky score of 70 or better while the secondary trial requires a Karnofsky score of 55 or better",
        "label": "Contradiction"
    },
    "0af975f2-157a-472d-a30e-9ad614342146": {
        "text_answer": "Contradiction The statement is incorrect as polyneuropathy was not reported as an adverse event in either the primary or secondary trials according to the provided evidence",
        "label": "Contradiction"
    },
    "10a1605b-bfd7-4196-9912-19b28f271ebd": {
        "text_answer": "Entailment assuming the patient meets all other inclusion criteria for both trials The primary trial includes a minimum tumor diameter of 1 cm and the secondary trial does not specify a maximum tumor diameter Therefore a tumor with a diameter of 33 mm which is greater than 1 cm would meet the minimum requirement for the primary trial and would not contradict the secondary trials inclusion criteria",
        "label": "Entailment"
    },
    "56d7443e-3522-40e2-bb3a-413fb5edea4e": {
        "text_answer": "Contradiction The evidence states that final eligibility is determined by the health professionals conducting the trial not by the first of kin",
        "label": "Contradiction"
    },
    "fabf3f7a-48df-4940-93e2-8cbe976c4246": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one case of Edema in Cohort 2 of the primary trial Therefore the statement that there were 0 cases of Edema in both cohorts is a contradiction to the evidence  However there is no evidence of Hypertension or Dyspnea in either cohort so the statement is an entailment with respect to those conditions",
        "label": "Contradiction"
    },
    "4229278c-db31-4842-8c04-1d5b30b39037": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the doses of talazoparib given to breast and ovarianperitoneal cancer patients are different",
        "label": "Contradiction"
    },
    "da4a10c9-b04c-4439-84f5-918325786672": {
        "text_answer": "Contradiction  The statement individuals who have had severe anaphylactic responses to herceptin or have shown no response to herceptin treatment are suitable candidates for the primary clinical trial is a contradiction to the exclusion criteria mentioned in the evidence According to the evidence individuals with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the clinical trial Therefore individuals with severe anaphyl",
        "label": "Contradiction"
    },
    "eaa447d4-2621-47ca-b543-5d1d956fec02": {
        "text_answer": "Contradiction The primary trial does not mention any criteria related to schizophrenia so it cannot entail that patients with severe insomnia and schizophrenia are eligible for the primary trial but not the secondary trial The statement is a contradiction because it makes a claim about the primary trial that is not supported by the evidence provided",
        "label": "Contradiction"
    },
    "789e28a0-3116-4b32-be0f-807ffce7f552": {
        "text_answer": "Neutral Irrelevant  Explanation The statement does not entail or contradict the evidence provided The evidence only mentions the interventions used in both trials it does not provide any information about the thyroglobulin antibody status of the patients",
        "label": "Entailment"
    },
    "56358f96-8cad-40a1-a59f-4746ebde10d3": {
        "text_answer": "Entailment The evidence provided includes detailed participant information for each cohort in the primary clinical trial",
        "label": "Entailment"
    },
    "b25a8f34-96ce-4ea1-a140-bf5b0ffe7f52": {
        "text_answer": "Entailment as per the provided evidence there is no mention of drugs radiotherapy or CBT being used in either intervention",
        "label": "Entailment"
    },
    "fb3c3307-16bd-4454-b8ee-6427743bc1ed": {
        "text_answer": "Contradiction The statement includes additional exclusion criteria abdominal fistula gastrointestinal perforation intrabdominal abscess that are not mentioned in the primary trials exclusion criteria and the time frame for myocardial infarction stroke and transient ischemic attacks is different last 180 days instead of last 6 months The statement is a contradiction to the primary trials excl",
        "label": "Contradiction"
    },
    "78aec7ae-20b1-413b-9cb7-9757274ff1aa": {
        "text_answer": "Entailment The statement Morbidly obese patients are eligible for the primary trial is an entailment of the inclusion criteria which state that patients must have a BMI of 25 kgm2 or greater and weight 400 lbs",
        "label": "Entailment"
    },
    "61e35a8d-77bb-4fef-b9fa-ad0380508fc9": {
        "text_answer": "Contradiction  The evidence states that the number of participants with stable disease decreased from week 12 to week 24 but the statement suggests an increase Additionally the evidence shows that no participants achieved a complete response during weeks 12 or 24 while the statement is neutral regarding complete response",
        "label": "Contradiction"
    },
    "9da65ef3-87a1-433d-943b-a2ecc45252e1": {
        "text_answer": "Entailment The evidence shows that the ORR in the Paclitaxel Plus Bevacizumab Plus Gemcitabine group was higher than that of the Paclitaxel Plus Bevacizumab group",
        "label": "Entailment"
    },
    "0cff9aa1-3486-4c0c-bda1-8850b3dc932e": {
        "text_answer": "Entailment The evidence shows that there were no instances of anorexia hypothermia or hallucinations recorded in the adverse events of both trials The statement that no instances of these conditions were recorded is a logical consequence of the evidence",
        "label": "Entailment"
    },
    "946b0905-73d8-4e13-867f-12ea3c67c52e": {
        "text_answer": "Contradiction  Explanation The statement more than 1 over 3 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 30 weeks of the study is a contradiction to the evidence provided The evidence shows that 381 of participants in Arm 1 and 333 of participants in Arm 2 experienced a pathologic",
        "label": "Contradiction"
    },
    "f48699d6-6352-4c94-9ef3-fe5060d07aeb": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events observed in the primary trial for both Adverse Events 1 and Adverse Events 2 while in the secondary trial there were also no adverse events observed for Adverse Events 1 However there were adverse events observed in Adverse Events 2 for the secondary trial Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "9d99fc21-4f9a-4c4a-b260-d8c17d1cbdd2": {
        "text_answer": "Contradiction The evidence does not provide any information about the presence or absence of ntrk2 fusion in the primary trial or the relationship of the adverse events to mental health",
        "label": "Contradiction"
    },
    "469e2131-ef6a-4478-8e87-f785804bf8a4": {
        "text_answer": "Contradiction The evidence shows that there were adverse events in both trials so it is not the case that over 99999 of patients in both trials did not suffer any adverse events",
        "label": "Contradiction"
    },
    "e386c5e7-d098-479c-b160-aa3dab13a8df": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The evidence discusses the proportion of patients who were up to date for colorectal breast and cervical cancer screenings before and after an intervention while the statement is about voice changes in the past seven days which is unrelated to the cancer screening data",
        "label": "Entailment"
    },
    "203914a5-0e0b-4e11-a138-6793a23218c8": {
        "text_answer": "Contradiction The evidence shows that there were no recorded deaths in the second group but it does not provide information about hospital stays However the statement asserts that there were no recorded deaths or hospital stays in the second group",
        "label": "Contradiction"
    },
    "2efa0e5d-84cd-4854-9558-6105af976610": {
        "text_answer": "Contradiction  The statement patients who have received chemotherapy or radiotherapy in the last 2 weeks are dealing with unstable angina or have grade 2 or above neuropathy are eligible to participate in the secondary clinical trial and excluded from the primary clinical trial is a contradiction based on the provided evidence  The primary clinical trial excludes patients who have received chemotherapy or radiotherapy within 2 weeks while the secondary clinical trial",
        "label": "Contradiction"
    },
    "bad9c481-e20c-49a7-b6b6-4e09991419c2": {
        "text_answer": "Contradiction  Explanation The statement in both the primary trial and the secondary trial they utilize pCR as a means of outcome measurement there are no observable differences in outcomes in the two cohorts in the primary trial in the secondary trial arm 1 reflects worse results than arm 2 with an increased percentage of arm 1 patients experiencing pCR is a contradiction based on the evidence provided  In the primary trial the",
        "label": "Contradiction"
    },
    "15ac7da3-01f5-4c67-a59a-d41619758b62": {
        "text_answer": "Contradiction The evidence states that adequate liver function is an inclusion criterion for the primary clinical trial",
        "label": "Contradiction"
    },
    "84942825-f636-4dcf-af2e-172012c0cc9d": {
        "text_answer": "Entailment The evidence states that in Intervention 1 the dose of Cyclophosphamide is higher than Eribulin and in Intervention 2 the dose of Cyclophosphamide is higher than Docetaxel Therefore the statement that cohort 1 receives higher doses of Cyclophosphamide than Eribulin and cohort 2 receives higher doses of Cyclophosphamide than Docetaxel is an ent",
        "label": "Entailment"
    },
    "e78805f7-1b81-4cd9-a3c7-591886fd5d70": {
        "text_answer": "Contradiction The statement is incorrect because the evidence shows that cohort 1 receives anastrozole and cohort 2 receives fulvestrant not paclitaxel and fulvestrant respectively",
        "label": "Contradiction"
    },
    "f6ce492e-e69c-4908-9b04-b0234a364e95": {
        "text_answer": "Neutral NA  Explanation The statement does not directly entail or contradict the evidence provided The evidence only mentions the routes of administration for the interventions while the statement is about a specific chromosome band",
        "label": "Entailment"
    },
    "9bc01b3d-99a3-47bf-9183-012d6686acc5": {
        "text_answer": "Contradiction The evidence does not support the statement as there is no mention of hypertension dehydration or dyspnea in the provided adverse events for either cohort",
        "label": "Contradiction"
    },
    "9bec84f1-9ea0-4a5c-a3d7-b368a302ad4a": {
        "text_answer": "Contradiction The evidence shows that the AZD0530 175 mg group had a greater percentage change in betaCTX at Week 4 compared to the Zoledronic Acid 4 mg group",
        "label": "Contradiction"
    },
    "dd9dfad7-d09d-49d3-ad2d-fe7421d3a8a0": {
        "text_answer": "Contradiction  In the primary trial participants received 5 injections at the beginning of the study whereas in the secondary trial the statement suggests that participants receive 3 weekly injections which is not the same as the primary trial",
        "label": "Contradiction"
    },
    "70d381b6-0605-4369-8342-5ee2fb69d878": {
        "text_answer": "Entailment The statement patients with a diagnosis of ductal carcinoma in situ who are thinking about AI therapy qualify for the primary clinical trial is an entailment of the evidence provided as DCIS is specifically listed as a type of breast cancer that is included in the trials inclusion criteria",
        "label": "Entailment"
    },
    "a263d5ff-4c27-4881-9209-87b1c1d69f94": {
        "text_answer": "Contradiction The primary trial requires resistance to aromatase inhibitors AI but there is no mention of mirtazapine in the primary trials inclusion or exclusion criteria The secondary trial does not mention AI therapy or resistance to it at all",
        "label": "Contradiction"
    },
    "a83ed07f-5ce3-44db-83d4-1629e6838c4a": {
        "text_answer": "Contradiction  The primary trial requires mammography as an inclusion criterion while the secondary trial does not mention it as a requirement",
        "label": "Contradiction"
    },
    "a3c50e76-dadb-4b34-8245-0fe0de3d19cb": {
        "text_answer": "Contradiction The statement is about a doctor asking a patient about their treatment preference while the evidence provided is about the results of two clinical trials with different outcome measures hot flash scores in the primary trial and overall response rate in the secondary trial",
        "label": "Contradiction"
    },
    "62dbb697-f709-40c2-a4b9-8ed098473bde": {
        "text_answer": "Contradiction The primary trial includes males with neuroblastoma regardless of age and ethnicity while the secondary trial only includes females with BRCA1positive ovarian cancer",
        "label": "Contradiction"
    },
    "c484c0e8-0530-47cb-89dc-da4c4a7f4c0b": {
        "text_answer": "Contradiction The primary trial is not testing different radiation therapies but rather different interventions Hydrophor and MediHoney for managing side effects of radiation therapy The secondary trial is testing different doses of the same treatment PF05212384  Docetaxel",
        "label": "Contradiction"
    },
    "58726c08-13a9-4168-afc3-14f8e7397f5b": {
        "text_answer": "Contradiction The young girl described in the statement does not meet the age requirement for the primary trial which is for female patients who are 18 years of age or older The secondary trial on the other hand includes both female and male patients who are 18 years of age or older Therefore the statement is a contradiction as the young girl with a newly diagnosed PRpositive HER2positive breast cancer would not be eligible for the",
        "label": "Contradiction"
    },
    "fea83da0-5960-4547-b662-fe6d139fe3f9": {
        "text_answer": "Contradiction  Explanation The statement the primary clinical trial found the bevacizumab cohorts outcomes to be more favorable than those of the bevacizumab  capecitabine cohort is a contradiction based on the evidence provided The evidence shows that the percentage of participants with disease progression or death was lower in the Bevacizumab cohort 883",
        "label": "Contradiction"
    },
    "791790a6-187b-4e4b-be5f-9e5304e9ec2c": {
        "text_answer": "Contradiction  Explanation In the primary trial patients receive 4 mgkg of trastuzumab as a loading dose followed by 2 mgkg weekly In contrast in cohort 2 of the secondary trial patients receive Herceptin 4 mgkg on Day 1 of Cycle 5 and 2 mgkg weekly starting from Day 8 The dosages are not the same throughout the entire duration",
        "label": "Contradiction"
    },
    "046aa480-39cc-4333-a815-bc4ec3ebfa7d": {
        "text_answer": "Contradiction The evidence does not indicate that the primary clinical trial is exclusively for Asian patients",
        "label": "Contradiction"
    },
    "73fd9671-363f-4bfa-91ad-1c8bacdf84ef": {
        "text_answer": "Entailment The evidence shows that no participants in either trial suffered from any adverse event AE so the statement that 0 of participants in both trials suffered from an AE is an entailment of the evidence",
        "label": "Entailment"
    },
    "aa9da5b8-f5de-4a49-a93c-9e354cdef066": {
        "text_answer": "Entailment The evidence shows that no adverse outcomes were recorded in more than 1 of participants in the primary trial for both Adverse Events 1 and 2 and in the secondary trial for Adverse Events 1 The statement that no adverse outcomes were recorded in more than 1 of participants in both trials for any type of adverse event entails the given evidence",
        "label": "Entailment"
    },
    "93381895-c0d3-40d1-96a0-b1aa23f65151": {
        "text_answer": "Contradiction The evidence states that there were no participants analyzed in the LBH589 and Lapatinib group but it does not explicitly state that there are no reported results for this group",
        "label": "Contradiction"
    },
    "286cb14c-39e1-4987-9de2-78de7e78a017": {
        "text_answer": "Contradiction The primary trial reported no cases of acute myocardial infarction not two",
        "label": "Contradiction"
    },
    "4a9c4fbc-53cf-4eff-b7ba-37a0f21386b4": {
        "text_answer": "Contradiction The evidence reports a total of 6 adverse events across both cohorts in the primary clinical trial",
        "label": "Contradiction"
    },
    "9c96be3d-39cf-4c1d-ae87-764621c1e0ca": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not mention anything about trna methyltransferase or its relationship to the eligibility criteria for the primary trial",
        "label": "Contradiction"
    },
    "c68e5909-668a-4b35-bf32-815624bf44da": {
        "text_answer": "Contradiction The statement specifies a dose of 150 mgm2 which is different from the dose given in the evidence 1500 mg Additionally the statement mentions a dosing schedule of once daily for two weeks while the evidence states that patients receive the drugs daily for 28 days",
        "label": "Contradiction"
    },
    "dec08a3f-8124-4d8a-b5cf-00231c2b5cec": {
        "text_answer": "Contradiction The statement is contradictory to the inclusion criteria which require a HER2 positive tumor either IHC 3 or FISH for participation in the primary clinical trial",
        "label": "Contradiction"
    },
    "9645eddb-eb1c-43ca-a899-a35db801217e": {
        "text_answer": "Contradiction  The primary trial does require written informed consent as an inclusion criterion",
        "label": "Contradiction"
    },
    "af3815c2-6d92-410b-ae62-5552ea998792": {
        "text_answer": "Contradiction  The evidence provided in the results of the primary trial indicates that the median overall survival for both groups was over 2 years so it is contradictory to state that the average lifespan of patients post the primary clinical trial is less than 2 years with no instances of patients from both cohorts passing away before the 2 year mark",
        "label": "Contradiction"
    },
    "8bf215f3-5795-4b6b-b193-354c87bc9496": {
        "text_answer": "Contradiction The median change in lean body mass for the GTx024 1mg group was 155 kg which is less than 157473 stones approximately 933 kg",
        "label": "Contradiction"
    },
    "76f87500-dd58-4086-9991-90e4f8206abf": {
        "text_answer": "Contradiction The primary trial has a cyclic treatment with a 21day cycle length not a 10month cycle The secondary trial does not have a cyclic treatment",
        "label": "Contradiction"
    },
    "ffb8a143-9dd7-4e61-8967-b0744c2dfa49": {
        "text_answer": "Contradiction The primary trial measures changes in pain intensity while the secondary trial measures changes in bone mineral density Although both trials involve the lumbar spine they assess different outcomes",
        "label": "Contradiction"
    },
    "3ed31a8a-dce6-4a6c-b1a6-143db3702546": {
        "text_answer": "Contradiction The statement that mcl1 inhibitor is any agent that inhibits mcl1 is not an entailment of the evidence that the primary trial intervention includes surgical and imaging procedures An mcl1 inhibitor is a type of drug while surgical and imaging procedures are not",
        "label": "Contradiction"
    },
    "1c594930-3c65-42d3-86ed-a0a8f46d369c": {
        "text_answer": "Contradiction  Explanation The statement does not relate to the given evidence as it mentions Febrile neutropenia or Cholelithiasis which is not mentioned in the evidence The evidence only provides the adverse events for each trial and the statement is about certain conditions not being present in both trials",
        "label": "Contradiction"
    },
    "43989f85-a059-4dc7-a805-16e081706b2f": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that both trials had 0 recorded adverse events",
        "label": "Entailment"
    },
    "7ccf8aef-b43b-4d01-9c86-7728378b2aeb": {
        "text_answer": "Contradiction The primary trial includes patients with metastatic or unresectable nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma or breast cancer whose disease has progressed after at least one line of standard therapy but it does not specifically mention histopathologically confirmed metastatic SBC small bowel cancer",
        "label": "Contradiction"
    },
    "3fd8c503-c6fa-45f1-8836-88a5b77873a3": {
        "text_answer": "Contradiction   The primary clinical trial involves vaginal interventions with Estring and testosterone cream while the secondary clinical trial involves intravenous drug administration of chemotherapy agents FEC paclitaxel and trastuzumab and acupuncture Neither trial involves oral medications",
        "label": "Contradiction"
    },
    "65bc201c-2957-4d21-88f1-05c2413a6e56": {
        "text_answer": "Contradiction The primary trial and the secondary trial evaluate different outcome measures The primary trial measures the number of participants with treatmentemergent adverse events while the secondary trial measures the change in total sleep time as measured by polysomnography",
        "label": "Contradiction"
    },
    "7b71e96e-63ed-43c9-9d9d-5abad0b53d32": {
        "text_answer": "Entailment Both trials focus on the same drug empegfilgrastim but they use different dosages and methods for measuring results duration vs incidence of neutropenia",
        "label": "Entailment"
    },
    "88148e83-625a-4004-8a2c-e4dec21c73e7": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the evidence shows a significant change in Ki67 expression which is a marker of tumor growth and the statement claims no significant change in tumor size However its important to note that the statement does not directly mention the dose of tamoxifen used in the study and the evidence describes a different dose 20 mg being used",
        "label": "Contradiction"
    },
    "308848e8-55ef-4799-9251-7dc54ddf0ac3": {
        "text_answer": "Entailment assuming Aes in the statement refers to Adverse Events and the evidence does not mention any adverse events related to microwave thermotherapy in the primary trial",
        "label": "Entailment"
    },
    "d118efb5-ea31-49ca-8e20-686c85081e94": {
        "text_answer": "Contradiction The evidence does not support the statement that Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants as Cholelithiasis was reported in 030 000 participants in the primary trial and 012 000 participants in the secondary trial",
        "label": "Contradiction"
    },
    "67f9627e-ec2e-49b5-bb2e-2adbb5debfef": {
        "text_answer": "Contradiction The secondary clinical trial lasts for 24 weeks which is longer than the 10 weeks of the primary clinical trial",
        "label": "Contradiction"
    },
    "46c9f061-408a-4845-b1ac-01b9c8eb5606": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as cohort 2 of the primary clinical trial reported no cases of adverse events in the secondary trial while the statement suggests that cohort 2 reported more cases of palpitations pericardial effusions and abdominal pains than cohort 1 of the secondary trial",
        "label": "Contradiction"
    },
    "20e22430-cc26-4cc4-b644-30dea07896e7": {
        "text_answer": "Contradiction  Explanation The evidence states that Intervention 1 is for the TripleNegative cohort and Intervention 2 is for the HER2Positive and HER2Amplified cohort The statement however asserts that both cohorts received Her2 treatment which is incorrect according to the provided evidence",
        "label": "Contradiction"
    },
    "3cbf5587-220b-4759-a93b-8dbd5e144939": {
        "text_answer": "Contradiction The evidence states that patients with nonmeasurable disease are eligible for the primary clinical trial This term includes patients with unmeasurable metastasis",
        "label": "Contradiction"
    },
    "98300332-951a-4da5-bdd9-42b17fd489b0": {
        "text_answer": "Contradiction  The evidence shows that 286 131 to 492 of participants in the ERpositive Luminal B group demonstrated a decrease in the growth factor signature while 176 67 to 352 of participants in the Triple Negative group demonstrated a decrease in the growth factor signature Therefore the statement that 33 more participants in",
        "label": "Contradiction"
    },
    "fd531ca0-8537-4395-abed-00fbc69c00a7": {
        "text_answer": "Entailment The statement candidates for the primary trial must have breast cancer and require hormonal treatment is an entailment of the inclusion criteria Breast Cancer has continued to grow after having received treatment with an antiestrogen hormonal treatment such as tamoxifen or an aromatase inhibitor Requiring hormonal treatment as both conditions are required for participation in the trial",
        "label": "Entailment"
    },
    "1ad82f60-7f4e-4e29-967f-c83e64180807": {
        "text_answer": "Contradiction  Explanation The statement is about the reduction in tumor diameter by 20 on average with tamoxifen 45 mg po daily for 15 days prior to surgery and for 30 days after breast cancer surgery However the evidence from the primary trial only shows a significant change in Ki67 expression in tumors with tamoxifen 20 mg po daily for 7 days prior to surgery and for",
        "label": "Contradiction"
    },
    "2e9395d7-1b38-4fc4-b0f4-121f89c1cfc2": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence shows that cohort 2 received half the number of capsules 2 instead of 4 not half the dose 80mg instead of 160mg of Enzalutamide",
        "label": "Contradiction"
    },
    "a993a4e8-00bf-47c9-95d2-a63d4666658e": {
        "text_answer": "Contradiction  Explanation  In the primary clinical trial the intervention is administered sublingually under the tongue while in the secondary clinical trial the intervention is administered orally by mouth These two methods of administration are different and the statement that they are the same implied by in the primary clinical trial the intervention is administered sublingually while oral administration is used in the secondary clinical trial is a contrad",
        "label": "Contradiction"
    },
    "f9759341-1ed2-4e44-8d4d-952bb366892f": {
        "text_answer": "Contradiction The statement does not entail the evidence as it makes a false claim about the absence of adverse events in the primary trial",
        "label": "Contradiction"
    },
    "f5a91b94-a81e-4c40-91df-b144e30df80b": {
        "text_answer": "Contradiction  Explanation  In the primary trial participants do receive epacadostat as part of their intervention Therefore the statement that primary trial participants never receive epacadostat is a contradiction to the evidence provided  In the secondary trial sunitinibnaive participants do receive sunitinib as part of their intervention However the statement does not necessarily mean that all participants in the secondary trial",
        "label": "Contradiction"
    },
    "62441471-f329-4540-9d4e-dc34c4d08d59": {
        "text_answer": "Contradiction The evidence states that for the secondary trial patients must be ambulatory with a functional ECOG  2 status which is the opposite of being completely disabled",
        "label": "Contradiction"
    },
    "f77c9775-9421-4d65-8860-c78a684fd886": {
        "text_answer": "Contradiction The statement implies that patients with unstable angina or Grade 2 or above neuropathy cannot participate in the secondary trial but can participate in the primary trial unless they have nonhealing surgical wounds However the evidence provided for the secondary trial states that patients with unstable angina and Grade 2 or above neuropathy are excluded from the study The evidence for the primary trial does not mention these conditions as exclusion criteria Therefore",
        "label": "Contradiction"
    },
    "12c5e376-9a01-4581-9d78-db71f92ef23d": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not provide any information about the administration manner of the placebo and Trabectedin being the same or different it only mentions the different days and drugs used",
        "label": "Contradiction"
    },
    "11de406a-fdd7-401a-a6b9-0c0b47bdf7f6": {
        "text_answer": "Contradiction The evidence shows that there were adverse events recorded for cohort 1 that were not oncological side effects such as acute coronary syndrome and angina pectoris",
        "label": "Contradiction"
    },
    "0d4acb50-cf28-4eb1-bd3f-1511d068e3a1": {
        "text_answer": "Contradiction  The evidence shows that a smaller percentage of participants in the Triple Negative group demonstrated a decrease in the growth factor signature compared to the ERpositive Luminal B group",
        "label": "Contradiction"
    },
    "e6bba244-c154-4143-a5f2-5f8b1c304a97": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the number of adverse events in the primary trial is 0 while in the secondary trial it is 0 for Adverse Events 1 and not provided for Adverse Events 2",
        "label": "Contradiction"
    },
    "374ebee5-982e-4ff5-bdf9-49414d417303": {
        "text_answer": "Contradiction  Explanation The primary trial does not mention claustrophobia as an exclusion criterion while the secondary trial does list it as an exclusion criterion However the statement also mentions IBS Irritable Bowel Syndrome which is not mentioned in the evidence at all Therefore the statement is a contradiction as it incorrectly states that women with claustrophobia and",
        "label": "Contradiction"
    },
    "f1b7b902-d67b-489f-9c93-de59c708d2fa": {
        "text_answer": "Contradiction The primary trial measures adverse events not hours of sleep and the secondary trial measures hours of sleep not adverse events",
        "label": "Contradiction"
    },
    "002e96b7-152f-4860-b61c-21327c2e6b23": {
        "text_answer": "  The statement is a Contradiction for the primary trial as the patients ANC is below the required minimum of 1800 cellsmm3 However the statement is an Entailment for the secondary trial as the patient meets all the other inclusion criteria",
        "label": "Contradiction"
    },
    "267240f0-f381-4c67-adf6-3121eea9396d": {
        "text_answer": "Contradiction  Explanation The evidence provided does not support the statement that the LBH589 and Lapatinib combination had superior results than the LBH589 with Capecitabine cohort as there is no data presented in the evidence to support this claim The evidence only provides information on the dosing and number of participants in each cohort but not on the outcomes or results of the trials",
        "label": "Contradiction"
    },
    "4ecece61-2e46-482f-a765-ac677ea3e19c": {
        "text_answer": "Contradiction The statement is not an entailment as the secondary trial has the same inclusionexclusion criteria for all participants but the primary trial has different inclusion criteria for different study groups The statement about thousand being a natural number following 999 and preceding 1001 is not related to the inclusionexclusion criteria and is a mathematical fact",
        "label": "Contradiction"
    },
    "37df336b-2fc4-4986-957b-5f62219c5bd4": {
        "text_answer": "Contradiction The evidence states that there is no intervention involving drugs in the primary trial",
        "label": "Contradiction"
    },
    "dbffbeee-66da-4e88-8a57-c4d08e214048": {
        "text_answer": "Contradiction The primary trial includes only ER HER2 or TNBC patients it does not include ER PR HER2 patients",
        "label": "Contradiction"
    },
    "18395ec3-337c-4e51-aef9-5b91423999ed": {
        "text_answer": "Contradiction The primary trial and secondary trial address different outcome measures overall response rate vs time to first onstudy SRE and do not provide evidence related to the ability of individuals to propel a wheelchair independently",
        "label": "Contradiction"
    },
    "f7de4d97-31e4-48e0-ab1a-1e3d8a152e8b": {
        "text_answer": "Contradiction The evidence shows that there were adverse events reported in both trials so it is not true that most patients in both trials did not suffer any adverse events",
        "label": "Contradiction"
    },
    "334b5f86-50c5-4711-994d-31ed67dd4282": {
        "text_answer": "Entailment  The secondary trial includes women aged 18 or older as a specific inclusion criterion and the primary trial also includes women aged 18 or older as a part of the broader inclusion criteria",
        "label": "Entailment"
    },
    "43ee44cf-35e5-4830-ab1f-d4f040487801": {
        "text_answer": "Contradiction The statement does not entail the conditions specified in the evidence for the primary clinical trial as the trial is for patients with metastatic invasive breast cancer that is negative for the estrogen receptor ER progesterone receptor PR and HER2 by institutional guidelines and who have measurable disease RECIST 11 The statement is more general and does not specify the type of cancer or the requirement for measurable",
        "label": "Contradiction"
    },
    "0f31bc6a-a228-49c2-afff-4177ef850272": {
        "text_answer": "Contradiction The primary trial had 13 participants and the secondary trial had 30 participants Therefore there were fewer participants in the primary trial",
        "label": "Contradiction"
    },
    "929ad524-174d-4586-b088-3b512e88bb8f": {
        "text_answer": "Contradiction The evidence does not support the statement as it does not provide information about the occurrence of lifethreatening adverse events in the PalbociclibLetrozole India Cohort",
        "label": "Contradiction"
    },
    "94b71d5a-37d7-485b-96b7-e0979141893b": {
        "text_answer": "Entailment assuming the collaborative care intervention is not specified in the evidence The statement does not contradict the evidence as it does not state that the first cohort received a different Cetuximab dose than the second cohort However the evidence does show that the first cohort received the same Cetuximab dose as the second cohort",
        "label": "Entailment"
    },
    "ac0df9a5-d909-40a6-9b57-391fef615fe9": {
        "text_answer": "Contradiction The primary trial reports adverse events for 37 patients while the secondary trial reports adverse events for 52 patients The statement does not specify that both trials involve the same patients so it is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "2bd35e15-a310-4660-8963-7f672733bb22": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of anemia being the most common adverse event in the primary trial",
        "label": "Contradiction"
    },
    "3278109c-54b8-4842-8a59-4dae9fac6280": {
        "text_answer": "Entailment The statement does not contradict the evidence as it applies to all participants in the primary trial regardless of their cancer status The evidence states that all participants receive the same intervention",
        "label": "Entailment"
    },
    "1d66459b-4624-4ea0-9cda-992c4146a454": {
        "text_answer": "Contradiction The evidence states that no prior gabapentin or pregabalin is allowed in the secondary trial but there is no mention of this exclusion criterion in the primary trial",
        "label": "Contradiction"
    },
    "04901c04-5a0e-46cb-8684-96ff864921fe": {
        "text_answer": "  Contradiction  Explanation  The patient described in the statement does not meet the eligibility criteria for both trials  For the primary trial the patients hemoglobin level of 009 gml is below the required minimum of 80 gdl  For the secondary trial the patients hemoglobin level of 009 gml is",
        "label": "Contradiction"
    },
    "a2ac2860-6f2d-4459-9c8e-748dddcc35e7": {
        "text_answer": "Contradiction  The primary trial includes women with locally advanced recurrent or metastatic breast cancer while the secondary trial includes women with early stage breast cancer The primary trial is for patients with ER breast cancer while the secondary trial does not mention ER status as a requirement The primary trial excludes patients who have undergone more than one chemotherapy line while the secondary trial does not mention any chemotherapy history The primary trial includes patients with meas",
        "label": "Contradiction"
    },
    "8db20184-7510-432f-aa95-c9f2c91326fd": {
        "text_answer": "Contradiction The primary trial reported cases of infection asymmetry and delayed healing wound while the secondary trial reported no adverse events at all",
        "label": "Contradiction"
    },
    "489c9279-ebca-4ff2-ae61-c8ff4275f3ac": {
        "text_answer": "Contradiction The evidence does not support the statement that all patients receiving the placebo intervention in the primary trial experienced emesis The evidence only states that there were 5 participants in the placebo group who were analyzed but it does not provide information about whether any of them experienced emesis",
        "label": "Contradiction"
    },
    "7d8d8409-5282-464a-a666-849f3eb36b6e": {
        "text_answer": "Entailment The statement is an entailment because the evidence clearly indicates that both trials have unique inclusion and exclusion criteria for different patient groups during their respective phases",
        "label": "Entailment"
    },
    "5bdb26f3-2166-41b4-bc39-a4d78e81d04f": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided as the evidence pertains to a HER2negative breast cancer clinical trial and the statement mentions nothing about the trial or the participants",
        "label": "Contradiction"
    },
    "96aaaf64-1a1e-4a5b-a2db-f99e2c199bec": {
        "text_answer": "  The statement is a Contradiction based on the evidence provided  Explanation  The primary trial requires a minimum ANC of 1800 cellsmm3 while the secondary trial requires a minimum ANC of 1500μL The patient in the statement has an ANC of 1600μL which is higher than the minimum requirement for the secondary trial but lower than the",
        "label": "Contradiction"
    },
    "7313a53a-9a67-4b81-ad79-4df7d1ced976": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of pain in the evidence",
        "label": "Contradiction"
    },
    "0de24040-4a99-4f16-8bba-6f2e78018aad": {
        "text_answer": "Contradiction  Explanation  In the primary trial Armodafinil is given daily for 47 days while in the secondary trial neither Armodafinil nor MCS110 are given daily and all participants receive a uniform dose of 100 mg PDR001 and 1mgkg of MCS110 Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "88b8e438-87f4-418b-903a-efe0f5a83882": {
        "text_answer": "Contradiction The primary trial intervention involves radioembolization using Yttrium90 glass microspheres and TheraSpheres while the secondary trial intervention consists of a chemotherapy regimen 560 mg of ibrutinib and 10 mgkg of MEDI4736 that is not related to radioembolization",
        "label": "Contradiction"
    },
    "c7c9fef0-9243-4cd8-8b8e-e9ab459b7420": {
        "text_answer": "Contradiction The primary trial measures the change in urinary isothiocyanate concentration while the secondary trial measures the percentage of participants with pain or no pain These are different outcome measures",
        "label": "Contradiction"
    },
    "f22453a4-5cb5-4180-8af7-a9f701d766d7": {
        "text_answer": "Entailment for cohort 1 of the primary trial with the given evidence",
        "label": "Entailment"
    },
    "a8bb394a-d996-4174-8800-a38db8905fce": {
        "text_answer": "Contradiction  The primary trial does measure time to progression but it is not the sole focus of the study as stated in the question The secondary trial does measure the number of participants with successful treatment response but it also measures time to progression Therefore the statements are not exact opposites but they do differ in emphasis",
        "label": "Contradiction"
    },
    "7d78fd1d-3d73-460c-a1b6-c0d9bf3a60a9": {
        "text_answer": "Contradiction  The evidence states that patients receive oral lapatinib once daily in the primary trial not twice daily as stated in the question",
        "label": "Contradiction"
    },
    "80e6c613-24ab-4d10-bed6-49388de175d4": {
        "text_answer": "Contradiction The statement has nothing to do with the length of the interventions in the primary and secondary trials",
        "label": "Contradiction"
    },
    "5da1c2df-9374-4de9-b43a-c19a03d5652c": {
        "text_answer": "Contradiction The primary trial includes patients with histologically or cytologically confirmed metastatic andor advanced solid tumor while the secondary trial includes patients with advanced solid tumors for which there is no approved therapy These two statements are not equivalent as the primary trial includes patients with cancer while the secondary trial specifically excludes patients with approved therapies for their cancer",
        "label": "Contradiction"
    },
    "1a76bce8-07e2-4b30-adc8-3c095f0d62b3": {
        "text_answer": "Contradiction  Explanation In the primary trial patients receive 2 mgkg of trastuzumab weekly while in the secondary trial patients in cohort 2 receive Herceptin 2 mgkg by IV infusion weekly However the dosages are not identical as the primary trial does not include any information about the administration schedule of Herceptin in the secondary trial Therefore the statement is a contradiction based on",
        "label": "Contradiction"
    },
    "594df991-cd8d-4ca0-9fe9-5c21a73a0bf3": {
        "text_answer": "Contradiction The primary trial and the secondary trial measure different outcomes isothiocyanate levels vs pain respectively",
        "label": "Contradiction"
    },
    "c870de83-33d4-4ea6-9482-afe2d7a47480": {
        "text_answer": "Contradiction The primary trial requires participants to receive denosumab while the secondary trial does not mention it and instead mentions the use of amifostine with a different dosage",
        "label": "Contradiction"
    },
    "3b8d5e1e-4c1e-4e6e-9890-8851c275cc0f": {
        "text_answer": "Contradiction The evidence does not support the statement as there is no mention of psychiatric adverse events in the secondary clinical trial",
        "label": "Contradiction"
    },
    "c4487f90-2a8e-4740-9d56-8fedbd7fb044": {
        "text_answer": "Contradiction The primary trial measures pain intensity using a visual analog scale while the secondary trial measures bone mineral density using DEXA scan These are not directly comparable outcomes",
        "label": "Contradiction"
    },
    "05056fdd-25bc-40ce-831b-e969e95eaa55": {
        "text_answer": "Contradiction  The evidence states that 98 of participants had Recurrencefree Survival of 3 years or more which implies that only 2 had Recurrencefree Survival less than 3 years The statement however refers to almost all participants reporting adverse events which is not directly related to Recurrencefree Survival and is not contradictory to the evidence but it is",
        "label": "Contradiction"
    },
    "e2979c27-0eb6-487d-a940-646685e1934b": {
        "text_answer": "Entailment The statement explicitly mentions the difference between the two interventions and the evidence supports that difference",
        "label": "Entailment"
    },
    "857f643d-b77b-4a11-94c7-7e05a7e3b0ef": {
        "text_answer": "Contradiction The primary trial administers its intervention orally as a vitamin B12 supplement while the secondary trial administers its intervention memantine hydrochloride orally by mouth as well There is no mention of transdermal or intranasal administration in either trial",
        "label": "Contradiction"
    },
    "fae264c6-e28a-42ba-9951-f27cdf917815": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with thalasemic syndromes and the statement includes them as eligible Similarly the primary trial excludes patients with epilepsy while the statement is silent on this criterion The statement also contradicts the primary trials exclusion of anemia due to causes other than iron deficiency",
        "label": "Contradiction"
    },
    "5da86b4b-b830-48a4-964d-c20207d55b3a": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with inflammatory breast cancer while the statement includes them for both trials Additionally the primary trial includes patients with NUT midline carcinoma identified by FISH but the secondary trial does not mention this specific diagnosis Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "ec1b0aa0-0d0b-45b9-9ba5-ad8b941d8647": {
        "text_answer": "Entailment assuming the patient meets all other inclusion criteria for both trials",
        "label": "Entailment"
    },
    "1b2512ba-9857-4fde-a25b-b4768b1ad748": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the evidence shows that gabapentin or pregabalin are exclusion factors in the primary trial but are not mentioned as inclusion or exclusion factors in the secondary trial Therefore the statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "f5fbfac5-bac3-4852-bb93-b262df8d1418": {
        "text_answer": "Contradiction The primary trial requires mammography while the secondary trial does not mention mammography and instead requires a CT scan and blood tests",
        "label": "Contradiction"
    },
    "91aed56a-2b8e-4f23-9885-4f05e6115537": {
        "text_answer": "Contradiction  Explanation The evidence shows that acupuncture patients had a mean arm circumference reduction of 045 cm from 474 cm to 429 cm at 6 weeks while waitlist patients had a mean arm circumference reduction of 006 cm from 482 cm to 476 cm at 6 weeks The difference between the two groups",
        "label": "Contradiction"
    },
    "e299d6fb-d590-417b-a9d3-88ee887d9c00": {
        "text_answer": "Contradiction The statement mentions several psychiatric issues but the evidence only mentions suicidal ideation and no mention of an eating disorder or schizophrenia as adverse events",
        "label": "Contradiction"
    },
    "948018b7-b40c-499c-bba8-e835222c3c00": {
        "text_answer": "Contradiction The statement is a contradiction of the evidence provided for the secondary trial as the evidence states that patients with unstable angina and grade 2 or higher neuropathy are eligible for the secondary trial while the statement excludes them The statement also incorrectly states that patients who have undergone chemotherapy or radiotherapy within the past two weeks are ineligible for the secondary trial while the evidence states that this is only an exclusion criter",
        "label": "Contradiction"
    },
    "0e0e3540-9217-435a-89d5-395a9c8af579": {
        "text_answer": "Contradiction The Intervention 1 description mentions the use of a validated webbased risk assessment in the primary trial",
        "label": "Contradiction"
    },
    "b9074beb-a639-46ba-966b-b0db266efffc": {
        "text_answer": "Entailment as the previous statement did not mention the method of administration and the new statement specifically excludes it",
        "label": "Entailment"
    },
    "f8895ab6-dbe2-4715-9567-7dfa9c4d46a8": {
        "text_answer": "Contradiction The primary trial does enforce a cyclebased intervention while the secondary trial does not specify a cyclebased intervention but rather mentions interventions happening in the operating room",
        "label": "Contradiction"
    },
    "b5349f06-8e89-4ff7-966e-00333de8b463": {
        "text_answer": "The statement is a Contradiction The evidence does not provide enough information to determine if the patient in question received chemotherapy or not The statement about the occurrence of certain adverse events in the primary trial compared to the secondary trial does not entail whether or not the patient received chemotherapy",
        "label": "Contradiction"
    },
    "5bf68801-c079-469b-a0a9-2a3d6fb379ed": {
        "text_answer": "Contradiction The primary trial does not include resectable nonsmall cell lung cancer or small cell lung cancer in its inclusion criteria",
        "label": "Contradiction"
    },
    "ecfd2566-6a41-4b0d-be72-eb143c114835": {
        "text_answer": "Entailment  Explanation The statement cohort 1 in the primary clinical trial is given larger doses of cyclophosphamide compared to eribulin is true based on the evidence as the dose of cyclophosphamide in Intervention 1 cohort 1 is 600 mgm2 while the dose of eribulin in Intervention 1 cohort 1 is",
        "label": "Entailment"
    },
    "af2a7153-f082-457c-be3e-e6716cdabe0d": {
        "text_answer": "Contradiction The statement is about a different drug regimen evac and does not relate to the evidence provided about GTx024",
        "label": "Contradiction"
    },
    "0790e3ed-6c8e-4b03-8eca-d80fa6296385": {
        "text_answer": "Contradiction  The evidence states that both interventions involve the injection of radioactive Tc99M sulfur colloid for lymphoscintigraphy but it does not state that standard gamma probes GP are used for both interventions Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "dce179aa-b35d-42dd-b97b-4c76f2e4d8b7": {
        "text_answer": "Contradiction The evidence from the primary trial includes adverse events related to the BloodBone Marrow system which is not a part of the musculoskeletal system",
        "label": "Contradiction"
    },
    "0bd4a2c1-4e4a-4752-a9e8-46a9a27885c1": {
        "text_answer": "Contradiction The statement does not entail the evidence as the evidence states that there were no adverse events reported in Cohort 1 of the primary trial and the statement is about a specific finding atypical lymphocytes in bone marrow that was not reported in the evidence",
        "label": "Contradiction"
    },
    "4f1bafd9-361f-4981-b6fd-46af736141b4": {
        "text_answer": "Contradiction The evidence states that the intervention section outlines a treatment with partial breast irradiation which does include a description of the irradiation doses and a treatment cycle",
        "label": "Contradiction"
    },
    "98e146d6-bc16-460b-92eb-826ddeb79a3d": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not provide information about the survival of patients with viral complications or the overall average survival of all patients in the trial",
        "label": "Contradiction"
    },
    "328b27ff-4e87-40df-824f-73fb1f01b8a7": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as only the intervention arm of the study uses the educational DVD",
        "label": "Contradiction"
    },
    "1f630d95-82b5-44fa-8f52-b19f1c9b75bb": {
        "text_answer": "Contradiction The primary trial recorded adverse events for infection asymmetry and deflation while the secondary trial recorded no adverse events at all The statement implies that the primary trial had lower incident rates than the secondary trial for these specific adverse events but the secondary trial had no recorded instances of these events",
        "label": "Contradiction"
    },
    "f102f343-80bc-4df9-87db-125fc783937c": {
        "text_answer": "Irrelevant The statement does not relate to the inclusion or exclusion criteria for the primary or secondary trials It describes a specific genetic mutation",
        "label": "Entailment"
    },
    "35fb0b2d-39d8-43f9-9e47-aceee416803b": {
        "text_answer": "Entailment with the given evidence less than 50 of 20 participants experienced acute vomiting which is a subset of the 35 participants in the primary trial",
        "label": "Entailment"
    },
    "5da3a98b-ffa7-4c54-a340-37986d6dcc20": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no information in the evidence about the number of cases of malignant sweat gland neoplasms in the primary trial",
        "label": "Contradiction"
    },
    "202f56bf-1317-4abc-803d-5ec37cd27624": {
        "text_answer": "Contradiction The primary trial involved 33 participants while the secondary trial involved 8 participants so they do not involve the same patient cohort",
        "label": "Contradiction"
    },
    "2ab5044b-9fa6-45ef-8c99-a2cd5e28f512": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the interventions have different administrations transendocardial injections of different solutions and different doses alloMSCs vs placebo",
        "label": "Contradiction"
    },
    "8f018706-e70d-4fa5-812c-9c8d57b97f46": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction as the performance status criteria are different between the two trials and smoking behavior is not mentioned in the given evidence for either trial",
        "label": "Entailment"
    },
    "d8da21ea-52ef-4b97-8344-6214bd3565b3": {
        "text_answer": "Contradiction  The primary trial involves a subcutaneous injection of Fluciclatide AH111585 18F Injection while the secondary trial involves oral administration of Chloroquine These are different interventions",
        "label": "Contradiction"
    },
    "073ce8e6-59a6-41e8-a45f-ca91d19dceec": {
        "text_answer": "Contradiction The primary trial has additional inclusion criteria related to hot flushes and menopausal status which are not present in the secondary trial Therefore patients in the secondary trial may not necessarily meet all the inclusion criteria for the primary trial",
        "label": "Contradiction"
    },
    "58ce2166-b909-4442-9118-11b9163fa9b1": {
        "text_answer": "Contradiction  The statement is not entailed by the evidence as the evidence only shows a significant change in Ki67 expression with tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery and no information is provided about the effect of tamoxifen 80 mg po daily for 21 days prior to surgery and for 10 days after breast cancer surgery on tumor diameter",
        "label": "Contradiction"
    },
    "61db27bd-2dc4-4c90-8d1e-058f61e1b59a": {
        "text_answer": "Contradiction The primary trial involves Denosumab and Zoledronic Acid not Tamoxifen or Evening Primrose Oil",
        "label": "Contradiction"
    },
    "e0a61eb2-f5c0-4885-94f5-4048944acd1c": {
        "text_answer": "Contradiction The statement implies that a control group exists in the primary trial for comparison but according to the evidence no such group is mentioned",
        "label": "Contradiction"
    },
    "e93765e3-d596-4009-8fc0-6d8433f19679": {
        "text_answer": "Contradiction  Explanation The statement all patients treated with gtx024 1mg in the primary clinical trial lost lean body mass over a 4 month period is a contradiction to the evidence because the results show that the median change in lean body mass for the group treated with 1mg of GTx024 ranged from a loss of 206 kg to a gain of 1264 kg",
        "label": "Contradiction"
    },
    "491a1da4-e9c1-43d9-ba9b-9e53d7f601f9": {
        "text_answer": "Contradiction The statement is not an entailment as the primary trial involves epacadostat being administered in combination with pembrolizumab while sunitinib is administered as a single agent in the secondary trial The comparison of administration frequencies should be made for the same drug not for different drugs",
        "label": "Contradiction"
    },
    "2312391b-799c-4dcc-9ba4-4b98c9c9642b": {
        "text_answer": "Contradiction Note The statement is contradictory to the evidence as Herceptin which contains trastuzumab is mentioned as an intervention in Arm 1 of the primary trial",
        "label": "Contradiction"
    },
    "650a33d5-ad44-40c8-a41c-1a4e7a5203b5": {
        "text_answer": "Contradiction The secondary trial does not measure muscle development as an outcome Instead it measures the percentage of participants with pain or no pain using the Numeric Pain Rating Scale",
        "label": "Contradiction"
    },
    "63acd7b4-dc08-415b-af25-c09e1db4e913": {
        "text_answer": "Contradiction The primary clinical trial uses an oral administration of cabergoline while the statement suggests a topical administration which is not the case",
        "label": "Contradiction"
    },
    "904b8443-c768-449d-81d7-e381dc0e0fb7": {
        "text_answer": "Entailment  Explanation The statement both the placebo and trabectedin in the primary clinical trial are given in similar ways is an entailment based on the evidence provided as both the placebo and trabectedin are administered intravenously as 3hour infusions even though they are given on different days",
        "label": "Entailment"
    },
    "f06f2517-d0fb-4494-a044-fd626c78187f": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence provided as the primary trial has no recorded adverse events and the secondary trial has recorded zero adverse events in the given data",
        "label": "Contradiction"
    },
    "2a05996c-d5fb-4aa8-9654-fb1d27180888": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence does not support the comparison of the two trials as they have different patient populations outcome measurements and time frames The primary trial measures the duration of neutropenia in breast cancer patients receiving doxorubicin and docetaxel chemotherapy while the secondary trial measures the incidence of neutropenia in patients receiving various doses of empegfilgrastim",
        "label": "Contradiction"
    },
    "d9a5cbf6-51ae-4c80-a222-534e7507c7f8": {
        "text_answer": "Contradiction  The evidence states that there were 3 cases of hepatotoxicity and 1 case each of hypertension and pancreatectomy Therefore the number of cases of hepatotoxicity 3 is greater than the number of cases of hypertension 1 and pancreatectomy 1",
        "label": "Contradiction"
    },
    "e60df76f-e6d9-4da1-8fe7-e23c8f38365f": {
        "text_answer": "Contradiction The evidence provided does not indicate that prior treatment with Herceptin within the last year is an exclusion criterion for the primary trial However the statement asserts that it is an exclusion criterion for the secondary trial",
        "label": "Contradiction"
    },
    "38ca4d41-1f13-4735-983d-9ac5b1b816f0": {
        "text_answer": "Contradiction The evidence does not provide any information about the maximum tolerated dose of MM111 in the secondary trial The statement is making a definitive statement about the maximum tolerated dose but the evidence does not support that claim",
        "label": "Contradiction"
    },
    "4ed1c5fd-58e5-4fe8-97b1-59ed509ccb10": {
        "text_answer": "Entailment  Explanation The statement there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial is an entailment based on the evidence because the evidence shows that there are indeed several different instances of cardiac related adverse events recorded for cohort 1 of the primary trial including acute coronary syndrome angina pectoris cardiac arrest cardiac failure and cardiac tam",
        "label": "Entailment"
    },
    "99925da5-1a89-471d-b3d9-a3e083fc1bda": {
        "text_answer": "Entailment The evidence shows that the number of adverse events was higher in one of the cohorts cohort 2 had 4000 adverse events compared to cohort 1s 5000 so the statement is an entailment",
        "label": "Entailment"
    },
    "10b61f57-c5c1-4d29-9838-bb14c4608bf4": {
        "text_answer": "Contradiction The Intervention 1 cohort receives a validated webbased risk assessment which is a form of counselling and decision support based on risk Therefore the statement is contradictory to the evidence",
        "label": "Contradiction"
    },
    "99d85210-19a0-4256-b092-c3a0f6ef322f": {
        "text_answer": "Contradiction  Explanation The evidence from the primary trial shows that the mean duration of neutropenia was shorter in the higher dose group 75 mg compared to the lower dose group 6 mg However the evidence from the secondary trial shows that the incidence of neutropenia was lower in the lower dose group 3 mg compared to the higher dose group 6 mg The statement in question suggests that the lower dose group in",
        "label": "Contradiction"
    },
    "0f5ce689-610f-4522-8082-23df226f2a42": {
        "text_answer": "Entailment The statement is an entailment because Arm 1 of Intervention 1 in the primary clinical trial includes Herceptin which is a form of trastuzumab and Arm 2 of Intervention 2 includes Herceptin as well",
        "label": "Entailment"
    },
    "d5e071e0-4705-474c-8820-9fbc7b377a8d": {
        "text_answer": "Contradiction The evidence states that both male and female participants are eligible for the secondary clinical trial",
        "label": "Contradiction"
    },
    "4192b30d-92ad-47c4-b88e-8f48ea048ee2": {
        "text_answer": "Contradiction  The evidence states that the final eligibility for the clinical trial is determined by the health professionals conducting the trial which contradicts the statement that the decision to include a patient is completely determined by the inclusion and exclusion criteria without any discretion from health professionals",
        "label": "Contradiction"
    },
    "8268f272-c82c-4cc3-87dd-8fdf59611a1c": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only mentions adverse events in the primary trial while the statement discusses thyroid gland follicular carcinoma",
        "label": "Contradiction"
    },
    "94849f18-76aa-4fdf-9f7b-2fb1c6b5bc9d": {
        "text_answer": "Contradiction  Explanation The primary and secondary trials have different interventions with the primary trial involving Abl Cells IV and Cyclophosphamide while the secondary trial involves DMCHOCPEN",
        "label": "Contradiction"
    },
    "1de04bd7-e1e7-42a6-a898-ae626a24b25b": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that the AZD0530 175 mg group had a greater percentage change in betaCTX at week four 711 vs 684 as stated in the statement",
        "label": "Entailment"
    },
    "40123001-b9eb-4d75-aa74-83865de37e70": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses adverse events from clinical trials and there is no mention of tricuspid valve regurgitant volume in the statement",
        "label": "Contradiction"
    },
    "6a119107-7a0d-421f-bfea-3671d97ed082": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence provided because the evidence does not indicate any information about the incidence of 3q21q24 chromosome abnormalities in the Bevacizumab and Bevacizumab  Capecitabine cohorts The evidence only reports the percentage of participants with disease progression or death in each cohort",
        "label": "Contradiction"
    },
    "f32516f0-768d-48db-a449-74ac774abbe0": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were 5 emesisfree participants in the placebo group and 13 emesisfree participants in the aprepitant group This means that the placebo group had a lower number of emesisfree participants than the aprepitant group contradicting the statement that patients receiving the placebo intervention had the same likelihood of experiencing emesis as patients receiving aprepitant",
        "label": "Contradiction"
    },
    "f178fb19-cc4a-4f58-b81a-aac7270f154b": {
        "text_answer": "Contradiction  Explanation  The primary trial involves massage therapy which is a nondrugbased treatment and notouch therapy which is also a nondrugbased treatment However the secondary trial focuses on testing different doses of the drug PF06647020 Therefore the statement that the secondary clinical trial involves testing several drugfree treatment solutions is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "a7999375-da80-4839-940a-bec673fb119f": {
        "text_answer": "Contradiction The primary trial includes all females with breast cancer while the secondary trial is specifically for BRCApositive breast cancer",
        "label": "Contradiction"
    },
    "a108f3f0-f18c-4bb3-87f1-5a1eee525f71": {
        "text_answer": "Contradiction The statement adverse events spanning a variety of types were evenly distributed among patients across multiple cohorts in the primary clinical trial is a contradiction to the evidence as the evidence shows that the total number of adverse events was the same in both cohorts but the specific types of adverse events were not evenly distributed",
        "label": "Contradiction"
    },
    "fd78876b-0b85-41e3-ad9f-8213dd9484ca": {
        "text_answer": "Contradiction  The evidence states that there were 24 participants with treatmentemergent adverse events and 11 participants with serious adverse events in the Sunitinib  Docetaxel  Trastuzumab arm of the primary trial Therefore the statement that treatmentemergent adverse events were experienced by 35 patients is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "f73ec9f6-b18c-4f32-9116-573f5f717e55": {
        "text_answer": "Contradiction The primary trial includes patients with a primary tumor greater than 2 cm diameter while the statement suggests a tumor smaller than 20mm which is not consistent with the primary trial inclusion criteria The secondary trial does not mention tumor size as an inclusion criterion",
        "label": "Contradiction"
    },
    "452f92e1-27bb-4452-8675-c6409ec6003a": {
        "text_answer": "Contradiction The primary trial explicitly states that women under the age of 20 are excluded",
        "label": "Contradiction"
    },
    "e0a117a2-c519-46f5-9c31-124234272ce1": {
        "text_answer": "Contradiction  Explanation The statement in the primary clinical trial all adverse event types impacted less than 10 of the patients is a contradiction to the evidence provided as the evidence shows that several adverse event types impacted more than 9 of the patients For example febrile neutropenia sinus tachycardia sepsis lymphocyte count decreased",
        "label": "Contradiction"
    },
    "9bd6ad87-470a-4fa3-9e29-bf5ba8c2b463": {
        "text_answer": "Contradiction  The statement implies that there were 3 times as many hepatotoxicity cases as hypertension and pancreatectomy cases combined However the evidence shows that there were 3 times as many hepatotoxicity cases as there were pancreatectomy cases alone Therefore the statement is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "2529171f-85e8-4d19-8023-dc1a28416fa1": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence provided indicates that there are no shared inclusion criteria between the two trials The primary trial has several inclusion criteria related to cancer diagnosis stage sensitivity to vinorelbine and life expectancy while the secondary trial only includes patients undergoing large core breast biopsy in the Radiology Department at the Beth Israel Deaconess Medical Center Boston There is no overlap in the inclusion criteria",
        "label": "Contradiction"
    },
    "254e8b1c-de9f-467b-b32a-a41ee97421b9": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence only excludes these conditions within the last 6 months",
        "label": "Contradiction"
    },
    "5db52328-ebdc-4961-bc21-7776db7d7876": {
        "text_answer": "Contradiction  The statement is incorrect because the primary trial does not involve the administration of Zoledronic Acid and Denosumab in the same intervention and the statement compares their concentrations in the initial interventions of the primary and secondary trials which are not comparable as they are different interventions",
        "label": "Contradiction"
    },
    "5f6cacb7-41e6-4d8c-9a43-7bd21202b11f": {
        "text_answer": "neutral neither entailment nor contradiction  Explanation  The statement intraoperative urinary injury CTCAE is a finding of damage to the urinary system during a surgical procedure is not directly related to the inclusion or exclusion criteria for the primary or secondary trials The statement does not entail or contradict any information provided in the evidence  The evidence focuses on the eligibility criteria for the primary and secondary trials",
        "label": "Entailment"
    },
    "6b0bc5aa-4540-4439-a2e3-c48abb937074": {
        "text_answer": "Contradiction  Explanation The statement all measured patients within the primary clinical trials group 1 were identified as having several lesions along with an overwhelming majority from the secondary trials group 1 showing healthy skin attributes is a contradiction based on the evidence provided  In the primary trial there were no lesions detected in the group of healthy volunteers In contrast in the secondary trial there were 12 lesions",
        "label": "Contradiction"
    },
    "d61c1b26-cf05-46e8-a156-a264f562dfa8": {
        "text_answer": "Contradiction The statement implies that patients with unstable angina or Grade 2 or above neuropathy cannot participate in the secondary trial but can participate in the primary trial unless they have nonhealing surgical wounds However the evidence provided for the secondary trial does not allow patients with unstable angina or Grade 2 or above neuropathy to participate at all Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "a127c618-ace8-46cf-9b52-7655f2ccee9c": {
        "text_answer": "Contradiction The primary trial explicitly states that children and adolescents are not accepted due to not meeting the height requirement while the secondary trial does not mention any age restrictions",
        "label": "Contradiction"
    },
    "01bff32b-6bba-4295-94e9-c3a8430670be": {
        "text_answer": "Entailment The evidence states that Intervention 1 uses pIHGC and Intervention 2 uses GP but both interventions involve the injection of radioactive Tc99M sulfur colloid for lymphoscintigraphy The statement correctly reflects this information",
        "label": "Entailment"
    },
    "24be42f5-01dc-487e-9ada-39d05b6d4e7e": {
        "text_answer": "Contradiction The primary trial does use a 21day cycle for its intervention but the secondary trial does not have a cyclic treatment specified in the evidence provided",
        "label": "Contradiction"
    },
    "d91ee458-d6de-4d45-8511-cabb52d2a64e": {
        "text_answer": "Contradiction The primary trial has specific genderbased inclusion criteria postmenopausal females or males with a female partner who is not of childbearing potential or using effective contraception The secondary trial specifically includes women with estrogenreceptor positive breast cancer",
        "label": "Contradiction"
    },
    "37a51d40-4b39-4488-b818-7495917d50a0": {
        "text_answer": "Entailment The evidence states that there were two participants in the second cohort who experienced doselimiting toxicity",
        "label": "Entailment"
    },
    "ffce31e9-2899-42af-8af0-e24be1ace812": {
        "text_answer": "Contradiction  Explanation The primary trial excludes women with osteoporosis while the secondary trial does not mention osteoporosis as a criterion for inclusion or exclusion However the statement specifically mentions women suffering from only osteoporosis which is not covered by the evidence provided for either trial Therefore the statement is a contradiction based on the given evidence",
        "label": "Contradiction"
    },
    "ffd7717b-fec1-4702-87a6-5345e8efe7ba": {
        "text_answer": "Contradiction The primary trial does not list cerebral metastases as an exclusion criterion but the secondary trial does exclude patients with more than one cerebral metastasis Therefore the statement that a diagnosis of 23 cerebral metastases would exclude a patient from the secondary clinical trial but not the primary clinical trial is a contradiction",
        "label": "Contradiction"
    },
    "a50ad70a-ff4c-4110-bfff-3fc230c44acc": {
        "text_answer": "Contradiction The evidence states that patients must have a life expectancy of greater than 3 months to participate in the trial",
        "label": "Contradiction"
    },
    "4b6aac05-1130-49c4-b5f6-9afe1227459c": {
        "text_answer": "Contradiction The primary clinical trial includes the criterion of gender as a factor for eligibility postmenopausal females only while the secondary clinical trial does not mention gender as a criterion",
        "label": "Contradiction"
    },
    "b9d16baf-ec50-40da-b2a4-68aa7abf1541": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions various cases of atrial fibrillation in cohort 2 but there were no reported cases of atrial fibration in the provided evidence",
        "label": "Contradiction"
    },
    "8101ccf6-e6f4-43ba-b22f-9a13e2ddd279": {
        "text_answer": "Entailment The evidence shows that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher ORR 0587 vs 0489 and more participants were analyzed in that group 92 vs 94 Therefore the statement that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR and more participants is an entailment based on the",
        "label": "Entailment"
    },
    "6e5ea627-075c-4b44-9605-4d440735d843": {
        "text_answer": "Contradiction The primary trials inclusion criteria do not mention anything about a previous cycle of progestogen therapy six months before the study",
        "label": "Contradiction"
    },
    "5c11d673-054f-4db7-a2d4-8c6243b3ba45": {
        "text_answer": "Contradiction The statement is contradictory to the evidence provided as the primary trial has no specific nationality requirement for female patients while the secondary trial does not mention any nationality requirement at all",
        "label": "Contradiction"
    },
    "bca4c94d-4a49-4e05-82ed-0d5c9707685b": {
        "text_answer": "Contradiction  Explanation In the primary trial the intervention in Intervention 1 consists of a single drug Gefitinib ZD1839 However in the secondary trial Intervention 1 consists of Zoledronic acid vitamin D and calcium supplements which is more than one drug Therefore the statement is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "42fc9190-b214-42bf-92fc-3678564083ca": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that ascites were more common in the primary trial 2223 or 090 and pneumocystis jirovecii pneumonia was more frequent in the secondary trial 19 or 1111",
        "label": "Contradiction"
    },
    "827af363-cfd3-4233-9029-e8c7e053c661": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events observed in the primary trial for both Adverse Events 1 and Adverse Events 2 while the secondary trial had no reported data for Adverse Events 2 However the statement suggests that there were more adverse events observed in the secondary trial which is not supported by the evidence",
        "label": "Contradiction"
    },
    "6515b0ad-cba7-4831-9b96-576faaa284f4": {
        "text_answer": "Contradiction  Explanation The primary trial involves the use of Zoledronic Acid 4 mg Q4W every 4 weeks or Denosumab 120 mg Q4W in the openlabel extension study The secondary trial involves the use of Tamoxifen 10 mg once daily for 3 months or Evening Primrose Oil 1000 mg once daily for 3 months The statement",
        "label": "Contradiction"
    },
    "f886baee-f1c6-4887-8068-5c779c6ebb60": {
        "text_answer": "Contradiction  Explanation In the primary trial Intervention 2 involves the administration of dexmedetomidine while in the secondary trial no dexmedetomidine is given to the patients Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "c51a2098-014f-410c-9722-eaadb298983d": {
        "text_answer": "Entailment assuming Pancytopenia refers to a condition characterized by a deficiency in all three types of blood cells red blood cells white blood cells and platelets which is not mentioned in the evidence The evidence states that there were no instances of intestinal obstructions or pancytopenia observed in both trials and the statement asserts that there were no intestinal obstructions or pancytopenia observed in the patient co",
        "label": "Entailment"
    },
    "0bca53f6-c609-4c49-a684-a2d71cff7086": {
        "text_answer": "Contradiction The evidence states that in the primary clinical trial the placebo is administered orally PO twice daily and memantine is administered orally PO in Arm I while in Arm II participants receive a placebo orally PO and no information about memantine administration is provided The statement suggests that the placebo is administered via intramuscular injection and memantine is administered topically which is not consistent with the evidence",
        "label": "Contradiction"
    },
    "197bf729-04f4-46f0-a746-8b55c088f0d6": {
        "text_answer": "Entailment The evidence states that there was a significant change in Ki67 expression in tumors with 7 days of presurgical tamoxifen and the statement accurately reflects that finding by stating that tamoxifen reduces Ki67 expression in tumors by 40 on average during that time frame",
        "label": "Entailment"
    },
    "a7f12911-d5b9-4cd0-a3c0-e1fb6ded7512": {
        "text_answer": "Contradiction  Explanation The statement suggests that there were more incidents of palpitations pericardial effusions and abdominal pains in the second cohort of the secondary clinical trial compared to the first cohort of the primary clinical trial However the evidence provided shows that there were no adverse events recorded in the secondary trial at all Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "249d272c-cbee-4395-bb73-7e6cde3a4677": {
        "text_answer": "  The statement is an Entailment based on the evidence provided as the given patient characteristics fall within the inclusion criteria for both trials",
        "label": "Entailment"
    },
    "f43b3f3f-f51c-49ff-b659-b3e97bf0ab0d": {
        "text_answer": "Contradiction The primary trial does not list hypopharyngeal squamous cell carcinoma as an exclusion criterion but the statement suggests that patients with this diagnosis are not permitted to participate in either trial The secondary trial also does not list this diagnosis as an exclusion criterion",
        "label": "Contradiction"
    },
    "cd247253-c2d6-4eb6-be06-90ef855748cf": {
        "text_answer": "Contradiction The primary trial requires an updated ECG while the secondary trial does not mention an ECG as a requirement The secondary trial mentions a recent colonoscopy report and a CBC as requirements instead",
        "label": "Contradiction"
    },
    "ae259f29-2da6-43fe-b89e-345be44688e8": {
        "text_answer": "Contradiction  The evidence states that both cohorts received Cetuximab with the same dosage in the primary trial",
        "label": "Contradiction"
    },
    "d1216971-8b18-427a-9f6e-de0fcddec7ea": {
        "text_answer": "Contradiction The primary trial has no gender restriction but the statement implies that only males are eligible",
        "label": "Contradiction"
    },
    "c99a0652-8f34-49d1-b98b-182553c58dbc": {
        "text_answer": "Contradiction  The primary trial involves alpha lipoic acid which has a baseline dose of 100 mg three times daily for four months with dose escalation to find the maximum tolerated dose This is in contrast to the secondary trial where cohort 1 patients receive necitumumab which is given at an absolute dose of 800 mg on Day 3 of the 3week PK runin period and on Days",
        "label": "Contradiction"
    },
    "2d320e21-8fce-4f6f-8bf3-dc68f1cb8b0e": {
        "text_answer": "Contradiction  Explanation The statement mentions that cohort 1 is PR negative ER negative and HER while cohort 2 receives HER2 treatment However the evidence provided does not mention anything about the ureter disorders in the cohorts or their status as neoplastic or nonneoplastic Therefore the statement is not directly related to the evidence and is a contradiction",
        "label": "Contradiction"
    },
    "d4045883-595f-4855-83ed-ca175a1d5aea": {
        "text_answer": "Contradiction  Explanation The statement compared to the primary clinical trial the secondary clinical trial experienced an excess of 11 occurrences of intestinal perforation is a contradiction to the evidence provided because the evidence from the primary trial shows no occurrences of intestinal perforation at all",
        "label": "Contradiction"
    },
    "29a26ffe-8fcd-4e93-b354-3ca65738c8e5": {
        "text_answer": "Entailment  Explanation  The statement the primary clinical trial and the secondary clinical trial reported zero deaths among their adverse events is an entailment based on the evidence provided Both trials reported zero deaths in their adverse events sections which means that the statement is a logical consequence of the evidence",
        "label": "Entailment"
    },
    "8a532b5a-1468-4de5-83ac-50179edb2ac8": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence reports that 5 out of 25 patients 2000 experienced adverse events",
        "label": "Contradiction"
    },
    "a4e6bb5b-69f1-451b-b278-0ce9c3e43bdf": {
        "text_answer": "Contradiction The evidence reports that 24 participants experienced treatmentemergent adverse events not 35 as stated in the question",
        "label": "Contradiction"
    },
    "a3191a50-4395-4bd8-a57a-5404fcfcd8c9": {
        "text_answer": "Entailment assuming ER negative breast cancer refers to Females with histologically confirmed advanced breast cancer TN breast cancer by local laboratory determination Hormonal Receptor HR negative defined as  1 positive cells by Immunohistochemistry IHC for both Estrogen Receptor ER and Progesterone Receptor PgR",
        "label": "Entailment"
    },
    "5de4ae02-a1df-430d-a793-803bfefb7b0e": {
        "text_answer": "Entailment Both trials focus on safety outcomes in their respective populations and use the same definitions for adverse events and serious adverse events The secondary trial focuses on objective response as an additional outcome measurement",
        "label": "Entailment"
    },
    "da18ab3b-cf80-4867-b3b9-0dccf4c523a2": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it relates to an average survival of over 104 weeks while the results only report the median survival for each group The statement also does not mention the primary trial or the cohorts in question",
        "label": "Contradiction"
    },
    "ae8cf6fd-ab5f-4f34-a135-ea8d0c0c58bc": {
        "text_answer": "Contradiction The evidence states that participants received niraparib 200 mg daily not talazoparib 1 mg",
        "label": "Contradiction"
    },
    "403ad287-6e25-4db0-a66b-fe4a7f15a983": {
        "text_answer": "Entailment assuming the patient meets all other inclusion criteria for both trials",
        "label": "Entailment"
    },
    "0069c252-1e8b-4209-af61-11e6ee9d3c2b": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the evidence shows that tamoxifen 20 mg po daily for 7 days prior to surgery resulted in a significant decrease in Ki67 expression which is a marker of tumor proliferation The statement suggests that tamoxifen had no impact on tumor diameter but the evidence does not provide information on tumor diameter",
        "label": "Contradiction"
    },
    "1cc18d8f-93f5-474e-9178-833b26150681": {
        "text_answer": "Contradiction  The statement is about fentanyl sublingual spray dosage during radiation therapy while the evidence is about the doses of vorinostat and radiation therapy There is no information provided in the evidence about the use or dosage of fentanyl sublingual spray during the primary trial",
        "label": "Contradiction"
    },
    "4e5fb5c5-d286-4109-a89b-28f399788cae": {
        "text_answer": "Contradiction The primary trial has an age limit of 20 years and above while the secondary trial includes women and men aged 18 or older However the statement does not mention anything about the primary trials age requirement making it a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "b95b7438-ec16-4d4d-826d-5891e7982b36": {
        "text_answer": "Entailment  Explanation The statement There are no cases of anorexia hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial is an entailment based on the evidence provided because the evidence does not report any cases of anorexia hypothermia or hallucinations in either trial",
        "label": "Entailment"
    },
    "66816aea-0de7-486c-b9d4-4ca6d9f09d52": {
        "text_answer": "Contradiction The secondary trial does not use a single set of criteria for all study participants but rather has no specific inclusion criteria mentioned in the provided evidence The primary trial on the other hand does categorize participants into different groups with unique inclusionexclusion criteria",
        "label": "Contradiction"
    },
    "587e611a-9c3b-4557-b3ca-56a7dcc6ce1b": {
        "text_answer": "Contradiction  Explanation  In the primary trial there are two intervention arms Arm 1 CBTI  Placebo and Arm 2 CBTI  Armodafinil In Arm 2 patients receive Armodafinil daily for 47 days  In the secondary trial there are also two intervention arms Intervention 1 MCS110 1 mgkg Q",
        "label": "Contradiction"
    },
    "8dd822a1-6d7b-4dca-b3fb-4841442aff93": {
        "text_answer": "Contradiction  The evidence states that 9 out of 21 participants had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products Therefore more than 01 of the participants had a reduction in CTCs which contradicts the statement",
        "label": "Contradiction"
    },
    "79923aba-be0b-476d-ae86-733fce590db1": {
        "text_answer": "Contradiction The statement about swelling in affected underarm arm or hand and the statement about AfricanAmerican patients residing in Texas for the duration of the study are unrelated",
        "label": "Contradiction"
    },
    "b2059651-24e7-4b6c-aeee-403ff32cf725": {
        "text_answer": "Contradiction  The statement is about adult diffuse mixed cell lymphoma which is not related to the eligibility criteria for the primary or secondary trials which are for women with breast cancer",
        "label": "Contradiction"
    },
    "66dff58d-73c8-46c8-afa7-9fe6e1231624": {
        "text_answer": "Entailment assuming that the several other types of AEs mentioned in the statement do not include cardiac or psychiatric AEs",
        "label": "Entailment"
    },
    "4bd8fa53-08b5-4b80-868a-4b535432f2e2": {
        "text_answer": "Contradiction The statement is not an entailment as patients with stage 4 cancer are not eligible for the secondary trial but the statement does not mention anything about the primary trial",
        "label": "Contradiction"
    },
    "d10a9ae2-cb0c-49e8-924c-906e3f2eb5a5": {
        "text_answer": "Contradiction  Explanation The primary clinical trial includes the following eligibility criteria for women   Women of childbearing potential WOCBP unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab  Women who were pregnant or breastfeeding  Sexually active fertile men whose partners were",
        "label": "Contradiction"
    },
    "db7671cb-a230-402e-beda-738af0753332": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the inclusion criteria specify a life expectancy of greater than 3 months",
        "label": "Contradiction"
    },
    "0fa2ee42-3800-49bc-838c-eb3dba41f01f": {
        "text_answer": "Contradiction  The primary clinical trial explicitly excludes patients with ductal carcinoma in situ while the secondary clinical trial includes them",
        "label": "Contradiction"
    },
    "24b7127a-5d4d-4a7d-b64b-8b2e12396b04": {
        "text_answer": "Contradiction The evidence provided states that the primary trial includes patients with adenocarcinoma of the breast while the secondary trial includes patients with locally advanced or metastatic breast cancer Colon cancer is not mentioned in either trial and the statement suggests that patients with colon cancer are allowed in both trials with small tumors and no specific marker status Therefore the statement contradicts the evidence",
        "label": "Contradiction"
    },
    "b395d278-bbad-4ba2-af5b-82dc8045482a": {
        "text_answer": "Entailment The secondary trial specifically includes patients with a diagnosed alteration in one or more of the listed genes",
        "label": "Entailment"
    },
    "9474451f-d601-4dcc-8304-50bc4d3ebf52": {
        "text_answer": "Contradiction  Explanation  The primary trials exclusion criteria do not mention gabapentin or pregabalin as disqualifying factors However the secondary trials prior concurrent therapy exclusion criteria state that no prior gabapentin or pregabalin is allowed Therefore the statement that previous use of gabapentin or pregabalin will disqualify a patient from participation in the secondary clinical trial but not in the primary clinical",
        "label": "Contradiction"
    },
    "ead18343-9437-4aa4-9bbc-2e20f7c28025": {
        "text_answer": "Contradiction The primary trial does not report the overall survival in months for all 300 patients included in the study but rather the median time to progression after 1 year from the treatment start day The secondary trial reports the percentage of nonresponding patients based on confirmed objective response according to RECIST criteria",
        "label": "Contradiction"
    },
    "951c2074-2100-4b9f-84e1-adec6a08c61b": {
        "text_answer": "Contradiction  Explanation The statement is contradictory to the evidence because the patients in the primary trial received trastuzumab continuously throughout the study while the patients in the secondary trial received Herceptin only during certain cycles The dosages of Herceptin in the secondary trial do not mirror the trastuzumab dosages in the primary trial throughout the trials",
        "label": "Contradiction"
    },
    "a2fa7138-cba9-4720-91a0-eb12a7356fa2": {
        "text_answer": "Contradiction  Explanation  The primary trial involves radiation therapy which is not related to oral administration of antiretroviral drugs or muscle relaxants alongside physical therapy sessions  The secondary trial involves the use of Enzastaurin which is not an antiretroviral drug and there is no mention of oral administration of antiretroviral drugs or muscle relaxants alongside physical therapy sessions",
        "label": "Contradiction"
    },
    "04067434-b300-40f1-9e6c-c986b4c602c5": {
        "text_answer": "Contradiction The statement is about cohort 2 not cohort 1",
        "label": "Contradiction"
    },
    "46cd405e-a401-4249-ad26-b48801b2c2c8": {
        "text_answer": "Contradiction The primary and secondary trials have different outcome measurements The primary trial measures the change in FSH levels while the secondary trial measures the maximum tolerated dose of Ruxolitinib in combination with paclitaxel",
        "label": "Contradiction"
    },
    "c3503b5e-ef92-4e90-bc0f-5ef7690a5908": {
        "text_answer": "Entailment The evidence shows that there were no reported cases of asthenia or pyrexia in both trials which entails that the statement is true based on the given evidence",
        "label": "Entailment"
    },
    "bcbeb637-d070-400b-a98e-e3380f009b21": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there were no instances of infection asymmetry or deflation reported in the secondary trial while the primary trial reported instances of each",
        "label": "Contradiction"
    },
    "62ecbc1b-eb8f-43ad-b997-a11c8d36b379": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence as the evidence shows that 13 of the participants with HER2 primary breast cancer treated with HER2targeted PETCT developed imagable HER2 metastases",
        "label": "Contradiction"
    },
    "00e018a5-5237-498b-8823-f47ac2d2697f": {
        "text_answer": "Contradiction The evidence provided does not mention IBS Irritable Bowel Syndrome in relation to the trials",
        "label": "Contradiction"
    },
    "c5f56599-f5cb-46c4-ac69-e298d37f0883": {
        "text_answer": "Contradiction The primary trial includes breast cancer patients with a primary tumor greater than 2 cm in diameter while the statement mentions a secondary tumor of 35mm in size which is larger than the minimum size for the primary trial However the secondary trial does not provide any information about the size of the primary tumor so its unclear if the patient would qualify for that trial based on the given information",
        "label": "Contradiction"
    },
    "fdc25a44-5f1f-4478-b1f4-78fbb95b112a": {
        "text_answer": "Contradiction The statement includes conditions abdominal fistula gastrointestinal perforation stroke transient ischemic attacks intrabdominal abscess that are in the exclusion criteria of the trial but the statement also includes postmenopausal adenocarcinoma which is an inclusion criterion Therefore the statement contradicts the evidence",
        "label": "Contradiction"
    },
    "8127d46a-3a48-4173-8d00-75e949755a74": {
        "text_answer": "Contradiction  Explanation  The primary trial includes HER2positive females with a history of previous nonmetastatic operable primary invasive HER2positive breast cancer and a baseline LVEF 55 The statement that Prior treatment with gabapentin or herceptin within the last year will result in exclusion from the secondary trial but not from the primary trial is a contradiction to the",
        "label": "Contradiction"
    },
    "40a16e0a-a4d4-49d0-8423-aa5b43688171": {
        "text_answer": "Contradiction The evidence does not support the statement as there is no mention of hypertension dehydration or dyspnea in the provided adverse events for either cohort",
        "label": "Contradiction"
    },
    "1f10dd13-d27c-4ff0-bcac-67f0da0ac487": {
        "text_answer": "Contradiction  Explanation  The primary trial has different inclusion criteria for its Phase I and Phase II portions while the secondary trial does not distinguish between healthy and cancer patients in its inclusion criteria This is a contradiction to the statement which suggests that both trials use the same inclusion criteria for each phase",
        "label": "Contradiction"
    },
    "0c72a56a-de46-498d-8706-04c1283bea04": {
        "text_answer": "Contradiction The evidence states that Cohort A receives multiple injections of V934 LD via electroporation not a single infusion",
        "label": "Contradiction"
    },
    "853967c7-51a1-4e08-88c0-d8e621129176": {
        "text_answer": "Contradiction The statement that there is a negligible variance in outcomes among the two subgroups of the primary clinical trial contradicts the evidence that the secondary clinical trial showed significantly better results in one arm",
        "label": "Contradiction"
    },
    "9a324039-2611-4433-821d-588c822c831f": {
        "text_answer": "Entailment The primary trial exclusion criteria include congestive heart failure clinically significant cardiac arrhythmia history or current evidence of a myocardial infarction during the last 6 months and unstable angina as examples of cardiovascular impairment The secondary trial exclusion criteria include uncontrolled cardiovascular disease Therefore if someone has a serious or undisciplined heartrelated disease they would be excluded from both trials",
        "label": "Entailment"
    },
    "849dbfea-186a-4983-b7a3-616679e3f2ec": {
        "text_answer": "Contradiction The primary trial measures changes in pain intensity at specific time points after dosing while the secondary trial measures the change in bone mineral density over a period of time These are different outcome measurements",
        "label": "Contradiction"
    },
    "da01cb99-7533-4cb5-ae01-16453c94cc7e": {
        "text_answer": "Contradiction  Explanation The statement is about the change in tumor diameter while the evidence is about the change in Ki67 expression which is a biomarker for cell proliferation The two are not directly related and the statement does not follow from the evidence",
        "label": "Contradiction"
    },
    "25f976a2-8a79-469f-90a3-6b9922382c76": {
        "text_answer": "Contradiction The primary trial determines the MTD for Ruxolitinib in combination with paclitaxel while the secondary trial determines the MTD or Maximum Feasible Dose for MM111 which is not mentioned in the primary trial The statement provides a specific value for the MTD of MM111 in the secondary trial but there is no evidence in the given data to support that value",
        "label": "Contradiction"
    },
    "cbc96b9d-b39c-4fbe-b8a7-e7df7490881b": {
        "text_answer": "Contradiction  Explanation The statement assumes that all participants in the trial had PR primary breast cancer but the evidence only provides information about the percentage of participants with HER2 primary breast cancer who developed HER2 metastases The two groups are not the same",
        "label": "Contradiction"
    },
    "d7f83dbb-ef9c-455b-a692-e99eefcddb05": {
        "text_answer": "Contradiction The evidence states that there were 2 cases of general symptoms recorded in the primary clinical trial",
        "label": "Contradiction"
    },
    "09819b6e-961a-47cf-9112-c43434e9ac19": {
        "text_answer": "Contradiction The statement is not related to the provided evidence The evidence only discusses the outcome measurements and results of the primary and secondary trials but it does not mention anything about a birc5 antibody being used in the trials",
        "label": "Contradiction"
    },
    "0ad73758-1efb-46e4-85e7-57dbfb5eb96d": {
        "text_answer": "Entailment assuming the patient does not have any other exclusionary conditions for both trials",
        "label": "Entailment"
    },
    "0eba9989-3611-49a8-958f-ea696ba94b3e": {
        "text_answer": "Contradiction The statement mentions a patient who lived 35 months without disease progression or mortality but the evidence only provides the median PFS for each group not individual patient data",
        "label": "Contradiction"
    },
    "85645da7-cf87-4b4d-a5eb-cab03a857cc4": {
        "text_answer": "Contradiction The statement is not related to the provided evidence The evidence discusses outcome measurements and participant data from two separate clinical trials one for breast and ovarian cancer secondary trial and one for TNBC HRHER2 mBC and metastatic urothelial cancer primary trial The statement is about the hyoepiglottic ligament which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "b56bc509-6ed3-4125-9587-407192b9b597": {
        "text_answer": "Contradiction The evidence does not mention anything about dysuria in the primary trial",
        "label": "Contradiction"
    },
    "f319d5bf-32fd-4505-aff1-02caa718676a": {
        "text_answer": "Entailment The evidence states that adverse events were not recorded for both trials and the statement also mentions that sequencing data files do not contain information on adverse events",
        "label": "Entailment"
    },
    "30988df5-0397-4199-ba63-0b95f1c0f4f5": {
        "text_answer": "Contradiction The evidence states that no adverse events were reported in both cohorts of the primary clinical trial",
        "label": "Contradiction"
    },
    "21e44cc9-f3ce-47b3-ace5-69718677308e": {
        "text_answer": "Entailment The statement is an entailment because the evidence provided in the primary and secondary trials both mention intravenous injections and MRIs but the drugs dosages and frequency of administration are different as stated in the question",
        "label": "Entailment"
    },
    "ab9018bd-df48-4ece-81d0-d85fee09a2f5": {
        "text_answer": "Contradiction The evidence does not support the statement as it does not mention the specific adverse events related to fatigue nausea and skin rashes in the given trials",
        "label": "Contradiction"
    },
    "25428be5-61e7-46d0-b713-8e831229abeb": {
        "text_answer": "Contradiction The evidence states that both trials have the same performance status requirement functional ECOG  2",
        "label": "Contradiction"
    },
    "a7d9d7dd-1f13-4a0e-883c-b322ed8780dd": {
        "text_answer": "Contradiction The primary clinical trial accepts patients with normal potassium levels 3553 mEqL and does not exclude those with high potassium levels However the statement suggests that the primary trial does not accept patients with low potassium levels but those with high potassium levels could be eligible for both the primary and secondary clinical trial which is incorrect",
        "label": "Contradiction"
    },
    "6046015d-1954-4914-aa65-98ca575e4936": {
        "text_answer": "Contradiction  Explanation  In the primary trial there are two arms Arm 1 CBTI  Placebo and Arm 2 CBTI  Armodafinil In Arm 2 patients receive Armodafinil for 47 days with a varying dosage schedule  In contrast the secondary trial has two interventions both in Phase Ib but they both receive different dos",
        "label": "Contradiction"
    },
    "e876c279-ae1c-4e26-a25b-4da7222957bf": {
        "text_answer": "Contradiction The primary and secondary trials both have performance status eligibility criteria Zubrod performance score 2 or better for the secondary trial and no unstable selfreported medical or psychiatric illness for the primary trial",
        "label": "Contradiction"
    },
    "593797dd-ff0f-46e5-ab50-0ea8d49fc4ad": {
        "text_answer": "Entailment The evidence indicates that there are two different cohorts in the primary clinical trial one for adult cancer patients 65 years of age and older and another for healthy volunteers both investigating vaccine responses against Pneumococcus and Influenza in adults 65 years of age and older The statement is an entailment as it correctly reflects the variation in the intervention based on the individuals health status and cancer presence as indicated in the evidence",
        "label": "Entailment"
    },
    "5d9fff0a-de7b-45a9-843f-7d083ef11b11": {
        "text_answer": "Contradiction The evidence states that 833 of participants in the Ketorolac 30 mg group achieved Recurrencefree Survival which is higher than the 897 reported in the NaCl 09 3mL group",
        "label": "Contradiction"
    },
    "e2551c0f-9b6a-4d0c-9f11-b5e301d7ff3c": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of eating disorders or schizophrenia in the provided adverse events",
        "label": "Contradiction"
    },
    "abf0f2b7-e989-49e0-82a7-7a2c594e1185": {
        "text_answer": "Contradiction  Explanation  The statement patients with stage 1 cancer are not eligible for the secondary trial but are ineligible for the primary trial is a contradiction based on the provided evidence According to the evidence patients with stage I breast cancer are eligible for the primary trial but they are not explicitly mentioned as being eligible or ineligible for the secondary trial However the secondary trial includes patients with a histologically verified diagnosis",
        "label": "Contradiction"
    },
    "658a645c-05f8-456d-be67-c5b7b6d427da": {
        "text_answer": "Entailment The statement Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial is an entailment of the evidence provided as both trials explicitly exclude patients with severe insomnia",
        "label": "Entailment"
    },
    "b8c7a9f1-a31e-4be6-a0ff-9452728c2e0c": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 60 days while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "f312eb67-0141-4a7b-a9a4-476a92c32484": {
        "text_answer": "Contradiction  Lenalidomide is given at a dose of 5mg orally daily for 573 days in the primary trial while lapatinib is given at a dose of 1500mg orally daily for 6 weeks in the secondary trial These doses are not equivalent",
        "label": "Contradiction"
    },
    "2ecb5932-45c6-491c-9b9f-01ab02877f78": {
        "text_answer": "Entailment assuming psychiatric event refers to conditions listed in the evidence such as Menieres disease and vertigo",
        "label": "Entailment"
    },
    "12954a74-e631-4318-ac00-0d09fd49e34a": {
        "text_answer": "Contradiction The evidence states that women of childbearing potential WOCBP must use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab Men who have undergone vasectomy are not WOCBP but the statement suggests that they do not need to use any birth control method",
        "label": "Contradiction"
    },
    "4bcd8725-f138-49c8-b6a9-4f0c6eaa756f": {
        "text_answer": "Contradiction The evidence does not support the statement as coronary artery stenosis is not mentioned as an adverse event in the provided data",
        "label": "Contradiction"
    },
    "2af8d00f-e0b6-4555-b649-796186334803": {
        "text_answer": "Entailment The statement is true for the intervention cohort and it does not contradict the information provided about the control cohort",
        "label": "Entailment"
    },
    "a6ee28c9-2b3a-47a6-b576-8ca75d38fb67": {
        "text_answer": "Contradiction  The statement implies that there were 375 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy combined since 100 is 375  275 However the evidence shows that there was only one case of pancreatectomy so the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "ad9fe1aa-9798-4c53-ab23-23ac2924918c": {
        "text_answer": "Contradiction  The evidence states that patients in the primary trial receive oral lapatinib once daily not twice daily and the dosage is given as lapatinib ditosylate not 2000 mgm2",
        "label": "Contradiction"
    },
    "fb67edbe-9758-4e64-acd0-263fe51ba74a": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 patients receive 1 mgkg of MCS110 every 3 weeks which is less than 3 mgkg every 2 weeks required for 90 mg every 2 weeks Similarly patients receive 100 mg of PDR001 every 3 weeks which is not over 180 mg every other week required for",
        "label": "Contradiction"
    },
    "1b4c8f0a-2d3e-40d3-b26a-426a4f32cb86": {
        "text_answer": "Contradiction The evidence states that Women of childbearing potential WOCBP and sexually active fertile men are eligible for the trial but they must use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab The statement however only mentions abstinence as a requirement for WOCBP and sexually active fertile men It does not mention the",
        "label": "Contradiction"
    },
    "b23563cf-e6c4-4279-92b7-39d5e4de96d2": {
        "text_answer": "Contradiction  Explanation In the primary trial both the intervention groups receive tablets Botulinum Toxin Type A or Placebo but they are not entericcoated tablets In the secondary trial the intervention groups receive entericcoated tablets MLN8237 which contradicts the statement that none of the cohorts receive entericcoated tablets",
        "label": "Contradiction"
    },
    "b6d2381f-f049-4747-ae82-5a9a321ec001": {
        "text_answer": "Contradiction The evidence states that patients with a BMI of 25 kgm2 or greater and weight 400 lbs are eligible for the trial",
        "label": "Contradiction"
    },
    "2855e123-6fa3-44b7-9eda-09603be206aa": {
        "text_answer": "Contradiction The statement implies that 50 of all participants developed imagable HER2 metastases while the evidence shows that 13 of the participants in one arm of the trial developed such metastases",
        "label": "Contradiction"
    },
    "e00ad4a5-25b8-4343-a353-be8b2e0d6c1b": {
        "text_answer": "Contradiction The psychiatric condition is an exclusion criterion for the primary trial but not mentioned in the secondary trials inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "62a0ed6c-dc2a-4223-9ee0-5b7422bf43da": {
        "text_answer": "Contradiction The primary trial results do not directly imply that Intraoperative Mammography performed better than Standard Mammography based on operative time alone",
        "label": "Contradiction"
    },
    "d3fe482c-e694-474a-8ba6-f089ea532040": {
        "text_answer": "Contradiction The primary trial recorded no adverse events while the secondary trial recorded several adverse events that affected more than 03 fraction of patients",
        "label": "Contradiction"
    },
    "348c5cf5-0756-4860-a83f-c9ead81ea4b3": {
        "text_answer": "Contradiction  The evidence shows that the total number of adverse events in the primary trial was 6 and the stated adverse events in the question were not the only ones experienced by patients",
        "label": "Contradiction"
    },
    "e29a77b0-a7de-44b8-8941-df0979682e4e": {
        "text_answer": "Contradiction The statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "8849827d-af65-44ae-ad32-b325f502f945": {
        "text_answer": "Contradiction The primary clinical trial has identical inclusion criteria for some patient groups eg advancedmetastatic solid tumors measurable or nonmeasurable disease but it also includes different groups with distinct criteria eg NSCLC melanoma triple negative breast cancer anaplastic thyroid cancer The secondary clinical trial on the other hand has different inclusion criteria for different patient populations breast cancer patients",
        "label": "Contradiction"
    },
    "b0c426df-6a70-4d19-a120-e3bc56c49918": {
        "text_answer": "Contradiction The primary trial includes only postmenopausal women with early stage breast cancer and serum 25OHD levels  40 ngml while the secondary trial includes healthy participants and HER2positive females with previous nonmetastatic operable primary invasive HER2positive breast cancer These populations are not identical",
        "label": "Contradiction"
    },
    "f9442384-0c19-4ffe-8906-c461b6dda9f7": {
        "text_answer": "Contradiction The statement mentions aggravated neurofibromatosis but there is no mention of neurofibromatosis in the given evidence",
        "label": "Contradiction"
    },
    "5abc6652-31bf-4ac6-a16b-432912aa6224": {
        "text_answer": "Contradiction The intervention in the primary trial lasts for 10 weeks 70 days while the intervention in the secondary trial lasts for 24 weeks 168 days which is not 25 days longer",
        "label": "Contradiction"
    },
    "2c95f252-a861-4569-a0b9-c214289da160": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events documented in both trials",
        "label": "Contradiction"
    },
    "9040286a-0801-494c-8c17-340323774082": {
        "text_answer": "Contradiction The primary trial excludes participants with 25OHD levels  40 ngml while the secondary trial does not mention anything about vitamin D levels as an inclusion or exclusion criterion",
        "label": "Contradiction"
    },
    "d4fd7d7a-53f4-4f5d-9640-717e26cbbcd9": {
        "text_answer": "Entailment The evidence states that laserassisted fluorescence angiography is used for monitoring perfusion in both the Inframammary Fold and Lateral Radial incision cohorts of the primary trial",
        "label": "Entailment"
    },
    "9ab82516-ba60-4c36-908d-5e0e56ec5fba": {
        "text_answer": "Contradiction  The evidence shows that 313 of patients in the primary trial and 667 in the secondary trial suffered from infections which is not equal to 2",
        "label": "Contradiction"
    },
    "a63b539f-034e-46c2-83e7-9cea8c282e1c": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were patients in both trials who developed infections",
        "label": "Contradiction"
    },
    "46c7e5c7-0834-45dd-952c-872502314fea": {
        "text_answer": "Contradiction  Explanation The statement More than 13 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study is a contradiction to the evidence provided as the number of participants with pCR in each cohort is given as 16 for Arm 1 381 and 14 for Arm",
        "label": "Contradiction"
    },
    "8c14522c-67de-490a-9be1-1c16d9fca742": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence does provide the count of participants in individual cohorts Arm II and Arm III",
        "label": "Contradiction"
    },
    "dce7c1b2-0e43-4c7b-8cc8-6a443fee7135": {
        "text_answer": "Contradiction The statement incorrectly states that cohort 1 receives 0035 mg less ALT801 than cohort 2 while the evidence shows that cohort 1 receives 0015 mgkgday and cohort 2 receives 0040 mgkgday which does not necessarily mean that cohort 1 receives less overall dosage depending on their body weight",
        "label": "Contradiction"
    },
    "2028a7ad-b89f-4927-8e74-db17555763c8": {
        "text_answer": "Contradiction The evidence states that participants received niraparib 200 mg daily not talazoparib 001 g",
        "label": "Contradiction"
    },
    "7df47095-163a-4062-9b5b-f2dfd02259fb": {
        "text_answer": "Contradiction  The primary trial administers oral pregabalin at a dose of 150 mg twice daily which is significantly lower than the stated 150000 mcg in the question The secondary trial administers Depocyt liposomal cytarabine and HDMTX which are not related to pregabalin",
        "label": "Contradiction"
    },
    "50ddb312-6c5e-476a-891e-95409d7239c5": {
        "text_answer": "Contradiction The primary trial is focused on evaluating toxicity while the secondary trial is focused on evaluating the percentage of participants with adverse events of primary interest Neither trial is focused on evaluating time to progression",
        "label": "Contradiction"
    },
    "18ff2056-f906-4f16-805f-76b4a51b77b7": {
        "text_answer": "Contradiction The primary trial does not report the MTD of an intervention called MM111",
        "label": "Contradiction"
    },
    "fc37e929-f3f3-43fb-b0c4-86521a18592f": {
        "text_answer": "Entailment for Results 1 only as the statement is true for the data provided in Result 1",
        "label": "Entailment"
    },
    "bdbbcf1d-df03-4ade-9967-5d9ca8bf9ce8": {
        "text_answer": "Contradiction The statement assumes that the concept of vector genomes per milliliter is relevant to the trials but it is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "69407358-a579-43ba-8b78-b75d7aebb163": {
        "text_answer": "Contradiction The primary trial does not report the MTD of an intervention called MM111",
        "label": "Contradiction"
    },
    "21a1ddb1-0d37-41e5-a08f-a7e9dc5b15ef": {
        "text_answer": "Entailment  Explanation The statement is an entailment because the evidence clearly shows that the primary and secondary trials are studying different drugs Extimia® versus empegfilgrastim different dosages 6 mg 75 mg and 3 mg and different outcome measurements duration of neutropenia versus incidence of neutropenia",
        "label": "Entailment"
    },
    "d14fe83a-0130-4c37-a55d-30ec0ecacdb1": {
        "text_answer": "Contradiction The evidence does not support a statement about a decrease in recurrencefree survival rate for the Ketorolac 30 mg group compared to the NaCl 09 3mL group The evidence only provides the percentage of participants achieving recurrencefree survival in each group",
        "label": "Contradiction"
    },
    "a1807b6a-6ee6-4c74-bf44-53d39c31c66f": {
        "text_answer": "Contradiction The secondary trial has a single set of inclusion criteria for all participants while the primary trial has multiple sets of inclusion criteria based on age groups",
        "label": "Contradiction"
    },
    "8d16932d-a485-4c58-828e-70f805bd82ef": {
        "text_answer": "Entailment Both trials exclude patients who are smokers",
        "label": "Entailment"
    },
    "2af38d73-ba19-4aa1-a571-5a576b4af7e3": {
        "text_answer": "Contradiction The statement is about a different subject matter The evidence is about adverse events in a primary trial while the statement is about a genus of bacteria",
        "label": "Contradiction"
    },
    "504dd694-4978-41f0-bee5-ccc6dd199752": {
        "text_answer": "Contradiction The statement is not related to the given evidence as it discusses muscle fibers which is not a criterion for inclusion in either trial",
        "label": "Contradiction"
    },
    "ea3a7d64-b464-4633-a198-794a4a45b201": {
        "text_answer": "Entailment The statement is an entailment as the evidence shows that tamoxifen reduces Ki67 expression by an average of 40 with a 95 confidence interval of 63 to 29",
        "label": "Entailment"
    },
    "ddafc0fa-fb54-4729-8c01-97cb30f293ed": {
        "text_answer": "Entailment as per the provided evidence neither cohort received fulvestrant so the statement that they did not receive fulvestaxel or fulvestrant is an entailment",
        "label": "Entailment"
    },
    "c638fd13-e832-4bc6-9b3a-ad9d8da4b1c4": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because there are only 3 shared inclusion criteria age  18 years advanced cancer potentially sensitive to vinorelbine and willingness and ability to provide written informed consent and 7 different exclusion criteria between the two trials",
        "label": "Contradiction"
    },
    "a0e45f2f-6f88-496e-9b14-2fe595be1286": {
        "text_answer": "Entailment assuming one psychiatric adverse event refers to suicidal ideation mentioned in the evidence  Explanation The statement in the primary clinical trial less than 10 of patients experienced one psychiatric adverse event is an entailment based on the evidence because the evidence shows that only 1 patient 200 experienced suicidal ideation which is considered a psychiatric adverse event",
        "label": "Entailment"
    },
    "176093eb-7c7f-4bca-80e2-566d4a135c47": {
        "text_answer": "Contradiction The statement does not entail or contradict the evidence provided The evidence pertains to adverse events in clinical trials while the statement is about a genus of bacteria",
        "label": "Contradiction"
    },
    "6654ce22-9470-43d1-9e51-a17f1a06f514": {
        "text_answer": "Contradiction  Explanation The statement 5 of the primary trial participants with HR primary breast cancer treated with HER2targeted PETCT 89Zrtrastuzumab developed her2 metastases is a contradiction to the evidence provided in the results 1 which states that 13 of the participants with HER2 primary breast cancer developed imagable HER2 metastases",
        "label": "Contradiction"
    },
    "dd5fcab9-ef7e-4f25-8040-81c0dd57aab5": {
        "text_answer": "Contradiction The statement mentions various cases of anaemia and febrile neutropenia but the evidence shows only one case of each in the first subgroup The statement does not entail the evidence",
        "label": "Contradiction"
    },
    "0f0ccab9-517a-44e5-8dda-96d1cb9ead51": {
        "text_answer": "Contradiction  The evidence states that the placebo is administered intravenously as normal saline while trabectedin is administered intravenously as well Neither is given orally",
        "label": "Contradiction"
    },
    "4527cc06-b4b2-4ebe-bba4-6f4e845b2984": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the primary trial involves the use of a single drug ZD1839 while the secondary trial involves the use of at least three different drugs Zoledronic acid Samarium153 and possibly pegfilgrastim The number and types of drugs used in the interventions are not the same between the two trials",
        "label": "Contradiction"
    },
    "87a0c1c5-507a-4188-87cf-57f27add4cf6": {
        "text_answer": "Contradiction  Explanation The statement is contradictory to the evidence because the secondary trial participants do receive weekly subcutaneous injections but the primary trial participants do not However the evidence does not mention anything about the location of the trials or the capital city of Rio de Janeiro",
        "label": "Contradiction"
    },
    "a9faa655-1f16-41b0-911e-0a560a1c1dc0": {
        "text_answer": "Entailment  Explanation The statement in both the primary trial and the secondary trial there were 0 adverse events which occurred in less than 2 of participants is an entailment based on the evidence provided Although the evidence does not explicitly state that no adverse events occurred in less than 2 of participants in the secondary trial it does state that no adverse events occurred at all in the secondary trial which is a subset of the",
        "label": "Entailment"
    },
    "fc1a7234-bf6c-4c29-9a82-eccacb0d4766": {
        "text_answer": "Contradiction  Explanation The primary trial involves the use of a Contour Profile Tissue Expander which does not involve any ultrasound procedures as part of the intervention The secondary trial on the other hand involves the use of allogeneic mesenchymal stem cells alloMSCs and a placebo both of which are administered via transendocardial injections using a NOGA Myostar injection",
        "label": "Contradiction"
    },
    "78cbe5c1-69a4-4194-9d3c-06b5f4b9af0b": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it only shows the percentage of participants with a decrease in the growth factor signature for each group but it does not provide information on the difference in percentage between the two groups",
        "label": "Contradiction"
    },
    "46669c3d-c42d-4b23-b8c5-256374e53cf1": {
        "text_answer": "Contradiction The evidence states that 2 subjects experienced adverse events in the primary trial which is more than 10 fewer than the 13 subjects 11 from cohort 2 and 2 from cohort 1 who experienced adverse events in the given data",
        "label": "Contradiction"
    },
    "191f4ac8-16c9-4be8-895f-4383c3d6f7b5": {
        "text_answer": "Contradiction The primary trial involves a cyclical approach to intervention while the secondary trial does not mention any cycles in its intervention",
        "label": "Contradiction"
    },
    "bf3034ec-679a-42d1-9d24-69b51c602233": {
        "text_answer": "Contradiction The primary trial includes specific gender requirements for eligibility while the secondary trial does not mention any gender requirements",
        "label": "Contradiction"
    },
    "a220e90b-6fd7-449f-878a-f870cd360de6": {
        "text_answer": "Contradiction The primary trial inclusion criteria state that the primary tumor diameter should be greater than 2 cm not 100 mm",
        "label": "Contradiction"
    },
    "51c9a1a4-9242-4880-b61e-b42a45b9017d": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence states that the dosages of NabPaclitaxel are the same but the dosages of the second agent Gemcitabine in Arm A and Carboplatin in Arm B are different",
        "label": "Contradiction"
    },
    "d09f927d-29c3-4370-a258-400c79f366fe": {
        "text_answer": "Contradiction  Explanation The evidence provided does not entail that several of the patients in the primary trial experienced the no pain whatsoever during the 25 months of the study The evidence only reports the average pain intensity scores and their confidence intervals for each group It does not provide information on the number of patients who experienced no pain at all during the study",
        "label": "Contradiction"
    },
    "421278d5-9ece-4425-b5b0-390cc6844de8": {
        "text_answer": "Contradiction The statement does not entail the information provided in the evidence as the primary trial is not related to pregnancy and the secondary trial is not related to age of participants",
        "label": "Contradiction"
    },
    "34b09027-2195-448e-ab3d-fb9d5a91301a": {
        "text_answer": "Entailment The evidence shows that there was one case of shingles in the secondary trial and the statement mentions a total of three shingles cases across both trials",
        "label": "Entailment"
    },
    "3de2cfe2-e886-45d3-a5fe-135005821732": {
        "text_answer": "Contradiction The primary trial does not involve alisertib at all while the secondary trial does involve alisertib in its interventions",
        "label": "Contradiction"
    },
    "ef7f4f02-ea16-458a-a225-875758ac5d1f": {
        "text_answer": "Contradiction  Explanation The statement there were no documented psychiatric adverse events in the primary clinical trial is a contradiction to the evidence as there was one documented case of suicidal ideation in the primary clinical trial",
        "label": "Contradiction"
    },
    "81651022-ae46-4e69-aa0b-1e1d576845ce": {
        "text_answer": "Neutral The statement does not directly relate to the inclusionexclusion criteria provided in the evidence",
        "label": "Entailment"
    },
    "c0267bfa-8985-4097-b6ba-0b908f4c46c5": {
        "text_answer": "Contradiction The evidence mentions that patients with some evidence of cognitive impairment are eligible for the trial but it does not mention Frontotemporal dementia or Mixed dementia specifically as eligible conditions Therefore the statement that patients with Frontotemporal dementia or Mixed dementia are eligible for the primary trial is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "7f128ec3-a88f-4cbe-9d79-0ef9e0f1d3bd": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as breast cancer and fallopian tube soft tissue neoplasms are different conditions Patients with breast cancer may be eligible for the studies mentioned but the statement adds the condition of fallopian tube soft tissue neoplasms which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "58acb205-1f9d-4dd2-9405-720b28f8581f": {
        "text_answer": "Contradiction The primary trial involves the use of Eribulin Mesylate which is a medication given intravenously not radiation treatment The secondary trial involves the use of Docetaxel which is a chemotherapy medication given intravenously not radiation treatment",
        "label": "Contradiction"
    },
    "fe4e3c5a-b190-4733-930a-abc0bfd29625": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it does not mention heartrelated events which were the focus of the given statement in the question",
        "label": "Contradiction"
    },
    "a9292fc9-f444-4e0a-8db1-c2a6ad9a7062": {
        "text_answer": "Neutral  The statement does not directly relate to the evidence provided The evidence only discusses the Progression Free Survival PFS of patients in a clinical trial while the statement describes a medical condition musculoskeletal chest pain due to rib injury unrelated to the trial results",
        "label": "Entailment"
    },
    "c5315113-8bc1-47d5-b1f7-ca7d59ab9cc4": {
        "text_answer": "Contradiction The primary trial involves the administration of dexmedetomidine which is not related to myalgias or vitamin D repletion The secondary trial involves patients with myalgias and vitamin D deficiency These are two different trials and patient populations",
        "label": "Contradiction"
    },
    "67a7f848-e9e5-46be-a37b-f0e46e643dcb": {
        "text_answer": "Contradiction  The evidence states that patients receive oral lapatinib once daily in the primary trial not twice daily and not in the specified dose of 25 mmml",
        "label": "Contradiction"
    },
    "57e2cf8a-6c67-4771-b180-70b613fff1cc": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not indicate that patients in both trials participate in a weekly cycle of 4demethyl4cholestryloxycarbonylpenclomedine Instead the evidence indicates that patients in the primary trial receive Abl Cells IV and Cyclophosphamide while patients in the secondary trial receive DMCHOCPEN",
        "label": "Contradiction"
    },
    "9b2a47ba-246e-4591-bf68-90c7124f800b": {
        "text_answer": "Contradiction  Explanation  In the primary trial patients are taking exemestane calcium carbonate and vitamin D daily for two years In contrast in the secondary trial patients receive epoetin beta as a weekly subcutaneous injection for 12 weeks The statement that in the secondary trial patients get a onetime injection at the beginning is not entailed by the evidence as patients in the secondary",
        "label": "Contradiction"
    },
    "45f78c14-258f-4db0-a0f4-10a46761ae2f": {
        "text_answer": "Contradiction The statement mentions a supplemental qualifiers dataset related to inclusionexclusion criteria not met but the provided evidence does not mention any such dataset for either the primary or secondary trial",
        "label": "Contradiction"
    },
    "475a8280-5855-4c8c-a9ca-7720f9a9be7f": {
        "text_answer": "Contradiction The primary trial requires a Karnofsky score of 70 or better while the secondary trial requires a score of 55 or better",
        "label": "Contradiction"
    },
    "dfc09a24-8631-4fa3-893e-4d10a9bac4b8": {
        "text_answer": "Contradiction  The statement is a contradiction because the evidence shows that breast cancer patients in the primary trial were administered various doses of talazoparib including 50 mcgday while ovarianperitoneal cancer patients were also administered various doses including 100 mcgday but it is not stated that breast cancer patients only received 50 mcgday and ovarianper",
        "label": "Contradiction"
    },
    "f5ae88a3-a083-405e-b3a8-282018d7f013": {
        "text_answer": "Contradiction The statement excludes individuals who have received antineoplastic chemotherapy androgens estrogens or progestogens a month prior to the start of the study while the evidence allows the use of tamoxifen raloxifene and aromatase inhibitors if the patient has been on a constant dose for at least 28 days and is not expected to stop the medication during the study period",
        "label": "Contradiction"
    },
    "80cb39bd-c370-4e7f-8f19-74725fed8805": {
        "text_answer": "Entailment The primary trial has a lower total number of adverse events and a lower number of cardiacischemiainfarction cases than the secondary trial as stated in the evidence",
        "label": "Entailment"
    },
    "64441aad-b959-41bb-aa81-2f594d00b70c": {
        "text_answer": "Contradiction The primary trial requires mammography while the secondary trial does not mention mammography as a requirement Instead it requires a CT scan and blood tests",
        "label": "Contradiction"
    },
    "99942306-e4cf-4405-80ca-914e689aef75": {
        "text_answer": "Contradiction  The evidence states that 53 of participants had an overall tumor response OR which includes both CR and PR The statement however specifically asks for CR and the evidence shows that fewer than half of the participants had a CR",
        "label": "Contradiction"
    },
    "d86f5f0a-32ec-4943-912f-9945c1cfe06f": {
        "text_answer": "Entailment The evidence does not contradict the statement as there are no cardiac or psychiatric adverse events mentioned in the evidence The statement goes beyond the evidence by discussing composite sequence and camage but the absence of cardiac or psychiatric adverse events is consistent with the evidence",
        "label": "Entailment"
    },
    "deba63cb-52ea-4b46-ad50-8cef93d8c5fd": {
        "text_answer": "Contradiction The evidence does not mention anorexia hypothermia or hallucinations in the adverse events of the secondary clinical trial",
        "label": "Contradiction"
    },
    "3f15d923-bf66-4188-8714-c9ae4921de1f": {
        "text_answer": "Entailment  Explanation Both trials include patients who are 18 years of age or older",
        "label": "Entailment"
    },
    "fd800c89-d30c-4a9a-970b-5385deeab52f": {
        "text_answer": "Contradiction The primary trial has 75 participants in the waitlist control group and 76 in the peer support program group while the secondary trial has 147 participants in the standard of care group and 163 in the device  standard of care group Therefore there are not significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial",
        "label": "Contradiction"
    },
    "5145d91d-ce46-4dda-961e-5bc7ddb6cda4": {
        "text_answer": "Contradiction The primary trial and the secondary trial measure different outcome measures The primary trial measures the number of participants with treatmentemergent adverse events while the secondary trial measures the change in total sleep time in minutes",
        "label": "Contradiction"
    },
    "d8d5125b-399a-4b78-b033-9603bfe8011e": {
        "text_answer": "Entailment The primary trial has different inclusion and exclusion criteria for its phases and the secondary trial has different criteria based on health status Both statements are true and the second statement follows from the first",
        "label": "Entailment"
    },
    "78865c57-db3b-4fbe-ab87-1f2d11f2c091": {
        "text_answer": "Contradiction  The statement patients participating in the primary trial receive 50 kgm2 oral lapatinib once a day for a full month is not entailed by the evidence as the evidence states that patients receive lapatinib ditosylate and tamoxifen citrate orally on days 128 but it does not specify the exact dosage of lapatinib or the dosing frequency beyond once daily The",
        "label": "Contradiction"
    },
    "ac14720a-7525-4fb0-b261-0ec5c818f85f": {
        "text_answer": "Contradiction The primary trial only includes postmenopausal female patients and male patients while the secondary trial includes female patients as well",
        "label": "Contradiction"
    },
    "44daf0ed-4b1a-4e95-aae4-71722fad8f09": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence explicitly states that women of childbearing potential and sexually active fertile men are not eligible for the trial unless they meet certain conditions regarding birth control",
        "label": "Contradiction"
    },
    "1da40d20-026a-4b22-8e6c-8943e0180ed7": {
        "text_answer": "Contradiction The primary trial does not list pulmonary embolisms as an exclusion criterion but the secondary trial does not include it as an inclusion or exclusion criterion at all Breast implants are an exclusion criterion in the secondary trial but the statement does not mention whether they are an exclusion criterion in the primary trial or not",
        "label": "Contradiction"
    },
    "6b6d3087-435b-4129-b368-29d8879f7ff4": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided about the primary trial",
        "label": "Contradiction"
    },
    "6acd26e7-8103-4b23-aa31-413998ccbde6": {
        "text_answer": "Contradiction The evidence states that patients in the primary clinical trial receive oral doses of lapatinib not intravenous doses",
        "label": "Contradiction"
    },
    "14954e3a-d984-46dc-af8d-29f22c0ca85e": {
        "text_answer": "Contradiction  The primary trial includes Triple negative breast cancer as an eligible diagnosis but clear cell carcinoma and pagets disease of the nipple are not mentioned as exclusions in the primary trial In contrast the secondary trial does not mention clear cell carcinoma or pagets disease of the nipple as inclusion or exclusion criteria Therefore the statement that patients with clearcell adenocarcinoma or gestational",
        "label": "Contradiction"
    },
    "f2bac26a-95c8-4ac8-8356-26c3d96e8797": {
        "text_answer": "Contradiction  Explanation The statement biliary colic and diarrhoea are more frequently observed in the secondary clinical trial as opposed to the primary clinical trial is a contradiction based on the evidence provided The evidence shows that diarrhoea is observed in one patient in the secondary trial and three patients in the primary trial while biliary colic is observed in one patient in the secondary trial and four patients in the primary trial Therefore the",
        "label": "Contradiction"
    },
    "fdc7efac-ca90-4897-9660-a42dbba2bd84": {
        "text_answer": "Entailment The evidence shows that the AZD0530 175 mg group had a greater percentage change in betaCTX at Week 4 compared to the Zoledronic Acid 4 mg group",
        "label": "Entailment"
    },
    "32cc173a-b271-47c9-997d-df17ce1c7494": {
        "text_answer": "Contradiction  The statement None of the individual adverse event types recorded in the primary trial affected more than one patient is contradicted by the evidence as there are two patients with disease progression recorded as an adverse event",
        "label": "Contradiction"
    },
    "74178d28-3c60-4439-944a-84318eff5c92": {
        "text_answer": "Contradiction The statement is not an entailment as a patient who has received an organ transplant within the last month and is still bedridden is excluded from the primary trial but there is no information provided in the secondary trials exclusion criteria regarding organ transplant and bedridden status",
        "label": "Contradiction"
    },
    "69959fb0-ee1c-4fb2-a968-677802eb1c82": {
        "text_answer": "Contradiction  The evidence shows that 286 95 CI 131492 of ERpositive Luminal B participants demonstrated a decrease in the growth factor signature while 176 95 CI 67352 of Triple Negative participants demonstrated a decrease in the growth factor signature A 72 difference in",
        "label": "Contradiction"
    },
    "f43219f1-3807-4c37-9240-bf1d9f54d5e8": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 5 days while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "987667fb-e888-40d7-ab77-f0138d9295ba": {
        "text_answer": "Contradiction The primary trial does not have a higher presence of biliary colic or clostridium difficile colitis compared to the secondary trial as these events were not reported in the secondary trial at all",
        "label": "Contradiction"
    },
    "02da2719-af96-4d84-bf69-ac1a2d6fd01c": {
        "text_answer": "Entailment The evidence shows that the percentage of participants with adverse events in the primary trial was 571 which is less than 5",
        "label": "Entailment"
    },
    "f3a4ac87-2a6b-476f-91e2-b056e231f20a": {
        "text_answer": "Neutral The evidence does not directly address the statement as it does not provide information about the presence or absence of a clear pattern for gene expression in the given patient groups",
        "label": "Entailment"
    },
    "cfcfc39b-c969-474d-b85c-090dda68b1f1": {
        "text_answer": "Entailment  Explanation The evidence shows that there were no instances of cardiac or psychiatric adverse events in both the primary and secondary trials The statement in question also asserts that there were no instances of such adverse events making it an entailment based on the provided evidence",
        "label": "Entailment"
    },
    "49c63fc5-be4b-4474-8bfc-0ddf9cf438db": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that there is one case of Bronchopneumonia and one case of General physical health deterioration in the primary trial while there is only one case of each in the secondary trial as well Therefore there are not more cases in the primary trial",
        "label": "Contradiction"
    },
    "4bebbb9f-9a62-4b07-b91a-1321f312229e": {
        "text_answer": "Contradiction The primary trial compares Epirubicin  Cyclophosphamide vs Docetaxel  Capecitabine while the secondary trial compares Zoledronic acid vs Denosumab The two trials are not directly comparable",
        "label": "Contradiction"
    },
    "5e7e3d88-6a13-4849-bad5-4ac52b100140": {
        "text_answer": "Entailment The evidence and the statement both indicate that there were no adverse events recorded in the primary clinical trial for both cohorts",
        "label": "Entailment"
    },
    "bd6fc353-2823-4e35-b811-a19c8318fda4": {
        "text_answer": "Contradiction The primary trial had a smaller participant count 13 than the secondary trial 30",
        "label": "Contradiction"
    },
    "ef2352dc-a976-47c6-91cd-6666e3f7b55a": {
        "text_answer": "Contradiction The primary trial measures the number of participants with treatmentemergent adverse events while the secondary trial measures the change in total sleep time in minutes These are not the same outcome measures",
        "label": "Contradiction"
    },
    "ef186582-5995-47ca-a190-616f94342715": {
        "text_answer": "Contradiction The statement children and adolescents are not eligible for the primary trial as they do not meet the height requirement is not directly related to the secondary trial which does not mention any height requirement The statement about urethral infection being a bacterial viral or fungal infectious process is an entailment as it follows logically from the definition of urethral infection",
        "label": "Contradiction"
    },
    "53459054-8f8c-4fd1-9d1f-2f109c45c5b8": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence because there were no adverse events reported in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "25c8668a-29f5-4bf0-9c35-89ba2e5e1776": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the number of adverse events in the secondary trial being 11 more than the primary trial does not relate to the type of tumor being ovarian rhabdomyosarcoma",
        "label": "Contradiction"
    },
    "2cc63d25-8209-41a8-b9a3-fcc4af6d9caa": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence states that for breast cancer to be eligible for Phase 2 it must be ER positive not ER negative",
        "label": "Contradiction"
    },
    "fe0da901-6c2a-4ae8-b35f-a3090f93f12d": {
        "text_answer": "Contradiction  Explanation  The statement suggests that cohort 1 and 2 receive the same dosage and frequency of CUDC101 administration However the evidence provided shows that the CUDC101 dosing schedule is different between the two cohorts with cohort 1 receiving the drug for 5 days consecutively every 14 days while cohort 2 receives the drug for",
        "label": "Contradiction"
    },
    "eab52a37-149f-4b49-bf37-891e8e201956": {
        "text_answer": "Entailment The statement does not contradict the evidence but rather describes a difference in the frequency of paced breathing practice between the two cohorts",
        "label": "Entailment"
    },
    "b17ff44f-d9dc-4be7-b087-4329493d1c95": {
        "text_answer": "Irrelevant  The statement about the number of participants treated with the vaccine and the statement about chromosome band 7q21q221 are not related to each other",
        "label": "Entailment"
    },
    "94ccff26-4026-4888-9ef8-2af5aaebefad": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence provided because there were no adverse events reported for palpitations pericardial effusions or abdominal pains in the secondary trial while these events were reported in the primary trial",
        "label": "Contradiction"
    },
    "94e5871f-085c-4757-9941-3c83a71da6a4": {
        "text_answer": "Contradiction The primary trial does not provide enough evidence to conclude that Arm A had a superior overall response rate compared to Arm B The secondary trial does not relate to the primary trial and only compares Zoledronic acid and Denosumab in terms of time to first onstudy SRE",
        "label": "Contradiction"
    },
    "c70735d3-1bc3-41d8-b0d3-15a49abe4862": {
        "text_answer": "Contradiction The statement is not an entailment as it mentions the participant with the highest PFS while the evidence only provides the median PFS for each group",
        "label": "Contradiction"
    },
    "f0278adc-ef45-43ab-b957-d26918e3a5e2": {
        "text_answer": "Contradiction  Explanation  The statement utilization of gabapentin or pregabalin in the past will dismiss the option of partaking in the secondary clinical trial but the primary clinical trial will not impose this restriction is a contradiction based on the provided evidence  The secondary clinical trial explicitly states that No prior gabapentin or pregabalin is an exclusion criterion This means that the utilization of gab",
        "label": "Contradiction"
    },
    "11d451c7-7354-44f6-95b4-2b794a72fdbb": {
        "text_answer": "Contradiction  Explanation The statement that the intervention in the secondary trial lasts 300 longer than the intervention in the primary trial is a contradiction based on the evidence provided The intervention in the primary trial lasted for 10 weeks while the intervention in the secondary trial lasted for 24 weeks which is 120 longer not 300",
        "label": "Contradiction"
    },
    "ef2bc415-dff4-4732-8e34-f538b570c671": {
        "text_answer": "Contradiction The primary trial intervention does not explicitly state that it necessitates psychosocial interventions and excludes surgical and imaging procedures The statement goes beyond the information provided in the trial intervention",
        "label": "Contradiction"
    },
    "2a3d4de3-5604-4959-8a60-2817faeee2b8": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the placebo and alloMSCs interventions are not administered at the same dosage level The alloMSCs intervention receives a dose of 100 million cells while the placebo receives a dose of Buminate solution",
        "label": "Contradiction"
    },
    "8948d41b-0742-43f8-a34f-2e1cfcaba149": {
        "text_answer": "Contradiction  Explanation  The primary trial intervention lasts for 10 weeks which is equivalent to approximately 420 hours assuming a weekly session of 45 minutes  The secondary trial interventions last for 24 weeks which is equivalent to approximately 10080 hours assuming a weekly dose administration  However the statement suggests a difference of 2520 hours between the inter",
        "label": "Contradiction"
    },
    "6ca72b87-353a-4ef1-89d7-b9a5bad97c27": {
        "text_answer": "Entailment  The evidence indicates that both trials exclude patients with fibromyalgia thalasemic syndromes and anemia",
        "label": "Entailment"
    },
    "4d384e46-7119-49f9-a627-0301c32ee334": {
        "text_answer": "Contradiction The primary trial measures changes in pain intensity at 30 minutes after dosing while the secondary trial measures the change from baseline to 9 months in bone mineral density of the lumbar spine",
        "label": "Contradiction"
    },
    "20493bc1-bda8-4255-a1d4-40cb499bd845": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was 1 case of infection in the primary trial but there were no cases of infection reported in the secondary trial Therefore the statement that there was at least 1 case of infection in both the primary trial and the secondary trial is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "8b0efa30-40c4-408e-a91b-ded68b61d9ff": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it only gives the median survival for each group and does not provide information on the survival distribution for the entire population The statement implies that all patients survive over 24 months on average but the evidence shows that some patients from both groups died before 24 months",
        "label": "Contradiction"
    },
    "8c07a493-66a5-4728-ae22-d6c45b2215a8": {
        "text_answer": "Contradiction  Explanation The statement mentions the difference between the interventions in terms of the drugs administered and their dosages but it does not correctly identify the specific cohorts receiving each intervention In the evidence provided Cohort 1 receives Sunitinib and Paclitaxel while Cohort 2 receives Bevacizumab and Paclitaxel The statement however states that Cohort 1 receives ",
        "label": "Contradiction"
    },
    "e9ad9d15-a15f-4f20-85f4-5da69c7592d6": {
        "text_answer": "Entailment The evidence provided in the inclusion and exclusion criteria for both trials confirms that patients with epilepsy thalasemic syndromes or anemia are excluded from both trials",
        "label": "Entailment"
    },
    "f05705d7-3be3-4d1d-9dca-c59c130446a1": {
        "text_answer": "Contradiction  The statement is not entailed by the evidence as the evidence does not mention anything about women with newly diagnosed stage IV breast cancer confirmed as ER considering a mastectomy being eligible for either the primary or secondary trial The evidence only mentions the eligibility criteria for each trial separately",
        "label": "Contradiction"
    },
    "f8adadc4-67d0-42d2-bcc9-c032279bb470": {
        "text_answer": "Entailment The statement dose regimen is a treatment plan that specifies the amount schedule and the duration of interventions is a general definition and the evidence provided in the primary trial for Sunitinib confirms that it meets this definition as it specifies the amount 375 mgday schedule every day and duration 21day cycles for the administration of Sunitinib to all patients in the",
        "label": "Entailment"
    },
    "d0e16cbb-09e6-4178-80c1-2004ac2239a0": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence states that no adverse events were reported in the first cohort while the statement suggests that none of the participants in the second cohort had no adverse events but instead all experienced at least one",
        "label": "Contradiction"
    },
    "964e4947-27a1-435e-84c6-d28b91d0dabe": {
        "text_answer": "Entailment Both trials require the patient to have intact mobility as a prerequisite for participation",
        "label": "Entailment"
    },
    "eba82ab1-0348-4090-81e6-fcb63ac45537": {
        "text_answer": "Contradiction  The evidence does not provide information on the average survival duration of patients in the primary trial being over 730 days The statement is not entailed by the evidence",
        "label": "Contradiction"
    },
    "4edb9b25-9a95-4a00-ae99-ebd722187d63": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence only provides the median PFS for each group and does not indicate that any individual patient survived 42 weeks without disease progression or death",
        "label": "Contradiction"
    },
    "3426fcd0-2d5b-4d82-a9a1-93450b3336ee": {
        "text_answer": "Contradiction The primary trial has specific inclusion criteria related to hot flushes and menopausal status which are not met by patients in the secondary trial making it impossible for them to participate in both trials concurrently",
        "label": "Contradiction"
    },
    "62112a3e-48e6-4e53-bfe4-53f07c84b815": {
        "text_answer": "Contradiction The evidence states that No meningeal carcinomatosis is a requirement for participation in the primary clinical trial Therefore leptomeningeal carcinoma patients who have meningeal involvement are not admissible for the trial",
        "label": "Contradiction"
    },
    "7ba831e1-4027-4ae2-842f-d52409a73ddc": {
        "text_answer": "Contradiction The primary trial examines vaginal topical treatments Estring and testosterone cream while the secondary trial examines acupuncture which is not a topical treatment and a waitlist control group",
        "label": "Contradiction"
    },
    "f9dfe1ca-aa97-4592-a67f-706e5453c822": {
        "text_answer": "Contradiction The primary trial measures the change in units on a scale for vaginal symptoms while the secondary trial measures the percentage of participants with objective response to treatment for HER2negative metastatic breast cancer",
        "label": "Contradiction"
    },
    "f994d3fb-5191-4800-beb7-02fdd6887e3e": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that in the secondary trial 3333 of patients experienced adverse effects not over 90",
        "label": "Contradiction"
    },
    "282b67f4-97cb-4680-8f21-0102c1c7851f": {
        "text_answer": "Irrelevant  The statement is not related to the given evidence as it discusses Chlamydophila a bacterial genus while the evidence only pertains to the interventions in the primary trial",
        "label": "Entailment"
    },
    "41b82c80-55fb-41c9-84c0-ae7f552c7cf8": {
        "text_answer": "Contradiction The primary trial excludes patients with epilepsy and thalasemic syndromes and the secondary trial excludes patients with anemia due to causes other than iron deficiency Therefore the statement that cancer patients with epilepsy thalasemic syndromes or anemia can participate in the secondary clinical trial is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "242dc321-0e46-4788-ac59-22120692fd8d": {
        "text_answer": "Contradiction The evidence states that patients receive oral lapatinib once daily in the primary trial not twice daily as stated in the question",
        "label": "Contradiction"
    },
    "784e6940-fead-497a-8d68-2869d17385ea": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the interventions AlloMSCs and Placebo are administered via different routes transendocardial injection for the primary trial and the statement refers to esophagus",
        "label": "Contradiction"
    },
    "27b7d06c-72ee-4a57-a88a-2654824853f2": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as the primary trial does not mention anything about hypertension or blood pressure criteria",
        "label": "Contradiction"
    },
    "5e2e6057-0a23-4780-9994-a239d28aee3a": {
        "text_answer": "Contradiction  Explanation The primary trial reports results using percentage of participants while the secondary trial reports results using number of participants These are not the same units of measure so the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "cd0b8308-0c5c-4e7c-9f4f-9e1714fc7db2": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction of the evidence provided as the evidence does not mention ER or PR factors in relation to the inclusion criteria for the clinical trial",
        "label": "Entailment"
    },
    "c6b64745-922b-40cb-9476-b7b696d4c8c0": {
        "text_answer": "Entailment with the caveat that majority implies more than half of the participants in cohort 2 and the evidence shows that 20 out of 35 participants did not exhibit any signs of acute vomiting",
        "label": "Entailment"
    },
    "11991b1b-f587-44fc-b675-603c06e680fe": {
        "text_answer": "Entailment The primary trial examines the effects of Eribulin Mesylate while the secondary trial examines the effects of Axitinib and Docetaxel separately",
        "label": "Entailment"
    },
    "5e0f26d8-5fcd-4187-9591-3508d99ffafc": {
        "text_answer": "Contradiction The primary trial provides the time to progression while the secondary trial focuses on the count of patients with objective response which are different types of outcome measurements",
        "label": "Contradiction"
    },
    "85815543-5f42-40bc-9ad1-98037b32433c": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were indeed cases of infections reported in both trials although the number and specific types of infections varied between the two trials Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "2da35e9e-caa7-47b4-883e-5ef8c7868708": {
        "text_answer": "Contradiction The primary trial reports on the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or maximum feasible dose of MM111 which is not related to the primary trial The statement provides a specific value for the MTD of MM111 but the trials do not compare or provide that information",
        "label": "Contradiction"
    },
    "951e007d-202c-4cd4-8db0-0218a7c9f851": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial does use docetaxel doxorubicin and cyclophosphamide in different combinations for each cohort",
        "label": "Contradiction"
    },
    "7e193fec-c5ef-4c86-8f5c-c7f6dffe11ec": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because there were no adverse events recorded in the secondary trial while the primary trial had palpitations pericardial effusions and abdominal pains reported",
        "label": "Contradiction"
    },
    "2d0d88d5-08ba-4d77-abbc-d8df34efa630": {
        "text_answer": "Entailment The statement does not mention cardiac or psychiatric adverse events in relation to satisfaction with the appearance of reconstructed nipples",
        "label": "Entailment"
    },
    "bb41bccb-2552-42ba-a5df-981bead7b941": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not provide information about the occurrence of proctitis in either trial",
        "label": "Contradiction"
    },
    "73b815f4-aae1-4202-a65e-5bba7b7c6676": {
        "text_answer": "Contradiction The statement is contradictory to the exclusion criteria mentioned in the evidence which states that individuals with a history of grade 3 or 4 allergic reactions attributed to trastuzumab are excluded from the clinical trial",
        "label": "Contradiction"
    },
    "292d0d60-e861-47b2-9484-53b0cc80ffe1": {
        "text_answer": "Contradiction The primary trial did not document any cases of chest pain",
        "label": "Contradiction"
    },
    "36eca12e-4e1f-4239-88bb-fdac29a6209c": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the dosages of Zoledronic Acid and Denosumab mentioned in the primary and secondary trials are not directly compared in the statement",
        "label": "Contradiction"
    },
    "b5701488-7b4a-4e1d-a318-4cc2f2b4df39": {
        "text_answer": "Contradiction  The primary trial involves sublingual administration of Vitamin B12 while the secondary trial involves oral administration of memantine These are not the same interventions so the statement is a contradiction",
        "label": "Contradiction"
    },
    "dece1720-0c33-4000-b6e1-879b75541c33": {
        "text_answer": "Contradiction The statement makes assumptions about the drugs used in the primary trial that are not supported by the evidence provided The statement mentions Arimidex is used in both cohorts of the primary trial but the evidence only mentions the use of Fulvestrant and Anastrozole in the primary trial not Arimidex Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "fa586070-5821-4a70-9812-9d7c6e5df330": {
        "text_answer": "Contradiction  The statement 5 patients in the primary trial suffered 3 or more adverse events is not an entailment or a contradiction based on the evidence provided The evidence only states the number of occurrences of each specific adverse event but it does not provide information about how many patients experienced 3 or more adverse events",
        "label": "Contradiction"
    },
    "5ad108af-177f-434d-b17a-67c11c484e9b": {
        "text_answer": "Entailment assuming that the asterisked adverse event of deep vein thrombosis is not considered as syncope",
        "label": "Entailment"
    },
    "ba202357-7330-4867-9527-10dee27a64b5": {
        "text_answer": "Entailment The evidence states that cohort A receives CUDC101 for 5 days consecutively every 14 days at a higher dose while cohort B receives CUDC101 for 3 days a week every 28 days at the same maximum tolerated dose This difference in dosage and frequency meets the criteria of the statement",
        "label": "Entailment"
    },
    "3eecf12f-23fb-45ab-bf91-cc84c01a1b6a": {
        "text_answer": "Contradiction The primary trial involves the administration of dexmedetomidine to Intervention Group 2 while the secondary trial does not involve the administration of dexmedetomidine to any group",
        "label": "Contradiction"
    },
    "0ab8abd1-3e9e-4c51-95c3-6a1114180100": {
        "text_answer": "Irrelevant The statement is not related to the eligibility criteria for the primary or secondary trials",
        "label": "Entailment"
    },
    "4dca77c0-d73d-4205-9d8e-8c2e897049d5": {
        "text_answer": "Contradiction The evidence states that no episodes of vomiting and no rescue medication were reported during the first 24 hours after cyclophosphamide administration for all participants in cohort 2 Therefore it is a contradiction to state that over 50 of patients suffered from acute vomiting",
        "label": "Contradiction"
    },
    "6668780b-0a4f-4c25-895f-3fb5fc7c604a": {
        "text_answer": "Contradiction  The evidence provided does not allow for the calculation of the total number of minutes of TAK228 plus tamoxifen treatment experienced by the patients in the primary trial as the duration of treatment and dosing frequency are not specified for each individual patient Therefore it is impossible to determine if the statement is an entailment or contradiction based on the given evidence alone",
        "label": "Contradiction"
    },
    "05cd9540-60f6-4255-a4a5-fadff61801eb": {
        "text_answer": "Contradiction The primary trial does not mention any requirement for a dental examination record or an eye examination report or immunization history",
        "label": "Contradiction"
    },
    "b544a7fd-b1d9-402c-b003-22d14774531c": {
        "text_answer": "Entailment The statement follows logically from the evidence as the evidence shows that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher ORR 0587 vs 0489 and a larger number of participants analyzed 92 vs 94",
        "label": "Entailment"
    },
    "ba5f6986-4060-4bcb-92ab-6423657d51ba": {
        "text_answer": "Contradiction  Explanation The primary trial does not involve insulin injections but rather radiation therapy The secondary trial involves Enzastaurin and Fulvestrant and there is no mention of insulin injections or tryptophan supplements being a part of the main procedure for participants Deep sleep therapy is also not mentioned in the evidence provided for the primary or secondary trials",
        "label": "Contradiction"
    },
    "0cbbe925-cc6b-464a-b601-176c35b63a31": {
        "text_answer": "Contradiction  Explanation The statement women with the ability to conceive and sexually productive men qualify for the primary clinical trial is a contradiction to the evidence as per the exclusion criteria mentioned in the trial The trial explicitly states that women of childbearing potential WOCBP and sexually active fertile men whose partners are WOCBP and not using an adequate method of birth control are excluded from the study",
        "label": "Contradiction"
    },
    "a6299338-84c5-469d-9bd0-eff13b90a7eb": {
        "text_answer": "Contradiction  Explanation The primary trial administers Vitamin B12 sublingually while the secondary trial administers memantine orally These are two different interventions and the mode of administration is not the same",
        "label": "Contradiction"
    },
    "0bfa5116-f8a5-4bba-b279-bc071c6ff725": {
        "text_answer": "Contradiction The primary trial does not include any information about appetite status in its inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "21400daa-b71d-43ac-9a54-fb9497b2a723": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as patients with a history of other malignancies including basal cell carcinoma are excluded from the primary trial",
        "label": "Contradiction"
    },
    "45741764-5967-4905-83dc-06481353f56b": {
        "text_answer": "Irrelevant The statement is not related to the evidence provided which only pertains to the MTD of different interventions in clinical trials The statement about roboticassisted imaging is unrelated to the MTD or the clinical trials mentioned in the evidence",
        "label": "Entailment"
    },
    "74f1ae66-88fd-4508-ba6b-2ad19274d6e3": {
        "text_answer": "Contradiction The statement implies that there are more than 42 participants with pCR in both cohorts but the evidence shows that a total of 16 participants in Result 1 and 14 participants in Result 2 experienced pCR for a total of 30 participants",
        "label": "Contradiction"
    },
    "9f402778-d71e-4f5b-9653-eed11679ecc9": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the two intervention groups in the primary trial have different conditions one for adult cancer patients and the other for healthy volunteers",
        "label": "Contradiction"
    },
    "1f54533d-d67f-4863-90a6-ebc13199f27e": {
        "text_answer": "Contradiction  Explanation  The statement no patients in the secondary clinical trial are given paclitaxel cyclophosphamide or pegfilgrastim is a contradiction to the evidence provided in the secondary trial In the secondary trial the intervention includes docetaxel  lapatinib which is a type of taxane similar to paclitaxel cyclophosphamide is given in the first part",
        "label": "Contradiction"
    },
    "3add5ce6-4581-491c-b501-2c071860ece3": {
        "text_answer": "Contradiction The primary trial involves oral pregabalin while the secondary trial involves intrathecal Liposomal Cytarabine Depocyt and intravenous HighDose Methotrexate HDMTX",
        "label": "Contradiction"
    },
    "31dea0ef-a953-4217-9e00-bac1c96a7325": {
        "text_answer": "Contradiction  Explanation The primary and secondary trials involve different treatments In the primary trial the interventions include Abl Cells IV  Cyclophosphamide doses escalated in Phase 1 while in the secondary trial the intervention is DMCHOCPEN with different doses for patients with and without liver involvement",
        "label": "Contradiction"
    },
    "4b6d301f-d0c7-45c9-a39a-ff973e0b9d45": {
        "text_answer": "Entailment The evidence does not indicate any requirement for participants to be of a certain nationality or gender in either trial",
        "label": "Entailment"
    },
    "0655111b-b8fe-46c7-8332-433a747efbcc": {
        "text_answer": "Contradiction The primary trial and the secondary trial measure different outcomes so it is not possible to directly compare the findings of the two trials The primary trial compares the diagnostic accuracy of two algorithms in breast cancer diagnosis while the secondary trial measures changes in fatigue levels in breast cancer patients undergoing radiation therapy and reflexology treatment",
        "label": "Contradiction"
    },
    "282c18a2-64b1-47cf-8563-db8db40dadb6": {
        "text_answer": "Entailment Both cohorts receive the same doses of radiation therapy and both undergo a SPECT scan",
        "label": "Entailment"
    },
    "1af4d0ac-d0f2-402a-8bdb-0e10c0823b0f": {
        "text_answer": "Contradiction The statement is not an entailment as Syncope was not the most commonly occurring adverse event in the secondary trial as there were no reported cases of Syncope in the secondary trial",
        "label": "Contradiction"
    },
    "9d196526-1000-4235-add7-49de8e168d3b": {
        "text_answer": "Entailment The secondary trial reports at least one case of both bronchopneumonia and general physical health deterioration which is not present in the primary trial",
        "label": "Entailment"
    },
    "664f769a-791d-4188-8937-c3269d6e0dde": {
        "text_answer": "Contradiction The primary trial includes patients with a breast tumor that is 1 cm in diameter while the statement mentions a tumor of 100mm 10 cm in diameter which is not consistent with the primary trials inclusion criteria",
        "label": "Contradiction"
    },
    "22f97249-204f-4d0e-a76f-eb9b8441c8da": {
        "text_answer": "Contradiction  The statement is stating that over 910 patients experienced either a confirmed complete response CR or a confirmed partial response PR but the evidence shows that 53 of the participants in the primary trial treated with lapatinib 1000 mg  nabpaclitaxel experienced either a confirmed complete response CR or a confirmed partial response PR The numbers do not match making the statement a contrad",
        "label": "Contradiction"
    },
    "de23d1f1-23e0-4f92-bdfd-b2bf37f08250": {
        "text_answer": "Entailment  Explanation The statement cohort 1 in the primary clinical trial receives 0035 mg less of alt801 than what is administered to cohort 2 is an entailment based on the evidence provided This is because the difference in doses between the two cohorts is 0025 mgkg 0040 mgkg for cohort ",
        "label": "Entailment"
    },
    "eb8dca8b-34a9-46d0-a845-80c4b5343ec6": {
        "text_answer": "Contradiction The primary trial and secondary trial are evaluating different outcome measures and populations so it is not possible to make a direct comparison between the results of the two trials based on the provided evidence",
        "label": "Contradiction"
    },
    "ae5ec938-2ef4-4533-9ab9-3314de8525a1": {
        "text_answer": "Contradiction  The evidence provided states that 80 out of 96 participants in the Ketorolac 30 mg group and 96 out of 107 participants in the NaCl 09 3mL group achieved recurrencefree survival However the statement in the question suggests that there were 208 participants in the Ketorolac 30 mg group and 156 in the",
        "label": "Contradiction"
    },
    "ea69e1bc-816a-4ba8-abd0-9882b12b70ea": {
        "text_answer": "Neutral  Explanation The statement is not directly related to the evidence provided The evidence only mentions the occurrence of adverse events while the statement is about the location of a specific type of cell in a type of epithelium",
        "label": "Entailment"
    },
    "fe6f8d5f-5105-4495-828f-f6ef19a7cc9d": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the administration of denosumab at a dose of 120 milligrams every 4 weeks which is equivalent to 480 milligrams per month The statement in the question incorrectly states that the primary trial requires patients to receive 120000 micrograms or 120 mg x 1000  12",
        "label": "Contradiction"
    },
    "deff33e5-6172-4caa-940e-4ca7aaca8d80": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events recorded in both trials so it is not possible for the primary trial to have recorded a greater number of adverse events than the secondary trial",
        "label": "Contradiction"
    },
    "057e665a-1e29-4e11-866e-16483eeb0420": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as yellow fever virus is not related to the inclusion or exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "4dd24d14-3357-43a0-973f-d535802507cb": {
        "text_answer": "Contradiction The primary trials Group 2 receives dexmedetomidine while the secondary trials patients do not receive any dexmedetomidine However the statement assumes that patients in the secondary trial do not receive dexmedetomidine at all which is not the case as it does not mention anything about dexmedetomidine in the secondary trial",
        "label": "Contradiction"
    },
    "f59c5c18-e772-4c9b-a5f2-cdb3bdd812f2": {
        "text_answer": "Contradiction  Explanation The statement makes a comparison between the frequency of pericardial effusions and corneal deposits between the two trials However the evidence provided does not support this comparison as it does not show the frequency of pericardial effusions in the secondary trial or the frequency of corneal deposits in the primary trial Therefore it is not possible to determine if the statement is an entailment or a contradiction based on",
        "label": "Contradiction"
    },
    "64d56259-f688-42c5-8946-0022bd4aa57c": {
        "text_answer": "Contradiction The statement is about intraosseous route of administration which is not related to the evidence provided about the primary trial that compares cryotherapy with standard of care during paclitaxel infusions",
        "label": "Contradiction"
    },
    "fe5928a4-1a0c-4c41-9b85-8d7785a8ab4c": {
        "text_answer": "Contradiction  Explanation  In the primary trial there are two cohorts one receives CBTI and placebo and the other receives CBTI and Armodafinil The Armodafinil group receives Armodafinil daily for 47 days with a varying dosage throughout the treatment period  In contrast the secondary trial has two identical interventions both receiving MCS110",
        "label": "Contradiction"
    },
    "e0cc56e6-9466-4d28-a94e-4a9dcceaee76": {
        "text_answer": "Contradiction The statement mentions electroporation injections for V934 LD but the evidence only shows that three electroporation injections of V934 LD are given to participants in Cohort B not two",
        "label": "Contradiction"
    },
    "29eab9d1-1649-401a-8ff7-95fcd6a2c09a": {
        "text_answer": "Contradiction The primary trials Group 2 receives 05ugkg of dexmedetomidine 5ml not 9ugkg 90ml The secondary trials patients do not receive any dexmedetomidine mentioned in the statement",
        "label": "Contradiction"
    },
    "67dcd165-45dd-439f-980d-62c960f50c37": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence allows for the use of antineoplastic chemotherapy with the exception of antiHER2 agents during the study period",
        "label": "Contradiction"
    },
    "96042d49-2f5a-44af-8899-2d5ba24c0f6f": {
        "text_answer": "Contradiction  The evidence states that 9 out of 21 participants had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products This is more than 10 of the participants",
        "label": "Contradiction"
    },
    "4ceb3f73-8812-4534-9688-52e5d3db524f": {
        "text_answer": "Contradiction The statement specifies a maximum dose of 01 gm2 which is not mentioned in the evidence The evidence lists the specific drugs and doses that participants receive throughout the study duration",
        "label": "Contradiction"
    },
    "f64f4990-f41a-49c2-ab74-5897b191c256": {
        "text_answer": "Neutral NA  Explanation The statement is not directly related to the given evidence as it does not address the administration of Eribulin Mesylate or Filgrastim or the comparison between the two trials The statement only mentions the use of Cyclophosphamide in both trials but it does not imply any connection to sexual activity",
        "label": "Entailment"
    },
    "2c8bef4e-9452-4ff9-b04d-66b0f42196d8": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence as the evidence shows that a total of 232 625 patients in the primary trial and 115 667 in the secondary trial suffered from infections which is far less than 185 of the total number of patients",
        "label": "Contradiction"
    },
    "e809d4b1-1730-49a2-aa9f-303afb27b175": {
        "text_answer": "Contradiction The statement does not relate to the information provided about the primary trial",
        "label": "Contradiction"
    },
    "e01e4e41-3577-4556-b481-de0d3777ba18": {
        "text_answer": "Contradiction The statement is not an entailment as mammography is required for the primary trial but not for the secondary trial",
        "label": "Contradiction"
    },
    "83e7efec-6077-4c3c-8ed6-ebe4f715da47": {
        "text_answer": "Contradiction The primary trial includes patients with invasive breast cancer while the secondary trial includes patients with metastatic solid tumors A patient with no detectable tumor based on clinical examination and ultrasonography would not meet the inclusion criteria for either trial",
        "label": "Contradiction"
    },
    "bffaad67-a8e9-43bf-a2ca-bbcaec96218c": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial includes patients with histologically verified stage IIbIIIIV breast cancer while the secondary clinical trial includes patients with a diagnosis of breast cancer and a life expectancy of at least 1 year Stage 4 cancer is a subtype of stage III or IV cancer but it is not the same as stage IIb or III cancer Therefore a patient with stage 4 cancer cannot qualify for both",
        "label": "Contradiction"
    },
    "201ec8b0-f2f0-4c60-8094-0f40761f6d88": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence provided as the primary trial had no reported adverse events and the secondary trial also had no reported adverse events",
        "label": "Contradiction"
    },
    "626b2407-ae7b-43ed-96b6-3ee9e3c290c8": {
        "text_answer": "Contradiction The evidence does not provide any information about the pregnancy status of the patients eligible for the clinical trial",
        "label": "Contradiction"
    },
    "6d595852-44de-4516-9ac8-441283808f1f": {
        "text_answer": "Contradiction  Explanation The evidence states that 98 of patients experienced no adverse events which is a higher percentage than the stated 97 Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "57d179a7-e550-486f-ba5b-40dcdc8927a0": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the primary trial does not mention anything about endobronchial ultrasoundguided miniforceps biopsy or severe anaphylactic reactions to trastuzumab in its inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "b315a999-4315-4e95-95e7-9f402f9d979e": {
        "text_answer": "Contradiction The evidence shows that there was one cardiacrelated adverse event Myocardial ischemia in the first cohort of the primary clinical trial",
        "label": "Contradiction"
    },
    "ba6526b2-e565-4c7b-b931-42590bb703c0": {
        "text_answer": "Entailment The evidence only mentions inclusion and exclusion criteria related to age diagnosis disease measurability and prior chemotherapy lines of treatment in the metastatic setting It does not mention any criteria related to mental health bodyweight size of tumors or estimated life expectancy",
        "label": "Entailment"
    },
    "81ec9878-e668-49dd-99eb-49ea13337c8f": {
        "text_answer": "Contradiction The statement is about an individuals ability to think and solve daytoday problems while the eligibility criteria for the primary trial are related to breast cancer diagnosis and treatment history",
        "label": "Contradiction"
    },
    "ef95d23d-9dc6-494b-9085-b5ccc6822525": {
        "text_answer": "Contradiction The evidence does not support the statement as there is no mention of hypertension dehydration or dyspnea in the provided adverse events for either cohort",
        "label": "Contradiction"
    },
    "41bf82f2-9544-471f-88b0-418e6cd9b5e1": {
        "text_answer": "Entailment for the part related to the infusion method  Explanation The statement that both the placebo and Trabectedin interventions are administered through a 3hour intravenous infusion on a biweekly basis is an entailment based on the evidence provided The evidence states that the placebo is administered as a 3hour intravenous infusion on Day 1 every 21 days and",
        "label": "Entailment"
    },
    "87d7f63c-5fa5-4820-af0e-391ef8986199": {
        "text_answer": "Contradiction  The statement is not an entailment as the evidence only reports that 53 of participants experienced a confirmed partial response or confirmed complete response not just a confirmed complete response",
        "label": "Contradiction"
    },
    "41e9a0e8-3838-4609-86e7-dc9b798db67c": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the alloMSCs intervention is administered via transendocardial injections not intravenous infusion and the given dose is lower than the stated higher dose in the statement",
        "label": "Contradiction"
    },
    "dc8d6268-fd08-4c31-b2d6-50e8a8e750c0": {
        "text_answer": "Contradiction  Explanation  The statement secondary trial participants are administered just one sc injection at the onset while the primary trial group gets weekly injections for a month is a contradiction based on the provided evidence  In the primary trial participants in Intervention 1 received Triptorelin or Degarelix injections every 28 days for 6 cycles and Letrozole tablets daily for 6 cycles",
        "label": "Contradiction"
    },
    "20e20d13-e73f-4df9-b6f7-37df97b32917": {
        "text_answer": "Contradiction  Explanation The evidence provided does not indicate the number of participants in either group who experienced no pain throughout the 10week trial The evidence only reports the average pain intensity scores and the confidence intervals for each group",
        "label": "Contradiction"
    },
    "cdbca781-b6cd-42a1-acac-80617aa1af67": {
        "text_answer": "Entailment  Explanation The evidence describes the patient population and interventions in the primary clinical trial but it does not mention any requirement for regular exercise in either intervention 1 or intervention 2 Therefore the statement that the intervention does not mandate regular exercise for its candidates is an entailment based on the given evidence",
        "label": "Entailment"
    },
    "695ba633-5bf3-48ee-b6f9-f77657f827b7": {
        "text_answer": "Contradiction The primary trial does not have any inclusion criteria related to patients being significantly limited in their selfcare ability",
        "label": "Contradiction"
    },
    "63c2b269-5155-4014-b033-2584a6773867": {
        "text_answer": "Entailment The statement does not contradict the evidence as it does not mention Paclitaxel which is not used in the primary trial interventions",
        "label": "Entailment"
    },
    "287c1319-d37b-4a6a-a0f3-2059ce18b07d": {
        "text_answer": "Contradiction The statement within the last 48 months is not consistent with the trials exclusion criteria which state No history of abdominal fistula gastrointestinal perforation or intrabdominal abscess in the past 6 months and No history of myocardial infarction MI stroke or transient ischemic attacks in the last 6 months",
        "label": "Contradiction"
    },
    "b639e0a1-6e1d-4940-9818-a268732ed88a": {
        "text_answer": "Contradiction  Explanation The statement mentions no recurrence of malignancies and normal red blood cell count which are not supported by the evidence in the primary trial as there was one case of recurrent malignancy and no information about red blood cell count was provided The rest of the statement seems to be a comparison of the frequency of certain adverse events between the two trials which is not directly related to the statement provided",
        "label": "Contradiction"
    },
    "0bd3433b-05d2-416a-b0c4-0a017f546dc2": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because both trials do measure outcomes but they do not employ the same units or outcome measures The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH in units of mIUml while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in units of mg",
        "label": "Contradiction"
    },
    "c6e636a5-7c18-47f4-9563-715fde497ee3": {
        "text_answer": "Contradiction  The evidence does not mention anything about the assessment of margin status or the involvement of a patients first of kin in the final decision for inclusion in the clinical trial",
        "label": "Contradiction"
    },
    "4f5fb0bf-e5bf-47ad-876c-e9aea07feaee": {
        "text_answer": "Contradiction  Explanation The statement eating disorders were frequently observed among the primary clinical trial candidates is a contradiction to the evidence as there is no mention of any eating disorders in the provided adverse events for the primary trial",
        "label": "Contradiction"
    },
    "4d36fe39-7874-4174-853e-dc6406bf9e0b": {
        "text_answer": "Contradiction  Explanation The evidence provided does not allow for a definitive answer regarding whether or not none of the patients in the primary trial experienced the worst pain imaginable for 20 minutes The evidence only reports the average pain intensity scores and the change in average pain intensity between the two intervention groups over a 10week period It does not provide any information about the occurrence or duration of the worst pain imaginable for individual patients",
        "label": "Contradiction"
    },
    "43658af8-5289-485f-98ed-50d005e452e1": {
        "text_answer": "Contradiction The primary trial results do not provide enough information to make a definitive statement about which intervention had the best overall response rate as the statement only mentions Arm A Additionally the secondary trial results do not directly compare the primary trial interventions as they involve different treatments and outcomes",
        "label": "Contradiction"
    },
    "c9d6f05e-40bd-49b1-8ba1-c5489208cede": {
        "text_answer": "Contradiction The primary trial defines each treatment cycle as 21 days and there is no mention of a 360day cycle in the evidence The secondary trial does not have a cyclic treatment in place as stated",
        "label": "Contradiction"
    },
    "0c570cce-3180-45b9-a0b3-4dd7200fc890": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not provide information about the frequency of diarrhea in relation to the nf1 gene mutation",
        "label": "Contradiction"
    },
    "04d76027-45a0-46e3-9308-acc4f8c02a73": {
        "text_answer": "Contradiction The primary trial measures pain intensity using SPID30 while the secondary trial measures bone mineral density using DEXA scan",
        "label": "Contradiction"
    },
    "d71c6377-89da-457d-acbc-827be4ddb8e5": {
        "text_answer": "Contradiction  Explanation The statement There was one psychiatric adverse event in the primary trial which affected less than 10 of patients is a contradiction to the evidence because the evidence states that there were 2 patients 100 each with suicidal ideation which is a psychiatric adverse event and together they affected more than 10 of the patients 200 x ",
        "label": "Contradiction"
    },
    "3afe5a55-731f-4015-85a2-e6df1caa2374": {
        "text_answer": "Contradiction The primary trial excludes patients with potassium levels below the normal range but it does not mention anything about hyperkalemia The secondary trial does not mention potassium levels at all",
        "label": "Contradiction"
    },
    "84859b73-1029-4815-a059-79c20cc06f91": {
        "text_answer": "Entailment assuming psychiatric disorders excludes suicidal ideation which was reported in the trial However its important to note that the statement is not directly addressing the evidence provided but rather making a broader claim about the primary clinical trial The evidence only speaks to the specific adverse events reported",
        "label": "Entailment"
    },
    "e1069782-98e2-4db7-aeed-460b846781c3": {
        "text_answer": "Contradiction The statement does not entail the evidence as the drugs mentioned in the statement epirubicin cyclophosphamide docetaxel and trastuzumab are different from the drugs mentioned in the evidence doxorubicin cyclophosphamide Herceptin and docetaxel Additionally the maximum dose of 100 mgm2 is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "53099f5c-4259-4ad7-bff2-65d2fe6250be": {
        "text_answer": "Contradiction  The primary trial does not provide information on the weekly quantities of MM121 and paclitaxel given to the candidates The statement makes a comparison between the two trials based on the quantities of certain drugs but the primary trial does not provide the necessary information to make that comparison",
        "label": "Contradiction"
    },
    "41b6a327-e552-4e26-971f-25096f53e72d": {
        "text_answer": "Contradiction The evidence states that 909 of the patients suffered from an increase in blood bilirubin which is higher than the stated 49",
        "label": "Contradiction"
    },
    "070ba2da-932a-4a62-861e-3f2c89630b4d": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of any eating disorders in the given adverse events",
        "label": "Contradiction"
    },
    "c38f4f43-886b-41e9-9d42-5ce12e838600": {
        "text_answer": "Contradiction The primary trial does report the percentage of participants with tumor response using RECIST criteria even though it does not specifically use the term Clinical Benefit",
        "label": "Contradiction"
    },
    "feb0cfe7-6bcf-4e82-82b7-460f9cc66a18": {
        "text_answer": "Contradiction The evidence states that patients with measurable or nonmeasurable disease are eligible for the trial Nonmeasurable disease refers to cancer that cannot be measured by current imaging techniques but is still present This includes micrometastatic disease that has spread beyond the primary tumor site but has not yet formed measurable lesions Therefore the statement that patients whose metastasis is not quantifiable or whose cancer hasn",
        "label": "Contradiction"
    },
    "a1a3cda8-7324-4270-aaf9-51ad1b40be07": {
        "text_answer": "Contradiction  Explanation The statement the secondary trial recorded 11 more AEs than the primary trial is a contradiction based on the evidence provided because the evidence shows that there were a total of 11 adverse events in the secondary trial while there were no adverse events reported in the primary trial Therefore the secondary trial did not record 11 more adverse events than the primary trial but rather it recorded 11",
        "label": "Contradiction"
    },
    "5caeaa69-840d-4a32-8279-416bbe1b570e": {
        "text_answer": "Contradiction The primary trial includes postmenopausal females while the secondary trial includes females",
        "label": "Contradiction"
    },
    "1ff9cfe0-06e6-4f99-961c-7854ba9e2c46": {
        "text_answer": "Neutral The statement is not directly related to the given inclusion and exclusion criteria in the evidence",
        "label": "Entailment"
    },
    "3f87dd7c-b00d-4840-b075-70b65e5bf00c": {
        "text_answer": "Contradiction  Explanation The primary trial does not report any instances of bronchopneumonia or general physical health deterioration Therefore the statement that the number of cases is equal in both trials is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "13d0bb71-fc81-4ecf-8628-1321816e41ce": {
        "text_answer": "Contradiction assuming Hypertension Dehydration and Dyspnea are adverse events  Explanation The evidence does not provide information about the occurrence or nonoccurrence of Hypertension Dehydration and Dyspnea in the primary trial The statement asserts that there were 0 cases of these conditions in both cohorts but the evidence does not support this claim",
        "label": "Contradiction"
    },
    "43e968bb-7167-4c0a-8105-8f3e854408af": {
        "text_answer": "Contradiction  The statement implies that there is a difference of nearly half between the percentage of participants in the ERpositive Luminal B group and the Triple Negative group who demonstrated a decrease in the growth factor signature However the evidence only shows that the percentage of participants in the ERpositive Luminal B group is higher than that of the Triple Negative group but it does not indicate that the difference is nearly half",
        "label": "Contradiction"
    },
    "cdd043e8-2430-409a-96b6-8e7b7a2d11f3": {
        "text_answer": "Contradiction  The primary trial includes patients with carcinoma of the breast undergoing lumpectomy while the secondary trial includes patients undergoing mastectomy with tissue expander reconstruction or skinsparing mastectomy These are different surgical procedures so a patient cannot participate in both trials at the same time",
        "label": "Contradiction"
    },
    "c44751aa-dc67-42de-a619-0f0834b88325": {
        "text_answer": "Contradiction The primary trial shows that both arms had lower pCR rates compared to the cohorts in the secondary trial not a small difference between the two arms Additionally the secondary trial shows that Arm 2 had a lower pCR rate than Arm 1",
        "label": "Contradiction"
    },
    "2d16916c-23f3-4638-8a1d-6638aeb46359": {
        "text_answer": "Contradiction  The statement higher count of patients having stable disease in the twelfth week as opposed to week twentyfour is contradicted by the evidence which shows that there were the same number of patients with stable disease at both time points 10 each",
        "label": "Contradiction"
    },
    "a24f59fe-0c4b-48bb-bbff-8dfb4b83ed6b": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there is no requirement for a single injection on the 8th day of the investigation according to the provided evidence",
        "label": "Contradiction"
    },
    "1e24905e-7bf9-4a79-8157-8948f108ecb7": {
        "text_answer": "Entailment assuming that neither the TripleNegative nor the HER2Amplified cohorts received invasive surgery or Neratinib in the provided evidence",
        "label": "Entailment"
    },
    "e4256cc3-09b7-4ad0-b1b1-467cd74b273c": {
        "text_answer": "Contradiction The statement is not related to the evidence provided as the evidence does not mention anything about the unit of time microsecond or the number of patients who suffered an Incidence of Doselimiting Toxicity being exactly two one from each cohort",
        "label": "Contradiction"
    },
    "50757da1-c674-43a7-a3ee-90750e166aa5": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement is about a concept that is not directly related to the evidence provided in the trial The evidence only describes the interventions Memantine and Placebo and their administration schedules The statement is about the meaning of an exacerbating factor and its relationship to the chief complaint The evidence does not provide any information about the effect of Memantine or Place",
        "label": "Entailment"
    },
    "2c4d4e4b-1b19-4a95-a18d-7d0585c90573": {
        "text_answer": "Contradiction  The evidence provided in the text does not support the statement as it relates to a different study with different outcome measurements and patient populations The statement is about patients surviving under 2 months on average while the evidence is about patients surviving up to 9 years in the primary trial and some patients from each cohort surviving more than 6 months",
        "label": "Contradiction"
    },
    "3ff601a7-b05a-4cc4-94e3-bbea555889cb": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement does not entail or contradict the evidence as it does not mention any specific drug used in the primary trial including paclitaxel The statement is about a different condition posterior tongue neoplasm that is not related to the interventions described in the evidence",
        "label": "Entailment"
    },
    "28d5dbe8-5006-4735-8274-fc37e55dbbbd": {
        "text_answer": "Contradiction The statement is not based on the evidence provided as the evidence does not mention any skin condition or bleeds in the adverse events for either cohort",
        "label": "Contradiction"
    },
    "671c7966-67b4-4279-b246-a4e415679a2d": {
        "text_answer": "Contradiction The evidence states that Intervention 1 uses a validated webbased risk assessment which can be considered a form of counselling and risk assessment",
        "label": "Contradiction"
    },
    "8942c478-a2ec-4b68-8da0-7fbce5bb70f7": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial and the secondary clinical trial do have some differences in their outcome assessments but they do share one common outcome assessment which is the measurement of adverse events The primary clinical trial measures the percentage of participants with any treatmentemergent adverse events and serious treatmentemergent adverse events while the secondary clinical trial does not explicitly mention the measurement of adverse events as an outcome assessment",
        "label": "Contradiction"
    },
    "0dd90e62-09f5-4282-9f52-c369a56ba3f5": {
        "text_answer": "Entailment The evidence shows that the median aAUCpa for Arm I Cryotherapy was less negative than Arm II Control indicating that the cryotherapy group had less worsening of symptoms on average",
        "label": "Entailment"
    },
    "fdf46294-f524-478f-9816-e13d7c7c3927": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug or any other hemorrhagebleeding event NCI CTCAE v30 Grade 3 within 4 weeks of first dose of study drug A pulmonary embolism is a type of hemorrhagebleeding event",
        "label": "Contradiction"
    },
    "f42c5f78-bcb9-46e9-8b77-a8b9cbb81b13": {
        "text_answer": "Contradiction The evidence does not provide information about the survival duration of any patient in either group under 30 minutes The statement makes an assertion about all patients in the trial surviving over 3 years on average but the evidence only reports median survival times and does not indicate that all patients survived beyond 3 years",
        "label": "Contradiction"
    },
    "a441e08e-affc-4228-bfac-18ab1ead4bce": {
        "text_answer": "Contradiction The primary trial and the secondary trial measure different outcomes Isothiocyanate concentration in urine vs pain",
        "label": "Contradiction"
    },
    "f9b21d3d-3d5d-4cc6-bf70-733083138b99": {
        "text_answer": "Contradiction The primary trial recorded 0 adverse events while the statement assumes there were 100 adverse events",
        "label": "Contradiction"
    },
    "13d5fd15-4fe1-4152-8987-050cfb32c8fb": {
        "text_answer": "Contradiction The evidence does not provide information about the difference in recurrencefree survival between the two groups",
        "label": "Contradiction"
    },
    "dd5c2791-351d-472f-8c50-a773aa9baa41": {
        "text_answer": "Contradiction The statement is not related to the given evidence The evidence only mentions the inclusion and exclusion criteria for the primary trial and there is no mention of the atrioventricular bundle or the role of a patients first of kin in the trial inclusion process",
        "label": "Contradiction"
    },
    "b71e8f1d-2910-4ac7-9aaf-e709679b0083": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention involves the use of Gefitinib ZD1839 which is a single drug  However in the secondary trial there are two interventions  1 Intervention 1 Zoledronic Acid which is a single drug but it is used in combination with vitamin D and calcium supplements 2 Intervention",
        "label": "Contradiction"
    },
    "3ad0bf0d-7929-4d29-9629-4fea3e6c8fc5": {
        "text_answer": "Contradiction The evidence from the primary trial mentions the use of Suramin and Paclitaxel not vinblastine and doxorubicin",
        "label": "Contradiction"
    },
    "2aa37ee1-47f4-4ee2-a2d5-b11181a89e78": {
        "text_answer": "Neutral  Explanation The statement does not directly entail or contradict the evidence provided The evidence describes the different administration schedules for V935 in Intervention 1 and Intervention 2 for Cohort A but it does not mention anything about preterm birth complications for Cohort A or B",
        "label": "Entailment"
    },
    "ea1d804d-bac9-4ebd-a6bd-0705c988927f": {
        "text_answer": "Contradiction The evidence states that the intervention section outlines a treatment which contradicts the statement that there is no treatment cycle or description of the treatment",
        "label": "Contradiction"
    },
    "5ab7ac4b-19cd-455c-8796-50680cedf7f1": {
        "text_answer": "Entailment The evidence states that both cohorts receive dexamethasone preoperatively which is what the statement asserts",
        "label": "Entailment"
    },
    "4e5a04a1-2513-472b-b2a7-891d68a3b549": {
        "text_answer": "Contradiction  The evidence shows that 286 of ERpositive Luminal B participants demonstrated a decrease in the Growth Factor Signature while 176 of Triple Negative participants did Therefore the ERpositive Luminal B group had a lower percentage of participants with a decrease in the Growth Factor Signature than the Triple Negative group",
        "label": "Contradiction"
    },
    "36969517-2743-4fc8-970a-0846cebda02f": {
        "text_answer": "Contradiction  The statement is about the feelings of the participants regarding their ability to deal with treatment and recovery while the evidence is about the number of participants who had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products These two pieces of information are not directly related to each other and do not entail or contradict each other",
        "label": "Contradiction"
    },
    "1b5d6416-bf6d-4d0b-8b9b-b982d1bbd8a8": {
        "text_answer": "Contradiction The primary trial does not have a requirement for Her2neu breast cancer",
        "label": "Contradiction"
    },
    "aecffac5-b441-4cf6-b939-c7fb19ebac05": {
        "text_answer": "Entailment The evidence shows that there were a total of 4 gastrointestinal adverse events diarrhea colitis ischaemic and vomiting and 3 psychiatric events Menieres disease and vertigo in the primary clinical trial Therefore the statement is an entailment as it is implied in the evidence",
        "label": "Entailment"
    },
    "b907c117-661f-4078-956a-be5b2560b5f4": {
        "text_answer": "Contradiction The evidence shows that no patient in either trial developed shingles",
        "label": "Contradiction"
    },
    "263e2baf-2196-42fb-8d68-e6dea7cad9b5": {
        "text_answer": "Contradiction The evidence states that one patient in the primary clinical trial experienced an increase in blood bilirubin levels",
        "label": "Contradiction"
    },
    "864e3d0c-60fb-43bf-a272-1d590ff8795b": {
        "text_answer": "Entailment The primary trial had a lower total number and fewer categories of adverse events compared to the secondary trial as shown in the evidence",
        "label": "Entailment"
    },
    "1a71b35f-9b20-478b-863d-f7411015d6e8": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 72 weeks while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "c5e1aaba-40f0-49e6-926b-2f28f74b2b1c": {
        "text_answer": "Contradiction The primary trial has different inclusion and exclusion criteria for its phases while the secondary trial has the same criteria for every participant",
        "label": "Contradiction"
    },
    "6e4be816-3da7-4def-ab23-2a4fda805cd0": {
        "text_answer": "Entailment The evidence states that laserassisted fluorescence angiography is used for monitoring perfusion at three separate time points for both interventions and lateral radial incisions are also used for both interventions Therefore the statement is an entailment based on the evidence provided",
        "label": "Entailment"
    },
    "01b56d67-6f6a-4102-959e-eb921954d268": {
        "text_answer": "Entailment for the Primary Trial as the secondary trial does not mention allergies to these antibiotics as an exclusion criterion",
        "label": "Entailment"
    },
    "6b03d4f0-29bf-4a64-8136-2042e2a609ef": {
        "text_answer": "Contradiction The evidence shows that there was an increase in pleural effusion in cohort 2 not a decrease",
        "label": "Contradiction"
    },
    "c216cb60-86c5-4ba4-9092-07bfe620c6ec": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the given evidence The evidence does not provide enough information to determine if the statement is true or false in this context",
        "label": "Entailment"
    },
    "1645d8e9-78e0-42e0-b46e-945c3c8e7d89": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the first cohort had no adverse events according to the evidence while the statement suggests that there were no adverse events in the first cohort but almost every individual in the second cohort encountered at least one However the evidence states that there were no adverse events in the first cohort at all",
        "label": "Contradiction"
    },
    "fe6abe4b-e77b-4ab7-a52c-3157a90f7a2d": {
        "text_answer": "Contradiction The statement is not related to the given evidence The first part of the statement refers to the secondary trial and the age eligibility for that trial while the second part of the statement is about the taxonomic category infraorder which is not related to the eligibility criteria for any trial",
        "label": "Contradiction"
    },
    "b98c3e78-273c-46dd-ad36-db7aabf5f3a9": {
        "text_answer": "Contradiction The primary trial does not provide sufficient evidence to make a definitive statement about the control group outperforming the test group based on operative time alone The secondary trial does not compare operative times between groups",
        "label": "Contradiction"
    },
    "74e35f39-c01b-435b-a5f8-cc1cc8204607": {
        "text_answer": "Contradiction The primary trial specifically states that the breast tumor must be at least 1 cm in diameter which is not met by patients with a breast tumor 200800 micrometers in diameter",
        "label": "Contradiction"
    },
    "19e0531d-7907-46b0-ab0c-e616746498e9": {
        "text_answer": "Contradiction The primary trial involves a different intervention dexmedetomidine administration compared to the secondary trial no dexmedetomidine administration",
        "label": "Contradiction"
    },
    "b6bd5750-21d0-4fcd-80af-749c6dc2a518": {
        "text_answer": "Contradiction  The evidence does not support the statement as it does not provide information about the number of participants with stable disease at week 6 or week 18 Additionally the statement mentions week 6 and week 18 but the evidence only provides data for week 12 and week 24",
        "label": "Contradiction"
    },
    "a0d11ea8-22ae-4af7-885c-40b9e3a98fac": {
        "text_answer": "Contradiction  The evidence mentions inclusion and exclusion criteria related to age mental and physical health status and prior chemotherapy treatments which contradicts the statement that there are no such conditions for eligibility The statement also incorrectly states that caspase3 staining is an immunohistochemical technique used to detect the presence of caspase3 in a tissue sample when in fact caspase3 is an en",
        "label": "Contradiction"
    },
    "663f13bf-bbc7-49f2-926e-b88da56cc74a": {
        "text_answer": "Contradiction The evidence shows that 24 out of 25 participants in the Sunitinib  Docetaxel  Trastuzumab arm of the primary trial experienced treatmentemergent adverse events",
        "label": "Contradiction"
    },
    "401f0d8c-4f4e-4693-8baa-3ae8664480d3": {
        "text_answer": "Entailment The primary trial includes breast cancer as one of the eligible tumor types for Phase 1 and the secondary trial includes breast cancer as one of the eligible tumor types for all cohorts",
        "label": "Entailment"
    },
    "fdce4005-3773-4350-b45b-1c1338e01a26": {
        "text_answer": "Contradiction  Explanation The primary trial reported 4 cases of abdominal pain out of which 1 was identified as biliary colic The secondary trial reported 1 case of biliary colic and 1 case of diarrhoea However the statement suggests that the number of biliary colic and diarrhoea cases are relatively equal across both trials which is not the case based on the provided evidence",
        "label": "Contradiction"
    },
    "3fd8d038-4c72-4f0f-b2d8-0e822f5b96a8": {
        "text_answer": "Contradiction The evidence does not mention any requirement for AfricanAmerican patients to reside in Texas for the duration of the study",
        "label": "Contradiction"
    },
    "7d818afc-93da-4098-a0f0-558bc0095687": {
        "text_answer": "Contradiction The primary trial includes all types of breast cancer for females over 18 while the secondary trial specifically includes BRCApositive breast cancer",
        "label": "Contradiction"
    },
    "4750e9e1-982d-4ca4-ab90-373832ed32d6": {
        "text_answer": "Contradiction The evidence shows that in cohort 1 769 of patients experienced increased pleural effusion and 769 experienced rapid disease progression for a total of 1538 In cohort 2 2500 of patients experienced increased pleural effusion but none experienced rapid disease progression Therefore the statement that 25 of patients experienced both increased ple",
        "label": "Contradiction"
    },
    "8393ad3d-8521-4316-b69e-64910d8af5e7": {
        "text_answer": "Contradiction The primary trial reports results in percentage while the secondary trial reports results in number of participants",
        "label": "Contradiction"
    },
    "aeddc485-09b1-4ddc-9a45-3a8bf0bec2c3": {
        "text_answer": "Entailment The evidence shows a median reduction of 5 percentage points in Ki67 expression at 6 weeks compared to baseline",
        "label": "Entailment"
    },
    "49b3b463-a496-404a-a3a5-07cd7d4aaa92": {
        "text_answer": "Contradiction The primary trial has an inclusion criterion for Japanese female patients but the secondary trial does not have any such requirement",
        "label": "Contradiction"
    },
    "dd4715db-f06d-4168-962c-22cdd764f2b0": {
        "text_answer": "Contradiction The primary clinical trial does not accept patients with a history of interstitial lung disease or pneumonitis",
        "label": "Contradiction"
    },
    "d1d5671f-79dd-4fd3-a4aa-b5f81d8a944f": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence indicates that there were no adverse events in either cohort 1 or cohort 2",
        "label": "Contradiction"
    },
    "f5231a1f-83ff-458f-9dbd-40bd55daae92": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the use of denosumab which is a monoclonal antibody that is injected subcutaneously every 4 weeks The secondary trial on the other hand involves the injection of radioactive Tc99M sulfur colloid for lymphoscintigraphy and the use of gamma probes during surgery There is no mention of the use of",
        "label": "Contradiction"
    },
    "b8b1d79d-ce73-4bf6-a67a-0aea38c604c5": {
        "text_answer": "Contradiction The primary trial involves Alpha Lipoic Acid while the secondary trial involves Necitumumab which are two different interventions",
        "label": "Contradiction"
    },
    "c724f8b4-74e9-4f48-ab39-cc8eb21890e6": {
        "text_answer": "Entailment The secondary trials intervention period is indeed extended by 10 weeks 15 weeks  5 weeks of primary trial compared to the primary trial",
        "label": "Entailment"
    },
    "f7cbcdf1-cee8-4b88-afff-45901ee871af": {
        "text_answer": "Neutral The statement does not directly entail or contradict the evidence provided  Explanation The statement is about a dataset containing supplemental information while the evidence provided is about the results of two clinical trials The statement does not directly relate to the trials or their results so it cannot be considered an entailment or contradiction based on the evidence alone",
        "label": "Entailment"
    },
    "fd5337ee-4098-440b-9e22-0d8c52dbab5a": {
        "text_answer": "Contradiction The statement is incorrect as the units of measure for the primary trial are change in units on a scale for vaginal symptoms and for the secondary trial it is percentage of participants for objective response rate of HER2negative metastatic breast cancer",
        "label": "Contradiction"
    },
    "b443ed89-9fcb-451a-b0f5-3f23183fbeb0": {
        "text_answer": "Contradiction The statement does not provide information about the incidence of acute vomiting in the primary trial for the specific patient population with lung large cell carcinoma The evidence only reports the proportion of participants in the trial who did not experience acute vomiting within the first 24 hours after cyclophosphamide administration",
        "label": "Contradiction"
    },
    "60df29e3-b115-4407-b1f9-dfc2c3d2d3d3": {
        "text_answer": "Contradiction The primary clinical trial includes patients who are 18 years of age or older while the secondary clinical trial specifically excludes children",
        "label": "Contradiction"
    },
    "d35e9b96-20fc-4778-a7db-e87c861c4938": {
        "text_answer": "Entailment  Explanation The statement More than 13 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study is an entailment based on the evidence provided The evidence shows that 381 of participants in Arm 1 and 333 of participants in Arm 2 experienced a p",
        "label": "Entailment"
    },
    "8b59c6dc-98ec-4f07-9274-ba4cc1ff8950": {
        "text_answer": "Contradiction The statement mentions swelling hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial but the evidence provided for both trials shows no reported cases of these adverse events",
        "label": "Contradiction"
    },
    "f5b7285d-3b0a-496a-84c8-012c4873a7be": {
        "text_answer": "Contradiction The secondary trial excludes patients with chemotherapy or radiotherapy within two weeks unstable angina and grade 2 or above neuropathy while the primary trial allows patients with nonhealing surgical wounds but does not mention any exclusion for chemotherapy or radiotherapy within a specific time frame unstable angina or grade 2 or above neuropathy",
        "label": "Contradiction"
    },
    "5dea6bbb-13c3-470c-98a6-3879f17de8c7": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement is not directly related to the evidence provided as the evidence only reports the number of participants analyzed in each arm of the trial not the total number of participants in the study However the statement itself is not contradictory or entailing based on the information given",
        "label": "Entailment"
    },
    "242b1a1a-4a5e-459b-88ea-41ca86093348": {
        "text_answer": "Entailment Both cohorts undergo the same imaging processes with 18FFDG and 18FFPPRGD2 with only a difference in the dosage of 18FFPPRGD2 for cohort 1",
        "label": "Entailment"
    },
    "437d5311-f0fd-4d61-82a2-5db0d07415f6": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention is given orally cabergoline In contrast in the secondary trial the intervention pixantrone dimaleate is exclusively administered intravenously IV Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "8180d5e0-b284-45fe-a390-0c3a54dc663f": {
        "text_answer": "Contradiction The primary trial involves an intraosseous injection of Fluciclatide while the secondary trial involves an oral administration of Chloroquine",
        "label": "Contradiction"
    },
    "d2e448c0-852f-41cc-a53b-866f56e62967": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not provide any information about the specific vaccines being administered to the digestive system kaposi sarcoma patients or healthy volunteers",
        "label": "Contradiction"
    },
    "c94fb60e-6f9e-48ed-b7b7-4468cb2aa6ee": {
        "text_answer": "Contradiction The primary trial only includes patients undergoing surgery for Stage IIII breast cancer and the secondary trial includes patients who have completed surgery for Stage IIII breast cancer However the statement does not specify that the woman has Stage IIII breast cancer after undergoing a mastectomy for Stage IV BC Therefore it is possible for a woman with Stage IV BC to not meet the requirements for either trial",
        "label": "Contradiction"
    },
    "f5a6f0ee-22bd-4731-b973-e8c4736e4d18": {
        "text_answer": "Contradiction The statement is not an entailment as ligament injury is not mentioned in the evidence provided for either trial The statement makes a connection between alcohol consumption and eligibility for the trials but the evidence only mentions alcohol consumption as an exclusion criterion for the primary trial and a potential inclusion criterion for the secondary trial without any mention of ligament injuries",
        "label": "Contradiction"
    },
    "b12011c4-fa87-4249-97e3-635e6e6805a4": {
        "text_answer": "Entailment The statement does not contradict the evidence as it is not related to the inclusion or exclusion criteria regarding nationality ethnicity psychiatric condition or gender",
        "label": "Entailment"
    },
    "7482499c-6836-4f68-83f4-4af09b14d566": {
        "text_answer": "Contradiction The evidence shows that there were no deaths or hospitalizations reported in cohort 2 of the primary trial but the statement asserts that there were no deaths or hospitalizations in the primary trial which includes both cohorts 1 and 2",
        "label": "Contradiction"
    },
    "232d082f-2684-445e-8ca6-9cf32c3d1b34": {
        "text_answer": "Contradiction The primary trial tests Eribulin Mesylate while the secondary trial tests Axitinib and Docetaxel",
        "label": "Contradiction"
    },
    "1fec40c0-4c6f-4e9d-ae16-a962eb45b4dd": {
        "text_answer": "Contradiction The statement is about a chemotherapy regimen for prostate cancer while the evidence is about a breast cancer trial with different inclusion criteria",
        "label": "Contradiction"
    },
    "a7c5f410-1001-4c4c-884d-cdbb9e8d69e4": {
        "text_answer": "Contradiction The evidence shows that 571 of patients in the primary trial suffered adverse events which is greater than 005",
        "label": "Contradiction"
    },
    "32f5c37f-6752-4ebd-840b-d232b65bc138": {
        "text_answer": "Contradiction The evidence does not state that only Australian nationals are eligible for participation in the primary or secondary clinical trials",
        "label": "Contradiction"
    },
    "635f6674-3151-46bc-8344-33ab60b59bd0": {
        "text_answer": "Contradiction The evidence provided for the primary trial mentions no exclusion criteria related to rectovesicovaginal fistulas However the evidence for the secondary trial does not mention any inclusion or exclusion criteria related to this condition Therefore the statement is a contradiction as it implies that the presence or absence of a rectovesicovaginal fistula could affect eligibility for both trials but the evidence does not support this",
        "label": "Contradiction"
    },
    "8af457d5-2a04-43df-a661-2cf10402def6": {
        "text_answer": "Contradiction The primary trial has 0 instances of anemia while the secondary trial has 4 instances",
        "label": "Contradiction"
    },
    "7b2b8832-6e8f-4b56-88fa-5cee3c4e82bf": {
        "text_answer": "Contradiction The evidence shows that there were different numbers of adverse events in the two cohorts",
        "label": "Contradiction"
    },
    "42a51c2f-6b39-487e-989c-dcdc0ad231e1": {
        "text_answer": "Contradiction  The statement does not provide any information about the occurrence or nonoccurrence of septal myocardial infarction in the primary trial participants The statement only discusses the reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products",
        "label": "Contradiction"
    },
    "831e3999-7ce1-4af9-9a28-1282d641a376": {
        "text_answer": "Contradiction The primary trial reports on the MTD of ruxolitinib in combination with paclitaxel while the secondary trial reports on the MTD or maximum feasible dose of MM111 which is not related to the primary trial The statement provides a specific value for the MTD of MM111 but the trials do not directly compare or provide that information",
        "label": "Contradiction"
    },
    "d0a08aeb-5c7c-44a9-a923-fd4e3b094ebd": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence shows that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a higher ORR 0587 compared to the Paclitaxel Plus Bevacizumab group 0489 Therefore the statement that the Paclitaxel Plus Bevacizumab Plus Gemcitabine group had an inferior",
        "label": "Contradiction"
    },
    "8bc20833-6293-47e3-aafe-c7a0ca3be9a6": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 6 months but there is no mention of this criterion in the secondary trial",
        "label": "Contradiction"
    },
    "1cebe988-ac21-4b72-a652-36778fb2cccf": {
        "text_answer": "Entailment The evidence shows that the median aAUCpa for the Arm II Control group was lower than that of Arm I Cryotherapy indicating that the symptoms in the Arm II group worsened more than in the Arm I group",
        "label": "Entailment"
    },
    "338fc59d-601e-42b6-8718-858ffe20928d": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the statement makes no mention of the trial interventions or cohorts and the evidence does not provide any information about the presence or absence of loss of chromosome 5 in the trial participants",
        "label": "Contradiction"
    },
    "77989b91-bbcc-401e-8cd9-bdd17c0d0e3a": {
        "text_answer": "Contradiction The primary trial investigates the effects of sulforaphane supplements on isothiocyanates in urine while the secondary trial investigates the effects of physical therapy on muscle augmentation and pain These are two different outcomes",
        "label": "Contradiction"
    },
    "e82b4df2-47c8-41ed-9b54-9b3c6917ead3": {
        "text_answer": "Contradiction The primary trial does not involve necitumumab but rather alpha lipoic acid which has a different dosing regimen",
        "label": "Contradiction"
    },
    "f0f71529-7742-45c4-945f-ae4e51f9029d": {
        "text_answer": "Contradiction  Explanation The evidence shows that there was one case of edema in each cohort Adverse Events 1 and Adverse Events 2 Therefore the statement that no incidents of hypertension edema and dyspnea were observed in both cohorts is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "1a8ad1c5-284a-4398-9659-2cdbcb4492d8": {
        "text_answer": "Entailment The primary trial had one test group Intervention 1 and one control group Intervention 2 as placebo and the secondary trial also had one test group Intervention 1 with oxybutynin chloride and one control group Intervention 2 with lower dose oxybutynin chloride Both trials followed the design of a pragmatic trial testing the effectiveness of an intervention in a realworld clinical setting",
        "label": "Entailment"
    },
    "c660c228-b490-4779-9ead-ad8b2be40520": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided",
        "label": "Contradiction"
    },
    "9d7e5e1f-b92f-464d-94ea-a7eb3ae730b5": {
        "text_answer": "  Entailment for the Primary Trial and Possible for the Secondary Trial depending on other eligibility criteria not mentioned in the statement  Explanation  The patient meets the eligibility criteria for the Primary Trial as stated in the given evidence However for the Secondary Trial the patients age 32 years falls outside the specified age range 1870 years However the",
        "label": "Entailment"
    },
    "5be5cc6c-ba08-4d21-9939-4ccde58aa23e": {
        "text_answer": "Contradiction The primary trial has specific cancer types listed in its inclusion criteria while the secondary trial is focused on breast biopsy patients and does not mention any specific cancer type Therefore the statement that there are 0 shared inclusionexclusion criteria between the secondary trial and the primary trial and the statement that the regimen used to treat malignant ovarian neoplasm is any regimen that can be used for the treatment of malignant o",
        "label": "Contradiction"
    },
    "ca20d0df-b712-4bb0-b320-704d565a99a6": {
        "text_answer": "Neutral The statement is not directly related to the inclusionexclusion criteria provided in the evidence",
        "label": "Entailment"
    },
    "a83ef28c-db79-4e1b-9ebd-f563905a9ac7": {
        "text_answer": "Contradiction  The evidence provided shows that the mean arm circumference for the waitlist group was actually slightly smaller at 6 weeks compared to baseline while the acupuncture group had a slightly larger reduction in mean arm circumference at 6 weeks compared to baseline Therefore the statement that the acupuncture patients reported greater changes in their lymphedema than those on the waiting list is contradictory to the evidence presented",
        "label": "Contradiction"
    },
    "28061f9c-36e0-4f1f-9f51-1c01efd608a1": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the evidence includes eligibility criteria related to gender age and nationality",
        "label": "Contradiction"
    },
    "c8556c5e-4962-4d9d-8f8d-3cdb07af0627": {
        "text_answer": "Contradiction The evidence provided does not indicate that cbt cognitive behavioral therapy is a component of the qualification criteria for either trial",
        "label": "Contradiction"
    },
    "0a418d49-392b-474e-ad3c-df66ab2566ab": {
        "text_answer": "Contradiction The primary trial uses a cyclic treatment schedule while the secondary trial does not have a cyclic treatment mentioned in the evidence The statement about longhandled appliances is not related to the trials and their interventions",
        "label": "Contradiction"
    },
    "5de55575-82d9-461f-af89-ae41ff70ecb2": {
        "text_answer": "Contradiction The evidence does not indicate that eligibility for the primary or secondary clinical trials is based on nationality or ethnicity",
        "label": "Contradiction"
    },
    "24523cd0-0fe8-455a-93b6-52367820879a": {
        "text_answer": "Entailment The statement that Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial is an entailment of the evidence as DCIS patients are included in the trials inclusion criteria The second part of the statement chemozol is a treatment arm for patients receiving chemotherapy in combination with zoledronic acid is not directly related to the eligibility of DCIS patients for",
        "label": "Entailment"
    },
    "3ee347d0-3ba9-4dc8-8387-1fb15cf1e8b3": {
        "text_answer": "Contradiction The primary trial specifically states that the breast tumor must be 1 cm in diameter while the statement in question specifies a tumor size of 510 cm",
        "label": "Contradiction"
    },
    "a7e7e8e0-d2c9-4eee-9aed-1d957044c7dc": {
        "text_answer": "Contradiction The statement that children and adolescents are not eligible for the primary trial as they do not meet the height requirement is not directly related to the secondary trial which does not mention height as a requirement The statement about childhood malignant penile neoplasm being a rare malignant neoplasm of the penis that occurs during childhood is not relevant to the inclusion or exclusion criteria of either trial",
        "label": "Contradiction"
    },
    "760d8b66-18ea-4e33-b83a-b88173ed8574": {
        "text_answer": "Contradiction  Explanation  The primary trial has several inclusion criteria related to cancer diagnosis stage sensitivity to vinorelbine and life expectancy It also has several exclusion criteria related to pregnancy previous vinorelbine treatment infection and prior anticancer therapy  The secondary trial on the other hand only includes patients undergoing large core breast biopsy in the Radiology Department at the Beth Israel Deacon",
        "label": "Contradiction"
    },
    "eb19e1ef-0bad-4d95-8ebd-dcc1f403a946": {
        "text_answer": "Entailment The primary trial lasts for 10 weeks longer than the secondary trial",
        "label": "Entailment"
    },
    "29cbfa09-f98c-4991-a6ab-0dc8cca951d3": {
        "text_answer": "Contradiction The primary trial had 34 patients and documented no adverse events while the secondary trial had 1 patient and also documented no adverse events However the statement does not specify that the number of adverse events must be the same in both trials for it to be considered entailing",
        "label": "Contradiction"
    },
    "8881c72a-24fc-48ab-86fb-a1d38392ec33": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports the units of measure used in each trial There is no mention of therapeutic nervous system procedures in the evidence",
        "label": "Contradiction"
    },
    "b5a078c6-afd5-427e-beab-c7c11cc96da2": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the dosages of Zoledronic Acid and Denosumab mentioned in the primary trial are different from those in the secondary trial The statement compares the dosages directly from the two trials which are not comparable",
        "label": "Contradiction"
    },
    "5d44d70b-1163-4a55-9247-db7bf9a901fc": {
        "text_answer": "Entailment The primary trial had fewer total adverse events and fewer types of adverse events than the secondary trial so the statement that the primary trial had more total adverse events and more types of adverse events is a contradiction of the evidence However the statement that the primary trial had fewer total adverse events and fewer types of adverse events is an entailment of the evidence Therefore the statement as given is a contradiction of the evidence but the neg",
        "label": "Entailment"
    },
    "fe0472bd-acfb-4a56-abed-20b0a4e6b48f": {
        "text_answer": "Contradiction  The evidence describes the eligibility criteria for the primary clinical trial which includes patients with histologically confirmed breast cancer that is metastatic M1 multiple sites of new disease measurable or nonmeasurable disease and no known brain or CNS metastases The statement however refers to patients with Tx Nx Mx T0 N1 M0 or T1 N1 M1 tumors which are",
        "label": "Contradiction"
    },
    "78c44e7a-6f94-4167-aafa-13c14da01bbf": {
        "text_answer": "Contradiction The statement specifies a time frame of 05 years while the exclusion criteria in the evidence state a time frame of 6 months",
        "label": "Contradiction"
    },
    "f8a72a9e-357d-4786-8d5d-66ee4ce4d1b2": {
        "text_answer": "Contradiction  The primary trial involves the use of 8 different interventions 7 drugs and surgery while the secondary trial involves the use of only 2 interventions two drugs Therefore the statement is a contradiction based on the evidence provided",
        "label": "Contradiction"
    },
    "c5ece9f7-9119-4fa2-b60d-f2f15c68ae02": {
        "text_answer": "Contradiction  Explanation The statement Recurrent malignancies Graftversushost disease Anaemia Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial is a contradiction based on the evidence provided  The evidence shows that Recurrent malignancies and Graftversushost disease were more",
        "label": "Contradiction"
    },
    "a68ff0d2-ddc4-4db1-9371-21bec6159585": {
        "text_answer": "Contradiction The primary trial measures treatmentemergent adverse events while the secondary trial measures changes in total sleep time These are not the same outcome measures",
        "label": "Contradiction"
    },
    "970f06b2-0935-4cde-a070-ddd7adb8ed5e": {
        "text_answer": "Contradiction The statement is a contradiction based on the evidence provided as the primary trial only includes postmenopausal female subjects and male subjects with a female partner who is not of childbearing potential or has undergone a successful vasectomy while the secondary trial only includes female patients",
        "label": "Contradiction"
    },
    "f1f9d4b4-4877-49ad-a2e2-f53efbe40ef9": {
        "text_answer": "Entailment  Explanation The statement All but one of the patients treated with Sunitinib  Docetaxel  Trastuzumab in the primary trial suffered a TreatmentEmergent adverse event is entailed by the evidence since the evidence reports that 24 out of 25 participants or 96 experienced treatmentemergent adverse events  The statement less than half the patients suffered",
        "label": "Entailment"
    },
    "25c9b995-fedc-45ae-a3c8-d66c116711b0": {
        "text_answer": "Entailment given that the negative occurrence is an adverse event and the statement only requires that there be one negative occurrence regardless of its nature",
        "label": "Entailment"
    },
    "1bf21a6b-6676-4da7-9b80-4fd67722e030": {
        "text_answer": "Contradiction  Explanation  The primary trial includes women with carcinoma of the breast undergoing lumpectomy while the secondary trial includes patients undergoing immediate tissue expander reconstruction following mastectomy or skinsparing mastectomy utilizing bioprosthetic mesh Both trials have the inclusion criterion of patients being 18 years of age or older However the primary trial also includes women with nonpalpable m",
        "label": "Contradiction"
    },
    "08793821-1888-49b3-9117-f0548482b5f9": {
        "text_answer": "Contradiction The primary trial had 76 participants in the intervention group and 75 in the control group while the secondary trial had 163 participants in the intervention group and 147 in the control group However the statement specifically asks about the second cohort which is not defined in the evidence provided Its possible that the statement is referring to a different cohort or that there is a mistake in the statement Without more",
        "label": "Contradiction"
    },
    "396eb2aa-c85e-4477-bdf5-a0926499350a": {
        "text_answer": "Contradiction The primary trial does not list organ transplant as an exclusion criterion within the given time frame but the secondary trial explicitly excludes patients who have undergone major surgery within 28 days prior to the study registration date which includes organ transplant",
        "label": "Contradiction"
    },
    "071c3399-1525-4965-8a3e-b3dfac561b6b": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as both cohorts in the primary clinical trial received preoperative dexamethasone intravenously",
        "label": "Contradiction"
    },
    "32d95cac-6a3d-4e4d-a8ac-3371ec9d0da4": {
        "text_answer": "Contradiction The evidence provided does not mention anything about lung cancer as an inclusion or exclusion criterion for either the primary or secondary trial",
        "label": "Contradiction"
    },
    "d1118512-9c0b-4480-ab67-d4e0c7de390d": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 3 years while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "ff258472-19f3-4dea-8edc-bc591c30fc37": {
        "text_answer": "Contradiction  Explanation The statement mentions adverse events such as recurrent cancers graftversushost disease anaemia heart failure and diffuse alveolar haemorrhage were seen more frequently in the primary clinical trial than in the secondary clinical trial However the evidence shows that there were no cases of graftversushost disease anaemia heart failure or diff",
        "label": "Contradiction"
    },
    "285b3905-8e47-4b26-8aa5-2d9d7f717a6c": {
        "text_answer": "Contradiction  Explanation  The primary trial participants do receive injections vitamin D repletion therapy but they are not weekly subcutaneous injections as stated in the given statement",
        "label": "Contradiction"
    },
    "3b6f6c52-5713-45fd-823a-23ab1754539a": {
        "text_answer": "Contradiction The primary trial administers its intervention sublingually while the secondary trial administers its intervention orally making the statements inconsistent with each other",
        "label": "Contradiction"
    },
    "bbb61326-9879-44f0-af97-523e7dc2231a": {
        "text_answer": "Contradiction  Explanation The evidence shows that the median aAUCpa for Arm I Cryotherapy was 14 117 to 68 while for Arm II Control it was 44 571 to 162 The difference between the two medians is statistically significant indicating that there is a difference in symptom severity between the two groups Therefore",
        "label": "Contradiction"
    },
    "95036529-d29d-4425-90a4-d366664c99c5": {
        "text_answer": "Contradiction The statement is not related to the evidence provided about the primary trial",
        "label": "Contradiction"
    },
    "1fa45a65-8a51-41e7-af9d-01ab8e0f3e1c": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that the incidence of hepatotoxicity was higher than both hypertension and pancreatectomy cases",
        "label": "Contradiction"
    },
    "2ad5cf58-daab-4432-8670-8964380a4fa9": {
        "text_answer": "Contradiction The statement is contradictory because the primary trial involved denosumab injections while the secondary trial did not The statement also incorrectly states that denosumab needs to be injected monthly when in fact it was given every 4 weeks in the primary trial The secondary trial utilized lymphoscintigraphy instead of denosumab injections",
        "label": "Contradiction"
    },
    "4cfe211a-a80a-48ee-993a-2b7c8a91b57c": {
        "text_answer": "Contradiction  Explanation The primary trial investigates Eribulin Mesylate while the secondary trial investigates Axitinib",
        "label": "Contradiction"
    },
    "f27a6b09-cfd5-48ac-80d8-a70bd15bcb4d": {
        "text_answer": "Contradiction  Explanation The primary trial reported no adverse events while the secondary trial reported several adverse events that affected more than 03 proportion of patients including diarrhea 2333 neutrophil count decreased 333 and platelet count decreased 1000",
        "label": "Contradiction"
    },
    "668cbbc7-bc89-440f-8503-a7e273c4fab3": {
        "text_answer": "Entailment The primary trial includes patients with stage 4 breast adenocarcinoma that is ER positive PR positive or HER2neu negative and the secondary trial also includes these patients so the statement is an entailment",
        "label": "Entailment"
    },
    "b995d047-8aaf-48fd-9fd7-ebed843b0877": {
        "text_answer": "Entailment  Explanation The statement in both the primary clinical trial and the secondary clinical trial a single death was noted in the adverse events is an entailment based on the evidence provided The evidence shows that one death was reported in the adverse events of both trials",
        "label": "Entailment"
    },
    "f22196d4-1e0f-4626-9736-d78452dc650a": {
        "text_answer": "Contradiction The statement has no relation to the provided evidence The evidence only discusses adverse events in the trials and does not mention anything about the cybb gene mutation",
        "label": "Contradiction"
    },
    "abb25993-d191-4b47-99c1-fe3b53732dc1": {
        "text_answer": "Contradiction The statement is contradictory because the evidence provided for the primary trial does not mention anything about ppp2r2a gene mutation as an inclusion or exclusion criterion",
        "label": "Contradiction"
    },
    "6d0812b9-f9bd-4cd6-82aa-9c272eba23be": {
        "text_answer": "Contradiction The primary trial did not report any Thromboembolic events",
        "label": "Contradiction"
    },
    "aff21004-0238-46bb-b68b-99d1e3035947": {
        "text_answer": "Contradiction The primary trial does not have any mention of obesity as an inclusion or exclusion criterion while the secondary trial does not mention anything about obesity",
        "label": "Contradiction"
    },
    "3762bbcc-dcb8-4173-bf16-934f3c590566": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the primary trial involves the administration of epacadostat twice daily BID while the secondary trial involves sunitinib being administered once daily The statement suggests that epacadostat is given to participants twice as often as sunitinib is given but this is not the case based on the evidence provided",
        "label": "Contradiction"
    },
    "1616266d-e1bf-4327-9523-f584f713b265": {
        "text_answer": "Entailment The statement implies a reduction of 10 in the percentage of cells with Ki67 expression which is consistent with the evidence showing a decrease from 15 to 10 in the median percentage of cells with Ki67 expression",
        "label": "Entailment"
    },
    "693c9e39-1648-4f3a-8a23-d642d7355b98": {
        "text_answer": "Contradiction The statement is not related to the evidence provided as the evidence only reports the Recurrencefree Survival rates for the two groups in the primary trial without mentioning squamous papillomatosis or a comparison of Recurrencefree Survival rates between the two groups with a specific percentage difference",
        "label": "Contradiction"
    },
    "9321cbe9-2f04-4751-90fd-47a92f424f04": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial does not accept patients with resectable nonsmall cell lung cancer or small cell lung cancer It only accepts patients with advanced andor unresectable disease for these types of lung cancer",
        "label": "Contradiction"
    },
    "e1c80f41-c3f0-49c8-8fc8-0bfc32e9936a": {
        "text_answer": "Contradiction The evidence shows that there were no hospital admissions in the second cohort but it does not provide information about deaths The statement goes beyond the evidence by claiming that there were no deaths as well",
        "label": "Contradiction"
    },
    "063f5147-ab53-4f22-b390-bdf6d6589a03": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that the primary clinical trial uses two different medication types each with their own unique administration routes IV bisphosphonate Q4W and subcutaneous denosumab Q12W",
        "label": "Entailment"
    },
    "1f6d3870-934f-4a75-87a3-0e52c19cd010": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 Cohort A two IM injections of V935 LD are given not a single oral dose In Intervention 2 Cohort B a different treatment regimen is used which includes three electroporation injections of V934 LD followed by two IM injections of V935 LD Therefore the statement that",
        "label": "Contradiction"
    },
    "6fd7b2ea-805b-45ad-b1e7-d073f9944d77": {
        "text_answer": "Irrelevant  Explanation The statement does not directly relate to the evidence provided as it discusses the presence of renal disease in an individual while the evidence only compares the dosages of lenalidomide and lapatinib used in the two trials",
        "label": "Entailment"
    },
    "4c926c31-8786-47b0-a032-1d59f759bca5": {
        "text_answer": "Entailment Both trials administer their interventions orally",
        "label": "Entailment"
    },
    "2278c029-239d-43ba-9da2-440281e4fd0e": {
        "text_answer": "Entailment The evidence does not mention invasive surgeries or the administration of neratinib as part of the primary clinical trial for any of the cohorts",
        "label": "Entailment"
    },
    "f3345897-b99a-4ff2-8bcd-5d1aeb3b698d": {
        "text_answer": "Contradiction The statement is about infant acute undifferentiated leukemia while the intervention section is about surgical and imaging procedures which are not related to the condition itself",
        "label": "Contradiction"
    },
    "32f90f55-6faf-41ed-991a-6f8e9e158200": {
        "text_answer": "Contradiction  Explanation In the primary trial group 2 receives 05μgkg of dexmedetomidine which is not the same as myalgias joint pains In contrast in the secondary trial no myalgias are given to any patients",
        "label": "Contradiction"
    },
    "27aec260-8dcc-4611-8389-dc9c10d3518d": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that tamoxifen reduces the Ki67 expression in tumors by an average of 40 but it does not provide information about the diameter of the tumors",
        "label": "Contradiction"
    },
    "6a83fd1d-9dde-419d-8342-ec1be514869e": {
        "text_answer": "Contradiction The statement is a contradiction to the inclusion criteria which state that candidates for the primary clinical trial must have a HER2 positive tumor either IHC 3 or FISH",
        "label": "Contradiction"
    },
    "91b35ed1-37f4-440a-a82d-99c639ad7e2a": {
        "text_answer": "Contradiction The evidence does not support the statement that the primary clinical trial had twice as many participants with cholelithiasis than the secondary clinical trial as there are no reported cases of cholelithiasis in either trial",
        "label": "Contradiction"
    },
    "6e1489a6-3a42-4b52-b690-fb1dd8892749": {
        "text_answer": "Contradiction The evidence shows that there were no recorded adverse events in cohort 2 but the statement implies that all recorded adverse events occurred in cohort 1",
        "label": "Contradiction"
    },
    "5ce47a02-7653-4be0-8747-cc04ae14145a": {
        "text_answer": "Contradiction  The evidence states that 98 of participants had no recurrence within 3 years but it does not provide information about adverse effects The statement about 97 of participants not encountering any adverse effects is not directly related to the evidence provided",
        "label": "Contradiction"
    },
    "84246007-e5dd-48da-b548-e0f6403bd67a": {
        "text_answer": "Contradiction The evidence does not provide any information about ki67 expression in the secondary clinical trial",
        "label": "Contradiction"
    },
    "a3ab9532-5335-47ab-b19f-33ab64372ce2": {
        "text_answer": "Contradiction The statement is not related to the evidence provided which is about units of measure in clinical trial results",
        "label": "Contradiction"
    },
    "19a043cf-96b9-4285-9e9c-1405403bf608": {
        "text_answer": "Contradiction The statement individuals with histologically proven metastatic scbc are not permitted to participate in the primary clinical trial is a contradiction to the inclusion criteria of the primary trial which states that patients must have histologically documented metastatic or unresectable nonsmall cell lung cancer head and neck cancer urothelial transitional cell carcinoma or breast cancer to be eligible for the study",
        "label": "Contradiction"
    },
    "d5abbde0-b23c-4e60-91fc-cb6a7735b68f": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of perfusion computed tomography target lesion or heartrelated adverse events in the evidence",
        "label": "Contradiction"
    },
    "7ebbbace-7ced-4e16-bfa7-681b1c6f00f3": {
        "text_answer": "Contradiction The primary trial does not mention the use of PDR001 or MCS110",
        "label": "Contradiction"
    },
    "5e38b301-c67d-47dc-8117-ad86b9eeb524": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the primary trial involves a combination of multiple drugs Dakins solution and radiation therapy are considered as separate interventions and surgical intervention therapeutic conventional surgery while the secondary trial also involves a combination of multiple drugs everolimus and exemestane but no surgical intervention is mentioned in the statement",
        "label": "Contradiction"
    },
    "db15e6cc-ceeb-4f48-b3a1-bca36a6b54f4": {
        "text_answer": "Contradiction The primary trial and the secondary trial measure different outcomes lesions vs radiation dermatitis and hyperpigmentation so it is not possible to make a direct comparison between their results",
        "label": "Contradiction"
    },
    "9f5587e3-ff70-42fa-9ddf-e59fc2729d77": {
        "text_answer": "Contradiction The evidence states that patients with severe intellectual impairment unable to carry out basic daily routines and established depression are excluded from the primary and secondary trials However the statement suggests that complete disability is a requirement for the secondary trial which is not the case based on the provided evidence",
        "label": "Contradiction"
    },
    "361464b0-c0ac-404a-8432-ff8100152bff": {
        "text_answer": "Contradiction The evidence shows that there is a different number of adverse events reported for each group in the primary trial",
        "label": "Contradiction"
    },
    "094e7aec-88db-4ad0-b995-ece8587fd48b": {
        "text_answer": "Contradiction The primary trial includes an intervention using a tissue expander which may involve periodic imaging for monitoring and the secondary trial includes interventions involving transendocardial injections",
        "label": "Contradiction"
    },
    "0c776d98-6a76-407b-9cc8-ded769af766e": {
        "text_answer": "Entailment Both trials recorded zero adverse events in their respective cohorts which is fewer than 50",
        "label": "Entailment"
    },
    "1d20e438-806f-4695-bc8f-d6a0ce1f0299": {
        "text_answer": "Entailment given that adequate liver function is an inclusion criterion in the trial",
        "label": "Entailment"
    },
    "28002c57-ff24-4b59-9f0e-0dfdbaab7f88": {
        "text_answer": "Contradiction The primary trial intervention is given orally paclitaxel carboplatin doxorubicin cyclophosphamide and cabergoline and intravenously paclitaxel and carboplatin while the secondary trial treatment is given intravenously pixantrone dimaleate Neither trial involves topical administration",
        "label": "Contradiction"
    },
    "55067973-6ec2-4cf7-b98a-6cd2210db8b0": {
        "text_answer": "Contradiction The primary trial involves the use of fluciclatide through intravenous injection not oral dosage The secondary trial involves the use of chloroquine through oral dosage not intradermal injection",
        "label": "Contradiction"
    },
    "84fe3c19-bee9-4639-9569-455cf74f8c64": {
        "text_answer": "Contradiction The evidence states that no adverse events were reported in cohort 1 of the primary clinical trial Therefore it contradicts the statement that numerous adverse events were reported by all participants in both cohort 1 and cohort 2",
        "label": "Contradiction"
    },
    "c7fd3efb-5319-40f3-aba0-a54c76a50768": {
        "text_answer": "Contradiction  Explanation The evidence shows that there were 10 participants with stable disease at week 24 while there were only 12 participants with stable disease at week 12 Therefore there were more participants with stable disease at week 12 than at week 24 which contradicts the statement that there were fewer patients with stable disease in week 12 compared to week 24 Additionally the statement does not",
        "label": "Contradiction"
    },
    "c70623c3-85f0-4480-a772-349a89de7d43": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because the primary trial includes adverse events related to the BloodBone Marrow system specifically Neutropenia Lymphopenia and Platelets which are not linked to the cardiovascular system In contrast the secondary trial does not report any adverse events related to the cardiovascular system",
        "label": "Contradiction"
    },
    "0f224562-3266-490d-9b52-10a4d84f5685": {
        "text_answer": "Contradiction based on the given evidence there have been no unexpected death incidents or hospital admissions recorded in either trial",
        "label": "Contradiction"
    },
    "9c10ceed-9cc6-473d-87c0-fa0b51353222": {
        "text_answer": "Contradiction The primary trial does conform to a specific cycle arrangement as shown in the evidence",
        "label": "Contradiction"
    },
    "e85599cc-08a6-4270-a168-cac94d5ce47d": {
        "text_answer": "Entailment The evidence confirms that both cohorts in the primary clinical trial received preoperative intravenous administration of dexamethasone",
        "label": "Entailment"
    },
    "e6a3ed43-5bb0-40b2-9c4b-8a60e2b201df": {
        "text_answer": "Contradiction The primary trial involves the use of fluciclatide while the secondary trial involves the use of chloroquine instead",
        "label": "Contradiction"
    },
    "e21cdb34-eb9d-4439-81ff-6dae554954c6": {
        "text_answer": "Contradiction  The statement implies that there were 11 more instances of intestinal perforation in the secondary trial compared to the primary trial However the evidence only shows that there was 1 instance of intestinal perforation in the secondary trial while there were no instances in the primary trial Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "d0a60b09-e029-4c35-b896-3647ce468594": {
        "text_answer": "Contradiction The evidence does not mention anything about the Her2neu peptide vaccine or sargramostim being administered in the primary trial",
        "label": "Contradiction"
    },
    "fbda9d7c-12d9-4b04-8047-da25419e1c3b": {
        "text_answer": "Contradiction  The statement mentions that participants receive 8 different drugs but the evidence only lists 7 drugs epirubicin cyclophosphamide docetaxel trastuzumab epirubicin cyclophosphamide docetaxel and trastuzumab are all different drugs but they are given in different combinations and doses throughout the study The maximum dose of 50",
        "label": "Contradiction"
    },
    "bf1b6561-6731-457a-801d-8af93bc8857b": {
        "text_answer": "Entailment assuming the patient meets all other inclusion criteria for both trials",
        "label": "Entailment"
    },
    "90c519e9-7981-4a72-af6a-cc032657458a": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the primary trial intervention section does not mention surgical and imaging procedures",
        "label": "Contradiction"
    },
    "68be42cb-7fb2-491a-a6ad-8f37972f9500": {
        "text_answer": "Contradiction The statement does not follow directly from the evidence as the eligibility criteria for the primary trial do not explicitly mention the presence or absence of a ccnd3 gene mutation as a requirement for participation",
        "label": "Contradiction"
    },
    "0ef9a5c8-1159-4147-a204-59a3ae183e7d": {
        "text_answer": "Contradiction The statement is about the number of drugs in the interventions not about thyroid gland lipoadenoma",
        "label": "Contradiction"
    },
    "f13676ce-309e-4cf5-866d-542b2a214b27": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it only shows the percentage of participants with a decrease in the growth factor signature for each group but it does not provide information about the magnitude or direction of the difference between the two groups",
        "label": "Contradiction"
    },
    "ce9ff719-a4b1-4506-91ef-eea478339ced": {
        "text_answer": "Contradiction The evidence clearly states that sunitinib was administered to participants in the primary clinical trial",
        "label": "Contradiction"
    },
    "dc545712-7b34-41d2-9166-441ee0366105": {
        "text_answer": "Entailment Both interventions in the primary trial involve multiple transendocardial injections",
        "label": "Entailment"
    },
    "b358fb9c-1152-4e1a-88eb-743e965d58fc": {
        "text_answer": "Entailment The statement is a specific case of the exclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "b9b32a2d-94f0-413e-95f3-08177622a743": {
        "text_answer": "Contradiction The statement is not related to the evidence provided in the primary trial The evidence only discusses the eligibility criteria for a patient with breast cancer to participate in the trial while the statement is about a patent delivery system vial which is an unrelated concept",
        "label": "Contradiction"
    },
    "591794ae-5578-4bb4-a527-106947636ddb": {
        "text_answer": "Contradiction The evidence shows that no more than 048 and 000 of participants in the primary trial and secondary trial respectively experienced several adverse events Neither of these percentages is greater than 30",
        "label": "Contradiction"
    },
    "270f0f03-2316-40b0-8e7a-e42c499258da": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the evidence shows that there were no recorded adverse events in the primary trial while the statement asserts that there were canine subjects in the primary trial",
        "label": "Contradiction"
    },
    "fa12778d-4f82-4dd9-8ac0-decbef38472b": {
        "text_answer": "Contradiction The statement provided is not related to the evidence given in the primary trial The evidence only provides information about the median overall survival in two groups of patients who underwent oophorectomy at different phases of their menstrual cycles The statement is about an individuals attendance at school social events due to their hearing",
        "label": "Contradiction"
    },
    "32c2c3e7-4421-49e2-b1d0-2e9b125245e1": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence reports the percentage of participants who experienced a confirmed complete response CR but the statement is about square milliseconds which is a unit of time and has no relation to the percentage of participants experiencing a CR in the primary trial",
        "label": "Contradiction"
    },
    "b032a728-a998-4b78-945a-048dbc5126f5": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence only reports data on changes in betaCTX levels and does not provide information on primary tumour diameter",
        "label": "Contradiction"
    },
    "bf5c5c27-0b57-4397-9ba9-3c2895bcbe5d": {
        "text_answer": "neutral neither entailment nor contradiction  Explanation The statement does not directly relate to the inclusion or exclusion criteria of the primary or secondary trials The first part of the statement is true as women aged 18 or older are eligible for both trials The second part of the statement is a medical fact about a specific type of adenocarcinoma which is not related to the eligibility criteria for the trials",
        "label": "Entailment"
    },
    "e200f18a-ae9e-490f-a348-537187a65300": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because the primary trial recorded the occurrence of palpitations pericardial effusions and abdominal pains while the secondary trial recorded none of these adverse events",
        "label": "Contradiction"
    },
    "d6716be9-247d-4c01-beb3-cd5bbbb6f9ec": {
        "text_answer": "Contradiction The evidence states that 18FFDG and 18FFPPRGD2 PETCT imaging is being used in the primary clinical trial study groups",
        "label": "Contradiction"
    },
    "61a20e23-7b57-4acc-b594-273f4536941c": {
        "text_answer": "Contradiction The primary trial has an age restriction less than 30 years old while the secondary trial does not mention any age restriction",
        "label": "Contradiction"
    },
    "872c6392-9ba9-4224-a579-de0deb401842": {
        "text_answer": "Contradiction  Explanation The statement mentions fewer cases of mucositis oral epileptic seizures and thromboembolic events reported in the primary trial compared to the secondary trial However neither mucositis oral nor epileptic seizures were reported in the primary trial according to the provided evidence Therefore the statement is a contradiction based on the given evidence",
        "label": "Contradiction"
    },
    "ef4f8fe9-1d8e-464f-aa42-c33c073bb493": {
        "text_answer": "Entailment assuming that psychiatric adverse event includes suicidal ideation as given in the evidence  Explanation The statement there was one psychiatric adverse event in the primary trial which affected less than 1 of patients is an entailment of the evidence because the evidence shows that there was one patient with suicidal ideation which is a psychiatric adverse event and this affected less",
        "label": "Entailment"
    },
    "44cf1331-403a-4711-84e0-93f677307a6c": {
        "text_answer": "Contradiction  Explanation  The primary trial determines the MTD using the number of patients who experience doselimiting toxicity DLT and identifies the MTD as the level below the cohort where DLT occurred in less than one third of patients The secondary trial defines the MTD as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 36 patients These definitions",
        "label": "Contradiction"
    },
    "4a88976f-0af4-449e-97d9-5b3f1ce94668": {
        "text_answer": "Entailment The statement includes all the exclusion criteria mentioned in the evidence Therefore if a patient has experienced any of those conditions in the past 6 months they would not be eligible for the trial according to the given criteria",
        "label": "Entailment"
    },
    "97acf304-2707-4a1b-81e7-339fde2ed0ee": {
        "text_answer": "Contradiction The inclusion criteria state that there should be no evidence of dementia  Mini Mental State Examination MMSE 23 but some evidence of cognitive impairment Frontotemporal dementia and Mixed dementia are both types of dementia",
        "label": "Contradiction"
    },
    "2a9e682e-382c-4361-a76f-f4cf5c39819d": {
        "text_answer": "Entailment The statement All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3 is an entailment of the inclusion criteria in the evidence which state that Histologically confirmed infiltrating primary breast cancer of  20 cm in largest clinical diameter and HER2 positive tumor either IHC 3 or FISH are required for participation in the trial",
        "label": "Entailment"
    },
    "0c27bcc9-3108-4d4a-901a-22718c22d288": {
        "text_answer": "Contradiction  Explanation The evidence shows that out of 25 participants none of them experienced a complete response by week 24 Therefore the statement that The majority of patients in the primary trial experienced complete response by week 24 is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "3153ffe1-3625-4900-8a12-861b575959b0": {
        "text_answer": "Contradiction  The statement all groups in the primary clinical trial are administered equal doses of docetaxel doxorubicin and cyclophosphamide during the trial with the same recurrent pattern is not an entailment or a contradiction to the evidence provided However the second statement however the second cohort undergoes three additional cycles of these specific medications contradicts the first statement as the",
        "label": "Contradiction"
    },
    "eabae980-d833-47b7-8f0e-82242e662880": {
        "text_answer": "Contradiction The primary trial only includes patients undergoing breast reconstruction and does not accept patients with stage IV breast cancer The secondary trial excludes patients with stage IV breast cancer",
        "label": "Contradiction"
    },
    "a8d30960-8533-42a5-949d-3fe706508806": {
        "text_answer": "Contradiction  The evidence states that the administration of dexamethasone is preoperative for both cohorts and intravenous but the statement suggests that it is preoperative for the first cohort and postoperative for the second cohort",
        "label": "Contradiction"
    },
    "28368708-e1e6-416e-8119-0d2712a89380": {
        "text_answer": "Contradiction The primary trial does not list severe obesity as an inclusion or exclusion criterion while the secondary trial does not mention anything about obesity Therefore the statement that patients with severe obesity may participate in both the primary clinical trial and the secondary clinical trial is not entailed or contradicted by the evidence provided",
        "label": "Contradiction"
    },
    "0b444449-045a-414d-be8e-1ff558525e83": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial administers Enzalutamide orally to both groups 1 and 2",
        "label": "Contradiction"
    },
    "84a23fa9-2758-4ea6-9eca-ca89b580378a": {
        "text_answer": "Contradiction The primary trial and secondary trial involve different interventions and fluorescence in situ hybridization is not mentioned as being performed in either trial",
        "label": "Contradiction"
    },
    "745a2452-3a24-4e39-971f-3f7fe661f999": {
        "text_answer": "Contradiction The evidence provided does not mention anything about xp222 or its relation to emesis in the primary trial",
        "label": "Contradiction"
    },
    "a184cea4-fa4e-4548-a5d7-b3a94ab1130b": {
        "text_answer": "Contradiction The primary trial does not report any cases of febrile neutropenia or cholelithiasis",
        "label": "Contradiction"
    },
    "552c79f8-3f17-4a7d-be66-d4cdc8749a66": {
        "text_answer": "Contradiction  Explanation The statement requires that patients receive at least 002g of mcs110 every 21 days which is equivalent to 002gkg if we assume an average patient weight of 70kg However the evidence shows that in Intervention 1 patients receive only 1 mgkg of MCS110 every 3 weeks which is less than 0",
        "label": "Contradiction"
    },
    "863f7074-fb4b-4c82-9e30-bb785f85f816": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the secondary trial does not involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine in a weekly cycle",
        "label": "Contradiction"
    },
    "70130418-63df-4ffb-9d78-7416daee50ba": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that no adverse events were recorded for cohort 1 or cohort 2 Therefore it is not possible for all adverse events to have been solely associated with members of cohort 2",
        "label": "Contradiction"
    },
    "1a8cfb13-ebf0-48c4-a452-e26ac7a14863": {
        "text_answer": "Contradiction for Intervention 1 only  Explanation The evidence states that Intervention 1 includes a validated webbased risk assessment which is a form of counselling and risk assessment Therefore the statement that neither cohort received any counselling or risk assessment is a contradiction for Intervention 1 However the statement is entailment for Intervention 2 as it is stated that Intervention 2 is the control",
        "label": "Contradiction"
    },
    "dd27a6e7-3b83-4a84-bc40-5ba39617a1c1": {
        "text_answer": "Contradiction The evidence states that patients with histologically documented metastatic or unresectable breast cancer are eligible for the trial but the statement excludes them unless they are positive for ER or PR",
        "label": "Contradiction"
    },
    "a4a2c0ba-3fa9-4fad-9258-7e517ae85e25": {
        "text_answer": "Contradiction The primary trial explicitly excludes alcoholic patients while the secondary trial allows them if they drink less than 5 alcoholic drinks a day",
        "label": "Contradiction"
    },
    "fdb097f0-b7ba-4314-a865-c89b1179aeb4": {
        "text_answer": "Contradiction The evidence states that there was only 1 case of increased pleural effusion in the second cohort which is not 25",
        "label": "Contradiction"
    },
    "93e1969e-1e96-49b2-874f-6cba2e42a6e4": {
        "text_answer": "Entailment The statement is an entailment of the inclusion criteria of the primary clinical trial as stated in the evidence",
        "label": "Entailment"
    },
    "95c7070d-76e7-4618-b95f-56b233dffb16": {
        "text_answer": "Contradiction The primary trial does not provide information on the amount of weekly MM121 and Paclitaxel received by the candidates",
        "label": "Contradiction"
    },
    "3592e711-ad4f-4f99-afde-3de2106ee5cd": {
        "text_answer": "Contradiction The evidence shows that there were no cases of diarrhea reported in the secondary trial while there were 7 cases in the primary trial Therefore the statement that the incidence of diarrhoea was higher among participants of the primary clinical trial than it was among the secondary clinical trial subjects is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "595cee41-9cd2-4e9e-8ba5-2b3620985018": {
        "text_answer": "Contradiction  Explanation The primary trial measures the change in units on a scale for vaginal symptoms and the secondary trial measures the percentage of participants with objective response rate using RECIST v10 criteria Both trials do utilize units and time frame for their measurements",
        "label": "Contradiction"
    },
    "32cd31d2-605b-4419-89a7-a6881bb792dd": {
        "text_answer": "Contradiction The primary trial does not provide information about age requirements for participation",
        "label": "Contradiction"
    },
    "e9941afc-cfd4-4bfa-bbce-eec2b84eb27d": {
        "text_answer": "Entailment The statement the protocol of the primary clinical trial includes a bitherapy regimen for its study duration is an entailment of the evidence as the evidence clearly states that the neoadjuvant therapy consists of two different drugs epirubicin and cyclophosphamide given in combination followed by docetaxel and trastuzumab",
        "label": "Entailment"
    },
    "893a5337-2aa9-4a87-a020-4c2f03cd4aea": {
        "text_answer": "Contradiction The primary trial does not provide information about age requirements",
        "label": "Contradiction"
    },
    "cbcbfb22-0467-4ba0-b2dc-1f9bd073c27f": {
        "text_answer": "Contradiction  Explanation  The statement in the primary trial results there were more patients with stable disease in the end of the third month than in the end of the sixth month but no patients with complete response in the end of third or sixth month is a contradiction to the evidence provided  The evidence shows that at week 12 there were 12 participants with stable disease and at week 24 there were 1",
        "label": "Contradiction"
    },
    "fe1ea6e0-dd6d-44d4-a9db-750c890f08c8": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "ab7fc69a-25c8-4bee-ad2b-526c6ea638e4": {
        "text_answer": "Contradiction  Explanation The evidence provided indicates that the data was collected at weeks 12 and 24 and the majority of patients had stable disease SD at both time points There were no complete responses CR reported at either time point Therefore the statement that the majority of patients in the primary trial experienced complete response by week 168 days is contradictory to the evidence presented",
        "label": "Contradiction"
    },
    "44b41322-9fb1-4a02-b2c5-4faead5489aa": {
        "text_answer": "Contradiction The statement is not related to the evidence provided as it does not mention any adverse events in the trials",
        "label": "Contradiction"
    },
    "278549fe-1d04-44de-88dc-e0661e8f234b": {
        "text_answer": "Contradiction  Explanation The statement the primary clinical trial has fewer total and different kinds of adverse events recorded compared to the secondary trial is a contradiction based on the evidence provided The evidence shows that the primary trial had no recorded adverse events while the secondary trial had a higher number of adverse events and some different kinds of adverse events",
        "label": "Contradiction"
    },
    "824add43-b242-4278-9be4-04f1566039cd": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as there is no mention of an injection being administered on the eighth day of the study in the provided evidence",
        "label": "Contradiction"
    },
    "bd89597d-82f5-461f-aa6e-ef215afcc6a5": {
        "text_answer": "Contradiction  Explanation  In the primary trial participants receive pembrolizumab every 3 weeks Q3W in combination with epacadostat which is taken orally twice daily BID  In the secondary trial sunitinib is administered to participants but there is no mention of pembrolizumab or its frequency The statement does not hold true as the frequency of pemb",
        "label": "Contradiction"
    },
    "46a79c10-315b-4975-9949-508fc379af87": {
        "text_answer": "Contradiction The statement 12 adverse events were observed in the course of the primary clinical trial is a contradiction to the evidence as the evidence shows that 0 adverse events were observed in the primary trial",
        "label": "Contradiction"
    },
    "6e971275-b508-4627-9380-39dc63e90b3d": {
        "text_answer": "Contradiction as the evidence mentions nothing about vaccines being administered in the trial",
        "label": "Contradiction"
    },
    "ab6d9f92-0380-4e3a-9bff-032ad4d918ed": {
        "text_answer": "Contradiction The primary trial did not report any cases of acute myocardial infarction",
        "label": "Contradiction"
    },
    "8d27bb53-e66e-4eab-bea4-0597fd5760b5": {
        "text_answer": "Contradiction The secondary trial does not include pulmonary embolisms as an exclusion criterion",
        "label": "Contradiction"
    },
    "a793df3f-fa04-4d48-a2c6-006589d52e84": {
        "text_answer": "Contradiction  Explanation The statement On average both cohorts of the primary trial suffered a deterioration in cognitive function is a contradiction to the evidence as the results show that the Tamoxifen group had a mean standardized score of 004 049 and the Ovarian Function Suppression group had a mean standardized score of 021 092 Since a negative standard",
        "label": "Contradiction"
    },
    "f54c9be8-81b3-4544-9e82-b7058b9911f5": {
        "text_answer": "Entailment Both trials require a baseline performance status but the specific scoring system may differ",
        "label": "Entailment"
    },
    "df43c972-9623-462c-9044-2d632e1daafb": {
        "text_answer": "Contradiction  The primary trial includes patients with benign breast disease including papillary carcinoma but the secondary trial does not mention papillary carcinoma as a qualifying condition",
        "label": "Contradiction"
    },
    "026b062f-0ebf-4e02-9ff8-3bbd12f09ea7": {
        "text_answer": "Entailment The statement is a subset of the inclusion criteria mentioned in the evidence",
        "label": "Entailment"
    },
    "70e1b8ee-05e4-4427-ba8b-c8762a677b9a": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy while the secondary trial does not involve radiation therapy at all The statement incorrectly assumes that both trials involve the administration of fulvestrant in a tablet form BID but it is only a part of the secondary trial",
        "label": "Contradiction"
    },
    "f96fa263-12b2-475c-926d-57b8588e85ef": {
        "text_answer": "Contradiction  Explanation The statement the primary clinical trial welcomes patients diagnosed with tx nx mx t0 nx m0 or t1 n1 m1 tumors refers to patients with Tx unknown Nx unknown Mx unknown stage breast cancer T0 no evidence of primary tumor Nx unknown M0 no evidence of metastasis stage breast cancer or T1",
        "label": "Contradiction"
    },
    "e9f1fcfa-40ed-4360-bf37-4260888d241b": {
        "text_answer": "Contradiction The primary trial involves whole breast radiation therapy while the secondary trial involves intramuscular injections and oral medication These are not the same treatments",
        "label": "Contradiction"
    },
    "e21904b2-3e78-4f20-80e3-562a82fc9cfe": {
        "text_answer": "Contradiction The statement children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial is a contradiction because the evidence states that children are not eligible for the primary trial but it does not mention anything about their eligibility for the secondary trial",
        "label": "Contradiction"
    },
    "0ff4990d-1f43-4516-a7b4-62b59526439d": {
        "text_answer": "Contradiction The statement Requiring considerable assistance and frequent medical care is not mentioned in the inclusion or exclusion criteria of the primary trial",
        "label": "Contradiction"
    },
    "02ef43dd-1a1c-49c4-8ce0-01f03f733e81": {
        "text_answer": "Contradiction  Explanation  The statement subject status subcategory is a subdivision of subject status data is a general statement that does not directly relate to the inclusion or exclusion criteria of the primary or secondary trials  However the statement 18 years olds are excluded from the secondary trial contradicts the primary trials lack of age restriction The primary trial includes patients presenting for large core breast biopsy without specifying",
        "label": "Contradiction"
    },
    "82080910-276d-4987-8d95-0a39b92ce3ee": {
        "text_answer": "Contradiction The primary clinical trial mentioned in the evidence is for breast cancer not colon cancer",
        "label": "Contradiction"
    },
    "159bf774-0488-4260-94ed-e106c3e02bf7": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that cohort 1 of the primary trial had more reported cases of palpitations pericardial effusions and abdominal pains compared to cohort 2 of the primary trial not fewer as stated in the statement The secondary trial had no reported cases for comparison",
        "label": "Contradiction"
    },
    "224ad5d9-659b-474a-b9ff-7cb17e104ddf": {
        "text_answer": "Contradiction The statement is not supported by the evidence as the evidence does not provide information about the individual with the longest PFS in cohort 1 having survived 35 months without disease progression or death The evidence only provides the median PFS for each cohort",
        "label": "Contradiction"
    },
    "46299940-216a-446b-bab8-6005845f46c6": {
        "text_answer": "Entailment The statement is an entailment of the evidence as it accurately summarizes the findings of the primary clinical trial",
        "label": "Entailment"
    },
    "f12f052d-fd1b-407b-a2d9-923f00111a45": {
        "text_answer": "Contradiction The evidence states that women of childbearing potential WOCBP and sexually active fertile men whose partners are WOCBP but not using an acceptable method of birth control are excluded from the study Therefore the statement that men of reproductive age and women who can bear children are suitable for the primary clinical trial is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "bd7ca920-80f7-4bf8-a09c-3f619056e700": {
        "text_answer": "Entailment assuming that minimal refers to less than 5 adverse events in the primary trial",
        "label": "Entailment"
    },
    "7e271bbd-26e8-422e-be5c-54d294da815a": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial only includes patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast that is estrogen andor progesterone receptor positive Patients with stage 4 invasive carcinoma are not eligible for the trial",
        "label": "Contradiction"
    },
    "8c002058-a160-4eab-bb58-5874ac1a86d4": {
        "text_answer": "Entailment The statement is entailed by the evidence as the evidence shows that specific symptoms are reported as adverse events in the primary clinical trial",
        "label": "Entailment"
    },
    "6734e552-d882-446e-a02f-c6bbe2eeb6ed": {
        "text_answer": "Entailment The patient meets all the inclusion criteria for both trials",
        "label": "Entailment"
    },
    "f72c1fc3-cfdb-4aa3-a8a8-968f416e35b7": {
        "text_answer": "Entailment  Explanation The statement during the primary clinical trial and the secondary clinical trial no adverse events relating to cardiac or psychiatric conditions were observed is an entailment based on the evidence provided The evidence shows that no adverse events relating to cardiac conditions were observed in either trial and no adverse events relating to psychiatric conditions were observed in the primary trial The secondary trial did not report data on psychiatric adverse",
        "label": "Entailment"
    },
    "8623aaca-7fb2-44d5-b968-a064007b7112": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial only includes patients with histologically proven DCIS or stage IIII invasive carcinoma of the breast Patients with stage 4 invasive breast carcinoma are not eligible for the trial",
        "label": "Contradiction"
    },
    "5df26e2d-1a55-4d02-b95b-1796c872a7ec": {
        "text_answer": "Contradiction The statement is not an entailment as over 910ths of patients did not suffer any adverse events in neither trial but the evidence shows that there were adverse events reported in both trials",
        "label": "Contradiction"
    },
    "048dc5c5-ef7e-4717-850e-521e58feecf0": {
        "text_answer": "Contradiction  Explanation The statement makes a comparison between the frequency of Epacadostat administration in the primary trial and the frequency of sunitinib administration in the secondary trial However the primary trial involves Epacadostat being given twice daily BID while the statement asserts that Epacadostat is given twice as frequently as sunitinib Sunitinib is given once daily in the secondary trial",
        "label": "Contradiction"
    },
    "5ba46a49-9158-4409-815d-0830526da5c4": {
        "text_answer": "Contradiction  The evidence states that 833 80 out of 96 of participants in the Ketorolac 30 mg group achieved recurrencefree survival while 897 96 out of 107 of participants in the NaCl 09 3ml group achieved recurrencefree survival The statement however claims that 130 participants from the",
        "label": "Contradiction"
    },
    "65130a82-a75f-4faa-85a9-5ec4535aa67b": {
        "text_answer": "Contradiction  Explanation The statement is a mathematical equation and does not directly relate to the evidence provided which pertains to adverse events in the primary trial and the number of patients in each cohort The evidence does not entail or contradict the statement",
        "label": "Contradiction"
    },
    "496667f2-e493-4b4e-a257-7b8de3833e8b": {
        "text_answer": "Entailment The placebo and Trabectedin interventions differ only in the drug administered not in the infusion schedule",
        "label": "Entailment"
    },
    "5b19b14f-2049-4c5f-8e3b-5d8dffa5d687": {
        "text_answer": "Contradiction The statement contradicts the inclusion criteria of the primary trial which excludes patients with ER and PR positive breast cancer",
        "label": "Contradiction"
    },
    "40d84c7b-e126-4d6f-9588-eb9c385ca716": {
        "text_answer": "Contradiction The primary trials Group 2 receives dexmedetomidine which is not the same as myalgias The secondary trials cohorts do not receive any myalgias as a treatment",
        "label": "Contradiction"
    },
    "18c09a69-f72b-42db-b15b-45e369db34e5": {
        "text_answer": "Contradiction  The primary trial explicitly states that patients with cerebral metastases are not eligible and the statement suggests that those with 45 cerebral metastases in the cerebral cortex are eligible for the secondary trial",
        "label": "Contradiction"
    },
    "cd2cb8fc-7624-479c-b9ee-e2ca3cf5ea18": {
        "text_answer": "Contradiction The primary trial does not provide information on ki67 expression but the secondary trial mentions correlative studies which could include ki67 analysis",
        "label": "Contradiction"
    },
    "6f4c1d2f-4b97-4f77-b25b-004addb58726": {
        "text_answer": "Contradiction The statement is contradictory to the evidence provided for the secondary trial as the use of Herceptin within the last six months is an exclusion criterion for the secondary trial",
        "label": "Contradiction"
    },
    "b9fd7445-fced-4f32-9efb-7e142d1963e2": {
        "text_answer": "Contradiction The evidence shows that the percentage of patients suffering adverse events is different between the two cohorts",
        "label": "Contradiction"
    },
    "a52b9758-f769-4350-b617-5215621b815b": {
        "text_answer": "Entailment The statement is an entailment because the evidence clearly states that the doses of carboplatin are different between the two cohorts in the primary clinical trial",
        "label": "Entailment"
    },
    "bad327e8-73f2-4903-a0bf-ed5d08c81f69": {
        "text_answer": "Contradiction The primary trial assesses the change in serum levels of Follicle Stimulating Hormone FSH while the secondary trial assesses the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel",
        "label": "Contradiction"
    },
    "9bd8875f-ce04-496a-b039-6a84bb2e5548": {
        "text_answer": "Irrelevant  The statement is irrelevant to the evidence provided as the primary and secondary trials measure different outcomes The primary trial measures the change in severity of vaginal symptoms while the secondary trial measures the objective response rate of HER2negative metastatic breast cancer",
        "label": "Entailment"
    },
    "602c538d-9b6f-4a94-8423-b7d5427ee15e": {
        "text_answer": "Contradiction The primary trial intervention section does provide a description of the treatment which includes partial breast irradiation in 4week cycles",
        "label": "Contradiction"
    },
    "5e094086-297e-44c7-9119-aa451e326e8c": {
        "text_answer": "Neutral The evidence does not provide enough information to determine if the statement is an entailment or a contradiction as the statement does not relate to the inclusion or exclusion criteria for the trials provided in the evidence",
        "label": "Entailment"
    },
    "fc16338c-2505-48c4-ab18-e7de394cab62": {
        "text_answer": "Neutral The evidence does not directly address the statement about AfricanAmerican patients and the concept of borderline resectable mass is not mentioned in the inclusion or exclusion criteria for the trial",
        "label": "Entailment"
    },
    "451c8e9e-03c1-4b7a-9b84-5129c5623f1b": {
        "text_answer": "Entailment The statement is a subset of the inclusion criteria in the evidence",
        "label": "Entailment"
    },
    "e561775c-d739-405c-ac1e-a8a9ccca4530": {
        "text_answer": "Contradiction The primary trial administers its intervention sublingually while the secondary trial administers its intervention orally",
        "label": "Contradiction"
    },
    "5ed2538b-155d-4527-aa80-b6a19c5a6602": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not provide information about primary tumour diameter",
        "label": "Contradiction"
    },
    "a680a9d1-387f-48e3-8e30-01b306c0b964": {
        "text_answer": "Contradiction The statement mentions nonneoplastic esophageal disorders which are not mentioned in the exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "3d580aba-2e7b-44bc-a094-83f404ebbd6a": {
        "text_answer": "Contradiction The primary trial does not use Objective cognitive function scores measured with CogState as its units of measure Instead it measures the severity of vaginal symptoms using the Vaginal Symptom Measure VSM on a 5point ordinal response scale",
        "label": "Contradiction"
    },
    "cf1b44d2-94e8-49b6-adbf-036a44f28402": {
        "text_answer": "Contradiction  Explanation The primary clinical trial records 0 cases of bronchopneumonia and general physical health deterioration while the secondary clinical trial records 1 case each Therefore the statement that the primary clinical trial records a larger number of cases is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "0c902de2-30b5-4ab8-9739-70be987d043a": {
        "text_answer": "Contradiction The statement is not an entailment as the evidence shows that only 2500 of cohort 2 patients suffered from increased pleural effusion but it also states that none of the patients in cohort 1 suffered from this adverse event",
        "label": "Contradiction"
    },
    "86dd343d-01be-46f6-aed5-9ad9423aca98": {
        "text_answer": "Contradiction  Explanation The primary trial did not record any adverse events while the secondary trial recorded several adverse events that affected more than 3333 of patients Therefore the statement that none of the adverse events in the secondary trial affected more than 60 of patients is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "22a06af0-a4f9-4311-92e0-d2d13a24b9b1": {
        "text_answer": "Entailment with the assumption that the number of occurrences in the primary trial is greater than in the secondary trial for the mentioned adverse events",
        "label": "Entailment"
    },
    "943f62ca-d87c-4a5e-9355-6750d7d9b58f": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the dosages mentioned in the statement do not correspond to the actual dosages given in the interventions described in the evidence  In the primary trial the dosage of Denosumab is 120 mg Q4W every 4 weeks and the dosage of Tamoxifen in the secondary trial is 10 mg once daily for 21 days out",
        "label": "Contradiction"
    },
    "6e2f3c50-84c2-41e2-8188-a83c94b2704b": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that there were adverse events other than eyelid oedema upper gastrointestinal haemorrhage and chest pain observed in the secondary clinical trial",
        "label": "Contradiction"
    },
    "bad8129b-64a4-4dfc-bb88-8bcea4fe2dc4": {
        "text_answer": "Contradiction  Explanation The evidence provided does not allow for a definitive answer on whether cohort 2 of the primary clinical trial experienced significantly fewer incidents of neutropenia compared to cohort 1 of the secondary clinical trial despite receiving larger doses of empegfilgrastim The evidence only shows the mean duration of neutropenia for each cohort in the primary trial and the number of participants experiencing neutropen",
        "label": "Contradiction"
    },
    "603ccef1-eacf-4053-85d3-106eda10ca83": {
        "text_answer": "Contradiction The inclusion criteria state that the breast cancer is unilateral one breast only",
        "label": "Contradiction"
    },
    "4ac023d3-e86c-47bb-bbd5-1b6907e8cab3": {
        "text_answer": "Entailment The evidence states that the doses of talazoparib vary between breast and ovarianperitoneal cancer patients but it also states that the treatment method talazoparib itself varies between the two patient groups Therefore the statement that the treatment method applied in the primary clinical trial varies depending on whether the patient has breast cancer or ovarianperitoneal cancer is an entailment based on the evidence provided",
        "label": "Entailment"
    },
    "ed3e6033-e499-4743-9aca-a275a80a1e4e": {
        "text_answer": "Contradiction The primary trial results do not provide any information about human papillomavirusrelated mucosal head and neck squamous cell carcinoma or its association with Vitamin D levels",
        "label": "Contradiction"
    },
    "3c749ffd-27b3-473d-92c9-c4d3899c9689": {
        "text_answer": "Contradiction The primary trial shows a small difference in pCR rates between the two cohorts while the secondary trial shows a much larger difference between the two arms",
        "label": "Contradiction"
    },
    "5ce949a2-19fb-4580-8b0e-f0652dd064e3": {
        "text_answer": "Contradiction The primary trial includes patients with a breast tumor 1 cm in diameter while the statement specifies a tumor of 200mm 8 inches in diameter which is not consistent with the inclusion criteria of the primary trial The secondary trial does not mention tumor size as a criterion so it is not directly related to the statement",
        "label": "Contradiction"
    },
    "2f5d2e0a-6378-4b00-b5ed-760d021808c8": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the provided evidence  Explanation The statement does not directly relate to the inclusion or exclusion criteria of the primary or secondary trials The statement is about a type of meningioma which is not mentioned in the trials Therefore it cannot be determined as an entailment or contradiction based on the provided evidence",
        "label": "Entailment"
    },
    "96ee335e-d938-4b45-a22d-49b03dbb2af0": {
        "text_answer": "Contradiction The statement does not relate to the provided evidence about hot flash frequency in the primary trial",
        "label": "Contradiction"
    },
    "38e0b539-6f73-4e11-bb55-0b021f66ee84": {
        "text_answer": "Contradiction The statement does not entail the evidence as the radiation therapy doses are the same but the duration of the intervention for cohort 1 is longer due to the inclusion of Active Breathing Coordination which is not present in cohort 2",
        "label": "Contradiction"
    },
    "ee03b5cc-6cfe-4b3a-8429-493f95c97b71": {
        "text_answer": "Contradiction The primary trial requires a primary tumor greater than 2 cm diameter while the statement suggests a patient whose primary tumor is not measurable",
        "label": "Contradiction"
    },
    "e9c0f175-b715-4b33-86a2-aa21c2990164": {
        "text_answer": "Entailment The evidence states that the radiation therapy doses are different between the two cohorts",
        "label": "Entailment"
    },
    "827cb89b-a78f-49e9-b342-d00e7b46e61f": {
        "text_answer": "Contradiction The statement is not supported by the evidence provided as the evidence only reports data on changes in betaCTX levels and does not provide information on primary tumour diameter",
        "label": "Contradiction"
    },
    "4bc6699d-0ac2-4358-9425-1d377151ffa8": {
        "text_answer": "Entailment Note The statement is an entailment as long as we assume that the term Maximum Tolerated Dose MTD is used interchangeably between the two trials even though the secondary trial also mentions the term Maximum Feasible Dose in addition to MTD",
        "label": "Entailment"
    },
    "a0ebcb11-7643-4861-b26c-8b1716fd00c1": {
        "text_answer": "Neutral  Explanation The statement is not directly related to the evidence provided The evidence only mentions the occurrence of adverse events deaths and hospitalizations in two cohorts of a primary trial while the statement is about the age when individuals first began smoking cigarettes regularly Therefore the statement is neither an entailment nor a contradiction based on the evidence",
        "label": "Entailment"
    },
    "13d13c8d-1d58-411f-943b-cbcd836b8d17": {
        "text_answer": "Contradiction  The statement assumes that Cohort 1 received less ALT801 than Cohort 2 but the evidence shows that Cohort 1 received 0015 mgkgdose and Cohort 2 received 0040 mgkgdose To determine if the statement is an entailment or contradiction we would need to compare the exact doses administered in",
        "label": "Contradiction"
    },
    "09f76c97-d8e4-45bd-9365-71e654770e39": {
        "text_answer": "Entailment Both trials involve the use of cyclophosphamide Paclitaxel and pegfilgrastim but the contexts in which they are used may differ The statement does not require that the use of these drugs be in the same context or with the same interventions for the statement to be true",
        "label": "Entailment"
    },
    "1ccb499d-d126-4ec6-bed1-c121dfa13d2d": {
        "text_answer": "Entailment  Explanation Both trials include patients who are 18 years of age or older This is one common inclusion criterion",
        "label": "Entailment"
    },
    "909d54ab-358d-4892-9bd1-e71d6d3bc24c": {
        "text_answer": "Contradiction  The statement says that the percentage of cells expressing Ki67 increased by 8 but the evidence shows that the median percentage of cells expressing Ki67 at 6 weeks was 10 238 which is lower than the baseline percentage of 15 1025 Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "15f4f1d2-c4db-403e-83ed-85e6958ee7ed": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events in both the primary and secondary trials Therefore it is a contradiction to the statement that the number of adverse events in the secondary clinical trial was greater than those in the primary clinical trial",
        "label": "Contradiction"
    },
    "0c4d0064-476e-426e-ae13-4f53c07ea0b4": {
        "text_answer": "Contradiction The primary trial excludes participants who have responded to aromatase inhibitor ai therapy while the secondary trial does not mention anything about ai therapy responsiveness as a criterion for inclusion or exclusion",
        "label": "Contradiction"
    },
    "34208e81-25b5-40a7-ba91-ffdece7c96e1": {
        "text_answer": "Contradiction  The evidence shows that the number of patients with stable disease remained the same at week 12 and week 24 with 10 patients at week 24 The statement suggests a decrease in the number of patients with stable disease from week 12 to week 24",
        "label": "Contradiction"
    },
    "afa65be8-62bf-4c63-8670-a997a06c6943": {
        "text_answer": "Contradiction The evidence does not support the statement as there were no fatalities reported in the primary trial",
        "label": "Contradiction"
    },
    "c4ab76ed-d3ce-4368-b081-c39413094966": {
        "text_answer": "Contradiction The statement is not an entailment as the primary trial did not report any adverse events while the secondary trial did report some adverse events",
        "label": "Contradiction"
    },
    "cac3538f-89a2-4037-9928-4aaa708ae34f": {
        "text_answer": "Contradiction The primary trial mentions Suramin and Paclitaxel as the interventions while the secondary trial does not mention any specific interventions in its intervention section",
        "label": "Contradiction"
    },
    "abd83d4d-ac75-4626-928d-1b511a61d2b7": {
        "text_answer": "Contradiction The statement refers to a specific patients PFS while the evidence only provides the median PFS for each treatment group",
        "label": "Contradiction"
    },
    "dc3aaeaa-d573-410b-a1f2-a55af755fc83": {
        "text_answer": "Contradiction The evidence clearly states that participants receive multiple types of drugs with prescribed dosages throughout the study duration",
        "label": "Contradiction"
    },
    "8a3619a4-4224-4451-b7f8-8fc2ff8ec26f": {
        "text_answer": "Contradiction The statement is not an entailment as the primary trial allows for the use of antineoplastic chemotherapy with the exception of antiHER2 agents androgens and estrogens with certain conditions but only if the patient has been on a constant dose for at least 28 days and is not expected to stop the medication during the study period",
        "label": "Contradiction"
    },
    "710206ba-d90c-4341-a1ae-b937ffc50a2f": {
        "text_answer": "Contradiction The statement does not relate to the evidence provided The evidence only discusses the number of participants with clinical benefit CR PR or SD at week 12 and week 24 and does not mention anything about feelings of anger",
        "label": "Contradiction"
    },
    "29fce0a9-c8ac-4851-afbf-a0fbd8357eb9": {
        "text_answer": "Contradiction  The statement is not supported by the evidence provided as the evidence only shows the Ki67 expression change from baseline to 6 weeks not after 12 months of treatment",
        "label": "Contradiction"
    },
    "08d2198a-3bd7-453e-8ad1-0e35312cb348": {
        "text_answer": "Contradiction The evidence does not provide information about whether any patient in the GTx024 1mg group gained over 10 kilos of lean body mass",
        "label": "Contradiction"
    },
    "d0856f66-d9fb-4bbd-906e-9602d9121c22": {
        "text_answer": "Entailment The primary trial includes patients with stage IV breast adenocarcinoma that are ER positive PR positive or HER2neu negative as a subset of its inclusion criteria The secondary trial specifically requires these same biomarker characteristics for eligibility Therefore the statement is an entailment as the secondary trials criteria are a subset of the primary trials criteria",
        "label": "Entailment"
    },
    "9ab1125f-0d0b-4480-b5c2-8a09378a8df4": {
        "text_answer": "Entailment The statement correctly identifies that the only difference between the two interventions is the dose of durvalumab",
        "label": "Entailment"
    },
    "fb362bcb-d93e-4d35-9127-db0efd9012dc": {
        "text_answer": "Entailment The evidence does not contradict the statement as it does not provide information about the number of adverse events in the secondary trials Adverse Events 2 category",
        "label": "Entailment"
    },
    "dcb23a61-648b-4831-92e9-9e61cc596be3": {
        "text_answer": "Contradiction The evidence mentions adequate liver function as an inclusion criterion for the primary trial",
        "label": "Contradiction"
    },
    "73876da9-0c79-43eb-9d1f-b7f2d729f43c": {
        "text_answer": "Contradiction  Explanation  In the primary trial there were two intervention groups one receiving doxorubicin HCl liposome and pyridoxine and the other receiving placebo  However in the secondary trial there were two test groups one receiving a higher dose of oxybutynin chloride and the other receiving a lower dose of oxybutynin chloride  The",
        "label": "Contradiction"
    },
    "2bf9e0d9-1195-4c03-b2bc-d491ff1cd174": {
        "text_answer": "Entailment The statement follows directly from the evidence as 1 out of 11 patients 909 had an increase in blood bilirubin which is equivalent to 3636 of the patients suffering from this adverse event",
        "label": "Entailment"
    },
    "726f25cd-4611-43a5-b7c6-15f7393b67ee": {
        "text_answer": "Contradiction  The evidence provided does not support the statement as it relates to monophasic synovial sarcoma as this condition is not mentioned in the provided data The statement compares the percentage of participants in two different groups of the trial who demonstrated a decrease in the growth factor signature but it does not provide any information about monophasic synovial sarcoma",
        "label": "Contradiction"
    },
    "3670694c-a13e-4639-bc3d-e51db3bf8149": {
        "text_answer": "Contradiction The statement does not relate to the evidence provided The evidence only discusses the proportion of participants who were up to date for colorectal breast and cervical cancer screenings before and after an intervention No information is given about the number of patients with cervical cancer or the status of their screenings before the intervention",
        "label": "Contradiction"
    },
    "a830799d-017f-4656-aed0-d428d5e0c73f": {
        "text_answer": "Contradiction The evidence shows that there were no documented adverse events in cohort 2 while the statement asserts that all documented adverse events occurred in cohort 1",
        "label": "Contradiction"
    },
    "2d241b66-d0a0-4012-9d5b-1ef1a74bcd79": {
        "text_answer": "Contradiction The primary trial lasts for 10 weeks 10 x 1  10 and the secondary trial lasts for 24 weeks 24 Ten is not three times longer than twentyfour",
        "label": "Contradiction"
    },
    "67fc355a-1537-479d-b0fc-cd39bdb3cf6d": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the dosages of Zoledronic Acid and Denosumab mentioned in the primary and secondary trials are not directly comparable",
        "label": "Contradiction"
    },
    "ef3e540e-b8dc-4fd5-9eaa-f32a657a57c6": {
        "text_answer": "Entailment Both trials have the same inclusion criteria regarding functional ECOG status 2 which can be considered a performance status condition",
        "label": "Entailment"
    },
    "9b49f98a-af07-455e-af36-4f6a3f7e3e52": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because pericardial effusions were not reported in the primary trial at all so they cannot be said to be less common than any condition in that trial",
        "label": "Contradiction"
    },
    "c6e42e3e-8900-43bb-b1de-61f1d1dcf075": {
        "text_answer": "Contradiction The primary trial results do not provide information about the cytogenetic finding t1114 and the secondary trial results do not provide information about the overall response rate",
        "label": "Contradiction"
    },
    "b181b889-6991-4710-a94c-536591db88fc": {
        "text_answer": "Contradiction The evidence states that candidates with HER2 positive tumors are eligible for the primary clinical trial",
        "label": "Contradiction"
    },
    "d3302027-c157-4d58-8653-cf5053658fad": {
        "text_answer": "Neutral The primary trial results do not directly address the statement about coughing up blood as it is not related to the given evidence",
        "label": "Entailment"
    },
    "e7203466-5ee1-4733-ac54-730489e348b2": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the placebo intervention is administered via transendocardial injections of Buminate solution which is not an oral medication and is given in the same volume as the alloMSCs intervention 04ml per injection",
        "label": "Contradiction"
    },
    "bb7c2e9b-0a9b-48da-97e8-3a78ca82966f": {
        "text_answer": "Contradiction  Explanation The evidence provided in the results shows that the majority of patients in both the Collaborative Care Intervention CCI and Prevention Care Management PCM groups were up to date for their colorectal breast and cervical cancer screenings after the intervention Therefore the statement that regardless of the type of cancer the majority of patients in the first cohort of the primary clinical trial did not",
        "label": "Contradiction"
    },
    "90432ec4-8df5-408b-8998-39f2a698314d": {
        "text_answer": "Contradiction The primary trial does not mention anything about heart transplant patients",
        "label": "Contradiction"
    },
    "a3b8086c-3eec-402c-8b95-4446b33673b6": {
        "text_answer": "Contradiction The primary trial includes all female breast cancer patients while the secondary trial specifically includes those with Her2neu breast cancer",
        "label": "Contradiction"
    },
    "6fe2c751-a06e-4679-a13d-3335fe5887e2": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as paclitaxel is not mentioned in the evidence for either cohort 1 or cohort 2 Instead cohort 1 receives anastrozole and cohort 2 receives fulvestrant",
        "label": "Contradiction"
    },
    "ed6a6f04-0b3d-4dc7-96fd-2f0547d6fe17": {
        "text_answer": "Contradiction A diagnosis of a single cerebral metastasis does not lead to an automatic exclusion from the primary trial as the primary trial allows for one to three presumed brain metastases However it does allow eligibility for the secondary trial",
        "label": "Contradiction"
    },
    "213bae99-da68-4307-a7c9-71343afbcd39": {
        "text_answer": "Contradiction The primary trial uses a 21day cycle not a 3week cycle The secondary trial does not have a specified cycle length",
        "label": "Contradiction"
    },
    "97e71457-8a63-4bf3-b1cf-b2743433e7f2": {
        "text_answer": "Entailment The evidence provided does not mention the use of drugs radiotherapy or CBT Cognitive Behavioral Therapy in the interventions of the primary trial",
        "label": "Entailment"
    },
    "eb93eb13-978c-4f27-8c2b-c3ddddcbafcf": {
        "text_answer": "Contradiction The statement does not provide any information about the amount of MM121 and Paclitaxel received by the candidates in the primary trial and the comparison made in the statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "783f37e2-d649-493a-9d0c-0de214ff8ad2": {
        "text_answer": "Contradiction  The evidence states that patients with recent chemotherapy or radiotherapy unstable angina or neuropathy greater than grade 1 are excluded from both the primary and secondary trials",
        "label": "Contradiction"
    },
    "eae69c88-b4bc-4683-aacf-60d287e4eebc": {
        "text_answer": "Irrelevant The statement is not related to the provided evidence",
        "label": "Entailment"
    },
    "21a5f296-5b3c-4860-be64-77ffb8f76501": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the number of participants in each arm of the trial was different with 1420 participants in the Neratinib arm and 1420 participants in the Placebo arm",
        "label": "Contradiction"
    },
    "f4fd9b7c-ccd9-4131-95d0-2a3a8071faf4": {
        "text_answer": "Contradiction The statement makes a comparison between the percentage of participants demonstrating a decrease in the growth factor signature between two different groups but the evidence provided does not include the percentage of participants in the ERpositive Luminal B group who demonstrated a decrease in the growth factor signature that is 11 more than in the Triple Negative group",
        "label": "Contradiction"
    },
    "8b2b5b8e-3723-4261-8fd5-a624c9367ef2": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as the evidence only compares the change in betaCTX levels between the two groups and does not mention anything about primary tumour diameter or gastric dysplasia",
        "label": "Contradiction"
    },
    "386a63a3-cd3f-4f8c-af45-cfe9b26e4bc6": {
        "text_answer": "Contradiction The primary trial does not report any cases of corneal deposits",
        "label": "Contradiction"
    },
    "d3177b24-1a89-40d0-b3a5-e79870dc216e": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not report the incidence of nausea in the primary trial",
        "label": "Contradiction"
    },
    "bc03d7d7-65ed-4331-a5c9-997968a47547": {
        "text_answer": "Entailment given that the evidence shows that adverse events were observed in cohort 1 of the primary trial",
        "label": "Entailment"
    },
    "ef73b41f-a188-41e1-af84-8ba9ee13d6c6": {
        "text_answer": "Contradiction The evidence shows that there were 3 participants in Cohort 1 and all 3 experienced adverse events but no information is provided about the severity of those events Therefore it cannot be determined from the evidence whether or not a single lifethreatening adverse event was registered among Cohort 1 participants",
        "label": "Contradiction"
    },
    "f11744ff-fa1a-4d98-ad4a-03fe1fa9e519": {
        "text_answer": "Entailment The evidence does not provide information about life expectancy pregnancy or age conditions for the participants so the statement is entailed by the neutral nature of the inclusion and exclusion criteria",
        "label": "Entailment"
    },
    "205a0d18-ba5e-4efd-b403-557bf188daa2": {
        "text_answer": "Contradiction  The evidence states that 9 out of 21 participants experienced a decrease in circulating tumor cells which is more than 50",
        "label": "Contradiction"
    },
    "b29091a1-befa-4edc-9bc9-06263826bfdd": {
        "text_answer": "Contradiction  The primary trial includes women with locally advanced recurrent or metastatic breast cancer while the secondary trial includes women with newly diagnosed or recurrent breast cancer The primary trial is for advancedstage breast cancer patients while the secondary trial is for earlystage breast cancer patients The primary trial excludes women who have undergone more than one chemotherapy line while the secondary trial includes women who are considering or completing a mastectomy",
        "label": "Contradiction"
    },
    "70310501-6b9e-4283-9981-5f709b9517b6": {
        "text_answer": "Contradiction  Explanation The statement over 015 of patients in the primary trial and the secondary trial suffered from infections during the study period is a contradiction to the evidence because the evidence shows that the number of patients with infections in each trial is less than 015 of the total number of patients In the primary trial 132 or 313 of patients had infections",
        "label": "Contradiction"
    },
    "5677aa15-f929-41ac-97e2-07857e792505": {
        "text_answer": "Entailment The primary trial and secondary trial involve different patient populations The primary trial focuses on patients receiving HER2specific T cells therapy while the secondary trial focuses on participants receiving trastuzumab emtansine",
        "label": "Entailment"
    },
    "a1c132f7-d56a-4d89-96eb-b37310cd37d6": {
        "text_answer": "Entailment The evidence shows that in both trials no adverse events occurred in more than 1100 participants",
        "label": "Entailment"
    },
    "cbe273ac-6267-4827-8ba2-8c8c34d69115": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence shows that no cases of anemia pneumonia or stupor were reported in the primary trial while the statement asserts that these conditions were experienced more frequently in the secondary trial Additionally the evidence shows that a higher occurrence of febrile infections was noted in the primary trial which is the opposite of what the statement asserts",
        "label": "Contradiction"
    },
    "f2217745-3601-4f6e-b893-11ca72e32556": {
        "text_answer": "Contradiction The primary trials Intervention 1 gives 05ugkg of dexmedetomidine not 45ugkg The secondary trial does not mention dexmedetomidine at all",
        "label": "Contradiction"
    },
    "9ddda9ad-0cb3-4ea8-8abe-59b227a8290d": {
        "text_answer": "Entailment The evidence clearly states that the number of participants analyzed in each cohort was different",
        "label": "Entailment"
    },
    "2bf60bd1-4d11-4a7d-9d69-7f13e93df39c": {
        "text_answer": "Contradiction The statement is not supported by the evidence provided as the statement compares acupuncture patients to those treated with testosterone cream but the evidence only compares acupuncture to a waitlist control group",
        "label": "Contradiction"
    },
    "75e0a9f9-003d-4bfe-a720-4f84d2d0e7b4": {
        "text_answer": "Contradiction The evidence shows that tamoxifen 20 mg po daily for 7 days prior to surgery led to a decrease in Ki67 expression not an increase in tumor size",
        "label": "Contradiction"
    },
    "7a4c195c-e5a6-49b5-b8de-842704bfe7f4": {
        "text_answer": "Entailment as per the provided evidence there is no mention of drug usage radiotherapy or cognitive behavioral therapy in the interventions described",
        "label": "Entailment"
    },
    "58c1c63d-fcf2-400d-af60-9f33c9820f1b": {
        "text_answer": "Contradiction The primary and secondary trials have different outcome measurements The primary trial measures the variation in serum levels of Follicle Stimulating Hormone FSH while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel",
        "label": "Contradiction"
    },
    "49a7e9fa-4a0f-4bce-ab0c-c13056e98de2": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence does not mention anything about improvement or a condition superior to an earlier condition The statement only mentions UTI and the absence of UTIs in the primary trial participants",
        "label": "Contradiction"
    },
    "8665ed72-5c94-4c4f-8dbc-a6950275ca98": {
        "text_answer": "Contradiction The statement implies that those with a history of chemotherapy or radiotherapy within the preceding 2 weeks or those exhibiting signs of unstable angina or showing grade 2 or better neuropathy are not eligible for the secondary clinical trial but could remain eligible for the primary clinical trial However the exclusion criteria for the primary clinical trial state that patients who have received chemotherapy or radiotherapy within 2 weeks are not eligible Therefore the statement",
        "label": "Contradiction"
    },
    "505ccc8c-b07a-4902-b8c3-4d3b4891779a": {
        "text_answer": "Entailment The evidence clearly states that patients will receive multiple injections of therapeutic autologous dendritic cells peptides GMCSF and trastuzumab",
        "label": "Entailment"
    },
    "c20de03b-8eba-4546-8f77-5e54cf25dfb2": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the dosages of the interventions in the two trials are not directly comparable",
        "label": "Contradiction"
    },
    "f82d082e-896d-4d9e-ad92-d64b655dafb8": {
        "text_answer": "Contradiction The patient described in the statement does not meet the inclusion criteria for the primary trial as they have a life expectancy of only 16 days which is less than the required life expectancy of greater than 3 months",
        "label": "Contradiction"
    },
    "4bfe4376-ffad-4132-8604-b5afbc78429d": {
        "text_answer": "Contradiction The statement is about a different trial involving pancreaticobiliary malunion and the evidence provided is about a trial for endoflife care for patients with cancer",
        "label": "Contradiction"
    },
    "0471ee43-16a7-417e-94db-0ef86bd5b0a9": {
        "text_answer": "Contradiction The primary trial only includes patients undergoing mastectomy for Stage IIII breast cancer while the secondary trial includes patients who have completed surgery for Stage IIII breast cancer which can include lumpectomy as well as mastectomy However Stage IV breast cancer is not included in the secondary trials inclusion criteria Therefore the statement is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "8e19b7e1-e5ac-473f-a4e7-2c8ddfa7a496": {
        "text_answer": "Contradiction The primary and secondary trials involve different interventions and patient populations The statement refers to a specific type of thyroid cancer and its TNM finding which is not related to the interventions described in the trials",
        "label": "Contradiction"
    },
    "2cff90dc-7bc3-4acb-a250-10de476d1d4c": {
        "text_answer": "Contradiction The evidence mentions that patients with a history of interstitial lung disease or pneumonitis are excluded from the trial but it does not specifically mention diffuse parenchymal lung disease within the prior 3 years Therefore the statement that the primary clinical trial would not include an adult diagnosed with diffuse parenchymal lung disease within the prior 3 years is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "b3b142e1-adad-429b-a7de-c852a74edaaa": {
        "text_answer": "Entailment The evidence provided does not indicate any discrimination based on nationality ethnicity mental health status or gender for either the primary or secondary trials",
        "label": "Entailment"
    },
    "a5eb56c2-6fc0-45da-8a6a-2818cb64a7f0": {
        "text_answer": "Contradiction  The evidence shows that 5 out of 20 patients in the placebo group were emesis free during the study period",
        "label": "Contradiction"
    },
    "a60a8f30-02a6-46a4-bb00-bea702d5103d": {
        "text_answer": "Contradiction The primary trial states that the breast tumor should be 1 cm in diameter while the statement suggests a tumor of 50 cm in diameter which is a significant contradiction",
        "label": "Contradiction"
    },
    "d9f28f1f-3a09-4ef9-a80a-9caa02f9069b": {
        "text_answer": "Contradiction The statement is not related to the inclusionexclusion criteria for the trials The statement is about a type of cyst that is not mentioned in the trials",
        "label": "Contradiction"
    },
    "b581bb7b-6aaa-4c8a-81a0-c5e6a58ebcdf": {
        "text_answer": "Contradiction The statement refers to a single patient while the evidence provides the median PFS for each group",
        "label": "Contradiction"
    },
    "4e56ec6c-1b0c-4d14-b53a-2695fb9dcb7d": {
        "text_answer": "Entailment The evidence states that the intervention includes irradiation and its administration protocol which aligns with the statement that the irradiation doses and administration protocol are detailed in the trial",
        "label": "Entailment"
    },
    "2bd78232-4872-4d66-ade9-836190b86e1d": {
        "text_answer": "Contradiction The evidence states that there should be no meningeal carcinomatosis in the patient characteristics for the primary trial",
        "label": "Contradiction"
    },
    "953b0337-0c43-42fb-a334-dad6900e2e0f": {
        "text_answer": "Contradiction  The evidence provided does not mention any information about treatment emergent adverse events or serious treatment emergent adverse events in the primary clinical trial for the paced respiration and fast shallow breathing groups",
        "label": "Contradiction"
    },
    "464e2cd9-6c59-4692-a3fc-083c374f4a5c": {
        "text_answer": "Contradiction Paraplatin is not mentioned in the given interventions Carboplatin and Cisplatin are different chemotherapeutic agents",
        "label": "Contradiction"
    },
    "91e585c8-503f-4253-b749-80caa8ebc3e1": {
        "text_answer": "Contradiction The statement makes assumptions about the types of adverse events in each trial that are not supported by the evidence provided The evidence only reports the number and types of adverse events in each trial but it does not mention anything about renal papillary adenomas or eosinophilic cells",
        "label": "Contradiction"
    },
    "577f3aad-32c6-4a0b-8df1-615a9a58fa29": {
        "text_answer": "Entailment assuming identical count means both trials had no adverse events  Explanation The evidence shows that both trials had no adverse events in their respective Adverse Events 1 groups Therefore the statement that they noted an identical count of adverse events is an entailment as the evidence supports the statement",
        "label": "Entailment"
    },
    "13765ddf-3be9-411a-ae7a-24a0bdffe2d8": {
        "text_answer": "Contradiction The primary clinical trial does not involve the use of 4demethyl4cholestryloxycarbonylpenclomedine",
        "label": "Contradiction"
    },
    "55bcb170-5b8a-4a7d-b509-f2ab4a2f587a": {
        "text_answer": "Contradiction The statement does not entail the evidence as it makes no mention of the number or types of adverse events in the primary trial related to the fear of rejection",
        "label": "Contradiction"
    },
    "06b2ed93-63bb-4ef0-964c-372ff9077cb4": {
        "text_answer": "Contradiction The primary trial measures pain intensity and the secondary trial measures bone mineral density which are not directly comparable",
        "label": "Contradiction"
    },
    "c6408b0b-2cdc-4298-a7d5-9e6fe3d52925": {
        "text_answer": "Contradiction The secondary trial has a consistent set of inclusion and exclusion criteria for all individuals while the primary trial has different inclusion criteria for its phase I and phase II parts",
        "label": "Contradiction"
    },
    "4cdd4dc9-e171-438b-8864-1f451af7c15e": {
        "text_answer": "Contradiction The evidence states that one cohort in the primary clinical trial receives the educational DVD as part of the intervention so it is not accurate to say that no cohort receives the educational DVD",
        "label": "Contradiction"
    },
    "2b24be38-efe1-4044-92ce-81cace8f239a": {
        "text_answer": "Contradiction  Explanation  In the primary trial Armodafinil is given daily for 47 days but it is only given to one cohort CBTI  Armodafinil while in the secondary trial PDR001 is given identically to every patient with differing amounts of MCS110 in two cohorts Ph Ib MCS110 1 mg",
        "label": "Contradiction"
    },
    "3ac1baef-7e74-405c-ae5a-897ac2b2fd5f": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that only 235 571 of patients in the primary trial suffered adverse events",
        "label": "Contradiction"
    },
    "c8990938-e3fe-470d-a6d2-d28a3fe89b0b": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial requires informed consent as an inclusion criterion while the secondary clinical trial does not mention informed consent as an inclusion or exclusion criterion Therefore the statement that the primary clinical trial requires informed consent but there is no corresponding requirement in the secondary trial is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "5ed2b8ad-5b6d-4397-80c5-48d08c8f51ed": {
        "text_answer": "Contradiction The statement does not hold true as cohort 1 and 2 receive different schedules of CUDC101 administration",
        "label": "Contradiction"
    },
    "3df32fab-15e5-4536-908f-d9c76529702e": {
        "text_answer": "Entailment The evidence states that 13 individuals participated in a clinical trial with the given vaccine therapy and the statement is about 13 individuals participating in a clinical trial with an unspecified therapy labeled as enhanced card T cell therapy Since the statement is less specific than the evidence it entails the evidence",
        "label": "Entailment"
    },
    "98e89253-c343-4f1f-b2a0-0e09e5cba8ee": {
        "text_answer": "Contradiction  The evidence shows that all 3 participants in Cohort 1 of the primary clinical trial reported adverse events",
        "label": "Contradiction"
    },
    "66362fd1-8e4f-49ad-9098-a67f65cb91c2": {
        "text_answer": "Contradiction The statement implies that 5 of the participants developed imagable HER2 metastases while the evidence states that 13 of the participants had imagable HER2 metastases",
        "label": "Contradiction"
    },
    "2f7bae39-4081-4328-85e2-2a400ec72589": {
        "text_answer": "Contradiction The primary trial has no mention of BMI as an inclusion or exclusion criterion",
        "label": "Contradiction"
    },
    "1bc6de92-961a-4a4f-8ead-8f5f6f496d70": {
        "text_answer": "Contradiction  Explanation The evidence provided in the results does not support the statement as it does not indicate that any patient in the GTx024 1mg group had an increase of over 10 kilos in lean body mass The median change in lean body mass for this group was 155 kg with a range of 206 to 1264 kg which does not include a value of",
        "label": "Contradiction"
    },
    "3c273853-f394-4550-9969-d476fff275db": {
        "text_answer": "Contradiction The primary trial had 0 cases of febrile neutropenia or cholelithiasis while the statement claims there were 52 cases in both trials",
        "label": "Contradiction"
    },
    "cc2428b1-d508-406f-a59f-186d62e93600": {
        "text_answer": "Contradiction  The evidence shows that the Arm I group cryotherapy had a median aAUCpa of 14 117 to 68 which is less negative than the Arm II group control with a median aAUCpa of 44 571 to 162 This indicates that the patients in the Arm I group had less worsening of symptoms on average compared to",
        "label": "Contradiction"
    },
    "4c42491a-5ff2-41f8-bb40-6c7fe4dd5c99": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not mention severe nausea or chronic fatigue as adverse events in the secondary clinical trial",
        "label": "Contradiction"
    },
    "27abad83-36b9-47a4-8d11-d08751d1d81a": {
        "text_answer": "Contradiction The evidence does not provide information on the number or percentage of patients in either group who experienced no pain whatsoever during the 5year study period",
        "label": "Contradiction"
    },
    "001da1c9-0fd7-4a15-baa5-9ee16f2a28bd": {
        "text_answer": "Contradiction The statement is not an entailment as resistance to AI therapy is a requirement for the primary trial but not for the secondary trial",
        "label": "Contradiction"
    },
    "5a6a1e08-4a0a-45ea-91f5-053182a352cc": {
        "text_answer": "Contradiction The statement does not relate to the provided evidence",
        "label": "Contradiction"
    },
    "afa9c5da-71e1-4c40-80fa-bcc02199e395": {
        "text_answer": "Contradiction The evidence shows that all patients in the secondary trial experienced adverse events which contradicts the statement that the secondary trial was free from any adverse events",
        "label": "Contradiction"
    },
    "37321416-91c4-4dd1-952b-6b23865d769c": {
        "text_answer": "Contradiction The evidence states that both cohorts use a CD for practicing paced breathing but different frequencies are mentioned for cohort 2 in the statement which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "3a141563-97b8-4154-8c9c-f1f551ec7969": {
        "text_answer": "Entailment The primary trial does not involve alisertib at all and the secondary trial involves different doses of alisertib",
        "label": "Entailment"
    },
    "fe5d5e2f-2b54-48f4-b95b-278456d1db46": {
        "text_answer": "Entailment  Explanation The primary and secondary trials both involve the use of lapatinib and paclitaxel with similar dosing schedules In the primary trial FMX is used in the pilot phase but lapatinib and paclitaxel are the same medications used in the secondary trial The doses and schedules are also similar Therefore the statement is an entailment based on the provided evidence",
        "label": "Entailment"
    },
    "a92239f6-9f31-4e7f-a8be-2792789ea5f1": {
        "text_answer": "Contradiction The evidence states that Herceptin is included in Intervention 1 making the statement a contradiction",
        "label": "Contradiction"
    },
    "c98e803e-a899-4ed8-aed0-0611eeef943d": {
        "text_answer": "Contradiction The primary trial explicitly states that patients with a pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug or any other hemorrhagebleeding event NCI CTCAE v30 Grade 3 within 4 weeks of first dose of study drug are not eligible The secondary trial does not mention any specific bleeding or pulmonary embolism",
        "label": "Contradiction"
    },
    "49e29ec7-08a2-481d-9fc4-ecb66b09cdfe": {
        "text_answer": "Contradiction The primary trial explicitly excludes smokers while the secondary trial mentions nothing about smoking status but includes a criterion for alcohol consumption",
        "label": "Contradiction"
    },
    "804aa28f-b791-4a99-98e7-a443456de4b2": {
        "text_answer": "Entailment assuming that the eligibility criteria for the primary trial do not specifically exclude patients based on their use of ct2584 hms or other lipid metabolism modulators",
        "label": "Entailment"
    },
    "045ad9d7-6830-4a3d-bba5-4e90ee838977": {
        "text_answer": "Irrelevant  Explanation The statement does not relate to the given evidence The evidence only discusses the radiation therapy doses and the use of Active Breathing Coordinator ABC in two different cohorts as well as the SPECT scan followups The statement is about the Leptospiraceae family which is unrelated to the primary trials details",
        "label": "Entailment"
    },
    "610662cd-053e-4396-a6d6-8aaac67a7440": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention only includes Gefitinib ZD1839 whereas in the secondary trial the intervention in Arm 1 includes Zoledronic Acid and in Arm 2 it includes Zoledronic Acid plus radiopharmaceuticals Sr89 or Sm153 However the statement suggests that the primary trial involves a single medication",
        "label": "Contradiction"
    },
    "10749f91-8743-4f6a-aa4b-6cc713e927c5": {
        "text_answer": "Contradiction  Explanation The primary trial involves the use of denosumab which is an injectable medication but it is not mentioned in the statement The secondary trial involves the use of a handheld gamma camera and gamma probes which are not related to the oral administration of palbociclib or the injection of tezacaftor mentioned in the statement",
        "label": "Contradiction"
    },
    "9cd909a2-b826-4e0d-bbbd-3ad52978d1d9": {
        "text_answer": "Contradiction  Explanation The primary clinical trial includes patients with HER2 FISH negative or unknown HER2 status who will receive single agent vinflunine and not trastuzumab However the statement in question is specifically about individuals who have never undergone Herceptin trastuzumab treatments Therefore the statement is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "ef0cf72d-6cc3-4589-8016-e96db1b9f33a": {
        "text_answer": "Contradiction  Explanation The statement not a single kind of adverse event registered in the primary clinical trial influenced more than a quarter of the patient group is a contradiction to the evidence as in Adverse Events 1 of the primary trial disease progression influenced 1429 of the patient group which is more than a quarter of the patient group",
        "label": "Contradiction"
    },
    "585bf6db-16c7-4433-8c98-30a6b5a88fc0": {
        "text_answer": "Contradiction The primary trial involves the use of alisertib in a different context Botulinum Toxin Type A trial than the secondary trial MLN8237 dose escalation trial",
        "label": "Contradiction"
    },
    "31464efc-048a-451b-a02b-5576933a893a": {
        "text_answer": "Contradiction The primary trial mentions no information about oral administration of captopril for cohort 1 The secondary trial mentions nothing about eribulin for cohort 1",
        "label": "Contradiction"
    },
    "a0e47b7d-7f2d-43ba-8f93-dc5f9dcd648b": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided The evidence only mentions the number and types of adverse events in the primary and secondary trials but it does not mention anything about cell surface receptors or infections being over 15",
        "label": "Contradiction"
    },
    "ce5dd10f-dad3-46a4-93de-fe57c657f6d9": {
        "text_answer": "Entailment The evidence shows that there were a total of 5 gastrointestinal adverse events diarrhea nausea and vomiting across both sets of adverse events which is more than one Therefore the statement is an entailment based on the evidence",
        "label": "Entailment"
    },
    "bb281225-8211-47ed-8789-a42a389fa379": {
        "text_answer": "Contradiction The statement is about Chryseobacterium a genus of bacteria while the evidence is about inclusion criteria for a breast cancer clinical trial",
        "label": "Contradiction"
    },
    "be98ce03-a87b-4fe5-9058-a56259581c41": {
        "text_answer": "Contradiction The statement does not follow from the evidence as it introduces the concept of blackout which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "4db7f58c-f006-48d0-944f-a02b3231615c": {
        "text_answer": "Contradiction The statements refer to different interventions Alpha Lipoic Acid vs Necitumumab and do not directly compare the same doses or durations",
        "label": "Contradiction"
    },
    "bcdef75a-f013-4d65-84e1-6004a054d574": {
        "text_answer": "Contradiction The evidence states that there should be no meningeal carcinomatosis in the primary trial Neoplastic meningitis is a type of meningeal carcinomatosis",
        "label": "Contradiction"
    },
    "6962c2aa-4df2-4479-8744-5784fe8c9fcf": {
        "text_answer": "Entailment The statement only one adverse event has been documented for the patient group in the primary clinical trial is an entailment of the evidence Adverse Events 1 Total 129 345 The evidence implies that there is only one type of adverse event documented and the statement further specifies that only one adverse event has been documented in total for the patient group",
        "label": "Entailment"
    },
    "a3be9d38-6897-4ead-9ada-790104f2de50": {
        "text_answer": "Contradiction The evidence states that individuals with a history of myocardial infarction stroke or transient ischemic attacks within the last six months are excluded from the primary clinical trial",
        "label": "Contradiction"
    },
    "12a03716-0ec6-4ffe-abd8-02411c083ee5": {
        "text_answer": "Contradiction  Explanation The evidence clearly states that the primary clinical trial involves the use of injections for its patients specifically for the administration of dendritic cells chemotherapy GMCSF and trastuzumab",
        "label": "Contradiction"
    },
    "156b015d-e2bb-4f38-a312-62e1cf7583d6": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as resistance to mirtazapine is not a requirement for the primary trial",
        "label": "Contradiction"
    },
    "d3aeafa2-2963-4220-b80d-cd5cde582fe8": {
        "text_answer": "Contradiction  The primary trial results show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery decreases Ki67 expression by approximately 40 on average The statement suggests that tamoxifen increases Ki67 expression by 200 on average which contradicts the evidence from the primary trial",
        "label": "Contradiction"
    },
    "d0bfc2f3-c94f-4d4c-ae87-9f9744bd767a": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as anaemia was not the most common adverse event in the primary trial and there were no recorded adverse events in the primary trial at all",
        "label": "Contradiction"
    },
    "9a814107-778f-43ba-bd59-383ae14594ed": {
        "text_answer": "Contradiction  The statement is about women with newly diagnosed locally advanced breast cancer confirmed as ER considering a mastectomy being eligible for both the primary and secondary trials However the evidence provided for the primary trial states that patients with locally advanced recurrent or metastatic breast cancer are eligible but it does not specifically mention newly diagnosed or considering a mastectomy Therefore the statement",
        "label": "Contradiction"
    },
    "2d007409-93ff-4753-a2e5-c5f94d4fe6dd": {
        "text_answer": "Contradiction The primary trial reports Time to Progression while the secondary trial reports the number of patients with Objective Response These are different outcome measurements",
        "label": "Contradiction"
    },
    "c51494ed-aee9-4219-b46b-ed47bc261788": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction to the evidence because the primary trial does not provide information on the weekly dosage of MM121 and Paclitaxel for the intervention group The evidence only states that the primary trial intervention group undergoes mastectomy surgery and does not specify the dosage or duration of MM121 and Paclitaxel administration In contrast the secondary trial provides",
        "label": "Contradiction"
    },
    "136f0a2e-563c-4085-b390-ac2db90f7aac": {
        "text_answer": "neutral The statement is consistent with the evidence but it does not directly follow from it  Explanation The statement both cohorts involved in the primary trial demonstrated an average decline in cognitive function although this was not the circumstance for all individuals is consistent with the evidence as both groups Tamoxifen and Tamoxifen  Ovarian Function Suppression showed a negative mean standardized score for cognitive function at the 1",
        "label": "Entailment"
    },
    "76eeb32c-d3c0-4ed0-91d4-104417af35e0": {
        "text_answer": "Contradiction  The evidence states that 98 of the patients had recurrencefree survival not 100",
        "label": "Contradiction"
    },
    "a402b1c9-c65b-48fb-a2d5-e08c0152e8c3": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 participants receive 1 mgkg of MCS110 every 3 weeks which is less than 20 mg per participant per 3 weeks In Intervention 2 participants receive 3 mgkg of MCS110 every 3 weeks which is more than 20 mg per participant per 3 weeks However the statement requires that each",
        "label": "Contradiction"
    },
    "431b6222-3b82-4eb4-af82-ef98b513e649": {
        "text_answer": "Entailment assuming unexpected deaths or hospitalizations refers to adverse events in the trials and not mentioned in the statement  Explanation The statement does not mention any deaths or hospitalizations in either trial and the evidence supports that no such events occurred Therefore the statement is an entailment given the evidence",
        "label": "Entailment"
    },
    "a5415a49-0b04-4f8f-a7ec-a8c276b2cf64": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that there is one case of biliary colic in the secondary trial and three cases of diarrhea in the primary trial while the statement suggests that there are more cases of biliary colic and diarrhea in the secondary trial than in the primary trial",
        "label": "Contradiction"
    },
    "a6d3fa8e-c521-4843-b4e7-0a9983acfad0": {
        "text_answer": "Contradiction In the primary trial pCR was the primary efficacy endpoint not ORR The discrepancy in results amongst the different cohorts was not mentioned to be insignificant In the secondary trial Arm 1 had a lower pCR rate than Arm 2",
        "label": "Contradiction"
    },
    "71ba0864-5490-4e25-989c-4672afa15599": {
        "text_answer": "Contradiction The primary trial includes patients with a solid tumor malignancy of lung breast or prostate but the patient described in the statement has a pathologically verified diagnosis of stage I prostate cancer which is not considered a metastatic disease and does not meet the inclusion criteria for either trial Additionally the patients ANC and platelet count are below the minimum requirements for the primary trial and the patients life expectancy is less than",
        "label": "Contradiction"
    },
    "f41f7611-7c20-4f71-8b2d-433e36f840de": {
        "text_answer": "Contradiction The statement is about changes in lymphedema for patients with appendiceal carcinoid and the use of acupuncture versus testosterone cream while the evidence provided is about changes in lymphedema for patients receiving acupuncture versus waitlist control The two statements are not directly related",
        "label": "Contradiction"
    },
    "3264decd-0cee-4137-a5da-e9a27e3b7791": {
        "text_answer": "Contradiction  Explanation In the primary trial the outcome measurement is reported as a percentage with a confidence interval In the secondary trial the outcome measurement is reported as a number of participants These are not the same units of measure so the statement that there is no uniform unit of measure utilized to report results between the primary clinical trial and the secondary clinical trial is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "5ac3610a-7854-4278-8a51-c1ef8c138ee9": {
        "text_answer": "Contradiction  The statement does not provide any information about the relationship between pulse wave increase and the reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products The two concepts are not directly related",
        "label": "Contradiction"
    },
    "08fb602d-3227-4329-98c8-7dc2a6135f5b": {
        "text_answer": "Contradiction  Explanation The statement is not an entailment or a contradiction based on the evidence provided The statement mentions that syncope occurred in 14 of the primary trial patients but the evidence shows that syncope occurred in 212 1667 of the primary trial patients not 14 Therefore the statement is not an entailment or a contradiction but rather an error",
        "label": "Contradiction"
    },
    "76c6b45f-5a4a-47bc-81b1-267a2981b096": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the inclusion criteria clearly state that the candidate must have a HER2 positive tumor either IHC 3 or FISH to be eligible for the primary clinical trial",
        "label": "Contradiction"
    },
    "95332a34-465b-4777-870b-e60e4c01e706": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial had a higher frequency of ascites while the secondary trial had a higher incidence of pneumocystis jirovecii pneumonia but these are two different adverse events",
        "label": "Contradiction"
    },
    "f6fbc102-de0c-44d5-943b-4baf66bc0d9b": {
        "text_answer": "Contradiction  Explanation The evidence provided in the results does not support the statement that all 61 cervical cancer patients were uptodate with their screenings prior to the intervention In fact the data shows that only 423 of the cervical cancer patients in the CCI group and 417 in the PCM group were uptodate with their cervical cancer screen",
        "label": "Contradiction"
    },
    "1c72bbf7-1c5b-4326-a9d1-9dc7677aeefd": {
        "text_answer": "Contradiction  The primary trial specifically excludes patients with stage IV disease while the secondary trial includes patients with newly diagnosed stage IV breast cancer",
        "label": "Contradiction"
    },
    "224b15b9-fc1d-4c8b-ae55-ec4731ae5d04": {
        "text_answer": "Contradiction  Explanation The statement it is dispensed more frequently to cohort 1 contradicts the evidence as the evidence states that the dosing frequency for CUDC101 is different between cohort 1 5 daysweek and cohort 2 3 daysweek",
        "label": "Contradiction"
    },
    "bd6fc6e9-c2ad-4803-b9ef-5a92d10e4155": {
        "text_answer": "Contradiction The patient does not meet the criteria for either trial based on the provided information",
        "label": "Contradiction"
    },
    "72de2f11-15c9-489a-aec1-5c5e0969f4b7": {
        "text_answer": "Contradiction The evidence provided does not address the primary tumour diameter only the percentage change in betaCTX at Week 4",
        "label": "Contradiction"
    },
    "0d58d43d-8edc-4846-9d16-b1573f00db28": {
        "text_answer": "Contradiction assuming the statement is about the primary trial interventions only and not about any potential use of paclitaxel outside of the trial",
        "label": "Contradiction"
    },
    "ea16ac84-1f11-45c6-a29a-b7159f4b49a1": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the percentage of patients suffering from adverse events in the primary trial was higher than in the secondary trial",
        "label": "Contradiction"
    },
    "c69a6bb3-93f7-4597-9359-64fd2541b1aa": {
        "text_answer": "Entailment The evidence provided in the results section of the primary trial does report the number of participants in each arm Arm II and Arm III",
        "label": "Entailment"
    },
    "db02f4a9-b294-40e7-861b-d2284c6155e6": {
        "text_answer": "Contradiction  The statement is contradictory to the evidence because Perjeta pertuzumab is not mentioned in the primary trial at all whereas in the secondary trial it is mentioned as a potential radiotracer for HER2targeted PETCT but it is not used in both cohorts as stated in the question",
        "label": "Contradiction"
    },
    "1b9551eb-0a5d-4d74-a460-a97ea9161f7f": {
        "text_answer": "Contradiction  Explanation The statement mentions that there were 0 cases of Hypertension Edema and Dyspnea in either cohort of the primary trial However the evidence shows that there was 1 case of Edema in the second cohort Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "d6c5a9e6-8db3-44f7-b865-4250c057f194": {
        "text_answer": "Contradiction  The primary trial only includes patients with breast adenocarcinoma while the statement mentions patients with stage 4 lung adenocarcinoma",
        "label": "Contradiction"
    },
    "a7f11aff-801c-4f1f-bc03-dc205289964a": {
        "text_answer": "Contradiction The evidence shows that there were no common adverse events between the primary and secondary trials",
        "label": "Contradiction"
    },
    "3e629df7-48b7-4ca1-8987-250629ce3e26": {
        "text_answer": "Entailment The primary trial had an active arm Pyridoxine and a placebo arm while the secondary trial had one active arm Highdose Oxybutynin Chloride and one control arm Lowdose Oxybutynin Chloride Both trials had a test group and a control group as stated in the question",
        "label": "Entailment"
    },
    "4f3ab82f-b17b-45a0-803e-901d0a58bcc6": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the primary trial recorded one death but the secondary trial did not record any deaths in the adverse events section",
        "label": "Contradiction"
    },
    "6dddad4e-4cde-4859-a518-897b16bdc042": {
        "text_answer": "Contradiction The primary trial excludes participants with a history of alcohol or substance abuse or dependence within the past 2 years while the secondary trial allows participants to consume a minimum of five alcoholic drinks daily",
        "label": "Contradiction"
    },
    "7ccd57f6-2147-4f27-a0a7-f9f7a573a3b5": {
        "text_answer": "Contradiction The primary trial and secondary trial are evaluating different outcome measures and populations so it is not possible to make a direct comparison between the two cohorts based on the provided evidence",
        "label": "Contradiction"
    },
    "86408afa-a3ca-41ee-ac9a-94aa3f2b203d": {
        "text_answer": "Entailment The evidence states that the final eligibility for the clinical trial is determined by the health professionals conducting the trial which aligns with the statement that the final decision for participation is in their power",
        "label": "Entailment"
    },
    "7ebe69db-dbde-41d9-b1c8-b866b2bc9e4c": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no evidence of nausea instances in either trial and the evidence shows a lower number of infection and asymmetry instances in the secondary trial",
        "label": "Contradiction"
    },
    "b447258d-c4d1-4f98-8cc0-9868cd316a3c": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because no cases of anemia pneumonia or stupor were reported in the primary trial according to the evidence provided",
        "label": "Contradiction"
    },
    "05772f95-990c-40ee-b29c-b5b2591d0e56": {
        "text_answer": "Entailment assuming the fibroblastic neoplasm mentioned in the statement is not relevant to the eligibility criteria for the trials and is a typo or error",
        "label": "Entailment"
    },
    "b7028956-b024-401f-b528-554559f8ce17": {
        "text_answer": "Contradiction The evidence provided does not mention follicular thyroid carcinoma or lymphedema as exclusion criteria for either trial",
        "label": "Contradiction"
    },
    "d2139fd7-7b3e-405a-a806-ca76d237c11f": {
        "text_answer": "Irrelevant The statement does not relate to the eligibility criteria for the primary or secondary trials",
        "label": "Entailment"
    },
    "039b25b3-517a-4663-9b95-94c941ffa30f": {
        "text_answer": "Contradiction  Explanation The statement in the primary clinical trial both cohorts 1 and 2 were administered identical doses of cetuximab is contradicted by the evidence as the evidence shows that cohort 1 received a higher dose of cetuximab 400 mgm2 during the loading dose compared to cohort 2 400 mgm2 The maintenance doses",
        "label": "Contradiction"
    },
    "a76b5162-0261-41d2-8d17-c88f5a0e21bc": {
        "text_answer": "Contradiction The evidence states that 2 patients in cohort 1 and 11 patients in cohort 2 encountered adverse events which is more than 10 patients in total",
        "label": "Contradiction"
    },
    "e4b2bcf4-85fa-499c-9d27-e1c3c46174bf": {
        "text_answer": "Entailment The statement that the same drug is being studied in both trials is true but the additional information about different dosages and outcome measurements does not contradict that fact",
        "label": "Entailment"
    },
    "37e14df5-fd3b-4c30-bda4-6527febc5e2b": {
        "text_answer": "Entailment The statement is a subset of the inclusion criteria listed in the evidence",
        "label": "Entailment"
    },
    "27d0d803-28d5-4b3d-a87e-8fbe577513a9": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the primary trial involves oral administration of cabergoline and the secondary trial involves intravenous administration of pixantrone",
        "label": "Contradiction"
    },
    "1f755559-38fb-4edc-a41a-91252b1dfb54": {
        "text_answer": "Contradiction The statement is not an entailment as alcoholic patients are excluded from the primary trial regardless of their alcohol consumption but they may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day However the statement incorrectly implies that being an alcoholic patient who drinks less than 5 alcoholic drinks a day entails eligibility for the primary trial which is not the case",
        "label": "Contradiction"
    },
    "acf4a907-c58c-46df-aa75-666e643cef4f": {
        "text_answer": "Contradiction The statement does not relate to the evidence provided The first part of the statement is about the length of interventions in two different trials while the second part is a fact about a chromosome band",
        "label": "Contradiction"
    },
    "6d5ac8ed-53a0-4b48-a521-7a9b53e82017": {
        "text_answer": "Entailment  Explanation The statement although the interventions in the primary clinical trial and the secondary clinical trial both involve intravenous injections there is a considerable distinction in the drugs dosages and frequency of administration used is an entailment based on the evidence provided The evidence clearly shows that the drugs dosages and frequency of administration are different in the two trials The fact that intravenous injections are used in both trials does",
        "label": "Entailment"
    },
    "256a6852-2768-4fc9-acae-f5fea437412c": {
        "text_answer": "Contradiction The statement has no relation to the evidence provided The evidence only reports the adverse events in two clinical trials and the statement is about a specific type of nonneoplastic disorder",
        "label": "Contradiction"
    },
    "113abff0-a728-40a6-b637-8bd60a53e626": {
        "text_answer": "Contradiction The statement is not an entailment as the MM121 doses are different between the two cohorts despite the same Cetuximab doses being used",
        "label": "Contradiction"
    },
    "9d447ab6-f75c-40b6-88ca-db2e904ef02d": {
        "text_answer": "Contradiction The evidence states that the inclusion criteria include a histologically or cytologically confirmed diagnosis of metastatic breast cancer and the exclusion criteria include a limit on the number of prior chemotherapy lines of treatment in the metastatic setting The statement however implies that there are no exclusion criteria related to mental health bodyweight age or prior treatments",
        "label": "Contradiction"
    },
    "624aeeea-894f-4100-86a2-724ef4842002": {
        "text_answer": "Entailment assuming the statement is about the patients in cohort 1 and 2 of the primary trial only and not making any assumptions about cutaneous schwannomas",
        "label": "Entailment"
    },
    "647016e6-71d4-4169-801d-e58e9b20171f": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only reports adverse event data from human trials and the statement mentions CDISC SEND Laboratory Animal Species Terminology which is not relevant to the human trials data",
        "label": "Contradiction"
    },
    "5ff5980d-28e1-46a7-9300-20792ad3dffd": {
        "text_answer": "Entailment The statement correctly identifies the difference in dosing between the two interventions",
        "label": "Entailment"
    },
    "29b78196-3625-46f2-baa9-45b6ab4b3823": {
        "text_answer": "Contradiction The primary trial measures change from baseline in patientspecified and reported symptoms on the Measure Yourself Medical Outcome Profile MYMOP while the secondary trial measures change in isothiocyanate in urine samples Neither trial directly measures treatmentemergent adverse events",
        "label": "Contradiction"
    },
    "afdafe17-63a8-4fca-b923-a2bb964493d1": {
        "text_answer": "Contradiction The evidence states that patients with a history of interstitial lung disease or pneumonitis are excluded from the trial but it does not specifically mention diffuse parenchymal lung disease within the last 3 years as an exclusion criterion",
        "label": "Contradiction"
    },
    "f9a077fc-18cf-418a-ac86-ddc89ea4259b": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the two interventions in the primary trial have different schedules for administering doxorubicin cyclophosphamide and docetaxel In Intervention 1 doxorubicin and cyclophosphamide are given together every 3 weeks for 4 cycles followed by docetaxel every 3 weeks for another 4 cycles",
        "label": "Contradiction"
    },
    "0c207e39-2335-46a1-8dbd-3be4b8d59a17": {
        "text_answer": "Contradiction regarding the mention of Active Breathing Coordination in the question and the absence of it in the evidence for Intervention 2",
        "label": "Contradiction"
    },
    "520f44e8-b74b-44a6-a7cf-496275847af1": {
        "text_answer": "Entailment The evidence supports the statement as both cohorts recorded no adverse events",
        "label": "Entailment"
    },
    "b51a60d1-5112-4972-a303-11b35ba07af1": {
        "text_answer": "Contradiction The primary trial includes women aged 20 and above while the secondary trial includes women and men aged 18 and above",
        "label": "Contradiction"
    },
    "44bb4ead-0597-4544-9b2c-3d99ff0a099b": {
        "text_answer": "Entailment The evidence states that 1 participant out of 11 had an increased blood bilirubin level which is 909 or approximately 3636 of the total number of participants",
        "label": "Entailment"
    },
    "caf14d83-76cb-4c21-b5c0-d83966973483": {
        "text_answer": "Contradiction The statement implies that no adverse events AEs were recorded in the primary trial but the evidence shows that there were in fact some AEs recorded although none of the specific types mentioned in the statement were among them",
        "label": "Contradiction"
    },
    "0d984537-a1c8-486f-840d-1a09f2bfa961": {
        "text_answer": "Contradiction  Explanation The evidence shows that in Cohort 1 769 of patients had increased pleural effusion and 769 had rapid disease progression In Cohort 2 2500 of patients had increased pleural effusion and 000 had rapid disease progression The statement that fewer than a quarter of the patients have registered",
        "label": "Contradiction"
    },
    "77890255-16cc-4dfb-b374-f2eba38238ce": {
        "text_answer": "Contradiction The statement does not follow from the evidence as there is no mention of bone marrow eosinophilia in the evidence",
        "label": "Contradiction"
    },
    "d0f95f01-4a54-4bdc-9059-50803485a1f5": {
        "text_answer": "Contradiction The primary trial specifically states that the breast tumor must be 1 cm in diameter while the statement in question specifies a tumor size of 311 cm",
        "label": "Contradiction"
    },
    "5628cfa9-df1b-4a19-9f6b-c513b1fb73db": {
        "text_answer": "Contradiction The primary trial measures tumor response using RECIST criteria while the secondary trial measures the number of participants with aromatase inhibitor associated musculoskeletal symptoms AIMSS The two trials are not directly comparable as they measure different outcomes",
        "label": "Contradiction"
    },
    "9915c5ea-d327-4cd9-a3e2-26cfa75cadb7": {
        "text_answer": "Contradiction The primary trial does compare the operative times between two arms but the statement makes an incorrect assumption about the meaning of the results The shorter operative time in the control group does not imply better performance The secondary trial does not have a control group for comparison",
        "label": "Contradiction"
    },
    "48262549-7f65-43b7-ac00-f11dfb93e900": {
        "text_answer": "Contradiction The primary trial involves the use of suramin and paclitaxel but the secondary trial does not mention the use of these drugs for all patients Instead it mentions a different intervention for that trial",
        "label": "Contradiction"
    },
    "06c2d2d2-93dc-44dd-a729-a11a4397db44": {
        "text_answer": "Entailment The statement correctly identifies that the only difference between the interventions is the dosage of durvalumab with cohort 2 receiving a higher dose",
        "label": "Entailment"
    },
    "7ae48994-9b72-4bc5-aab2-adcc9f0e1735": {
        "text_answer": "Contradiction The primary trial excludes patients with fibromyalgia but the secondary trial does not mention fibromyalgia as an exclusion criterion However the primary trial includes anemia and thalasemic syndromes as exclusion criteria and the secondary trial does not mention these conditions as inclusion or exclusion criteria Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "adbb33ae-2076-4850-bfd7-967119d8e169": {
        "text_answer": "Contradiction  Explanation The primary trial uses the change in units on a scale as the unit of measure for the outcome measurement of alleviation of the most bothersome vaginal symptom The secondary trial uses percentage of participants as the unit of measure for the outcome measurement of objective response rate of HER2negative metastatic breast cancer Both trials use different units of measure and neither of them use centimeters number of individuals",
        "label": "Contradiction"
    },
    "846578ce-00a5-487a-80d0-c5922f2c0c20": {
        "text_answer": "Contradiction  The statement says that patients experienced a 30 reduction in the percentage of cells with Ki67 expression after 2 weeks of treatment but the evidence shows that Ki67 expression at 6 weeks was only reduced by a median of 38 from baseline and it was measured after 16 weeks of treatment not 2 weeks",
        "label": "Contradiction"
    },
    "ba5d4784-f20f-4d77-b133-ab700624da3e": {
        "text_answer": "Contradiction The primary trial presented 0 cases of intestinal perforation while the secondary trial presented 1 case",
        "label": "Contradiction"
    },
    "638143cc-bcdc-422b-8695-ec836f17edae": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the primary trial involves the use of multiple drugs and surgery while the secondary trial only involves the use of two drugs and no surgery",
        "label": "Contradiction"
    },
    "d80d13ef-0da7-4203-af51-52c08253aefe": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided  Explanation The statement is not directly related to the evidence provided as it does not mention any adverse events related to bowel movements in the primary or secondary trials The evidence only provides information about the number and types of adverse events recorded in each trial",
        "label": "Entailment"
    },
    "9730b1a6-e9cd-4fd6-b1e4-9916b5903c63": {
        "text_answer": "Entailment The statement two patients suffered an Incidence of Doselimiting Toxicity is an entailment of the evidence as the evidence reports that one patient from each cohort suffered a doselimiting toxicity",
        "label": "Entailment"
    },
    "73feb437-66f3-44fd-8d9c-ab3204e6eac3": {
        "text_answer": "Entailment assuming Aes in the statement refers to Adverse Events as it is used in the context provided",
        "label": "Entailment"
    },
    "e6954b69-b723-4a51-8a5b-6e7461028b60": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the provided evidence alone The evidence does not specify whether or not participants in the placebo or memantine arms of the trial have reported getting a ringing or buzzing in their ears",
        "label": "Entailment"
    },
    "5fbe4001-1044-4684-a2a2-e34bf233fafb": {
        "text_answer": "Contradiction The statement is not related to the evidence provided",
        "label": "Contradiction"
    },
    "410a0a55-a31f-4a57-9de1-3eacd3da7650": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence mentions one case of suicidal ideation which is a psychiatric event",
        "label": "Contradiction"
    },
    "0585f6bd-d582-4fc9-b96b-1355fa083e33": {
        "text_answer": "Contradiction  The primary trial involves the use of IV PO and SC routes of administration for various drugs as well as surgery The secondary trial only mentions the use of PO route for two drugs Therefore the statement that the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery whereas the secondary trial participants only receive two different drugs and several different imaging scans is a contrad",
        "label": "Contradiction"
    },
    "2bc6306e-445f-459e-afab-b445eedd5711": {
        "text_answer": "Contradiction The evidence does not mention Paraplatin at all in the primary trial",
        "label": "Contradiction"
    },
    "ecb7babe-941e-41bf-89a3-0b8387fdd239": {
        "text_answer": "Contradiction The statement is not related to the evidence provided which is about the change in betaCTX levels in the two groups",
        "label": "Contradiction"
    },
    "4d77b4db-8260-4ec9-af60-660f7a2a4833": {
        "text_answer": "Contradiction The primary trial excludes patients who require use of coumarinderivative anticoagulants such as warfarin while the secondary trial permits its use under certain conditions",
        "label": "Contradiction"
    },
    "a3954ec9-3fdd-4183-844d-1a13f70350e8": {
        "text_answer": "Contradiction   Explanation The statement in the primary clinical trial there were no reported cases of adverse events amongst patients while every patient had at least one recorded adverse event in the secondary clinical trial is a contradiction based on the evidence provided In the primary trial there were no reported adverse events at all while in the secondary trial every patient had at least one recorded adverse event These two statements are contradictory",
        "label": "Contradiction"
    },
    "5c14c797-4995-467f-a993-bc75ad197093": {
        "text_answer": "Contradiction The statement mentions dfs as the mode of outcome measurement but the evidence provided in the text does not mention dfs diseasefree survival as the outcome measurement in either the primary or secondary trials The primary trial measures pCR pathological complete response and the secondary trial measures pathological complete response",
        "label": "Contradiction"
    },
    "00831e0c-eaad-4fe9-a791-f105815fa215": {
        "text_answer": "Contradiction The primary trial includes patients with a score of 3 on the Sleep Disruption Evaluation form or a score of 8 on Insomnia Severity Index ISI as inclusion criteria which means that patients with severe insomnia are not excluded from the primary trial However the statement asserts that patients suffering from severe insomnia are excluded from both trials which is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "c0151b24-14ab-4837-965d-88bb8115a560": {
        "text_answer": "Contradiction The statement that the patient with the longest PFS in the primary trial was in cohort 1 and he survived 35 months without disease progression or death is a contradiction to the evidence as the median PFS for cohort 1 was 16 months 16 to 32 and there is no mention of any individual patient surviving 35 months in the evidence",
        "label": "Contradiction"
    },
    "86da40aa-8994-4fb7-8628-098d347b5864": {
        "text_answer": "Contradiction The evidence does not provide information about the number or percentage of patients in either group who experienced no pain whatsoever during the 10week study",
        "label": "Contradiction"
    },
    "e6b59a72-62ef-4752-8464-902ca8d09119": {
        "text_answer": "Entailment  Explanation The statement both the primary and the secondary clinical trials registered just one death in the adverse events is an entailment based on the evidence provided The evidence shows that in the primary trial there was one death reported in the adverse events section and in the secondary trial there was also one death reported Therefore the statement that both trials reported one death is a logical conclusion that follows from the evidence",
        "label": "Entailment"
    },
    "a1e54b35-4b25-4194-8a44-7c8e587a1c83": {
        "text_answer": "Entailment The evidence states that both interventions use equal doses of radioactive Tc99M sulfur colloid",
        "label": "Entailment"
    },
    "e9bc72c1-1933-4ac1-b21b-35bf90b82c48": {
        "text_answer": "Contradiction  Explanation The statement There were no deaths or Hospitalizations in cohort 2 of the primary trial is a contradiction to the evidence as there are no data provided in the evidence regarding the occurrence of grade 1 joint effusions in cohort 2 The statement assumes that the absence of deaths and hospitalizations implies the absence of any adverse events but the evidence does not support this assumption",
        "label": "Contradiction"
    },
    "1f400417-bb05-4885-a46b-d348c2353ae9": {
        "text_answer": "Entailment The statement participants of the primary clinical trial are subjected to four different pharmaceutical treatments throughout the duration of the study is an entailment based on the evidence provided in the primary trial as the trial involves the use of epirubicin cyclophosphamide docetaxel and trastuzumab in the neoadjuvant therapy regimen",
        "label": "Entailment"
    },
    "e8e2db51-2ec2-4e88-9096-cbe5d5933286": {
        "text_answer": "Contradiction The primary trial measures the change in serum levels of Follicle Stimulating Hormone FSH while the secondary trial measures the Maximum Tolerated Dose MTD of Ruxolitinib in combination with paclitaxel",
        "label": "Contradiction"
    },
    "86ee12d2-2095-4ece-a7d6-f9494b51f3a6": {
        "text_answer": "Contradiction The primary trial involves hormonal interventions Estring and Testosterone Cream while the secondary trial does not involve any hormonal interventions but rather an acupuncture intervention",
        "label": "Contradiction"
    },
    "b7d3d4f9-44da-4fba-9005-e650cf0e2bb8": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the primary trial involves Alpha Lipoic Acid while the secondary trial involves Necitumumab which are two different interventions The comparison of dose escalation in the primary trial for Alpha Lipoic Acid and the fixed dose of Necitumumab in the secondary trial is not directly comparable",
        "label": "Contradiction"
    },
    "8ffe96d0-134e-438b-884e-8c4f05b57b03": {
        "text_answer": "Contradiction  Explanation  The primary trial intervention uses Yttrium90 Radioembolization which is a type of radiation therapy but it is not a combination of radiation therapy and surgery  The secondary trial intervention uses a combination of ibrutinib and MEDI4736 which are gene therapy and antibody treatments respectively  Therefore the statement is a contradiction as the primary trial intervention",
        "label": "Contradiction"
    },
    "f9172aa9-f9ea-44cc-9669-f72874fcbef2": {
        "text_answer": "Contradiction   Explanation   The primary trial involves the use of two different interventions one being massage therapy and the other being notouch therapy Both interventions are nondrug therapies   The secondary trial on the other hand involves the testing of two different doses of a drug therapy PF06647020 in the dose escalation phase   Therefore",
        "label": "Contradiction"
    },
    "42b44f03-de67-4d76-a566-2669f0768a23": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction to the evidence because the evidence shows that there were no recorded cases of anaemia in the primary trial while the statement claims that anaemia was the most common adverse event in the secondary trial affecting more than 34 patients",
        "label": "Contradiction"
    },
    "da1010e7-b58a-438b-b93d-cc53b6d4476e": {
        "text_answer": "Contradiction The primary trial did not record any cases of acute myocardial infarction",
        "label": "Contradiction"
    },
    "a0428861-8e0f-42ca-889f-b2546ae3dbe6": {
        "text_answer": "Contradiction The primary trial only includes patients undergoing surgery for Stage IIII breast cancer and the secondary trial includes patients who have completed surgery for Stage IIII breast cancer However a woman with Stage IV BC has not completed surgery for her breast cancer so she would not meet the inclusion criteria for either trial",
        "label": "Contradiction"
    },
    "59017303-759d-4b61-a272-efd6364a0b93": {
        "text_answer": "Entailment The statement that Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy is an entailment of the evidence as the evidence states that Patients will be treated on a dose escalation model for vorinostat and concurrently receive radiation therapy and that Patients will take Vorinostat daily during radiation therapy",
        "label": "Entailment"
    },
    "88d91a58-834e-4e7b-8b8d-f9ef0d075dab": {
        "text_answer": "Contradiction The primary trial does not have any age restrictions but the secondary trial specifically excludes children and adolescents",
        "label": "Contradiction"
    },
    "1defe036-8290-4a01-bec7-f75305d1e88e": {
        "text_answer": "Contradiction The primary trial uses the change in units on a scale as its unit of measure which can be considered a unit and the secondary trial uses percentage of participants and number as its units of measure",
        "label": "Contradiction"
    },
    "1514ac93-96a8-4d16-a572-d2a829af84c4": {
        "text_answer": "Contradiction The statement mentions cisplatintopotecan as a combination of agents containing cisplatin and topotecan but the evidence only mentions epirubicin cyclophosphamide docetaxel and trastuzumab as the drugs used in the primary trial",
        "label": "Contradiction"
    },
    "61c97e3c-0456-4a0f-a261-d8ab75386686": {
        "text_answer": "Entailment  Explanation The evidence shows that no cardiacrelated adverse events were reported in cohort 1 of the primary trial The statement in the primary clinical trial cardiacrelated adverse events were not reported in cohort 1 is an entailment of the evidence as it accurately reflects the information provided",
        "label": "Entailment"
    },
    "1aa7e1a8-707d-4c18-bdec-a750f59ffd1b": {
        "text_answer": "Entailment The statement is entailed by the evidence as the evidence states that over 12 of the patients in the Lapatinib 1000 mg  NabPaclitaxel arm experienced either a confirmed complete response CR or a confirmed partial response PR which is exactly what the statement is saying",
        "label": "Entailment"
    },
    "1f30e035-2441-4585-826a-9150678cb094": {
        "text_answer": "Contradiction The statement is not supported by the evidence as there are no palpitations pericardial effusions or abdominal pains recorded in the secondary trial and the number of these events in the primary trial is not mentioned in the statement",
        "label": "Contradiction"
    },
    "7b0752c4-ecc6-426a-82c9-e14bb237cfdc": {
        "text_answer": "Contradiction The statement is not an entailment as diffuse parenchymal lung disease is not listed as an exclusion criterion in the evidence provided for the primary trial",
        "label": "Contradiction"
    },
    "34a95632-c79d-4704-8a4a-56c4ddce6070": {
        "text_answer": "Contradiction The primary trial only includes female patients who are 18 years of age or older while the secondary trial includes both female and male patients who are 18 years of age The statement suggests a young girl who is not eligible for the primary trial based on age",
        "label": "Contradiction"
    },
    "587de897-adb2-4752-bd48-c9240b9bd956": {
        "text_answer": "Contradiction  Explanation The statement suggests that the growth factor signature increased in more participants from the dalotuzumab 20 mgkg group compared to the triple negative group However the evidence provided shows that a smaller percentage of participants in the dalotuzumab 20 mgkg group had a decrease in the growth factor signature 286 compared to the triple negative group 176 A decrease",
        "label": "Contradiction"
    },
    "fd0b6abb-37f4-4b91-9b9f-433cbced84a7": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the first cohort receives more frequent administration of CUDC101 but the statement asserts that they receive the same amount",
        "label": "Contradiction"
    },
    "2c3adca5-a150-4c23-aa83-2cc8caeb0deb": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 8 weeks while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "6ddf4b5b-69e2-46e1-b032-69c3173fd8ef": {
        "text_answer": "Contradiction The primary trial uses a 21day cycle for its intervention not a 1month cycle The secondary trial does not have a cyclic treatment specified but that does not contradict the primary trials 21day cycle",
        "label": "Contradiction"
    },
    "e9602bad-7e97-41b5-9d08-f02f259a75e6": {
        "text_answer": "Entailment Both trials involve the use of cyclophosphamide in the treatment of gastric neuroendocrine carcinoma",
        "label": "Entailment"
    },
    "1fa2d084-6a29-44c1-9e0f-53eb6d932247": {
        "text_answer": "Contradiction  The statement does not provide any information about the presence or absence of bsymptoms in the participants of the primary trial The evidence only reports the number of participants who had a reduction in circulating tumor cells following highdose chemotherapy with purged autologous stem cell products",
        "label": "Contradiction"
    },
    "ce232ee1-c38c-4eee-bb4a-eaa33f0c75a8": {
        "text_answer": "Contradiction The evidence states that a history of abdominal fistula gastrointestinal perforation or intrabdominal abscess in the past 6 months is an exclusion criterion for the primary clinical trial Therefore a recent diagnosis of an intrabdominal abscess would disqualify a patient from participating in the trial Similarly the evidence states that a history of significant psychiatric disorders is an exclusion criterion",
        "label": "Contradiction"
    },
    "26f39f2a-dad6-40ed-8fa4-5abd8847021f": {
        "text_answer": "Contradiction The primary trial includes patients undergoing mastectomy while the secondary trial includes patients who have completed surgery for breast cancer These surgeries are not mutually exclusive and a woman with Stage II BC could be eligible for one or the other trial depending on the specifics of her case",
        "label": "Contradiction"
    },
    "b37fc6a3-d231-478b-a18e-aa3439a972f1": {
        "text_answer": "Contradiction The evidence provided is about a clinical trial using highdose chemotherapy with autologous stem cell transplantation not lowdose standard chemotherapy",
        "label": "Contradiction"
    },
    "e7af2ad2-7001-40c6-93cd-ddfd4d436170": {
        "text_answer": "Contradiction The evidence states that the inclusion criteria include No evidence of dementia  Mini Mental State Examination MMSE 23 but some evidence of cognitive impairment which is not the same as a diagnosis of frontotemporal or mixed dementia",
        "label": "Contradiction"
    },
    "5abfa152-2c23-40b4-ba00-b28336b8b8b5": {
        "text_answer": "Entailment The statement is a restatement of the information provided in the evidence The final decision for inclusion in the trial is indeed made by the health professionals conducting the trial regardless of whether a patient satisfies the inclusion and exclusion criteria or not",
        "label": "Entailment"
    },
    "42c38d71-6a83-4967-ad81-ec38c6b5aafd": {
        "text_answer": "Entailment The statement is an entailment because the evidence indicates that cohort 2 received twice the dose of Enzalutamide as cohort 1 160 mg vs 80 mg",
        "label": "Entailment"
    },
    "5e301f1c-087e-4ca4-b679-cc229d1c0d27": {
        "text_answer": "Contradiction The statement does not account for the difference in tremelimumab dosing between the two interventions",
        "label": "Contradiction"
    },
    "63a2b921-08f3-456f-9710-fc74ec13954e": {
        "text_answer": "Contradiction The statement does not provide any information about the presence or absence of pi3k gene mutation in the primary trial",
        "label": "Contradiction"
    },
    "bbc8e272-7c58-4e53-a78b-4b634add9932": {
        "text_answer": "Entailment  Explanation  The statement the primary clinical trial employs a higher dosage of lenalidomide during the first intervention in comparison to the smaller dosage used for lapatinib in the secondary clinical trial is an entailment because the evidence states that participants in the primary trial received lenalidomide 5mg orally daily while participants in the secondary trial received oral lapatinib 1500 mg daily",
        "label": "Entailment"
    },
    "a7382edb-9b99-468d-99f2-2030aa61005c": {
        "text_answer": "Contradiction The statement is not an entailment as the primary trial and secondary trial evaluate different outcomes toxicity vs percentage of participants with adverse events",
        "label": "Contradiction"
    },
    "709bff7a-2384-4cac-ac70-00b4e91a6bce": {
        "text_answer": "Contradiction The statement does not entail the evidence as it makes no mention of the number or percentage of participants with clinical benefit CR PR or SD at weeks 12 and 24 and instead focuses on anxiety frequency",
        "label": "Contradiction"
    },
    "7c192c20-49e2-4b5c-b4ac-1131b7e9e4d0": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses the number of adverse events in two trials but it does not mention anything about the deleterious atm gene mutation",
        "label": "Contradiction"
    },
    "608a57fb-72d5-4837-a491-2d0bc83a7776": {
        "text_answer": "Contradiction The primary trial and the secondary trial report different outcome measurements The primary trial reports Time to Progression while the secondary trial reports the number of participants with Objective Response",
        "label": "Contradiction"
    },
    "58f6494f-860a-4f94-9fa1-895637730938": {
        "text_answer": "Contradiction The dosages are not equivalent Denosumab is given at a dose of 120 mg Q4W every 4 weeks in the primary trial while Tamoxifen is given at a dose of 10 mg once daily for 21 days out of a 28day menstrual cycle in the secondary trial",
        "label": "Contradiction"
    },
    "a08b1e1e-385a-40e6-990d-05b9aebc7335": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the administration of denosumab while the secondary trial does not involve any injection but rather the use of lymphoscintigraphy with gamma probes The statement suggests that the primary trial requires twice the amount of denosumab and a monthly injection while the secondary trial does not involve any injection at all This is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "a1eb1305-f49e-4773-aa30-033093afeb64": {
        "text_answer": "Contradiction  Explanation  The evidence provided shows that there were differences in the percentage of participants demonstrating a decrease in the growth factor signature between the ERpositive Luminal B and Triple Negative groups Therefore the statement that there was no significant difference is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "36c3d1c3-d4dc-49bf-97a8-49608799cc35": {
        "text_answer": "Contradiction The statement is about satisfaction with treatment effects which is not related to the eligibility criteria for the primary trial which pertains to histologic documentation of metastatic or unresectable SCBC and specific eligibility criteria related to organ function age and prior therapy",
        "label": "Contradiction"
    },
    "227071c8-f195-4c9c-993d-3f57a9062a6f": {
        "text_answer": "Contradiction The statement is not related to the provided evidence as the trials are for different types of cancer breast cancer and glioblastoma and the statement mentions a condition Vitamin D deficiency that is excluded from one trial but not mentioned in the other",
        "label": "Contradiction"
    },
    "a06e0782-9249-48ae-a2a3-70dffa452aab": {
        "text_answer": "Contradiction The evidence states that there are inclusion criteria for adequate life expectancy 1 year and age 18 years in the primary trial",
        "label": "Contradiction"
    },
    "7eb81981-e3ca-42f2-ba8f-d1582e00f54d": {
        "text_answer": "Contradiction  Explanation  Although both trials involve the use of trastuzumab the primary trial also includes cyclophosphamide and pegylated liposomal doxorubicin hydrochloride which are not present in the secondary trial Additionally the dosages and intervals of the pharmacological substances used in the two trials differ significantly In the primary trial trastuzumab is given IV",
        "label": "Contradiction"
    },
    "b60cdaf1-5a83-4738-b15d-d857c6d0924a": {
        "text_answer": "Contradiction The primary trial intervention is not related to the intervention in the secondary trial which involves ibrutinib and MEDI4736",
        "label": "Contradiction"
    },
    "43b9c2c8-0785-4885-901b-91a1f893858f": {
        "text_answer": "Contradiction The primary trial intervention is Radioembolization using TheraSpheres while the secondary trial intervention is based on ibrutinib and MEDI4736 which are different treatments",
        "label": "Contradiction"
    },
    "7e232984-9a95-44b0-85b0-ecbeb50655b7": {
        "text_answer": "Entailment The evidence provided does not indicate any restriction on participation based on nationality ethnicity weight or gender for either the primary or secondary clinical trials",
        "label": "Entailment"
    },
    "f5c83e99-e58f-4e5a-9fde-836480522184": {
        "text_answer": "Irrelevant The statement is not related to the evidence provided The evidence only reports the occurrence of adverse events in the primary and secondary trials and the statement is about squamous differentiation in tumor samples",
        "label": "Entailment"
    },
    "23727e9e-6589-475f-9c29-0a7880f6d8af": {
        "text_answer": "Contradiction The evidence shows that some individuals in the Tamoxifen group experienced an improvement in cognitive performance negative standardized score while the statement asserts that all individuals experienced a decline",
        "label": "Contradiction"
    },
    "05971ed1-8162-4f52-8361-6fae652d03e2": {
        "text_answer": "Contradiction The statement is incorrect as there is no evidence of a testosterone cream group in the provided data",
        "label": "Contradiction"
    },
    "99b57587-ea7a-496f-a7f9-9b2a7837ccc7": {
        "text_answer": "Contradiction  Explanation  The primary trial measures the impact of interventions on pain intensity using the Summed Pain Intensity Differences SPID at 30 minutes after dosing while the secondary trial measures the change in bone mineral density BMD of the lumbar spine using Dualenergy Xray Absorptiometry DEXA scan at 9 months The statement provided is incorrect because the primary trial",
        "label": "Contradiction"
    },
    "af9cfc7a-95f4-494a-b68f-128961cf1a5b": {
        "text_answer": "Contradiction The primary trial is for patients with locally advanced or metastatic breast cancer and the statement is about a patient diagnosed with a nonneoplastic disorder",
        "label": "Contradiction"
    },
    "55af1301-2370-48bf-8dde-50c589448da1": {
        "text_answer": "Contradiction The evidence does not provide any information about individuals with eating disorders being candidates in the primary clinical trial",
        "label": "Contradiction"
    },
    "7d0d3d69-d8ff-4671-9251-6f7a5f19a5ad": {
        "text_answer": "Irrelevant  The statement does not relate to the evidence provided The evidence only discusses the doses of drugs used in the primary and secondary trials The statement is about an individuals satisfaction with their physical attractiveness after gynecologic cancer",
        "label": "Entailment"
    },
    "9fcf0873-73d2-48e3-87ac-ee5df19f7810": {
        "text_answer": "Contradiction The statement is not an entailment as it goes beyond the information provided in the evidence which only states the median PFS for each cohort",
        "label": "Contradiction"
    },
    "54c9c0a9-c38d-46b1-a96b-1335daaaef85": {
        "text_answer": "Contradiction The primary trial does not specify that intervention 1 is administered transdermally but rather that zoledronic acid is given intravenously The secondary trial specifies that all intervention drugs are given intramuscularly but it does not apply to intervention 1 in the primary trial",
        "label": "Contradiction"
    },
    "24493091-48f3-4e50-ae2c-5d23fb12c376": {
        "text_answer": "Contradiction The primary trial includes all types of female breast cancer patients while the secondary trial specifically includes BRCApositive breast cancer patients",
        "label": "Contradiction"
    },
    "64e0d68e-9fdb-4625-b179-316cf3772ee9": {
        "text_answer": "Entailment The statement is an entailment because the evidence shows that the interventions in the primary trial are given via both intravenous IV and subcutaneous SC routes",
        "label": "Entailment"
    },
    "fed83886-1413-49c9-91ab-3f1bea54db23": {
        "text_answer": "Contradiction The statement the secondary clinical trial was unfortunately halted due to a number of significant adverse events encountered by most participants is a contradiction to the evidence provided as no significant adverse events were recorded in the secondary trial according to the given data",
        "label": "Contradiction"
    },
    "7138e72c-d5e7-4c18-ba8c-b71be945ac2d": {
        "text_answer": "Contradiction The evidence does not provide sufficient information to determine if the statement is entailed or contradicted The statement makes a claim about the reason for the tailored interventions but the evidence only mentions the age of the participants and the diseases they have or do not have and the vaccines they are receiving",
        "label": "Contradiction"
    },
    "4db16d69-4db6-410a-a48a-215903320e43": {
        "text_answer": "Contradiction  Explanation  The statement Breast cancer patients with estrogen negative progesterone negative and HER2 tumors are eligible for the primary trial is a subset of the inclusion criteria for the primary trial mentioned in the evidence However the statement in the question is about a medical device timetoevent dataset which is not related to the primary trials inclusion criteria Therefore the statement is a contrad",
        "label": "Contradiction"
    },
    "bfe7b8a8-8d7d-404c-b369-9bf059ae079c": {
        "text_answer": "Entailment The primary trial explicitly excludes patients with thalasemic syndromes and anemia while the secondary trial excludes patients with anemia due to causes other than iron deficiency Epilepsy is not mentioned in the primary trial but it is explicitly excluded in the secondary trial",
        "label": "Entailment"
    },
    "054618c6-0f9d-46de-94f3-e69e066a8432": {
        "text_answer": "Contradiction The primary trial did not report any cases of radiation dermatitis or hyperpigmentation while the secondary trial reported that 30 of participants in group 1 had radiation dermatitis and hyperpigmentation Therefore the statement that only 30 of participants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation contradicts the evidence from the primary trial that no cases",
        "label": "Contradiction"
    },
    "3db34e4f-ae01-424d-a8b8-7d1a16e2f898": {
        "text_answer": "Contradiction The evidence states that individuals with interstitial lung disease or pneumonitis are excluded from the trial Diffuse parenchymal lung disease is a type of interstitial lung disease",
        "label": "Contradiction"
    },
    "f300c26a-9ae0-4474-8fb3-34435ecdcf11": {
        "text_answer": "Contradiction  Explanation In the primary trial the participants in Intervention 1 receive entericcoated tablets of Botulinum Toxin Type A In the secondary trial participants in both Intervention 1 and Intervention 2 receive entericcoated tablets of MLN8237 Therefore the statement no participant in the primary clinical trial or the secondary clinical trial receives entericcoated tablets",
        "label": "Contradiction"
    },
    "5031f62e-54ed-4635-b136-7f90d6eb2535": {
        "text_answer": "Entailment Both trials use the same units of measure which are cm for tumor diameter in the primary trial and number of participants with solid tumor response in the secondary trial",
        "label": "Entailment"
    },
    "efdd9a96-8d0a-40ae-bcf7-f27abe59658d": {
        "text_answer": "Contradiction for the primary trial pulmonary embolism is an exclusion criterion and there is no mention of a time limit in the secondary trial",
        "label": "Contradiction"
    },
    "b89171bc-ed32-4c9b-91ee-545a95b809fc": {
        "text_answer": "Entailment given that the evidence mentions no use of drugs radiotherapy or CBT in the primary trial",
        "label": "Entailment"
    },
    "b0a8feea-e233-4a75-992e-698a978045a5": {
        "text_answer": "Contradiction The primary trial shows similar results between the two groups while the secondary trial shows a difference between the reflexology group and the control group",
        "label": "Contradiction"
    },
    "1d8a752e-8628-40d5-b134-e523b5dead07": {
        "text_answer": "Neutral  Explanation The evidence provided does not directly address the statement about severe discomfort during the entirety of the 10week study for any of the intervention groups The evidence only reports the average pain intensity scores and the changes in these scores between the lowdose and highdose intervention groups Therefore it is neutral with respect to the statement",
        "label": "Entailment"
    },
    "7c81475d-c4f3-45cd-8481-400d43c45a7e": {
        "text_answer": "Contradiction The evidence states that androgenbased therapy is an exclusion criterion for the primary clinical trial",
        "label": "Contradiction"
    },
    "9e5f5682-6d2b-40df-b271-a0da55928c97": {
        "text_answer": "Entailment The evidence states that both interventions memantine and placebo are administered orally but the statement specifically mentions once a day which is also true for both interventions in the trial",
        "label": "Entailment"
    },
    "40034c62-a8d9-424f-ac22-2d5fcab4dfc0": {
        "text_answer": "Contradiction The statement contradicts the information provided in the evidence as the evidence mentions nothing about a succeeding cohort undergoing standard radiotherapy treatment instead of the educational DVD intervention",
        "label": "Contradiction"
    },
    "711218ac-a329-4d4e-a66b-3c4b2d9116b5": {
        "text_answer": "Entailment assuming unexpected deaths or Hospitalizations refers to adverse events recorded in the trials",
        "label": "Entailment"
    },
    "ba6548a1-7dbf-4924-91ed-da83ecb2e8ef": {
        "text_answer": "Contradiction The statement is not an entailment as the diagnosis of 23 cerebral metastases within the brainstem is an exclusion criterion for the secondary trial but it does not necessarily exclude patients from the primary trial",
        "label": "Contradiction"
    },
    "06008bc8-58da-4762-9c98-830f2bd92325": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the evidence shows that breast cancer patients received a higher dose of talazoparib per week 7000 mcg compared to ovarianperitoneal cancer patients 175 mcg",
        "label": "Contradiction"
    },
    "68fe8d71-5200-4e77-a560-0fb7e67127a6": {
        "text_answer": "Irrelevant The statement has no relation to the given evidence",
        "label": "Contradiction"
    },
    "cd18deca-a213-4d53-af34-88624163f68e": {
        "text_answer": "Entailment   Explanation In the primary trial Paclitaxel is given as part of the Weekly CarboplatinNabPaclitaxel regimen In the secondary trial Paclitaxel is given as part of the docetaxel  lapatinib regimen Therefore Paclitaxel is indeed given to participants in both trials",
        "label": "Entailment"
    },
    "f2006562-69ab-4062-a5be-943cb905ee95": {
        "text_answer": "Contradiction The primary trial eligibility criteria do not mention anything about Alzheimers patients",
        "label": "Contradiction"
    },
    "f3f438bb-2af4-44b9-9bf7-28dc232feacb": {
        "text_answer": "Contradiction The statement contradicts the evidence as capecitabine not carboplatin was administered orally twice a week in the first intervention of the primary clinical trial",
        "label": "Contradiction"
    },
    "b0410aa1-2da2-4399-b673-45157d3c3fb7": {
        "text_answer": "Entailment The evidence states that 1 patient in the primary trial had an increased blood bilirubin level which is a part of the statement that 3636 of the patients had an increased blood bilirubin level",
        "label": "Entailment"
    },
    "52db4188-de06-4a23-91e2-bc899f33f0e5": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 patients receive 1 mgkg of MCS110 every 3 weeks and in Intervention 2 patients receive 3 mgkg of MCS110 every 3 weeks To determine if all patients receive at least 1300mg of MCS110 every 3 weeks we need to calculate the total amount of MCS",
        "label": "Contradiction"
    },
    "33c89b93-d655-4154-9712-0803974c65f7": {
        "text_answer": "Contradiction  The evidence provided does not indicate that every participant in the primary clinical trial experienced an adverse event The data only shows the number of participants with adverse events in two specific arms of the study",
        "label": "Contradiction"
    },
    "936d7822-fd4b-42fc-abc5-d5ad838f148c": {
        "text_answer": "Contradiction  The primary trial specifically excludes individuals who have received hormone therapy with exemestane mTOR inhibitors PI3K inhibitors or AKT inhibitors while the statement includes individuals who are considering hormone therapy The secondary trial does not mention any hormone therapy exclusions",
        "label": "Contradiction"
    },
    "b99886d6-98a7-4746-bc6c-1f70c8cdd0c6": {
        "text_answer": "Contradiction   The statement is a contradiction to the evidence because the evidence shows that there were adverse events recorded in both trials not just the secondary trial as stated in the question The statement implies that no adverse events were recorded in the primary trial but the evidence shows that there were no specific types of adverse events Eyelid oedema and Chest pain recorded in the primary trial not that no adverse events were recorded at",
        "label": "Contradiction"
    },
    "c2c4cbf5-1469-42bf-b243-9080648b458b": {
        "text_answer": "Entailment The statement implies a reduction of 20 or more while the evidence shows a median reduction of 35 from 15 to 10 A reduction of 20 is within the range of the observed reduction",
        "label": "Entailment"
    },
    "cc807530-f293-4c99-921b-f6e303d2b825": {
        "text_answer": "Contradiction  Explanation  The primary trial includes patients with benign breast disease while the secondary trial includes patients with a history of breast cancer Therefore healthy patients without cancer would be included in the primary trial but excluded from the secondary trial making the statement a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "82c8c33d-a45b-4897-8ac5-407ec39564fd": {
        "text_answer": "Contradiction The primary trial involves oral pregabalin while the secondary trial involves intravenous Liposomal Cytarabine and Highdose Methotrexate",
        "label": "Contradiction"
    },
    "a4cc14a3-7e05-4f72-b2f1-c9bb11720917": {
        "text_answer": "Entailment with the caveat that majority implies more than half of the participants and the evidence shows that 20 out of 35 participants had no acute vomiting episodes",
        "label": "Entailment"
    },
    "bacab9f7-0d0a-49e1-a503-e959c33bfe6a": {
        "text_answer": "Entailment The evidence states that the final eligibility for the clinical trial is determined by the health professionals conducting the trial which aligns with the statement that the ultimate verdict on inclusion lies in their hands",
        "label": "Entailment"
    },
    "d11e7175-a122-475f-862e-c5215d821f34": {
        "text_answer": "Contradiction The primary trial does not have any age or cancer type restrictions for males while the secondary trial specifically requires males to have prostate cancer",
        "label": "Contradiction"
    },
    "99eb2e5a-77d2-4ab1-a25b-b6d8a8bcf412": {
        "text_answer": "Contradiction The evidence does not mention anything about a court appointed guardian or representative in the inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "c00fd72d-2cbe-4988-a861-60a707684af7": {
        "text_answer": "Entailment The evidence shows that there were a total of 5 gastrointestinal adverse events diarrhea nausea and vomiting across both sets of data which is more than the minimum of one required by the statement",
        "label": "Entailment"
    },
    "7ade4e76-2f1d-452d-b9e4-499e0aabbe0c": {
        "text_answer": "Contradiction The evidence does not mention swelling hypothermia or confusion in the adverse events of either trial",
        "label": "Contradiction"
    },
    "652e7c7c-998b-4a7d-b170-bcbe79729d93": {
        "text_answer": "Contradiction The primary trial measures changes in vaginal symptoms using a selfreported questionnaire while the secondary trial measures objective response rate of HER2negative metastatic breast cancer using imaging studies",
        "label": "Contradiction"
    },
    "d8d046cc-99cc-4a31-94de-6dd290f504e7": {
        "text_answer": "Contradiction The evidence shows that no adverse events were recorded in the primary trial for any of the patients",
        "label": "Contradiction"
    },
    "9b09c156-bc43-445b-83ca-3831b111056f": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as there were no adverse events reported in either trial",
        "label": "Contradiction"
    },
    "8b3dbda5-ee27-4d74-b6ab-d4bb1cc5c86b": {
        "text_answer": "Contradiction The primary trial permits lowdose warfarin less than or equal to 1 mgday but the secondary trial excludes patients receiving warfarinbased therapy",
        "label": "Contradiction"
    },
    "e115c2a9-a31e-4a26-a96b-cd038666ced0": {
        "text_answer": "Contradiction The primary trial uses patientreported outcomes as its unit of measure while the secondary trial uses biomarker data These are not the same types of units of measure",
        "label": "Contradiction"
    },
    "4662f196-5472-4321-846e-c1576bc0be70": {
        "text_answer": "Entailment Both trials report that none of the participants experienced cholelithiasis",
        "label": "Entailment"
    },
    "76032781-7c1c-4518-b9c5-13f8d7a5b443": {
        "text_answer": "Contradiction The statement is about chest pain which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "2c29a565-bdcd-464c-85a4-361ab767c0d9": {
        "text_answer": "Contradiction  Explanation  The primary trial reported one death 1111 and the secondary trial reported one death 1111 but the statement claims that there were multiple deaths in each trial Therefore the statement is a contradiction based on the provided evidence",
        "label": "Contradiction"
    },
    "bd759cf8-b82f-496f-a8f7-1ab39f0d4724": {
        "text_answer": "neither entailment nor contradiction The statement does not directly relate to the eligibility criteria for the primary or secondary trials",
        "label": "Entailment"
    },
    "7531054e-9cf3-43a1-bba4-19e90a2c5ef0": {
        "text_answer": "Entailment The primary trial measures adverse events while the secondary trial measures objective response but both trials are related to the treatment of cancer patients",
        "label": "Entailment"
    },
    "dd3d2183-d062-41ed-af63-ae475f2246ec": {
        "text_answer": "Contradiction The evidence shows that in neither trial did more than 30 of participants experience adverse events",
        "label": "Contradiction"
    },
    "129d4bb1-11bc-4aa4-b75a-fa8d0832e2ff": {
        "text_answer": "Entailment assuming that greater implies a difference greater than the 95 confidence interval  Explanation The statement in the primary clinical trial the group taking azd0530 175 mg experienced a greater percentage change in betactx at the fourth week than the group on zoledronic acid 4 mg is an entailment based on the evidence provided assuming that greater implies a difference",
        "label": "Entailment"
    },
    "4a21310d-d0b8-44c7-ac08-ca9164bdc49f": {
        "text_answer": "Contradiction The primary trial uses Yttrium90 Radioembolization with TheraSphere while the secondary trial uses ibrutinib and MEDI4736 These interventions are not the same",
        "label": "Contradiction"
    },
    "57656a6d-8e1c-4cb8-b80d-605174d0577c": {
        "text_answer": "Contradiction The primary trial includes anemia as an exclusion criterion but the secondary trial does not mention anemia as an exclusion criterion Fibromyalgia and thalasemic syndromes are exclusion criteria for both trials",
        "label": "Contradiction"
    },
    "19dbbcf2-63e2-4f96-a672-8c184edb025b": {
        "text_answer": "Contradiction The Intervention 1 description mentions a validated webbased risk assessment and decision support for providers for prevention based on risk which contradicts the statement that neither cohort receives any counselling risk assessment or CBT",
        "label": "Contradiction"
    },
    "3607f455-e990-4306-8b23-52d930ccbdff": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the occurrence of ascites was higher in the primary trial but there were no cases of pneumocystis jirovecii pneumonia in the secondary trial",
        "label": "Contradiction"
    },
    "db2684e9-bcdc-482b-bfe4-4d6b2f6862c0": {
        "text_answer": "Neutral The statement is not directly related to the evidence provided",
        "label": "Entailment"
    },
    "40fceb75-d0d5-4926-8d3d-7e5f3c5b7931": {
        "text_answer": "Contradiction The evidence does not mention any cases of eating disorders among the adverse events reported in the primary clinical trial",
        "label": "Contradiction"
    },
    "b72d4b5e-e31f-47aa-979a-8253ec455cd1": {
        "text_answer": "Contradiction The evidence states that there were 3 cases of hepatotoxicity while the statement claims that there were an equal number of cases for hepatotoxicity hypertension and pancreatectomy",
        "label": "Contradiction"
    },
    "fc9a9de5-319a-465e-82ce-3c95b9a42728": {
        "text_answer": "Contradiction  The primary trial reported 1 infection case while the secondary trial reported 1 infection case for unspecified infections Therefore the statement that both trials reported zero infection cases is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "3870c72e-cf9d-461b-9dfd-ef407d84e8cf": {
        "text_answer": "Contradiction  Explanation  The primary clinical trial involves patients undergoing whole breast radiation therapy not proton therapy  The secondary clinical trial involves patients receiving intramuscular injections of fulvestrant not a transdermal patch",
        "label": "Contradiction"
    },
    "83e0c108-bbbe-4b9b-97b6-62ea72e374d8": {
        "text_answer": "Contradiction The evidence shows that there were no infections and infestations cases in cohort 2",
        "label": "Contradiction"
    },
    "8b047df3-cd4b-4c75-97b5-4081f65512eb": {
        "text_answer": "Contradiction The primary trial does not involve a 2mgkg dosage of dexmedetomidine in group 2",
        "label": "Contradiction"
    },
    "e92e432c-9e5c-451c-9bb2-ff89a618126c": {
        "text_answer": "Contradiction The primary trial does not mention any exclusion criteria related to potassium levels",
        "label": "Contradiction"
    },
    "d7f818fb-a383-41c3-ac12-788228db7cf9": {
        "text_answer": "Contradiction  Explanation  In the primary trial the intervention consists of a single drug ZD1839 In contrast in the secondary trial the intervention in Intervention 1 includes Zoledronic acid and in Intervention 2 it includes Zoledronic acid Samarium153 and pegfilgrastim Therefore the statement that the intervention in the secondary trial requires at least 3",
        "label": "Contradiction"
    },
    "d39e0799-d31d-4759-96ed-716b92f924a6": {
        "text_answer": "Contradiction The intervention in the primary trial lasts for 10 weeks while the intervention in the secondary trial lasts for 24 weeks which is more than three times longer However the statement only mentions that it lasts three times longer not specifically that it lasts exactly three times longer Therefore the statement is a contradiction because it does not accurately reflect the evidence",
        "label": "Contradiction"
    },
    "fbe81247-571c-43a1-a2eb-439e579cf229": {
        "text_answer": "Contradiction The statement mentions swelling hypothermia and confusion but the evidence provided does not mention any cases of these conditions in either trial",
        "label": "Contradiction"
    },
    "952fd1e7-65a2-417f-b1b8-188bce187c04": {
        "text_answer": "Contradiction The primary trial has different eligibility criteria for Phase I and Phase II while the secondary trial has different criteria altogether",
        "label": "Contradiction"
    },
    "551bc048-5bac-47a0-a2bf-17844970c8dc": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence describes injections of specific treatments dendritic cell vaccine trastuzumab vinorelbine and sargramostim for patients in the primary trial while the statement is about a gas cylinder which is not mentioned in the evidence",
        "label": "Contradiction"
    },
    "03c087ae-9ad2-4db3-a913-e6ba85dc15b0": {
        "text_answer": "Contradiction  Explanation The primary trial has no mention of any specific requirement related to the percentage of waking hours spent in bed The secondary trial however does not include bedridden for less than 50 of their waking hours as an inclusion criterion Therefore the statement is a contradiction to the evidence provided",
        "label": "Contradiction"
    },
    "9c459c1c-bfc4-4fef-ba9f-6052b9622c69": {
        "text_answer": "Neutral The statement does not directly follow from the evidence but it is not contradictory either  Explanation The statement is about the presence or absence of calr gene mutation and adverse events which are two different things The evidence only provides information about adverse events not about the presence or absence of calr gene mutation Therefore the statement is not an entailment or a contradiction based on the given evidence",
        "label": "Entailment"
    },
    "a79aa893-e44c-4077-8791-47fb56351b5e": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as there is no mention of radiation therapy in either the primary or secondary trials",
        "label": "Contradiction"
    },
    "f3e56d1d-af35-462c-ac1e-7e995543f505": {
        "text_answer": "Neutral The statement does not directly follow from the evidence provided  Explanation The statement does not provide any information about the adverse events Aes in the primary trial so it cannot be determined if it is an entailment or a contradiction based on the evidence alone The evidence only tells us that less than 5 of patients in the primary trial suffered from adverse events but it does not specify what those events were or how they",
        "label": "Entailment"
    },
    "88574a43-d4c9-4db7-8f47-307722095b0d": {
        "text_answer": "Contradiction The statement is about joint flexibility in the secondary trial and zinc levels in the primary trial which are not related concepts",
        "label": "Contradiction"
    },
    "c7e1e07a-e363-47f7-9ec3-21fbd1da79b3": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided for both trials The evidence states that patients with unstable angina and Grade 2 or above neuropathy are excluded from the secondary trial but there is no mention of these conditions in relation to the primary trial The statement about breast feeling heavy is not related to the eligibility criteria for either trial",
        "label": "Contradiction"
    },
    "eca608f4-6f65-4fc9-96cb-d1bb45749048": {
        "text_answer": "Contradiction  Explanation The evidence provided does not entail that several of the patients in the primary trial experienced the no pain whatsoever during the 1680 hours of the study While the evidence indicates that both the lowdose and highdose groups received a psychoeducational intervention aimed at improving cancer pain management it does not provide information on the number of patients who experienced no pain during the study",
        "label": "Contradiction"
    },
    "a8353a78-23fe-4aba-aaef-06d3fb8dd41a": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the evidence provides the median PFS in months and 14 days is significantly less than the reported median PFS",
        "label": "Contradiction"
    },
    "cb591a65-2304-40bc-ad66-ddd4f3376bdc": {
        "text_answer": "Contradiction The statement does not follow from the evidence provided as the evidence does not mention anything about peripheral primitive neuroectodermal tumors or smoking in relation to the inclusion or exclusion criteria for the primary or secondary trials",
        "label": "Contradiction"
    },
    "c566ae79-b43a-4e83-8336-da8613e19e7f": {
        "text_answer": "Contradiction The inclusion criteria state that participants must have no evidence of dementia but Alzheimers disease is a type of dementia",
        "label": "Contradiction"
    },
    "b0bedf1c-a1ed-4bf5-9ad1-ac22f0681d03": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not address the number of participants with treatmentemergent adverse events",
        "label": "Contradiction"
    },
    "a3fb7d8d-5911-41d4-b3da-9a018bb256f6": {
        "text_answer": "Contradiction The primary trial did not report any cases of lesions in the healthy volunteers group while the secondary trial reported cases of radiation dermatitis and hyperpigmentation in the breast cancer patients group but no mention of lesions",
        "label": "Contradiction"
    },
    "5ccd39fd-215e-4699-8d02-a13d68ec34d3": {
        "text_answer": "Contradiction The primary trial does not provide any information about the use of Paraplatin in the study",
        "label": "Contradiction"
    },
    "1304d51c-38a5-4851-9241-b0cb6993b013": {
        "text_answer": "Contradiction The primary trial measures hot flash scores on a scale while the secondary trial measures overall response rate as a proportion of responders",
        "label": "Contradiction"
    },
    "5794c670-e60c-4d2a-8d09-744e644c3e34": {
        "text_answer": "Contradiction The statement Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial is not explicitly stated in the inclusion or exclusion criteria provided The statement History of grade 3 or 4 allergic reactions attributed to trastuzumab is mentioned in the exclusion criteria but it does not specify that the reactions must be severe anaphylactic reactions",
        "label": "Contradiction"
    },
    "cdc43061-760e-4de2-946e-93d74f8ab544": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the two cohorts in the primary trial consist of different populations adult cancer patients and healthy volunteers",
        "label": "Contradiction"
    },
    "5758ac46-f46b-452f-aa99-5d9c86700447": {
        "text_answer": "Contradiction  Explanation The statement makes a comparison between the primary and secondary trials regarding the occurrence of specific adverse events However the evidence provided does not support the statement as it only lists the occurrence of Recurrent malignancies Graftversushost disease Anaemia Cardiac failure and Diffuse alveolar hemorrhage in the primary trial and does not provide information about their occurrence in the",
        "label": "Contradiction"
    },
    "42857f32-4798-4767-a0c7-f74cdcab7a9b": {
        "text_answer": "Entailment The statement entails that participants receive 4 different drugs which is true based on the evidence and the maximum dose of epirubicin is 100 mgm2",
        "label": "Entailment"
    },
    "707a6e1b-520e-4052-bbd8-c932c4cc65e2": {
        "text_answer": "Entailment The evidence states that both GBM and gynecological cancer patients undergo 18FFDG and 18FFPPRGD2 PETCT imaging with the same protocol for both radiotracers",
        "label": "Entailment"
    },
    "0359c605-2a3a-4696-8d14-ba214c571f1b": {
        "text_answer": "Contradiction The primary trial has a breast tumor size inclusion criterion of 1 cm while the statement mentions a TNBC tumor of 100mm in diameter which is not consistent with the primary trials inclusion criteria",
        "label": "Contradiction"
    },
    "ed820c4c-4119-4e93-894f-8484407c9ce6": {
        "text_answer": "Entailment The primary trial examines the effects of different interventions Hydrophor and MediHoney on patients with cancer while the secondary trial examines the effects of different dosages 90 mg and 110 mg of the same drug PF05212384 on its cohort Both trials are focused on evaluating the impact of different interventions or treatments on study groups",
        "label": "Entailment"
    },
    "36cbd8dd-9c77-496c-ab43-af1942c86339": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as the two cohorts in the primary trial receive different regimens one with gemcitabine and the other with carboplatin and there is no mention of the same doses of Abraxane being administered in both arms",
        "label": "Contradiction"
    },
    "14fdb2fc-e19d-4628-ada4-37ea935a2b4a": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence because there is no mention of respiratory complications in the adverse events of the primary trial The evidence only mentions various adverse events related to the blood and bone marrow and lymphatics",
        "label": "Contradiction"
    },
    "9783fc05-3652-41b2-8ba0-8a276889692a": {
        "text_answer": "Contradiction The primary trial explicitly states that there is an exclusion criterion for pulmonary hemorrhagebleeding event NCI CTCAE v30 Grade 2 within 4 weeks of first dose of study drug but it does not mention anything about a pulmonary embolism history The secondary trial does not mention anything about pulmonary embolism in its inclusion or exclusion criteria",
        "label": "Contradiction"
    },
    "b6b71c5a-8d4b-4ae1-9b57-45a5c9112543": {
        "text_answer": "Contradiction The evidence states that the medications are given orally on a daily basis for 28 days not subcutaneously and not once a fortnight for a year",
        "label": "Contradiction"
    },
    "bed229d6-8924-4753-a297-d49d4c128166": {
        "text_answer": "Contradiction The statement is not related to the eligibility criteria for the trials provided in the evidence",
        "label": "Contradiction"
    },
    "a434b916-659c-46a6-81c3-1654f561a2c2": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there is no mention of eating disorders in the list of adverse events",
        "label": "Contradiction"
    },
    "3c96d823-bc6c-4c7e-b490-50a0870076c5": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the interventions in the primary clinical trial are not administered via inhalation but rather via transendocardial injections",
        "label": "Contradiction"
    },
    "f5e483ed-caec-4142-baa9-15ba42da5f03": {
        "text_answer": "Contradiction  Explanation The statement All AE types in the primary trial affected less than 10 of patients is a contradiction to the evidence as the evidence shows that several adverse events affected more than 9 of patients in the primary trial For example febrile neutropenia sinus tachycardia sepsis lymphocyte count decreased neutrophil count",
        "label": "Contradiction"
    },
    "a993ae6a-f86f-478e-af30-584181f09531": {
        "text_answer": "Entailment Both interventions are given twice daily for a duration of 81 days",
        "label": "Entailment"
    },
    "f119d419-b22b-4b4d-84ea-f7ab7dba7522": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the given evidence alone The evidence does not provide sufficient information to determine if there is a relationship between the primary and secondary trial participants occupations and the doses of drugs they receive",
        "label": "Entailment"
    },
    "d7750102-df82-4668-8c6d-60e73b3241b5": {
        "text_answer": "Contradiction The primary trial uses a cyclic treatment schedule while the secondary trial does not have a cyclic treatment mentioned in the evidence The statement about benign pericardial neoplasm is not related to the trials and is not relevant to the question",
        "label": "Contradiction"
    },
    "d269b697-c96f-4317-99c9-e465c7e935a7": {
        "text_answer": "Contradiction The evidence shows that there were different numbers of participants in each group The Neratinib group had 1420 participants and the Placebo group had 1420 participants but the percentage of participants with events was different 47 for Neratinib and 75 for Placebo",
        "label": "Contradiction"
    },
    "0a74e0af-2534-45f3-b003-ba68e6e52d94": {
        "text_answer": "Entailment The evidence states that in the primary trial Intervention 1 uses pIHGC and Intervention 2 uses GP which are different imaging modalities",
        "label": "Entailment"
    },
    "c6788d02-11df-4099-a395-c1e3dbc17f35": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as anaemia was not a common adverse event in the primary trial and there were no recorded adverse events at all",
        "label": "Contradiction"
    },
    "f1dca117-1368-4d17-bdb6-52d1b3816ed5": {
        "text_answer": "Contradiction The primary trial explicitly excludes patients with a pulmonary embolism within the last 1095 days while the secondary trial does not mention any such exclusion",
        "label": "Contradiction"
    },
    "b1d950c2-dbd9-4cb4-b291-9406d84cd8de": {
        "text_answer": "Contradiction The primary trial does not mention anything about ai therapy and mirtazapine responsiveness as a requirement while the secondary trial does not mention it as a mandatory requirement at all",
        "label": "Contradiction"
    },
    "1f63524b-443d-4382-9df4-ea83eda85940": {
        "text_answer": "Entailment assuming normal weighted refers to individuals who meet the stated weight criteria in both trials The primary trial includes the requirement of being able to understand and sign informed consent which does not exclude individuals based on weight or pregnancy status The secondary trial also includes the requirement of being nonpregnant but it does not mention any weight restrictions Therefore the statement that normal weighted nonpregnant individuals can participate in the primary clinical trial and",
        "label": "Entailment"
    },
    "ad1c4967-3600-4953-a7fb-e48c9f4aa01f": {
        "text_answer": "Contradiction The statement is incorrect because a 20yearold female patient with a newly diagnosed ERpositive HER2negative breast cancer cannot meet the age requirement for the primary trial which is for female patients who are 18 years of age",
        "label": "Contradiction"
    },
    "6f4a77ce-3f70-4b57-ae45-e9825753d9ee": {
        "text_answer": "Contradiction The primary trial defines each treatment cycle as 21 days not 30 days",
        "label": "Contradiction"
    },
    "73a0936e-5144-4b8c-b230-389d8ed451af": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as individuals who have been treated with androgens in the last month are explicitly listed as an exclusion criterion for the primary clinical trial",
        "label": "Contradiction"
    },
    "37c939aa-c2b0-4fcc-a90a-d7fa36fc8571": {
        "text_answer": "Entailment  Explanation The evidence provided indicates that both cohorts in the primary clinical trial were not subjected to invasive surgical procedures or given neratinib The statement that neither cohort underwent surgical procedures or received neratinib is an entailment of the evidence as the evidence explicitly states that neither drug was given to either cohort",
        "label": "Entailment"
    },
    "a12ed2c0-b402-445b-b21b-7497389b39ec": {
        "text_answer": "Contradiction The statement does not entail the evidence as it refers to metastatic SCBC small cell lung cancer while the evidence refers to metastatic nonsmall cell lung cancer breast cancer head and neck cancer and urothelial transitional cell carcinoma",
        "label": "Contradiction"
    },
    "d4bd0ed2-5753-470c-b804-00bbebdfc2d7": {
        "text_answer": "Contradiction The primary trial includes the exclusion of patients with a history of pulmonary embolisms but it does not mention anything about breast implants The secondary trial excludes patients with breast implants but does not mention anything about pulmonary embolisms",
        "label": "Contradiction"
    },
    "44b930a2-5810-41aa-a70c-e7eaa3730bc0": {
        "text_answer": "Contradiction The statement mentions 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but no cases of Pancytopenia while the evidence shows 1 case of Anaemia and 1 case of Febrile neutropenia were recorded in cohort 1 of the primary trial The statement is incorrect because it states that there were no cases of Pancytopenia",
        "label": "Contradiction"
    },
    "7c28d575-cd75-418e-83bb-fae7457d9428": {
        "text_answer": "Contradiction The statement is about changes in lymphedema and satisfaction with sexual life which are two different outcome measures",
        "label": "Contradiction"
    },
    "9a9bd166-1319-4a61-a8c2-e42ee878bf83": {
        "text_answer": "Contradiction  The statement mentions nothing about the primary trial or the two patients suffering from doselimiting toxicity experiencing errors on the ADASCOG executive function maze task",
        "label": "Contradiction"
    },
    "b032dff4-0d5d-4ee3-a4b2-c22ab3b8823f": {
        "text_answer": "Contradiction  The primary trial includes a performance status criterion Zubrod performance score 2 or better while the secondary trial does not mention performance status as an inclusion or exclusion criterion",
        "label": "Contradiction"
    },
    "dd52a82a-b788-4048-ba8d-525ee119a78f": {
        "text_answer": "Contradiction The primary trial employs hormonal methods Estring and Testosterone Cream while the secondary trial does not Instead it uses acupuncture",
        "label": "Contradiction"
    },
    "d93422f2-c5ab-4aa0-90a3-478b05a17c4e": {
        "text_answer": "Contradiction The evidence shows that there were no adverse events reported in both trials",
        "label": "Contradiction"
    },
    "480133d8-93ea-46f0-86e5-b92c380bb7f9": {
        "text_answer": "Neutral The statement is neither an entailment nor a contradiction based on the provided evidence The statement is true but not directly related to the information provided about the use of trastuzumab in the primary and secondary trials",
        "label": "Entailment"
    },
    "2ac85077-e695-40c7-a9a9-d9901eceaeb2": {
        "text_answer": "Entailment Both trials involve the use of cyclophosphamide",
        "label": "Entailment"
    },
    "e4221b6d-f3d7-4299-bcba-19c02be74cdd": {
        "text_answer": "Contradiction The statement noncontinuous spinal cord parenchymal is a description that locations of interest are noncontinuous and within the spinal parenchyma is not related to the inclusion criteria for the primary trial The primary trials inclusion criteria are related to having a solid tumor that is locally advanced andor metastatic",
        "label": "Contradiction"
    },
    "a16ff39b-cc99-4214-9af5-910eb9384a97": {
        "text_answer": "Contradiction The evidence shows that in both trials no adverse events occurred in more than 90 of participants",
        "label": "Contradiction"
    },
    "571d4650-e64b-4cb2-b719-0d7064e51745": {
        "text_answer": "Contradiction  The statement implies that there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy combined since 10 times the number implies 3 times for each of the two events However the evidence shows that there were 3 times the number of Hepatotoxicity cases compared to the total number of Thrombocytopenia Hypertension",
        "label": "Contradiction"
    },
    "f9d0c257-bd9a-484e-bae7-802c0246372c": {
        "text_answer": "Contradiction The primary trial compares Arm A and Arm B while the secondary trial compares Zoledronic acid and Denosumab which are different interventions",
        "label": "Contradiction"
    },
    "15a422cf-fc00-4451-bddc-af67f7437e83": {
        "text_answer": "Contradiction The statement that cohort 1 and 2 receive the same dosage of CUDC101 contradicts the evidence that cohort 1 receives CUDC101 more often even though the dosage may be the same per infusion",
        "label": "Contradiction"
    },
    "cdcb40f6-994c-4085-869a-dab87e67ba04": {
        "text_answer": "Contradiction The statement does not follow from the evidence as the evidence only reports the percentage of patients with Recurrencefree Survival not the percentage of patients who reported experiencing adverse events",
        "label": "Contradiction"
    },
    "8e661d16-bf69-4d02-a437-5a77f12c1bd0": {
        "text_answer": "Entailment Both trials involve the use of 4Demethyl4cholestryloxycarbonylpenclomedine in a weekly cycle so the statement that the interventions in both trials require patients to undergo a weekly cycle of 4Demethyl4cholestryloxycarbonylpenclomedine is an entailment",
        "label": "Entailment"
    },
    "ac4c15e0-c711-4583-a9d4-1dbc682cd7f7": {
        "text_answer": "Entailment The statement during the primary clinical trial the initial assembly documented one instance each of anaemia and febrile neutropenia but recorded no instances of pancytopenia is an entailment of the evidence provided as the evidence also reports one instance each of anaemia and febrile neutropenia and no instances of pancytopenia in the primary trial",
        "label": "Entailment"
    },
    "fac10570-e1ed-4b0a-b847-55eb25265d25": {
        "text_answer": "Contradiction  The evidence shows that there was 1 case of anemia and 1 case of febrile neutropenia in cohort 1 of the primary trial but no cases of pancytopenia However the statement asserts that there was 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial but no cases of Pancytopenia which",
        "label": "Contradiction"
    },
    "1cab397e-60fd-460d-8f56-978ca8a2bb78": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not support the claim that hepatotoxicity cases were ten times more frequent than hypertension and pancreatectomy cases",
        "label": "Contradiction"
    },
    "ed2174d9-375c-4ed0-b880-56d13f6fb069": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions no adverse events occurred in more than 30 of participants in either trial and the statement asserts that there were ionizing radiationrelated malignant neoplasms in more than 30 of participants",
        "label": "Contradiction"
    },
    "ac271988-c319-4b6f-b7bf-f3c86072cf93": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction because the primary trial does not involve the use of ALT801 at all whereas the secondary trial does",
        "label": "Contradiction"
    },
    "915adcaa-4b9a-4df9-9803-4c5c0c52bf48": {
        "text_answer": "Entailment The evidence does not mention the use of paclitaxel in any of the interventions",
        "label": "Entailment"
    },
    "3cdc1ca9-f403-4e4b-878e-678d8dbc6090": {
        "text_answer": "Contradiction The evidence does not support the statement as it mentions no occurrences of hypertension in the primary trial but it does not explicitly state that there were no occurrences of dehydration or dyspnea",
        "label": "Contradiction"
    },
    "c179d073-c910-42ab-9fde-85e976e52203": {
        "text_answer": "Contradiction The evidence does not mention anything about morbidly obese patients being eligible or not for the primary or secondary trials The statement is not supported by the given evidence",
        "label": "Contradiction"
    },
    "7e529d12-16a2-4711-b7f8-b454800447f2": {
        "text_answer": "Contradiction The primary trial specifically states that patients must have a tumor size of 1 cm or less while the statement in question allows for a tumor size ranging from 02 to 08 cm",
        "label": "Contradiction"
    },
    "b71a1480-2037-4a01-8a4f-95a34aa172c2": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as there are no instances of mucositis oral thromboembolic events or bladder infection recorded in the secondary trial",
        "label": "Contradiction"
    },
    "6690be43-edee-4061-a850-47540cc49bee": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence describes the adverse events observed in a primary trial while the statement is about juvenile idiopathic arthritis",
        "label": "Contradiction"
    },
    "13d879d7-e968-4de9-ad06-458eb72759d5": {
        "text_answer": "Contradiction The evidence shows that no adverse events were recorded in both trials The statement however asserts that there were 10 recorded adverse events",
        "label": "Contradiction"
    },
    "c46fb676-9060-4d56-9097-af79bb762f50": {
        "text_answer": "Contradiction The evidence states that the final eligibility for the clinical trial is determined by the health professionals conducting the trial which contradicts the statement that the acceptance into the trial solely depends on the inclusion and exclusion criteria",
        "label": "Contradiction"
    },
    "14be6911-9b8c-4eb2-bcb9-bb5e892a57d1": {
        "text_answer": "Contradiction The primary trial does test a massage therapy intervention which is not a drugbased treatment but not explicitly stated in the provided evidence that the secondary trial does not test any drugbased treatments",
        "label": "Contradiction"
    },
    "e1cb3a7c-2881-41b9-8dc5-c6a1d311afc6": {
        "text_answer": "Entailment The statement an increase of 11 adverse events is greater than the observed difference of 14 adverse events in the secondary trial compared to the primary trial",
        "label": "Entailment"
    },
    "2ce0537c-cd90-47dd-83e3-79a690cdc101": {
        "text_answer": "Contradiction  The evidence shows that 286 95 CI 131492 of ERpositive Luminal B participants demonstrated a decrease in the growth factor signature while 176 95 CI 67352 of Triple Negative participants demonstrated a decrease in the growth factor signature A difference of 90",
        "label": "Contradiction"
    },
    "ff1759ba-f09e-4ecf-8316-aac2a78d6c26": {
        "text_answer": "Contradiction The statement is not related to the evidence provided The evidence only discusses adverse events from two clinical trials and there is no mention of external ear actinic keratosis anywhere in the evidence",
        "label": "Contradiction"
    },
    "db493601-5dae-4077-a455-582cd9e28315": {
        "text_answer": "Contradiction The secondary trial includes patients undergoing skinsparing mastectomy utilizing bioprosthetic mesh which is not mentioned in the primary trials inclusion criteria",
        "label": "Contradiction"
    },
    "e10d648e-a24d-4358-b81f-77b68fce3dc8": {
        "text_answer": "Contradiction The statement is not entailed by the evidence as the evidence does not provide information about the number of cases of biliary colic or diarrhea in the primary trial",
        "label": "Contradiction"
    },
    "df709118-7130-4d0e-8150-a05fa7f1a6d1": {
        "text_answer": "Contradiction The statement is contradictory to the evidence as patients with stage 4 invasive carcinoma of the breast are not eligible for the primary trial according to the inclusion criteria",
        "label": "Contradiction"
    },
    "077cc008-c777-4fa3-826b-8cc903eab60e": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as cohort 1 receives a lower dosage 0015 mgkgdose than cohort 2 0040 mgkgdose",
        "label": "Contradiction"
    },
    "a36a79c9-39aa-493e-a7f9-18771e4a50cf": {
        "text_answer": "Contradiction  Explanation  The statement no notable occurrence of pathologic complete response was observed in breast and axillary lymph nodes among trial participants in either cohort of the primary clinical trial after around 7 months postsurgery is a contradiction to the evidence presented in the trial results In Results 1 and 2 there are 16 and 14 participants respectively who achieved pCR in",
        "label": "Contradiction"
    },
    "3a027890-3744-44b7-a008-b18f60b0fdd4": {
        "text_answer": "Contradiction  Explanation The evidence does not provide enough information to determine if none of the patients in the primary trial experienced the worst pain imaginable for 70 days as there is no mention of pain intensity scores beyond the 10week time frame",
        "label": "Contradiction"
    },
    "028e1c85-f23e-411f-bf70-3621480de375": {
        "text_answer": "Contradiction  The statement is a contradiction to the evidence because the evidence shows that no cases of anemia pneumonia or stupor were reported in the primary trial while the statement asserts that these conditions were more common in the secondary trial Additionally the statement does not address the number of febrile infection cases in the secondary trial which is reported to be lower than in the primary trial according to the evidence",
        "label": "Contradiction"
    },
    "634ef5d6-4281-4d39-b876-59be4ed256ec": {
        "text_answer": "Entailment Both trials use RECIST criteria to evaluate tumor response although the primary trial focuses on the number of participants with tumor response after 24 doses of 852A while the secondary trial does not provide the specific percentage of participants with clinical benefit based on RECIST criteria However the statement that they both track the percentage of participants showing clinical benefit based on RECIST criteria is an entailment because the secondary trial does in fact use",
        "label": "Entailment"
    },
    "af0e8d9b-f748-424d-a4e7-6bb3bf0ee7a2": {
        "text_answer": "Entailment The evidence does not indicate any exclusion of AfricanAmerican patients from the primary trial",
        "label": "Entailment"
    },
    "42746679-44a5-4854-ba22-6557c0c34ff8": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction because the secondary trial participants do receive weekly subcutaneous injections as stated in the evidence The primary trial participants do not receive any injections as stated in the evidence as well However the statement incorrectly states that the primary trial participants do not receive any injections at all",
        "label": "Contradiction"
    },
    "5af6aa8c-69f5-44a5-9c7c-6c94a0fda6e8": {
        "text_answer": "Contradiction The statement is a contradiction to the evidence as the evidence shows that no adverse events were recorded in the primary trial while the statement asserts that no specific types of adverse events were recorded in the secondary trial but does not mention the primary trial",
        "label": "Contradiction"
    },
    "4138d4cd-bc5a-44db-8dc2-f64fbfb28b94": {
        "text_answer": "Entailment The evidence confirms that adverse effects were noted in patients belonging to cohort 1 of the primary clinical trial",
        "label": "Entailment"
    },
    "f51d8422-1f2c-45bf-8de8-ce554a19c011": {
        "text_answer": "Contradiction The primary clinical trial includes patients with ER positive HER2 negative invasive breast cancer Group 1 or invasive triplenegative breast cancer Group 2 but it does not include patients with ER positive HER2 positive breast cancer",
        "label": "Contradiction"
    },
    "74b24825-1c77-48e6-a1ce-c5b7e60b2b61": {
        "text_answer": "Contradiction The primary trial involves vaginal interventions Estring and testosterone cream while the secondary trial involves acupuncture which is not a topical intervention and there is no mention of an inhalation intervention in either trial",
        "label": "Contradiction"
    },
    "137bb76f-a37e-4339-af7e-f0c647a01baa": {
        "text_answer": "Contradiction  Explanation The statement is a contradiction based on the evidence provided because the evidence shows that the percentage of participants with disease progression or death was lower in the Bevacizumab  Capecitabine cohort 758 compared to the Bevacizumab monotherapy cohort 883 Therefore the Bevacizumab cohort had a higher incidence of disease",
        "label": "Contradiction"
    },
    "e0b061e1-ee74-46e0-a223-de370cfffc8a": {
        "text_answer": "Contradiction The evidence shows that in both trials no adverse events occurred in more than 03 of the participants",
        "label": "Contradiction"
    },
    "9625e56f-5de0-4cbd-8e30-a944bf6d6244": {
        "text_answer": "Contradiction  The evidence states that both cohorts receive preoperative intravenous dexamethasone administration which contradicts the statement that cohort 1 is administered the drug postoperatively",
        "label": "Contradiction"
    },
    "cb88e277-c79d-4bb1-8d63-c637a14d0f48": {
        "text_answer": "Contradiction  Explanation  The primary trial involves the use of denosumab which is a drug administered via injection The secondary trial involves the use of intraoperative handheld gamma camera pIHGC and gamma probes GP both of which involve the injection of radioactive Tc99M sulfur colloid Therefore the statement that the secondary trial does not employ any form of injection",
        "label": "Contradiction"
    },
    "af615add-c0e4-4046-9968-9d5805d2620e": {
        "text_answer": "Entailment The statement cancerfree patients are eligible for the primary clinical trial is an entailment based on the evidence provided in the inclusion criteria as the trial only includes patients with unilateral breast cancer who have undergone surgery and lymph node dissection and are cancerfree",
        "label": "Entailment"
    },
    "9477c88f-8957-4925-8c5d-0061409159f8": {
        "text_answer": "Entailment The evidence states that patients will take Vorinostat daily during radiation therapy so the statement that patients ingest Vorinostat capsule on a daily basis throughout radiation therapy is a requirement is an entailment",
        "label": "Entailment"
    },
    "04e554aa-1522-4fd6-a508-e0f13fa38832": {
        "text_answer": "Contradiction The evidence provided does not indicate that any participant in Cohort 1 suffered a lifethreatening adverse event",
        "label": "Contradiction"
    },
    "e762873d-0ab8-4732-8c17-fdab7712a8e5": {
        "text_answer": "Contradiction The primary trial does not report any thromboembolic events",
        "label": "Contradiction"
    },
    "c9514ddd-0486-4aca-a0b7-4e03a2effc90": {
        "text_answer": "Neutral  Explanation The evidence does not directly address the statement about several participants did not report any pain during the 10week duration of the primary clinical trial The evidence only provides data on the change in average pain intensity scores between the low dose and high dose groups",
        "label": "Entailment"
    },
    "570f69cb-de78-48d6-916b-bcb3ef0a27a7": {
        "text_answer": "Entailment The evidence states that perfusion of the involved breast is monitored using laserassisted fluorescence angiography at three separate time points for both interventions",
        "label": "Entailment"
    },
    "54c9f3b4-b90f-4b60-a924-5a26c4097521": {
        "text_answer": "Contradiction The primary trial involves the use of oral pregabalin while the secondary trial involves the use of intravenous Liposomal Cytarabine Depocyt and intravenous HighDose Methotrexate HDMTX These interventions are not equivalent as they involve different medications and routes of administration",
        "label": "Contradiction"
    },
    "f95613c7-63f9-4f97-adbd-176220391993": {
        "text_answer": "Contradiction  Explanation  The primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every 4 weeks not every week as stated in the question  The secondary trial involves the use of an intraoperative handheld gamma camera pIHGC or gamma probes GP for lymphoscintigraphy which involves the injection",
        "label": "Contradiction"
    },
    "4a7035e5-7fdf-461e-9d63-8e52be720d96": {
        "text_answer": "Contradiction The primary trial requires mammography while the secondary trial does not mention mammography as a requirement",
        "label": "Contradiction"
    },
    "29f65923-503d-402b-b0a3-150f741d8c2b": {
        "text_answer": "Entailment The statement is a requirement for inclusion in the clinical trial as stated in the provided evidence",
        "label": "Entailment"
    },
    "096f687a-6eec-4648-b8f8-6d423d84f3ae": {
        "text_answer": "Contradiction The evidence shows that no adverse event affected more than 50 of patients in the primary trial",
        "label": "Contradiction"
    },
    "869ef7c8-edf9-4eb0-8654-3bb28fa1b4aa": {
        "text_answer": "Contradiction Perjeta is not mentioned in the primary trial at all and fibrous meningioma is not related to the interventions in either trial",
        "label": "Contradiction"
    },
    "df8057c4-0640-488f-9a63-9036703fbf83": {
        "text_answer": "Contradiction The statement does not entail the information given in the evidence as it does not specify the dose of MCS110 in terms of mg only in ml and the conversion between mg and ml for MCS110 depends on its density which is not provided in the evidence",
        "label": "Contradiction"
    },
    "4aae628e-86f0-4851-9319-0a7d44d488b9": {
        "text_answer": "Contradiction The primary trial explicitly states that potassium must be within the normal range 3553 mEqL which is not a requirement for the secondary trial Therefore the statement that the primary trial does not accommodate patients with hypokalemia while the secondary trial may is a contradiction",
        "label": "Contradiction"
    },
    "9dd72932-f9f7-4ad7-8c3e-15f284d93d89": {
        "text_answer": "Contradiction The primary trial includes females only while the secondary trial includes patients with histologically documented breast or ovarian cancer as well as triplenegative breast cancer but not prostate cancer",
        "label": "Contradiction"
    },
    "cc6d64c8-a841-4a6b-bf57-df451ad47edb": {
        "text_answer": "Contradiction The evidence states that there were no severe adverse events reported in cohort 1 of the primary clinical trial",
        "label": "Contradiction"
    },
    "d803d6fb-f2af-4470-8cf9-7f68d6c53baf": {
        "text_answer": "Contradiction The primary and secondary trials do not involve orthodontic treatment",
        "label": "Contradiction"
    },
    "9c7521a7-87fc-4dc0-8c1e-5720836763e2": {
        "text_answer": "Contradiction The primary trial requires participants to be resistant to AI therapy but there is no such requirement for the secondary trial",
        "label": "Contradiction"
    },
    "b2ef7c16-b0e9-48dd-be60-9243443535b7": {
        "text_answer": "Contradiction  Explanation The primary trial includes patients with NUT midline carcinoma but the secondary trial does not Therefore the statement that patients diagnosed with NUT midline carcinoma can participate in both trials is a contradiction to the evidence provided Similarly the statement does not hold for castrateresistant prostate cancer and inflammatory breast cancer as well as the secondary trial does not include these patient populations",
        "label": "Contradiction"
    },
    "0b659007-1edc-43da-aafe-0024c2bb233e": {
        "text_answer": "Contradiction The evidence does not provide any information about the number or percentage of patients in either group experiencing no pain whatsoever during the 10week study",
        "label": "Contradiction"
    },
    "1d828a72-b303-4395-bab6-31865552caff": {
        "text_answer": "Contradiction The statement is not related to the given evidence The evidence provided pertains to inclusion and exclusion criteria for a clinical trial on breast cancer patients and there is no mention of mixed glioma or disability requirements in the statement",
        "label": "Contradiction"
    },
    "13f17e45-4ce5-4de3-8a67-eee3ca98c4eb": {
        "text_answer": "Contradiction The statement is incorrect as per the evidence provided as cohort 1 uses anastrozole or fulvestrant in interventions 1 and 2 respectively neither of which is paclitaxel",
        "label": "Contradiction"
    },
    "d85fd7f3-2765-407e-a8a3-49c19d9a4311": {
        "text_answer": "Contradiction The primary trial includes only postmenopausal women with early stage breast cancer while the secondary trial includes HER2positive females with a history of nonmetastatic operable primary invasive breast cancer These are not the same patient population",
        "label": "Contradiction"
    },
    "6efe0add-df04-4255-a81f-8a542c0b810f": {
        "text_answer": "Contradiction  Explanation The evidence does not mention anything about the use or nonuse of fentanyl sublingual spray during the primary clinical trial",
        "label": "Contradiction"
    },
    "9a276dfa-f4f9-4abe-837e-18cca465967e": {
        "text_answer": "Irrelevant The statement does not relate to the given evidence as it mentions cytomegalovirus positive which is not present in the evidence",
        "label": "Entailment"
    },
    "19ad39bd-9620-4ff6-8afe-a81348b4fada": {
        "text_answer": "Contradiction  Explanation  The statement is a contradiction to the evidence because  1 In the primary trial participants receive a single subcutaneous injection at the beginning of the study 2 In the secondary trial participants in the intervention group receive 15 subcutaneous injections in total not weekly  Therefore the statement that candidates for the secondary trial study group receive 15 weekly sub",
        "label": "Contradiction"
    },
    "773d939c-db89-4999-9903-89da67345b49": {
        "text_answer": "Contradiction  The evidence states that sunitinib was administered orally from Day 1 at a continuous daily dosing schedule but it also mentions that dosing could be interrupted or reduced according to individual tolerance which implies that some patients did not receive sunitinib every day However the statement goes further by suggesting that some patients did not receive sunitinib for the entire duration of the study which is not explicitly stated in the evidence",
        "label": "Contradiction"
    },
    "a8f421ec-e3c7-43b4-96da-b6bca22d68ed": {
        "text_answer": "Contradiction The evidence shows that 381 of participants in Arm 1 and 333 of participants in Arm 2 experienced pathologic complete response in breast and axillary lymph nodes after approximately 7 months of the study Therefore it is contradictory to state that 0 of participants in both cohorts experienced pathologic complete response after only 4 weeks",
        "label": "Contradiction"
    },
    "c91a6c5a-27f1-4e7b-8f91-34e3d2236e8b": {
        "text_answer": "Contradiction The evidence does not support the statement that on average patients from the primary trial survive over 2 years as the median survival for both groups is less than 2 years The statement that over 50 patients from each cohort survived more than 24 months is also not directly related to the evidence provided",
        "label": "Contradiction"
    },
    "6ee00118-66be-4e39-85a7-2dd1feaca87b": {
        "text_answer": "Contradiction  The statement implies a ratio of 13 hepatotoxicity  hypertension  pancreatectomy based on the given text while the evidence shows a ratio of 12 hepatotoxicity  hypertension and no recorded cases of pancreatectomy",
        "label": "Contradiction"
    },
    "d1123c9b-e0d4-412d-bcf6-a69bbb07a0f4": {
        "text_answer": "Contradiction  Explanation The statement an instance of doselimiting toxicity was identified in two different patients each from separate cohorts implies that there were two instances of doselimiting toxicity in total However the evidence only shows that one instance of doselimiting toxicity was identified in each cohort Therefore the statement is a contradiction to the evidence",
        "label": "Contradiction"
    },
    "8bc95ffe-c455-4563-bc81-a7530f6fb500": {
        "text_answer": "Contradiction  Explanation The evidence provided does not mention anything related to chondrosarcoma or its grades so the statement is not entailed by the evidence and is a contradiction",
        "label": "Contradiction"
    },
    "9f08a841-c0c4-42e4-984f-0700bb46f18f": {
        "text_answer": "Contradiction  Explanation The evidence states that in Intervention 1 patients receive 1 mgkg of MCS110 every 3 weeks and in Intervention 2 patients receive 3 mgkg of MCS110 every 3 weeks To calculate the amount of MCS110 received every 21 days we need to find the total amount of MCS110 given in 21",
        "label": "Contradiction"
    },
    "921d278b-11fe-4f67-883a-cd10b15c20f2": {
        "text_answer": "Contradiction The statement assumes that all Infections and Fever cases were in cohort 1 but the evidence shows that there were no Fever cases in cohort 2",
        "label": "Contradiction"
    },
    "17ca93e8-5115-4f53-8d4a-b3ce6c43ea58": {
        "text_answer": "Contradiction The primary trial has specific inclusion criteria related to hot flushes and menopausal status which are not met by patients in the secondary trial making simultaneous participation impossible",
        "label": "Contradiction"
    },
    "04191593-f36e-4fc0-8af5-7591059640a4": {
        "text_answer": "Contradiction The evidence shows that there was one instance of pancytopenia in the first cohort but there were also instances of anaemia and febrile neutropenia recorded in the same cohort",
        "label": "Contradiction"
    }
}